FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Cormack, RA Nguyen, PL D'Amico, AV Sridhar, S Makrigiorgos, M AF Cormack, R. A. Nguyen, P. L. D'Amico, A. V. Sridhar, S. Makrigiorgos, M. TI In Situ Radiosensitization of Brachytherapy: Image Guided Planned Biologic Enhancement of Brachytherapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Cormack, R. A.; Makrigiorgos, M.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. [Cormack, R. A.; Nguyen, P. L.; D'Amico, A. V.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Nguyen, P. L.; D'Amico, A. V.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Sridhar, S.] Northeastern Univ, Nanomed Sci & Technol Ctr, Boston, MA 02115 USA. [Sridhar, S.] Northeastern Univ, Dept Phys, Boston, MA 02115 USA. [Makrigiorgos, M.] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3591 BP E649 EP E649 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804171 ER PT J AU Gentile, MS Jacobson, A Wang, H Goldberg, S Choy, E Mullen, JT Hornicek, FJ Chen, YLE DeLaney, TF AF Gentile, M. S. Jacobson, A. Wang, H. Goldberg, S. Choy, E. Mullen, J. T. Hornicek, F. J. Chen, Y. L. E. DeLaney, T. F. TI Outcomes in Patients With Recurrent Desmoid Tumor Managed With Surgery Alone, Combined Surgery and Radiation Therapy, or Radiation Therapy Alone SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Gentile, M. S.; Jacobson, A.; Chen, Y. L. E.; DeLaney, T. F.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Wang, H.; Goldberg, S.; Hornicek, F. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Choy, E.] Massachusetts Gen Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02114 USA. [Mullen, J. T.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3728 BP E704 EP E705 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804307 ER PT J AU Giacalone, NJ Faridi, K Wang, H Jacobson, A Choy, E Mullen, JT DeLaney, TF Chen, YLE AF Giacalone, N. J. Faridi, K. Wang, H. Jacobson, A. Choy, E. Mullen, J. T. DeLaney, T. F. Chen, Y. L. E. TI Outcomes After Definitive Management of Primary Genitourinary Sarcomas: A Single-Institution Experience SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Giacalone, N. J.; Faridi, K.; Wang, H.; Jacobson, A.; DeLaney, T. F.; Chen, Y. L. E.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Giacalone, N. J.] Harvard Radiat Oncol Program, Boston, MA USA. [Choy, E.] Massachusetts Gen Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02114 USA. [Mullen, J. T.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3746 BP E712 EP E712 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804325 ER PT J AU Giantsoudi, D Depauw, N Paganetti, H MacDonald, S AF Giantsoudi, D. Depauw, N. Paganetti, H. MacDonald, S. TI Cardiac Toxicity From Proton Radiation Therapy of Left-Sided Breast Cancer: LET and RBE Considerations SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Giantsoudi, D.; Depauw, N.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Paganetti, H.; MacDonald, S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3672 BP E682 EP E683 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804251 ER PT J AU Hu, YH Rottmann, J Myronakis, M Berbeco, RI AF Hu, Y. H. Rottmann, J. Myronakis, M. Berbeco, R. I. TI Using Fractal Dimension Analysis to Distinguish Lung Tumors in MV Imaging SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3581 BP E644 EP E645 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804161 ER PT J AU Kim, J Park, YK Sharp, GC Busse, PM Winey, B AF Kim, J. Park, Y. K. Sharp, G. C. Busse, P. M. Winey, B. TI Feasibility of the Use of Scatter Corrected Cone Beam Computed Tomography Images to Evaluate Range Variations During Proton Radiation Therapy of Head and Neck Patients SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Kim, J.; Park, Y. K.; Sharp, G. C.; Winey, B.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Busse, P. M.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3647 BP E672 EP E672 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804226 ER PT J AU Moreau, M Foade, A Ngwa, W AF Moreau, M. Foade, A. Ngwa, W. TI High-Capacity Multifunctional Radiation Therapy Biomaterials SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Moreau, M.] Univ Massachusetts Lowell, Boston, MA USA. [Moreau, M.; Foade, A.; Ngwa, W.] Harvard Med Sch Boston, Boston, MA USA. [Foade, A.] Univ Massachusetts, Boston, MA 02125 USA. [Ngwa, W.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3720 BP E701 EP E701 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804299 ER PT J AU Myronakis, M Rottmann, J Hu, YH Wang, A Shedlock, D Morf, D Star-Lack, J Berbeco, RI AF Myronakis, M. Rottmann, J. Hu, Y. H. Wang, A. Shedlock, D. Morf, D. Star-Lack, J. Berbeco, R. I. TI Megavoltage Spectral Imaging Using a Layered Imager SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Myronakis, M.; Rottmann, J.; Hu, Y. H.; Berbeco, R. I.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. [Myronakis, M.; Rottmann, J.; Hu, Y. H.; Berbeco, R. I.] Harvard Med Sch, Boston, MA USA. [Wang, A.; Star-Lack, J.] Varian Med Syst, Palo Alto, CA USA. [Shedlock, D.] Varian Med Syst, Knoxville, TN USA. [Morf, D.] Varian Med Syst, Badden Dattwil, Switzerland. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3610 BP E656 EP E656 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804189 ER PT J AU Pankuch, M Gao, M Gans, S Kaplan, D Schmidt, S McGee, LA Chang, JHC Hartsell, WF Cahlon, O MacDonald, S Lu, HM AF Pankuch, M. Gao, M. Gans, S. Kaplan, D. Schmidt, S. McGee, L. A. Chang, J. H. C. Hartsell, W. F. Cahlon, O. MacDonald, S. Lu, H. M. TI A Novel Proton Therapy Technique for Treatment of Postmastectomy Breast Cancer Patients With Tissue Expanders Containing High-Density Metallic Filling Ports SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Pankuch, M.; Gao, M.; Gans, S.; Kaplan, D.; Schmidt, S.] Northwestern Med Chicago Proton Ctr, Warrenville, IL USA. [McGee, L. A.; Chang, J. H. C.; Hartsell, W. F.] Radiat Oncol Consultants Ltd, Oak Brook, IL USA. [Cahlon, O.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. [Lu, H. M.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3689 BP E689 EP E689 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804268 ER PT J AU Park, YK Sharp, GC Winey, B AF Park, Y. K. Sharp, G. C. Winey, B. TI During-Treatment Verification of Spine Position Using a Single kV Projection of an On-board Cone Beam Computed Tomography System: Simulation Study SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Park, Y. K.; Sharp, G. C.; Winey, B.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3587 BP E647 EP E647 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804167 ER PT J AU Raldow, A Jacobson, A Goldberg, S Wang, H Choy, E Cote, G Hornicek, FJ DeLaney, TF Chen, YLE AF Raldow, A. Jacobson, A. Goldberg, S. Wang, H. Choy, E. Cote, G. Hornicek, F. J. DeLaney, T. F. Chen, Y. L. E. TI Adult Rhabdomyosarcoma: A Retrospective Analysis of 40 Patients Treated at a Single Institution SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Raldow, A.] Harvard Radiat Oncol Program, Boston, MA USA. [Jacobson, A.; Wang, H.; DeLaney, T. F.; Chen, Y. L. E.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Goldberg, S.; Cote, G.; Hornicek, F. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Choy, E.] Massachusetts Gen Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3741 BP E710 EP E710 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804320 ER PT J AU Shen, C Kummerlowe, M Morris, C Meyer, C Habibi, M Frassica, DA Levin, A Thornton, K Terezakis, SA AF Shen, C. Kummerlowe, M. Morris, C. Meyer, C. Habibi, M. Frassica, D. A. Levin, A. Thornton, K. Terezakis, S. A. TI Combined Modality Therapy Results in Improved Overall Survival for Angiosarcoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Shen, C.; Kummerlowe, M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Morris, C.; Levin, A.] Johns Hopkins Univ, Sch Med, Dept Orthopaed Surg, Baltimore, MD USA. [Meyer, C.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA. [Habibi, M.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA. [Frassica, D. A.; Terezakis, S. A.] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD USA. [Thornton, K.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3732 BP E706 EP E706 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804311 ER PT J AU Wang, H Jacobson, A Goldberg, S Stanton, T Harmon, D Choy, E Cote, G Hornicek, FJ Raskin, K DeLaney, TF Nielsen, G Chen, YLE AF Wang, H. Jacobson, A. Goldberg, S. Stanton, T. Harmon, D. Choy, E. Cote, G. Hornicek, F. J. Raskin, K. DeLaney, T. F. Nielsen, G. Chen, Y. L. E. TI Osteosarcoma of the Spine and Pelvis: One hundred fifteen Patients of a Single Institution SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Wang, H.; Jacobson, A.; DeLaney, T. F.; Chen, Y. L. E.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Goldberg, S.; Stanton, T.; Harmon, D.; Cote, G.; Hornicek, F. J.; Raskin, K.; Nielsen, G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Choy, E.] Massachusetts Gen Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3736 BP E708 EP E708 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804315 ER PT J AU Yasmin-Karim, S Moreau, M Ngwa, W AF Yasmin-Karim, S. Moreau, M. Ngwa, W. TI In Vitro Study of Small-Sized Nanoparticle-Aided Radiation Therapy for Prostate Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Yasmin-Karim, S.; Moreau, M.; Ngwa, W.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. [Yasmin-Karim, S.; Moreau, M.; Ngwa, W.] Harvard Med Sch, Boston, MA USA. [Moreau, M.] Univ Massachusetts Lowell, Lowell, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3707 BP E696 EP E696 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804286 ER PT J AU Agrawal, S Stephenson, AJ Michalski, J Efstathiou, JA Pisansky, TM Feng, F Hamstra, DA Koontz, BF Liauw, S Abramowitz, MC Pollack, A Anscher, MS Moghanaki, D Den, RB Stephans, KL Gao, T Kattan, M Tendulkar, RD AF Agrawal, S. Stephenson, A. J. Michalski, J. Efstathiou, J. A. Pisansky, T. M. Feng, F. Hamstra, D. A. Koontz, B. F. Liauw, S. Abramowitz, M. C. Pollack, A. Anscher, M. S. Moghanaki, D. Den, R. B. Stephans, K. L. Gao, T. Kattan, M. Tendulkar, R. D. TI Prostate Cancer-Specific Mortality and Survival Outcomes for Salvage Radiation Therapy After Radical Prostatectomy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Agrawal, S.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA. [Stephenson, A. J.; Stephans, K. L.; Gao, T.; Tendulkar, R. D.] Cleveland Clin, Cleveland, OH 44106 USA. [Michalski, J.] Washington Univ, Sch Med, St Louis, MO USA. [Efstathiou, J. A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA. [Pisansky, T. M.] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA. [Feng, F.] Univ Michigan, Ann Arbor, MI 48109 USA. [Hamstra, D. A.] Texas Oncol, Irving, TX USA. [Koontz, B. F.] Duke Univ, Med Ctr, Durham, NC USA. [Liauw, S.] Univ Chicago, Chicago, IL 60637 USA. [Abramowitz, M. C.; Pollack, A.] Univ Miami, Miami, FL USA. [Anscher, M. S.] Virginia Commonwealth Univ, Med Ctr, Richmond, VA USA. [Moghanaki, D.] Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA USA. [Den, R. B.] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA. [Kattan, M.] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 228 BP S101 EP S101 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804565 ER PT J AU Bell, EH McElroy, JP Fleming, J Timmers, C Chakraborty, AR Salavaggione, AL Chang, SM Shaw, EG Aldape, K Brachman, D Schultz, CJ Shih, HA Curtis, M Hunter, GK Murtha, AD Zhang, P Won, M Mehta, MP Chakravarti, A AF Bell, E. H. McElroy, J. P. Fleming, J. Timmers, C. Chakraborty, A. R. Salavaggione, A. L. Chang, S. M. Shaw, E. G. Aldape, K. Brachman, D. Schultz, C. J. Shih, H. A. Curtis, M. Hunter, G. K. Murtha, A. D. Zhang, P. Won, M. Mehta, M. P. Chakravarti, A. TI A Mutation and Prognostic Biomarker Study in Grade II and III Gliomas Utilizing a Combined Cohort of NRG Oncology/RTOG 9802 and 9813 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Bell, E. H.; McElroy, J. P.; Fleming, J.; Timmers, C.; Chakraborty, A. R.; Salavaggione, A. L.; Chakravarti, A.] Ohio State Univ, Columbus, OH 43210 USA. [Chang, S. M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Shaw, E. G.] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA. [Aldape, K.] Univ Texas MD Anderson, Houston, TX USA. [Brachman, D.] Arizona Oncol Serv Fdn, Phoenix, AZ USA. [Schultz, C. J.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Shih, H. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Curtis, M.] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA. [Hunter, G. K.] Intermt Healthcare, Murray, UT USA. [Murtha, A. D.] Cross Canc Inst, Edmonton, AB, Canada. [Zhang, P.; Won, M.] NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA. [Mehta, M. P.] Univ Maryland, Baltimore, MD 21201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 206 BP S91 EP S91 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804543 ER PT J AU Belz, J Ojo, NC Kumar, R Cormack, RA Makrigiorgos, M Sridhar, S D'Amico, AV Nguyen, PL AF Belz, J. Ojo, N. Castilla Kumar, R. Cormack, R. A. Makrigiorgos, M. Sridhar, S. D'Amico, A. V. Nguyen, P. L. TI Docetaxel-Loaded Brachytherapy Spacers for Combined Chemoradiation Therapy in Prostate Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Belz, J.; Ojo, N. Castilla] Northeastern Univ, Boston, MA 02115 USA. [Kumar, R.; Sridhar, S.] Northeastern Univ, Nanomed Sci & Technol Ctr, Boston, MA 02115 USA. [Kumar, R.; Sridhar, S.] Northeastern Univ, Dept Phys, Boston, MA 02115 USA. [Cormack, R. A.; Makrigiorgos, M.; Nguyen, P. L.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. [Makrigiorgos, M.; Nguyen, P. L.] Harvard Med Sch, Boston, MA USA. [D'Amico, A. V.] Dana Farber Canc Inst, Boston, MA 02115 USA. [D'Amico, A. V.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 244 BP S109 EP S109 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804581 ER PT J AU Bruner, DW Pugh, SL Lee, WR Dignam, JJ Low, D Swanson, GP Shah, AB D'Souza, DP Michalski, JM Dayes, IS Seaward, SA Nguyen, PL Hall, WA Pisansky, TM Chen, Y Sandler, HM Movsas, B AF Bruner, D. Watkins Pugh, S. L. Lee, W. R. Dignam, J. J. Low, D. Swanson, G. P. Shah, A. B. D'Souza, D. P. Michalski, J. M. Dayes, I. S. Seaward, S. A. Nguyen, P. L. Hall, W. A. Pisansky, T. M. Chen, Y. Sandler, H. M. Movsas, B. TI NRG Oncology/RTOG 0415, Phase 3 Noninferiority Study Comparing 2 Fractionation Schedules in Patients With Low-Risk Prostate Cancer: Prostate-Specific Quality of Life Results SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Bruner, D. Watkins] Emory Univ, Nell Hodgson Woodruff Sch Nursing, Winship Canc Inst, Atlanta, GA 30322 USA. [Pugh, S. L.] NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA. [Lee, W. R.] Duke Univ, Durham, NC USA. [Dignam, J. J.] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA. [Low, D.; Michalski, J. M.] Washington Univ, Sch Med, St Louis, MO USA. [Swanson, G. P.] Baylor Scott & White Healthcare Temple Clin, Temple, TX USA. [Shah, A. B.] York Canc Ctr, York, PA USA. [D'Souza, D. P.] Western Univ, London, ON, Canada. [Dayes, I. S.] McMaster Univ, Hamilton, ON, Canada. [Seaward, S. A.] Kaiser Permanente Northern Calif, Santa Clara, CA USA. [Nguyen, P. L.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Nguyen, P. L.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Hall, W. A.] Emory Univ, Atlanta, GA 30322 USA. [Pisansky, T. M.] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA. [Chen, Y.] Univ Rochester, Wilmot Canc Inst, Rochester, NY USA. [Sandler, H. M.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Movsas, B.] Henry Ford Hlth Syst, Detroit, MI USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 4 BP S2 EP S3 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804342 ER PT J AU Burgess, L Pulsifer, M Yeap, BY Grieco, J Weinstein, ER MacDonald, S Tarbell, NJ Yock, TI AF Burgess, L. Pulsifer, M. Yeap, B. Y. Grieco, J. Weinstein, E. R. MacDonald, S. Tarbell, N. J. Yock, T. I. TI Estimated IQ (EIQ) Systematically Overestimates Full-Scale IQ (FSIQ) in Survivors Irradiated for Pediatric Brain Tumors SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Burgess, L.; Pulsifer, M.; Grieco, J.; Weinstein, E. R.; MacDonald, S.; Yock, T. I.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Yeap, B. Y.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA. [Tarbell, N. J.] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 1161 BP S232 EP S232 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655805164 ER PT J AU Chen, AB Li, L Cronin, A Brooks, G Kavanagh, BD Schrag, D AF Chen, A. B. Li, L. Cronin, A. Brooks, G. Kavanagh, B. D. Schrag, D. TI Total Medicare and Radiation-Specific Costs During a Palliative "Radiation Episode" SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Chen, A. B.] Harvard Med Sch, Dana Farber Canc Inst, Brigham & Womens Hosp, Boston, MA USA. [Li, L.; Cronin, A.; Brooks, G.; Schrag, D.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Kavanagh, B. D.] Univ Colorado Denver, Dept Radiat Oncol, Aurora, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 306 BP S136 EP S136 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804644 ER PT J AU Chen, YLE Faridi, K Wang, H Lim, R Schroeder, H Bernstein, K Choy, E Hornicek, FJ DeLaney, TF AF Chen, Y. L. E. Faridi, K. Wang, H. Lim, R. Schroeder, H. Bernstein, K. Choy, E. Hornicek, F. J. DeLaney, T. F. TI Predictive Value of FMISO Positron Emission Tomography/Computed Tomography Hypoxic Subvolume for Long-Term Disease Recurrence or Metastases in Mobile Spine and Sacrococcygeal Chordoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Chen, Y. L. E.; Faridi, K.; Wang, H.; DeLaney, T. F.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Chen, Y. L. E.; Lim, R.; Choy, E.; Hornicek, F. J.] Harvard Med Sch, Boston, MA USA. [Lim, R.; Schroeder, H.; Bernstein, K.; Hornicek, F. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Choy, E.] Massachusetts Gen Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 1124 BP S216 EP S217 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655805128 ER PT J AU Chino, F Peppercorn, JM Rushing, C Samsa, G Nicolla, J Altomare, I Zafar, SY AF Chino, F. Peppercorn, J. M. Rushing, C. Samsa, G. Nicolla, J. Altomare, I. Zafar, S. Y. TI "Going for Broke": Out-of-Pocket Costs, Financial Distress, and Patient-Reported Willingness to Pay and Sacrifice in Cancer Care SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Chino, F.; Rushing, C.; Samsa, G.; Nicolla, J.] Duke Univ, Med Ctr, Durham, NC USA. [Peppercorn, J. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Altomare, I.; Zafar, S. Y.] Duke Canc Inst, Durham, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 305 BP S135 EP S136 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804643 ER PT J AU Churilla, TM Handorf, E Soffietti, R Kocher, M Aizer, AA Collette, L Collette, S Dong, Y Alexander, BM Weiss, SE AF Churilla, T. M. Handorf, E. Soffietti, R. Kocher, M. Aizer, A. A. Collette, L. Collette, S. Dong, Y. Alexander, B. M. Weiss, S. E. TI Does Whole-Brain Radiation Therapy for Oligometastatic Brain Metastases Translate Into a Survival Benefit for Patients With a Limited Competing Risk From Extracranial Disease? A Secondary Analysis of EORTC 22952-26001 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Churilla, T. M.; Handorf, E.; Dong, Y.; Weiss, S. E.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Soffietti, R.] Univ Turin, Turin, Italy. [Soffietti, R.] City Hlth & Sci Hosp, Turin, Italy. [Kocher, M.] Univ Cologne, Radiotherapy & Oncol, Cologne, Germany. [Aizer, A. A.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. [Collette, L.; Collette, S.] EORTC Headquarters, Brussels, Belgium. [Alexander, B. M.] Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 126 BP S56 EP S57 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804463 ER PT J AU DeLaney, TF Chen, YLE Adams, JA Hickey, S Wang, D Baldini, EH Bernstein, K Yeap, BY Hahn, SM Nielsen, GP Choy, E Mullen, JT Yoon, SS AF DeLaney, T. F. Chen, Y. L. E. Adams, J. A. Hickey, S. Wang, D. Baldini, E. H. Bernstein, K. Yeap, B. Y. Hahn, S. M. Nielsen, G. P. Choy, E. Mullen, J. T. Yoon, S. S. TI Phase 1 Trial of Preoperative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) With Simultaneously Integrated Boost to the High Risk Margin for Retroperitoneal Sarcomas SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [DeLaney, T. F.; Chen, Y. L. E.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [DeLaney, T. F.] Harvard Med Sch, Boston, MA USA. [Adams, J. A.; Hickey, S.; Bernstein, K.; Nielsen, G. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Wang, D.] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Baldini, E. H.] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA. [Yeap, B. Y.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA. [Hahn, S. M.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA. [Choy, E.] Massachusetts Gen Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02114 USA. [Mullen, J. T.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Yoon, S. S.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 49 BP S23 EP S23 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804386 ER PT J AU Detappe, A Kunjachan, S Sancey, L Makrigiorgos, M Langer, R Tillement, O Berbeco, RI AF Detappe, A. Kunjachan, S. Sancey, L. Makrigiorgos, M. Langer, R. Tillement, O. Berbeco, R. I. TI Gadolinium Nanoparticles for Magnetic Resonance Guided Radiation Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Detappe, A.; Kunjachan, S.; Makrigiorgos, M.; Berbeco, R. I.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. [Detappe, A.; Kunjachan, S.; Makrigiorgos, M.; Berbeco, R. I.] Harvard Med Sch, Boston, MA USA. [Detappe, A.; Sancey, L.; Tillement, O.] Inst Lumiere Matiere, Lyon, France. [Langer, R.] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 248 BP S110 EP S111 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804585 ER PT J AU Dhou, S Ionascu, D Cai, W Hurwitz, M Williams, CL Lewis, J AF Dhou, S. Ionascu, D. Cai, W. Hurwitz, M. Williams, C. L. Lewis, J. TI Interfraction Variability of Motion Models Derived Using Patient 4-Dimensional Cone Beam Computed Tomography Images for Lung Cancer Stereotactic Body Radiation Therapy (SBRT) Patients SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Dhou, S.; Cai, W.; Hurwitz, M.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. [Dhou, S.; Cai, W.; Hurwitz, M.] Harvard Med Sch, Boston, MA USA. [Ionascu, D.] William Beaumont Hosp, Royal Oak, MI 48072 USA. [Williams, C. L.] Harvard Med Sch, Massachusetts Gen Hosp, Brigham & Womens Hosp, Boston, MA USA. [Lewis, J.] Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 1109 BP S210 EP S211 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655805113 ER PT J AU Eaton, BR Goldberg, S Gaudet, D Morgan, ML MacDonald, S Tarbell, NJ Yock, TI AF Eaton, B. R. Goldberg, S. Gaudet, D. Morgan, M. L. MacDonald, S. Tarbell, N. J. Yock, T. I. TI Radiation Dosimetry and Health-Related Quality of Life in Pediatric Brain Tumor Survivors Treated With Proton Therapy at <= 3 Years of Age SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Eaton, B. R.] Emory Univ, Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA 30322 USA. [Goldberg, S.; Gaudet, D.; Morgan, M. L.; MacDonald, S.; Tarbell, N. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Yock, T. I.] Massachusetts Gen Hosp, Dept Radiat Oncol, Francis H Burr Proton Therapy Ctr, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 270 BP S121 EP S121 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804608 ER PT J AU Garg, MK Zhao, F Lee, J Sparano, J Palefsky, J Henry, D Wachsman, W Rajdev, L Aboulafia, D Mitchell, E Onitilo, A El-Rayes, B Nabbout, N Fitzgerald, T Mitsuyasu, R Benson, AB Kachnic, LA AF Garg, M. K. Zhao, F. Lee, J. Sparano, J. Palefsky, J. Henry, D. Wachsman, W. Rajdev, L. Aboulafia, D. Mitchell, E. Onitilo, A. El-Rayes, B. Nabbout, N. Fitzgerald, T. Mitsuyasu, R. Benson, A. B. Kachnic, L. A. TI Radiation Therapy Compliance/Quality Assurance (QA) in 2 Phase 2 Trials of Cetuximab Plus Combined Modality Therapy (CMT) Including Chemotherapy and Radiation Therapy (RT) for Patients With Squamous Cell Carcinoma of the Anal Canal (SCCAC) (AMC045) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Garg, M. K.] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA. [Zhao, F.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Lee, J.] Univ Arkansas, Little Rock, AR 72204 USA. [Sparano, J.; Rajdev, L.] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA. [Palefsky, J.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Henry, D.] Univ Penn, Philadelphia, PA 19104 USA. [Wachsman, W.] Univ Calif San Diego, San Diego, CA 92103 USA. [Aboulafia, D.] Univ Washington, St Louis, CO USA. [Mitchell, E.] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Onitilo, A.] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA. [El-Rayes, B.] Emory Univ, Atlanta, GA 30322 USA. [Nabbout, N.] Canc Ctr Kansas, Wichita, KS USA. [Fitzgerald, T.] Univ Massachusetts, Mem Med Ctr, Dept Radiat Oncol, Worcester, MA 01605 USA. [Mitsuyasu, R.] Univ Calif Los Angeles, Los Angeles, CA USA. [Benson, A. B.] Northwestern Univ, Chicago, IL 60611 USA. [Kachnic, L. A.] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 239 BP S106 EP S107 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804576 ER PT J AU Gill, BS Viswanathan, AN Balasubramani, GK Sukumvanich, P Beriwal, S AF Gill, B. S. Viswanathan, A. N. Balasubramani, G. K. Sukumvanich, P. Beriwal, S. TI Implication of Adjuvant Radiation Therapy and Dose-Response Relationship for Margin-Positive Vulvar Squamous Cell Carcinoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Gill, B. S.; Beriwal, S.] Univ Pittsburgh, Inst Canc, Dept Radiat Oncol, Pittsburgh, PA USA. [Viswanathan, A. N.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. [Balasubramani, G. K.] Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Sukumvanich, P.] Univ Pittsburgh, Magee Womens Hosp, Med Ctr, Pittsburgh, PA 15213 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 110 BP S50 EP S50 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804447 ER PT J AU Grassberger, C Dinkelborg, P McNamara, A Schuemann, JP McMahon, SJ Willers, H Paganetti, H Wang, M AF Grassberger, C. Dinkelborg, P. McNamara, A. Schuemann, J. P. McMahon, S. J. Willers, H. Paganetti, H. Wang, M. TI Digital Holographic Microscopy for Nanoscale Dose Calculation and Assessing Gold Nanoparticle Uptake in Live Cells SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Grassberger, C.; Paganetti, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Dinkelborg, P.; McNamara, A.; Schuemann, J. P.; McMahon, S. J.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Willers, H.; Wang, M.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RI McNamara, Aimee/C-9432-2009 OI McNamara, Aimee/0000-0001-8792-0464 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 1013 BP S169 EP S170 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655805018 ER PT J AU Grassberger, C Wo, JY Hato, T Bortfeld, T Wolfgang, JA Zhu, AX Duda, DG Hong, TI AF Grassberger, C. Wo, J. Y. Hato, T. Bortfeld, T. Wolfgang, J. A. Zhu, A. X. Duda, D. G. Hong, T. I. TI Treatment-Induced Changes in Circulating Lymphocyte Populations Associate With Survival of Patients With Hepatocellular Carcinoma (HCC) and Intrahepatic Cholangiocarcinoma (ICC) Treated With Hypofractionated Proton Therapy (HPT) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Grassberger, C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Wo, J. Y.; Hato, T.; Bortfeld, T.; Wolfgang, J. A.; Zhu, A. X.; Duda, D. G.; Hong, T. I.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 321 BP S142 EP S142 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804659 ER PT J AU Guthier, CV Damato, AL Viswanathan, AN Hesser, J Cormack, RA AF Guthier, C. V. Damato, A. L. Viswanathan, A. N. Hesser, J. Cormack, R. A. TI A Fast Inverse Treatment Planning Strategy Facilitating Optimized Catheter Selection in Image Guided Interstitial High-Dose-Rate Gynecologic Brachytherapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Guthier, C. V.; Cormack, R. A.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Guthier, C. V.; Hesser, J.] Heidelberg Univ, Med Fac Mannheim, Mannheim, Germany. [Damato, A. L.] Harvard Med Sch, Boston, MA USA. [Damato, A. L.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. [Viswanathan, A. N.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 183 BP S81 EP S81 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804520 ER PT J AU Hall, DC Trofimov, AV Winey, B Paganetti, H AF Hall, D. C. Trofimov, A. V. Winey, B. Paganetti, H. TI A Geometric Knowledge-Based Model to Quickly Predict the Patient-Specific Benefits of Proton Therapy in Clival Chordoma Patients SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Hall, D. C.; Trofimov, A. V.; Winey, B.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Paganetti, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 184 BP S81 EP S82 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804521 ER PT J AU Hashmi, AH Guckenberger, M Kersh, R Gerszten, PC Mantel, F Grills, IS Flickinger, JC Shin, J Fahim, D Winey, B Oh, KS Cho, J Letourneau, D Sheehan, JP Sahgal, A AF Hashmi, A. H. Guckenberger, M. Kersh, R. Gerszten, P. C. Mantel, F. Grills, I. S. Flickinger, J. C., Sr. Shin, J. Fahim, D. Winey, B. Oh, K. S. Cho, J. Letourneau, D. Sheehan, J. P. Sahgal, A. TI Reirradiation Stereotactic Body Radiation Therapy (SBRT) for Spinal Metastases: A Multi-Institutional Outcome Analysis SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Hashmi, A. H.] Clatterbridge Canc Ctr, Merseyside CH63 4JY, England. [Guckenberger, M.; Mantel, F.] Univ Hosp Wuerzburg, Wurzburg, Germany. [Kersh, R.] Univ Virginia, Charlottesville, VA USA. [Gerszten, P. C.] Univ Pittsburgh, Pittsburgh, PA USA. [Grills, I. S.] Beaumont Hlth Syst, Royal Oak, MI USA. [Flickinger, J. C., Sr.] Univ Pittsburgh, Inst Canc, Dept Radiat Oncol, Pittsburgh, PA USA. [Shin, J.] Harvard Med Sch, Boston, MA USA. [Fahim, D.] William Beaumont Hosp, Dept Neurosurg, Royal Oak, MI 48072 USA. [Winey, B.; Oh, K. S.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Cho, J.] Univ Toronto, Princess Margaret Canc Ctr, Dept Radiat Oncol, Toronto, ON, Canada. [Letourneau, D.] Princess Margaret Hosp, Toronto, ON, Canada. [Sheehan, J. P.] Univ Virginia, Sch Med, Dept Neurosurg, Charlottesville, VA 22908 USA. [Sahgal, A.] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 276 BP S123 EP S124 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804614 ER PT J AU Holdsworth, CH Kukluk, J Czerminska, MA Hancox, C Molodowitch, C Cormack, RA Killoran, JH AF Holdsworth, C. H. Kukluk, J. Czerminska, M. A. Hancox, C. Molodowitch, C. Cormack, R. A. Killoran, J. H. TI Computerized System for Safety Verification of External Beam Radiation Therapy Planning SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Holdsworth, C. H.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Kukluk, J.; Czerminska, M. A.; Molodowitch, C.] BWH DFCI, Boston, MA USA. [Hancox, C.] Brigham & Womens Hosp, Fall River, MA USA. [Cormack, R. A.; Killoran, J. H.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 165 BP S73 EP S74 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804502 ER PT J AU Huynh, MA Catalano, PJ Chen, YH Marcus, KJ Michaelson, E Silver, BJ Mauch, PM Ng, AK Wong, JS AF Huynh, M. A. Catalano, P. J. Chen, Y. H. Marcus, K. J. Michaelson, E. Silver, B. J. Mauch, P. M. Ng, A. K. Wong, J. S. TI Significant Reduction in Breast Cancer Risk as Long-Term Hodgkin Lymphoma Survivors Reach Menopausal Age SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Huynh, M. A.] Harvard Radiat Oncol Program, Boston, MA USA. [Catalano, P. J.; Chen, Y. H.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Marcus, K. J.; Michaelson, E.; Silver, B. J.; Ng, A. K.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Mauch, P. M.] Harvard Med Sch, Boston, MA USA. [Wong, J. S.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 280 BP S125 EP S125 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804618 ER PT J AU Kanwar, A Mohamed, ASR Court, LE Zhang, L Marai, GE Canahuate, G Lee, JS Perni, S Messer, JA Pham, BH Youssef, B Vock, D Rao, A Kalpathy-Cramer, J Gunn, GB Rosenthal, DI Fuller, CD AF Kanwar, A. Mohamed, A. S. R. Court, L. E. Zhang, L. Marai, G. E. Canahuate, G. Lee, J. S. Perni, S. Messer, J. A. Pham, B. H. Youssef, B. Vock, D. Rao, A. Kalpathy-Cramer, J. Gunn, G. B. Rosenthal, D. I. Fuller, C. D. TI Development of a Predictive Quantitative Contrast Computed Tomography-Based Feature (Radiomics) Profile for Local Recurrence in Oropharyngeal Cancers SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Kanwar, A.; Zhang, L.; Lee, J. S.; Messer, J. A.; Youssef, B.; Gunn, G. B.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Kanwar, A.] Texas Tech Univ, Hlth Sci Ctr, Sch Med, Lubbock, TX 79430 USA. [Mohamed, A. S. R.; Rosenthal, D. I.; Fuller, C. D.] Univ Texas MD Anderson Canc Ctr, Div Radiat Oncol, Houston, TX 77030 USA. [Court, L. E.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA. [Marai, G. E.] Univ Illinois, Chicago, IL USA. [Canahuate, G.] Univ Iowa, Iowa City, IA USA. [Perni, S.] Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA. [Pham, B. H.] Rosalind Franklin Univ Med & Sci, Chicago Med Sch, N Chicago, IL USA. [Vock, D.] Univ Minnesota, Minneapolis, MN USA. [Rao, A.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA. [Kalpathy-Cramer, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 1064 BP S191 EP S191 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655805068 ER PT J AU Krishnan, MS Shiloh, R Dougherty, P Whitehouse, CM Buckman, A Balboni, TA AF Krishnan, M. S. Shiloh, R. Dougherty, P. Whitehouse, C. M. Buckman, A. Balboni, T. A. TI The TEACHH Model: Clinical Utility of Identifying Patients Living Fewer Than 2 Months SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Krishnan, M. S.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA. [Shiloh, R.; Dougherty, P.; Whitehouse, C. M.; Buckman, A.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Balboni, T. A.] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 1072 BP S194 EP S194 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655805076 ER PT J AU Kunjachan, S Detappe, A Kumar, R Sridhar, S Makrigiorgos, M Berbeco, RI AF Kunjachan, S. Detappe, A. Kumar, R. Sridhar, S. Makrigiorgos, M. Berbeco, R. I. TI Nanoparticle-Mediated Tumor Vascular Disruption: A Novel Strategy in Radiation Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Kunjachan, S.; Detappe, A.; Makrigiorgos, M.; Berbeco, R. I.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. [Kunjachan, S.; Detappe, A.; Makrigiorgos, M.; Berbeco, R. I.] Harvard Med Sch, Boston, MA USA. [Kumar, R.; Sridhar, S.] Northeastern Univ, Nanomed Sci & Technol Ctr, Boston, MA 02115 USA. [Kumar, R.; Sridhar, S.] Northeastern Univ, Dept Phys, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 219 BP S97 EP S97 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804556 ER PT J AU Mak, RH Hermann, G Aerts, H Chen, AB Baldini, EH Kozono, DE Chen, YH Catalano, PJ Janne, P AF Mak, R. H. Hermann, G. Aerts, H. Chen, A. B. Baldini, E. H. Kozono, D. E. Chen, Y. H. Catalano, P. J. Janne, P. TI Outcomes by EGFR, KRAS and ALK Genotype After Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Mak, R. H.] Dana Farber Canc Inst, Brigham & Womens Canc Ctr, Boston, MA 02115 USA. [Hermann, G.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Aerts, H.; Chen, A. B.; Baldini, E. H.; Kozono, D. E.] Harvard Med Sch, Dana Farber Canc Inst, Brigham & Womens Hosp, Boston, MA USA. [Chen, Y. H.; Catalano, P. J.; Janne, P.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 352 BP S156 EP S156 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804690 ER PT J AU McDuff, S Skolny, M Horick, N Miller, C Warren, L Taghian, AG AF McDuff, S. Skolny, M. Horick, N. Miller, C. Warren, L. Taghian, A. G. TI Timing of Lymphedema Following Treatment for Breast Cancer: When Are Patients Most at Risk? SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [McDuff, S.; Warren, L.] Harvard Radiat Oncol Program, Boston, MA USA. [Skolny, M.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Horick, N.; Miller, C.; Taghian, A. G.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 1101 BP S207 EP S207 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655805105 ER PT J AU Mouw, K Braunstein, LZ Kim, J Polak, P Getz, G D'Andrea, AD AF Mouw, K. Braunstein, L. Z. Kim, J. Polak, P. Getz, G. D'Andrea, A. D. TI Somatic ERCC2 Mutations Are Associated With a Distinct Mutational Signature in Muscle-Invasive Bladder Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Mouw, K.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. [Braunstein, L. Z.] Harvard Radiat Oncol Program, Boston, MA USA. [Kim, J.; Polak, P.; Getz, G.] Broad Inst, Cambridge, MA USA. [D'Andrea, A. D.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 120 BP S54 EP S54 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804457 ER PT J AU Ramey, SJ Abramowitz, MC Moghanaki, D Agrawal, S Efstathiou, JA Pisansky, TM Michalski, JM Koontz, BF Hamstra, DA Feng, FY Liauw, S Anscher, MS Pollack, A Den, RB Stephans, KL Kattan, M Gao, T Stephenson, AJ Tendulkar, RD AF Ramey, S. J. Abramowitz, M. C. Moghanaki, D. Agrawal, S. Efstathiou, J. A. Pisansky, T. M. Michalski, J. M. Koontz, B. F. Hamstra, D. A. Feng, F. Y. Liauw, S. Anscher, M. S. Pollack, A. Den, R. B. Stephans, K. L. Kattan, M. Gao, T. Stephenson, A. J. Tendulkar, R. D. TI Benefit of Elective Nodal Irradiation and Androgen Deprivation Therapy with Postprostatectomy Salvage Radiation Therapy for Prostate Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Ramey, S. J.; Abramowitz, M. C.; Pollack, A.] Univ Miami, Miami, FL USA. [Moghanaki, D.] Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA USA. [Agrawal, S.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA. [Efstathiou, J. A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA. [Pisansky, T. M.] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA. [Michalski, J. M.] Washington Univ, Sch Med, St Louis, MO USA. [Koontz, B. F.] Duke Univ, Med Ctr, Durham, NC USA. [Hamstra, D. A.] Texas Oncol, Irving, TX USA. [Feng, F. Y.] Univ Michigan, Ann Arbor, MI 48109 USA. [Feng, F. Y.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Liauw, S.] Univ Chicago, Chicago, IL 60637 USA. [Anscher, M. S.] Virginia Commonwealth Univ, Med Ctr, Richmond, VA USA. [Den, R. B.] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA. [Stephans, K. L.; Gao, T.; Stephenson, A. J.; Tendulkar, R. D.] Cleveland Clin, Cleveland, OH 44106 USA. [Kattan, M.] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 230 BP S102 EP S102 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804567 ER PT J AU Roberts, HJ Krasnow, RE Drumm, MR Niemierko, A Wu, CL Feldman, AS Wszolek, MF Lee, RJ Blute, M Zietman, AL Shipley, WU Efstathiou, JA AF Roberts, H. J. Krasnow, R. E. Drumm, M. R. Niemierko, A. Wu, C. L. Feldman, A. S. Wszolek, M. F. Lee, R. J. Blute, M. Zietman, A. L. Shipley, W. U. Efstathiou, J. A. TI Clinical Outcomes of Combined Modality Bladder-Sparing Therapy for Patients With Histologic Variants of Bladder Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Roberts, H. J.] Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA. [Roberts, H. J.; Krasnow, R. E.; Blute, M.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Drumm, M. R.; Lee, R. J.; Zietman, A. L.; Shipley, W. U.; Efstathiou, J. A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA. [Niemierko, A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Biostat, Boston, MA USA. [Wu, C. L.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Feldman, A. S.; Wszolek, M. F.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Urol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 214 BP S95 EP S95 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804551 ER PT J AU Rose, B Chen, MH Wu, J Braccioforte, MH Moran, BJ Dosoretz, DE Katin, M Ross, R Salenius, S D'Amico, AV AF Rose, B. Chen, M. H. Wu, J. Braccioforte, M. H. Moran, B. J. Dosoretz, D. E. Katin, M. Ross, R. Salenius, S. D'Amico, A. V. TI Androgen Deprivation Therapy Use in the Setting of High-Dose Radiation Therapy and the Risk of Prostate Cancer-Specific Mortality Stratified by the Extent of Competing Mortality SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Rose, B.] Harvard Radiat Oncol Program, Boston, MA USA. [Chen, M. H.; Wu, J.] Univ Connecticut, Storrs, CT USA. [Braccioforte, M. H.; Moran, B. J.] Prostate Canc Fdn Chicago, Westmont, IL USA. [Dosoretz, D. E.; Katin, M.; Ross, R.; Salenius, S.] 21st Century Oncol, Ft Myers, FL USA. [D'Amico, A. V.] Dana Farber Canc Inst, Boston, MA 02115 USA. [D'Amico, A. V.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 313 BP S139 EP S139 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804651 ER PT J AU Sanchez, A Wszolek, MF Drumm, MR Niemierko, A Clayman, RH Rodriguez, D Feldman, AS McGovern, FJ Zietman, AL Heney, NM Shipley, WU Efstathiou, JA AF Sanchez, A. Wszolek, M. F. Drumm, M. R. Niemierko, A. Clayman, R. H. Rodriguez, D. Feldman, A. S. McGovern, F. J. Zietman, A. L. Heney, N. M. Shipley, W. U. Efstathiou, J. A. TI The Natural History of Nonmuscle-Invasive Bladder Cancer Recurrences After Complete Response to Combined-Modality Organ-Preserving Therapy for Muscle-Invasive Bladder Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Sanchez, A.; Wszolek, M. F.; Rodriguez, D.; Feldman, A. S.; McGovern, F. J.; Heney, N. M.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Urol, Boston, MA USA. [Drumm, M. R.; Clayman, R. H.; Zietman, A. L.; Shipley, W. U.; Efstathiou, J. A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA. [Niemierko, A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Biostat, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 215 BP S95 EP S95 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804552 ER PT J AU Sanford, NN Wang, H Goldberg, S Chen, YLE Jacobson, A Choy, E Cote, G Stanton, T Hornicek, FJ DeLaney, TF Harmon, D AF Sanford, N. N. Wang, H. Goldberg, S. Chen, Y. L. E. Jacobson, A. Choy, E. Cote, G. Stanton, T. Hornicek, F. J. DeLaney, T. F. Harmon, D. TI Secondary Leukemia and Myelodysplastic Syndrome in 375 Patients With Ewing Sarcoma and Osteosarcoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Sanford, N. N.] Harvard Radiat Oncol Program, Boston, MA USA. [Wang, H.; Chen, Y. L. E.; Jacobson, A.; DeLaney, T. F.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Goldberg, S.; Cote, G.; Stanton, T.; Hornicek, F. J.; Harmon, D.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Choy, E.] Massachusetts Gen Hosp, Dept Med, Div Hematol Oncol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 55 BP S25 EP S26 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804392 ER PT J AU Sperduto, PW Jiang, W Brown, PD Braunstein, SE Sneed, PK Wattson, DA Shih, HA Bangdiwala, A Shanley, R Lockney, NA Beal, K Lou, E Amatruda, T Sperduto, WA Kirkpatrick, JP Yeh, N Gaspar, LE Molitoris, JK Masucci, L Roberge, D Yu, JB Chiang, VL Mehta, MP AF Sperduto, P. W. Jiang, W. Brown, P. D. Braunstein, S. E. Sneed, P. K. Wattson, D. A. Shih, H. A. Bangdiwala, A. Shanley, R. Lockney, N. A. Beal, K. Lou, E. Amatruda, T. Sperduto, W. A. Kirkpatrick, J. P. Yeh, N. Gaspar, L. E. Molitoris, J. K. Masucci, L. Roberge, D. Yu, J. B. Chiang, V. L. Mehta, M. P. TI The Effect of Gene Mutations on Survival in Patients With Melanoma Following the Development of Brain Metastases SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Sperduto, P. W.] Minneapolis Radiat Oncol PA, Minneapolis, MN USA. [Sperduto, P. W.] Univ Minnesota, Med Ctr, Gamma Knife Ctr, Minneapolis, MN 55455 USA. [Jiang, W.; Brown, P. D.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Braunstein, S. E.; Sneed, P. K.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Wattson, D. A.] Minneapolis Radiat Oncol, Minneapolis, MN USA. [Shih, H. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bangdiwala, A.; Shanley, R.; Lou, E.] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA. [Lockney, N. A.; Beal, K.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. [Amatruda, T.] Minnesota Oncol, Minneapolis, MN USA. [Sperduto, W. A.] Duke Univ, Durham, NC USA. [Kirkpatrick, J. P.] Duke Univ, Med Ctr, Durham, NC USA. [Yeh, N.] Univ Colorado, Aurora, CO USA. [Gaspar, L. E.] Univ Colorado Denver, Dept Radiat Oncol, Aurora, CO USA. [Molitoris, J. K.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Masucci, L.; Roberge, D.] Ctr Hosp Univ Montreal, Montreal, PQ, Canada. [Yu, J. B.] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA. [Chiang, V. L.] Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT USA. [Mehta, M. P.] Baptist Hlth South Florida, Miami Canc Inst, Miami, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 1034 BP S178 EP S178 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655805038 ER PT J AU Spratt, DE Zhao, SG Chang, SL Cooperberg, MR Erho, NG Speers, C Mera, R Niknafs, YS Nguyen, PL Den, RB Dicker, AP Klein, EA Karnes, RJ Schaeffer, EM Davicioni, E Carroll, P Chinnaiyan, A Tomlins, SA Ross, AE Feng, FY AF Spratt, D. E. Zhao, S. G. Chang, S. L. Cooperberg, M. R. Erho, N. G. Speers, C. Mera, R. Niknafs, Y. S. Nguyen, P. L. Den, R. B. Dicker, A. P. Klein, E. A. Karnes, R. J. Schaeffer, E. M. Davicioni, E. Carroll, P. Chinnaiyan, A. Tomlins, S. A. Ross, A. E. Feng, F. Y. TI Identification and Validation of Intrinsic Subtypes of Prostate Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Spratt, D. E.; Zhao, S. G.; Chang, S. L.; Mera, R.; Niknafs, Y. S.; Tomlins, S. A.] Univ Michigan, Ann Arbor, MI 48109 USA. [Cooperberg, M. R.; Carroll, P.; Feng, F. Y.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Erho, N. G.; Davicioni, E.] GenomeDx Biosci, Vancouver, BC, Canada. [Speers, C.] Vet Affairs Hosp Ann Arbor, Ann Arbor, MI USA. [Nguyen, P. L.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. [Nguyen, P. L.] Harvard Med Sch, Boston, MA USA. [Den, R. B.; Dicker, A. P.] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA. [Klein, E. A.] Cleveland Clin, Cleveland, OH 44106 USA. [Karnes, R. J.] Mayo Clin, Rochester, MN USA. [Schaeffer, E. M.; Ross, A. E.] Johns Hopkins Univ, Baltimore, MD USA. [Chinnaiyan, A.] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 6 BP S3 EP S4 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804344 ER PT J AU Underwood, TSA Grassberger, C MacDonald, S Jimenez, RB Paganetti, H AF Underwood, T. S. A. Grassberger, C. MacDonald, S. Jimenez, R. B. Paganetti, H. TI Late-Phase Radiographic Changes in Lung Following Proton Irradiation of the Chest Wall SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Underwood, T. S. A.; Grassberger, C.; MacDonald, S.; Jimenez, R. B.; Paganetti, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Underwood, T. S. A.; Grassberger, C.; Paganetti, H.] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 272 BP S122 EP S122 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804610 ER PT J AU Vatner, RE Weyman, E Goebel, C Ebb, DH Jones, RM Huang, MS MacDonald, S Tarbell, NJ Yock, TI AF Vatner, R. E. Weyman, E. Goebel, C. Ebb, D. H. Jones, R. M. Huang, M. S. MacDonald, S. Tarbell, N. J. Yock, T. I. TI Endocrine Deficiency as a Function of Proton Radiation Dose to the Hypothalamus in Children With Brain Tumors SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Vatner, R. E.; Goebel, C.; Yock, T. I.] Massachusetts Gen Hosp, Dept Radiat Oncol, Francis H Burr Proton Therapy Ctr, Boston, MA 02114 USA. [Weyman, E.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA. [Ebb, D. H.; Huang, M. S.] Massachusetts Gen Hosp, Dept Pediat Oncol, Boston, MA 02114 USA. [Jones, R. M.] Massachusetts Gen Hosp, Dept Pediat Neurol, Boston, MA 02114 USA. [MacDonald, S.; Tarbell, N. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 1160 BP S231 EP S232 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655805163 ER PT J AU Viswanathan, AN Winter, K Miller, BE Xiao, Y Jhingran, A Portelance, L Bosch, WR Matulonis, U Horowitz, N Mannel, R Souhami, L Erickson, BA Small, W Gaffney, DK AF Viswanathan, A. N. Winter, K. Miller, B. E. Xiao, Y. Jhingran, A. Portelance, L. Bosch, W. R. Matulonis, U. Horowitz, N. Mannel, R. Souhami, L. Erickson, B. A. Small, W., Jr. Gaffney, D. K. TI Updated 4-Year Results for NRG Oncology/RTOG 0921: A Phase 2 Study of Postoperative Intensity Modulated Radiation Therapy With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Viswanathan, A. N.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. [Winter, K.] NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA. [Miller, B. E.] Carolinas Med Ctr, Concord, NC USA. [Xiao, Y.] Univ Penn, Philadelphia, PA 19104 USA. [Jhingran, A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Portelance, L.] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Radiat Oncol, Miami, FL USA. [Bosch, W. R.] Washington Univ, Sch Med, St Louis, MO USA. [Matulonis, U.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Horowitz, N.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Mannel, R.] Univ Oklahoma, Hlth Serv Ctr, Oklahoma City, OK USA. [Souhami, L.] McGill Univ, Ctr Hlth, Montreal, PQ, Canada. [Erickson, B. A.] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA. [Small, W., Jr.] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA. [Gaffney, D. K.] Univ Utah, Huntsman Canc Hosp, Salt Lake City, UT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 109 BP S49 EP S50 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804446 ER PT J AU Willers, H Liu, Q Efstathiou, JA Gheorghiu, L Drumm, MR Clayman, RH Eidelman, A Wszolek, MF Feldman, AS Wang, M Marcar, L Citrin, DE Wu, CL Benes, C AF Willers, H. Liu, Q. Efstathiou, J. A. Gheorghiu, L. Drumm, M. R. Clayman, R. H. Eidelman, A. Wszolek, M. F. Feldman, A. S. Wang, M. Marcar, L. Citrin, D. E. Wu, C. L. Benes, C. TI PARP1 Inhibition Radiosensitizes A Subset Of Genotype-Defined Bladder Cancers Through Modulation Of Reactive Oxygen Species SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Willers, H.; Liu, Q.; Efstathiou, J. A.; Gheorghiu, L.; Wang, M.; Marcar, L.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Drumm, M. R.; Clayman, R. H.; Eidelman, A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA. [Wszolek, M. F.; Feldman, A. S.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Urol, Boston, MA USA. [Citrin, D. E.] NCI, Radiat Oncol Branch, Bldg 10, Bethesda, MD 20892 USA. [Wu, C. L.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Benes, C.] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 1175 BP S237 EP S238 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655805178 ER PT J AU Woodward, WA Barlow, WE Jagsi, R Buchholz, TA Shak, S Baehner, F Yoshizawa, CN Whelan, TJ Davidson, NE Ingle, JN King, TA Ravdin, PM Osborne, CK Tripathy, D Livingston, RB Gralow, JR Hortobagyi, GN Hayes, DF Albain, KS AF Woodward, W. A. Barlow, W. E. Jagsi, R. Buchholz, T. A. Shak, S. Baehner, F. Yoshizawa, C. N. Whelan, T. J. Davidson, N. E. Ingle, J. N. King, T. A. Ravdin, P. M. Osborne, C. K. Tripathy, D. Livingston, R. B. Gralow, J. R. Hortobagyi, G. N. Hayes, D. F. Albain, K. S. TI The 21-Gene Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer Treated on SWOG S8814 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Woodward, W. A.; Buchholz, T. A.; Tripathy, D.; Hortobagyi, G. N.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Barlow, W. E.] Canc Res & Biostat, Seattle, WA USA. [Jagsi, R.; Hayes, D. F.] Univ Michigan Hlth Syst, Ann Arbor, MI USA. [Shak, S.; Baehner, F.; Yoshizawa, C. N.] Genom Hlth Inc, Redwood City, CA USA. [Whelan, T. J.] McMaster Univ, Hamilton, ON, Canada. [Davidson, N. E.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. [Ingle, J. N.] Mayo Clin, Rochester, MN USA. [King, T. A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ravdin, P. M.] Univ Texas Hlth Sci Ctr San Antonio, CTRC, San Antonio, TX 78229 USA. [Osborne, C. K.] Baylor Coll Med, Houston, TX 77030 USA. [Livingston, R. B.] Univ Arizona, Tucson, AZ USA. [Gralow, J. R.] Univ Washington, Seattle, WA 98195 USA. [Albain, K. S.] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA. RI Whelan, Timothy/D-3185-2017 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 329 BP S146 EP S146 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804667 ER PT J AU Yard, B Adams, D Tamayo, P Hammerman, P Abazeed, M AF Yard, B. Adams, D. Tamayo, P. Hammerman, P. Abazeed, M. TI A Genetic Basis for Variation in the Vulnerability of Cancer to Ionizing Radiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Yard, B.; Abazeed, M.] Cleveland Clin, Cleveland, OH 44106 USA. [Adams, D.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Tamayo, P.] UCSD, La Jolla, CA USA. [Hammerman, P.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 1117 BP S214 EP S214 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655805121 ER PT J AU Zureick, AH Pulsifer, M Niemierko, A Nichols, AJ Paganetti, H Grassberger, C Fullerton, BC Khan, F Tarbell, NJ MacDonald, S Yock, TI AF Zureick, A. H. Pulsifer, M. Niemierko, A. Nichols, A. J. Paganetti, H. Grassberger, C. Fullerton, B. C. Khan, F. Tarbell, N. J. MacDonald, S. Yock, T. I. TI Elevated Proton Radiation Therapy Dose to Left Temporal Lobe or Whole-Brain Correlates With Decline in Full-Scale IQ Components for Pediatric CNS Tumor Survivors SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Zureick, A. H.; Pulsifer, M.; Niemierko, A.; Nichols, A. J.; Paganetti, H.; Grassberger, C.; Fullerton, B. C.; Khan, F.; Tarbell, N. J.; MacDonald, S.; Yock, T. I.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 268 BP S120 EP S120 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804606 ER PT J AU Basu, PP Fortuzi, K Shehi, E Kavali, L Aloysius, M Shah, N AF Basu, P. Patrick Fortuzi, Ked Shehi, Elona Kavali, Leena Aloysius, Mark Shah, Niraj TI Adult Sucrase-isomaltase Defi ciency (ASID); An Unrecognized Overlap with Functional Bowel Disease (FBD). an Observational Cross-sectional Study SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Basu, P. Patrick] Weill Cornell Med Coll, Ctr Liver Dis & Transplantat, New York Presbyterian, New York, NY USA. [Fortuzi, Ked; Shehi, Elona; Kavali, Leena] Kings Cty Hosp, Med Ctr, New York, NY USA. [Aloysius, Mark] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA. [Shah, Niraj] Univ N Carolina, Sch Med, Carolinas Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 1094 BP S478 EP S478 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764601525 ER PT J AU Basu, PP Aloysius, M Fortuzi, K Kavali, L Shehi, E Shah, N AF Basu, P. Patrick Aloysius, Mark Fortuzi, Ked Kavali, Leena Shehi, Elona Shah, Niraj TI Low Titer Endomysial Antibody (EMA) in Non-celiac Population Segregated from a Community with Immune Mediated Vasculitis. an Observational Study SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Basu, P. Patrick] New York Presbyterian, Weill Cornell Med Coll, Ctr Liver Dis & Transplantat, New York, NY USA. [Aloysius, Mark] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA. [Fortuzi, Ked; Kavali, Leena; Shehi, Elona] Kings Cty Hosp Med Ctr, New York, NY USA. [Shah, Niraj] Univ N Carolina, Sch Med, Carolinas Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 1046 BP S455 EP S455 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764601477 ER PT J AU Basu, PP Fortuzi, K Kavali, L Shehi, E John, N Aloysius, M Shah, N AF Basu, P. Patrick Fortuzi, Ked Kavali, Leena Shehi, Elona John, Nimy Aloysius, Mark Shah, Niraj TI Ombitasvir, Ritanavir Boost with Dastasbuvir and Prataspravir with or without Ribavirin in G1 Special Population in Hemodialysis in Chronic Hepatitis C Patients DROP C Trial: A Prospective Clinical Pilot Study SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Basu, P. Patrick] New York Presbyterian, Weill Cornell Med Coll, Ctr Liver Dis & Transplantat, New York, NY USA. [Fortuzi, Ked; Kavali, Leena; Shehi, Elona; John, Nimy] Kings Cty Hosp, Med Ctr, New York, NY USA. [Aloysius, Mark] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA. [Shah, Niraj] Univ N Carolina, Sch Med, Carolinas Med Ctr, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 880 BP S385 EP S386 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764601313 ER PT J AU Chandradas, S Wayman, C Waalen, J Reidel, W Khalili, H Ananthakrishnan, A Konijeti, G AF Chandradas, Sajiv Wayman, Connor Waalen, Jill Reidel, Warren Khalili, Hamed Ananthakrishnan, Ashwin Konijeti, Gauree TI Does Obesity Influence the Risk of C. difficile Infection Among Patients with Ulcerative Colitis? SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Chandradas, Sajiv; Reidel, Warren] Scripps Clin, San Diego, CA USA. [Wayman, Connor] Scripps Clin, La Jolla, CA 92037 USA. [Waalen, Jill] Scripps Res Inst, Scripps Translat Sci Inst, San Diego, CA USA. [Khalili, Hamed; Ananthakrishnan, Ashwin] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Konijeti, Gauree] Scripps Clin, Scripps Translat Sci Inst, La Jolla, CA 92037 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 661 BP S302 EP S302 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764601096 ER PT J AU Daglilar, E Perepletchikov, A Kozyreva, O AF Daglilar, Ebubekir Perepletchikov, Aleksandr Kozyreva, Olga TI Krukenberg Tumor with Colonic Origin and Normal Colonoscopy: Where Did It Come From? SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Daglilar, Ebubekir] Tufts Univ, Sch Med, St Elizabeths Med Ctr, Brighton, MA USA. [Perepletchikov, Aleksandr] Tufts Univ, Sch Med, St Elizabeths Med Ctr, Brighton, MA USA. [Kozyreva, Olga] Dana Farber Canc Inst, Brighton, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 2599 BP S1308 EP S1310 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764604360 ER PT J AU Dokmak, A Tsipotis, E Skef, W Kozyreva, O AF Dokmak, Amr Tsipotis, Evangelos Skef, Wasseem Kozyreva, Olga TI Hepatic Congestion Mimicking a Liver Tumor in a Patient with Hepatitis B Virus Infection SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Dokmak, Amr] St Elizabeths Med Ctr, Brighton, MA USA. [Tsipotis, Evangelos] St Elizabeths Med Ctr, Boston, MA USA. [Skef, Wasseem] Univ Illinois, Chicago, IL USA. [Kozyreva, Olga] Dana Farber Canc Inst, Brighton, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 1809 BP S867 EP S867 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764603109 ER PT J AU Francis, F Hashash, JG AF Francis, Fadi Hashash, Jana G. TI Incidental Diverticulitis on Surveillance Colonoscopy SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Francis, Fadi] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Hashash, Jana G.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 2620 BP S1321 EP S1321 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764604381 ER PT J AU Francis, F Frye, R Shaikh, O Hashash, JG AF Francis, Fadi Frye, Roy Shaikh, Obaid Hashash, Jana G. TI Cholelithiasis and Cirrhosis in a 28-Year-Old Man SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Francis, Fadi; Frye, Roy; Shaikh, Obaid] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Hashash, Jana G.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 1947 BP S929 EP S930 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764603245 ER PT J AU GarzaOvalle, O Hughston, A Kowalewski, C Kundrotas, L AF GarzaOvalle, Oscar Hughston, Adam Kowalewski, Catherine Kundrotas, Leon TI Inflammatory Bowel Disease and Concomitant SAPHO Syndrome: A Challenging Treatment SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [GarzaOvalle, Oscar; Hughston, Adam] Univ Texas San Antonio, San Antonio, TX USA. [Kowalewski, Catherine; Kundrotas, Leon] Audie L Murphy VA Hosp, South Texas Vet Hlth Care Syst, San Antonio, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 1741 BP S833 EP S833 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764603042 ER PT J AU Imperiale, TF Imler, T Sherer, EA Kahi, C Larson, J Cardwell, J Johnson, CS Antaki, F Ashley, C Baffy, G Cho, I Dominitz, JA Hou, JK Korsten, MA Nagar, AB Patel, S Promrat, K Robertson, D Saini, S Shaw, R Shergill, A Smalley, WE AF Imperiale, Thomas F. Imler, Timothy Sherer, Eric A. Kahi, Charles Larson, Jason Cardwell, Jon Johnson, Cynthia S. Antaki, Fadi Ashley, Christopher Baffy, Gyorgy Cho, Ilseung Dominitz, Jason A. Hou, Jason K. Korsten, Mark A. Nagar, Anil B. Patel, Swati Promrat, Kittichai Robertson, Douglas Saini, Sameer Shaw, Robert Shergill, Amandeep Smalley, Walter E. TI Risk Factors for Advanced Colorectal Neoplasia in Veterans SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Imperiale, Thomas F.; Imler, Timothy] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Sherer, Eric A.] Louisiana Tech Univ, Ruston, LA 71270 USA. [Kahi, Charles; Larson, Jason; Cardwell, Jon] Roudebush VA Med Ctr, Indianapolis, IN USA. [Johnson, Cynthia S.] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN 46202 USA. [Antaki, Fadi] John D Dingell VA Med Ctr, Detroit, MI USA. [Antaki, Fadi] Wayne State Univ, Detroit, MI USA. [Ashley, Christopher] Samuel S Stratton VAMC, Albany, NY USA. [Baffy, Gyorgy] VA Boston HealthCare Syst, Boston, MA USA. [Cho, Ilseung] NYU, New York, NY USA. [Dominitz, Jason A.] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Hou, Jason K.] Baylor Coll Med, Houston, TX 77030 USA. [Korsten, Mark A.] James J Peters VA Med Ctr, Bronx, NY USA. [Nagar, Anil B.] West Haven VA Med Ctr, West Haven, CT USA. [Patel, Swati] Denver VA Med Ctr, Denver, CO USA. [Promrat, Kittichai] Brown Univ, Providence, RI 02912 USA. [Robertson, Douglas] White River Junct VA Med Ctr, White River Jct, VT USA. [Saini, Sameer] Ann Arbor VA Healthcare Syst, Ann Arbor, MI USA. [Shaw, Robert] New York VA Med Ctr, Northport, NY USA. [Shergill, Amandeep] San Francisco VA Med Ctr, San Francisco, CA USA. [Smalley, Walter E.] Nashville VA Med Ctr, Nashville, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 292 BP S136 EP S137 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764600289 ER PT J AU Imperiale, TF Imler, T Sherer, EA Kahi, C Larson, J Cardwell, J Johnson, CS Antaki, F Ashley, C Baffy, G Cho, I Dominitz, JA Hou, JK Korsten, MA Nagar, AB Patel, S Promrat, K Robertson, D Saini, S Shaw, R Shergill, A Smalley, WE AF Imperiale, Thomas F. Imler, Timothy Sherer, Eric A. Kahi, Charles Larson, Jason Cardwell, Jon Johnson, Cynthia S. Antaki, Fadi Ashley, Christopher Baffy, Gyorgy Cho, Ilseung Dominitz, Jason A. Hou, Jason K. Korsten, Mark A. Nagar, Anil B. Patel, Swati Promrat, Kittichai Robertson, Douglas Saini, Sameer Shaw, Robert Shergill, Amandeep Smalley, Walter E. TI An Electronic Medical Record-based Scoring System for Estimating the Risk of Advanced Colorectal Neoplasia in Veterans SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Imperiale, Thomas F.; Imler, Timothy] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [Sherer, Eric A.] Louisiana Tech Univ, Ruston, LA 71270 USA. [Kahi, Charles; Larson, Jason; Cardwell, Jon] Roudebush VA Med Ctr, Indianapolis, IN USA. [Johnson, Cynthia S.] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN 46202 USA. [Antaki, Fadi] John D Dingell VA Med Ctr, Detroit, MI USA. [Antaki, Fadi] Wayne State Univ, Detroit, MI USA. [Ashley, Christopher] Samuel S Stratton VAMC, Albany, NY USA. [Baffy, Gyorgy] VA Boston HealthCare Syst, Boston, MA USA. [Cho, Ilseung] NYU, New York, NY USA. [Dominitz, Jason A.] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Hou, Jason K.] Baylor Coll Med, Houston, TX 77030 USA. [Korsten, Mark A.] James J Peters VA Med Ctr, Bronx, NY USA. [Nagar, Anil B.] West Haven VA Med Ctr, West Haven, CT USA. [Patel, Swati] Denver VA Med Ctr, Denver, CO USA. [Promrat, Kittichai] Brown Univ, Providence, RI 02912 USA. [Robertson, Douglas] White River Junct VA Med Ctr, White River Jct, VT USA. [Saini, Sameer] Ann Arbor VA Healthcare Syst, Ann Arbor, MI USA. [Shaw, Robert] New York VA Med Ctr, Northport, NY USA. [Shergill, Amandeep] San Francisco VA Med Ctr, San Francisco, CA USA. [Smalley, Walter E.] Nashville VA Med Ctr, Nashville, TN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 223 BP S105 EP S106 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764600220 ER PT J AU Imran, A Khosla, M Fidias, P AF Imran, Ali Khosla, Manraj Fidias, Panos TI A Rare Case of Diff use Gastric Cancer with Unique Metastasis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Imran, Ali] Ross Univ, Sch Med, Phoenix, AZ USA. [Khosla, Manraj] Creighton Univ, Sch Med, St Josephs Hosp & Med Ctr, Phoenix, AZ USA. [Fidias, Panos] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 2358 BP S1148 EP S1149 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764604119 ER PT J AU Jacob, N Benhammou, JN Yu, C Shojamanesh, H Merchant, J Lewis, M Metz, DC Sedarat, A Pisegna, J AF Jacob, Noam Benhammou, Jihane N. Yu, Christine Shojamanesh, Homayoun Merchant, Juanita Lewis, Michael Metz, David C. Sedarat, Alireza Pisegna, Joseph TI Characteristics of Duodenal Neuroendocrine Tumors (DNETs) and Establishment of a Natural History and Genetics Registry SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Jacob, Noam; Benhammou, Jihane N.; Yu, Christine; Pisegna, Joseph] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Shojamanesh, Homayoun] Univ Calif Davis, Sch Med, Mather, CA USA. [Merchant, Juanita] Univ Michigan Hlth Syst, Ann Arbor, MI USA. [Lewis, Michael] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Metz, David C.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Sedarat, Alireza] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA. [Sedarat, Alireza] VA GLAHS West Los Angeles Healthcare Ctr, Los Angeles, CA USA. [Shojamanesh, Homayoun] VA Northern Calif Healthcare Syst, Mather, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 1085 BP S474 EP S474 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764601516 ER PT J AU Kaltenbach, T Gawron, A Gupta, S Shergill, A Dominitz, JA Soetikno, R Whooley, M Kahi, C AF Kaltenbach, Tonya Gawron, Andrew Gupta, Samir Shergill, Amandeep Dominitz, Jason A. Soetikno, Roy Whooley, Mary Kahi, Charles TI Screening Indication for Colonoscopy May Not Be Necessary to Measure Adenoma Detection Rates SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Kaltenbach, Tonya; Shergill, Amandeep; Whooley, Mary] Univ Calif San Francisco, VA San Francisco, San Francisco, CA 94143 USA. [Gawron, Andrew] Univ Utah, Sch Med, Salt Lake City, UT USA. [Gawron, Andrew] Salt Lake City VA Healthcare Syst, Salt Lake City, UT USA. [Gupta, Samir] Univ Calif San Diego, VA San Diego Healthcare Syst, San Diego, CA 92103 USA. [Dominitz, Jason A.] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Soetikno, Roy] Singhealth, Singapore, Singapore. [Kahi, Charles] Roudebush VA Med Ctr, Indianapolis, IN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 156 BP S73 EP S74 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764600153 ER PT J AU Kassam, Z Lieberman, A Munoz, R Edelstein, C Osman, M Smith, M Allegretti, JR Panchal, P AF Kassam, Zain Lieberman, Alexandra Munoz, Rodrigo Edelstein, Carolyn Osman, Majdi Smith, Mark Allegretti, Jessica R. Panchal, Pratik TI The Impact of Stool Banks on Access to Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection in the United States: A Geospatial Analysis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Kassam, Zain; Lieberman, Alexandra; Munoz, Rodrigo; Edelstein, Carolyn; Osman, Majdi; Smith, Mark] OpenBiome, Medford, MA USA. [Lieberman, Alexandra] George Washington Univ, Sch Med & Hlth Sci, Medford, MA USA. [Munoz, Rodrigo] Univ Alabama Birmingham, Sch Med, Medford, MA USA. [Allegretti, Jessica R.] Brigham & Womens Hosp, Cambridge, MA USA. [Panchal, Pratik] Massachusetts Gen Hosp, Medford, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 948 BP S410 EP S410 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764601380 ER PT J AU Khosla, M Chow, C Eiben, P Grewal, J Dhillon, S Fidias, P AF Khosla, Manraj Chow, Courtney Eiben, Patrick Grewal, Jaskaran Dhillon, Sonu Fidias, Panos TI Rare Case of Painless Jaundice SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Khosla, Manraj] Creighton Univ, Sch Med, St Josephs Hosp & Med Ctr, Phoenix, AZ USA. [Chow, Courtney] Creighton Univ, Sch Med, Phoenix, AZ USA. [Eiben, Patrick] Jacobi Med Ctr, Phoenix, AZ USA. [Grewal, Jaskaran] Amer Univ Antigua, Miami, FL USA. [Dhillon, Sonu] Univ Illinois Hosp & Hlth Sci Syst, Peoria, IL USA. [Fidias, Panos] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 1172 BP S511 EP S512 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764602021 ER PT J AU Krishna, SG Brugge, WR Dewitt, JM Kongkam, P Napoleon, B Robles-Medranda, C Tan, D El-Dika, S McCarthy, S Walker, J Dillhoff, ME Manilchuk, A Schmidt, C Hart, PA Conwell, DL AF Krishna, Somashekar G. Brugge, William R. Dewitt, John M. Kongkam, Pradermchai Napoleon, Bertrand Robles-Medranda, Carlos Tan, Damien El-Dika, Samer McCarthy, Sean Walker, Jon Dillhoff, Mary E. Manilchuk, Andrei Schmidt, Carl Hart, Philip A. Conwell, Darwin L. TI Needle Based Confocal Laser Endomicroscopy Can Reliably Distinguish Mucinous from Non-mucinous Pancreatic Cystic Lesions: An International External Inter- and Intra-observer Study SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Krishna, Somashekar G.; McCarthy, Sean; Dillhoff, Mary E.; Schmidt, Carl; Hart, Philip A.; Conwell, Darwin L.] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA. [Brugge, William R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Dewitt, John M.] Indiana Univ, Med Ctr, Indianapolis, IN USA. [Kongkam, Pradermchai] Chulalongkorn Univ, Gastrointestinal Endoscopy Excellence Ctr, Bangkok, Thailand. [Kongkam, Pradermchai] King Chulalongkorn Mem Hosp, Bangkok, Thailand. [Napoleon, Bertrand] Hop Prive Jean Mermoz, Gen Sante, Lyon, Rhone Alpes, France. [Robles-Medranda, Carlos] Inst Ecuatoriano Enfermedades Digest, Guayaquil, Guayas, Ecuador. [Tan, Damien] Singapore Gen Hosp, Singapore, Singapore. [El-Dika, Samer] Ohio State Univ, Div Gastroenterol Hepatol & Nutr, Columbus, OH 43210 USA. [Walker, Jon] Ohio State Univ, Coll Med, Columbus, OH 43210 USA. [Manilchuk, Andrei] Ohio State Univ, Columbus, OH 43210 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 3 BP S1 EP S2 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764600004 ER PT J AU Kumar, V Shah, Y Patel, D Khan, N AF Kumar, Vinayak Shah, Yash Patel, Dhruvan Khan, Nabeel TI Clinical Course of Patients with a New Age Threshold for Elderly Onset Ulcerative Colitis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Kumar, Vinayak] Univ Penn, Perelman Sch Med, Collegeville, PA USA. [Shah, Yash; Khan, Nabeel] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Patel, Dhruvan] Mercy Catholic Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 585 BP S269 EP S269 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764601020 ER PT J AU Lawitz, E Kowdley, K Curry, M Reau, N Nguyen, M Kwo, P Jacobson, IM Tran, T Nahass, R Hinestrosa, F Herring, R Bennett, M Llewellyn, J Yang, J Stamm, L Brainard, DM McHutchison, JG Schiff, E Davis, M Etzkorn, K Chung, R Pound, D Rodriguez-Torres, M Reddy, KR Gane, E AF Lawitz, Erik Kowdley, Kris Curry, Michael Reau, Nancy Nguyen, Mindie Kwo, Paul Jacobson, Ira M. Tran, Tram Nahass, Ronald Hinestrosa, Frederico Herring, Robert Bennett, Michael Llewellyn, Joseph Yang, Jenny Stamm, Luisa Brainard, Diana M. McHutchison, John G. Schiff, Eugene Davis, Mitchell Etzkorn, Kyle Chung, Raymond Pound, David Rodriguez-Torres, Maribel Reddy, K. Rajender Gane, Edward TI High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Lawitz, Erik] Texas Liver Inst, Dallas, TX USA. [Kowdley, Kris] Swedish Med Ctr, Seattle, WA USA. [Curry, Michael] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA USA. [Reau, Nancy] Rush Univ, Med Ctr, Chicago, IL 60612 USA. [Nguyen, Mindie] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA. [Kwo, Paul] Indiana Univ, Med Ctr, Indianapolis, IN USA. [Jacobson, Ira M.] Mt Sinai Beth Israel Hosp, New York, NY USA. [Tran, Tram] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Nahass, Ronald] Infect Dis Care, Hillsborough, NJ USA. [Hinestrosa, Frederico] Orlando Immunol Ctr, Orlando, FL USA. [Herring, Robert] Nashville Gastrointestinal Specialists Inc, Nashville, TN USA. [Bennett, Michael] Med Associates Res Grp, San Diego, CA USA. [Llewellyn, Joseph] Gilead Sci Inc, San Francisco, CA USA. [Yang, Jenny; Stamm, Luisa; Brainard, Diana M.; McHutchison, John G.] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA. [Schiff, Eugene] Univ Miami Hlth Syst, Miami, FL USA. [Davis, Mitchell] South Florida Ctr Gastroenterol, Digest Care, Wellington, FL USA. [Etzkorn, Kyle] Borland Groover Clin, Jacksonville, FL USA. [Chung, Raymond] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Pound, David] Indianapolis Gastroenterol Res Fdn, Indianapolis, IN USA. [Rodriguez-Torres, Maribel] Fdn Invest Diego, San Juan, PR USA. [Reddy, K. Rajender] Univ Penn Hlth Syst, Philadelphia, PA USA. [Gane, Edward] Auckland Clin Studies, Auckland, New Zealand. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 868 BP S380 EP S380 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764601301 ER PT J AU Leung, F Cadoni, S Falt, P Hsieh, YH Amato, A Erriu, M Fojtik, P Gallittu, P Hu, CT Koo, M Liggi, M Paggi, S Radaelli, F Rondonotti, E Smajstrla, V Tseng, CW Urban, O Leung, J AF Leung, Felix Cadoni, Sergio Falt, Premysl Hsieh, Yu-Hsi Amato, Arnaldo Erriu, Matteo Fojtik, Petr Gallittu, Paolo Hu, Chi-Tan Koo, Malcolm Liggi, Mauro Paggi, Silvia Radaelli, Franco Rondonotti, Emanuele Smajstrla, Vit Tseng, Chih-Wei Urban, Ondrej Leung, Joseph TI Randomized Controlled Trials Confirm Water Exchange to Be Significantly Superior in Quality of Bowel Cleansing and Adenoma Detection Rate Compared to Water Immersion and Air Insufflation, Even Aft er Split-Dose Preparation SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Leung, Felix] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA. [Leung, Felix] Univ Calif Los Angeles, David Geffen Sch Med, North Hills, CA USA. [Cadoni, Sergio; Gallittu, Paolo; Liggi, Mauro] CTO Hosp, Digest Endoscopy Unit, Iglesias, Sardegna, Italy. [Falt, Premysl; Fojtik, Petr; Smajstrla, Vit; Urban, Ondrej] Vitkovice Hosp, Ctr Digest Dis, Ostrava, Moravskoslezsky, Czech Republic. [Hsieh, Yu-Hsi; Tseng, Chih-Wei] Buddhist Tzu Chi Univ, Sch Med, Chiayi, Taiwan. [Hsieh, Yu-Hsi; Tseng, Chih-Wei] Dalin Tzu Chi Hosp, Div Gastroenterol, Buddhist Tzu Chi Med Fdn, Chiayi, Taiwan. [Amato, Arnaldo] Valduce Hosp, Gastroenterol, Como, Lombardia, Italy. [Erriu, Matteo] Univ Cagliari, Dept Surg, Cagliari, Sardegna, Italy. [Hu, Chi-Tan] Buddhist Tzu Chi Univ, Sch Med, Hualien, Taiwan. [Hu, Chi-Tan] Hualien Tzu Chi Hosp, Gastroenterol, Hualien, Taiwan. [Hu, Chi-Tan] Tzu Chi Univ, Hualien, Taiwan. [Koo, Malcolm] Dalin Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Dept Med Res, Chiayi, Taiwan. [Koo, Malcolm] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada. [Paggi, Silvia; Radaelli, Franco; Rondonotti, Emanuele] Valduce Hosp, Div Gastroenterol, Como, Lombardia, Italy. [Leung, Joseph] Sacramento VA Med Ctr, Sacramento, CA USA. [Leung, Joseph] Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 247 BP S116 EP S116 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764600244 ER PT J AU Leung, J Pearcy, J Yen, AW Leung, F AF Leung, Joseph Pearcy, Jaymie Yen, Andrew W. Leung, Felix TI Cap-Assisted Total Water (CATW) Colonocopy Further Improved Proximal ADR Than Cap-Assisted Water Exchange (CAWE) Colonoscopy in Screening and Surveillance Colonoscopy SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Leung, Joseph] Sacramento VA Med Ctr, VANCHCS, Sacramento, CA USA. [Pearcy, Jaymie; Yen, Andrew W.] Sacramento VA Med Ctr, Mather, CA USA. [Yen, Andrew W.] Univ Calif Davis, Sch Med, Mather, CA USA. [Leung, Felix] VA Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, North Hills, CA USA. [Leung, Felix] Univ Calif Los Angeles, David Geffen Sch Med, North Hills, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 213 BP S102 EP S102 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764600210 ER PT J AU Lin, L Yu, C Lally, K Oh, D Lewis, M May, F Pisegna, J AF Lin, Lisa Yu, Christine Lally, Kimberly Oh, David Lewis, Michael May, Folasade Pisegna, Joseph TI Colorectal Adenocarcinomas with Positive Immunohistochemical NET Features: A Descriptive Study of Their Clinical Behavior SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Lin, Lisa; Yu, Christine; May, Folasade; Pisegna, Joseph] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Lally, Kimberly] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Oh, David] Univ Calif Los Angeles, Los Angeles, CA USA. [Lewis, Michael] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 206 BP S99 EP S100 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764600203 ER PT J AU Ohning, G Jensen, D Kovacs, O Ghassemi, K Jutabha, R Machicado, G Dulai, G Sedarat, A AF Ohning, Gordon Jensen, Dennis Kovacs, Omas Ghassemi, Kevin Jutabha, Rome Machicado, Gustavo Dulai, Gareth Sedarat, Alireza TI Long-term Outcomes in Patients with Diverticular Hemorrhage Based upon Initial Diagnosis with Urgent Colonoscopy and Different Treatments SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Ohning, Gordon; Jensen, Dennis; Sedarat, Alireza] West Los Angeles Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Ohning, Gordon; Jensen, Dennis; Kovacs, Omas; Jutabha, Rome; Machicado, Gustavo; Dulai, Gareth; Sedarat, Alireza] Univ Calif Los Angeles, David Geffen Sch Med, CURE Digest Dis Res Ctr, Los Angeles, CA 90095 USA. [Ghassemi, Kevin] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA. [Machicado, Gustavo] VA GLAHS West Los Angeles Healthcare Ctr, Van Nuys, CA USA. [Machicado, Gustavo; Dulai, Gareth] VA GLAHS West Los Angeles Healthcare Ctr, Downey, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 157 BP S74 EP S74 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764600154 ER PT J AU Patel, D Khan, N Shah, Y Yang, YX AF Patel, Dhruvan Khan, Nabeel Shah, Yash Yang, Yu-Xiao TI A Prediction Model for Incident Moderate to Severe Anemia and Iron Deficiency Anemia in Patients with Newly Diagnosed Ulcerative Colitis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Patel, Dhruvan] Mercy Catholic Med Ctr, Philadelphia, PA USA. [Khan, Nabeel; Shah, Yash] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Yang, Yu-Xiao] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 743 BP S333 EP S334 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764601176 ER PT J AU Perez, BL Trivedi, H Krishnan, S Lee, D Kozyreva, O AF Perez, Blanca Lizaola Trivedi, Hirsh Krishnan, Sandeep Lee, David Kozyreva, Olga TI Combined Hepatocellular and Cholangiocarcinoma Arising from the Retroperitoneum with Favorable Response to Systemic Chemotherapy with GemOX-B SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Perez, Blanca Lizaola; Trivedi, Hirsh] Tufts Univ, St Elizabeths Med Ctr, Sch Med, Brighton, MA USA. [Krishnan, Sandeep] St Elizabeths Med Ctr, Brighton, MA USA. [Lee, David] Tufts Univ, Sch Med, St Elizabeths Med Ctr, Boston, MA 02111 USA. [Kozyreva, Olga] Dana Farber Canc Inst, Brighton, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 1994 BP S951 EP S951 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764603292 ER PT J AU Pimienta, M Lotshaw, E Elperin, J Malla, S Ohmuraya, M Mareninova, O Gukovskaya, A Gukovsky, I AF Pimienta, Michael Lotshaw, Ethan Elperin, Jason Malla, Sudarshan Ohmuraya, Masaki Mareninova, Olga Gukovskaya, Anna Gukovsky, Ilya TI p62/SQSTM1, a Key Autophagy Mediator, Is Regulated in Pancreatitis Through mTOR-Mediated Pathways SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Pimienta, Michael] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Sherman Oaks, CA USA. [Pimienta, Michael] Southern Calif Res Ctr ALPD & Cirrhosis, Sherman Oaks, CA USA. [Lotshaw, Ethan; Malla, Sudarshan; Mareninova, Olga; Gukovskaya, Anna; Gukovsky, Ilya] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Lotshaw, Ethan; Malla, Sudarshan; Mareninova, Olga; Gukovskaya, Anna; Gukovsky, Ilya] Southern Calif Res Ctr ALPD & Cirrhosis, Los Angeles, CA USA. [Elperin, Jason] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Calabasas, CA USA. [Elperin, Jason] Southern Calif Res Ctr ALPD & Cirrhosis, Calabasas, CA USA. [Ohmuraya, Masaki] Kumamoto Univ, Kyoto, Japan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 32 BP S14 EP S14 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764600032 ER PT J AU Refaai, M Straub, S Falcon, J Sarode, R Goldstein, J Kothari, TH Brainsky, A Omert, L Lee, M Milling, T AF Refaai, Majed Straub, Shana Falcon, Jacob Sarode, Ravi Goldstein, Joshua Kothari, Truptesh H. Brainsky, Andres Omert, Laurel Lee, Martin Milling, Truman TI 4-Factor Prothrombin Complex Concentrate Reduces Time to Procedure in Vitamin K Antagonist-Treated Patients Experiencing Gastrointestinal Bleeding SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Refaai, Majed; Straub, Shana] Univ Rochester, Med Ctr, Rochester, NY 14642 USA. [Falcon, Jacob; Milling, Truman] Univ Med Ctr Brackenridge, Dell Childrens Med Ctr, Stroke Inst, Seton Dell Med Sch, Austin, TX USA. [Sarode, Ravi] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. [Goldstein, Joshua] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Kothari, Truptesh H.] Univ Rochester, Med Ctr, Ctr Adv Therapeut Endoscopy, Div Gastroenterol & Hepatol, Rochester, NY 14642 USA. [Brainsky, Andres; Omert, Laurel] CSL Behring, King Of Prussia, PA USA. [Lee, Martin] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 930 BP S402 EP S403 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764601362 ER PT J AU Singh, H Moghe, A Mcgrath, K Khalid, A Chennat, J Brand, R Fasanella, K AF Singh, Harkirat Moghe, Akshata Mcgrath, Kevin Khalid, Asif Chennat, Jennifer Brand, Randall Fasanella, Kenneth TI Annual Surveillance of Small Gastric Stomal Tumors Is Unnecessarily Frequent SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Singh, Harkirat; Moghe, Akshata; Mcgrath, Kevin; Chennat, Jennifer; Brand, Randall; Fasanella, Kenneth] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Khalid, Asif] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 1119 BP S489 EP S489 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764601550 ER PT J AU Turner, K Spechler, SJ Sonnenberg, A Genta, RM AF Turner, Kevin Spechler, Stuart J. Sonnenberg, Amnon Genta, Robert M. TI Incidental Goblet Cells at the Gastroesophageal Junction: Intestinal Metaplasia of the Esophagus or Stomach? SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Turner, Kevin; Genta, Robert M.] Miraca Life Sci Res Inst, Irving, TX USA. [Spechler, Stuart J.] Dallas VA Med Ctr, Dallas, TX USA. [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 464 BP S209 EP S209 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764600459 ER PT J AU Turner, K Genta, RM Lash, R Sonnenberg, A AF Turner, Kevin Genta, Robert M. Lash, Richard Sonnenberg, Amnon TI Colorectal Polyps: Lesions of All Types Exist in Polyps of All Sizes SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Turner, Kevin; Genta, Robert M.; Lash, Richard] Miraca Life Sci Res Inst, Irving, TX USA. [Sonnenberg, Amnon] Portland VA Med Ctr, Portland, OR USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 152 BP S72 EP S72 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764600149 ER PT J AU Vachon, AI Francis, F Handzel, R Beasley, HS Holtzman, MP Hashash, JG AF Vachon, Ashley I. Francis, Fadi Handzel, Robert Beasley, H. Scott. Holtzman, Matthew P. Hashash, Jana G. TI Perforated Hemorrhagic Cholecystitis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Vachon, Ashley I.; Handzel, Robert; Beasley, H. Scott.; Holtzman, Matthew P.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Francis, Fadi] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Hashash, Jana G.] Univ Pittsburgh, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 1222 BP S536 EP S537 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764602071 ER PT J AU Venkatesh, R Campbell, E Thiim, M Rao, S Ferris, T Wasfy, J Richter, J AF Venkatesh, Rajitha Campbell, Emily Thiim, Michael Rao, Sandhya Ferris, Timothy Wasfy, Jason Richter, James TI An Innovative Approach: Implementation of an Asynchronous Pilot Adult Gastroenterology E-Consult Program SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Venkatesh, Rajitha] Massachusetts Gen Hosp Children, Boston, MA USA. [Campbell, Emily; Thiim, Michael; Rao, Sandhya; Ferris, Timothy; Wasfy, Jason; Richter, James] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 940 BP S407 EP S408 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764601372 ER PT J AU Wayman, C Chandradas, S Waalen, J Khalili, H Ananthakrishnan, A Ghorbani, S Singh, E Konijeti, G AF Wayman, Connor Chandradas, Sajiv Waalen, Jill Khalili, Hamed Ananthakrishnan, Ashwin Ghorbani, Shireen Singh, Emily Konijeti, Gauree TI Influence of Age and Gender on Assessment of IBD Quality Measures in Patients with Ulcerative Colitis SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Wayman, Connor] Scripps Clin, La Jolla, CA 92037 USA. [Chandradas, Sajiv; Singh, Emily] Scripps Clin, San Diego, CA USA. [Waalen, Jill] Scripps Res Inst, Scripps Translat Sci Inst, San Diego, CA USA. [Khalili, Hamed; Ananthakrishnan, Ashwin] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Ghorbani, Shireen] Sharp Rees Stealy Med Grp, San Diego, CA USA. [Konijeti, Gauree] Scripps Translat Sci Inst, Scripps Clin, La Jolla, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 626 BP S289 EP S289 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764601061 ER PT J AU Weber, HC Sachdev, R Patel, G Singh, V Haroon, M Strymish, J Gupte, G AF Weber, Horst C. Sachdev, Rishabh Patel, Gayatri Singh, Vikram Haroon, Mustafa Strymish, Judith Gupte, Gouri TI Utilization of Gastroenterology Electronic Consultations in the Veteran Administration Boston Healthcare System SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Weber, Horst C.] Boston Med Ctr, Jamaica Plain, MA USA. [Sachdev, Rishabh; Patel, Gayatri; Singh, Vikram; Haroon, Mustafa] Boston Med Ctr, Boston, MA USA. [Strymish, Judith] VA Boston HealthCare Syst, West Roxbury, MA USA. [Gupte, Gouri] Boston Univ, Sch Publ Hlth, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 1053 BP S458 EP S458 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764601484 ER PT J AU Wheat, CL Gunnink, E Paski, S Dominitz, JA Lynge, D Zhou, XH Zeliadt, S AF Wheat, Chelle L. Gunnink, Eric Paski, Shirley Dominitz, Jason A. Lynge, Dana Zhou, Xiao-Hua (Andrew) Zeliadt, Steven TI Variation in Complications and Costs from Colorectal Resections Across VA Facilities SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Meeting Abstract CT 81st Annual Scientific Meeting of the American-College-of-Gastroenterology CY OCT 21-26, 2016 CL Las Vegas, NV SP Amer Coll Gastroenterol C1 [Wheat, Chelle L.; Gunnink, Eric; Paski, Shirley; Dominitz, Jason A.; Lynge, Dana; Zhou, Xiao-Hua (Andrew); Zeliadt, Steven] VA Puget Sound Healthcare Syst, Seattle, WA USA. FU VA Health Services Research & Development IIR research grant [IIR-10 365] FX This research is supported by a VA Health Services Research & Development IIR research grant IIR-10 365 (Zhou). NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 SU 1 MA 941 BP S408 EP S408 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN1IV UT WOS:000395764601373 ER PT J AU Cai, L Michelakos, T Fernandez-del Castillo, C Warshaw, AL Lillemoe, KD Ferrone, S Mino-Kenudson, M Ferrone, CR AF Cai, Lei Michelakos, Theodoros Fernandez-del Castillo, Carlos Warshaw, Andrew L. Lillemoe, Keith D. Ferrone, Soldano Mino-Kenudson, Mari Ferrone, Cristina R. TI Potential Role of NK Cells in Progression of Intraductal Papillary Mucinous Neoplasms (IPMN) SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT Clinical Congress and Scientific Forum of the American-College-of-Surgeons CY OCT 15-20, 2016 CL Washington, DC SP Amer Coll Surg C1 [Cai, Lei; Michelakos, Theodoros; Fernandez-del Castillo, Carlos; Warshaw, Andrew L.; Lillemoe, Keith D.; Ferrone, Soldano; Mino-Kenudson, Mari; Ferrone, Cristina R.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2016 VL 223 IS 4 SU 2 BP E142 EP E143 PG 2 WC Surgery SC Surgery GA EN2FL UT WOS:000395825100314 ER PT J AU Dolgin, NH Martins, PNA Adler, JT Bozorgzadeh, A AF Dolgin, Natasha H. Martins, Paulo N. A. Adler, Joel T. Bozorgzadeh, Adel TI 'Weekend Bias' Increases Likelihood of Donor Organ Discard: A National Analysis SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT Clinical Congress and Scientific Forum of the American-College-of-Surgeons CY OCT 15-20, 2016 CL Washington, DC SP Amer Coll Surg C1 UMass Med Sch, Worcester, MA USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2016 VL 223 IS 4 SU 2 BP E189 EP E189 PG 1 WC Surgery SC Surgery GA EN2FL UT WOS:000395825100418 ER PT J AU Liu, YM Inoue, Y Otawara, M Yu, YM Chang, PH Tompkins, RG Vakoc, B Goverman, J Irimia, D AF Liu, Yuk M. Inoue, Yoshitaka Otawara, Masayuki Yu, Yong-Ming Chang, Philip H. Tompkins, Ronald G. Vakoc, Benjamin Goverman, Jeremy Irimia, Daniel TI Secondary Wound Necrosis is Suppressed by Resolvin D2 SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT Clinical Congress and Scientific Forum of the American-College-of-Surgeons CY OCT 15-20, 2016 CL Washington, DC SP Amer Coll Surg C1 [Liu, Yuk M.; Inoue, Yoshitaka; Otawara, Masayuki; Yu, Yong-Ming; Chang, Philip H.; Tompkins, Ronald G.; Vakoc, Benjamin; Goverman, Jeremy; Irimia, Daniel] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2016 VL 223 IS 4 SU 2 BP E55 EP E55 PG 1 WC Surgery SC Surgery GA EN2FL UT WOS:000395825100118 ER PT J AU Michelakos, T Cai, L Goyal, L Zhu, AX Tanabe, KK Ferrone, S Ferrone, CR AF Michelakos, Theodoros Cai, Lei Goyal, Lipika Zhu, Andrew X. Tanabe, Kenneth K. Ferrone, Soldano Ferrone, Cristina R. TI Glucose-Regulated Protein of 94kDa (Grp94)-Targeted Antibody-Based Combinatorial Immunotherapy for Intrahepatic Cholangiocarcinoma SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT Clinical Congress and Scientific Forum of the American-College-of-Surgeons CY OCT 15-20, 2016 CL Washington, DC SP Amer Coll Surg C1 [Michelakos, Theodoros; Cai, Lei; Goyal, Lipika; Zhu, Andrew X.; Tanabe, Kenneth K.; Ferrone, Soldano; Ferrone, Cristina R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2016 VL 223 IS 4 SU 2 BP E136 EP E137 PG 2 WC Surgery SC Surgery GA EN2FL UT WOS:000395825100298 ER PT J AU Peponis, T Bohnen, JD Sangji, NF Nandan, AR Martinez-Aguilar, MM Han, K de Moya, M Velmahos, GC Chang, DC Kaafarani, HM AF Peponis, Thomas Bohnen, Jordan D. Sangji, Naveen F. Nandan, Anirudh R. Martinez-Aguilar, Myriam M. Han, Kelsey de Moya, Marc Velmahos, George C. Chang, David C. Kaafarani, Haytham M. TI Does the Emergency Surgery Acuity Score (ESAS) Accurately Predict Outcomes in Emergent Laparotomies? SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT Clinical Congress and Scientific Forum of the American-College-of-Surgeons CY OCT 15-20, 2016 CL Washington, DC SP Amer Coll Surg C1 [Peponis, Thomas; Bohnen, Jordan D.; Sangji, Naveen F.; Nandan, Anirudh R.; Martinez-Aguilar, Myriam M.; Han, Kelsey; de Moya, Marc; Velmahos, George C.; Chang, David C.; Kaafarani, Haytham M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2016 VL 223 IS 4 SU 2 BP E18 EP E19 PG 2 WC Surgery SC Surgery GA EN2FL UT WOS:000395825100039 ER PT J AU Thompson, R Thornblade, LW Khor, S Flum, DR Sobel, M AF Thompson, Rachel Thornblade, Lucas W. Khor, Sara Flum, David R. Sobel, Michael TI Patterns of Inflammation in Patients with Hyperglycemia after Vascular Surgery SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract CT Clinical Congress and Scientific Forum of the American-College-of-Surgeons CY OCT 15-20, 2016 CL Washington, DC SP Amer Coll Surg C1 VA Puget Sound Hlth Care Syst, Seattle, WA USA. Univ Nebraska Med Ctr, Omaha, NE USA. Univ Washington, Med Ctr, Seattle, WA 98195 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2016 VL 223 IS 4 SU 2 BP E61 EP E62 PG 2 WC Surgery SC Surgery GA EN2FL UT WOS:000395825100132 ER PT J AU Adeduntan, R Francis, S Meyersohn, N Gallotto, S Redd, R Hochberg, E Winkfield, KM AF Adeduntan, R. Francis, S. Meyersohn, N. Gallotto, S. Redd, R. Hochberg, E. Winkfield, K. M. TI Comparison of Coronary Artery Calcification in Patients Who Received Proton Versus Photon Radiation for Treatment of Mediastinal Lymphoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Adeduntan, R.; Gallotto, S.; Winkfield, K. M.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Francis, S.] Massachusetts Gen Hosp, Div Cardiooncol, Boston, MA 02114 USA. [Meyersohn, N.] Massachusetts Gen Hosp, Div Cardiac Imaging, Boston, MA 02114 USA. [Redd, R.] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA. [Hochberg, E.] Massachusetts Gen Hosp, Div Med Oncol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3218 BP E496 EP E496 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655803530 ER PT J AU Agrawal, V Coroller, TP Hou, Y Lee, S Romano, J Baldini, EH Chen, AB Kozono, DE Swanson, SJ Wee, J Aerts, H Mak, RH AF Agrawal, V. Coroller, T. P. Hou, Y. Lee, S. Romano, J. Baldini, E. H. Chen, A. B. Kozono, D. E. Swanson, S. J. Wee, J. Aerts, H. Mak, R. H. TI Mediastinal Lymph Node Volume Is Associated With Locoregional Recurrence and Overall Survival in Stage IIIA-IIIB Non-Small Cell Lung Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Agrawal, V.; Coroller, T. P.; Hou, Y.; Lee, S.; Romano, J.; Baldini, E. H.; Chen, A. B.; Kozono, D. E.; Swanson, S. J.; Wee, J.; Aerts, H.; Mak, R. H.] Harvard Med Sch, Dana Farber Canc Inst, Brigham & Womens Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3111 BP E451 EP E451 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655803423 ER PT J AU Baldwin, P Van De Ven, AL Seitzer, N Clohessy, S Cormack, RA Makrigiorgos, M Pandolfi, PP Sridhar, S AF Baldwin, P. Van De Ven, A. L. Seitzer, N. Clohessy, S. Cormack, R. A. Makrigiorgos, M. Pandolfi, P. P. Sridhar, S. TI Nanoformulation of the PARP Inhibitor Olaparib Enables Radiosensitization of a Radiation-Resistant Prostate Cancer Model SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Baldwin, P.; Van De Ven, A. L.] Northeastern Univ, Boston, MA 02115 USA. [Seitzer, N.; Clohessy, S.; Pandolfi, P. P.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Seitzer, N.; Clohessy, S.; Cormack, R. A.; Makrigiorgos, M.; Pandolfi, P. P.] Harvard Med Sch, Boston, MA USA. [Cormack, R. A.; Makrigiorgos, M.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. [Sridhar, S.] Northeastern Univ, Nanomed Sci & Technol Ctr, Boston, MA 02115 USA. [Sridhar, S.] Northeastern Univ, Dept Phys, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3460 BP E595 EP E595 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804040 ER PT J AU Coroller, TP Agrawal, V Narayan, V Grossmann, P Hou, Y Lee, S Mak, RH Aerts, H AF Coroller, T. P. Agrawal, V. Narayan, V. Grossmann, P. Hou, Y. Lee, S. Mak, R. H. Aerts, H. TI Radiomics Predict Pathological Response in Non-Small Cell Lung Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Coroller, T. P.; Agrawal, V.; Narayan, V.; Grossmann, P.; Hou, Y.; Lee, S.; Aerts, H.] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA. [Mak, R. H.] Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3436 BP E586 EP E586 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804016 ER PT J AU Drapek, LC AF Drapek, L. C. TI An International Collaborative Design of Clinical Nursing Practice Guidelines for Care of Patients With Cholangiocarcinoma Receiving Chemotherapy and Radiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Drapek, L. C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3242 BP E506 EP E506 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655803554 ER PT J AU Elnahal, SM Peabody, H Ippolito, A Littlefield, P Clancy, C Shulkin, D AF Elnahal, S. M. Peabody, H. Ippolito, A. Littlefield, P. Clancy, C. Shulkin, D. TI Diffusing Oncology Care Model Best Practices Across America's Largest Integrated Hospital System SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Elnahal, S. M.] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD USA. [Peabody, H.] Atlas Res, Washington, DC USA. [Ippolito, A.; Littlefield, P.; Clancy, C.; Shulkin, D.] US Dept Vet Affairs, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2980 BP E397 EP E398 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655803294 ER PT J AU Ermoian, RP Breneman, JC Walterhouse, DO Meza, JL Anderson, J Hawkins, DS Hayes-Jordan, AA Yock, TI Donaldson, SS Wolden, SL AF Ermoian, R. P. Breneman, J. C. Walterhouse, D. O. Meza, J. L. Anderson, J. Hawkins, D. S. Hayes-Jordan, A. A. Yock, T. I. Donaldson, S. S. Wolden, S. L. TI Is 45 Gy a Sufficient Radiation Therapy Dose for Unresected Orbital Embryonal Rhabdomyosarcoma? A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Ermoian, R. P.] Univ Washington, Dept Radiat Oncol, Seattle, WA 98195 USA. [Breneman, J. C.] Univ Cincinnati, Cincinnati, OH USA. [Walterhouse, D. O.] Lurie Childrens Hosp, Chicago, IL USA. [Meza, J. L.] Univ Nebraska, Dept Biostat, Omaha, NE 68182 USA. [Anderson, J.] Merck & Co Inc, Madison, WI USA. [Hawkins, D. S.] Univ Washington, Dept Pediat, Div Hematol Oncol, Seattle, WA 98195 USA. [Hawkins, D. S.; Hayes-Jordan, A. A.] Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, Houston, TX 77030 USA. [Yock, T. I.] Massachusetts Gen Hosp, Dept Radiat Oncol, Francis H Burr Proton Therapy Ctr, Boston, MA 02114 USA. [Donaldson, S. S.] Stanford Canc Inst, Stanford, CA USA. [Wolden, S. L.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3344 BP E548 EP E548 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655803656 ER PT J AU Franco, I Romano, J Chipidza, F Baldini, EH Chen, AB Chen, YH Colson, Y Hou, Y Kozono, DE Wee, J Mak, RH AF Franco, I. Romano, J. Chipidza, F. Baldini, E. H. Chen, A. B. Chen, Y. H. Colson, Y. Hou, Y. Kozono, D. E. Wee, J. Mak, R. H. TI Modified Frailty Index as a Predictor of Overall and Other Cause-Specific Survival in Early-Stage Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Franco, I.; Baldini, E. H.; Chen, A. B.; Colson, Y.; Hou, Y.; Kozono, D. E.; Wee, J.; Mak, R. H.] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA. [Romano, J.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Chipidza, F.] Harvard Med Sch, Boston, MA USA. [Chen, Y. H.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3107 BP E449 EP E450 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655803419 ER PT J AU Geng, C Daartz, J Cheung, KLT Bussiere, MR Shih, HA Paganetti, H Schuemann, JP AF Geng, C. Daartz, J. Cheung, K. Lam Tin Bussiere, M. R. Shih, H. A. Paganetti, H. Schuemann, J. P. TI Dosimetric Uncertainties and Their Impact on Treatment Planning in Stereotactic Proton Radiosurgery SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Geng, C.; Daartz, J.; Cheung, K. Lam Tin; Bussiere, M. R.; Schuemann, J. P.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Shih, H. A.; Paganetti, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3517 BP E618 EP E618 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804097 ER PT J AU Huynh, E Coroller, TP Narayan, V Agrawal, V Hou, Y Romano, J Franco, I Mak, RH Aerts, H AF Huynh, E. Coroller, T. P. Narayan, V. Agrawal, V. Hou, Y. Romano, J. Franco, I. Mak, R. H. Aerts, H. TI Radiomics Analysis of Stereotactic Body Radiation Therapy Patients With Lung Cancer Predicts Recurrent Disease SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Huynh, E.; Coroller, T. P.; Narayan, V.; Agrawal, V.; Hou, Y.; Franco, I.; Aerts, H.] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA. [Romano, J.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Mak, R. H.] Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3434 BP E585 EP E585 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804014 ER PT J AU Jamorabo, D Chang, DT Bennett, K Zietman, AL Jabbour, SK AF Jamorabo, D. Chang, D. T. Bennett, K. Zietman, A. L. Jabbour, S. K. TI Can Gender Predict Differences in Behavior, Manuscript Ratings, and Quality of Reviews Among Red Journal Reviewers? SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Jamorabo, D.] Univ Med & Dent New Jersey, New Brunswick, NJ USA. [Chang, D. T.] Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA. [Bennett, K.] ASTRO, Arlington, VA USA. [Zietman, A. L.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA. [Jabbour, S. K.] Rutgers Canc Inst New Jersey, Dept Radiat Oncol, New Brunswick, NJ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3033 BP E419 EP E419 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655803346 ER PT J AU Kamran, SC Chun, TT Ancukiewicz, M Niemierko, A Fischman, A Choi, NC AF Kamran, S. C. Chun, T. T. Ancukiewicz, M. Niemierko, A. Fischman, A. Choi, N. C. TI Radiation Esophagitis Graded With Common Terminology Criteria for Adverse Events (CTCAE) Revisited With 10 Days and 3 Months Posttherapy F-18-FDG Positron Emission Tomography in Lung Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Kamran, S. C.] Harvard Radiat Oncol Program, Boston, MA USA. [Chun, T. T.; Choi, N. C.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Chun, T. T.] Rhode Isl Hosp, Brown Med Sch, Providence, RI USA. [Ancukiewicz, M.; Niemierko, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Fischman, A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Fischman, A.] Shriners Burns Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3116 BP E453 EP E454 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655803428 ER PT J AU Kauffmann, G Gunther, JR Braunstein, SE Hara, W Spektor, A Brower, JV Stahl, JM Rao, YJ Vargo, J Ye, JC Fields, EC Thomas, CR Du, KL Kruser, TJ Jimenez, RB Hirsch, AE Currey, AD Yechieli, R Mohindra, P Golden, DW AF Kauffmann, G. Gunther, J. R. Braunstein, S. E. Hara, W. Spektor, A. Brower, J. V. Stahl, J. M. Rao, Y. J. Vargo, J. Ye, J. C. Fields, E. C. Thomas, C. R., Jr. Du, K. L. Kruser, T. J. Jimenez, R. B. Hirsch, A. E. Currey, A. D. Yechieli, R. Mohindra, P. Golden, D. W. TI Updated Analysis of a Multi-Institutional Radiation Oncology Clerkship Curriculum: A Report From the Radiation Oncology Education Collaborative Study Group SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Kauffmann, G.; Golden, D. W.] Univ Chicago, Chicago, IL 60637 USA. [Gunther, J. R.] Univ Texas MD Anderson Canc Ctr, Div Radiat Oncol, Houston, TX 77030 USA. [Braunstein, S. E.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hara, W.] Stanford Radiat Oncol, Stanford, CA USA. [Spektor, A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Brower, J. V.] Univ Wisconsin Hosp & Clin, Dept Human Oncol, Madison, WI 53792 USA. [Stahl, J. M.] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA. [Rao, Y. J.] Washington Univ, Sch Med, St Louis, MO USA. [Vargo, J.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA. [Ye, J. C.] NewYork Presbyterian Weill Cornell Med Ctr, New York, NY USA. [Fields, E. C.] Virginia Commonwealth Univ, Richmond, VA USA. [Thomas, C. R., Jr.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Du, K. L.] NYU, Langone Med Ctr, New York, NY USA. [Kruser, T. J.] Delnor Hosp, Cadence Canc Ctr, Geneva, IL USA. [Jimenez, R. B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hirsch, A. E.] Boston Univ, Sch Med, Dept Radiat Oncol, Boston, MA 02118 USA. [Hirsch, A. E.] Boston Med Ctr, Boston, MA USA. [Currey, A. D.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Yechieli, R.] Univ Miami, Dept Radiat Oncol, Sylvester Comprehens Canc Ctr, Miami, FL USA. [Mohindra, P.] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3015 BP E412 EP E412 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655803329 ER PT J AU Kovtun, K Chen, MH Braccioforte, MH Moran, BJ D'Amico, AV AF Kovtun, K. Chen, M. H. Braccioforte, M. H. Moran, B. J. D'Amico, A. V. TI Race and the Risk of Death Following High-Dose Radiation Therapy in Men Treated With or Without Androgen Suppression Therapy for Favorable-Risk Prostate Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Kovtun, K.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Kovtun, K.] Harvard Radiat Oncol Program, Boston, MA USA. [Chen, M. H.] Univ Connecticut, Storrs, CT USA. [Braccioforte, M. H.; Moran, B. J.] Prostate Canc Fdn Chicago, Westmont, IL USA. [D'Amico, A. V.] Dana Farber Canc Inst, Boston, MA 02115 USA. [D'Amico, A. V.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2990 BP E402 EP E402 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655803304 ER PT J AU Luo, L Niemierko, A Gray, PJ AF Luo, L. Niemierko, A. Gray, P. J. TI Cost-Effectiveness Analysis of Early Salvage Radiation Therapy Versus Adjuvant Radiation Therapy After Radical Prostatectomy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Luo, L.; Gray, P. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Niemierko, A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Biostat, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2997 BP E405 EP E405 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655803311 ER PT J AU Mahal, A Mahal, BA Singh, R Green, AR Nguyen, PL Yu, JB AF Mahal, A. Mahal, B. A. Singh, R. Green, A. R. Nguyen, P. L. Yu, J. B. TI The Effect of Race and Decision Aids on Physician Recommendation for Prostate Cancer Treatment Planning SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Mahal, A.] Yale Sch Med, New Haven, CT USA. [Mahal, B. A.] Harvard Med Sch, Harvard Radiat Oncol Program, Boston, MA USA. [Singh, R.] Cleveland Clin, Weston, FL USA. [Green, A. R.] Harvard Med Sch, Massachusetts Gen Hosp, Dispar Solut Ctr, Boston, MA USA. [Nguyen, P. L.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. [Nguyen, P. L.] Harvard Med Sch, Boston, MA USA. [Yu, J. B.] Yale Sch Med, Canc Outcomes Publ Policy & Effectiveness Res COP, New Haven, CT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2976 BP E396 EP E396 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655803290 ER PT J AU Mampuya, AW Matsuo, Y Nakamura, A Hiraoka, M AF Mampuya, A. W. Matsuo, Y. Nakamura, A. Hiraoka, M. TI Evaluation of the Prevalence of Burnout and Psychological Morbidity Among Japanese Radiation Oncologists Practicing in Kyoto University Hospital and Affiliated Institutions SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Mampuya, A. W.; Matsuo, Y.; Hiraoka, M.] Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Appl Therapy, Kyoto, Japan. [Nakamura, A.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2994 BP E404 EP E404 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655803308 ER PT J AU Nipp, R Drapek, LC Moran, S D'Arpino, S Mitra, D Hong, TI Dizon, DS Ryan, DP Temel, J Wo, JY AF Nipp, R. Drapek, L. C. Moran, S. D'Arpino, S. Mitra, D. Hong, T. I. Dizon, D. S. Ryan, D. P. Temel, J. Wo, J. Y. TI Sexual Function, Quality of Life (QOL), and Mood After Radiation Therapy in Patients With Anal Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Nipp, R.; Moran, S.; D'Arpino, S.] MGH Canc Ctr, Boston, MA USA. [Drapek, L. C.; Dizon, D. S.; Temel, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mitra, D.] Harvard Radiat Oncol Program, Boston, MA USA. [Hong, T. I.; Wo, J. Y.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Ryan, D. P.] Masschusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3306 BP E533 EP E533 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655803618 ER PT J AU Patel, SA Aizer, AA Weyman, E Lu, HM Yeap, BY Busse, PM Chan, AW AF Patel, S. A. Aizer, A. A. Weyman, E. Lu, H. M. Yeap, B. Y. Busse, P. M. Chan, A. W. TI Multimodal Assessment of Hearing Function After Chemoradiation for Nasopharyngeal Carcinoma: A Prospective Study SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Patel, S. A.] Harvard Radiat Oncol Program, Boston, MA USA. [Aizer, A. A.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. [Weyman, E.; Lu, H. M.; Yeap, B. Y.; Busse, P. M.; Chan, A. W.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2830 BP E338 EP E338 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655803146 ER PT J AU Patel, VL Busch, E D'Amico, AV Rebbeck, TR AF Patel, V. L. Busch, E. D'Amico, A. V. Rebbeck, T. R. TI BRCA2 Mutations in Prostate Cancer Assort Into Cluster Regions SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Patel, V. L.; Busch, E.; D'Amico, A. V.; Rebbeck, T. R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Patel, V. L.; D'Amico, A. V.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Busch, E.; Rebbeck, T. R.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3396 BP E569 EP E570 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655803708 ER PT J AU Rao, AD Ermoian, RP Alcorn, SR Figueiredo, MLS Chen, MJ Dieckmann, K MacDonald, S Ladra, M Kobyzeva, D Nechesnyuk, A Nilsson, K Winey, B Villar, RC Terezakis, SA AF Rao, A. D. Ermoian, R. P. Alcorn, S. R. Figueiredo, M. L. S. Chen, M. J. Dieckmann, K. MacDonald, S. Ladra, M. Kobyzeva, D. Nechesnyuk, A. Nilsson, K. Winey, B. Villar, R. C. Terezakis, S. A. TI Practice Patterns of Palliative Radiation Therapy in Pediatric Oncology Patients Amongst an International Pediatric Research Consortium SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Rao, A. D.; Terezakis, S. A.] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD USA. [Ermoian, R. P.] Univ Washington, Dept Radiat Oncol, Seattle, WA 98195 USA. [Alcorn, S. R.] Johns Hopkins Univ, Baltimore, MD USA. [Figueiredo, M. L. S.] Med Radioterapeuta, Sao Paulo, Brazil. [Chen, M. J.] AC Camargo Canc Ctr, Sao Paulo, Brazil. [Dieckmann, K.] Univ Klin Strahlentherapie & Strahlenbiol, Vienna, Austria. [MacDonald, S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Ladra, M.] Provis Ctr Proton Therapy, Knoxville, TN USA. [Kobyzeva, D.] Fed Sci Clin Ctr Pediat Hematol Oncol & Immunol, Moscow, Russia. [Nechesnyuk, A.] Fed Sci Clin Ctr Childrens Hematol Oncol & Immuno, Moscow, Russia. [Nilsson, K.] Akad Sjukhuset, Uppsala, Sweden. [Winey, B.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Villar, R. C.] Ctr Infantil Boldrini, Campinas, SP, Brazil. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3345 BP E548 EP E549 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655803657 ER PT J AU Rotenstein, L Killoran, JH Balboni, TA Krishnan, MS Taylor, A Martin, NE AF Rotenstein, L. Killoran, J. H. Balboni, T. A. Krishnan, M. S. Taylor, A. Martin, N. E. TI Development and Implementation of a Clinical Pathway for Radiation of Bone Metastases on a Palliative Radiation Oncology Service SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Rotenstein, L.] Harvard Med Sch, Boston, MA USA. [Killoran, J. H.; Balboni, T. A.; Krishnan, M. S.; Taylor, A.; Martin, N. E.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3332 BP E543 EP E543 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655803644 ER PT J AU Shusharina, N Liao, Z Mohan, R Choi, NC Bortfeld, T AF Shusharina, N. Liao, Z. Mohan, R. Choi, N. C. Bortfeld, T. TI Radiation Pneumonitis Dose Response After Photon or Proton Radiation Therapy Assessed by F-18-FDG Uptake SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Shusharina, N.; Choi, N. C.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Liao, Z.; Mohan, R.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA. [Bortfeld, T.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3509 BP E615 EP E615 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804089 ER PT J AU Warren, L Turcotte, JC Wehrenberg-Klee, E Oxnard, G Mak, RH Willers, H Sequist, LV AF Warren, L. Turcotte, J. C. Wehrenberg-Klee, E. Oxnard, G. Mak, R. H. Willers, H. Sequist, L. V. TI Phase 2 Trial of Afatinib Sequenced With Concurrent Chemo/Radiation in EGFR-Mutant Non-Small Cell Lung Cancer: Initial Feasibility and Response Analysis SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Warren, L.] Harvard Radiat Oncol Program, Boston, MA USA. [Turcotte, J. C.; Wehrenberg-Klee, E.; Sequist, L. V.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Oxnard, G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Mak, R. H.] Dana Farber Canc Inst, Brigham & Womens Canc Ctr, Boston, MA 02115 USA. [Willers, H.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3120 BP E455 EP E455 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655803432 ER PT J AU Wo, JY Drapek, LC Niemierko, A Silvia, BL Russo, AL Gray, PJ Miyamoto, DT Hong, TI Efstathiou, JA Zietman, AL Temel, J Dizon, DS AF Wo, J. Y. Drapek, L. C. Niemierko, A. Silvia, B. L. Russo, A. L. Gray, P. J. Miyamoto, D. T. Hong, T. I. Efstathiou, J. A. Zietman, A. L. Temel, J. Dizon, D. S. TI Clinical Needs Assessment for Sexual Health Among Cancer Patients Receiving Pelvic Radiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Wo, J. Y.; Hong, T. I.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Drapek, L. C.; Silvia, B. L.; Gray, P. J.; Miyamoto, D. T.; Temel, J.; Dizon, D. S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Niemierko, A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Biostat, Boston, MA USA. [Russo, A. L.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Efstathiou, J. A.; Zietman, A. L.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3296 BP E528 EP E529 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655803608 ER PT J AU Xiang, HF Cheng, J Alshammari, M Lee, C Bloch, NB Keohan, S Jaffe, C Efstathiou, JA Zietman, AL Lu, HM Hirsch, AE AF Xiang, H. F. Cheng, J. Alshammari, M. Lee, C. Bloch, N. B. Keohan, S. Jaffe, C. Efstathiou, J. A. Zietman, A. L. Lu, H. M. Hirsch, A. E. TI Dosimetric Validation of Robotic Prostate SBRT With Simultaneous Integrated Dose Escalation to Dominant Intraprostatic Lesion Using a Magnetic Resonance-Based 3D-Printed Prostate Model in an Anthropomorphic Pelvis Phantom SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Xiang, H. F.; Alshammari, M.; Bloch, N. B.; Keohan, S.; Jaffe, C.; Hirsch, A. E.] Boston Univ, Sch Med, Dept Radiat Oncol, Boston, MA 02118 USA. [Xiang, H. F.; Alshammari, M.; Bloch, N. B.; Keohan, S.; Jaffe, C.; Hirsch, A. E.] Boston Med Ctr, Boston, MA USA. [Cheng, J.] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Lee, C.] Franklin W Olin Coll Engn, Needham, MA USA. [Efstathiou, J. A.; Zietman, A. L.; Lu, H. M.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3503 BP E613 EP E613 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804083 ER PT J AU Yamoah, K Lal, P Mahajan, S Naghavi, AO Rebbeck, TR AF Yamoah, K. Lal, P. Mahajan, S. Naghavi, A. O. Rebbeck, T. R. TI Clinical Implications of TMPRSS2-ERG Fusion in African American Men With Localized Prostate Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Yamoah, K.; Naghavi, A. O.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Lal, P.] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Mahajan, S.] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Rebbeck, T. R.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Rebbeck, T. R.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3394 BP E569 EP E569 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655803706 ER PT J AU Yang, D O'Leary, C Deraska, V D'Andrea, AD Haas-Kogan, DA Kozono, DE AF Yang, D. O'Leary, C. Deraska, V. D'Andrea, A. D. Haas-Kogan, D. A. Kozono, D. E. TI Exploiting Homologous Recombination Defects in N on-Small Cell Lung Cancer Through Combined PARP and Wee1 Inhibition SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO) CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Yang, D.; O'Leary, C.; Deraska, V.; D'Andrea, A. D.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Haas-Kogan, D. A.] Harvard Med Sch, Boston, MA USA. [Kozono, D. E.] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 3425 BP E581 EP E582 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655804005 ER PT J AU Joaquin, ML Mariateresa, F Maria, L Stefania, O Rajya, LB Annamaria, G Raphael, LS Mehmet, KS Yan, X Nicola, A Michele, C William, S Erkan, B Christian, A Kenneth, CA Nikhil, CM AF Joaquin, Martinez-Lopez Mariateresa, Fulciniti Maria, Linares Stefania, Oliva Rajya, Lakshmi Bandi Annamaria, Gulla Raphael, Szalat L. Mehmet, Samur K. Yan, Xu Nicola, Amodio Michele, Cea William, Senapedis Erkan, Baloglu Christian, Argueta Kenneth, Anderson C. Nikhil, Munshi C. TI IMPORTANCE OF SERINE/THREONINE KINASE PAK4 IN MULTIPLE MYELOMA: THERAPEUTIC APPLICATIONS OF A NEW CLASS OF INHIBITORS SO HAEMATOLOGICA LA Spanish DT Meeting Abstract CT 58th National Congress of the Spanish-Society-of-Hematology-and-Hemotherapy CY OCT 20-22, 2016 CL Santiago de Compostela, SPAIN SP Spanish Soc Hematol & Hemotherapy C1 [Joaquin, Martinez-Lopez; Stefania, Oliva; Nikhil, Munshi C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Joaquin, Martinez-Lopez] Hosp Univ 12 Octubre, Complutense Sch Med, CNIO, Madrid, Spain. [Maria, Linares] Hosp Univ 12 Octubre, CNIO, Madrid, Spain. [Stefania, Oliva] Univ Turin, Turin, Italy. [Nicola, Amodio] Univ Catanzaro, Catanzaro, Italy. [Michele, Cea] Farber Canc Inst, Boston, MA USA. [Michele, Cea] Univ Genoa, Genoa, Italy. [William, Senapedis; Erkan, Baloglu; Christian, Argueta] Karyopharm Therapeut Inc, Newton, MA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD OCT PY 2016 VL 101 SU 4 MA CO-028 BP 21 EP 21 PG 1 WC Hematology SC Hematology GA EI5QG UT WOS:000392548800030 ER PT J AU Ali, SM Fedorchak, K Schrock, AB Johnson, J Gowen, K Elvin, JA Vergilio, JA Klempner, SJ Mehra, R Ho, A Pavlick, D Suh, J Bordoni, R Jung, DH Stephens, P Chung, CH Ross, JS Miller, V AF Ali, S. M. Fedorchak, K. Schrock, A. B. Johnson, J. Gowen, K. Elvin, J. A. Vergilio, J-A. Klempner, S. J. Mehra, R. Ho, A. Pavlick, D. Suh, J. Bordoni, R. Jung, D. H. Stephens, P. Chung, C. H. Ross, J. S. Miller, V. TI Advanced acinic cell carcinoma harbors kinase rearrangements including BRAF kinase domain duplications SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Ali, S. M.; Fedorchak, K.; Gowen, K.; Pavlick, D.; Stephens, P.] Fdn Med Inc, Res & Dev, Cambridge, MA USA. [Schrock, A. B.; Miller, V.] Fdn Med Inc, Clin Dev, Cambridge, MA USA. [Johnson, J.] Thomas Jefferson Univ, Kimmel Canc Ctr, Med Oncol, Philadelphia, PA 19107 USA. [Elvin, J. A.; Vergilio, J-A.; Suh, J.] Fdn Med Inc, Pathol, Cambridge, MA USA. [Klempner, S. J.] Angeles Clin & Res Inst, Med Oncol, Los Angeles, CA USA. [Mehra, R.] Fox Chase Canc Ctr, Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Ho, A.] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA. [Bordoni, R.] Georgia Canc Specialists, Med Oncol, Marietta, GA USA. [Jung, D. H.] Mass Eye & Ear Infirm, Otolarynol, Boston, MA USA. [Chung, C. H.] Univ S Florida, H Lee Moffitt Canc Ctr, Med Oncol, Tampa, FL USA. [Ross, J. S.] Albany Med Ctr, Pathol, Albany, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 980P DI 10.1093/annonc/mdw376.32 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000076 ER PT J AU Andre, F Kaufman, B Juric, D Ciruelos, E Iwata, H Mayer, IA Conte, P Rugo, HS Loibl, S Rubovszky, G Tesch, H Inoue, K Lu, YS Ryvo, L Longin, AS Mills, D Wilke, C Germa, C Campone, M AF Andre, F. Kaufman, B. Juric, D. Ciruelos, E. Iwata, H. Mayer, I. A. Conte, P. Rugo, H. S. Loibl, S. Rubovszky, G. Tesch, H. Inoue, K. Lu, Y-S. Ryvo, L. Longin, A-S. Mills, D. Wilke, C. Germa, C. Campone, M. TI A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Andre, F.] Inst Gustave Roussy, Dept Med Oncol, Breast Canc Unit, Villejuif, France. [Kaufman, B.] Chaim Sheba Med Ctr, Breast Canc Unit, Ramat Gan, Israel. [Juric, D.] Massachusetts Gen Hosp, Termeer Ctr Targeted Therapies, Boston, MA 02114 USA. [Ciruelos, E.] Univ Hosp 12 Octubre, Dept Med Oncol, Madrid, Spain. [Iwata, H.] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi, Japan. [Mayer, I. A.] Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN USA. [Conte, P.] Univ Padua, Ist Oncol Veneto IRCCS, Padua, Italy. [Rugo, H. S.] Univ Calif San Francisco, Ctr Comprehens Canc, Med Hematol Oncol, San Francisco, CA 94143 USA. [Loibl, S.] German Breast Grp, Med & Res, Neu Isenburg, Germany. [Rubovszky, G.] Natl Inst Oncol, Internal Med Oncol Div B, Budapest, Hungary. [Rubovszky, G.] Natl Inst Oncol, Dept Clin Pharmacol, Budapest, Hungary. [Tesch, H.] Ctr Hamatol & Onkol Bethanien, Dept Oncol, Frankfurt, Germany. [Inoue, K.] Saitama Canc Ctr, Div Breast Oncol, Saitama, Japan. [Lu, Y-S.] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan. [Ryvo, L.] Tel Aviv Sourasky Med Ctr Ichilov, Div Oncol, Tel Aviv, Israel. [Longin, A-S.; Mills, D.] Novartis Pharma SAS, Paris, France. [Mills, D.; Wilke, C.] Novartis Pharma AG, Basel, Switzerland. [Germa, C.] Novartis Pharmaceut, E Hanover, NJ USA. [Campone, M.] Ctr Rene Gauducheau, Med Oncol, Inst Cancerol Ouest Site, St Herblain, France. FU Novartis Pharmaceuticals Corporation FX Novartis Pharmaceuticals Corporation NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 311TiP DI 10.1093/annonc/mdw365.90 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500310 ER PT J AU Angevin, E Kelly, K Heist, R Morgensztern, D Weekes, C Bauer, TM Ramanathan, RK Nemunaitis, J Fan, X Olyaie, O Parikh, A Reilly, E Afar, D Naumovski, L Strickler, J AF Angevin, E. Kelly, K. Heist, R. Morgensztern, D. Weekes, C. Bauer, T. M. Ramanathan, R. K. Nemunaitis, J. Fan, X. Olyaie, O. Parikh, A. Reilly, E. Afar, D. Naumovski, L. Strickler, J. TI First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Angevin, E.] Gustave Roussy, Early Drug Dev Dept, Villejuif, France. [Kelly, K.] Univ Calif Davis, Ctr Comprehens Canc, Internal Med, Sacramento, CA 95817 USA. [Heist, R.] Massachusetts Gen Hosp, Children Canc Ctr, Boston, MA 02114 USA. [Morgensztern, D.] Washington Univ, Sch Med, Oncol, St Louis, MO USA. [Weekes, C.] Univ Colorado, Dept Med, Ctr Canc, Anschutz Canc Pavil, Aurora, CO USA. [Bauer, T. M.] Tennessee Oncol, Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA. [Ramanathan, R. K.] Mayo Clin, Ctr Canc, Hematol Oncol, Phoenix, AZ USA. [Nemunaitis, J.] Mary Crowley Canc Res Ctr, Oncol, Dallas, TX USA. [Fan, X.; Olyaie, O.; Parikh, A.; Afar, D.; Naumovski, L.] AbbVie, Biotherapeut, Redwood City, CA USA. [Reilly, E.] AbbVie Inc, Oncol, N Chicago, IL USA. [Strickler, J.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. FU AbbVie, Inc. FX AbbVie, Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 371P DI 10.1093/annonc/mdw368.14 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500369 ER PT J AU Argiris, A Gillison, M Ferris, RL Harrington, K Sanchez, TK Baudelet, C Geese, WJ Shaw, J Haddad, R AF Argiris, A. Gillison, M. Ferris, R. L. Harrington, K. Sanchez, T. K. Baudelet, C. Geese, W. J. Shaw, J. Haddad, R. TI A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab plus cisplatin/carboplatin plus fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651 SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Argiris, A.] Hygeia Hosp, Med Oncol, Athens, Greece. [Gillison, M.] Ohio State Univ, Coll Med, Internal Med, Columbus, OH 43210 USA. [Ferris, R. L.] Univ Pittsburgh, Inst Eye & Ear, Dept Otolaryngol, Div Head & Neck Surg, Pittsburgh, PA 15213 USA. [Harrington, K.] Inst Canc Res, Div Radiotherapy & Imaging, London, England. [Sanchez, T. K.] Bristol Myers Squibb, Oncol, Global Clin Res, Princeton, NJ USA. [Baudelet, C.] Bristol Myers Squibb, Biostat, Princeton, NJ USA. [Geese, W. J.] Bristol Myers Squibb, Oncol, Lawrence Township, NJ USA. [Shaw, J.] Bristol Myers Squibb, Clin Outcomes Assessment, Princeton, NJ USA. [Shaw, J.] Bristol Myers Squibb, I O LCM Worldwide Hlth Econ & Outcomes Res, Princeton, NJ USA. [Haddad, R.] Dana Farber Harvard Canc Ctr, Head & Neck Oncol Program, Boston, MA USA. FU Bristol-Myers Squibb FX Sponsored by Bristol-Myers Squibb. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1016TiP DI 10.1093/annonc/mdw376.68 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000112 ER PT J AU Ascierto, PA Ribas, A Larkin, J McArthur, GA Lewis, KD Hauschild, A Flaherty, KT McKenna, E Zhu, Q Mun, Y Dreno, B AF Ascierto, P. A. Ribas, A. Larkin, J. McArthur, G. A. Lewis, K. D. Hauschild, A. Flaherty, K. T. McKenna, E. Zhu, Q. Mun, Y. Dreno, B. TI Prognostic subgroups and impact of treatment for post-progression overall survival (ppOS) in patients (pts) with BRAFV600-mutated metastatic melanoma treated with dacarbazine (DTIC) or vemurafenib (VEM) +/- cobimetinib (COBI): A pooled analysis SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Ascierto, P. A.] Ist Nazl Tumori Fdn Pascale, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, Italy. [Ribas, A.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Med Hematol & Oncol, Los Angeles, CA 90024 USA. [Larkin, J.] Royal Marsden Hosp NHS Fdn Trust, Med, London, England. [McArthur, G. A.] Peter MacCallum Canc Ctr, Oncol, East Melbourne, Australia. [Lewis, K. D.] Univ Colorado, Ctr Comprehens Canc, Oncol, Aurora, CO USA. [Hauschild, A.] Univ Hosp Schleswig Holstein, Dept Dermatol, Kiel, Germany. [Flaherty, K. T.] Massachusetts Gen Hosp, Med, Boston, MA 02114 USA. [McKenna, E.; Zhu, Q.; Mun, Y.] Genentech Inc, Med Affairs, San Francisco, CA 94080 USA. [Dreno, B.] Univ Nantes, Dermato Cancerol, Nantes, France. FU F. Hoffman-La Roche, Ltd. FX F. Hoffman-La Roche, Ltd. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1142P DI 10.1093/annonc/mdw379.37 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000235 ER PT J AU Atkins, MB Plimack, ER Puzanov, I Fishman, MN McDermott, D Cho, DC Vaishampayan, U George, S Olencki, T Tarazi, J Rosbrook, B Fernandez, K Keefe, S Choueiri, T AF Atkins, M. B. Plimack, E. R. Puzanov, I. Fishman, M. N. McDermott, D. Cho, D. C. Vaishampayan, U. George, S. Olencki, T. Tarazi, J. Rosbrook, B. Fernandez, K. Keefe, S. Choueiri, T. TI Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Atkins, M. B.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Med Oncol, Washington, DC USA. [Plimack, E. R.] Fox Chase Canc Ctr, Hematol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Puzanov, I.] Vanderbilt Ingram Canc Ctr, Hematol Oncol, Nashville, TN USA. [Fishman, M. N.] Univ S Florida, Med Oncol, H Lee Moffitt Canc Ctr, Tampa, FL USA. [McDermott, D.] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA. [Cho, D. C.] NYU, Langone Med Ctr, Med Oncol, New York, NY USA. [Vaishampayan, U.] Karmanos Canc Inst, Med Oncol, Detroit, MI USA. [George, S.] Roswell Pk Canc Inst, Med, Buffalo, NY 14263 USA. [Olencki, T.] Ohio State Univ, Med Ctr, Med Oncol, Columbus, OH 43210 USA. [Tarazi, J.; Rosbrook, B.] Pfizer Inc, Oncol, San Diego, CA USA. [Fernandez, K.] Pfizer, Oncol, Cambridge, MA USA. [Keefe, S.] Merck & Co Inc, Oncol, Kenilworth, NJ USA. [Choueiri, T.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. FU Pfizer Inc FX Pfizer Inc NR 0 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 773PD DI 10.1093/annonc/mdw373.1 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500769 ER PT J AU Balar, A Bellmunt, J O'Donnell, PH Castellano, D Grivas, P Vuky, J Powles, T Plimack, ER Hahn, NM de Wit, R Pang, L Savage, MJ Perini, R Keefe, S Bajorin, D AF Balar, A. Bellmunt, J. O'Donnell, P. H. Castellano, D. Grivas, P. Vuky, J. Powles, T. Plimack, E. R. Hahn, N. M. de Wit, R. Pang, L. Savage, M. J. Perini, R. Keefe, S. Bajorin, D. TI Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Balar, A.] NYU, Langone Med Ctr, Med Oncol, Perlmutter Canc Ctr, New York, NY USA. [Bellmunt, J.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [O'Donnell, P. H.] Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA. [Castellano, D.] Hosp Univ 12 Octubre, Med Oncol, Madrid, Spain. [Grivas, P.] Cleveland Clin, Hematol Oncol, Cleveland, OH 44106 USA. [Vuky, J.] Oregon Hlth & Sci Univ, Hematol & Oncol, Portland, OR USA. [Powles, T.] Queen Mary Univ London, Barts Canc Inst, Genitourinary Oncol, London, England. [Plimack, E. R.] Fox Chase Canc Ctr, Dept Hematol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Hahn, N. M.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Oncol & Urol, Baltimore, MD USA. [de Wit, R.] Erasmus MC, Inst Canc, Med Oncol, Rotterdam, Netherlands. [Pang, L.] Merck & Co Inc, BARDS Late Dev Stat, Kenilworth, NJ USA. [Savage, M. J.] Merck & Co Inc, Compan Diagnost, Kenilworth, NJ USA. [Perini, R.] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA. [Keefe, S.] Merck & Co Inc, Clin Res & Dev, Kenilworth, NJ USA. [Bajorin, D.] Mem Sloan Kettering Canc Ctr, Med, 1275 York Ave, New York, NY 10021 USA. FU Merck Co., Inc. FX Merck & Co., Inc. NR 0 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA LBA32_PR DI 10.1093/annonc/mdw435.25 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000714 ER PT J AU Balmana, J Cruz, C Arun, BK Telli, M Garber, J Domchek, S Fernandez, CM Kahatt, C Szyldergemajn, S Soto-Matos, A de la Haza, AP Fidalgo, JAP Lluch-Hernandez, A Antolin, S Tung, NM Vahdat, LT Lopez, R Isakoff, SJJ AF Balmana, J. Cruz, C. Arun, B. K. Telli, M. Garber, J. Domchek, S. Fernandez, C. M. Kahatt, C. Szyldergemajn, S. Soto-Matos, A. Perez de la Haza, A. Perez Fidalgo, J. A. Lluch-Hernandez, A. Antolin, S. Tung, N. M. Vahdat, L. T. Lopez, R. Isakoff, S. J. J. TI Anti-tumor activity of PM01183 (lurbinectedin) in BRCA1/2-associated metastatic breast cancer patients: results of a single-agent phase II trial SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Balmana, J.; Cruz, C.] Hosp Valle De Hebron, Med Oncol, Barcelona, Spain. [Balmana, J.; Cruz, C.] Vall dHebron Inst Oncol, Barcelona, Spain. [Arun, B. K.] Univ Texas MD Anderson Canc Ctr, Breast Med Oncol, Houston, TX 77030 USA. [Telli, M.] Stanford Univ, Med Oncol, Med Ctr, Stanford, CA 94305 USA. [Garber, J.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Domchek, S.] Hosp Univ Penn, Med Oncol, 3400 Spruce St, Philadelphia, PA 19104 USA. [Fernandez, C. M.; Kahatt, C.; Szyldergemajn, S.; Soto-Matos, A.; Perez de la Haza, A.] PharmaMar SA, Clin Dev, Colmenar Viejo, Spain. [Perez Fidalgo, J. A.; Lluch-Hernandez, A.] Hosp Clin Univ Valencia, Med Oncol, Valencia, Spain. [Antolin, S.] Complejo Univ Hosp La Coruna, Med Oncol, La Coruna, Spain. [Tung, N. M.] Beth Israel Deaconess Med Ctr, Med Oncol, Boston, MA 02215 USA. [Vahdat, L. T.] Weill Cornell Med, Med Oncol, New York, NY USA. [Lopez, R.] Complejo Hosp Univ Santiago de Compostela, Med Oncol, Santiago De Compostela, Spain. [Isakoff, S. J. J.] Massachusetts Gen Hosp, Med Oncol, Boston, MA 02114 USA. FU PharmaMar S.A. FX PharmaMar S.A. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 223O DI 10.1093/annonc/mdw365.2 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500222 ER PT J AU Bamias, A Tzannis, K Liontos, M Crabb, SJ Harshman, L De Giorgi, U Bellmunt, J Wong, YN Pal, SK Ladoire, S Sternberg, CN Powles, TB Yu, EY Niegisch, G Necchi, A Vaishampayan, U Agarwal, N Rosenberg, J Investigators, R AF Bamias, A. Tzannis, K. Liontos, M. Crabb, S. J. Harshman, L. De Giorgi, U. Bellmunt, J. Wong, Y-N. Pal, S. K. Ladoire, S. Sternberg, C. N. Powles, T. B. Yu, E. Y. Niegisch, G. Necchi, A. Vaishampayan, U. Agarwal, N. Rosenberg, J. Investigators, R. TI Adherence to cisplatin-based regimens prescription in "fit" patients fulfilling platinum eligibility criteria. Impact on outcomes: a retrospective international study of invasive/advanced cancer of the urothelium (RISC) analysis SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Bamias, A.; Tzannis, K.] Univ Athens, Clin Therapeut, Athens, Greece. [Liontos, M.] Alexandra Hosp, Dept Clin Therapeut, Oncol Unit, Athens, Greece. [Crabb, S. J.] Univ Southampton, Med Oncol, Southampton, Hants, England. [Harshman, L.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [De Giorgi, U.] Ist Tumori Romagna IRST, Med Oncol, Meldola, Italy. [Bellmunt, J.] Dana Farber Canc Inst, Oncol, Boston, MA 02115 USA. [Wong, Y-N.] Fox Chase Canc Ctr, Med Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Pal, S. K.] City Hope Natl Med Ctr, Med Oncol & Expt Therapeut, Duarte, CA USA. [Ladoire, S.] Ctr Georges Francois Leclerc Dijon, Med Oncol, Dijon, France. [Sternberg, C. N.] Azienda Osped S Camillo Forlanini, Med Oncol, Rome, Italy. [Powles, T. B.] St Bartholomews Hosp, Dept Med Oncol, London, England. [Yu, E. Y.] Univ Washington, VAPSHCS, Med Oncol, Seattle, WA 98195 USA. [Niegisch, G.] Univ Klinikum Dusseldorf, Med Oncol, Dusseldorf, Germany. [Necchi, A.] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy. [Vaishampayan, U.] Karmanos Canc Inst, Med Oncol, Detroit, MI USA. [Agarwal, N.] Huntsman Canc Inst, Med Oncol, Salt Lake City, UT USA. [Rosenberg, J.] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA. [Investigators, R.] Mt SInai Med Coll, Oncol, New York, NY USA. FU Icahn School of Medicine at Mount Sinai, USA FX Icahn School of Medicine at Mount Sinai, USA NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 799P DI 10.1093/annonc/mdw373.27 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500795 ER PT J AU Bamias, A Tzannis, K Liontos, M Harshman, L Crabb, SJ Wong, YN Pal, SK Powles, TB Bellmunt, J De Giorgi, U Ladoire, S Agarwal, N Yu, EY Niegisch, G Sternberg, CN Alva, A Srinivas, S Rosenberg, J Investigators, R AF Bamias, A. Tzannis, K. Liontos, M. Harshman, L. Crabb, S. J. Wong, Y-N. Pal, S. K. Powles, T. B. Bellmunt, J. De Giorgi, U. Ladoire, S. Agarwal, N. Yu, E. Y. Niegisch, G. Sternberg, C. N. Alva, A. Srinivas, S. Rosenberg, J. Investigators, R. TI Patterns of chemotherapy utilization in metastatic urothelial cancer (mUC): analysis from the retrospective international study of invasive/advanced cancer of the urothelium (RISC) database SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Bamias, A.; Tzannis, K.] Univ Athens, Clin Therapeut, Athens, Greece. [Liontos, M.] Alexandra Hosp, Dept Clin Therapeut, Oncol Unit, Athens, Greece. [Harshman, L.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Crabb, S. J.] Univ Southampton, Med Oncol, Southampton, Hants, England. [Wong, Y-N.] Fox Chase Canc Ctr, Med Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Pal, S. K.] City Hope Natl Med Ctr, Med Oncol & Expt Therapuet, Duarte, CA USA. [Powles, T. B.] St Bartholomews Hosp, Dept Med Oncol, London, England. [Bellmunt, J.] Dana Farber Canc Inst, Oncol, Boston, MA 02115 USA. [De Giorgi, U.] Ist Tumori Romagna IRST, Med Oncol, Meldola, Italy. [Ladoire, S.] Ctr Georges Francois Leclerc Dijon, Med Oncol, Dijon, France. [Agarwal, N.] Huntsman Canc Inst, Med Oncol, Salt Lake City, UT USA. [Yu, E. Y.] Univ Washington, VAPSHCS, Med Oncol, Seattle, WA 98195 USA. [Niegisch, G.] Univ Klinikum Dusseldorf, Med Oncol, Dusseldorf, Germany. [Sternberg, C. N.] Azienda Osped S Camillo Forlanini, Med Oncol, Rome, Italy. [Alva, A.] Univ Michigan, Med Oncol, E Lansing, MI USA. [Srinivas, S.] Stanford Univ, Med Oncol, Palo Alto, CA 94304 USA. [Rosenberg, J.] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA. [Investigators, R.] Mt SInai Med Coll, Oncol, New York, NY USA. FU Icahn School of Medicine, Mount Sinai USA FX Icahn School of Medicine, Mount Sinai USA NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 798P DI 10.1093/annonc/mdw373.26 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500794 ER PT J AU Baselga, J Castan, JC De Laurentiis, M Dieras, V Harbeck, N Hsu, J Jin, H Schimmoller, F Wilson, TR Im, YH Jacot, W Krop, IE Verma, S AF Baselga, J. Cortes Castan, J. De Laurentiis, M. Dieras, V. Harbeck, N. Hsu, J. Jin, H. Schimmoller, F. Wilson, T. R. Im, Y-H. Jacot, W. Krop, I. E. Verma, S. TI SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Baselga, J.] Mem Hosp, Mem Sloan Kettering Canc Ctr, Dept Med, Human Oncol & Pathogenesis Program HOPP, New York, NY USA. [Cortes Castan, J.] Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain. [Cortes Castan, J.] Ramon & Cajal Univ Hosp, Madrid, Spain. [De Laurentiis, M.] Fdn G Pascale, Ist Nazl Tumori, Breast Oncol Dept, Naples, Italy. [Dieras, V.] Inst Curie, Dept Med Oncol, Paris, France. [Harbeck, N.] Univ Munich, Breast Canc Ctr, Munich, Germany. [Hsu, J.] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA. [Jin, H.] Genentech Inc, Dept Oncol, San Francisco, CA 94080 USA. [Wilson, T. R.] Genentech Inc, Oncol Biomarker Dept, San Francisco, CA 94080 USA. [Im, Y-H.] Samsung Med Ctr, Dept Med, Seoul, South Korea. [Jacot, W.] Inst Canc Montpellier ICM, Dept Med Oncol, Montpellier, France. [Krop, I. E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Verma, S.] Univ Calgary, Dept Oncol, Tom Baker Canc Ctr, Calgary, AB, Canada. FU F. Hoffmann-La Roche/Genentech FX F. Hoffmann-La Roche/Genentech NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 313TiP DI 10.1093/annonc/mdw365.92 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500312 ER PT J AU Bauer, S Demetri, G Jeay, S Dummer, R Guerreiro, N Tan, DS Kumar, A Meille, C Van Bree, L Halilovic, E Wuerthner, JU Cassier, P AF Bauer, S. Demetri, G. Jeay, S. Dummer, R. Guerreiro, N. Tan, D. S. Kumar, A. Meille, C. Van Bree, L. Halilovic, E. Wuerthner, J. U. Cassier, P. TI A phase I, open-label, multi-center, dose escalation study of oral NVP-CGM097, a p53/HDM2-protein-protein interaction inhibitor, in adult patients with selected advanced solid tumors SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Bauer, S.] Univ Klinikum Essen, Internal Med, Essen, Germany. [Demetri, G.] Dana Farber Canc Inst, Ludwig Ctr, Boston, MA 02115 USA. [Jeay, S.; Guerreiro, N.; Meille, C.; Van Bree, L.; Wuerthner, J. U.] Novartis Pharma AG, Basel, Switzerland. [Dummer, R.] Univ Zurich Hosp, Zurich, Switzerland. [Tan, D. S.] Natl Canc Ctr, Singapore, Singapore. [Kumar, A.] Novartis Healthcare Pvt Ltd, Hyderabad, Andhra Pradesh, India. [Halilovic, E.] Novartis Inst BioMed Res, Cambridge, MA USA. [Cassier, P.] Ctr Leon Berard, Lyon, France. FU Novartis Pharma AG FX Novartis Pharma AG NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 366PD DI 10.1093/annonc/mdw368.9 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500364 ER PT J AU Bazhenova, L Mehra, R Nagy, T Cavanna, L Lee, JS Han, JY Kim, HK Halmos, B Shum, M Schreeder, M Rybkin, I Badin, F Mena, R Janne, PA Christensen, J Tassell, V Chao, R Faltaos, D Kim, DW AF Bazhenova, L. Mehra, R. Nagy, T. Cavanna, L. Lee, J-S. Han, J-Y. Kim, H. K. Halmos, B. Shum, M. Schreeder, M. Rybkin, I. Badin, F. Mena, R. Janne, P. A. Christensen, J. Tassell, V. Chao, R. Faltaos, D. Kim, D-W. TI Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor tyrosine kinase (RTK) inhibitor, MGCD265 in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with activating genetic alterations in mesenchymal-epithelial transition factor (MET) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Bazhenova, L.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA. [Mehra, R.] Fox Chase Canc Ctr, Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Nagy, T.] Natl Inst Oncol, Oncol, Budapest, Hungary. [Cavanna, L.] Osped Guglielmo Saliceto, Azienda Unita Sanit Locale Piacenza, Oncol, Piacenza, Italy. [Lee, J-S.] Seoul Natl Univ, Bundang Hosp, Oncol, Seongnam Si, South Korea. [Han, J-Y.] Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea. [Kim, H. K.] Catholic Univ Korea, St Vincent Hosp, Oncol, Suwon, South Korea. [Halmos, B.] Montefiore Med Ctr, Oncol, New York, NY USA. [Shum, M.] Innovat Clin Res Inst, Oncol, Whittier, CA USA. [Schreeder, M.] Clearview Canc Inst, Oncol, Huntsville, AL USA. [Rybkin, I.] Henry Ford Hlth Syst, Oncol, Detroit, MI USA. [Badin, F.] Lexington Oncol Associates LLC, Oncol, Lexington, KY USA. [Mena, R.] Providence St Joseph Med Ctr, Oncol, Burbank, CA USA. [Janne, P. A.] Dana Farber Canc Inst, Oncol, Boston, MA 02115 USA. [Christensen, J.] Mirati Therapeut, Res, San Diego, CA USA. [Tassell, V.; Chao, R.] Mirati Therapeut, Clin Sci, San Diego, CA USA. [Faltaos, D.] Mirati Therapeut, Pharmacol, San Diego, CA USA. [Kim, D-W.] Seoul Natl Univ Hosp, Dept Internal Med, SNUH Yongon Campus, Seoul, South Korea. FU Mirati Therapeutics FX Mirati Therapeutics NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1293TiP DI 10.1093/annonc/mdw383.93 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000385 ER PT J AU Bazhenova, L Gettinger, S Langer, C Salgia, R Gold, K Rosell, R Shaw, A Weiss, G Haney, J Rivera, V Haluska, F Kerstein, D Camidge, DR AF Bazhenova, L. Gettinger, S. Langer, C. Salgia, R. Gold, K. Rosell, R. Shaw, A. Weiss, G. Haney, J. Rivera, V. Haluska, F. Kerstein, D. Camidge, D. R. TI Brigatinib (BRG) in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in a phase 1/2 trial SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Bazhenova, L.; Gold, K.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA. [Gettinger, S.] Yale Sch Med, Yale Canc Ctr, New Haven, CT USA. [Langer, C.] Univ Penn, Abramson Canc Ctr, Oncol, Philadelphia, PA 19104 USA. [Salgia, R.] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA. [Rosell, R.] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol ICO Badalona, Med Oncol Serv, Badalona, Spain. [Shaw, A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Weiss, G.] Western Reg Med Ctr, Canc Treatment Ctr Amer, Goodyear, AZ USA. [Haney, J.; Haluska, F.] ARIAD Pharmaceut Inc, Clin Res & Dev, Cambridge, MA 02139 USA. [Rivera, V.; Kerstein, D.] ARIAD Pharmaceut Inc, Preclin & Translat Res, Cambridge, MA 02139 USA. [Camidge, D. R.] Univ Colorado, Ctr Canc, Aurora, CO USA. FU ARIAD Pharmaceuticals, Inc. FX ARIAD Pharmaceuticals, Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1207PD PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000300 ER PT J AU Beeram, M Tolaney, SM Beck, JT Dickler, MN Conlin, AK Dees, C Helsten, TL Conkling, PR Edenfield, WJ Richards, DA Kambhampati, SRP Costigan, TM Chan, E Pant, S Kalinsky, K Burris, HA Becerra, CH Rexer, BN Puhalla, SL Goetz, MP AF Beeram, M. Tolaney, S. M. Beck, J. T. Dickler, M. N. Conlin, A. K. Dees, C. Helsten, T. L. Conkling, P. R. Edenfield, W. J. Richards, D. A. Kambhampati, S. R. P. Costigan, T. M. Chan, E. Pant, S. Kalinsky, K. Burris, H. A. Becerra, C. H. Rexer, B. N. Puhalla, S. L. Goetz, M. P. TI A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Beeram, M.] START, START Ctr Canc Care, San Antonio, TX USA. [Tolaney, S. M.] Dana Farber Canc Inst, Breast Oncol Ctr, Boston, MA 02115 USA. [Beck, J. T.] Highlands Oncol Grp, Hematol, Rogers, AR USA. [Dickler, M. N.] Mem Sloan Kettering Canc Ctr, Oncol, 1275 York Ave, New York, NY 10021 USA. [Conlin, A. K.] Providence Canc Ctr, Med Oncol, Portland, OR USA. [Dees, C.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Oncol, Chapel Hill, NC USA. [Helsten, T. L.] Univ Calif San Diego, Med, La Jolla, CA 92093 USA. [Conkling, P. R.] US Oncol Res, Virginia Oncol Associates, Norfolk, VA USA. [Edenfield, W. J.] Greenville Hosp Syst, Inst Translat Oncol Res, Clin Res Unit, Greenville, SC USA. [Richards, D. A.] US Oncol Res, Texas Oncol, Tyler, TX USA. [Kambhampati, S. R. P.; Costigan, T. M.; Chan, E.] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA. [Pant, S.] Univ Texas MD Anderson Canc Ctr, Canc Therapeut, Houston, TX 77030 USA. [Kalinsky, K.] Columbia Univ, Med Ctr, New York, NY USA. [Burris, H. A.] Sarah Cannon Res Inst, Dept Drug Dev, Nashville, TN USA. [Becerra, C. H.] Baylor Univ, Med Ctr, US Oncol Res, Texas Oncol, Dallas, TX USA. [Rexer, B. N.] Vanderbilt Univ, Med, 221 Kirkland Hall, Nashville, TN 37235 USA. [Puhalla, S. L.] UPMC, Magee Womens Hosp, Med, Pittsburgh, PA USA. [Goetz, M. P.] Mayo Clin, Oncol, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA LBA18 DI 10.1093/annonc/mdw435.8 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000697 ER PT J AU Bellmunt, J Mullane, SA Jacobus, S Polacek, L Takeda, DY Harshman, L Choueiri, T Wagle, N Van Allen, EM Kantoff, P Rosenberg, JE AF Bellmunt, J. Mullane, S. A. Jacobus, S. Polacek, L. Takeda, D. Y. Harshman, L. Choueiri, T. Wagle, N. Van Allen, E. M. Kantoff, P. Rosenberg, J. E. TI Everolimus / pazopanib (E/P) benefits genomically selected patients (pts) with metastatic urothelial carcinoma (mUC) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Bellmunt, J.; Mullane, S. A.; Jacobus, S.; Polacek, L.; Takeda, D. Y.; Harshman, L.; Choueiri, T.; Wagle, N.; Van Allen, E. M.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Kantoff, P.] Mem Sloan Kettering Canc Ctr, Med, 1275 York Ave, New York, NY 10021 USA. [Rosenberg, J. E.] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA. FU Novartis; Dana-Farber FX Novartis, Dana-Farber NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 785P DI 10.1093/annonc/mdw373.13 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500781 ER PT J AU Bellmunt, J Balar, A Galsky, MD Loriot, Y Theodore, C Pulido, EG Castellano, D Retz, M Niegisch, G Bracarda, S Necchi, A Vaishampayan, U Sridhar, S Eigl, BJ Hussain, S van der Heijden, M Danner, B Mariathasan, S Legrand, F Rosenberg, JE AF Bellmunt, J. Balar, A. Galsky, M. D. Loriot, Y. Theodore, C. Grande Pulido, E. Castellano, D. Retz, M. Niegisch, G. Bracarda, S. Necchi, A. Vaishampayan, U. Sridhar, S. Eigl, B. J. Hussain, S. van der Heijden, M. Danner, B. Mariathasan, S. Legrand, F. Rosenberg, J. E. TI IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Bellmunt, J.] Dana Farber Canc Inst, Bladder Canc Ctr, Boston, MA 02115 USA. [Balar, A.] NYU, Langone Med Ctr, Perlmutter Canc Ctr, New York, NY USA. [Galsky, M. D.] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Oncol, New York, NY 10029 USA. [Loriot, Y.] Inst Gustave Roussy, Oncol, Villejuif, France. [Theodore, C.] Hop Foch, Med Oncol, Serv Oncol, Suresnes, France. [Grande Pulido, E.] Hosp Univ Ramon & Cajal, Med Oncol, Madrid, Spain. [Castellano, D.] Univ Hosp 12 Octubre, Med Oncol, Madrid, Spain. [Retz, M.] Tech Univ Munich, Urol Klin & Poliklin, Munich, Germany. [Niegisch, G.] Heinrich Heine Univ Dusseldorf, Univ Klinikum Dusseldorf, Dusseldorf, Germany. [Bracarda, S.] Osped San Donato, Dept Oncol, USL Toscana Sud Est, Arezzo, Italy. [Necchi, A.] Fdn IRCCS, Med Oncol Urol Unit, Ist Nazl Tumori, Milan, Italy. [Vaishampayan, U.] Karmanos Canc Inst, Med Oncol, Detroit, MI USA. [Sridhar, S.] Princess Margaret Hosp, Oncol, Toronto, ON, Canada. [Eigl, B. J.] British Columbia Canc Agcy, Oncol, Vancouver, BC, Canada. [Hussain, S.] Univ Liverpool, Royal Liverpool Univ Hosp, Mol & Clin Canc Med, Liverpool, Merseyside, England. [van der Heijden, M.] Netherlands Canc Inst, Oncol, Amsterdam, Netherlands. [Danner, B.; Mariathasan, S.; Legrand, F.] Genentech Inc, Oncol, San Francisco, CA 94080 USA. [Rosenberg, J. E.] Mem Sloan Kettering Canc Ctr, Oncol, 1275 York Ave, New York, NY 10021 USA. FU F. Hoffmann-La Roche Ltd. FX F. Hoffmann-La Roche Ltd. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 782PD DI 10.1093/annonc/mdw373.10 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500778 ER PT J AU Bossi, A Dearnaley, D McKenzie, M Baskin-Bey, E Tyler, R Tombal, B Freedland, SJ Roach, M Widmark, A Dicker, AP Wiegel, T Shore, N Smith, M Yu, M Kheoh, T Thomas, S Sandler, HM AF Bossi, A. Dearnaley, D. McKenzie, M. Baskin-Bey, E. Tyler, R. Tombal, B. Freedland, S. J. Roach, M., III Widmark, A. Dicker, A. P. Wiegel, T. Shore, N. Smith, M. Yu, M. Kheoh, T. Thomas, S. Sandler, H. M. TI ATLAS: A phase 3 trial evaluating the efficacy of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Bossi, A.] Inst Gustave Roussy, Radiat Oncol, Villejuif, France. [Dearnaley, D.] Inst Canc Res, Acad Radiotherapy, London, England. [Dearnaley, D.] Royal Marsden Hosp, London, England. [McKenzie, M.] British Columbia Canc Agcy, Med Oncol, Vancouver, BC, Canada. [Baskin-Bey, E.; Tyler, R.; Yu, M.] Janssen Res & Dev, WC Clin Oncol, Los Angeles, CA USA. [Tombal, B.] Clin Univ St Luc, Urol, Brussels, Belgium. [Freedland, S. J.] Cedars Sinai Med Ctr, Surg, Los Angeles, CA 90048 USA. [Roach, M., III] Univ Calif San Francisco, Radiat Oncol, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. [Widmark, A.] Umea Univ, Radiat Sci, Umea, Sweden. [Dicker, A. P.] Thomas Jefferson Univ, Radiat Oncol, Philadelphia, PA 19107 USA. [Wiegel, T.] Ulm Med Univ, Radiat Oncol, Ulm, Germany. [Shore, N.] Carolina Urol Res Ctr, Urol, Myrtle Beach, SC USA. [Smith, M.] Massachusetts Gen Hosp, Ctr Canc, Hematol Oncol, Boston, MA USA. [Smith, M.] Harvard Med Sch, Boston, MA USA. [Kheoh, T.] Janssen Res & Dev, Clin Biostat, San Diego, CA USA. [Thomas, S.] Janssen Pharmaceut, Oncol Translat Res, Spring House, PA USA. [Sandler, H. M.] Cedars Sinai Med Ctr, Radiat Oncol, Los Angeles, CA 90048 USA. FU Janssen Research Development FX Janssen Research & Development NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 769TiP DI 10.1093/annonc/mdw372.52 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500765 ER PT J AU Cella, D Escudier, B Tannir, N Powles, T Donskov, F Peltola, K Schmidinger, M Heng, D Mainwaring, P Hammers, H Lee, JL Rini, BI Roth, B Baer, J Mangeshkar, M Scheffold, C Hutson, T Pal, S Motzer, J Choueiri, TK AF Cella, D. Escudier, B. Tannir, N. Powles, T. Donskov, F. Peltola, K. Schmidinger, M. Heng, D. Mainwaring, P. Hammers, H. Lee, J-L. Rini, B. I. Roth, B. Baer, J. Mangeshkar, M. Scheffold, C. Hutson, T. Pal, S. Motzer, J. Choueiri, T. K. TI Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Cella, D.] Northwestern Univ, Dept Med Social Sci, Chicago, IL 60611 USA. [Escudier, B.] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France. [Tannir, N.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Oncol, Houston, TX 77030 USA. [Powles, T.] Queen Mary Univ London, Barts Canc Inst, Expt Canc Med, London, England. [Donskov, F.] Aarhus Univ, Dept Oncol, Aarhus, Denmark. [Peltola, K.] HUCH Helsinki Univ Cent Hosp, Comprehens Canc Ctr, Helsinki, Finland. [Schmidinger, M.] Med Univ Vienna, Dept Med 1, Vienna, Austria. [Heng, D.] Tom Baker Canc Clin, Med Oncol, Calgary, AB, Canada. [Mainwaring, P.] ICON Canc Care, Med Oncol, South Brisbane, Australia. [Hammers, H.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Lee, J-L.] Asan GU Med Ctr, Asan Med Ctr, Dept Oncol & Internal Med, Seoul, South Korea. [Rini, B. I.] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Oncol, Cleveland, OH 44106 USA. [Roth, B.] Washington Univ, Sch Med, Sect Med Oncol, Div Oncol, St Louis, MO USA. [Baer, J.] Exelixis Inc, Translat Med, San Francisco, CA USA. [Mangeshkar, M.] Exelixis Inc, Biostat, San Francisco, CA USA. [Scheffold, C.] Exelixis Inc, Clin Res, San Francisco, CA USA. [Hutson, T.] Baylor Univ, Med Ctr, Charles A Sammons Canc Ctr, Dallas, TX USA. [Pal, S.] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA. [Motzer, J.] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA. [Choueiri, T. K.] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Genitourinary Oncol, 75 Francis St, Boston, MA 02115 USA. FU Exelixis, Inc. FX Exelixis, Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 816P DI 10.1093/annonc/mdw373.43 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500811 ER PT J AU Choueiri, T Agarwal, N Ho, T Pal, SK Seon, B Jivani, M Adams, B Shazer, R Theuer, C AF Choueiri, T. Agarwal, N. Ho, T. Pal, S. K. Seon, B. Jivani, M. Adams, B. Shazer, R. Theuer, C. TI TRAXAR study: a randomized phase 2 trial of axitinib and TRC105 versus axitinib alone in patients with advanced or metastatic renal cell carcinoma (mRCC) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Choueiri, T.] Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02115 USA. [Agarwal, N.] Huntsman Canc Inst, Med Oncol, Salt Lake City, UT USA. [Ho, T.] Mayo Clin, Ctr Canc, Div Hematol Oncol, Scottsdale, CA USA. [Pal, S. K.] City Hope Natl Med Ctr, Med Oncol & Expt Therapeut, Duarte, CA USA. [Seon, B.] Roswell Pk Canc Inst, Immunol, Buffalo, NY 14263 USA. [Jivani, M.; Adams, B.; Shazer, R.; Theuer, C.] TRACON Pharmaceut Inc, Clin Operat, San Diego, CA USA. FU TRACON Pharmacuticals, Inc. FX TRACON Pharmacuticals, Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 851TiP DI 10.1093/annonc/mdw373.78 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500846 ER PT J AU Choueiri, T Michaelson, MD Posadas, E Sonpavde, G McDermott, D Seon, B Jivani, M Shazer, R Adams, B Theuer, C AF Choueiri, T. Michaelson, M. D. Posadas, E. Sonpavde, G. McDermott, D. Seon, B. Jivani, M. Shazer, R. Adams, B. Theuer, C. TI A phase 1b dose-escalation study of TRC105 (endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Choueiri, T.] Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02115 USA. [Michaelson, M. D.] Massachusetts Gen Hosp, Med Oncol, Boston, MA 02114 USA. [Posadas, E.] Cedars Sinai Med Ctr, Urol Oncol Program, Los Angeles, CA 90048 USA. [Sonpavde, G.] Univ Alabama Birmingham Hosp, Med Oncol, Birmingham, LA USA. [McDermott, D.] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA. [Seon, B.] Roswell Pk Canc Inst, Immunol, Buffalo, NY 14263 USA. [Jivani, M.; Shazer, R.; Adams, B.; Theuer, C.] TRACON Pharmaceut Inc, Clin Operat, San Diego, CA USA. FU TRACON Pharmaceuticals, Inc. FX Sponsor: TRACON Pharmaceuticals, Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 804P DI 10.1093/annonc/mdw373.32 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500800 ER PT J AU Choueiri, TK Halabi, S Sanford, B Hahn, O Michaelson, MD Walsh, M Olencki, T Picus, J Small, EJ Dakhil, S George, D Morris, MJ AF Choueiri, T. K. Halabi, S. Sanford, B. Hahn, O. Michaelson, M. D. Walsh, M. Olencki, T. Picus, J. Small, E. J. Dakhil, S. George, D. Morris, M. J. TI CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Choueiri, T. K.; Walsh, M.] Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02115 USA. [Halabi, S.; Sanford, B.] Duke Univ, Biostat & Bioinformat, Durham, NC USA. [Hahn, O.] Univ Chicago, Med Ctr, Med Oncol, Chicago, IL 60637 USA. [Michaelson, M. D.] Massachusetts Gen Hosp, Med Oncol, Boston, MA 02114 USA. [Olencki, T.] Ohio State Univ, Med Ctr, Med Oncol, Columbus, OH 43210 USA. [Picus, J.] Washington Univ, Sch Med, Med Oncol, St Louis, MO USA. [Small, E. J.] UCSF, Helen Diller Family Comprehens Canc Ctr, Med Oncol, San Francisco, CA USA. [Dakhil, S.] Canc Ctr Kansas, Hematol, Wichita, KS USA. [George, D.] Duke Univ, Med Oncol, Durham, NC USA. [Morris, M. J.] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA. FU Exelixis FX Exelixis NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA LBA30_PR DI 10.1093/annonc/mdw435.23 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000712 ER PT J AU Cohen, E Saba, NF Gitlitz, B Haddad, R Sukari, A Neupane, P Morris, JC Misiukiewicz, K Manjarrez, KL Dietsch, GN Bryan, JK Hershberg, RM Ferris, RL AF Cohen, E. Saba, N. F. Gitlitz, B. Haddad, R. Sukari, A. Neupane, P. Morris, J. C. Misiukiewicz, K. Manjarrez, K. L. Dietsch, G. N. Bryan, J. K. Hershberg, R. M. Ferris, R. L. TI Active8: A randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with motolimod immunotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Cohen, E.] UCSD Moores Canc Ctr, Translat Sci, La Jolla, CA USA. [Saba, N. F.] Emory Univ, Winship Canc Inst, Head & Neck Oncol, Atlanta, GA 30322 USA. [Gitlitz, B.] Univ Southern Calif, Keck Sch Med, Oncol, Los Angeles, CA USA. [Haddad, R.] Dana Farber Canc Inst, Head & Neck Oncol Program, Boston, MA 02115 USA. [Sukari, A.] Karmanos Canc Inst, Oncol, Detroit, MI USA. [Neupane, P.] Univ Kansas, Ctr Canc, Med Oncol, Kansas City, KS USA. [Morris, J. C.] Univ Cincinnati, Comprehens Lung Canc Ctr, Inst Canc, Cincinnati, OH USA. [Misiukiewicz, K.] Mt Sinai Med Ctr, Hematol Oncol, New York, NY 10029 USA. [Manjarrez, K. L.; Bryan, J. K.] VentiRx Pharmaceut, Clin, Seattle, WA USA. [Dietsch, G. N.] VentiRx Pharmaceut, Res & Dev, Seattle, WA USA. [Hershberg, R. M.] VentiRx Pharmaceut, Seattle, WA USA. [Ferris, R. L.] Univ Pittsburgh, Dept Otolaryngol, Inst Canc, Div Head & Neck Surg, Pittsburgh, PA 15260 USA. FU VentiRx Pharmaceuticals, Inc. FX VentiRx Pharmaceuticals, Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA LBA37 DI 10.1093/annonc/mdw435.33 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000722 ER PT J AU Corcoran, RB Andre, T Yoshino, T Bendell, JC Atreya, CE Schellens, JHM Ducreux, MP McRee, A Siena, S Middleton, G Gordon, M Humblet, Y Muro, K Elez, E Yaeger, R Sidhu, R Squires, M Jaeger, S Rangwala, F Van Cutsem, E AF Corcoran, R. B. Andre, T. Yoshino, T. Bendell, J. C. Atreya, C. E. Schellens, J. H. M. Ducreux, M. P. McRee, A. Siena, S. Middleton, G. Gordon, M. Humblet, Y. Muro, K. Elez, E. Yaeger, R. Sidhu, R. Squires, M. Jaeger, S. Rangwala, F. Van Cutsem, E. TI Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E-mutated (BRAFm) metastatic colorectal cancer (mCRC) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Corcoran, R. B.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Andre, T.] Hop St Antoine, Oncol Med, Paris, France. [Yoshino, T.] Natl Canc Ctr Hosp East, Gastroenterol & Gastrointestinal Oncol, Chiba, Japan. [Bendell, J. C.] Sarah Cannon Res Inst, GI Oncol Res, Nashville, TN USA. [Atreya, C. E.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. [Schellens, J. H. M.] Netherlands Canc Inst, Clin Pharmacol, Amsterdam, Netherlands. [Ducreux, M. P.] Inst Gustave Roussy, Med, Villejuif, France. [McRee, A.] Univ North Carolina Chapel Hill, GI Med Oncol, Chapel Hill, NC USA. [Siena, S.] Univ Milan, Niguarda Canc Ctr, Osped Niguarda, Milan, Italy. [Middleton, G.] Univ Birmingham, Sch Canc Sci, Birmingham, W Midlands, England. [Gordon, M.] Pinnacle Oncol Hematol, Div Arizona Ctr Canc Care, Scottsdale, AZ USA. [Humblet, Y.] St Luc Univ Hosptial, Dept Med Oncol, Brussels, Belgium. [Muro, K.] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan. [Elez, E.] Vall Hebron Univ Hosp, Med Oncol, Barcelona, Spain. [Yaeger, R.] Mem Sloan Kettering Canc Ctr, Gastrointestinal Oncol, 1275 York Ave, New York, NY 10021 USA. [Sidhu, R.] Amgen Inc, Hematol Oncol, Thousand Oaks, CA 91320 USA. [Squires, M.] Novartis Pharma AG, Global Oncol, Basel, Switzerland. [Jaeger, S.] Novartis Inst Biomed Res Inc, Biomarkers & Diagnost Biometr, Boston, MA USA. [Rangwala, F.] Novartis Pharmaceut, Global Oncol, East Rutherford, NJ USA. [Van Cutsem, E.] Univ Hosp Leuven, Digest Oncol, Leuven, Belgium. FU GlaxoSmithKline FX Supported by GlaxoSmithKline. Dabrafenib and trametinib are assets of Novartis AG as of 2 March 2015. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 455O DI 10.1093/annonc/mdw370.4 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500453 ER PT J AU Castan, JC Verma, S Hurvitz, S Krop, IE Tripathy, D Yardley, DA Dionne, M Reynolds, J Wickham, T Molnar, I Miller, K AF Cortes Castan, J. Verma, S. Hurvitz, S. Krop, I. E. Tripathy, D. Yardley, D. A. Dionne, M. Reynolds, J. Wickham, T. Molnar, I. Miller, K. TI HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and T-DM1 SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Cortes Castan, J.] Ramon & Cajal Univ Hosp, Med Oncol, Madrid, Spain. [Cortes Castan, J.] Vall dHebron Inst Oncol VHIO, Barcelona, Spain. [Verma, S.] Sunnybrook HSC, Sunnybrook Odette Canc Ctr, Med Oncol, Toronto, ON, Canada. [Hurvitz, S.] UCLA Med Ctr, Hematol Oncol, Santa Monica, CA USA. [Krop, I. E.] Dana Farber Canc Inst, Breast Canc Treatment Ctr, Boston, MA 02115 USA. [Tripathy, D.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA. [Yardley, D. A.] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Breast Canc Res Program, Nashville, TN USA. [Dionne, M.; Reynolds, J.; Wickham, T.; Molnar, I.] Merrimack, Dev, Cambridge, MA USA. [Miller, K.] Indiana Univ, Oncol, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA. FU Merrimack Pharmaceuticals FX Merrimack Pharmaceuticals NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 315TiP DI 10.1093/annonc/mdw365.94 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500314 ER PT J AU Crawley, D Chandra, A Loda, M Gillett, C Cathcart, P Challacombe, B Cook, G Cahill, D Cahill, F Santa Olalla, A George, G Rudman, S van Hemelrijck, M AF Crawley, D. Chandra, A. Loda, M. Gillett, C. Cathcart, P. Challacombe, B. Cook, G. Cahill, D. Cahill, F. Santa Olalla, A. George, G. Rudman, S. van Hemelrijck, M. TI Metformin and longevity (METAL): A window of opportunity study investigating the biological effects of metformin in localised prostate cancer SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Crawley, D.; Cahill, F.; Santa Olalla, A.; George, G.; van Hemelrijck, M.] Kings Coll London, Res Oncol, Guys Hosp, London, England. [Chandra, A.] Guys & St Thomas Hosp NHS Trust, Histopathol, London, England. [Loda, M.] Dana Farber Canc Inst, Mol Pathol, Boston, MA 02115 USA. [Gillett, C.] Kings Coll London, Div Canc Studies, Guys Hosp, London, England. [Cathcart, P.; Challacombe, B.] Guys & St Thomas Hosp NHS Trust, Urol, London, England. [Cook, G.] Guys & St Thomas Hosp NHS Trust, Nucl Med, London, England. [Cahill, F.] Royal Marsden Hosp NHS Fdn Trust, Urol, London, England. [Rudman, S.] Guys & St Thomas Hosp NHS Trust, Med Oncol, London, England. FU JP Moulton Charitable Foundation FX JP Moulton Charitable Foundation NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 765TiP DI 10.1093/annonc/mdw372.49 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500762 ER PT J AU Currow, D Temel, J Abernethy, A Friend, J Giorgino, R Fearon, KC AF Currow, D. Temel, J. Abernethy, A. Friend, J. Giorgino, R. Fearon, K. C. TI Anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and acute phase protein reaction (APPR): Pooled analysis of two phase 3 trials (ROMANA 1 and ROMANA 2) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Currow, D.] Flinders Univ S Australia, Discipline Palliat & Support Serv, Adelaide, SA, Australia. [Temel, J.] Massachusetts Gen Hosp, Ctr Canc, Hematol Oncol, Boston, MA USA. [Abernethy, A.] Flatiron Hlth, New York, NY USA. [Friend, J.] Helsinn Therapeut US Inc, R&D, Iselin, NJ USA. [Giorgino, R.] Helsinn Healthcare SA, R&D, Pambio Noranco, Switzerland. [Fearon, K. C.] Royal Infirm, Surg, Edinburgh, Midlothian, Scotland. FU Helsinn Therapeutics FX Helsinn Therapeutics NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1446P DI 10.1093/annonc/mdw390.14 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000533 ER PT J AU Davies, M Grob, JJ Long, GV Flaherty, K Nathan, P Ribas, A Schadendorf, D Mookerjee, B Legos, JJ Lane, S Robert, C AF Davies, M. Grob, J. J. Long, G. V. Flaherty, K. Nathan, P. Ribas, A. Schadendorf, D. Mookerjee, B. Legos, J. J. Lane, S. Robert, C. TI Pooled analysis of factors to predict durable clinical outcomes with combination dabrafenib (D) and trametinib (T) across registration trials SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Davies, M.] Univ Texas MD Anderson Canc Ctr, Melanoma Med Oncol, Houston, TX 77030 USA. [Grob, J. J.] Aix Marseille Univ, Serv Dermatol & Cancerol Cutanee, Marseille, France. [Long, G. V.] Melanoma Inst Australia, Med Oncol, Sydney, NSW, Australia. [Long, G. V.] Univ Sydney, Sydney, NSW, Australia. [Flaherty, K.] Harvard Med Sch, Dana Farber Canc Inst, Melanoma, Boston, MA USA. [Flaherty, K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nathan, P.] Mt Vernon Canc Ctr, Dept Med Oncol, Northwood, Middx, England. [Ribas, A.] Univ Calif Los Angeles, Med Hematol & Oncol, Los Angeles, CA USA. [Ribas, A.] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA. [Schadendorf, D.] Univ Hosp Essen, Dept Dermatol, Essen, Germany. [Mookerjee, B.; Legos, J. J.; Lane, S.] Novartis Pharmaceut, Global Oncol, E Hanover, NJ USA. [Robert, C.] Gustave Roussy Comprehens Canc Ctr, Dermatol, Villejuif, France. FU GlaxoSmithKline FX Supported by GlaxoSmithKline. Dabrafenib and trametinib are assets of Novartis AG as of 2 March 2015. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1134P DI 10.1093/annonc/mdw379.29 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000227 ER PT J AU de Wit, R Kamat, AM Bellmunt, J Choueiri, TK Nam, K De Santis, M Dreicer, R Hahn, NM Perini, R Siefker-Radtke, AO Sonpavde, G Witjes, JA Keefe, S Bajorin, D AF de Wit, R. Kamat, A. M. Bellmunt, J. Choueiri, T. K. Nam, K. De Santis, M. Dreicer, R. Hahn, N. M. Perini, R. Siefker-Radtke, A. O. Sonpavde, G. Witjes, J. A. Keefe, S. Bajorin, D. TI Pembrolizumab in patients with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [de Wit, R.] Erasmus MC Canc Inst, Oncol, Rotterdam, Netherlands. [Kamat, A. M.] Univ Texas MD Anderson Canc Ctr, Urol, Houston, TX 77030 USA. [Bellmunt, J.] Harvard Med Sch, Dana Farber Canc Inst, Bladder Canc Ctr, Boston, MA USA. [Choueiri, T. K.] Brigham & Womens Hosp, Dana Farber Canc Inst, Oncol, 75 Francis St, Boston, MA 02115 USA. [Nam, K.; Perini, R.; Keefe, S.] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA. [De Santis, M.] Univ Warwick, Oncol, Coventry, W Midlands, England. [Dreicer, R.] Univ Virginia, Sch Med, Dept Med, Div Hematol Oncol, Charlottesville, VA 22908 USA. [Hahn, N. M.] Johns Hopkins Univ, Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Siefker-Radtke, A. O.] Univ Texas MD Anderson Canc Ctr, Genitourinary Med Oncol, Houston, TX 77030 USA. [Sonpavde, G.] Univ Alabama Birmingham, Ctr Comprehens Canc, Med Oncol, Hematol, Birmingham, AL 35294 USA. [Witjes, J. A.] Univ Radboud, Urol, Nijmegen, Netherlands. [Bajorin, D.] Mem Sloan Kettering Canc Ctr, Div Solid Tumor Oncol, Genitourinary Oncol Serv, New York, NY 10021 USA. FU Merck Co., Inc. FX Merck & Co., Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 849TiP DI 10.1093/annonc/mdw373.76 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500844 ER PT J AU Demetri, GD Reichardt, P Kang, YK Blay, JY Joensuu, H Kappeler, C Wuchter-Czerwony, C Chung, J Wagner, A Casali, PG AF Demetri, G. D. Reichardt, P. Kang, Y-K. Blay, J-Y. Joensuu, H. Kappeler, C. Wuchter-Czerwony, C. Chung, J. Wagner, A. Casali, P. G. TI Long-term safety of regorafenib (REG) in advanced gastrointestinal stromal tumors (GIST): updated safety data of the phase 3 GRID trial SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Demetri, G. D.] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA. [Demetri, G. D.] Harvard Med Sch, Ludwig Ctr, Boston, MA USA. [Reichardt, P.] Helios Klinikum Berlin Buch, Dept Hematol Oncol & Palliat Med, Berlin, Germany. [Kang, Y-K.] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea. [Blay, J-Y.] Univ Claude Bernard, Ctr Leon Berard, Lyon, France. [Joensuu, H.] Univ Helsinki, Cent Hosp, Dept Oncol, Helsinki, Finland. [Kappeler, C.] Bayer Pharma AG, Clin Stat Europe, Berlin, Germany. [Wuchter-Czerwony, C.] Bayer Pharma AG, Pharmacovigilance, Berlin, Germany. [Chung, J.] Bayer HealthCare Pharmaceut, Clin Dev Oncol, Whippany, NJ USA. [Wagner, A.] Bayer Pharma AG, Clin Dev Oncol, Berlin, Germany. [Casali, P. G.] Ist Nazl Tumori, Adult Sarcoma Med Oncol Unit, Milan, Italy. FU Bayer FX Bayer NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1415P DI 10.1093/annonc/mdw388.21 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000502 ER PT J AU Desai, J Hong, YS Kim, JE Kim, TW Han, SW Bang, YJ Chee, CE Heong, VYM Mcree, A Chow, LQ Kwak, EL Infante, JR Wallin, J Das Thakur, M Mwawasi, G Foster, P Cha, E Bendell, JC AF Desai, J. Hong, Y. S. Kim, J. E. Kim, T. W. Han, S. W. Bang, Y-J. Chee, C. E. Heong, V. Y. M. Mcree, A. Chow, L. Q. Kwak, E. L. Infante, J. R. Wallin, J. Das Thakur, M. Mwawasi, G. Foster, P. Cha, E. Bendell, J. C. TI Efficacy and safety of cobimetinib (cobi) and atezolizumab (atezo) in an expanded phase 1b study of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Desai, J.] Royal Melbourne Hosp, Med Oncol, Melbourne, Vic, Australia. [Hong, Y. S.; Kim, J. E.; Kim, T. W.] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea. [Han, S. W.; Bang, Y-J.] Seoul Natl Univ Hosp, Oncol, Seoul, South Korea. [Chee, C. E.; Heong, V. Y. M.] Natl Univ Singapore Hosp, Inst Canc, Oncol, Singapore, Singapore. [Mcree, A.] Univ North Carolina Chapel Hill, GI Med Oncol, Chapel Hill, NC USA. [Chow, L. Q.] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA. [Kwak, E. L.] Massachusetts Gen Hosp, Oncol, Boston, MA 02114 USA. [Infante, J. R.; Bendell, J. C.] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Drug Dev Program, Nashville, TN USA. [Wallin, J.; Das Thakur, M.; Mwawasi, G.; Foster, P.; Cha, E.] Genentech Inc, Oncol, San Francisco, CA 94080 USA. FU F. Hoffmann La-Roche Ltd. FX F. Hoffmann La-Roche Ltd. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 470P DI 10.1093/annonc/mdw370.19 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500525 ER PT J AU Eads, J Stein, S El-Khoueiry, A Manji, G Abrams, T Khorana, AA Miksad, R Mahalingam, D Sirard, C Zhu, AX Goyal, L AF Eads, J. Stein, S. El-Khoueiry, A. Manji, G. Abrams, T. Khorana, A. A. Miksad, R. Mahalingam, D. Sirard, C. Zhu, A. X. Goyal, L. TI Phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer (ABC) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Eads, J.] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA. [Stein, S.] Yale Univ, Sch Med Med Oncol, Ctr Canc, New Haven, CT USA. [El-Khoueiry, A.] Univ Southern Callifornia, Norris Comprehens Canc Ctr, Los Angeles, CA USA. [Manji, G.] Columbia Univ, Div Hematol & Oncol, New York, NY USA. [Abrams, T.] Dana Farber Canc Inst, Gastrointestinal Canc, Boston, MA 02115 USA. [Khorana, A. A.] Cleveland Clin, Hematol & Oncol, Cleveland, OH 44106 USA. [Miksad, R.] Beth Israel Deaconess Med Ctr, Hematol Oncol, Boston, MA 02215 USA. [Mahalingam, D.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA. [Sirard, C.] Leap Therapeut Inc, Clin Res, Cambridge, MA USA. [Zhu, A. X.; Goyal, L.] Massachusetts Gen Hosp, Hematol Oncol, Boston, MA 02114 USA. FU Leap Therapeutics, Inc. FX Leap Therapeutics, Inc. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 698P DI 10.1093/annonc/mdw371.90 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500704 ER PT J AU Falcone, A Ohtsu, A Van Cutsem, E Mayer, R Buscaglia, M Bendell, JC Kopetz, S Wahba, M Bebeau, P Yoshino, T AF Falcone, A. Ohtsu, A. Van Cutsem, E. Mayer, R. Buscaglia, M. Bendell, J. C. Kopetz, S. Wahba, M. Bebeau, P. Yoshino, T. TI Integrated safety summary (ISS) for trifluridine/tipiracil (TAS-102) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Falcone, A.] Azienda Osped Univ Pisana, Med Oncol, Pisa, Italy. [Ohtsu, A.] Natl Canc Ctr Hosp East, Clin Dev, Kashiwa, Chiba, Japan. [Van Cutsem, E.] Univ Hosp Leuven, Med Digest Oncol, Campus Gasthuisberg, Leuven, Belgium. [Mayer, R.] Dana Farber Canc Inst, Gastrointestinal Canc, Boston, MA 02115 USA. [Buscaglia, M.] IRCCS AOU San Martino IST, Med Oncol, Genoa, Italy. [Bendell, J. C.] Tennessee Oncol, Sarah Cannon Res Inst, Drug Dev, GI Oncol Res, Nashville, TN USA. [Kopetz, S.] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Gastrointestinal GI Med Oncol, Houston, TX 77030 USA. [Wahba, M.] Taiho Oncol Inc, Med Pharmacovigilance, Med Affairs, Princeton, NJ USA. [Bebeau, P.] Taiho Oncol Inc, Pharmacovigilance, Princeton, NJ USA. [Yoshino, T.] Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, Japan. FU Taiho Pharmaceutical Co., Ltd. FX Taiho Pharmaceutical Co., Ltd. NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 555P DI 10.1093/annonc/mdw370.103 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500463 ER PT J AU Felip, E Orlov, S Park, K Yu, CJ Tsai, CM Nishio, M Dols, MC McKeage, M Su, WC Mok, TSK Scagliotti, G Spigel, DR Passos, VQ Chen, V Munarini, F Shaw, A AF Felip, E. Orlov, S. Park, K. Yu, C-J. Tsai, C-M. Nishio, M. Dols, M. C. McKeage, M. Su, W-C. Mok, T. S. K. Scagliotti, G. Spigel, D. R. Passos, V. Q. Chen, V. Munarini, F. Shaw, A. TI Phase 2 study of ceritinib in ALKi-naive patients (pts) with ALK-rearranged (ALK plus ) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Felip, E.] Vall dHebron Univ Hosp, Med Oncol, Inst Oncol, Barcelona, Spain. [Orlov, S.] Pavlov State Med Univ St Petersburg, Thorac Oncol, St Petersburg, Russia. [Park, K.] Innovat Canc Med Inst, Hematol Oncol, Seoul, South Korea. [Yu, C-J.] Natl Taiwan Univ, Internal Med, Coll Med, Taipei, Taiwan. [Tsai, C-M.] Taipei Vet Gen Hosp, Thorac Oncol, Taipei, Taiwan. [Nishio, M.] JFCR, Canc Inst Hosp, Thorac Med Oncol, Tokyo, Japan. [Dols, M. C.] Hosp Univ Malaga Gen Carlos Haya, Med Oncol, Malaga, Spain. [McKeage, M.] Univ Auckland, Clin Pharmacol, Auckland, New Zealand. [Su, W-C.] Natl Cheng Kung Univ Hosp, Internal Med, Tainan, Taiwan. [Mok, T. S. K.] Chinese Univ Hong Kong, Clin Oncol, Hong Kong, Hong Kong, Peoples R China. [Scagliotti, G.] Univ Turin, Oncol, Orbassano, Italy. [Spigel, D. R.] Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA. [Passos, V. Q.; Chen, V.] Novartis Pharmaceut, Oncol, E Hanover, NJ USA. [Munarini, F.] Novartis Pharma AG, Oncol Clin Dev, Basel, Switzerland. [Shaw, A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. FU Novartis Pharmaceutical Corporation FX Novartis Pharmaceutical Corporation NR 0 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1208O PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000295 ER PT J AU Ferrari, A Chen, YH Hudes, G Carducci, M Antonarakis, ES Hahn, NM Ma, H Wong, YN Mayer, T Somer, RA Carthon, B Dipaola, R AF Ferrari, A. Chen, Y-H. Hudes, G. Carducci, M. Antonarakis, E. S. Hahn, N. M. Ma, H. Wong, Y-N. Mayer, T. Somer, R. A. Carthon, B. Dipaola, R. TI E2809. Androgen receptor (AR) modulation by bicalutamide (Bic) and MK-2206 (MK) in prostate cancer (PC) patients (pts) with rising PSA at high risk of progression after local treatment (tx) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Ferrari, A.; Mayer, T.; Dipaola, R.] Canc Inst New Jersey, Med Oncol, New Brunswick, NJ USA. [Chen, Y-H.] Dana Farber Canc Inst, Biostastict, Boston, MA 02115 USA. [Hudes, G.; Wong, Y-N.] Fox Chase Canc Ctr, Med Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Carducci, M.] Johns Hopkins Univ, Oncol, Baltimore, MD USA. [Antonarakis, E. S.] Johns Hopkins Univ, Med Oncol, Baltimore, MD USA. [Hahn, N. M.] Johns Hopkins Med Inst, Canc Pavil, Indianapolis, IN USA. [Ma, H.] NYU, Ctr Canc, New York, NY USA. [Somer, R. A.] Cooper Univ Hosp, Med Oncol, Camden, NJ USA. [Carthon, B.] Emory Univ, Winship Canc Inst, Hematol Oncol, Atlanta, GA 30322 USA. FU National Cancer Institute, Cancer Treatment Evaluation Program FX National Cancer Institute, Cancer Treatment Evaluation Program NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 733P DI 10.1093/annonc/mdw372.17 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500730 ER PT J AU Finn, R Chan, SL Zhu, AX Knox, J Cheng, AL Siegel, A Bautista, O Watson, PA Kudo, M AF Finn, R. Chan, S. L. Zhu, A. X. Knox, J. Cheng, A-L. Siegel, A. Bautista, O. Watson, P. A. Kudo, M. TI Pembrolizumab vs best supportive care for second-line advanced hepatocellular carcinoma: Randomized, phase 3 KEYNOTE-240 study SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Finn, R.] Univ Calif Los Angeles, Geffen Sch Med, Oncol, Los Angeles, CA USA. [Chan, S. L.] Chinese Univ Hong Kong, Clin Oncol, Prince Wales Hosp, Hong Kong, Peoples R China. [Zhu, A. X.] Massachusetts Gen Hosp, Med, Boston, MA 02114 USA. [Knox, J.] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada. [Cheng, A-L.] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan. [Siegel, A.] Merck & Co Inc, Oncol Clin Res, Kenilworth, NJ USA. [Bautista, O.] Merck & Co Inc, Oncol, Kenilworth, NJ USA. [Watson, P. A.] Merck & Co Inc, Clin Res, Kenilworth, NJ USA. [Kudo, M.] Kindai Univ, Gastroenterol & Hepatol, Osaka, Japan. FU Merck Co., Inc. FX Merck & Co., Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 713TiP DI 10.1093/annonc/mdw371.105 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500621 ER PT J AU Fracasso, PM Freeman, DJ Simonsen, K Shen, Y Gupta, M Comprelli, A Gainor, JF Hellmann, M Chow, LQ Forde, PM Govindan, R Reilly, TP Cassidy, J AF Fracasso, P. M. Freeman, D. J. Simonsen, K. Shen, Y. Gupta, M. Comprelli, A. Gainor, J. F. Hellmann, M. Chow, L. Q. Forde, P. M. Govindan, R. Reilly, T. P. Cassidy, J. TI A phase 2, fast real-time assessment of combination therapies in immuno-oncology trial in patients with advanced non-small cell lung cancer (FRACTION-lung) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Fracasso, P. M.] Bristol Myers Squibb Co, Exploratory Clin & Translat Res, Immunooncol Oncol, Princeton, NJ USA. [Freeman, D. J.] Bristol Myers Squibb Co, Oncol Biomarkers, Princeton, NJ USA. [Simonsen, K.; Shen, Y.] Bristol Myers Squibb Co, Biostat, Princeton, NJ USA. [Gupta, M.] Bristol Myers Squibb Co, Clin Pharmacol & Pharmacometr, Princeton, NJ USA. [Comprelli, A.; Cassidy, J.] Bristol Myers Squibb Co, Oncol, Princeton, NJ USA. [Gainor, J. F.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Hellmann, M.] Mem Sloan Kettering Canc Ctr, Oncol, 1275 York Ave, New York, NY 10021 USA. [Chow, L. Q.] Univ Washington, Div Med Oncol, Dept Med, Seattle, WA USA. [Forde, P. M.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Govindan, R.] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA. [Reilly, T. P.] Bristol Myers Squibb Co, Immunooncol, Princeton, NJ USA. FU Bristol Myers-Squibb FX Sponsored by Bristol Myers-Squibb NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1295TiP DI 10.1093/annonc/mdw383.95 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000387 ER PT J AU Frigault, MM Stetson, D Maloney, E Kramkowski, JF Barry, E Lamberth, EK Signoretti, S D'Cruz, C Dougherty, B Barrett, JC Choueiri, TK AF Frigault, M. M. Stetson, D. Maloney, E. Kramkowski, J. F. Barry, E. Lamberth, E. K. Signoretti, S. D'Cruz, C. Dougherty, B. Barrett, J. C. Choueiri, T. K. TI Response to savolitinib (AZD6094/HMPL-504, a potent and selective MET inhibitor) in a papillary renal cell carcinoma patient harbouring a novel MET activating mutation SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Frigault, M. M.; Stetson, D.; Barry, E.; Dougherty, B.] AstraZeneca PLC, Oncol Translat Sci, Boston, MA USA. [Maloney, E.] AstraZeneca PLC, Oncol Sci, Boston, MA USA. [Kramkowski, J. F.] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA. [Lamberth, E. K.] Sarah Cannon Res Inst, Cin Operat, Nashville, TN USA. [Signoretti, S.] Brigham & Womens Hosp, Pathol, 75 Francis St, Boston, MA 02115 USA. [D'Cruz, C.] AstraZeneca, BioSci, Boston, MA USA. [Barrett, J. C.] AstraZeneca PLC, Oncol Translat Sci, Boston, MA USA. [Choueiri, T. K.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. FU AstraZeneca PLC FX AstraZeneca PLC NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1549P DI 10.1093/annonc/mdw392.30 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000635 ER PT J AU Gandhi, L Gadgeel, S Shaw, A Barlesi, F Crino, L Yang, JCH Dingemans, AMC Kim, DW de Marinis, F Schulz, M Liu, S Fish, S Kotb, A Ou, SHI AF Gandhi, L. Gadgeel, S. Shaw, A. Barlesi, F. Crino, L. Yang, J. C-H. Dingemans, A-M. C. Kim, D-W. de Marinis, F. Schulz, M. Liu, S. Fish, S. Kotb, A. Ou, S-H. I. TI Time to response in patients with ALK plus NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Gandhi, L.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Gadgeel, S.] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. [Shaw, A.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Barlesi, F.] Aix Marseille Univ, Multidisciplinary Oncol & Therapeut Innovat, Marseille, France. [Crino, L.] Santa Maria della Misericordia Hosp, Med Oncol, Perugia, Italy. [Yang, J. C-H.] Natl Taiwan Univ Hosp, Grad Inst Oncol, Taipei, Taiwan. [Yang, J. C-H.] Natl Taiwan Univ Hosp, Canc Res Ctr, Taipei, Taiwan. [Dingemans, A-M. C.] MUMC, Pulmonol, Maastricht, Netherlands. [Kim, D-W.] Seoul Natl Univ Hosp, Med Oncol, Seoul, South Korea. [de Marinis, F.] European Inst Oncol, Thorac Inst Oncol, Milan, Italy. [Schulz, M.; Liu, S.; Fish, S.] Genentech Inc, US Med Affairs, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA. [Kotb, A.] F Hoffmann La Roche Ltd, Med Affairs, Basel, Switzerland. [Ou, S-H. I.] Univ Calif Irvine, Med Oncol, Orange, CA 92668 USA. FU F. Hoffmann-La Roche Ltd FX F. Hoffmann-La Roche Ltd NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1209PD PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000301 ER PT J AU Geretti, E Espelin, C Adiwijaya, B Dumont, N Coma, S Koncki, Z Garcia, G Bloom, T Rimkunas, V Reynolds, J Campbell, K Moyo, V Molnar, I Lorusso, P Miller, K Ma, C Krop, IE Munster, P Wickham, T AF Geretti, E. Espelin, C. Adiwijaya, B. Dumont, N. Coma, S. Koncki, Z. Garcia, G. Bloom, T. Rimkunas, V. Reynolds, J. Campbell, K. Moyo, V. Molnar, I. Lorusso, P. Miller, K. Ma, C. Krop, I. E. Munster, P. Wickham, T. TI Quantitative evaluation of HER2-mediated cellular uptake of the HER2-targeted antibody-liposomal doxorubicin conjugate MM-302 suggests potential for treating HER2-intermediate tumors SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Geretti, E.; Espelin, C.; Adiwijaya, B.; Dumont, N.; Coma, S.; Koncki, Z.; Garcia, G.; Bloom, T.; Rimkunas, V.; Reynolds, J.; Campbell, K.; Moyo, V.; Molnar, I.; Wickham, T.] Merrimack Pharmaceut Inc, Dev, Cambridge, MA USA. [Lorusso, P.] Yale Sch Med, Yale Canc Ctr, New Haven, CT USA. [Miller, K.] Indiana Univ, Melvin & Bren Simon Canc Ctr, Oncol, Indianapolis, IN 46204 USA. [Ma, C.] Washington Univ, Sch Med, St Louis, MO USA. [Krop, I. E.] Dana Farber Canc Inst, Breast Canc Treatment Ctr, Boston, MA 02115 USA. [Munster, P.] Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA. FU Merrimack Pharmaceuticals, Inc. FX Merrimack Pharmaceuticals, Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1560P DI 10.1093/annonc/mdw392.41 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000646 ER PT J AU Grob, JJ Robert, C Long, GV Stroyakovskiy, D Levchenko, E Chiarion-Sileni, V Flaherty, K Nathan, P Ribas, A Davies, M Zhang, J Chen, L Mookerjee, B Redhu, S Schadendorf, D AF Grob, J. J. Robert, C. Long, G. V. Stroyakovskiy, D. Levchenko, E. Chiarion-Sileni, V. Flaherty, K. Nathan, P. Ribas, A. Davies, M. Zhang, J. Chen, L. Mookerjee, B. Redhu, S. Schadendorf, D. TI Health-related quality-of-life (HRQOL) impact of dabrafenib (D) and trametinib (T) vs BRAF inhibitor (BRAFi) monotherapy by lactate dehydrogenase (LDH) in patients (pts) with BRAF V600-mutant melanoma SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Grob, J. J.] Aix Marseille Univ, Serv Dermatol & Cancerol Cutanee, Marseille, France. [Robert, C.] Gustave Roussy Comprehens Canc Ctr, Dermatol, Villejuif, France. [Long, G. V.] Melanoma Inst Australia, Med Oncol, Sydney, NSW, Australia. [Long, G. V.] Univ Sydney, Sydney, NSW, Australia. [Stroyakovskiy, D.] Moscow City Oncol Hosp 62, Dept Chemotherapy, Moscow, Russia. [Levchenko, E.] NN Petrov Res Inst Oncol, Oncol, St Petersburg, Russia. [Chiarion-Sileni, V.] Veneto Oncol Inst, Melanoma & Skin Canc Unit, Padua, Italy. [Flaherty, K.] Harvard Med Sch, Dana Farber Canc Inst, Melanoma, Boston, MA USA. [Flaherty, K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nathan, P.] Mt Vernon Canc Ctr, Dept Med Oncol, Northwood, Middx, England. [Ribas, A.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Med Hematol & Oncol, Los Angeles, CA 90024 USA. [Davies, M.] Univ Texas MD Anderson Canc Ctr, Melanoma Med Oncol, Houston, TX 77030 USA. [Zhang, J.; Chen, L.; Mookerjee, B.; Redhu, S.] Novartis Pharmaceut, Global Oncol, E Hanover, NJ USA. [Schadendorf, D.] Univ Hosp Essen, Dept Dermatol, Essen, Germany. FU GlaxoSmithKline FX Supported by GlaxoSmithKline. Dabrafenib and trametinib are assets of Novartis AG as of 2 March 2015. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1137P DI 10.1093/annonc/mdw379.32 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000230 ER PT J AU Haddad, R Gillison, M Ferris, RL Harrington, K Monga, M Baudelet, C Geese, WJ Argiris, A AF Haddad, R. Gillison, M. Ferris, R. L. Harrington, K. Monga, M. Baudelet, C. Geese, W. J. Argiris, A. TI Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) - CheckMate 714 SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Haddad, R.] Dana Farber Harvard Canc Ctr, Head & Neck Oncol Program, Boston, MA USA. [Gillison, M.] Ohio State Univ, Coll Med, Internal Med, Columbus, OH 43210 USA. [Ferris, R. L.] Univ Pittsburgh, Dept Otolaryngol, Inst Canc, Div Head & Neck Surg, Pittsburgh, PA 15260 USA. [Harrington, K.] Inst Canc Res, Div Radiotherapy & Imaging, London, England. [Harrington, K.] Royal Marsden Hosp, London, England. [Monga, M.] Bristol Myers Squibb, Global Clin Res, Princeton, NJ USA. [Baudelet, C.] Bristol Myers Squibb, Biostat, Princeton, NJ USA. [Geese, W. J.] Bristol Myers Squibb, Oncol, Princeton, NJ USA. [Argiris, A.] Hygeia Hosp, Med Oncol, Athens, Greece. FU Bristol-Myers Squibb FX Sponsored by Bristol-Myers Squibb. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1017TiP DI 10.1093/annonc/mdw376.69 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000113 ER PT J AU Haddad, R Seiwert, T Pfister, DG Worden, F Liu, SV Gilbert, J Saba, NF Weiss, J Wirth, LJ Sukari, A Kang, H Gibson, MK Massarelli, E Powell, S Meister, A Shu, X Cheng, J Bauml, J AF Haddad, R. Seiwert, T. Pfister, D. G. Worden, F. Liu, S. V. Gilbert, J. Saba, N. F. Weiss, J. Wirth, L. J. Sukari, A. Kang, H. Gibson, M. K. Massarelli, E. Powell, S. Meister, A. Shu, X. Cheng, J. Bauml, J. TI Pembrolizumab after progression on platinum and cetuximab in head and neck squamous cell carcinoma (HNSCC): results from KEYNOTE-055 SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Haddad, R.] Harvard Med Sch, Dana Farber Canc Inst, Oncol, Boston, MA USA. [Seiwert, T.] Univ Chicago, Oncol, Chicago, IL 60637 USA. [Pfister, D. G.] Mem Sloan Kettering Canc Ctr, Oncol, 1275 York Ave, New York, NY 10021 USA. [Worden, F.] Univ Michigan, Ctr Comprehens Canc, Oncol, Ann Arbor, MI 48109 USA. [Liu, S. V.] Georgetown Univ Hosp, Oncol, Washington, DC 20007 USA. [Gilbert, J.] Vanderbilt Univ, Sch Med, Oncol, Nashville, TN 37212 USA. [Saba, N. F.] Emory Univ, Winship Canc Inst, Oncol, Atlanta, GA 30322 USA. [Weiss, J.] Univ N Carolina, Thorac Oncol, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA. [Wirth, L. J.] Massachusetts Gen Hosp, Oncol, Boston, MA 02114 USA. [Sukari, A.] Wayne State Univ, Karmanos Canc Inst, Oncol, Detroit, MI USA. [Kang, H.] Johns Hopkins Univ, Sch Med, Oncol, Baltimore, MD USA. [Gibson, M. K.] Univ Hosp Case Med Ctr, Oncol, Cleveland, OH USA. [Massarelli, E.] Univ Texas MD Anderson Canc Ctr, Oncol, Houston, TX 77030 USA. [Powell, S.] Sanford Hlth, Oncol, Sioux Falls, SD USA. [Meister, A.; Shu, X.; Cheng, J.] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA. [Bauml, J.] Univ Penn, Oncol, Philadelphia, PA 19104 USA. FU Merck and Co., Inc. FX Merck and Co., Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 957PD DI 10.1093/annonc/mdw376.9 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000053 ER PT J AU Hamid, O Puzanov, I Dummer, R Schachter, J Daud, A Schadendorf, D Blank, C Cranmer, LD Robert, C Pavlick, AC Gonzalez, R Hodi, FS Ascierto, PA Salama, A Margolin, KA Gangadhar, TC Wei, Z Ebbinghaus, SW Ibrahim, N Ribas, A AF Hamid, O. Puzanov, I. Dummer, R. Schachter, J. Daud, A. Schadendorf, D. Blank, C. Cranmer, L. D. Robert, C. Pavlick, A. C. Gonzalez, R. Hodi, F. S. Ascierto, P. A. Salama, A. Margolin, K. A. Gangadhar, T. C. Wei, Z. Ebbinghaus, S. W. Ibrahim, N. Ribas, A. TI Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Hamid, O.] Angeles Clin & Res Inst, Melanoma & Skin Canc Ctr, Los Angeles, CA USA. [Puzanov, I.] Vanderbilt Ingram Canc Ctr, Hematol Oncol, Nashville, TN USA. [Dummer, R.] Univ Zurich, Dermatol, Zurich, Switzerland. [Schachter, J.] Sheba Canc Res Ctr, Ella Inst Melanoma, Oncol, Tel Hashomer, Israel. [Daud, A.] Univ Calif San Francisco, Med, San Francisco, CA 94143 USA. [Schadendorf, D.] Univ Hosp Essen, Dermatol, Essen, Germany. [Blank, C.] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Med Oncol, Amsterdam, Netherlands. [Cranmer, L. D.] Univ Washington, Med, Seattle, WA 98195 USA. [Cranmer, L. D.] Seattle Canc Care Alliance, Seattle, WA USA. [Robert, C.] Gustave Roussy, Dermatol, Villejuif, France. [Robert, C.] Univ Paris Sud, Villejuif, France. [Pavlick, A. C.] NYU, Inst Canc, Med, New York, NY USA. [Gonzalez, R.] Univ Colorado Denver, Med, Aurora, CO USA. [Hodi, F. S.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Ascierto, P. A.] Fdn Pascale, IRCCS, Ist Nazl Tumori, Unit Melanoma Canc Immunotherapy & Innovat Therap, Naples, Italy. [Salama, A.] Duke Univ, Med, Durham, NC USA. [Margolin, K. A.] City Hope Natl Med Ctr, Med Oncol, 1500 E Duarte Rd, Duarte, CA 91010 USA. [Gangadhar, T. C.] Univ Penn, Abramson Canc Ctr, Div Hematol Oncol, Philadelphia, PA 19104 USA. [Wei, Z.; Ebbinghaus, S. W.; Ibrahim, N.] Merck & Co Inc, Clin Res, Kenilworth, NJ USA. [Ribas, A.] Univ Calif Los Angeles, Med, Los Angeles, CA USA. FU Merck & Co., Inc., Kenilworth, NJ, USA FX Merck & Co., Inc., Kenilworth, NJ, USA NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1107O DI 10.1093/annonc/mdw379.2 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000200 ER PT J AU Hessel, C Mangeshkar, M Motzer, RJ Escudier, B Powles, TB Schwab, G Choueiri, TK AF Hessel, C. Mangeshkar, M. Motzer, R. J. Escudier, B. Powles, T. B. Schwab, G. Choueiri, T. K. TI Evaluation of the novel "trial within a trial" design of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Hessel, C.; Mangeshkar, M.] Exelixis Inc, Biostat, San Francisco, CA USA. [Motzer, R. J.] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA. [Escudier, B.] Inst Gustave Roussy, Med Oncol, Villejuif, France. [Powles, T. B.] Queen Mary Univ London, Barts Canc Inst, Med Oncol, London, England. [Schwab, G.] Exelixis Inc, Prod Dev & Med Affairs, San Francisco, CA USA. [Choueiri, T. K.] Brigham & Womens Hosp, Dana Farber Canc Inst, Genitourinary Oncol, 75 Francis St, Boston, MA 02115 USA. FU Exelixis, Inc. FX Exelixis, Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 815P DI 10.1093/annonc/mdw373.42 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500810 ER PT J AU Hortobagyi, GN Stemmer, SM Burris, HA Yap, YS Sonke, GS Paluch-Shimon, S Campone, M Blackwell, K Andre, F Winer, EP Janni, W Verma, S Conte, P Arteaga, CL Cameron, D Xuan, F Souami, F Miller, M Germa, C O'Shaughnessy, J AF Hortobagyi, G. N. Stemmer, S. M. Burris, H. A. Yap, Y. S. Sonke, G. S. Paluch-Shimon, S. Campone, M. Blackwell, K. Andre, F. Winer, E. P. Janni, W. Verma, S. Conte, P. Arteaga, C. L. Cameron, D. Xuan, F. Souami, F. Miller, M. Germa, C. O'Shaughnessy, J. TI First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Hortobagyi, G. N.] Univ Texas MD Anderson Canc Ctr, Breast Med Oncol, Houston, TX 77030 USA. [Stemmer, S. M.] Tel Aviv Univ, Rabin Med Ctr, Davidoff Ctr, Tel Aviv, Israel. [Burris, H. A.] Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA. [Yap, Y. S.] Natl Canc Ctr, Div Med Oncol, Singapore, Singapore. [Sonke, G. S.] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands. [Sonke, G. S.] BOOG Study Ctr, Amsterdam, Netherlands. [Paluch-Shimon, S.] Sheba Med Ctr, Inst Oncol, Ramat Gan, Israel. [Campone, M.] Inst Cancerol Ouest, Rene Gauducheau, St Herblain, France. [Blackwell, K.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Andre, F.] Univ Paris Sud, Inst Gustave Roussy, Dept Med Oncol, Villejuif, France. [Winer, E. P.] Dana Farber Canc Inst, Breast Oncol Ctr, Boston, MA 02115 USA. [Janni, W.] Univ Ulm, Dept Gynecol & Obstet, Ulm, Germany. [Verma, S.] Tom Baker Canc Clin, Dept Oncol, Calgary, AB, Canada. [Conte, P.] Univ Padua, Ist Oncol Veneto IRCCS, Padua, Italy. [Arteaga, C. L.] Vanderbilt Ingram Canc Ctr, Ctr Canc Targeted Therapies, Nashville, TN USA. [Cameron, D.] Univ Edinburgh, Canc Res Ctr, Edinburgh, Midlothian, Scotland. [Xuan, F.; Miller, M.; Germa, C.] Novartis Pharmaceut, Oncol, E Hanover, NJ USA. [Souami, F.] Novartis Pharma AG, Oncol, Basel, Switzerland. [O'Shaughnessy, J.] US Oncol Network, Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA. FU Novartis Pharmaceuticals Corporation FX Novartis Pharmaceuticals Corporation NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA LBA1_PR DI 10.1093/annonc/mdw435.3 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000692 ER PT J AU Hwu, P Hamid, O Gonzalez, R Infante, JR Patel, MR Hodi, FS Lewis, KD Wallin, J Mwawasi, G Cha, E Richie, N Ballinger, M Sullivan, R AF Hwu, P. Hamid, O. Gonzalez, R. Infante, J. R. Patel, M. R. Hodi, F. S. Lewis, K. D. Wallin, J. Mwawasi, G. Cha, E. Richie, N. Ballinger, M. Sullivan, R. TI Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Hwu, P.] Univ Texas MD Anderson Canc Ctr, Melanoma Med Oncol, Houston, TX 77030 USA. [Hamid, O.] Angeles Clin & Res Inst, Melanoma Therapeut, Los Angeles, CA USA. [Gonzalez, R.; Lewis, K. D.] Univ Colorado, Ctr Comprehens Canc, Oncol, Aurora, CO USA. [Infante, J. R.] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Drug Dev Program, Nashville, TN USA. [Patel, M. R.] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA. [Hodi, F. S.; Sullivan, R.] Dana Farber Canc Inst, Oncol, Boston, MA 02115 USA. [Wallin, J.; Mwawasi, G.; Cha, E.; Richie, N.; Ballinger, M.] Genentech Inc, Oncol, San Francisco, CA 94080 USA. FU F. Hoffmann-La Roche Ltd FX F. Hoffmann-La Roche Ltd NR 0 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1109PD DI 10.1093/annonc/mdw379.5 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000203 ER PT J AU Janne, PA van den Heuvel, M Barlesi, F Cobo, M Mazieres, J Crino, L Orlov, S Blackhall, F Wolf, J Garrido, P Poltoratskiy, A Mariani, G Ghiorghiu, D Kilgour, E Smith, P Kohlmann, A Carlile, D Lawrence, D Bowen, K Vansteenkiste, JF AF Janne, P. A. van den Heuvel, M. Barlesi, F. Cobo, M. Mazieres, J. Crino, L. Orlov, S. Blackhall, F. Wolf, J. Garrido, P. Poltoratskiy, A. Mariani, G. Ghiorghiu, D. Kilgour, E. Smith, P. Kohlmann, A. Carlile, D. Lawrence, D. Bowen, K. Vansteenkiste, J. F. TI Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Janne, P. A.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA. [Janne, P. A.] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA. [van den Heuvel, M.] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands. [Barlesi, F.] Aix Marseille Univ, Multidisciplinary Oncol & Therapeut Innovat Dept, APHM, Marseille, France. [Cobo, M.] Hosp Clin Carlos Haya, Dept Med Oncol, Malaga, Spain. [Mazieres, J.] Toulouse Univ Hosp, Dept Pulmonol, Toulouse, France. [Crino, L.] Santa Maria Misericordia Hosp, Div Med Oncol, Perugia, Italy. [Orlov, S.] Pavlov Med Univ, Dept Med, St Petersburg, Russia. [Blackhall, F.] Univ Manchester, Med Oncol, Manchester, Lancs, England. [Blackhall, F.] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England. [Wolf, J.] Univ Hosp Cologne, Dept Internal Med, Ctr Integrated Oncol, Cologne, Germany. [Garrido, P.] Univ Hosp Ramon & Cajal, Dept Med Oncol, Madrid, Spain. [Poltoratskiy, A.] Petrov Res Inst Oncol, Dept Clin & Preclin Trials, St Petersburg, Russia. [Mariani, G.; Ghiorghiu, D.] AstraZeneca, Global Med Dev, Oncol, Cambridge, England. [Kilgour, E.] AstraZeneca, Oncol, Macclesfield, Cheshire, England. [Smith, P.] AstraZeneca, Canc Biosci, Cambridge, England. [Kohlmann, A.] AstraZeneca, Personalised Healthcare & Biomarkers, IMED, Cambridge, England. [Carlile, D.] AstraZeneca, Innovat Med, Cambridge, England. [Lawrence, D.] AstraZeneca, Biostat & Informat Sci, Cambridge, England. [Bowen, K.] AstraZeneca, Global Med Dev, Cambridge, England. [Vansteenkiste, J. F.] Univ Hosp KU Leuven, Resp Oncol Unit, Dept Respiraory Dis, Leuven, Belgium. FU AstraZeneca FX AstraZeneca NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA LBA47_PR DI 10.1093/annonc/mdw435.46 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000735 ER PT J AU Kieran, MW Bouffet, E Tabori, U Broniscer, A Cohen, K Hansford, J Geoerger, B Hingorani, P Dunkel, I Russo, M Tseng, L Liu, Q Nebot, N Whitlock, J Hargrave, D AF Kieran, M. W. Bouffet, E. Tabori, U. Broniscer, A. Cohen, K. Hansford, J. Geoerger, B. Hingorani, P. Dunkel, I. Russo, M. Tseng, L. Liu, Q. Nebot, N. Whitlock, J. Hargrave, D. TI The first study of dabrafenib in pediatric patients with BRAF V600-mutant relapsed or refractory low-grade gliomas SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Kieran, M. W.] Harvard Med Sch, Boston Childrens Hosp, Pediat Med Neurooncol, Dana Farber Canc Inst, Boston, MA USA. [Bouffet, E.; Whitlock, J.] Univ Toronto, Hosp Sick Children, Haematol Oncol, Toronto, ON, Canada. [Tabori, U.] Univ Toronto, Hosp Sick Children, Div Haematol Oncol, Arthur & Sonia Labatt Brain Tumor Res Ctr, Toronto, ON, Canada. [Broniscer, A.] St Jude Childrens Res Hosp, Dept Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA. [Cohen, K.] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Pediat Oncol, Baltimore, MD USA. [Hansford, J.] Univ Melbourne, Murdoch Childrens Res Inst, Royal Childrens Hosp, Childrens Canc Ctr, Melbourne, Vic, Australia. [Geoerger, B.] Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France. [Hingorani, P.] Phoenix Childrens Hosp, Hematol Oncol, Phoenix, AZ USA. [Dunkel, I.] Mem Sloan Kettering Canc Ctr, Pediat Oncol, 1275 York Ave, New York, NY 10021 USA. [Russo, M.; Tseng, L.; Liu, Q.; Nebot, N.] Novartis Pharmaceut, Global Oncol, E Hanover, NJ USA. [Hargrave, D.] Great Ormond St Hosp Sick Children, Haematol & Oncol, London, England. FU GlaxoSmithKline FX Supported by GlaxoSmithKline. Dabrafenib is an asset of Novartis AG as of 2 March 2015. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA LBA19_PR DI 10.1093/annonc/mdw435.9 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000698 ER PT J AU Krasner, CN Schilder, RJ Brady, WE Duska, LR O'Malley, D Disilvestro, A Li, J Downing, W Senderowicz, A AF Krasner, C. N. Schilder, R. J. Brady, W. E. Duska, L. R. O'Malley, D. Disilvestro, A. Li, J. Downing, W. Senderowicz, A. TI A phase 1b study of the nanoparticle-drug conjugate (NDC) CRLX101 in combination with weekly paclitaxel in patients (pts) with platinum-resistant ovarian cancer (OC) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Krasner, C. N.] Massachusetts Gen Hosp, Hematol Oncol, Boston, MA 02114 USA. [Schilder, R. J.] Thomas Jefferson Univ, Med Oncol, Philadelphia, PA 19107 USA. [Brady, W. E.] Roswell Pk Canc Inst, Biostat & Bioinformat, Buffalo, NY 14263 USA. [Duska, L. R.] Univ Virginia, Gynecol Oncol, Charlottesville, VA USA. [O'Malley, D.] Ohio State Univ, James Canc Hosp, Obstet & Gynecol, Columbus, OH 43210 USA. [Disilvestro, A.] Brown Univ, Women & Infants Hosp, Gynecol Oncol, Warren Alpert Med Sch, Providence, RI USA. [Li, J.; Downing, W.; Senderowicz, A.] Cerulean Pharma Inc, Med Affairs, Waltham, MA USA. FU Cerulean Pharma, Inc. FX Cerulean Pharma, Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 864P DI 10.1093/annonc/mdw374.11 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500859 ER PT J AU Kristeleit, RS Shapira-Frommer, R Oaknin, A Balmana, J Ray-Coquard, IL Domchek, S Tinker, AV Castro, CM Welch, S Poveda, AM Bell-Mcguinn, K Konecny, G Giordano, H Maloney, L Goble, S Rolfe, L Oza, A AF Kristeleit, R. S. Shapira-Frommer, R. Oaknin, A. Balmana, J. Ray-Coquard, I. L. Domchek, S. Tinker, A. V. Castro, C. M. Welch, S. Poveda, A. M. Bell-Mcguinn, K. Konecny, G. Giordano, H. Maloney, L. Goble, S. Rolfe, L. Oza, A. TI Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Kristeleit, R. S.] UCL, Inst Canc, Oncol, London, England. [Shapira-Frommer, R.] Sheba Med Ctr, Med Oncol, Ramat Gan, Israel. [Oaknin, A.; Balmana, J.] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Med Oncol, Barcelona, Spain. [Ray-Coquard, I. L.] Ctr Leon Berard, GINECO, Oncol, Lyon, France. [Ray-Coquard, I. L.] Univ Claude Bernard, Lyon, France. [Domchek, S.] Univ Penn, Med Oncol, Philadelphia, PA 19104 USA. [Tinker, A. V.] British Columbia Canc Agcy, Med, Vancouver, BC, Canada. [Castro, C. M.] Harvard Med Sch, Massachusetts Gen Hosp, Med, Gynecol Oncol, Boston, MA USA. [Welch, S.] London Reg Canc Program, Div Med Oncol, London, ON, Canada. [Poveda, A. M.] Valencian Inst Oncol, Gynecol, Clin Area Gynecol Oncol, Valencia, Spain. [Bell-Mcguinn, K.] Mem Sloan Kettering Canc Ctr, Gynecol Med Oncol, 1275 York Ave, New York, NY 10021 USA. [Konecny, G.] Univ Calif Los Angeles, Med Hematol & Oncol, Los Angeles, CA USA. [Giordano, H.; Maloney, L.] Clovis Oncol Inc, Clin Sci, Boulder, CO USA. [Goble, S.] Clovis Oncol Inc, Biostat, Boulder, CO USA. [Rolfe, L.] Clovis Oncol Inc, Clin & Preclin Dev, Boulder, CO USA. [Oza, A.] Univ Hlth Network, Princess Margaret Canc Ctr, Med Oncol, Toronto, ON, Canada. FU Clovis Oncology, Inc. FX Clovis Oncology, Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 856O DI 10.1093/annonc/mdw374.3 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500851 ER PT J AU Kulke, M Horsch, D Caplin, M Anthony, L Bergsland, E Oberg, K Welin, S Warner, R Bohas, CL Kunz, PL Grande, E Valle, JW Lapuerta, P Banks, P Jackson, S Jiang, W Biran, T Pavel, M AF Kulke, M. Hoersch, D. Caplin, M. Anthony, L. Bergsland, E. Oberg, K. Welin, S. Warner, R. Bohas, C. Lombard Kunz, P. L. Grande, E. Valle, J. W. Lapuerta, P. Banks, P. Jackson, S. Jiang, W. Biran, T. Pavel, M. TI Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Kulke, M.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Hoersch, D.] Zent Klin Bad Berka GmbH, Ctr Neuroendocrine Tumors Bad Berka, Gastroenterol & Endocrinol, Bad Berka, Germany. [Caplin, M.] Royal Free Hosp, Sch Med, Gastroenterol & Neuroendocrine Tumours, London, England. [Anthony, L.] Univ Kentucky, Med Oncol, Lexington, KY USA. [Bergsland, E.] UCSF Helen Diller Family Comprehens Canc Ctr, Hematol Oncol, San Francisco, CA USA. [Oberg, K.] Univ Uppsala Hosp, Dept Med Sci, Uppsala, Sweden. [Welin, S.] Univ Uppsala Hosp, Dept Endocrine Oncol, Uppsala, Sweden. [Warner, R.] Mt SInai Med Coll, Gastroenterol, New York, NY USA. [Bohas, C. Lombard] Hop Edouard Herriot, Med Oncol, Pav E Bis, Lyon, France. [Kunz, P. L.] Stanford Univ, Sch Med, Med Oncol, Palo Alto, CA 94304 USA. [Grande, E.] Hosp Univ Ramon & Cajal, Med Oncol, Madrid, Spain. [Valle, J. W.] Univ Manchester, Christie NHS Fdn Trust, Med Oncol, Manchester, Lancs, England. [Lapuerta, P.; Banks, P.; Jiang, W.] Lexicon Pharmaceut, Med Affairs, The Woodlands, TX USA. [Jackson, S.; Biran, T.] Lexicon Pharmaceut Inc, Clin Operat, The Woodlands, TX USA. [Pavel, M.] Charite, Endocrinol, Berlin, Germany. FU Lexicon Pharmaceuticals, Inc. FX Lexicon Pharmaceuticals, Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 422PD DI 10.1093/annonc/mdw369.7 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500420 ER PT J AU Labidi-Galy, I Elias, KM Tsantoulis, P Vitonis, A Doyle, L Hornick, J Cramer, DW Goggins, M Kerr, CL Birrer, M Hirsch, M Drapkin, R AF Labidi-Galy, I. Elias, K. M. Tsantoulis, P. Vitonis, A. Doyle, L. Hornick, J. Cramer, D. W. Goggins, M. Kerr, C. L. Birrer, M. Hirsch, M. Drapkin, R. TI Primordial germ cell as potent cell of origin of mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Labidi-Galy, I.; Tsantoulis, P.] HUG, Dept Oncol, Geneva, Switzerland. [Elias, K. M.; Vitonis, A.; Cramer, D. W.] Brigham & Womens Hosp, Dept Obstet & Gynecol, 75 Francis St, Boston, MA 02115 USA. [Doyle, L.; Hornick, J.; Hirsch, M.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA. [Goggins, M.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA. [Kerr, C. L.] Univ Maryland, Sch Med, Dept Biol, Baltimore, MD 21201 USA. [Birrer, M.] Massachusetts Gen Hosp, Hematol Oncol, Boston, MA 02114 USA. [Drapkin, R.] Penn Ovarian Canc Res Ctr, Dept Obstet & Gynecol, Philadelphia, PA USA. FU Fondation de France, Arthur Sachs/Harvard FX Fondation de France, Arthur Sachs/Harvard NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1591P DI 10.1093/annonc/mdw393.11 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000676 ER PT J AU Langer, C Gaddgeel, SM Borghaei, H Papadimitrakopoulou, VA Patnaik, A Powell, S Gentzler, RD Martins, RG Stevenson, JP Jalal, SI Panwalkar, A Yang, JCH Gubens, MA Sequist, LV Awad, MM Fiore, JJ Ge, Y Raftopoulos, H Gandhi, L AF Langer, C. Gaddgeel, S. M. Borghaei, H. Papadimitrakopoulou, V. A. Patnaik, A. Powell, S. Gentzler, R. D. Martins, R. G. Stevenson, J. P. Jalal, S. I. Panwalkar, A. Yang, J. C-H. Gubens, M. A. Sequist, L. V. Awad, M. M. Fiore, J. J. Ge, Y. Raftopoulos, H. Gandhi, L. TI Randomized, phase 2 study of carboplatin and pemetrexed with or without pembrolizumab as first-line therapy for advanced NSCLC: KEYNOTE-021 cohort G SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Langer, C.] Univ Penn, Oncol, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Gaddgeel, S. M.] Karmanos Canc Inst, Clin Hematol Oncol, Detroit, MI USA. [Gaddgeel, S. M.] Wayne State Univ, Detroit, MI USA. [Borghaei, H.] Fox Chase Canc Ctr, Dept Hematol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Papadimitrakopoulou, V. A.] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA. [Patnaik, A.] South Texas Accelerated Res Therapeut START, Dept Clin Res, San Antonio, TX USA. [Powell, S.] Sanford Hlth, Oncol, Sioux Falls, SD USA. [Gentzler, R. D.] Univ Virginia, Hematol Oncol, Charlottesville, VA USA. [Martins, R. G.] Univ Washington, Med, Div Med Oncol, Seattle Canc Care Alliance, Seattle, WA 98195 USA. [Stevenson, J. P.] Cleveland Clin, Hematol & Oncol, Cleveland, OH 44106 USA. [Jalal, S. I.] Indiana Univ Sch Med, Internal Med, Indianapolis, IN 46202 USA. [Panwalkar, A.] Sanford Roger Maris Canc Ctr, Med Oncol, Fargo, ND USA. [Yang, J. C-H.] Natl Taiwan Univ Hosp, Oncol, Taipei, Taiwan. [Gubens, M. A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Sequist, L. V.] Massachusetts Gen Hosp, Ctr Thorac Canc, Boston, MA 02114 USA. [Awad, M. M.] Dana Farber Canc Inst, Thorac Oncol, Boston, MA 02115 USA. [Fiore, J. J.; Ge, Y.; Raftopoulos, H.] Merck & Co Inc, Clin Sci & Study Management, Kenilworth, NJ USA. [Gandhi, L.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. FU Merck Co., Inc. FX Merck & Co., Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA LBA46_PR DI 10.1093/annonc/mdw435.45 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000734 ER PT J AU Larkin, J Rini, BI Nathan, P Thistlethwaite, F Gordon, M Martgnoni, M Magazzu, D Chiruzzi, C Di Pietro, A Choueiri, TK AF Larkin, J. Rini, B. I. Nathan, P. Thistlethwaite, F. Gordon, M. Martgnoni, M. Magazzu, D. Chiruzzi, C. Di Pietro, A. Choueiri, T. K. TI Phase 1b dose-finding study of avelumab (anti-PD-L1) + axitinib in treatment-naive patients with advanced renal cell carcinoma SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Larkin, J.] Royal Marsden Hosp, Dept Med Oncol, London, England. [Rini, B. I.] Cleveland Clin, Dept Hematol & Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA. [Nathan, P.] Mt Vernon Canc Ctr, Dept Med Oncol, Northwood, Middx, England. [Thistlethwaite, F.] Univ Manchester, Dept Med Oncol, Christie NHS Fdn Trust, Manchester, Lancs, England. [Gordon, M.] Pinnacle Oncol Hematol, Div Arizona Ctr Canc Care, Scottsdale, AZ USA. [Martgnoni, M.; Magazzu, D.; Chiruzzi, C.; Di Pietro, A.] Pfizer Inc, Immunooncol, Milan, Italy. [Choueiri, T. K.] Brigham & Womens Hosp, Lank Ctr Genitourinary Oncol, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. FU Pfizer Inc. FX Pfizer Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 775PD DI 10.1093/annonc/mdw373.3 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500771 ER PT J AU Lassman, AB van den Bent, M Gan, HK Reardon, DA Kumthekar, P Butowski, N Lwin, Z Mikkelsen, T Nabors, LB Papadopoulos, KP Penas-Prado, M Simes, J Wheeler, H Gomez, E Lee, HJ Roberts-Rapp, L Xiong, H Bain, E Holen, K Merrell, R AF Lassman, A. B. van den Bent, M. Gan, H. K. Reardon, D. A. Kumthekar, P. Butowski, N. Lwin, Z. Mikkelsen, T. Nabors, L. B. Papadopoulos, K. P. Penas-Prado, M. Simes, J. Wheeler, H. Gomez, E. Lee, H-J. Roberts-Rapp, L. Xiong, H. Bain, E. Holen, K. Merrell, R. TI Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Lassman, A. B.] Columbia Univ, Dept Neurol, New York, NY USA. [Lassman, A. B.] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA. [van den Bent, M.] Erasmus MC Canc Inst, Dept Neurooncol, Rotterdam, Netherlands. [Gan, H. K.] Austin Hlth, Dept Med Oncol, Melbourne, Vic, Australia. [Gan, H. K.] Olivia Newton John Canc Res Inst, Melbourne, Vic, Australia. [Reardon, D. A.] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA. [Kumthekar, P.] Northwestern Univ, Dept Neurol, Chicago, IL 60611 USA. [Butowski, N.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA. [Lwin, Z.] Univ Queensland, Sch Med, Dept Med Oncol, Brisbane, Qld, Australia. [Mikkelsen, T.] Henry Ford Hlth Syst, Neurosurg & Neurosci Res, Detroit, MI USA. [Nabors, L. B.] Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL USA. [Papadopoulos, K. P.] START, Dept Clin Res, San Antonio, TX USA. [Penas-Prado, M.] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA. [Simes, J.] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia. [Wheeler, H.] Royal North Shore Hosp, Med Oncol, Sydney, NSW, Australia. [Gomez, E.; Lee, H-J.; Roberts-Rapp, L.; Xiong, H.; Bain, E.; Holen, K.] AbbVie, Global Pharmaceut R&D, N Chicago, IL USA. [Merrell, R.] NorthShore Univ HealthSyst, Dept Neurol, Evanston, IL USA. FU AbbVie, Inc. FX AbbVie, Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 326PD DI 10.1093/annonc/mdw367.4 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500325 ER PT J AU Long, GV Larkin, J Ascierto, PA Hodi, FS Rutkowski, P Sileni, V Hassel, J Lebbe, C Pavlick, AC Wagstaff, J Schadendorf, D Dummer, R Hogg, D Haanen, JBAG Corrie, P Hoeller, C Horak, C Wolchok, J Robert, C AF Long, G. V. Larkin, J. Ascierto, P. A. Hodi, F. S. Rutkowski, P. Sileni, V. Hassel, J. Lebbe, C. Pavlick, A. C. Wagstaff, J. Schadendorf, D. Dummer, R. Hogg, D. Haanen, J. B. A. G. Corrie, P. Hoeller, C. Horak, C. Wolchok, J. Robert, C. TI PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Long, G. V.] Melanoma Inst Australia, Med Oncol, Sydney, NSW, Australia. [Larkin, J.] Royal Marsden Hosp, Dept Med Oncol, London, England. [Ascierto, P. A.] Fdn Pascale, Ist Nazl Tumori, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, Italy. [Hodi, F. S.] Dana Farber Canc Inst, Oncol, Boston, MA 02115 USA. [Rutkowski, P.] MSC Mem Canc Ctr, Oncol, Warsaw, Poland. [Rutkowski, P.] Inst Maria Sklodowska Curie, Warsaw, Poland. [Sileni, V.] Ist Oncol Veneto, Oncol, Padua, Italy. [Hassel, J.] Univ Heidelberg Hosp, Oncol, Heidelberg, Germany. [Lebbe, C.] Hop St Louis, Dermatol, Paris, France. [Pavlick, A. C.] NYU, Sch Med, Dept Med, New York, NY USA. [Wagstaff, J.] Singleton Hosp, South West Wales Canc Inst, Swansea, W Glam, Wales. [Schadendorf, D.] Univ Hosp Essen, Canc, Essen, Germany. [Dummer, R.] Univ Zurich Hosp, Dept Dermatol, Zurich, Switzerland. [Hogg, D.] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON, Canada. [Haanen, J. B. A. G.] Antoni van Leeuwenhoek Hosp, Dept Med Oncol, Netherlands Canc Inst, Amsterdam, Netherlands. [Corrie, P.] Univ Cambridge Hosp, Addenbrookes Hosp, Oncol Ctr, Cambridge, England. [Hoeller, C.] Med Univ Wien, Dept Dermatol & Dermatooncol, Vienna, Austria. [Horak, C.] BMS, Clin Biomarkers, Princeton, NJ USA. [Wolchok, J.] Mem Sloan Kettering Canc Ctr, Ludwig Ctr, 1275 York Ave, New York, NY 10021 USA. [Robert, C.] Gustave Roussy, Oncol, Villejuif, France. [Robert, C.] Univ Paris Sud, Villejuif, France. FU Bristol-Myers Squibb FX Bristol-Myers Squibb NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1112PD DI 10.1093/annonc/mdw379.7 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000205 ER PT J AU Martin-Algarra, S Haanen, JB Horak, C Bhatia, S Ribas, A Hwu, WJ Slingluff, CL Sharfman, WH Callahan, M Hodi, FS Wolchok, JD Luke, J Young, TC Qureshi, A Urba, WJ AF Martin-Algarra, S. Haanen, J. B. Horak, C. Bhatia, S. Ribas, A. Hwu, W-J. Slingluff, C. L. Sharfman, W. H. Callahan, M. Hodi, F. S. Wolchok, J. D. Luke, J. Young, T. C. Qureshi, A. Urba, W. J. TI Safety of reduced infusion times for nivolumab plus ipilimumab (N plus I) and nivolumab alone (N) in advanced melanoma SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Martin-Algarra, S.] Univ Navarra, Med Oncol, Pamplona, Spain. [Haanen, J. B.] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands. [Horak, C.; Young, T. C.] BMS, Clin Biomarkers, Princeton, NJ USA. [Bhatia, S.] Univ Washington, Med Oncol, Seattle, WA 98195 USA. [Ribas, A.] Univ Calif Los Angeles, Med, Los Angeles, CA USA. [Hwu, W-J.] Univ Texas MD Anderson Canc Ctr, Med Oncol, Houston, TX 77030 USA. [Slingluff, C. L.] Univ Virginia, Sch Med, Surg, Charlottesville, VA 22908 USA. [Sharfman, W. H.] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Oncol & Dermatol, Baltimore, MD USA. [Callahan, M.; Wolchok, J. D.] Mem Sloan Kettering Canc Ctr, Med, 1275 York Ave, New York, NY 10021 USA. [Hodi, F. S.] Dana Farber Canc Inst, Oncol, Boston, MA 02115 USA. [Luke, J.] Univ Chicago, Med Ctr, Hematol Oncol Sect, Chicago, IL 60637 USA. [Qureshi, A.] BMS, Global Clin Res, Princeton, NJ USA. [Urba, W. J.] Providence Canc Ctr, Earle A Chiles Res Inst, Providence Melanoma Program, Portland, OR USA. FU Bristol-Myers Squibb FX Bristol-Myers Squibb NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1125P DI 10.1093/annonc/mdw379.20 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000218 ER PT J AU Matulonis, UA Chen, M Puhlmann, M Shentu, Y Ledermann, J AF Matulonis, U. A. Chen, M. Puhlmann, M. Shentu, Y. Ledermann, J. TI KEYNOTE-100: Phase 2 trial of pembrolizumab in patients with advanced recurrent ovarian cancer SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Matulonis, U. A.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Chen, M.; Puhlmann, M.; Shentu, Y.] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA. [Ledermann, J.] Univ Coll London Hosp, Oncol, London, England. FU Merck Co., Inc FX Merck & Co., Inc NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 900TiP DI 10.1093/annonc/mdw374.47 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500895 ER PT J AU Meille, C Guerreiro, N Bauer, S Cassier, P Demetri, G Dummer, R Tan, DS Van Bree, L Ramkumar, T Halilovic, E Jeay, S Jullion, A Hourcade-Potelleret, F Wuerthner, JU AF Meille, C. Guerreiro, N. Bauer, S. Cassier, P. Demetri, G. Dummer, R. Tan, D. S. Van Bree, L. Ramkumar, T. Halilovic, E. Jeay, S. Jullion, A. Hourcade-Potelleret, F. Wuerthner, J. U. TI Modeling of pharmacokinetics, thrombocytopenia, plasma GDF-15 levels and tumor kinetics in response to treatment with the p53-HDM2 protein-protein interaction inhibitor NVP-CGM097 SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Meille, C.; Guerreiro, N.; Van Bree, L.; Jeay, S.; Jullion, A.; Hourcade-Potelleret, F.; Wuerthner, J. U.] Novartis Pharma AG, Basel, Switzerland. [Bauer, S.] West German Canc Ctr, Essen, Germany. [Cassier, P.] Ctr Leon Berard, Lyon, France. [Demetri, G.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Dummer, R.] Univ Zurich Hosp, Zurich, Switzerland. [Tan, D. S.] Natl Canc Ctr, Singapore, Singapore. [Ramkumar, T.; Halilovic, E.] Novartis Inst BioMed Res, Cambridge, MA USA. FU Novartis Pharma AG FX Novartis Pharma AG NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 380P DI 10.1093/annonc/mdw368.23 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500378 ER PT J AU Michot, JM Armand, P Ding, W Ribrag, V Christian, B Balakumaran, A Marinello, P Chlosta, S Zhang, Y Shipp, M Zinzani, PL AF Michot, J-M. Armand, P. Ding, W. Ribrag, V. Christian, B. Balakumaran, A. Marinello, P. Chlosta, S. Zhang, Y. Shipp, M. Zinzani, P. L. TI Pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory Richter syndrome (rrRS): Phase 2 KEYNOTE-170 study SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Michot, J-M.; Ribrag, V.] Inst Gustave Roussy, Oncol, Villejuif, France. [Armand, P.; Shipp, M.] Dana Farber Canc Inst, Oncol, Boston, MA 02115 USA. [Ding, W.] Mayo Clin, Oncol, Rochester, MN USA. [Christian, B.] Ohio State Univ, Internal Med, Columbus, OH 43210 USA. [Balakumaran, A.; Marinello, P.; Chlosta, S.; Zhang, Y.] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA. [Zinzani, P. L.] Univ Bologna, Oncol, Bologna, Italy. FU Merck Co., Inc. FX Merck & Co., Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 944TiP DI 10.1093/annonc/mdw375.39 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000040 ER PT J AU Mirza, MR Monk, BJ Oza, A Mahner, S Redondo, A Fabbro, M Ledermann, J Lorusso, D Vergote, IB Rosengarten, O Berek, J Herrstedt, J Tinker, AV Dubois, A Martin, AG Follana, P Benigno, B Rimel, BJ Agarwal, S Matulonis, U AF Mirza, M. R. Monk, B. J. Oza, A. Mahner, S. Redondo, A. Fabbro, M. Ledermann, J. Lorusso, D. Vergote, I. B. Rosengarten, O. Berek, J. Herrstedt, J. Tinker, A. V. Dubois, A. Gonzalez Martin, A. Follana, P. Benigno, B. Rimel, B. J. Agarwal, S. Matulonis, U. TI A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Mirza, M. R.] NSGO, Dept Oncol 5073, Copenhagen, Denmark. [Mirza, M. R.] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark. [Monk, B. J.] Univ Arizona, Canc Ctr Phoenix, Dept Oncol, Phoenix, AZ USA. [Oza, A.] Univ Hlth Network, Dept Oncol, Toronto, ON, Canada. [Mahner, S.] AGO, Dept Gynegol, Hamburg, Germany. [Mahner, S.] Univ Munich, Hamburg, Germany. [Redondo, A.] GEICO, Dept Oncol, Madrid, Spain. [Redondo, A.] Univ Hosp, Madrid, Spain. [Fabbro, M.] GINECO, Dept Oncol, Montpellier, France. [Fabbro, M.] Inst Canc Montpellier, Montpellier, France. [Ledermann, J.] NCRI, Dept Med Oncol, London, England. [Ledermann, J.] UCL, London, England. [Lorusso, D.] MITO MaNGO, Dept Gynecol Oncol, Milan, Italy. [Lorusso, D.] Fdn IRCCS Natl Canc Inst, Milan, Italy. [Vergote, I. B.] BGOG, Dept Obstet & Gynecol, Leuven, Belgium. [Vergote, I. B.] Univ Leuven, Leuven, Belgium. [Rosengarten, O.] ISGO, Dept Gynecol Oncol, Jerusalem, Israel. [Rosengarten, O.] Shaare Zedek Med Ctr, Jerusalem, Israel. [Berek, J.] Stanford Womens Canc Ctr, Dept Oncol, Stanford, CA USA. [Herrstedt, J.] NSGO, Dept Oncol, Odense, Denmark. [Herrstedt, J.] Odense Univ Hosp, Odense, Denmark. [Tinker, A. V.] British Columbia Canc Agcy, Dept Med, Vancouver, BC, Canada. [Dubois, A.] AGO, Dept Oncol, Essen, Germany. [Dubois, A.] Kliniken Essen Mitte, Essen, Germany. [Gonzalez Martin, A.] GEICO, Med Oncol Dept, Madrid, Spain. [Gonzalez Martin, A.] MD Anderson Canc Ctr Madrid, Madrid, Spain. [Follana, P.] GINECO, Dept Med Oncol, Nice, France. [Follana, P.] Ctr Antoine Lacassagne, Nice, France. [Benigno, B.] Univ Gynecol Oncol, Dept Gynecol Oncol, Atlanta, GA USA. [Rimel, B. J.] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, West Hollywood, CA USA. [Agarwal, S.] Tesaro Inc, Dept Med Affairs, Waltham, MA USA. [Matulonis, U.] Dana Farber Canc Inst, Dept Gynecol Oncol, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA LBA3_PR DI 10.1093/annonc/mdw435.26 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000715 ER PT J AU Modi, S Eder, JP Lorusso, P Weekes, C Chandarlapaty, S Tolaney, SM McLaughlin, J Camidge, DR Chang, CW Nazzal, D Chen, SC Schuth, E Brunstein, F Darbonne, W Flanagan, W Ungewickell, A Shapiro, G AF Modi, S. Eder, J. P. Lorusso, P. Weekes, C. Chandarlapaty, S. Tolaney, S. M. McLaughlin, J. Camidge, D. R. Chang, C-W. Nazzal, D. Chen, S-C. Schuth, E. Brunstein, F. Darbonne, W. Flanagan, W. Ungewickell, A. Shapiro, G. TI A phase I study evaluating DLYE5953A, an antibody-drug conjugate targeting the tumor-associated antigen lymphocyte antigen 6 complex locus E (Ly6E), in patients (Pts) with solid tumors SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Modi, S.] Mem Sloan Kettering Canc Ctr, Med, 1275 York Ave, New York, NY 10021 USA. [Eder, J. P.; Lorusso, P.; McLaughlin, J.] Yale Canc Ctr, Yale Sch Med, New Haven, CT USA. [Weekes, C.] Univ Colorado, Ctr Canc, Dept Med, Anschutz Canc Pavil, Aurora, CO USA. [Chandarlapaty, S.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA. [Tolaney, S. M.] Dana Farber Canc Inst, Breast Oncol Ctr, Boston, MA 02115 USA. [Camidge, D. R.] Univ Colorado, Ctr Canc, Aurora, CO USA. [Chang, C-W.; Nazzal, D.; Chen, S-C.; Schuth, E.; Brunstein, F.; Darbonne, W.; Flanagan, W.; Ungewickell, A.] Genentech Inc, Early Dev, San Francisco, CA 94080 USA. [Shapiro, G.] Dana Farber Canc Inst, Early Drug Dev Ctr, Boston, MA 02115 USA. FU Genentech, Inc. FX Study sponsored by Genentech, Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 357O DI 10.1093/annonc/mdw368.1 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500356 ER PT J AU Motzer, RJ Choueiri, T Larkin, J Albiges, L Haanen, JB Schmidinger, M Atkins, MB Mariani, M Shnaidman, M Di Pietro, A Rini, BI AF Motzer, R. J. Choueiri, T. Larkin, J. Albiges, L. Haanen, J. B. Schmidinger, M. Atkins, M. B. Mariani, M. Shnaidman, M. Di Pietro, A. Rini, B. I. TI Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Motzer, R. J.] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, 1275 York Ave, New York, NY 10021 USA. [Choueiri, T.] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA. [Choueiri, T.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Larkin, J.] Royal Marsden Hosp, Dept Med Oncol, London, England. [Albiges, L.] Univ Paris Sud, Dept Canc Med, Gustave Roussy Canc Campus, Villejuif, France. [Haanen, J. B.] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands. [Schmidinger, M.] Med Univ Vienna, Dept Med 1, Vienna, Austria. [Atkins, M. B.] Georgetown Univ, Dept Med Oncol, Lombardi Comprehens Canc Ctr, Washington, DC USA. [Mariani, M.; Di Pietro, A.] Pfizer Inc, Immunooncol, Milan, Italy. [Shnaidman, M.] Pfizer Inc, Immunooncol, New York, NY USA. [Rini, B. I.] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Oncol, Cleveland, OH 44106 USA. FU Pfizer Inc. FX Pfizer Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 844TiP DI 10.1093/annonc/mdw373.71 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500839 ER PT J AU Naing, A Papadopoulos, KP Autio, KA Ott, PA Patel, MR Wong, DJ Falchook, G Pant, S Whiteside, M Rasco, D Patnaik, A Bendell, JC Bauer, TM Colen, RR Hong, D Van Vlasselaer, P Brown, GL Oft, M Tannir, N Infante, JR AF Naing, A. Papadopoulos, K. P. Autio, K. A. Ott, P. A. Patel, M. R. Wong, D. J. Falchook, G. Pant, S. Whiteside, M. Rasco, D. Patnaik, A. Bendell, J. C. Bauer, T. M. Colen, R. R. Hong, D. Van Vlasselaer, P. Brown, G. L. Oft, M. Tannir, N. Infante, J. R. TI Anti-tumor activity of PEGylated human IL-10 (AM0010) in renal cancer alone and in combination with anti-PD1 SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Naing, A.; Pant, S.; Colen, R. R.; Hong, D.; Tannir, N.] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut, Houston, TX 77030 USA. [Papadopoulos, K. P.; Wong, D. J.; Whiteside, M.; Van Vlasselaer, P.; Brown, G. L.; Oft, M.] ARMO Biosci, Clin Operat, Redwood City, CA USA. [Autio, K. A.] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA. [Ott, P. A.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Patel, M. R.] Florida Canc Specialists Sarah Cannon Res Inst, Drug Dev Unit, Sarasota, FL USA. [Falchook, G.] Sarah Cannon Res Inst, Drug Dev, Denver, CO USA. [Rasco, D.] START, San Antonio, TX USA. [Patnaik, A.] START, Med Oncol, San Antonio, TX USA. [Bendell, J. C.] Sarah Cannon Res Inst, GI Oncol Res, Nashville, TN USA. [Bauer, T. M.] Tennessee Oncol, Sarah Cannon Res Inst, Drug Dev, Nashville, TN USA. [Infante, J. R.] Tennessee Oncol PLLC, Dept Med, Nashville, TN USA. FU ARMO Biosciences FX ARMO Biosciences NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 364PD DI 10.1093/annonc/mdw368.7 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500362 ER PT J AU Necchi, A Sonpavde, G Lo Vullo, S Bamias, A Crabb, SJ Harshman, L Bellmunt, J De Giorgi, U Sternberg, C Ladoire, S Yu, YNWEY Yu, EY Chowdhury, S Niegisch, G Srinivas, S Vaishampayan, U Pal, SK Rosenberg, J Mariani, L Galsky, MD AF Necchi, A. Sonpavde, G. Lo Vullo, S. Bamias, A. Crabb, S. J. Harshman, L. Bellmunt, J. De Giorgi, U. Sternberg, C. Ladoire, S. Wong, Y-N. Yu, E. Y. Chowdhury, S. Niegisch, G. Srinivas, S. Vaishampayan, U. Pal, S. K. Rosenberg, J. Mariani, L. Galsky, M. D. TI Nomogram-based prediction of overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (UC) receiving first-line platinum-based chemotherapy: retrospective international study of invasive/advanced cancer of the urothelium (RISC) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Necchi, A.] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy. [Sonpavde, G.] Univ Alabama Birmingham Hosp, Med Oncol, Birmingham, AL USA. [Lo Vullo, S.; Mariani, L.] Fdn IRCCS Ist Nazl Tumori, Clin Epidemiol & Trials Org Unit, Milan, Italy. [Bamias, A.] Univ Athens, Clin Therapeut, Athens, Greece. [Crabb, S. J.] Univ Southampton, Med Oncol, Southampton, Hants, England. [Harshman, L.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Bellmunt, J.] Dana Farber Canc Inst, Bladder Canc Ctr, Boston, MA 02115 USA. [De Giorgi, U.] Ist Tumori Romagna IRST, Med Oncol, Meldola, Italy. [Sternberg, C.] San Camillo Forlanini Hosp, Oncol, Rome, Italy. [Ladoire, S.] Ctr Georges Francois Leclerc Dijon, Med Oncol, Dijon, France. [Wong, Y-N.] Fox Chase Canc Ctr, Med Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Yu, E. Y.] Univ Washington, VAPSHCS, Med Oncol, Seattle, WA 98195 USA. [Chowdhury, S.] Guys & St Thomas Hosp NHS Trust, Oncol, London, England. [Niegisch, G.] Univ Klinikum Dusseldorf, Med Oncol, Dusseldorf, Germany. [Srinivas, S.] Stanford Univ, Med Ctr, Med Oncol, Stanford, CA 94305 USA. [Vaishampayan, U.] Karmanos Canc Inst, Med Oncol, Detroit, MI USA. [Pal, S. K.] City Hope Natl Med Ctr, Med Oncol & Expt Therapuet, Duarte, CA USA. [Rosenberg, J.] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA. [Galsky, M. D.] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA. FU Fondazione IRCCS Istituto Nazionale dei Tumori FX Fondazione IRCCS Istituto Nazionale dei Tumori NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 797P DI 10.1093/annonc/mdw373.25 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500793 ER PT J AU Neelapu, SS Locke, FL Bartlett, NL Siddiqi, T Braunschweig, I Lekakis, LJ Goy, A Castro, J Oluwole, O Miklos, D Timmerman, J Jacobson, C Reagan, PM Flinn, I Farooq, U Stiff, P Navale, L Elias, M Wiezorek, J Go, WY AF Neelapu, S. S. Locke, F. L. Bartlett, N. L. Siddiqi, T. Braunschweig, I. Lekakis, L. J. Goy, A. Castro, J. Oluwole, O. Miklos, D. Timmerman, J. Jacobson, C. Reagan, P. M. Flinn, I. Farooq, U. Stiff, P. Navale, L. Elias, M. Wiezorek, J. Go, W. Y. TI ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Neelapu, S. S.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA. [Locke, F. L.] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA. [Bartlett, N. L.] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA. [Siddiqi, T.] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, 1500 E Duarte Rd, Duarte, CA 91010 USA. [Braunschweig, I.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10467 USA. [Lekakis, L. J.] Univ Miami, Sylvester Canc Ctr, Miami, FL USA. [Goy, A.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Clin Div, Hackensack, NJ USA. [Castro, J.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA. [Oluwole, O.] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr,Dept Med, Hematol & Stem Cell Transplantat Sect,Div Hematol, Nashville, TN USA. [Miklos, D.] Stanford Univ, Sch Med, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA. [Timmerman, J.] Univ Calif Los Angeles, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90024 USA. [Timmerman, J.] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA USA. [Jacobson, C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Reagan, P. M.] Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA. [Flinn, I.] Sarah Cannon Res Inst, Dept Hematol & Oncol, Nashville, TN USA. [Farooq, U.] Univ Iowa Hosp & Clin, Div Hematol Oncol & Blood & Marrow Transplantat, Iowa City, IA 52242 USA. [Stiff, P.] Loyola Univ, Med Ctr, Cardinal Bernardin Canc Ctr, 2160 S 1st Ave, Maywood, IL 60153 USA. [Navale, L.; Elias, M.; Wiezorek, J.; Go, W. Y.] Kite Pharma, Santa Monica, CA USA. FU Kite Pharma FX Kite Pharma NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 943TiP DI 10.1093/annonc/mdw375.38 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000039 ER PT J AU Okusaka, T Blanc, JF Chau, I Yang, L Abada, P Zhu, AX AF Okusaka, T. Blanc, J-F. Chau, I. Yang, L. Abada, P. Zhu, A. X. TI Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Prognosis, efficacy, and safety by liver disease etiology SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Okusaka, T.] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan. [Blanc, J-F.] Hop St Andre, Hepatogastroenterol & Digest Oncol, Bordeaux, France. [Chau, I.] Royal Marsden NHS Fdn Trust, Dept Med, London, England. [Chau, I.] Royal Marsden NHS Fdn Trust, Dept Med, Sutton, Surrey, England. [Yang, L.] Eli Lilly & Co, Biostat, Bridgewater, NJ USA. [Abada, P.] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA. [Zhu, A. X.] Massachusetts Gen Hosp, Dept Med, Ctr Canc, Boston, MA 02114 USA. FU Eli Lilly and Company FX Eli Lilly and Company NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 617PD DI 10.1093/annonc/mdw371.9 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500614 ER PT J AU Ott, PA Pavlick, AC Johnson, DB Hart, LL Infante, JR Luke, JJ Lutzky, J Rothschild, N Spitler, L Cowey, CL Alizadeh, A Salama, A He, Y Bagley, RG Zhang, J Hamid, O AF Ott, P. A. Pavlick, A. C. Johnson, D. B. Hart, L. L. Infante, J. R. Luke, J. J. Lutzky, J. Rothschild, N. Spitler, L. Cowey, C. L. Alizadeh, A. Salama, A. He, Y. Bagley, R. G. Zhang, J. Hamid, O. TI A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Ott, P. A.] Dana Farber Canc Inst, Melanoma Ctr, Boston, MA 02115 USA. [Ott, P. A.] Dana Farber Canc Inst, Ctr Immunooncol, Boston, MA 02115 USA. [Pavlick, A. C.] NYU, Sch Med, Dept Med, New York, NY USA. [Johnson, D. B.] Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN USA. [Hart, L. L.] Florida Canc Specialists, Hematol Oncol, Ft Myers, FL USA. [Infante, J. R.] Tennessee Oncol PLLC, Dept Med, Nashville, TN USA. [Luke, J. J.] Univ Chicago, Hematol Oncol, Chicago, IL 60637 USA. [Lutzky, J.] Mt Sinai Comprehens Canc Ctr, Div Hematol Oncol, Dept Med, Miami Beach, FL USA. [Rothschild, N.] Florida Canc Specialists, Dept Med, W Palm Beach, FL USA. [Spitler, L.] St Marys Hosp, Northern Calif Melanoma Ctr, San Francisco, CA USA. [Cowey, C. L.] Baylor Univ, Med Ctr, Baylor Skin Malignancy & Treatment Ctr, Dallas, TX USA. [Alizadeh, A.] Georgia Canc Specialists, Cent Res, Decatur, GA USA. [Salama, A.] Duke Univ, Dept Med, Durham, NC USA. [He, Y.] Celldex Therapeut Inc, Biostat, Hampton, NJ USA. [Bagley, R. G.; Zhang, J.] Celldex Therapeut Inc, Clin Sci, Hampton, NJ USA. [Hamid, O.] Angeles Clin & Res Inst, Dept Translat Res ImmunoOncol, Los Angeles, CA USA. FU Celldex Therapeutics, Inc. FX Celldex Therapeutics, Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1147P DI 10.1093/annonc/mdw379.42 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000240 ER PT J AU Piotrowska, Z Liu, E Varga, A Thakur, M Narayanan, V Liu, SV Neal, J Spiegel, M Solomon, B Yu, H Ou, SHI Papadimitrakopoulou, VA Gadgeel, S Camidge, DR Soria, JC Wakelee, H Goldman, J Kopani, K Rolfe, L Sequist, LV AF Piotrowska, Z. Liu, E. Varga, A. Thakur, M. Narayanan, V. Liu, S. V. Neal, J. Spiegel, M. Solomon, B. Yu, H. Ou, S-H. I. Papadimitrakopoulou, V. A. Gadgeel, S. Camidge, D. R. Soria, J-C. Wakelee, H. Goldman, J. Kopani, K. Rolfe, L. Sequist, L. V. TI Rociletinib-associated cataracts in EGFR-mutant NSCLC SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Piotrowska, Z.; Sequist, L. V.] Massachusetts Gen Hosp, Ctr Thorac Canc, Boston, MA 02114 USA. [Liu, E.; Kopani, K.] Tufts Univ, Tufts Med Ctr, Ophthalmol, Boston, MA 02111 USA. [Varga, A.] Inst Gustave Roussy, Dept Med DITEP, Villejuif, France. [Thakur, M.] Karmanos Canc Inst, Med Oncol, Detroit, MI USA. [Narayanan, V.] Univ Colorado, Med Oncol, Denver, CO 80202 USA. [Liu, S. V.] Georgetown Univ, Lombardi Canc Ctr, Med, Washington, DC USA. [Neal, J.; Wakelee, H.] Stanford Univ, Med Ctr, Med Oncol, Stanford, CA 94305 USA. [Spiegel, M.] Univ Calif Los Angeles, Sch Med, Hematol Oncol, Los Angeles, CA USA. [Solomon, B.] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia. [Yu, H.] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA. [Ou, S-H. I.] Univ Calif Irvine, Sch Med, Dept Med, Div Hematol Oncol, Irvine, CA 92717 USA. [Papadimitrakopoulou, V. A.] Univ Texas MD Anderson Canc Ctr, Med Oncol, Houston, TX 77030 USA. [Gadgeel, S.] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA. [Camidge, D. R.] Univ Colorado, Ctr Canc, Aurora, CO USA. [Soria, J-C.] Inst Cancerol Gustave Roussy, Dept Med, Villejuif, France. [Goldman, J.] Univ Calif Los Angeles, Oncol, Los Angeles, CA USA. [Rolfe, L.] Clovis Oncol UK Ltd, Sheraton House, Cambridge, England. FU Clovis Oncology FX Clovis Oncology NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1239P DI 10.1093/annonc/mdw383.39 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000331 ER PT J AU Powles, TB Escudier, B de Souza, P Chowdhury, S Pook, D Harmenberg, U Basappa, N Geynisman, D Merchan, J Redman, BG Ryan, C Goodman, O Ho, T Singh, P Lougheed, J Patel, M Knox, JJ Motzer, RJ Choueiri, TK AF Powles, T. B. Escudier, B. de Souza, P. Chowdhury, S. Pook, D. Harmenberg, U. Basappa, N. Geynisman, D. Merchan, J. Redman, B. G. Ryan, C. Goodman, O. Ho, T. Singh, P. Lougheed, J. Patel, M. Knox, J. J. Motzer, R. J. Choueiri, T. K. TI Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Powles, T. B.] Queen Mary Univ London, Barts Canc Inst, Med Oncol, London, England. [Escudier, B.] Inst Gustave Roussy, Med Oncol, Villejuif, France. [de Souza, P.] St George Hosp, Med Oncol, Canc Care Ctr, Kogarah, NSW, Australia. [Chowdhury, S.] Guys & St Thomas Hosp NHS Trust, Oncol, London, England. [Pook, D.] Monash Canc Ctr, Med Oncol, Bentleigh East, Australia. [Harmenberg, U.] Karolinska Univ Hosp Radiumhemmet, Oncol, Stockholm, Sweden. [Basappa, N.] Univ Alberta, Cross Canc Inst, Med Oncol, Edmonton, AB, Canada. [Basappa, N.] Fox Chase Canc Ctr, Med Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Merchan, J.] Univ Miami, Sylvester Comprehens Canc Ctr, Med Oncol, Miami, FL USA. [Redman, B. G.] Univ Michigan, Hematol & Oncol, Ann Arbor, MI 48109 USA. [Ryan, C.] Oregon Hlth & Sci Univ, Med Hematol Oncol, Portland, OR USA. [Goodman, O.] Comprehens Canc Crts NV, US Oncol Res, Hematol & Med Oncol, Las Vegas, NV USA. [Ho, T.] Mayo Clin Arizona, Hematol & Oncol, Phoenix, AZ USA. [Singh, P.] Univ Arizona, Hematol & Med Oncol, Tucson, AZ USA. [Lougheed, J.] Exelixis Inc, Med Affairs, San Francisco, CA USA. [Patel, M.] Exelixis Inc, Regulatory Affairs, San Francisco, CA USA. [Knox, J. J.] Princess Margaret Hosp, Med Oncol & Hematol, Toronto, ON, Canada. [Motzer, R. J.] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA. [Choueiri, T. K.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. FU Exelixis, Inc FX Exelixis, Inc NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 814P DI 10.1093/annonc/mdw373.41 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500809 ER PT J AU Rini, BI Grunwald, V Jonasch, E Fishman, MN Tomita, Y Michaelson, MD Tarazi, J Cisar, L Blair, AH Rosbrook, B Hutson, T AF Rini, B. I. Gruenwald, V. Jonasch, E. Fishman, M. N. Tomita, Y. Michaelson, M. D. Tarazi, J. Cisar, L. Blair, A. H. Rosbrook, B. Hutson, T. TI Long-term duration of axitinib treatment in advanced renal cell carcinoma SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Rini, B. I.] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Oncol, Cleveland, OH 44106 USA. [Gruenwald, V.] Hannover Med Sch, Clin Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany. [Jonasch, E.] Univ Texas MD Anderson Canc Ctr, Genitourinary Oncol, Houston, TX 77030 USA. [Fishman, M. N.] Univ S Florida, H Lee Moffitt Canc Ctr, Med Oncol, Tampa, FL USA. [Tomita, Y.] Niigata Univ, Grad Sch Med & Dent Sci, Dev Urol, Niigata, Japan. [Michaelson, M. D.] Massachusetts Gen Hosp, Med Oncol, Boston, MA 02114 USA. [Tarazi, J.; Blair, A. H.; Rosbrook, B.] Pfizer Inc, Oncol, San Diego, CA USA. [Cisar, L.] Pfizer Inc, Oncol, New York, NY USA. [Hutson, T.] Baylor Sammons Canc Ctr, Texas Oncol, GU Med Oncol, Dallas, TX USA. FU Pfizer, Inc. FX Pfizer, Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 825P DI 10.1093/annonc/mdw373.52 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500820 ER PT J AU Robert, C Schadendorf, D Long, GV Stroyakovskiy, D Levchenko, E Chiarion-Sileni, V Flaherty, K Nathan, P Ribas, A Davies, M Zhang, J Chen, L Mookerjee, B Redhu, S Grob, JJ AF Robert, C. Schadendorf, D. Long, G. V. Stroyakovskiy, D. Levchenko, E. Chiarion-Sileni, V. Flaherty, K. Nathan, P. Ribas, A. Davies, M. Zhang, J. Chen, L. Mookerjee, B. Redhu, S. Grob, J. J. TI Analysis of patient- reported outcomes by disease progression status in patients (pts) with BRAF V600-mutant metastatic melanoma in the COMBI-d and COMBI-v trials SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Robert, C.] Inst Gustave Roussy, Dermatol, Villejuif, France. [Schadendorf, D.] Univ Hosp Essen, Dept Dermatol, Essen, Germany. [Long, G. V.] Melanoma Inst Australia, Melanoma, Sydney, NSW, Australia. [Long, G. V.] Univ Sydney, Sydney, NSW, Australia. [Stroyakovskiy, D.] Moscow City Oncol Hosp 62, Dept Chemotherapy, Moscow, Russia. [Levchenko, E.] NN Petrov Res Inst Oncol, Oncol, St Petersburg, Russia. [Chiarion-Sileni, V.] Veneto Oncol Inst, Melanoma & Skin Canc Unit, Padua, Italy. [Flaherty, K.] Harvard Med Sch, Dana Farber Canc Inst, Melanoma, Boston, MA USA. [Flaherty, K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Nathan, P.] Mt Vernon Canc Ctr, Dept Med Oncol, Northwood, Middx, England. [Ribas, A.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Med Hematol & Oncol, Los Angeles, CA 90024 USA. [Davies, M.] Univ Texas MD Anderson Canc Ctr, Melanoma Med Oncol, Houston, TX 77030 USA. [Zhang, J.; Chen, L.; Mookerjee, B.; Redhu, S.] Novartis Pharmaceut, Global Oncol, E Hanover, NJ USA. [Grob, J. J.] Aix Marseille Univ, Serv Dermatol & Cancerol Cutanee, Marseille, France. FU GlaxoSmithKline FX Supported by GlaxoSmithKline. Dabrafenib and trametinib are assets of Novartis AG as of 2 March 2015. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1140P DI 10.1093/annonc/mdw379.35 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000233 ER PT J AU Robinson, B Schlumberger, M Wirth, LJ Dutcus, CE Binder, TA Guo, M Taylor, M Kim, SB Krzyzanowska, MK Capdevilla, J Sherman, SI Tahara, M AF Robinson, B. Schlumberger, M. Wirth, L. J. Dutcus, C. E. Binder, T. A. Guo, M. Taylor, M. Kim, S. B. Krzyzanowska, M. K. Capdevilla, J. Sherman, S. I. Tahara, M. TI Responses in specific metastases following treatment with lenvatinib (LN): Results from the phase 3 SELECT trial SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Robinson, B.] Univ Sydney, Kolling Inst Med Res, St Leonards, NSW, Australia. [Schlumberger, M.] Gustave Roussy, Dept Nucl Med & Endocrine Oncol, Villejuif, France. [Schlumberger, M.] Univ Paris Sud, Villejuif, France. [Wirth, L. J.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Dutcus, C. E.; Binder, T. A.; Guo, M.] Eisai Inc, Woodcliff Lake, NJ USA. [Taylor, M.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR USA. [Kim, S. B.] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea. [Krzyzanowska, M. K.] Princess Margaret Canc Ctr, Div Hematol & Med Oncol, Toronto, ON, Canada. [Capdevilla, J.] Vall dHebron Univ Hosp, VHIO, Dept Med Oncol, Barcelona, Spain. [Sherman, S. I.] Univ Texas MD Anderson Canc Ctr, Div Internal Med, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA. [Tahara, M.] Natl Canc Ctr Hosp East, Dept Head & Neck Med Oncol, Kashiwa, Chiba, Japan. FU Eisai Inc. FX Eisai Inc., NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 962P DI 10.1093/annonc/mdw376.14 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000058 ER PT J AU Rosenberg, JE Bono, P Kim, J Spiliopoulou, P Calvo, E Pillai, R Ott, PA de Braud, F Morse, M Le, D Jaeger, D Chan, E Harbison, C Lin, CS Tschaika, M Azrilevich, A Sharma, P AF Rosenberg, J. E. Bono, P. Kim, J. Spiliopoulou, P. Calvo, E. Pillai, R. Ott, P. A. de Braud, F. Morse, M. Le, D. Jaeger, D. Chan, E. Harbison, C. Lin, C. S. Tschaika, M. Azrilevich, A. Sharma, P. TI Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Rosenberg, J. E.] Mem Sloan Kettering Canc Ctr, Clin Oncol, 1275 York Ave, New York, NY 10021 USA. [Bono, P.] Helsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland. [Bono, P.] Univ Helsinki, Helsinki, Finland. [Kim, J.] Yale Sch Med, Prostate & Urol Canc Program, New Haven, CT USA. [Spiliopoulou, P.] Gartnavel Royal Hosp, Beatson West Scotland Canc Ctr, Med Oncol, Glasgow, Lanark, Scotland. [Calvo, E.] Ctr Integral Oncol Clara Campal, START Madrid, Early Clin Drug Dev Unit, START Madrid CIOCC, Madrid, Spain. [Pillai, R.] Emory Univ, Winship Canc Inst, Hematol & Oncol, Atlanta, GA 30322 USA. [Ott, P. A.] Dana Farber Canc Inst, ImmunoOncol, Boston, MA 02115 USA. [de Braud, F.] Univ Milan, Ist Nazl Tumori, Fdn IRCCS, Oncol, Milan, Italy. [Morse, M.] Duke Canc Inst, Canc, Durham, NC USA. [Le, D.] Johns Hopkins Med, Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Jaeger, D.] Univ Med Ctr Heidelberg, Med Oncol, Heidelberg, Germany. [Chan, E.] Vanderbilt Ingram Canc Ctr, Med & Hematol Oncol, Nashville, TN USA. [Harbison, C.] Bristol Myers Squibb, Res, Princeton, NJ USA. [Lin, C. S.] Bristol Myers Squibb, Stat, Princeton, NJ USA. [Tschaika, M.; Azrilevich, A.] Bristol Myers Squibb, Global Clin Res, Princeton, NJ USA. [Sharma, P.] Univ Texas MD Anderson Canc Ctr, Genitourinary Med Oncol, Houston, TX 77030 USA. FU Bristol-Myers Squibb FX Bristol-Myers Squibb NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 784P DI 10.1093/annonc/mdw373.12 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500780 ER PT J AU Scagliotti, G Kim, TM Crino, L Liu, G Gridelli, C Novello, S Kiura, K Bearz, A Gautschi, O Felip, E Nishio, M Spigel, DR Mok, TSK Urban, P Deudon, S Zheng, C Shaw, AT AF Scagliotti, G. Kim, T. M. Crino, L. Liu, G. Gridelli, C. Novello, S. Kiura, K. Bearz, A. Gautschi, O. Felip, E. Nishio, M. Spigel, D. R. Mok, T. S. K. Urban, P. Deudon, S. Zheng, C. Shaw, A. T. TI Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Scagliotti, G.; Novello, S.] Univ Turin, Dept Oncol, Turin, Italy. [Kim, T. M.] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea. [Crino, L.] Univ Med Sch Perugia, Med Oncol, Perugia, Italy. [Liu, G.] Princess Margaret Canc Ctr, Med, Toronto, ON, Canada. [Gridelli, C.] SG Moscati Hosp, Med Oncol, Avellino, Italy. [Kiura, K.] Okayama Univ Hosp, Dept Allergy & Resp Med Thorac Oncol, Okayama, Japan. [Bearz, A.] IRCCS CRO, Div Med Oncol, Aviano, Italy. [Gautschi, O.] Cantonal Hosp Lucerne, Dept Med, Med Oncol, Luzern, Switzerland. [Felip, E.] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain. [Nishio, M.] JFCR, Canc Inst Hosp, Thorac Med Oncol, Tokyo, Japan. [Spigel, D. R.] Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA. [Mok, T. S. K.] Chinese Univ Hong Kong, Clin Oncol, Shatin, Hong Kong, Peoples R China. [Urban, P.; Deudon, S.] Novartis Pharma AG, Clin Res, Basel, Switzerland. [Zheng, C.] Novartis Pharmaceut, Biostat, E Hanover, NJ USA. [Shaw, A. T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. FU Novartis Pharmaceutical Corporation FX Novartis Pharmaceutical Corporation NR 0 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA LBA42_PR DI 10.1093/annonc/mdw435.41 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000730 ER PT J AU Segal, NH Infante, JR Sanborn, RE Gibney, GT Lawrence, DP Rizvi, N Leidner, R Gajewski, TF Bertino, E Sharfman, WH Cooley, S Topalian, SL Urba, WJ Wolchok, JD Gu, X Passey, C McDonald, D Aanur, P Srivastava, S Hodi, FS AF Segal, N. H. Infante, J. R. Sanborn, R. E. Gibney, G. T. Lawrence, D. P. Rizvi, N. Leidner, R. Gajewski, T. F. Bertino, E. Sharfman, W. H. Cooley, S. Topalian, S. L. Urba, W. J. Wolchok, J. D. Gu, X. Passey, C. McDonald, D. Aanur, P. Srivastava, S. Hodi, F. S. TI Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Segal, N. H.; Wolchok, J. D.] Mem Sloan Kettering Canc Ctr, Med, 1275 York Ave, New York, NY 10021 USA. [Infante, J. R.] Tennessee Oncol PLLC, Med, Nashville, TN USA. [Sanborn, R. E.; Leidner, R.] Providence Canc Ctr, Chiles Res Inst, Med Oncol, Portland, OR USA. [Gibney, G. T.] Georgetown Univ, Lombardi Canc Ctr, Melanoma Dis Grp, Washington, DC USA. [Lawrence, D. P.] Massachusetts Gen Hosp, Hematol Oncol, Boston, MA 02114 USA. [Rizvi, N.] Mem Sloan Kettering Canc Ctr, Hematol & Oncol, 1275 York Ave, New York, NY 10021 USA. [Gajewski, T. F.] Univ Chicago, Hematol Oncol Sect, Pathol & Med, Chicago, IL 60637 USA. [Bertino, E.] Ohio State Univ, Med Ctr, Div Med Oncol, Internal Med, Columbus, OH 43210 USA. [Sharfman, W. H.] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Oncol & Dermatol, Baltimore, MD USA. [Cooley, S.] Univ Minnesota, Masonic Canc Ctr, Div Hematol Oncol & Transplantat, Minneapolis, MN USA. [Topalian, S. L.] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Surg, Baltimore, MD USA. [Urba, W. J.] Providence Canc Ctr, Earle A Chiles Res Inst, Providence Melanoma Program, Portland, OR USA. [Gu, X.] Bristol Myers Squibb, Biostat, Princeton, NJ USA. [Passey, C.; Srivastava, S.] Bristol Myers Squibb, Oncol, Princeton, NJ USA. [McDonald, D.; Aanur, P.] Bristol Myers Squibb, Immunooncol, Princeton, NJ USA. [Hodi, F. S.] Dana Farber Canc Inst, Oncol, Boston, MA 02115 USA. FU Bristol-Myers Squibb FX Sponsored by Bristol-Myers Squibb NR 0 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1086P DI 10.1093/annonc/mdw378.40 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000180 ER PT J AU Sequist, LV Chiang, A Gilbert, J Gordon, M Conkling, PR Thompson, D Marcoux, JP Antonia, SJ Liu, B Shames, DS Lopez-Chavez, A O'Hear, C Fasso, M Gettinger, S AF Sequist, L. V. Chiang, A. Gilbert, J. Gordon, M. Conkling, P. R. Thompson, D. Marcoux, J. P. Antonia, S. J. Liu, B. Shames, D. S. Lopez-Chavez, A. O'Hear, C. Fasso, M. Gettinger, S. TI Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Sequist, L. V.] Massachusetts Gen Hosp, Ctr Thorac Canc, Boston, MA 02114 USA. [Chiang, A.; Gettinger, S.] Yale Sch Med, Yale Canc Ctr, New Haven, CT USA. [Gilbert, J.] Vanderbilt Univ, Sch Med, Oncol, Nashville, TN 37212 USA. [Gordon, M.] Pinnacle Oncol Hematol, Div Arizona Ctr Canc Care, Scottsdale, AZ USA. [Conkling, P. R.] US Oncol Res, Virginia Oncol Associates, Norfolk, VA USA. [Thompson, D.] Sarah Cannon Res Inst, Oncol, Nashville, TN USA. [Marcoux, J. P.] Dana Farber Canc Inst, Thorac Oncol, Boston, MA 02115 USA. [Antonia, S. J.] H Lee Moffitt Canc Ctr & Res Inst, Dept Thorac Oncol, Tampa, FL USA. [Liu, B.; Lopez-Chavez, A.; O'Hear, C.; Fasso, M.] Genentech Inc, Prod Dev Oncol, San Francisco, CA USA. [Shames, D. S.] Genentech Inc, Oncol Biomarker Dept, San Francisco, CA USA. FU F. Hoffmann-La Roche Ltd. FX F. Hoffmann-La Roche Ltd. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1425PD DI 10.1093/annonc/mdw389.3 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000512 ER PT J AU Sequist, LV Anderson, I Bauer, TM Demars, N Felip, E Frost, N Harb, W Horn, L Huber, RM Kudla, AJ Lee, J Mathews, S Mehra, R Nieva, J Perol, M Shepherd, F Spira, A Czibere, A AF Sequist, L. V. Anderson, I. Bauer, T. M. Demars, N. Felip, E. Frost, N. Harb, W. Horn, L. Huber, R. M. Kudla, A. J. Lee, J. Mathews, S. Mehra, R. Nieva, J. Perol, M. Shepherd, F. Spira, A. Czibere, A. TI A phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG plus ), locally advanced or metastatic non-small cell lung cancer (NSCLC) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Sequist, L. V.] Massachusetts Gen Hosp, Med Oncol, Boston, MA 02114 USA. [Anderson, I.] St Joseph Heritage Healthcare, Res, Santa Rosa, CA USA. [Bauer, T. M.] Tennessee Oncol, Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA. [Demars, N.; Mathews, S.; Czibere, A.] Merrimack Pharmaceut, Clin Dev, Cambridge, MA USA. [Felip, E.] Vall dHebron Univ Hosp, Inst Oncol, Oncol Med, Barcelona, Spain. [Frost, N.] Charite, Campus Virchow Klinikum, Infektiol & Pneumol, Berlin, Germany. [Harb, W.] Horizon Oncol Ctr, Unity Campus, Lafayette, IN USA. [Horn, L.] Vanderbilt Ingram Canc Ctr, Oncol, Nashville, TN USA. [Huber, R. M.] LMU Klinikum Univ Munchen, Thorac Oncol Ctr Munich, Munich, Germany. [Lee, J.] NYU Med Ctr, Med, New York, NY 10016 USA. [Mehra, R.] Fox Chase Canc Ctr, Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Nieva, J.] Univ Southern Calif, Norris Comprehens Canc Ctr, Dept Med, Los Angeles, CA USA. [Perol, M.] Ctr Leon Berard, Serv Oncol Med, Lyon, France. [Shepherd, F.] Princess Margaret Hosp, Med, Toronto, ON, Canada. [Spira, A.] Virginia Canc Specialists, Fairfax Off, Arlington, VA USA. FU Merrimack Pharmaceuticals FX Merrimack Pharmaceuticals NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1296TiP DI 10.1093/annonc/mdw383.96 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000388 ER PT J AU Shapiro, G Infante, J Bauer, TM Prawira, A Bedard, P Laskin, O Weetall, M Baird, J O'Mara, E Spiegel, R AF Shapiro, G. Infante, J. Bauer, T. M. Prawira, A. Bedard, P. Laskin, O. Weetall, M. Baird, J. O'Mara, E. Spiegel, R. TI Initial first-in-human phase 1 results of PTC596, a novel small molecule that targets cancer stem cells (CSCs) by reducing BMI1 protein levels SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Shapiro, G.] Dana Farber Canc Inst, Oncol, Boston, MA 02115 USA. [Infante, J.] Sarah Cannon Res Inst, Other, Nashville, TN USA. [Bauer, T. M.] Tennessee Oncol, Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA. [Prawira, A.] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON, Canada. [Bedard, P.] Princess Margaret Hosp, Med Oncol, Toronto, ON, Canada. [Laskin, O.; O'Mara, E.] PTC Therapeut, Clin, South Plainfield, NJ USA. [Weetall, M.] PTC Therapeut Inc, Pharmacol, South Plainfield, NJ USA. [Baird, J.; Spiegel, R.] PTC Therapeut Inc, Clin, South Plainfield, NJ USA. FU PTC Therapeutics FX PTC Therapeutics NR 0 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 384P DI 10.1093/annonc/mdw368.27 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500382 ER PT J AU Shaw, A Riley, GJ Bang, YJ Kim, DW Camidge, DR Varella-Garcia, M Lafrate, AJ Shapiro, G Winter, M Usari, T Wang, SC Wilner, K Clark, JW Ou, SHI AF Shaw, A. Riley, G. J. Bang, Y-J. Kim, D-W. Camidge, D. R. Varella-Garcia, M. Lafrate, A. J. Shapiro, G. Winter, M. Usari, T. Wang, S. C. Wilner, K. Clark, J. W. Ou, S-H. I. TI Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): updated results from PROFILE 1001 SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Shaw, A.; Lafrate, A. J.; Clark, J. W.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA. [Riley, G. J.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. [Bang, Y-J.; Kim, D-W.] Seoul Natl Univ Hosp, Dept Internal Med, Yongon Campus, Seoul, South Korea. [Camidge, D. R.; Varella-Garcia, M.] Univ Colorado, Ctr Canc, Aurora, CO USA. [Shapiro, G.] Dana Farber Canc Inst, Early Drug Dev Ctr, Boston, MA 02115 USA. [Winter, M.; Wang, S. C.; Wilner, K.] Pfizer, Oncol, La Jolla, CA USA. [Usari, T.] Pfizer, Oncol, Milan, Italy. [Ou, S-H. I.] Univ Calif Irvine, Irvine, CA USA. FU Pfizer FX Pfizer NR 0 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1206PD PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000299 ER PT J AU Shum, M Beck, JT Meyerhardt, J Patel, R Kochenderfer, M Crocenzi, T Patchen, M Gargano, MA Ma, B Lowe, J Iglesias, JL AF Shum, M. Beck, J. T. Meyerhardt, J. Patel, R. Kochenderfer, M. Crocenzi, T. Patchen, M. Gargano, M. A. Ma, B. Lowe, J. Iglesias, J. L. TI Levels of endogenous anti-beta-glucan IgG antibodies (ABA) predict clinical outcomes for imprime PGG: Evidence from phase 3 PRIMUS study in patients (pts) with metastatic colorectal cancer (mCRC) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Shum, M.] Innovat Clin Res Inst, Oncol, Whittier, CA USA. [Beck, J. T.] Highlands Oncol Grp, Med Oncol, Fayetteville, AR USA. [Meyerhardt, J.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Patel, R.] Comprehens Blood & Canc Ctr, Med Oncol, Bakersfield, CA USA. [Kochenderfer, M.] Blue Ridge Canc Care, Med Oncol, Roanoke, VA USA. [Crocenzi, T.] Providence Portland Med Ctr, Med Oncol, Portland, OR USA. [Patchen, M.] Biothera Pharmaceut, Res, Eagan, MN USA. [Gargano, M. A.; Lowe, J.; Iglesias, J. L.] Biothera Pharmaceut, Clin Res, Eagan, MN USA. [Ma, B.] Biothera Pharmaceut, Biostat, Eagan, MN USA. FU Biothera Pharmaceuticals FX Biothera Pharmaceuticals NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 139P DI 10.1093/annonc/mdw363.87 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500139 ER PT J AU Soria, JC Italiano, A Cervantes, A Tabernero, J Infante, J Lara, PN Spira, A Calvo, E Moreno, V Blay, JY Lauer, R Chan, N Zhong, B Santiago-Walker, AA Bussolari, J Luo, FR Xie, H Hammerman, P AF Soria, J-C. Italiano, A. Cervantes, A. Tabernero, J. Infante, J. Lara, P. N. Spira, A. Calvo, E. Moreno, V. Blay, J-Y. Lauer, R. Chan, N. Zhong, B. Santiago-Walker, A. Ademi Bussolari, J. Luo, F. R. Xie, H. Hammerman, P. TI Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Soria, J-C.] Gustave Roussy Canc Campus, Dept Med DITEP, Villejuif, France. [Soria, J-C.] Univ Paris Sud, Villejuif, France. [Italiano, A.] Inst Bergonie, Med Oncol, Bordeaux, France. [Cervantes, A.] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain. [Cervantes, A.] Inst Oncol VHIO, Barcelona, Spain. [Tabernero, J.] Hosp Gen Valle Hebron, Med Oncol, Barcelona, Spain. [Infante, J.] Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA. [Lara, P. N.] Univ Calif Davis, Internal Med Hematol Oncol, Ctr Canc, Sacramento, CA 95817 USA. [Spira, A.] US Oncol Res, Med Oncol, The Woodlands, TX USA. [Calvo, E.] Ctr Integral Oncol Clara Campal, START Madrid, Early Clin Drug Dev Unit, START Madrid CIOCC, Madrid, Spain. [Moreno, V.] Hosp Univ Fdn Jimenez Diaz Hosp, Med Oncol, START Madrid FJD, Madrid, Spain. [Blay, J-Y.] Univ Claude Bernard Lyon I, Ctr Leon Berard, Lyon, France. [Lauer, R.] Univ New Mexico, Internal Med, Albuquerque, NM 87131 USA. [Chan, N.] Rutgers State Univ, Dept Med, New Brunswick, NJ USA. [Zhong, B.] Janssen Res & Dev, Biostat, Raritan, NJ USA. [Santiago-Walker, A. Ademi] Janssen Res & Dev, Oncol Translat Res, Raritan, NJ USA. [Bussolari, J.] Janssen Res & Dev, Compound Dev, Raritan, NJ USA. [Luo, F. R.; Xie, H.] Janssen Res & Dev, Expt Med, Raritan, NJ USA. [Hammerman, P.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. FU Janssen Research & Development, LLC FX Janssen Research & Development, LLC NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 781PD DI 10.1093/annonc/mdw373.9 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500777 ER PT J AU Strosberg, J Wolin, E Chasen, B Kulke, M Bushnell, D Caplin, M Baum, R Kunz, PL Hobday, T Hendifar, A Oberg, K Sierra, ML Kwekkeboom, D Ruszniewski, P Krenning, E AF Strosberg, J. Wolin, E. Chasen, B. Kulke, M. Bushnell, D. Caplin, M. Baum, R. Kunz, P. L. Hobday, T. Hendifar, A. Oberg, K. Sierra, M. Lopera Kwekkeboom, D. Ruszniewski, P. Krenning, E. TI NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate: Efficacy, safety, QoL results and subgroup analysis SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Strosberg, J.] Univ S Florida, H Lee Moffitt Canc Ctr, Oncol, Tampa, FL USA. [Wolin, E.] Univ Kentucky, Oncol, Lexington, KY USA. [Chasen, B.] Univ Texas Hlth Sci Ctr Houston, Nucl Med, Houston, TX 77030 USA. [Kulke, M.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Bushnell, D.] Univ Iowa, Div Nucl Med, Iowa City, IA USA. [Caplin, M.] Royal Free Hosp, Sch Med, Neuroendocrine Tumour Unit, Gastroenterol, London, England. [Baum, R.] Zent Klin Bad Berka GmbH, Nucl Med, Bad Berka, Germany. [Kunz, P. L.] Stanford Univ, Med Ctr, Oncol, Stanford, CA 94305 USA. [Hobday, T.] Mayo Clin, Oncol, Rochester, NY USA. [Hendifar, A.] Cedars Sinai Med Ctr, Oncol, Los Angeles, CA 90048 USA. [Oberg, K.] Univ Uppsala Hosp, Endocrine Oncol, Akad Sjukhuset, Uppsala, Sweden. [Sierra, M. Lopera] Adv Accelerator Applicat, New York, NY USA. [Kwekkeboom, D.] Erasmus Univ, Med Ctr, Nucl Med Dept, Rotterdam, Netherlands. [Ruszniewski, P.] Hop Beaujon, Gastroenterol, Clichy, France. [Krenning, E.] Erasmus Univ, Med Ctr, Oncol, Rotterdam, Netherlands. FU Advanced Accelerator Applications FX Advanced Accelerator Applications NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 420PD DI 10.1093/annonc/mdw369.5 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500418 ER PT J AU Sweeney, C Chen, YH Liu, G Carducci, M Jarrard, D Eisenberger, M Wong, YN Patrick-Miller, L Hahn, N Kohli, M Conney, M Dreicer, R Vogelzang, NJ Picus, J Shevrin, D Hussain, M Garcia, J Dipaola, R AF Sweeney, C. Chen, Y-H. Liu, G. Carducci, M. Jarrard, D. Eisenberger, M. Wong, Y-N. Patrick-Miller, L. Hahn, N. Kohli, M. Conney, M. Dreicer, R. Vogelzang, N. J. Picus, J. Shevrin, D. Hussain, M. Garcia, J. Dipaola, R. TI Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone naive metastatic prostate cancer (PrCa): E3805 CHAARTED trial SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Sweeney, C.] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA. [Chen, Y-H.] Dana Farber Canc Inst, Biostastict, Boston, MA 02115 USA. [Liu, G.; Jarrard, D.] UW Carbone Canc Ctr, Oncol, Madison, WI USA. [Carducci, M.; Eisenberger, M.; Hahn, N.] Johns Hopkins Univ Hosp, Oncol, Baltimore, MD 21287 USA. [Wong, Y-N.] Fox Chase Canc Ctr, Med Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Patrick-Miller, L.] Univ Chicago, Med Ctr, Med Oncol, Chicago, IL 60637 USA. [Kohli, M.] Mayo Clin, Med Oncol, Rochester, NY USA. [Conney, M.] Univ Hosp Case Med Ctr, Med Oncol, Cleveland, OH USA. [Dreicer, R.] Univ Virginia, Med Oncol, Charlottesville, VA USA. [Vogelzang, N. J.] US Oncol Res, Comprehens Canc Ctr NV, Med Oncol, Las Vegas, NV USA. [Picus, J.] Washington Univ, Sch Med, Med Oncol, St Louis, MO USA. [Shevrin, D.] NorthShore Univ HealthSyst, Med Oncol, Chicago, IL USA. [Hussain, M.] Univ Michigan, Med Oncol, Ann Arbor, MI 48109 USA. [Garcia, J.] Cleveland Clin Fdn, Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA. [Dipaola, R.] Univ Kentucky, Med Oncol, Lexington, KY USA. FU NCI FX NCI NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 720PD DI 10.1093/annonc/mdw372.4 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500717 ER PT J AU Sznol, M Ferrucci, PF Hogg, D Atkins, M Wolter, P Guidoboni, M Lebbe, C Kirkwood, J Schachter, J Daniels, G Hassel, J Cebon, J Gerritsen, W Atkinson, V Thomas, L McCaffrey, J Power, D Jiang, J Hodi, FS Wolchok, J AF Sznol, M. Ferrucci, P. F. Hogg, D. Atkins, M. Wolter, P. Guidoboni, M. Lebbe, C. Kirkwood, J. Schachter, J. Daniels, G. Hassel, J. Cebon, J. Gerritsen, W. Atkinson, V. Thomas, L. McCaffrey, J. Power, D. Jiang, J. Hodi, F. S. Wolchok, J. TI Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Sznol, M.] Yale Univ, Sch Med Med Oncol, Med Oncol, New Haven, CT USA. [Ferrucci, P. F.] Ist Europeo Oncol, Melanoma & Sarcoma, Milan, Italy. [Hogg, D.] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON, Canada. [Atkins, M.] Georgetown Univ, Hematol Oncol, Lombardi Canc Ctr, Washington, DC USA. [Wolter, P.] Univ Hosp Leuven, Dept Gen Med Oncol, Campus Gasthuisberg, Leuven, Belgium. [Guidoboni, M.] Ist Tumori Romagna IRST, Immunotherapy Unit, Meldola, Italy. [Lebbe, C.] Hop St Louis, Dermatol, Paris, France. [Kirkwood, J.] Hillman Canc Ctr, Med Oncol & Hematol, Pittsburgh, PA USA. [Schachter, J.] Sheba Med Ctr, Ella Lemelbaum Inst Melanoma, Ramat Gan, Israel. [Daniels, G.] Moores UCSD Canc Ctr, Med, La Jolla, CA USA. [Hassel, J.] Univ Heidelberg Hosp, Oncol, Heidelberg, Germany. [Cebon, J.] Olivia Newton John Canc Res Inst, Canc Immunobiol, Heidelberg, Australia. [Gerritsen, W.] Radboud Univ Nijmegen, Med Ctr Nijmegen, Dept Med Oncol, Nijmegen, Netherlands. [Atkinson, V.] Gallipoli Med Res Fdn, Oncol, Greenslopes, Australia. [Atkinson, V.] Princess Alexandra Hosp, Greenslopes, Australia. [Thomas, L.] Ctr Hosp Lyon Sud, Dermatol, Pierre Benite, France. [McCaffrey, J.] Irish Clin Oncol Res Grp, Med Oncol, Dublin, Ireland. [Power, D.] Irish Clin Oncol Res Grp, Med Oncol, Cork, Ireland. [Jiang, J.] BMS, Oncol, Princeton, NJ USA. [Hodi, F. S.] Dana Farber Canc Inst, Oncol, Boston, MA 02115 USA. [Wolchok, J.] Mem Sloan Kettering Canc Ctr, Ludwig Ctr, 1275 York Ave, New York, NY 10021 USA. FU Bristol-Myers Squibb FX Bristol-Myers Squibb NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1123P DI 10.1093/annonc/mdw379.18 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000216 ER PT J AU Tannir, N Powles, T Motzer, RJ Rolland, F Gravis, G Staehler, M Rink, M Retz, M Csoszi, T McCaffrey, J De Giorgi, U Caserta, C Cheporov, S Gonzalez, EE Duran, I Larkin, JG Berg, W Clary, D Escudier, B Choueiri, TK AF Tannir, N. Powles, T. Motzer, R. J. Rolland, F. Gravis, G. Staehler, M. Rink, M. Retz, M. Csoszi, T. McCaffrey, J. De Giorgi, U. Caserta, C. Cheporov, S. Esteban Gonzalez, E. Duran, I. Larkin, J. G. Berg, W. Clary, D. Escudier, B. Choueiri, T. K. TI Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Tannir, N.] Univ Texas MD Anderson Canc Ctr, Genitourinary Med Oncol, Houston, TX 77030 USA. [Powles, T.] Queen Mary Univ London, Barts Canc Inst, Expt Canc Med, London, England. [Motzer, R. J.] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA. [Rolland, F.] ICO Inst Cancerol Ouest Rene Gauducheau, Med Oncol, St Herblain, France. [Gravis, G.] Inst Paoli Calmettes, Med Outpatient, Urol, Marseille, France. [Staehler, M.] Maximilians Univ Munchen, Klinikum Ludwig, Urol, Munich, Germany. [Rink, M.] Univ Med Ctr Hamburg Eppendorf, Urol, Hamburg, Germany. [Retz, M.] Klinikum Rechts Isar Tech, Urol, Munich, Germany. [Csoszi, T.] Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz R, Med Oncol & Hematol, Szolnok, Hungary. [McCaffrey, J.] Mater Private Hosp, Med Oncol, Oncol, Dublin, Ireland. [De Giorgi, U.] Ist Sci Romagnolo Studio & Cura Tumori, Med Oncol, Meldola, Italy. [Caserta, C.] Azienda Osped Sta Maria, Oncol, Terni, Italy. [Cheporov, S.] Reg Clin Oncol Hosp, Clin Oncol, Yaroslavl, Russia. [Esteban Gonzalez, E.] Clinica, Oncol, Edificio Consultas Externas, Oviedo, Spain. [Duran, I.] Hosp Univ Virgen del Rocio, Med Oncol, Seville, Spain. [Larkin, J. G.] Royal Marsden Hosp NHS Fdn Trust, Med Oncol, London, England. [Berg, W.; Clary, D.] Exelixis Inc, Med Affairs, San Francisco, CA USA. [Escudier, B.] Inst Gustave Roussy, Immunotherapy & Innovat Therapy Unit, Villejuif, France. [Choueiri, T. K.] Brigham & Womens Hosp, Dana Farber Canc Inst, Genitourinary Oncol, 75 Francis St, Boston, MA 02115 USA. FU Exelixis, Inc. FX Exelixis, Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 818P DI 10.1093/annonc/mdw373.45 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500813 ER PT J AU Tolaney, SM Cortes, J Dickler, MN Zamora, E Caldwell, CW Nguyen, TS Nanda, S Koustenis, A Rugo, HS AF Tolaney, S. M. Cortes, J. Dickler, M. N. Zamora, E. Caldwell, C. W. Nguyen, T. S. Nanda, S. Koustenis, A. Rugo, H. S. TI Exploratory biomarkers in MONARCH 1, a phase II study of abemaciclib monotherapy in hormone-receptor positive (HR) HER2-metastatic breast cancer (MBC) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Tolaney, S. M.] Dana Farber Canc Inst, Breast Oncol Ctr, Boston, MA 02115 USA. [Cortes, J.; Zamora, E.] VHIO, Med Oncol, Barcelona, Spain. [Dickler, M. N.] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA. [Caldwell, C. W.] Eli Lilly & Co, Diagnost & Expt Pathol, Indianapolis, IN 46285 USA. [Nguyen, T. S.; Nanda, S.] Eli Lilly & Co, Stat Oncol, Indianapolis, IN 46285 USA. [Koustenis, A.] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA. [Rugo, H. S.] Univ Calif San Francisco, Med Hematol Oncol, San Francisco, CA 94143 USA. FU Eli Lilly and Company FX Eli Lilly and Company NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA LBA12 DI 10.1093/annonc/mdw435.1 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000690 ER PT J AU Tolaney, SM Bourayou, N Goel, S Forrester, T Andre, F AF Tolaney, S. M. Bourayou, N. Goel, S. Forrester, T. Andre, F. TI monarcHER: A phase 2 randomized open-label study of abemaciclib plus trastuzumab (T) with or without fulvestrant (F) compared to standard-of-care chemotherapy of physician's choice plus T in women with HR +, HER2+advanced breast cancer SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Tolaney, S. M.; Goel, S.] Dana Farber Canc Inst, Breast Oncol Ctr, Boston, MA 02115 USA. [Bourayou, N.] Eli Lilly & Co, Med Oncol, Paris, France. [Forrester, T.] Eli Lilly & Co, Stat Oncol, Indianapolis, IN 46285 USA. [Andre, F.] Inst Gustave Roussy, Dept Med Oncol, Breast Canc Unit, Villejuif, France. FU Eli Lilly and Company FX Eli Lilly and Company NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 314TiP DI 10.1093/annonc/mdw365.93 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500313 ER PT J AU Van Cutsem, E Garcia-Carbonero, R Pastorino, A Zaniboni, A Falcone, A Amellal, N Benedetti, F Mayer, R Ohtsu, A Tabernero, J AF Van Cutsem, E. Garcia-Carbonero, R. Pastorino, A. Zaniboni, A. Falcone, A. Amellal, N. Benedetti, F. Mayer, R. Ohtsu, A. Tabernero, J. TI RECOURSE trial: Performance status at discontinuation in patients receiving trifluridine/tipiracil (TAS-102) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Van Cutsem, E.] Univ Hosp Leuven, Digest Oncol, Campus Gasthuisberg, Leuven, Belgium. [Garcia-Carbonero, R.] Univ Hosp 12 Octubre, Oncol, Madrid, Spain. [Pastorino, A.] IRCCS AOU San Martino IST Ist Nazl Ric Canc, Dept Med Oncol, Genoa, Italy. [Zaniboni, A.] Fdn Poliambulanza, Oncol, Brescia, Italy. [Falcone, A.] Univ S Chiara, Azienda Osped, Dept Oncol, Presidio Osped, Pisa, Italy. [Amellal, N.] IRIS, F-92284 Suresnes, France. [Benedetti, F.] Taiho, Oncol, Tokyo, Japan. [Mayer, R.] Dana Farber Canc Inst, Gastrointestinal Canc, Boston, MA 02115 USA. [Ohtsu, A.] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan. [Tabernero, J.] Vall dHebron Univ Hosp, Inst Oncol, Oncol Med, Barcelona, Spain. FU Taiho; Institut de Recherches Internationales Servier FX Taiho and Institut de Recherches Internationales Servier NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 515P DI 10.1093/annonc/mdw370.63 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500569 ER PT J AU Weber, J Horak, C Hodi, FS Chang, H Woods, D Sanders, C Robins, H Yusko, E AF Weber, J. Horak, C. Hodi, F. S. Chang, H. Woods, D. Sanders, C. Robins, H. Yusko, E. TI Baseline tumor T cell receptor (TcR) sequencing analysis and neo antigen load is associated with benefit in melanoma patients receiving sequential nivolumab and ipilimumab SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract C1 [Weber, J.] NYU, Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA. [Horak, C.; Chang, H.] BMS, Biomarkers, Princeton, NJ USA. [Hodi, F. S.] Dana Farber Canc Inst, Oncol, Boston, MA 02115 USA. [Woods, D.] Laura & Isaac Perlmutter Canc Ctr, Canc Ctr, New York, NY USA. [Sanders, C.; Yusko, E.] Adapt Biotechnol, Computat Biol, Seattle, WA USA. [Robins, H.] Fred Hutchinson Canc Res Ctr, Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA. FU BMS FX BMS NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 1047O DI 10.1093/annonc/mdw378.1 PG 1 WC Oncology SC Oncology GA EK4QX UT WOS:000393913000141 ER PT J AU Weller, M Vlahovic, G Khasraw, M Brandes, AA Zwirtes, R Tatsuoka, K Carpentier, AF Reardon, DA van den Bent, M AF Weller, M. Vlahovic, G. Khasraw, M. Brandes, A. A. Zwirtes, R. Tatsuoka, K. Carpentier, A. F. Reardon, D. A. van den Bent, M. TI A randomized phase 2, single-blind study of temozolomide (TMZ) and radiotherapy (RT) combined with nivolumab or placebo (PBO) in newly diagnosed adult patients (pts) with tumor O6-methylguanine DNA methyltransferase (MGMT)-methylated glioblastoma (GBM) - CheckMate-548 SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Weller, M.] Univ Zurich Hosp, Dept Neurol, Zurich, Switzerland. [Vlahovic, G.] Duke Univ, Med Ctr, Brain Tumor Immunotherapy Clin Res, Durham, NC USA. [Khasraw, M.] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia. [Brandes, A. A.] AUSL BOLOGNA Italy, Dept Med Oncol, Bologna, Italy. [Zwirtes, R.] Bristol Myers Squibb, Med Monitor, Princeton, NJ USA. [Tatsuoka, K.] Bristol Myers Squibb, Biostat, Princeton, NJ USA. [Carpentier, A. F.] Hop Avicenne, AP HP, Serv Neurol, Bobigny, France. [Reardon, D. A.] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA. [van den Bent, M.] Erasmus MC Daniel den Hoed Canc Ctr, Neurooncol, Rotterdam, Netherlands. FU Bristol-Myers Squibb FX Bristol-Myers Squibb NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 356TiP DI 10.1093/annonc/mdw367.34 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500355 ER PT J AU Xie, W Sweeney, C Regan, M Nakabayashi, M Buyse, M Clarke, N Collette, L Dignam, J Fizazi, K Habibian, M Halabi, S Kantoff, P Parulekar, W Sandler, HM Sartor, O Soule, H Sydes, M Tombal, B Williams, S AF Xie, W. Sweeney, C. Regan, M. Nakabayashi, M. Buyse, M. Clarke, N. Collette, L. Dignam, J. Fizazi, K. Habibian, M. Halabi, S. Kantoff, P. Parulekar, W. Sandler, H. M. Sartor, O. Soule, H. Sydes, M. Tombal, B. Williams, S. TI Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Xie, W.; Regan, M.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Sweeney, C.; Nakabayashi, M.] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA. [Buyse, M.] IDDI Int Drug Dev Inst, Louvain La Neuve, Belgium. [Clarke, N.] Christie NHS Fdn Trust, Urol Oncol, Manchester, Lancs, England. [Collette, L.] EORTC, Brussels, Belgium. [Dignam, J.] Univ Illlinois Chicago, Dept Publ Hlth Sci, Chicago, IL USA. [Fizazi, K.] Inst Gustave Roussy, Dept Canc Med, Villejuif, France. [Habibian, M.] UNICANCER, R&D, Paris, France. [Halabi, S.] Duke Univ, Biostat & Bioinformat, Durham, NC USA. [Kantoff, P.] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA. [Parulekar, W.] Queens Univ, Canc Res Inst, NCIC Clin Trials Grp, Kinston, ON, Canada. [Sandler, H. M.] Cedars Sinai Med Ctr, Radiat Oncol, Los Angeles, CA 90048 USA. [Sartor, O.] Tulane Univ, Dept Med & Urol, New Orleans, LA 70118 USA. [Soule, H.] Prostate Canc Fdn, Santa Monica, CA USA. [Sydes, M.] Inst Clin Trials & Methodol UCL, MRC Clin Trials Unit, London, England. [Tombal, B.] Catholic Univ Louvain, Inst Rech Clin, Brussels, Belgium. [Williams, S.] Peter MacCallum Canc Ctr, Urol Canc Res, East Melbourne, Australia. FU Prostate Cancer Foundation, CA, United States FX Prostate Cancer Foundation, CA, United States NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 717O DI 10.1093/annonc/mdw372.1 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500714 ER PT J AU Yoshino, T Cleary, J Mayer, R Yoshida, K Makris, L Yamashita, F Ohtsu, A Lenz, HJ Van Cutsem, E AF Yoshino, T. Cleary, J. Mayer, R. Yoshida, K. Makris, L. Yamashita, F. Ohtsu, A. Lenz, H-J. Van Cutsem, E. TI Pharmacokinetic and pharmacodynamic (PK/PD) analysis results from the phase 3 RECOURSE trial of trifluridine and tipiracil (TAS-102) versus placebo (pbo) in patients (pts) with refractory metastatic colorectal cancer (mCRC) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Yoshino, T.; Ohtsu, A.] Natl Canc Ctr Hosp East, Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan. [Cleary, J.; Mayer, R.] Dana Farber Canc Inst, Gastrointestinal Canc, Boston, MA 02115 USA. [Yoshida, K.] Taiho Oncol Inc, Clin Pharmacol, Princeton, NJ USA. [Makris, L.] Stathmi Inc, Biostat, New Hope, PA USA. [Yamashita, F.] Taiho Oncol Inc, Bioanalyt & DMPK, Princeton, NJ USA. [Lenz, H-J.] Univ Southern Calif, Norris Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA USA. [Van Cutsem, E.] Univ Hosp Leuven, Leuven Canc Inst, Gastroenterol Digest Oncol, Leuven, Belgium. FU Taiho Pharmaceutical Co., Ltd. FX Taiho Pharmaceutical Co., Ltd. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 513P DI 10.1093/annonc/mdw370.61 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500567 ER PT J AU Zhu, A Knox, J Kudo, M Chan, S Finn, R Siegel, A Ma, J Watson, PA Cheng, AL AF Zhu, A. Knox, J. Kudo, M. Chan, S. Finn, R. Siegel, A. Ma, J. Watson, P. A. Cheng, A-L. TI Pembrolizumab in patients with previously treated advanced hepatocellular carcinoma: Phase 2 KEYNOTE-224 study SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Zhu, A.] Massachusetts Gen Hosp, Med Oncol, Boston, MA 02114 USA. [Knox, J.] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada. [Kudo, M.] Kinki Univ, Med, Sch Med, Osaka, Japan. [Chan, S.] Prince Wales Hosp, Med Oncol, Shatin, Hong Kong, Peoples R China. [Finn, R.] Univ Calif Los Angeles, Med, Los Angeles, CA USA. [Siegel, A.; Ma, J.; Watson, P. A.] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA. [Cheng, A-L.] Natl Taiwan Univ Hosp, Grad Inst Oncol, Taipei, Taiwan. FU Merck Co., Inc. FX Merck & Co., Inc. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 716TiP DI 10.1093/annonc/mdw371.108 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500624 ER PT J AU Zhu, AX Galle, PR Kudo, M Finn, R Yang, L Abada, P Llovet, JM AF Zhu, A. X. Galle, P. R. Kudo, M. Finn, R. Yang, L. Abada, P. Llovet, J. M. TI A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2) SO ANNALS OF ONCOLOGY LA English DT Meeting Abstract CT 41st Congress of the European-Society-for-Medical-Oncology (ESMO) CY OCT 07-11, 2016 CL Copenhagen, DENMARK SP European Soc Med Oncol C1 [Zhu, A. X.] Dana Farber Canc Inst, Med, Boston, MA 02115 USA. [Galle, P. R.] Johannes Gutenberg Univ Mainz, Internal Med Gastroenterol, Mainz, Germany. [Kudo, M.] Kinki Univ, Gastroenterol, Hepatol, Osaka, Japan. [Finn, R.] Univ Calif Los Angeles, Med, Santa Monica, CA USA. [Yang, L.] Eli Lilly & Co, Biostat, Bridgewater, NJ USA. [Abada, P.] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA. [Llovet, J. M.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. FU Eli Lilly and Company FX Eli Lilly and Company NR 0 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0923-7534 EI 1569-8041 J9 ANN ONCOL JI Ann. Oncol. PD OCT 1 PY 2016 VL 27 SU 6 MA 710TiP DI 10.1093/annonc/mdw371.102 PG 1 WC Oncology SC Oncology GA EK4QS UT WOS:000393912500618 ER PT J AU Bond, SM Schumacher, K Sherrod, A Dietrich, MS Wells, N Lindau, RH Murphy, BA AF Bond, Stewart M. Schumacher, Karen Sherrod, Amanda Dietrich, Mary S. Wells, Nancy Lindau, Robert H., III Murphy, Barbara A. TI Development of the Head and Neck Cancer Caregiving Task Inventory SO EUROPEAN JOURNAL OF ONCOLOGY NURSING LA English DT Article DE Head and neck cancer; Family caregiving; Caregiving tasks; Caregiving burden; Instrument development; Measurement ID FAMILY CAREGIVERS; TREATMENT TIME; MOOD STATES; SHORT-FORM; CARE; BURDEN; RADIOTHERAPY; PREPAREDNESS; TRACHEOSTOMY; SUPPORT AB Purpose: Family caregivers provide vital support for patients with head and neck cancer (HNC), yet few studies have focused on HNC caregiving. Our objective was to develop and conduct initial validation of the HNC Caregiving Task Inventory, an instrument to characterize caregiving task burden in the HNC population. Methods: This 5-phase instrument development project involved the conceptualization of caregiving task burden (Phase 1), initial instrument development (Phase 2), assessment of content validity through expert panel review (Phase 3), assessment of face validity through family caregiver review (Phase 4), and preliminary validation in a sample of 106 family caregivers (Phase 5). Results: We identified 11 domains of the HNC caregiving role and caregiving tasks for each domain. In Phase 3, the experts deemed all tasks relevant to HNC family caregiving. No tasks were eliminated and 19 were added. In Phase 4, family caregiver feedback indicated that the tasks were comprehensive and relevant. Wording and formatting changes were made and one task was added. In Phase 5, we evaluated discrimination of responses to derive a final version comprised of 58 tasks in 11 domains. Kuder-Richardson values for domains with >= 3 items ranged from 0.65 to 0.94. Associations were generally high with the Caregiving Burden Scale, moderate with the Caregiver Reaction Assessment and Profile of Mood States-Short Form, and low or non-existent with the Preparedness Scale. Conclusion: Convergent and divergent validity were supported. The HNC Caregiving Task Inventory can be used to evaluate caregiving task burden across the treatment trajectory and identify targets for intervention. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Bond, Stewart M.] Boston Coll, William F Connell Sch Nursing, 378C Maloney Hall,140 Commonwealth Ave, Chestnut Hill, MA 02467 USA. [Bond, Stewart M.] Massachusetts Gen Hosp, Yvonne L Munn Ctr Nursing Res, 55 Fruit St, Boston, MA 02114 USA. [Schumacher, Karen] Coll Nursing, 985330 Nebraska Med Ctr,4111 Dewey Ave, Omaha, NE 68190 USA. [Sherrod, Amanda] D2215 Garland Ave Light Hall, Nashville, TN 37232 USA. [Dietrich, Mary S.] 410 Godchaux Hall,461 21st Ave South, Nashville, TN 37240 USA. [Wells, Nancy] S-2411 Med Ctr North,1161 21st Ave South, Nashville, TN 37232 USA. [Lindau, Robert H., III] Dept Otolaryngol Head & Neck Surg, 981225 Nebraska Med Ctr, Omaha, NE 68198 USA. [Murphy, Barbara A.] 777 Preston Res Bldg,2220 Pierce Ave, Nashville, TN 37232 USA. [Sherrod, Amanda] Rex Hematol Oncol Associates Cary, 150 Pkwy Off Court,Pkwy Profess Pk,Suite 200, Cary, NC 27518 USA. [Lindau, Robert H., III] Methodist Estabrook Canc Ctr, 8303 Dodge St, Omaha, NE 68114 USA. RP Bond, SM (reprint author), Boston Coll, William F Connell Sch Nursing, 378C Maloney Hall,140 Commonwealth Ave, Chestnut Hill, MA 02467 USA. EM stewart.bond@bc.edu; kschumacher@unmc.eclu; sherroam@gmail.com; mary.dietrich@vanderbilt.edu; nancy.wells@vanderbilt.edu; Robert.lindauIII@nmhs.org; barbara.murphy@vanderbilt.edu NR 34 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1462-3889 EI 1532-2122 J9 EUR J ONCOL NURS JI Eur. J. Oncol. Nurs. PD OCT PY 2016 VL 24 BP 29 EP 38 DI 10.1016/j.ejon.2016.08.004 PG 10 WC Oncology; Nursing SC Oncology; Nursing GA EJ9JA UT WOS:000393541200006 PM 27697275 ER PT J AU Gumber, S Woollard, S Amancha, PK Yen, PJ Gabuzda, D Villinger, F Byrareddy, S AF Gumber, Sanjeev Woollard, Shawna Amancha, Praveen Kumar Yen, Po-Jen Gabuzda, Dana Villinger, Francois Byrareddy, Siddappa TI Macrophage-tropic Simian Immunodeficiency Virus Molecular Clone causes NeuroAIDS in Rhesus Macaques SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 14th International Symposium on NeuroVirology CY OCT 25-28, 2016 CL Toronto, CANADA C1 [Gumber, Sanjeev] Emory Univ, Yerkes Natl Primate Res Ctr, Div Pathol, Atlanta, GA 30329 USA. [Woollard, Shawna; Byrareddy, Siddappa] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA. [Amancha, Praveen Kumar; Villinger, Francois] Univ Louisiana Lafayette, New Iberia Res Ctr, New Iberia, LA 70560 USA. [Yen, Po-Jen; Gabuzda, Dana] Dana Farber Canc Inst, Dept Canc Immunol & Virol, Boston, MA 02115 USA. EM sid.byrareddy@unmc.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2016 VL 22 SU 1 MA P52 BP S25 EP S26 PG 2 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA EK7GH UT WOS:000394093700053 ER PT J AU Hixon, AM Yu, GX Leser, JS Yagi, S Clarke, P Chiu, CY Tyler, KL AF Hixon, Alison M. Yu, Guixia Leser, J. Smith Yagi, Shigeo Clarke, Penny Chiu, Charles Y. Tyler, Kenneth L. TI A mouse model of enterovirus D68-induced paralysis SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 14th International Symposium on NeuroVirology CY OCT 25-28, 2016 CL Toronto, CANADA C1 [Hixon, Alison M.] Univ Colorado, Med Scientist Training Program, Neurosci Program, Boulder, CO 80309 USA. [Yu, Guixia; Chiu, Charles Y.] Univ Calif San Francisco, Abbott Viral Diagnost & Discovery Ctr, Div Infect Dis, Dept Lab Med & Med, San Francisco, CA 94143 USA. [Leser, J. Smith; Clarke, Penny] Univ Colorado, Dept Neurol, Boulder, CO 80309 USA. [Yagi, Shigeo] Calif Dept Publ Hlth, Sacramento, CA USA. [Tyler, Kenneth L.] Denver VA Med Ctr, Denver, CO USA. [Tyler, Kenneth L.] Univ Colorado, Dept Med, Dept Microbiol & Immunol, Dept Neurol, Boulder, CO 80309 USA. EM alison.hixon@ucdenver.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2016 VL 22 SU 1 MA P59 BP S29 EP S29 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA EK7GH UT WOS:000394093700060 ER PT J AU Mukerji, S Misra, V Lorenz, D Cervantes-Arslanian, A Lyons, J Chalkias, S Wurcel, A Burke, D Venna, N Morgello, S Koralnik, I Gabuzda, D AF Mukerji, Shibani Misra, Vikas Lorenz, David Cervantes-Arslanian, Anna Lyons, Jennifer Chalkias, Spyridon Wurcel, Alysse Burke, Deirdre Venna, Nagagopal Morgello, Susan Koralnik, Igor Gabuzda, Dana TI Cerebrospinal Fluid Viral Escape in ART-experienced HIV-1-Infected Adults SO JOURNAL OF NEUROVIROLOGY LA English DT Meeting Abstract CT 14th International Symposium on NeuroVirology CY OCT 25-28, 2016 CL Toronto, CANADA C1 [Mukerji, Shibani; Lorenz, David; Gabuzda, Dana] Dana Farber Canc Inst, Dept Canc Immunol & Virol, Boston, MA 02115 USA. [Mukerji, Shibani; Misra, Vikas; Venna, Nagagopal] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Cervantes-Arslanian, Anna] Boston Med Ctr, Dept Neurol, Boston, MA USA. [Cervantes-Arslanian, Anna] Boston Med Ctr, Dept Neurosurg, Boston, MA USA. [Lyons, Jennifer] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA. [Chalkias, Spyridon; Koralnik, Igor] Beth Israel Deaconess Med Ctr, Div NeuroImmunol, Boston, MA 02215 USA. [Wurcel, Alysse; Burke, Deirdre] Tufts Med Ctr, Dept Geog Med & Infect Dis, Boston, MA USA. [Morgello, Susan] Icahn Sch Med Mt Sinai, Div Infect Dis, New York, NY 10029 USA. [Koralnik, Igor] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA. EM smukerji@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD OCT PY 2016 VL 22 SU 1 MA P115 BP S56 EP S56 PG 1 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA EK7GH UT WOS:000394093700116 ER PT J AU Williams, KA Swedo, SE Farmer, CA Grantz, H Grant, PJ D'Souza, P Hommer, R Katsovich, L King, RA Leckman, JF AF Williams, Kyle A. Swedo, Susan E. Farmer, Cristan A. Grantz, Heidi Grant, Paul J. D'Souza, Precilla Hommer, Rebecca Katsovich, Liliya King, Robert A. Leckman, James F. TI Randomized, Controlled Trial of Intravenous Immunoglobulin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Article DE PANDAS; obsessive-compulsive disorder; WIG; group A streptococcus pyogenes ID OBSESSIVE-COMPULSIVE DISORDER; TIC-SEVERITY-SCALE; PLASMA-EXCHANGE; BASAL GANGLIA; TOURETTE-SYNDROME; SYDENHAMS CHOREA; CHILDREN; ANTIBODIES; CHILDHOOD; MODEL AB Objective: Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) are hypothesized to occur as a result of cross-reactive antibodies produced in response to group A streptococcal infections. Previous research suggests that immunomodulatory therapies, such as intravenous immunoglobulin (WIG), may lead to rapid and sustained symptom improvement in patients with PANDAS. Method: A total of 35 children meeting criteria for PANDAS and moderate to severe obsessive-compulsive disorder (OCD) were enrolled in a randomized-entry, double-blind, placebo-controlled, 6-week trial of WIG (1 g/kg/day on 2 consecutive days), followed by optional open-label treatment for nonresponders, with follow-up at 12 and 24 weeks. Primary outcome measures were the Children's Yale Brown Obsessive Compulsive Scale (CY-BOCS) and the Clinical Global Impressions Improvement (CGI-I) rating. "Responders" were defined, a priori, by a >= 30% decrease in CY-BOCS total score, and a "much" or "very much" improved rating on CGI-I. Results: During the double-blind phase, the mean decrease in CY-BOCS score was 24% +/- 31% in the WIG group (n = 17) and 12% +/- 27% in the placebo group (n = 18), with six responders in the WIG group (35%) versus four (22%) in the placebo group; these differences were not statistically significant. Twenty-four participants met criteria for nonresponse to double-blind infusion and received open-label IVIG at week 6. Among all participants, the mean CY-BOCS improvement from baseline was 55% +/- 33% at week 12 and 62% +/- 33% at week 24. Conclusion: WIG was safe and well tolerated. Between group differences were smaller than anticipated, and the double-blind comparison failed to demonstrate superiority of WIG over placebo. The observed open-label improvements indicate that future trials would benefit from larger sample sizes designed in part to aid in the identification of biomarkers predictive of a positive response to immunotherapy. Future investigations focused on the natural history of PANDAS are also warranted. C1 [Williams, Kyle A.; Grantz, Heidi; Katsovich, Liliya; King, Robert A.; Leckman, James F.] Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06510 USA. [Williams, Kyle A.] Massachusetts Gen Hosp, Pediat Neuropsychiat & Immunol Program, Boston, MA 02114 USA. [Swedo, Susan E.; Farmer, Cristan A.; Grant, Paul J.; D'Souza, Precilla; Hommer, Rebecca] NIMH, Pediat & Dev Neurosci Program, Bethesda, MD USA. RP Swedo, SE (reprint author), 10 Ctr Dr,MSC 1255, Bethesda, MD 20892 USA. EM swedos@mail.nih.gov FU Grifols Laboratories; National Institutes of Health (NIH) Bench-to-Bedside Program; National Institute of Mental Health (NIMH) [NCT01281969, protocol 11-M-0058] FX Grifols Laboratories supplied intravenous immunoglobulin for the trial, as well as financial support to the Yale investigators. Additional support was provided by the National Institutes of Health (NIH) Bench-to-Bedside Program, and by the Intramural Research Program of the National Institute of Mental Health (NIMH) (NCT01281969; protocol 11-M-0058). Dr. Williams had full access to all the data in the study and takes responsibility for the integrity of the data analysis. NR 46 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0890-8567 EI 1527-5418 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD OCT PY 2016 VL 55 IS 10 BP 860 EP 867 DI 10.1016/j.jaac.2016.06.017 PG 8 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA EK6YQ UT WOS:000394072600007 PM 27663941 ER PT J AU Middeldorp, CM Hammerschlag, AR Ouwens, KG Groen-Blokhuis, MM St Pourcain, B Greven, CU Pappa, I Tiesler, CMT Ang, W Nolte, IM Vilor-Tejedor, N Bacelis, J Ebejer, JL Zhao, HY Davies, GE Ehli, EA Evans, DM Fedko, IO Guxens, M Hottenga, JJ Hudziak, JJ Jugessur, A Kemp, JP Krapohl, E Martin, NG Murcia, M Myhre, R Ormel, J Ring, SM Standl, M Stergiakouli, E Stoltenberg, C Thiering, E Timpson, NJ Trzaskowski, M van der Most, PJ Wang, C Nyholt, DR Medland, SE Neale, B Jacobsson, B Sunyer, J Hartman, CA Whitehouse, AJO Pennell, CE Heinrich, J Plomin, R Smith, GD Tiemeier, H Posthuma, D Boomsma, DI AF Middeldorp, Christel M. Hammerschlag, Anke R. Ouwens, Klaasjan G. Groen-Blokhuis, Maria M. St Pourcain, Beate Greven, Corina U. Pappa, Irene Tiesler, Carla M. T. Ang, Wei Nolte, Ilja M. Vilor-Tejedor, Natalia Bacelis, Jonas Ebejer, Jane L. Zhao, Huiying Davies, Gareth E. Ehli, Erik A. Evans, David M. Fedko, Iryna O. Guxens, Monica Hottenga, Jouke-Jan Hudziak, James J. Jugessur, Astanand Kemp, John P. Krapohl, Eva Martin, Nicholas G. Murcia, Mario Myhre, Ronny Ormel, Johan Ring, Susan M. Standl, Marie Stergiakouli, Evie Stoltenberg, Camilla Thiering, Elisabeth Timpson, Nicholas J. Trzaskowski, Maciej van der Most, Peter J. Wang, Carol Nyholt, Dale R. Medland, Sarah E. Neale, Benjamin Jacobsson, Bo Sunyer, Jordi Hartman, Catharina A. Whitehouse, Andrew J. O. Pennell, Craig E. Heinrich, Joachim Plomin, Robert Smith, George Davey Tiemeier, Henning Posthuma, Danielle Boomsma, Dorret I. CA EArly Genetics Lifecourse Psychiatric Genomics Consortium TI A Genome-Wide Association Meta-Analysis of Attention-Deficit/Hyperactivity Disorder Symptoms in Population-Based Pediatric Cohorts SO JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY LA English DT Article DE GWA; SNP heritability; attention problems; ADHD symptoms; meta-analysis ID DEFICIT HYPERACTIVITY DISORDER; NETHERLANDS TWIN REGISTER; PERSONALITY CONSORTIUM; GENETIC INFLUENCES; BEHAVIOR PROBLEMS; CHILDHOOD; CHILDREN; PROFILE; ADHD; RISK AB Objective: The aims of this study were to elucidate the influence of common genetic variants on childhood attention-deficit/hyperactivity disorder (ADHD) symptoms, to identify genetic variants that explain its high heritability, and to investigate the genetic overlap of ADHD symptom scores with ADHD diagnosis. Method: Within the EArly Genetics and Lifecourse Epidemiology (EAGLE) consortium, genome-wide single nucleotide polymorphisms (SNPs) and ADHD symptom scores were available for 17,666 children (<13 years of age) from nine population-based cohorts. SNP-based heritability was estimated in data from the three largest cohorts. Meta-analysis based on genome-wide association (GWA) analyses with SNPs was followed by gene-based association tests, and the overlap in results with a meta analysis in the Psychiatric Genomics Consortium (PGC) case-control ADHD study was investigated. Results: SNP-based heritability ranged from 5% to 34%, indicating that variation in common genetic variants influences ADHD symptom scores. The meta-analysis did not detect genome-wide significant SNPs, but three genes, lying close to each other with SNPs in high linkage disequilibrium (LD), showed a gene-wide significant association (p values between 1.46 x 10(-6) and 2.66 x 10(-6)). One gene, WASL, is involved in neuronal development. Both SNP- and gene-based analyses indicated overlap with the PGC meta-analysis results with the genetic correlation estimated at 0.96. Conclusion: The SNP-based heritability for ADHD symptom scores indicates a polygenic architecture, and genes involved in neurite outgrowth are possibly involved. Continuous and dichotomous measures of ADHD appear to assess a genetically common phenotype. A next step is to combine data from population-based and case-control cohorts in genetic association studies to increase sample size and to improve statistical power for identifying genetic variants. C1 [Middeldorp, Christel M.] Vrije Univ Amsterdam, Neurosci Campus Amsterdam, Biol Psychol, Amsterdam, Netherlands. [Middeldorp, Christel M.] Vrije Univ Amsterdam Med Ctr, GGZinGeest, Amsterdam, Netherlands. [Hammerschlag, Anke R.] Erasmus MC, Generat R Study Grp, Rotterdam, Netherlands. [Hammerschlag, Anke R.] Vrije Univ Amsterdam, Neurosci Campus Amsterdam, Ctr Neurogen & Cognit Res, Complex Trait Genet, Amsterdam, Netherlands. [Ouwens, Klaasjan G.; Groen-Blokhuis, Maria M.; Fedko, Iryna O.] Vrije Univ Amsterdam, Biol Psychol, Van der Boechorststr 1, NL-1081 BT Amsterdam, Netherlands. [Ouwens, Klaasjan G.; Groen-Blokhuis, Maria M.; Hottenga, Jouke-Jan; Boomsma, Dorret I.] Vrije Univ Amsterdam Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands. [St Pourcain, Beate] Univ Bristol, MRC IEU, Bristol, Avon, England. [St Pourcain, Beate] Max Planck Inst Psycholinguist, Nijmegen, Netherlands. [St Pourcain, Beate] Univ Bristol, Sch Expt Psychol, Bristol, Avon, England. [Greven, Corina U.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Karakter Child & Adolescent Psychiat Univ Ctr, Nijmegen, Netherlands. [Greven, Corina U.; Krapohl, Eva; Trzaskowski, Maciej; Plomin, Robert] Kings Coll London, MRC Social Genet & Dev Psychiat Ctr, London, England. [Pappa, Irene] Erasmus Univ, Generat R Study Grp, Rotterdam, Netherlands. [Pappa, Irene] Erasmus Univ, Pedag & Educ Sci, Rotterdam, Netherlands. [Tiesler, Carla M. T.; Standl, Marie; Thiering, Elisabeth; Heinrich, Joachim] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol 1, Neuherberg, Germany. [Tiesler, Carla M. T.; Thiering, Elisabeth] Div Metab & Nutr Med, Munich, Germany. [Tiesler, Carla M. T.; Thiering, Elisabeth] Univ Munich, Med Ctr, Dr von Hauner Childrens Hosp, Munich, Germany. [Ang, Wei; Wang, Carol; Pennell, Craig E.] Univ Western Australia, Sch Womens & Infants Hlth, Perth, WA, Australia. [Nolte, Ilja M.] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands. [Vilor-Tejedor, Natalia] UPF, Ctr Res Environm Epidemiol CREAL, Barcelona, Spain. [Vilor-Tejedor, Natalia] CIBER Epidemiol & Publ Hlth CIBERESP, Madrid, Spain. [Bacelis, Jonas] Gothenburg Univ, Gothenburg, Sweden. [Ebejer, Jane L.; Medland, Sarah E.] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia. [Zhao, Huiying; Nyholt, Dale R.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia. [Davies, Gareth E.; Ehli, Erik A.] Avera Inst Human Genet, Sioux Falls, SD USA. [Evans, David M.; Kemp, John P.; Ring, Susan M.] Univ Bristol, Sch Social & Community Med, MRC IEU, Bristol, Avon, England. [Evans, David M.; Kemp, John P.; Ring, Susan M.; Timpson, Nicholas J.] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England. [Evans, David M.; Kemp, John P.; Ring, Susan M.] Univ Queensland, Translat Res Inst, Diamantina Inst, Brisbane, Qld, Australia. [Guxens, Monica] UPF, CIBERESP, CREAL, Barcelona, Spain. [Guxens, Monica] Erasmus Univ, Sophia Childrens Hosp, Med Ctr, Child & Adolescent Psychiat Psychol, Rotterdam, Netherlands. [Hottenga, Jouke-Jan] Vrije Univ Amsterdam, Biol Psychol, Amsterdam, Netherlands. [Hudziak, James J.] Univ Vermont, Vermont Ctr Children Youth & Families, Burlington, VT 05405 USA. [Hudziak, James J.] Univ Vermont, Coll Med, Burlington, VT 05405 USA. [Hudziak, James J.] Erasmus MC, Child & Adolescent Psychiat, Rotterdam, Netherlands. [Jugessur, Astanand; Myhre, Ronny; Stoltenberg, Camilla; Jacobsson, Bo] Norwegian Inst Publ Hlth, Oslo, Norway. [Krapohl, Eva; Trzaskowski, Maciej; Plomin, Robert] Kings Coll London, MRC Social Genet & Dev Psychiat Ctr, London, England. [Murcia, Mario] CIBERESP, Valencia, Spain. [Murcia, Mario] FISABIO Univ Jaume I Univ Valencia Joint Res Unit, Valencia, Spain. [Ormel, Johan; Hartman, Catharina A.] Univ Med Ctr Groningen, Interdisciplinary Ctr Psychopathol & Emot Regulat, Groningen, Netherlands. [Stergiakouli, Evie; Timpson, Nicholas J.] MRC IEU, Groningen, Netherlands. [van der Most, Peter J.] Univ Groningen, Groningen, Netherlands. [van der Most, Peter J.] Univ Med Ctr Groningen, Groningen, Netherlands. [Neale, Benjamin] Broad Inst Massachusetts Inst Technol, Program Med & Populat Genet, Boston, MA USA. [Neale, Benjamin] Broad Inst Massachusetts Inst Technol, Stanley Ctr Psychiat Genet, Boston, MA USA. [Neale, Benjamin] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Cambridge, MA USA. [Neale, Benjamin] Harvard Med Sch, Boston, MA USA. [Neale, Benjamin] Harvard Univ, Cambridge, MA 02138 USA. [Jacobsson, Bo] Gothenburg Univ, Obstet & Gynecol, Gothenburg, Sweden. [Sunyer, Jordi] Hosp del Mar, Med Res Inst, IMIM, CREAL, Barcelona, Spain. [Sunyer, Jordi] UPF, Barcelona, Spain. [Sunyer, Jordi] CIBERESP, Barcelona, Spain. [Whitehouse, Andrew J. O.] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia. [Smith, George Davey] MRC IEU, Perth, WA, Australia. [Smith, George Davey] Sch Social & Community Med, Perth, WA, Australia. [Tiemeier, Henning] Erasmus MC, Epidemiol Child & Adolescent Psychiat & Psychiat, Rotterdam, Netherlands. [Posthuma, Danielle] Erasmus MC, Generat R Study Grp, Rotterdam, Netherlands. [Posthuma, Danielle] Vrije Univ Amsterdam, Neurosci Campus Amsterdam, Ctr Neurogen & Cognit Res,Child & Adolescent Psyc, Erasmus Med Ctr,Complex Trait Genet, Rotterdam, Netherlands. [Posthuma, Danielle] VU Univ Med Center, Clin Genet, Amsterdam, Netherlands. [Boomsma, Dorret I.] Vrije Univ Amsterdam, Neurosci Campus Amsterdam, Biol Psychol, Amsterdam, Netherlands. RP Middeldorp, CM (reprint author), Vrije Univ Amsterdam, Biol Psychol, Van der Boechorststr 1, NL-1081 BT Amsterdam, Netherlands. EM c.m.middeldorp@vu.nl RI Ormel, Johan/C-6094-2013; Fox, Laura /C-6249-2016; OI Trzaskowski, Maciej/0000-0001-8559-6525; Bacelis, Jonas/0000-0002-2450-732X; Kemp, John/0000-0002-9105-2249; Evans, David/0000-0003-0663-4621; Stergiakouli, Evangelia/0000-0003-3586-0927; Middeldorp, Christel/0000-0002-6218-0428; Ouwens, Klaasjan/0000-0002-3864-7710 FU Wellcome Trust [102215/2/13/2]; Erasmus Medical Center, Rotterdam; Erasmus University Rotterdam; Netherlands Organization for Health Research and Development (ZonMw); Netherlands Organisation for Scientific Research (NWO); Ministry of Health, Welfare and Sport; Netherlands Organization for Health Research and Development (ZonMw VIDI) [017.106 370]; Dutch Scientific Organisation for Scientific Research [NWO 433-09-228, 453-14-005]; Munich Center of Health Sciences (MCHEALTH) as part of the Ludwig-Maximilians University Munich LMU innovative; Spanish Instituto de Salud Carlos III [CB06/02/0041, G03/176, FIS PI041436, PI081151, PI041705, PI061756, PI091958, PS09/00432]; FIS-FEDER [03/1615, 04/1509, 04/1112, 04/1931, 05/1079, 05/1052, 06/1213, 07/0314, 09/02647, 11/01007, 11/02591, 11/02038, 13/1944, 13/2032, CP11/0178, MS13/00054]; Spanish Ministry of Science and Innovation [SAF2008-00357]; European Commission [HEALTH-F4-2007- 201413, HEALTH.2010.2.45-1, FP7-ENV-2011, 282957]; Fundacio La Marato de TV3; Generalitat de Catalunya-CIRIT [1999SGR 00241]; Conselleria de Sanitat Generalitat Valenciana; Agencia de Gestio d'Ajuts Universitans i de Recerca - Generalitat de Catalunya [2015 FI_B 00636]; Norwegian Research Council [FUGE 183220/S10, FRIMEDKLI-05 ES236011]; Swedish Medical Society [SLS 2008-21198]; Jane and Dan Olsson Foundations; Swedish government [ALFGBG-2863, ALFGBG-11522, ALFGBG-426411]; European Community; ENGAGE Consortium [HEALTH-F4- 2007-201413]; Norwegian Ministry of Health; Ministry of Education and Research; NIH/NIEHS [N01-ES-75558]; NIH/NINDS [1 UO1 NS 047537-01, 2 UO1 NS 047537-06A1]; Norwegian Research Council/FUGE [151918/S10]; Community's Seventh Framework Program; ENGAGE [HEALTH-F42007-201413]; Avera Institute, Sioux Falls, South Dakota, USA; Grand Opportunity [1RC2 MH089951, 1RC2 MH089995]; NHMRC; Healthway Western Australia; National Health and Medical Research Council of Australia [572613]; Canadian Institutes of Health Research [82893]; NHMRC [1077966]; Pawsey Supercomputing Centre; Australian Government; Government of Western Australia; UK Medical Research Council [G0901245]; US National Institutes of Health [HD044454, HD059215]; Medical Research Council [G19/2]; European Research Council [295366]; British Academy [pf140018]; Institute of Psychiatry Excellence/Medical Research Council; Netherlands Organization for Scientific Research NWO (Medical Research Council) [GB-MW 940-38-011]; ZonMW Brainpower grant [100-001-004]; ZonMw Risk Behavior and Dependence grants [60-60600-97-118]; ZonMw Culture and Health [261-98-710]; Social Sciences Council [GB-MaGW 480-01-006, GB-MaGW 480-07-001, GB-MaGW 452-04-314, GB-MaGW 452-06-004]; NWO large-sized investment grant [175.010.2003.005]; NWO Longitudinal Survey and Panel Funding [481-08-013, 481-11-001]; Dutch Ministry of Justice (WODC); European Science Foundation [FP-006]; Biobanking and Biomolecular Resources Research Infrastructure BBMRI-NL [CP 32] FX ALSPAC: The UK Medical Research Council and the Wellcome Trust (Grant ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors and they will serve as guarantors for the contents of this paper. GWAS data were generated by Sample Logistics and Genotyping Facilities at the Wellcome Trust Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe.; Generation R: The Generation R Study is made possible by financial support from the Erasmus Medical Center, Rotterdam, the Erasmus University Rotterdam, the Netherlands Organization for Health Research and Development (ZonMw), the Netherlands Organisation for Scientific Research (NWO), and the Ministry of Health, Welfare and Sport H.T. received additional grants from the Netherlands Organization for Health Research and Development (ZonMw VIDI 017.106 370) The work of A.H. and D.P. was supported by a grant from the Dutch Scientific Organisation for Scientific Research (NWO 433-09-228 and 453-14-005).; GINI/LISA: Personal and financial support by the Munich Center of Health Sciences (MCHEALTH) as part of the Ludwig-Maximilians University Munich LMU innovative is gratefully acknowledged.; INMA This study was funded by grants from the Spanish Instituto de Salud Carlos III (CB06/02/0041, G03/176, FIS PI041436, PI081151, PI041705, PI061756, PI091958, and PS09/00432, FIS-FEDER 03/1615, 04/1509, 04/1112, 04/1931, 05/1079, 05/1052, 06/1213, 07/0314, 09/02647, 11/01007, 11/02591, 11/02038, 13/1944, 13/2032, CP11/0178 and MS13/00054), Spanish Ministry of Science and Innovation (SAF2008-00357), European Commission (ENGAGE project and grant agreement HEALTH-F4-2007- 201413, HEALTH.2010.2.4 5-1, FP7-ENV-2011 cod 282957), Fundacio La Marato de TV3, Generalitat de Catalunya-CIRIT 1999SGR 00241, and Conselleria de Sanitat Generalitat Valenciana. Part of the DNA extractions and genotyping was performed at the Spanish National Genotyping Centre (CEGEN-Barcelona). N. Vilor-Tejedor thanks the Agencia de Gestio d'Ajuts Universitans i de Recerca - Generalitat de Catalunya for her pre-doctoral grant (2015 FI_B 00636).; MoBa (Mother and Child Cohort of NIPH): This work was supported by grants from the Norwegian Research Council (FUGE 183220/S10, FRIMEDKLI-05 ES236011), Swedish Medical Society (SLS 2008-21198), Jane and Dan Olsson Foundations, and Swedish government grants to researchers in the public health service (ALFGBG-2863, ALFGBG-11522, ALFGBG-426411), and the European Community's Seventh Framework Programme (FP7/2007-2013), ENGAGE Consortium, grant agreement HEALTH-F4- 2007-201413. The Norwegian Mother and Child Cohort Study was also supported by the Norwegian Ministry of Health and the Ministry of Education and Research, NIH/NIEHS (contract no N01-ES-75558), NIH/NINDS (grant no.1 UO1 NS 047537-01 and grant no 2 UO1 NS 047537-06A1), and the Norwegian Research Council/FUGE (grant no 151918/S10). Researchers' interested in using MoBa data must obtain approval from the Scientific Management Committee of MoBa and from the Regional Committee for Medical and Health Research Ethics for access to data and biological material. Researchers are required to follow the terms of an Assistance Agreement containing a number of clauses designed to ensure protection of privacy and compliance with relevant laws. For further information, contact the principal investigator of MoBa, Per Magnus (per.magnus@fhi.no).; The Netherlands Twin Register: Genetics of Mental Illness (European Research Council ERC-230374); Genetic influences on stability and change in psychopathology from childhood to young adulthood (ZonMW 91210020); Biobanking and Bimolecular Resources Research Infrastructure (BBMRI -NL, 184.021.007); VU University's Institute for Health and Care Research (EMGO+) and Neuroscience Campus Amsterdam INCA); Community's Seventh Framework Program (FP7/2007-2013); ENGAGE (HEALTH-F42007-201413); the Avera Institute, Sioux Falls, South Dakota, USA, and Grand Opportunity (grants 1RC2 MH089951 and 1RC2 MH089995).; Raine: The authors gratefully acknowledge the NHMRC for their long-term contribution to funding the study over the last 25 years and also the following Institutions for providing funding for Core Management of the Raine Study. The University of Western Australia (UWA), Raine Medical Research Foundation, UWA Faculty of Medicine, Dentistry and Health Sciences, Telethon Kids Institute and Women and Infants Research Foundation (King Edward Memorial Hospital), Curtin University, and Edith Cowan University. The authors gratefully acknowledge the assistance of the Western Australian Genetic Epidemiology Resource and the Western Australian DNA Bank (both National Health and Medical Research Council of Australia National Enabling Facilities). The authors also acknowledge the support of the Healthway Western Australia, the National Health and Medical Research Council of Australia (Grant 572613), and the Canadian Institutes of Health Research (Grant MOP 82893). The authors gratefully acknowledge the assistance of the Wind Over Water Foundation, the Telethon Institute for Child Health Research, and the Raine Medical Research Foundation of the University of Western Australia. A.J.O.W. was supported by a Senior Research Fellowship from the NHMRC (Grant number 1077966). This work was supported by resources provided by the Pawsey Supercomputing Centre with funding from the Australian Government and the Government of Western Australia.; TEDS The Twins Early Development Study (TEDS) is supported by a program grant to R.P from the UK Medical Research Council [G0901245; and previously G0500079], with additional support from the US National Institutes of Health [HD044454; HD059215]. R.P. is supported by a Medical Research Council Research Professorship award [G19/2] and a European Research Council Advanced Investigator award [295366]; M.T. is supported by British Academy Post-doctoral Fellowship [pf140018] E K. is supported by an Institute of Psychiatry Excellence/Medical Research Council postgraduate Studentship.; TRAILS This research is part of the TRacking Adolescents' Individual Lives Survey (TRAILS). Participating centers of TRAILS include the University Medical Center and University of Groningen, the Erasmus University Medical Center Rotterdam, the University of Utrecht, the Radboud Medical Center Nijmegen, and the Parnassia Bavo group, all in the Netherlands. TRAILS has been financially supported by various grants from the Netherlands Organization for Scientific Research NWO (Medical Research Council program grant GB-MW 940-38-011; ZonMW Brainpower grant 100-001-004; ZonMw Risk Behavior and Dependence grants 60-60600-97-118; ZonMw Culture and Health grant 261-98-710; Social Sciences Council medium-sized investment grants GB-MaGW 480-01-006 and GB-MaGW 480-07-001; Social Sciences Council project grants GB-MaGW 452-04-314 and GB-MaGW 452-06-004; NWO large-sized investment grant 175.010.2003.005; NWO Longitudinal Survey and Panel Funding 481-08-013 and 481-11-001), the Dutch Ministry of Justice (WODC), the European Science Foundation (EuroSTRESS project FP-006), Biobanking and Biomolecular Resources Research Infrastructure BBMRI-NL (CP 32), and the participating universities. NR 69 TC 3 Z9 3 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0890-8567 EI 1527-5418 J9 J AM ACAD CHILD PSY JI J. Am. Acad. Child Adolesc. Psychiatr. PD OCT PY 2016 VL 55 IS 10 BP 896 EP 905 DI 10.1016/j.jaac.2016.05.025 PG 10 WC Psychology, Developmental; Pediatrics; Psychiatry SC Psychology; Pediatrics; Psychiatry GA EK6YQ UT WOS:000394072600011 PM 27663945 ER PT J AU Heinz, AJ Cohen, NL Holleran, L Alvarez, JA Bonn-Miller, MO AF Heinz, Adrienne J. Cohen, Nicole L. Holleran, Lori Alvarez, Jennifer A. Bonn-Miller, Marcel O. TI Firearm Ownership Among Military Veterans With PTSD: A Profile of Demographic and Psychosocial Correlates SO MILITARY MEDICINE LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; COMBAT VETERANS; SUICIDE; RISK; METAANALYSIS; AGGRESSION; COLLECTION; HOSTILITY; PROGRAMS; VIOLENCE AB Post-traumatic stress disorder (PTSD), a condition that disproportionately affects military veterans, is associated with heightened rates of aggression and suicide. Although experience with firearms is common among this population, virtually nothing is known regarding who is more likely to own a firearm and whether firearm ownership is differentially associated with psychological and behavioral risk factors among veterans with PTSD. Of 465 veterans (79% male) entering PTSD treatment, 28% owned a firearm (median number of firearms among owners = 3, range = 1-40). Firearm owners reported higher income were less likely to be unemployed, and were more likely to be male, Caucasian, married, and living in permanent housing. Ownership was associated with higher combat exposure and driving aggression, yet lower rates of childhood and military sexual trauma, suicidal ideation, and incarceration. Ownership was not associated with previous suicide attempt, arrest history, number of traumas experienced, PTSD symptoms, or depression. Together, among a sample of treatment-seeking military veterans with PTSD, those who owned a firearm appeared to demonstrate greater stability across a number of domains of functioning. Importantly though, routine firearm safety discussions (e.g., accessibility restrictions; violence risk assessments) and bolstering of anger management skills remain critical when working with this high-risk population. C1 [Heinz, Adrienne J.; Cohen, Nicole L.; Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, 795 Willow Rd, Menlo Pk, CA 94025 USA. [Heinz, Adrienne J.; Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd, Menlo Pk, CA 94025 USA. [Holleran, Lori] Palo Alto Univ, 1791 Arastradero Rd, Palo Alto, CA 94304 USA. [Alvarez, Jennifer A.] VA Palo Alto Hlth Care Syst, 3801 Miranda Ave, Menlo Pk, CA 94304 USA. [Bonn-Miller, Marcel O.] Philadelphia VA Med Ctr, Ctr Excellence Subst Abuse Treatment & Educ, 3900 Woodland Ave, Philadelphia, PA 19104 USA. [Bonn-Miller, Marcel O.] Univ Penn, Perelman Sch Med, Dept Psychiat, 3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA. RP Heinz, AJ (reprint author), VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, 795 Willow Rd, Menlo Pk, CA 94025 USA.; Heinz, AJ (reprint author), VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd, Menlo Pk, CA 94025 USA. FU Rehabilitation Research and Development Career Development Award-2 FX This work was supported by a Rehabilitation Research and Development Career Development Award-2 awarded to Dr. Heinz. NR 26 TC 0 Z9 0 U1 1 U2 1 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD OCT PY 2016 VL 181 IS 10 BP 1207 EP 1211 DI 10.7205/MILMED-D-15-00552 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA EL3DB UT WOS:000394498700014 PM 27753553 ER PT J AU Metraux, S Treglia, D O'Toole, TP AF Metraux, Stephen Treglia, Dan O'Toole, Thomas P. TI Migration by Veterans Who Received Homeless Services From the Department of Veterans Affairs SO MILITARY MEDICINE LA English DT Article ID MOBILITY; CARE AB We examined migration patterns among 113,400 homeless veterans, focusing on the prevalence and the basic geographic patterns of this migration. Data were for all veterans who initiated use of Veterans Affairs homeless services in 2011 or 2012; and we followed them using Veterans Affairs administrative records for up to 2 years following this initial contact. Results showed that 15.3% of the veterans migrated across regions while homeless. Those who were homeless for longer periods were more likely to migrate, and migration, were it to occur, was most likely earlier on in veterans' homelessness episodes. There were no clear geographic correlates that explained the dynamics of this migration as, overall, in-migration tended to roughly balance out-migration in a region. These findings suggest that concerns about the extent of migration and its impact on localities are exaggerated, but also sets forth an agenda for more in-depth study of these data to gain a deeper and more expansive understanding of this phenomenon. C1 [Metraux, Stephen; Treglia, Dan; O'Toole, Thomas P.] Philadelphia VA Med Ctr Annex, US Dept Vet Affairs, Natl Ctr Homelessness Vet, 4100 Chester Ave, Philadelphia, PA 19104 USA. RP Metraux, S (reprint author), Philadelphia VA Med Ctr Annex, US Dept Vet Affairs, Natl Ctr Homelessness Vet, 4100 Chester Ave, Philadelphia, PA 19104 USA. NR 20 TC 0 Z9 0 U1 0 U2 0 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD OCT PY 2016 VL 181 IS 10 BP 1212 EP 1217 DI 10.7205/MILMED-D-15-00504 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA EL3DB UT WOS:000394498700015 PM 27753554 ER PT J AU Berg, KM Smith, SS Cook, JW Fiore, MC Jorenby, DE AF Berg, Kristin M. Smith, Stevens S. Cook, Jessica W. Fiore, Michael C. Jorenby, Douglas E. TI Identifying Opportunities to Improve Smoking Cessation Among Women Veterans at a Veterans Hospital SO MILITARY MEDICINE LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; GENDER-DIFFERENCES; FEMALE VETERANS; MENTAL-HEALTH; LUNG HEALTH; TOBACCO USE; NICOTINE; PREDICTORS; SMOKERS; INTERVENTIONS AB While women Veterans have a higher prevalence of smoking than civilian women, little is known about their quitting behavior. Via a chart review, we characterized referral and enrollment patterns in tobacco cessation services (TCS), and quit attempts among 366 women Veteran smokers at a Midwestern Veterans Hospital. Cases receiving referrals to TCS (n = 183) were matched 1:1 to controls who did not (n = 183), by year of referral. Variables included age, marital status, urbanicity, smoking status, comorbidities, pregnancy, packs per day, number of prior smoking cessation medications, provider gender, provider type, and clinical location of referral placement. Of women Veteran smokers, 24% were referred to TCS, and tended to be older, heavier smokers, with more comorbidities, more prior cessation medication prescriptions, and more likely seen by a resident or attending physician. Only 54% of referred women enrolled, and these women were older, had more medical comorbidities and prior cessation medication prescriptions than nonenrolled women. Primary care providers were more likely to have patients enroll versus inpatient providers. Only 8% of enrolled women achieved abstinence at 6 months. Quit attempts were associated with the number of cessation medication prescriptions for enrolled women, and lighter smoking histories for nonenrolled women. C1 [Berg, Kristin M.; Smith, Stevens S.; Cook, Jessica W.; Fiore, Michael C.; Jorenby, Douglas E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Ctr Tobacco Res & Intervent, 1930 Monroe St,Suite 200, Madison, WI 53711 USA. [Berg, Kristin M.] William S Middleton Mem Vet Adm Med Ctr, Adv Fellowship Womens Hlth, 2500 Overlook Terrace, Madison, WI 53705 USA. [Berg, Kristin M.] Univ Wisconsin, Dept Family Med & Community Hlth, 1100 Delaplaine Court, Madison, WI 53715 USA. RP Berg, KM (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Ctr Tobacco Res & Intervent, 1930 Monroe St,Suite 200, Madison, WI 53711 USA.; Berg, KM (reprint author), William S Middleton Mem Vet Adm Med Ctr, Adv Fellowship Womens Hlth, 2500 Overlook Terrace, Madison, WI 53705 USA.; Berg, KM (reprint author), Univ Wisconsin, Dept Family Med & Community Hlth, 1100 Delaplaine Court, Madison, WI 53715 USA. FU UW Center for Tobacco Research and Intervention; Division of General Internal Medicine; Advanced Fellowship in Women's Health through the VA; National Research Service Award from the Health Resources and Services Administration [T32HP10010] FX This project fulfilled degree requirements for KMB, supported by the UW Center for Tobacco Research and Intervention, the Division of General Internal Medicine, and the Advanced Fellowship in Women's Health through the VA. During the writing of this article, author KMB was supported by a National Research Service Award from the Health Resources and Services Administration [T32HP10010] to the University of Wisconsin Department of Family Medicine and Community Health. NR 35 TC 0 Z9 0 U1 0 U2 0 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD OCT PY 2016 VL 181 IS 10 BP 1340 EP 1347 DI 10.7205/MILMED-D-15-00469 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA EL3DB UT WOS:000394498700034 PM 27753573 ER PT J AU Donelan, K Romano, C Buerhaus, P DesRoches, C Applebaum, S Ward, JRM Schoneboom, BA Hinshaw, AS AF Donelan, Karen Romano, Carol Buerhaus, Peter DesRoches, Catherine Applebaum, Sandra Ward, Johanna R. M. Schoneboom, Bruce A. Hinshaw, Ada Sue TI National Surveys of Military Personnel, Nursing Students, and the Public: Drivers of Military Nursing Careers (vol 179, pg 565, 2014) SO MILITARY MEDICINE LA English DT Correction C1 [Donelan, Karen] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, 50 Staniford St,9th Floor, Boston, MA 02114 USA. [Romano, Carol; Hinshaw, Ada Sue] Uniformed Serv Univ Hlth Sci, Grad Sch Nursing, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA. [Buerhaus, Peter] Vanderbilt Univ, Med Ctr, Inst Med & Publ Hlth, Ctr Interdisciplinary Hlth Workforce Studies, 2525 West End Ave,Suite 600,Sixth Floor, Nashville, TN 37203 USA. [DesRoches, Catherine] Math Policy Res, 955 Massachusetts Ave,Suite 900, Cambridge, MA 02139 USA. [Applebaum, Sandra] Harris Interact Inc, 902 Broadway,6th Floor, New York, NY 10010 USA. [Ward, Johanna R. M.] Math Policy Res, POB 2393, Princeton, NJ 08543 USA. [Schoneboom, Bruce A.] US Army, Med Res Inst Chem Def, 3100 Ricketts Point Rd, Aberdeen Proving Ground, MD 21010 USA. RP Donelan, K (reprint author), Massachusetts Gen Hosp, Mongan Inst Hlth Policy, 50 Staniford St,9th Floor, Boston, MA 02114 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD OCT PY 2016 VL 181 IS 10 BP 1391 EP 1391 DI 10.7205/MILMED-D-16-00295 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA EL3DB UT WOS:000394498700045 PM 27753584 ER PT J AU Zhan, YS Duchamp, M Oklu, R Ellisen, LW Langer, R Khademhosseini, A AF Zhan, Yu Shrike Duchamp, Margaux Oklu, Rahmi Ellisen, Leif W. Langer, Robert Khademhosseini, Ali TI Bioprinting the Cancer Microenvironment SO ACS BIOMATERIALS SCIENCE & ENGINEERING LA English DT Review DE cancer biology; cancer model; bioprinting; vascularization; drug screening ID MULTICELLULAR TUMOR SPHEROIDS; IN-VITRO; TISSUE CONSTRUCTS; BIOMEDICAL APPLICATIONS; PROJECTION STEREOLITHOGRAPHY; MATRIX STIFFNESS; CELL MIGRATION; SHEAR-STRESS; 3D; HYDROGELS AB Cancer is intrinsically complex, comprising both heterogeneous cellular compositions and microenvironmental cues. During the various stages of cancer initiation, development, and metastasis, cell-cell interactions (involving vascular and immune cells besides cancerous cells) as well as cell-extracellular matrix (ECM) interactions (e.g., alteration in stiffness and composition of the surrounding matrix) play major roles. Conventional cancer models both two- and three-dimensional (2D and 3D) present numerous limitations as they lack good vascularization and cannot mimic the complexity of tumors, thereby restricting their use as biomimetic models for applications such as drug screening and fundamental cancer biology studies. Bioprinting as an emerging biofabrication platform enables the creation of high-resolution 3D structures and has been extensively used in the past decade to model multiple organs and diseases. More recently, this versatile technique has further found its application in studying cancer genesis, growth, metastasis, and drug responses through creation of accurate models that recreate the complexity of the cancer microenvironment. In this review we will focus first on cancer biology and limitations with current cancer models. We then detail the current bioprinting strategies including the selection of bioinks for capturing the properties of the tumor matrices, after which we discuss bioprinting of vascular structures that are critical toward construction of complex 3D cancer organoids. We finally conclude with current literature on bioprinted cancer models and propose future perspectives. C1 [Zhan, Yu Shrike; Duchamp, Margaux; Khademhosseini, Ali] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Biomat Innovat Res Ctr,Div Biomed Engn, 65 Landsdowne St, Cambridge, MA 02139 USA. [Zhan, Yu Shrike; Duchamp, Margaux; Langer, Robert; Khademhosseini, Ali] Harvard Mit Div Hlth Sci & Technol, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Zhan, Yu Shrike; Khademhosseini, Ali] Harvard Univ, Wyss Inst Biol Inspired Engn, 3 Blackfan Circle, Boston, MA 02115 USA. [Duchamp, Margaux] Ecole Polytech Fed Lausanne, Dept Bioengn, Route Cantonale, CH-1015 Lausanne, Switzerland. [Oklu, Rahmi] Mayo Clin, Div Vasc & Intervent Radiol, 13400 East Shea Blvd, Scottsdale, AZ 85259 USA. [Ellisen, Leif W.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St, Boston, MA 02114 USA. [Langer, Robert] MIT, David H Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Langer, Robert] MIT, Dept Chem Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Langer, Robert] MIT, Inst Med Engn & Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Langer, Robert] Boston Childrens Hosp, Dept Anesthesiol, 300 Longwood Ave, Boston, MA 02115 USA. [Khademhosseini, Ali] Konkuk Univ, Coll Anim Biosci & Technol, Dept Bioind Technol, 120 Neungdong Ro, Seoul 143701, South Korea. [Khademhosseini, Ali] King Abdulaziz Univ, Dept Phys, Abdullah Sulayman St, Jeddah 21569, Saudi Arabia. RP Zhan, YS; Khademhosseini, A (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Biomat Innovat Res Ctr,Div Biomed Engn, 65 Landsdowne St, Cambridge, MA 02139 USA.; Zhan, YS; Khademhosseini, A (reprint author), Harvard Mit Div Hlth Sci & Technol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Zhan, YS; Khademhosseini, A (reprint author), Harvard Univ, Wyss Inst Biol Inspired Engn, 3 Blackfan Circle, Boston, MA 02115 USA.; Khademhosseini, A (reprint author), Konkuk Univ, Coll Anim Biosci & Technol, Dept Bioind Technol, 120 Neungdong Ro, Seoul 143701, South Korea.; Khademhosseini, A (reprint author), King Abdulaziz Univ, Dept Phys, Abdullah Sulayman St, Jeddah 21569, Saudi Arabia. EM yszhang@research.bwh.harvard.edu; alik@bwh.harvard.edu FU National Institutes of Health [AR057837, DE021468, D005865, AR068258, AR066193, EB022403, EB021148]; Office of Naval Research Presidential Early Career Award for Scientists and Engineers (PECASE); National Cancer Institute Pathway to Independence Award [1K99CA201603-01A1] FX The authors acknowledge funding from the National Institutes of Health (AR057837, DE021468, D005865, AR068258, AR066193, EB022403, EB021148), and the Office of Naval Research Presidential Early Career Award for Scientists and Engineers (PECASE). Y.S.Z. acknowledges the National Cancer Institute Pathway to Independence Award (1K99CA201603-01A1). NR 114 TC 3 Z9 3 U1 11 U2 11 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 2373-9878 J9 ACS BIOMATER SCI ENG JI ACS Biomater. Sci. Eng. PD OCT PY 2016 VL 2 IS 10 BP 1710 EP 1721 DI 10.1021/acsbiomaterials.6b00246 PG 12 WC Materials Science, Biomaterials SC Materials Science GA DY6KB UT WOS:000385213700005 PM 28251176 ER PT J AU Robinson, LR Sabharwal, S Driscoll, S Raddatz, M Chiodo, AE AF Robinson, Lawrence R. Sabharwal, Sunil Driscoll, Sherilyn Raddatz, Mikaela Chiodo, Anthony E. TI How Do Candidates Perform When Repeating the American Board of Physical Medicine and Rehabilitation Certification Examinations? SO AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION LA English DT Article DE Certification Examination; Repeat Candidates; American Board of Physical Medicine and Rehabilitation; Board Certification ID CERTIFYING EXAMINATION; ORAL EXAMINATIONS; SURGERY; SUCCESS; RESIDENTS AB Objective The objective of this study was to examine the likelihood of passing the Part I and Part II American Board of Physical Medicine and Rehabilitation (ABPMR) certification examinations after initially failing. Design This was a retrospective review of candidates who had taken the ABPMR initial certification examinations between 2010 and 2014. Results Passing rates declined markedly with repeated attempts for both part I and part II. Passing rates (mean [95% confidence interval]) for part I were first attempt, 90% (87%-92%); second attempt, 58% (52%-66%); third attempt, 41% (26%-54%); fourth or greater attempt, 17% (3%-31%). For part II, the passing rates were first attempt, 87% (82%-92%); second attempt, 65% (56%-75%); third attempt, 41% (17%-65%); fourth or greater attempt, 20% (0%-59%). Those who were closer to the passing score on their initial attempt had a greater chance of passing on successive attempts. Conclusions Passing rates for the ABPMR certification examination decline markedly with greater numbers of attempts. Those who fail again after one repeat attempt should rethink their examination preparation strategy before attempting the examination again. C1 [Robinson, Lawrence R.] Univ Toronto, Div Phys Med & Rehabil, Toronto, ON, Canada. [Sabharwal, Sunil] Harvard Med Sch, Dept Phys Med & Rehabil, VA Boston Healthcare Syst, Boston, MA USA. [Driscoll, Sherilyn] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA. [Raddatz, Mikaela] Amer Board Phys Med & Rehabil, Rochester, MN USA. [Chiodo, Anthony E.] Dept Phys Med & Rehabil, Ann Arbor, MI USA. RP Robinson, LR (reprint author), St Johns Rehab, S125,285 Cummer Ave, Toronto, ON M2M 2G1, Canada. NR 14 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0894-9115 EI 1537-7385 J9 AM J PHYS MED REHAB JI Am. J. Phys. Med. Rehabil. PD OCT PY 2016 VL 95 IS 10 BP 718 EP 724 DI 10.1097/PHM.0000000000000470 PG 7 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA DX5UL UT WOS:000384447800006 ER PT J AU Cannon, TD Yu, CH Addington, J Bearden, CE Cadenhead, KS Cornblatt, BA Heinssen, R Jeffries, CD Mathalon, DH McGlashan, TH Perkins, DO Seidman, LJ Tsuang, MT Walker, EF Woods, SW Kattan, MW AF Cannon, Tyrone D. Yu, Changhong Addington, Jean Bearden, Carrie E. Cadenhead, Kristin S. Cornblatt, Barbara A. Heinssen, Robert Jeffries, Clark D. Mathalon, Daniel H. McGlashan, Thomas H. Perkins, Diana O. Seidman, Larry J. Tsuang, Ming T. Walker, Elaine F. Woods, Scott W. Kattan, Michael W. TI An Individualized Risk Calculator for Research in Prodromal Psychosis SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID CLINICAL HIGH-RISK; CONTROLLED-TRIAL; YOUNG-ADULTS; SCHIZOPHRENIA; PREVENTION; PREDICTION; YOUTH; INTERVENTIONS; METAANALYSIS; ADOLESCENTS AB Objective: Approximately 20%-35% of individuals 12-35 years old who meet criteria for a prodromal risk syndrome convert to psychosis within 2 years. However, this estimate ignores the fact that clinical high-risk cases vary considerably in risk. The authors sought to create a risk calculator, based on profiles of risk indicators, that can ascertain the probability of conversion to psychosis in individual patients. Method: The study subjects were 596 clinical high-risk participants from the second phase of the North American Prodrome Longitudinal Study who were followed lip to the time of conversion to psychosis or last contact (up to 2 years). The predictors examined were limited to those that are supported by previous studies and are readily obtainable in general clinical settings. Time-to-event regression was used to build a multivariate model predicting conversion, with internal validation using 1,000 bootstrap resamples. Results: The 2-year probability of conversion to psychosis was 16%. Higher levels of unusual thought content and suspiciousness, greater decline in social functioning, lower verbal learning and memory performance, slower speed of processing, and younger age at baseline each contributed to individual risk for psychosis. Stressful life events, trauma, and family history of schizophrenia were not significant predictors. The multivariate model achieved a concordance index of 0.71 and, as reported in an article by Carrion et al., published concurrently with this one, was validated in an independent external data set. The results are instantiated in a web-based risk prediction tool envisioned to be most useful in research protocols involving the psychosis prodrome. Conclusions: A risk calculator comparable in accuracy to those for cardiovascular disease and cancer is available to predict individualized conversion risks in newly ascertained clinical high-risk cases. Given that the risk calculator can be validly applied only for patients who screen positive on the Structured Clinical Interview for Psychosis Risk Syndromes, which requires training to administer, its most immediate uses will be in research on psychosis risk factors and in research-driven clinical (prevention) trials. C1 [Cannon, Tyrone D.] Yale Univ, Dept Psychol, New Haven, CT 06520 USA. Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA. Univ Calgary, Dept Psychiat, Hotchkiss Brain Inst, Calgary, AB T2N 1N4, Canada. Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA USA. Univ Calif San Diego, Dept Psychiat, San Diego, CA USA. Zucker Hillside Hosp, Dept Psychiat, Glen Oaks, NY USA. NIMH, Bethesda, MD 20892 USA. Univ N Carolina, Renaissance Comp Inst, Chapel Hill, NC USA. UCSF, Dept Psychiat, San Francisco, CA USA. Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA. Beth Israel Deaconess Med Ctr, Dept Psychiat, Harvard Med Sch, Boston, MA 02215 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. UCSD, Ctr Behav Genom, Dept Psychiat, La Jolla, CA USA. UCSD, Inst Genom Med, La Jolla, CA USA. Emory Univ, Dept Psychol, Atlanta, GA 30322 USA. Emory Univ, Dept Psychiat, Atlanta, GA 30322 USA. RP Cannon, TD (reprint author), Yale Univ, Dept Psychol, New Haven, CT 06520 USA. FU NIH [U01 MH081902, P50 MH066286, U01 MH081857, U01 MH82022, U01 MH 066134, U01 MH081944, R01 U01MH066069, R01 MH076989, U01 MH081928, U01 MH081988]; Genentech; Pfizer; Auspex; Teva FX Supported by NIH grants U01 MH081902 (to Dr. Cannon), P50 MH066286 (to Dr. Bearden), U01 MH081857 (to Dr. Cornblatt), U01 MH82022 (to Dr. Woods), U01 MH 066134 (to Dr. Addington), U01 MH081944 (to Dr. Cadenhead), R01 U01MH066069 (to Dr. Perkins), R01 MH076989 (to Dr. Mathalon), U01 MH081928 (to Dr Seidman), and U01 MH081988 (to Dr. Walker).; Dr. Cannon has served as a consultant for the Los Angeles County Department of Mental Health and Boehringer-Ingelheim Pharmaceuticals. Dr. Mathalon has served as a consultant for Boehringer-Ingelheim Pharmaceuticals. Dr. Perkins has served as a consultant for Genentech, Lundbeck, Otsuka, and Sunovion, has participated in educational activity for Otsuka, and has received research support from Genentech. Dr. Woods has received investigator-initiated research support from Pfizer and sponsor-initiated research support from Auspex and Teva; he has served as a consultant for Biomedisyn (unpaid), Boehringer-Ingelheim, and Merck and as an unpaid consultant to DSM-5; he has been granted a patent for a method of treating prodromal schizophrenia with glycine agonists and is named as an inventor on a patent pending for a method of predicting psychosis risk using blood biomarker analysis; and he has received royalties from Oxford University Press The other authors report no financial relationships with commercial interests. NR 41 TC 12 Z9 12 U1 3 U2 3 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X EI 1535-7228 J9 AM J PSYCHIAT JI Am. J. Psychiat. PD OCT PY 2016 VL 173 IS 10 BP 980 EP 988 DI 10.1176/appi.ajp.2016.15070890 PG 9 WC Psychiatry SC Psychiatry GA DX1WT UT WOS:000384158400009 PM 27363508 ER PT J AU Oxnard, GR Thress, KS Alden, RS Lawrance, R Paweletz, CP Cantarini, M Yang, JCH Barrett, JC Janne, PA AF Oxnard, Geoffrey R. Thress, Kenneth S. Alden, Ryan S. Lawrance, Rachael Paweletz, Cloud P. Cantarini, Mireille Yang, James Chih-Hsin Barrett, J. Carl Janne, Pasi A. TI Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID FREE-TUMOR-DNA; KINASE INHIBITORS; EGFR MUTATIONS; NSCLC PATIENTS; RESISTANCE; RECEPTOR; T790M; ADENOCARCINOMA; GEFITINIB; TKI AB Purpose Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have demonstrated potent activity against TKI resistance mediated by EGFR T790M. We studied whether noninvasive genotyping of cell-free plasma DNA (cfDNA) is a useful biomarker for prediction of outcome from a third-generation EGFR-TKI, osimertinib. Methods Plasma was collected from all patients in the first-in-man study of osimertinib. Patients who were included had acquired EGFR-TKI resistance and evidence of a common EGFR-sensitizing mutation. Genotyping of cell-free plasma DNA was performed by using BEAMing. Plasma genotyping accuracy was assessed by using tumor genotyping from a central laboratory as reference. Objective response rate (ORR) and progression-free survival (PFS) were analyzed in all T790M-positive or T790M-negative patients. Results Sensitivity of plasma genotyping for detection of T790M was 70%. Of 58 patients with T790M-negative tumors, T790M was detected in plasma of 18 (31%). ORR and median PFS were similar in patients with T790M-positive plasma (ORR, 63%; PFS, 9.7 months) or T790M-positive tumor (ORR, 62%; PFS, 9.7 months) results. Although patients with T790M-negative plasma had overall favorable outcomes (ORR, 46%; median PFS, 8.2 months), tumor genotyping distinguished a subset of patients positive for T790M who had better outcomes (ORR, 69%; PFS, 16.5 months) as well as a subset of patients negative for T790M with poor outcomes (ORR, 25%; PFS, 2.8 months). Conclusion In this retrospective analysis, patients positive for T790M in plasma have outcomes with osimertinib that are equivalent to patients positive by a tissue-based assay. This study suggests that, upon availability of validated plasma T790M assays, some patients could avoid a tumor biopsy for T790M genotyping. As a result of the 30% false-negative rate of plasma genotyping, those with T790M-negative plasma results still need a tumor biopsy to determine presence or absence of T790M. (C) 2016 by American Society of Clinical Oncology. C1 [Oxnard, Geoffrey R.; Alden, Ryan S.; Paweletz, Cloud P.; Janne, Pasi A.] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA. [Thress, Kenneth S.; Barrett, J. Carl] AstraZeneca, Waltham, MA USA. [Lawrance, Rachael; Cantarini, Mireille] AstraZeneca, Macclesfield, Cheshire, England. [Yang, James Chih-Hsin] Natl Taiwan Univ, Taipei, Taiwan. [Yang, James Chih-Hsin] Natl Taiwan Univ Hosp, Taipei, Taiwan. RP Oxnard, GR (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02115 USA. EM geoffrey_oxnard@dfci.harvard.edu FU AstraZeneca FX We thank Rachel Hodge for statistical support. Editorial assistance for this manuscript was provided by Donna Tillotson, from iMed Comms, an Ashfield Company, funded by AstraZeneca. NR 23 TC 24 Z9 24 U1 4 U2 4 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD OCT 1 PY 2016 VL 34 IS 28 BP 3375 EP + DI 10.1200/JCO.2016.66.7162 PG 15 WC Oncology SC Oncology GA DW9CR UT WOS:000383953100006 PM 27354477 ER PT J AU Colleoni, M Gray, KP Gelber, S Lang, I Thurlimann, B Gianni, L Abdi, EA Gomez, HL Linderholm, BK Puglisi, F Tondini, C Kralidis, E Eniu, A Cagossi, K Rauch, D Chirgwin, J Gelber, RD Regan, MM Coates, AS Price, KN Viale, G Goldhirsch, A AF Colleoni, Marco Gray, Kathryn P. Gelber, Shari Lang, Istvan Thurlimann, Beat Gianni, Lorenzo Abdi, Ehtesham A. Gomez, Henry L. Linderholm, Barbro K. Puglisi, Fabio Tondini, Carlo Kralidis, Elena Eniu, Alexandru Cagossi, Katia Rauch, Daniel Chirgwin, Jacquie Gelber, Richard D. Regan, Meredith M. Coates, Alan S. Price, Karen N. Viale, Giuseppe Goldhirsch, Aron TI Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00 SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID ADJUVANT CHEMOTHERAPY; RANDOMIZED-TRIALS; ANTITUMOR-ACTIVITY; PRIMARY THERAPY; RECURRENCE; POLYCHEMOTHERAPY; ANGIOGENESIS; TRASTUZUMAB; BEVACIZUMAB; MANAGEMENT AB Purpose To evaluate the benefit of low-dose cyclophosphamide and methotrexate (CM) maintenance, which previously demonstrated antitumor activity and few adverse effects in advanced breast cancer, in early breast cancer. Patients and Methods International Breast Cancer Study Group (IBCSG) Trial 22-00, a randomized phase III clinical trial, enrolled 1,086 women (1,081 intent-to-treat) from November 2000 to December 2012. Women with estrogen receptor- and progesterone receptor-negative (< 10% positive cells by immunohistochemistry) early breast cancer any nodal and human epidermal growth factor receptor 2 status, were randomly assigned anytime between primary surgery and 56 days after the first day of last course of adjuvant chemotherapy to CM maintenance (cyclophosphamide 50 mg/day orally continuously and methotrexate 2.5 mg twice/day orally on days 1 and 2 of every week for 1 year) or to no CM. The primary end point was disease-free survival (DFS), which included invasive recurrences, second (breast and nonbreast) malignancies, and deaths. Results After a median of 6.9 years of follow-up, DFS was not significantly better for patients assigned to CM maintenance compared with patients assigned to no CM, both overall (hazard ratio [HR], 0.84; 95% CI, 0.66 to 1.06;P = .14) and in triple-negative (TN) disease (n = 814; HR, 0.80; 95% CI, 0.60 to 1.06). Patients with TN, node-positive disease had a nonstatistically significant reduced HR (n = 340; HR, 0.72; 95% CI, 0.49 to 1.05). Seventy-one (13%) of 542 patients assigned to CM maintenance did not start CM. Of 473 patients who received at least one CM maintenance dose (including two patients assigned to no CM), 64 (14%) experienced a grade 3 or 4 treatment-related adverse event; elevated serum transaminases was the most frequently reported (7%), followed by leukopenia (2%). Conclusion CM maintenance did not produce a significant reduction in DFS events in hormone receptor-negative early breast cancer. The trend toward benefit observed in the TN, node-positive subgroup supports additional exploration of this strategy in the TN, higher-risk population. (C) 2016 by American Society of Clinical Oncology. C1 [Colleoni, Marco; Viale, Giuseppe; Goldhirsch, Aron] European Inst Oncol, Milan, Italy. [Viale, Giuseppe] Univ Milan, Milan, Italy. [Gianni, Lorenzo] Osped Infermi, Rimini, Italy. [Puglisi, Fabio] Univ Udine, Univ Hosp Udine, Udine, Italy. [Tondini, Carlo] Osp Papa Giovanni XXIII, Bergamo, Italy. [Cagossi, Katia] Osped Carpi, Carpi, Italy. [Gray, Kathryn P.; Gelber, Shari; Gelber, Richard D.; Regan, Meredith M.; Price, Karen N.] Int Breast Canc Study Grp, Stat Ctr, Boston, MA USA. [Gray, Kathryn P.; Gelber, Shari; Gelber, Richard D.; Regan, Meredith M.] Dana Farber Canc Inst, Boston, MA USA. [Gray, Kathryn P.; Gelber, Richard D.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA. [Gelber, Richard D.; Regan, Meredith M.] Harvard Med Sch, Boston, MA USA. [Gelber, Richard D.; Price, Karen N.] Frontier Sci & Technol Fdn, Boston, MA USA. [Lang, Istvan] Natl Inst Oncol, Budapest, Hungary. [Thurlimann, Beat] Kantonsspital, St Gallen, Switzerland. [Thurlimann, Beat; Kralidis, Elena; Rauch, Daniel] Swiss Grp Clin Canc Res, Bern, Switzerland. [Kralidis, Elena] Kantonsspital Aarau, Aarau, Switzerland. [Rauch, Daniel] Spital Thun, Thun, Switzerland. [Abdi, Ehtesham A.] Tweed Head Hosp, Tweed Heads, NSW, Australia. [Abdi, Ehtesham A.] Griffith Univ, Southport, Qld, Australia. [Abdi, Ehtesham A.; Chirgwin, Jacquie] Australia & New Zealand Breast Canc Trials Grp, Newcastle, NSW, Australia. [Chirgwin, Jacquie] Box Hill Hosp, Box Hill, Vic, Australia. [Chirgwin, Jacquie] Maroondah Hosp, Ringwood, Vic, Australia. [Chirgwin, Jacquie] Monash Univ, Melbourne, Vic, Australia. [Coates, Alan S.] Int Breast Canc Study Grp, Sydney, NSW, Australia. [Coates, Alan S.] Univ Sydney, Sch Publ Hlth, Sydney, NSW, Australia. [Gomez, Henry L.] Inst Nacl Enfermedades Neoplas, Lima, Peru. [Linderholm, Barbro K.] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Gothenburg, Sweden. [Linderholm, Barbro K.] Sahlgrens Univ Hosp, Gothenburg, Sweden. [Eniu, Alexandru] Canc Inst Ion Chiricuta, Cluj Napoca, Romania. RP Colleoni, M (reprint author), European Inst Oncol, Div Med Senol, Via Ripamonti 435, I-20141 Milan, Italy. EM marco.colleoni@ieo.it FU Swedish Cancer League; Cancer Council Australia; Australia and New Zealand Breast Cancer Trials Group; Frontier Science and Technology Research Foundation; Swiss Group for Clinical Cancer Research (SAKK); Swiss Cancer League/Oncosuisse; United States National Cancer Institute [CA-75362] FX Funded by the International Breast Cancer Study Group, participating centers, and for central coordination, data management, and statistics by the Swedish Cancer League, The Cancer Council Australia, Australia and New Zealand Breast Cancer Trials Group, the Frontier Science and Technology Research Foundation, the Swiss Group for Clinical Cancer Research (SAKK), the Swiss Cancer League/Oncosuisse, and the United States National Cancer Institute (Grant No. CA-75362). NR 30 TC 4 Z9 4 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD OCT 1 PY 2016 VL 34 IS 28 BP 3400 EP + DI 10.1200/JCO.2015.65.6595 PG 11 WC Oncology SC Oncology GA DW9CR UT WOS:000383953100009 PM 27325862 ER PT J AU Sheth, RA Feldman, AS Paul, E Thiele, EA Walker, TG AF Sheth, Rahul A. Feldman, Adam S. Paul, Elahna Thiele, Elizabeth A. Walker, T. Gregory TI Sporadic versus Tuberous Sclerosis Complex-Associated Angiomyolipomas: Predictors for Long-Term Outcomes following Transcatheter Embolization SO JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY LA English DT Article ID SELECTIVE ARTERIAL EMBOLIZATION; RENAL ANGIOMYOLIPOMA; MANAGEMENT; LYMPHANGIOLEIOMYOMATOSIS; SURVEILLANCE; SIROLIMUS; DIAGNOSIS AB Purpose: To evaluate risk factors for long-term outcomes following embolization of sporadic versus tuberous sclerosis complex (TSC) associated angiomyolipomas (AMLs). Materials and Methods: A retrospective review of consecutive transcatheter embolization of renal AMLs between 2002 and 2014 was performed. Tumor volumetrics including density analysis were obtained. Treatment outcomes were assessed at 1 year after embolization using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 and volumetric RECIST criteria. A total of 56 patients, 70% (39/56) of whom had TSC, underwent embolization of 72 renal AMLs: Embolization was most commonly performed (70/72, 97%) using microspheres (300-500 mu m or 500-700 mu m Embosphere). Results: Between the sporadic and TSC-associated populations, there was no difference in follow-up time (648 d vs 583 d, P = .78), initial tumor diameter (6.68 cm vs 5.71 cm, P = .09), or percent tumoral fat content (39.5% vs 8.6%, P = .35). Progressive disease was noted in 9 TSC-associated AMLs by volume and 3 TSC-associated AMLs by diameter but in no sporadic AMLs. Growth suppression curves were remarkable for rebound growth in TSC patients, particularly in TSC patients younger than 18 years. Patient age (P = .007) and tumor volume (P = .03) were found to correlate with tumor regrowth within the TSC population, No difference was found in median change in. total volume after embolization based on fat content (-57.9% vs -54.2%, P = .68). Conclusions: TSC, patient age, and tumoral volume before embolization are risk factors for AML growth following embolization. Intratumoral fat content was not found to predict response to embolization. C1 [Sheth, Rahul A.; Walker, T. Gregory] Massachusetts Gen Hosp, Div Intervent Radiol, Boston, MA 02114 USA. [Feldman, Adam S.] Massachusetts Gen Hosp, Dept Radiol, Dept Urol, Boston, MA USA. [Paul, Elahna] Massachusetts Gen Hosp, Dept Pediat Nephrol, Boston, MA USA. [Thiele, Elizabeth A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Sheth, Rahul A.] MD Anderson Canc Ctr, Div Diagnost Imaging, Dept Intervent Radiol, FCT 14-5092,1400 Pressler St, Houston, TX 77030 USA. RP Sheth, RA (reprint author), Massachusetts Gen Hosp, Div Intervent Radiol, Boston, MA 02114 USA.; Sheth, RA (reprint author), MD Anderson Canc Ctr, Div Diagnost Imaging, Dept Intervent Radiol, FCT 14-5092,1400 Pressler St, Houston, TX 77030 USA. EM rasheth@mdanderson.org FU Novartis Pharmaceuticals (Easel, Switzerland) FX A.S.F. and E.P. are paid consultants for Novartis Pharmaceuticals (Easel, Switzerland). None of the other authors have identified a conflict of interest. NR 30 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1051-0443 EI 1535-7732 J9 J VASC INTERV RADIOL JI J. Vasc. Interv. Radiol. PD OCT PY 2016 VL 27 IS 10 BP 1542 EP 1549 DI 10.1016/j.jvir.2016.05.029 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging; Peripheral Vascular Disease SC Radiology, Nuclear Medicine & Medical Imaging; Cardiovascular System & Cardiology GA DY9UB UT WOS:000385479500010 PM 27522275 ER PT J AU Zheng, Y Li, YP Qi, QB Hruby, A Manson, JE Willett, WC Wolpin, BM Hu, FB Qi, L AF Zheng, Yan Li, Yanping Qi, Qibin Hruby, Adela Manson, JoAnn E. Willett, Walter C. Wolpin, Brian M. Hu, Frank B. Qi, Lu TI Cumulative consumption of branched-chain amino acids and incidence of type 2 diabetes SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY LA English DT Article DE Diet; branched-chain amino acids; type 2 diabetes; cohort study ID FOOD FREQUENCY QUESTIONNAIRE; DIET-INDUCED OBESITY; TOTAL-ENERGY-INTAKE; INSULIN-RESISTANCE; METABOLIC SIGNATURE; WEIGHT-LOSS; RISK; PREVENTION; HEALTH; WOMEN AB Background: Plasma branched-chain amino acids (BCAAs, including leucine, isoleucine and valine) were recently related to risk of type 2 diabetes (T2D). Dietary intake is the only source of BCAAs; however, little is known about whether habitual dietary intake of BCAAs affects risk of T2D. Methods: We assessed associations between cumulative consumption of BCAAs and risk of T2D among participants from three prospective cohorts: the Nurses' Health Study (NHS; followed from 1980 to 2012); NHS II (followed from 1991 to 2011); and the Health Professionals Follow-up Study (HPFS; followed from 1986 to 2010). Results: We documented 16 097 incident T2D events during up to 32 years of follow-up. After adjustment for demographics and traditional risk factors, higher total BCAA intake was associated with an increased risk of T2D in men and women. In the meta-analysis of all cohorts, comparing participants in the highest quintile with those in the lowest quintile of intake, hazard ratios (95% confidence intervals) were for leucine 1.13 (1.07-1.19), for isoleucine 1.13 (1.07-1.19) and for valine 1.11 (1.05-1.17) (all P for trend < 0.001). In a healthy subsample, higher dietary BCAAs were significantly associated with higher plasma levels of these amino acids (P for trend = 0.01). Conclusions: Our data suggest that high consumption of BCAAs is associated with an increased risk of T2D. C1 [Zheng, Yan; Li, Yanping; Hruby, Adela; Willett, Walter C.; Hu, Frank B.; Qi, Lu] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA. [Qi, Qibin] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY USA. [Manson, JoAnn E.; Willett, Walter C.; Hu, Frank B.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Manson, JoAnn E.; Willett, Walter C.; Wolpin, Brian M.; Hu, Frank B.] Harvard Med Sch, Boston, MA USA. [Manson, JoAnn E.; Willett, Walter C.; Hu, Frank B.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Manson, JoAnn E.] Brigham & Womens Hosp, Dept Med, Div Prevent Med, 75 Francis St, Boston, MA 02115 USA. [Wolpin, Brian M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Qi, Lu] Tulane Univ, Dept Epidemiol, Sch Publ Hlth & Trop Med, 1440 Canal St,Suite 1724, New Orleans, LA 70112 USA. RP Qi, L (reprint author), Tulane Univ, Dept Epidemiol, Sch Publ Hlth & Trop Med, 1440 Canal St,Suite 1724, New Orleans, LA 70112 USA. EM lqi1@tulane.edu FU National Institutes of Health [P01 CA87969, UM1 CA186107, R01 CA49449, UM1 CA176726, UM1 CA167552, R01 DK091718, HL71981, DK58845, HL60712]; United States - Israel Binational Science Foundation [2011036]; American Heart Association Scientist Development Award; Boston Obesity Nutrition Research Center [DK46200] FX This study was supported by the: National Institutes of Health P01 CA87969, UM1 CA186107, R01 CA49449, UM1 CA176726, UM1 CA167552, R01 DK091718, HL71981, DK58845 and HL60712; United States - Israel Binational Science Foundation Grant 2011036; American Heart Association Scientist Development Award; and Boston Obesity Nutrition Research Center (DK46200). NR 38 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0300-5771 EI 1464-3685 J9 INT J EPIDEMIOL JI Int. J. Epidemiol. PD OCT PY 2016 VL 45 IS 5 BP 1482 EP 1492 DI 10.1093/ije/dyw143 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EJ4KA UT WOS:000393184400022 PM 27413102 ER PT J AU Wilens, TE Biederman, J Martelon, M Zulauf, C Anderson, JP Carrellas, NW Yule, A Wozniak, J Fried, R Faraone, SV AF Wilens, Timothy E. Biederman, Joseph Martelon, MaryKate Zulauf, Courtney Anderson, Jesse P. Carrellas, Nicholas W. Yule, Amy Wozniak, Janet Fried, Ronna Faraone, Stephen V. TI Further Evidence for Smoking and Substance Use Disorders in Youth With Bipolar Disorder and Comorbid Conduct Disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; SPECTRUM DISORDERS; I DISORDER; FOLLOW-UP; 1ST HOSPITALIZATION; DRUG-ABUSE; ADOLESCENTS; CHILDREN; CHILDHOOD; MANIA AB Objective: Bipolar disorder (BPD) is a highly morbid disorder increasingly recognized in adolescents. The aim of this study was to examine the relative risk for substance use disorders (SUDs; alcohol or drug abuse or dependence) and cigarette smoking in adolescents with BPD. Methods: We evaluated the relative risk for SUDs and cigarette smoking in a case-controlled, 5-year prospective follow-up of adolescents with (n = 105, mean +/- SD baseline age = 13.6 +/- 2.5 years) and without ("controls"; n = 98, baseline age = 13.7 +/- 2.1 years) BPD. Seventy-three percent of subjects were retained at follow-up (BPD: n = 68; controls: n = 81; 73% reascertainment). Our main outcomes were assessed by blinded structured interviews for DSM-IV criteria. Results: Maturing adolescents with BPD, compared to controls, were more likely to endorse higher rates of SUD (49% vs 26%; hazard ratio [HR] = 2.0; 95% confidence interval (CI), 1.1-3.6; P = .02) and cigarette smoking (49% vs 17%; HR = 2.9; 95% CI, 1.4-6.1; P =.004), as well as earlier onset of SUD (14.9 +/- 2.6 [SD] years vs 16.5 +/- 1.6 [SD] years; t = 2.6; P =.01). Subjects with conduct disorder (CD) were more likely to have SUD and nicotine dependence than subjects with BPD alone or controls (all P values < .05). When we added conduct disorder to the model with socioeconomic status and parental SUD, all associations lost significance (all P values > .05). Subjects with the persistence of a BPD diagnosis were also more likely to endorse cigarette smoking and SUD in comparison to those who lost a BPD diagnosis or controls at follow-up. Conclusions: The results provide further evidence that adolescents with BPD, particularly those with comorbid CD, are significantly more likely to endorse cigarette smoking and SUDs when compared to their non-mood disordered peers. These findings indicate that youth with BPD should be carefully monitored for comorbid CD and the development of cigarette smoking and SUDs. (C) Copyright 2016 Physicians Postgraduate Press, Inc. C1 [Wilens, Timothy E.; Biederman, Joseph; Martelon, MaryKate; Zulauf, Courtney; Anderson, Jesse P.; Carrellas, Nicholas W.; Yule, Amy; Wozniak, Janet; Fried, Ronna] Massachusetts Gen Hosp, Clin & Res Programs Pediat Psychopharmacol & Adul, Boston, MA 02114 USA. [Wilens, Timothy E.; Biederman, Joseph] Harvard Med Sch, Dept Psychiat, Boston, MA USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat & Neurosci & Physiol, Syracuse, NY 13210 USA. RP Wilens, TE (reprint author), Massachusetts Gen Hosp, Pediat Psychopharmacol, 55 Fruit St,YAW 6A, Boston, MA 02114 USA. EM twilens@partners.org FU NIH [RO1 DA12945, K24 DA016264] FX All phases of this study were supported by NIH grants RO1 DA12945 and K24 DA016264 to Dr Wilens. NR 54 TC 0 Z9 0 U1 0 U2 0 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD OCT PY 2016 VL 77 IS 10 BP 1420 EP 1427 DI 10.4088/JCP.14m09440 PG 8 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA EJ2DQ UT WOS:000393020500033 PM 27574842 ER PT J AU Chen, JA Shapero, BG Trinh, NHT Chang, TE Parkin, S Alpert, JE Fava, M Yeung, AS AF Chen, Justin A. Shapero, Benjamin G. Trinh, Nhi-Ha T. Chang, Trina E. Parkin, Susannah Alpert, Jonathan E. Fava, Maurizio Yeung, Albert S. TI Association Between Stigma and Depression Outcomes Among Chinese Immigrants in a Primary Care Setting SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID SENSITIVE COLLABORATIVE TREATMENT; MENTAL-ILLNESS STIGMA; ASIAN-AMERICANS; PUBLIC-HEALTH; RATING-SCALE; SELF-STIGMA; SATISFACTION; RELIABILITY; VALIDITY; CULTURE AB Objective: Stigma has been proposed to be a major underlying factor contributing to lower rates of mental health service utilization among racial/ethnic minorities in the United States. Yet, surprisingly little research has specifically explored associations between stigma, race/ethnicity, and psychiatric morbidity. This study aims to assess the impact of stigmatizing attitudes on depression outcomes among a psychiatrically underserved, immigrant Chinese population. Methods: Between 2009 and 2012, 190 Chinese immigrants with major depressive disorder as diagnosed by the Mini International Neuropsychiatric Interview were enrolled in a trial of culturally sensitive collaborative care for depression. Participants' self-reported stigma regarding their symptoms was assessed at study entry using the Explanatory Model Interview Catalogue, and depressive symptoms were assessed with the Hamilton Depression Rating Scale (HDRS) at baseline and follow-up. Hierarchical linear regression was used to assess the association between baseline stigma score and change in HDRS score, adjusting for potential confounders. Results: Higher stigma scores at baseline were significantly associated with attenuated improvement in both HDRS score and quality of life at 6 months (P<.05 for both). Conclusions: Stigma has a directly harmful effect on depression outcomes, even after individuals have been accurately diagnosed within a culturally sensitive community health center and agreed to treatment. These results support further research into interventions targeting stigma to improve mental health outcomes among minority populations. (C) Copyright 2016 Physicians Postgraduate Press, Inc. C1 [Chen, Justin A.; Shapero, Benjamin G.; Trinh, Nhi-Ha T.; Chang, Trina E.; Parkin, Susannah; Alpert, Jonathan E.; Fava, Maurizio; Yeung, Albert S.] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA. [Chen, Justin A.; Shapero, Benjamin G.; Trinh, Nhi-Ha T.; Chang, Trina E.; Alpert, Jonathan E.; Fava, Maurizio; Yeung, Albert S.] Harvard Med Sch, Boston, MA USA. [Yeung, Albert S.] South Cove Community Hlth Ctr, Boston, MA USA. RP Chen, JA (reprint author), 1 Bowdoin Sq,6th Floor, Boston, MA 02114 USA. EM jchen37@partners.org FU Harvard Medical School, Boston, MA; National Institute of Mental Health [R01 MH079831] FX Dr Chen's work on this project was supported by the Dupont-Warren and Livingston Research Fellowships from Harvard Medical School, Boston, MA. The randomized controlled trial of T-CSCT on which this analysis was based was supported by the National Institute of Mental Health (R01 MH079831). NR 42 TC 0 Z9 0 U1 2 U2 2 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD OCT PY 2016 VL 77 IS 10 BP E1287 EP E1292 DI 10.4088/JCP.15m10225 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA EJ2DQ UT WOS:000393020500012 PM 27631145 ER PT J AU Manber, R Buysse, DJ Edinger, J Krystal, A Luther, JF Wisniewski, SR Trockel, M Kraemer, HC Thase, ME AF Manber, Rachel Buysse, Daniel J. Edinger, Jack Krystal, Andrew Luther, James F. Wisniewski, Stephen R. Trockel, Mickey Kraemer, Helena C. Thase, Michael E. TI Efficacy of Cognitive-Behavioral Therapy for Insomnia Combined With Antidepressant Pharmacotherapy in Patients With Comorbid Depression and Insomnia: A Randomized Controlled Trial SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID SLEEP-MAINTENANCE INSOMNIA; LATE-LIFE INSOMNIA; OLDER-ADULTS; METAANALYSIS; DISORDER; MODERATORS; MEDIATORS; COMPRESSION; EXPERIENCE; EDUCATION AB Objectives: The Treatment of Insomnia and Depression (TRIAD) study evaluated the efficacy of combining depression pharmacotherapy (using MED, an ecologically valid and generalizable antidepressant medication algorithm) with cognitive-behavioral therapy for insomnia (CBT-I) among individuals with comorbid insomnia and major depressive disorder (MDD) to determine if change in insomnia severity mediates antidepressant outcome. Methods: This 16-week, 3-site, randomized controlled trial (RCT) randomly assigned 150 participants (recruited between March 2009 and August 2013), who met DSM-IV-TR criteria for insomnia and MDD and were not receiving treatment for either, to receive depression pharmacotherapy plus 7 sessions of either CBT-I or a credible control therapy for insomnia (CTRL). Depression pharmacotherapy followed a standardized 2-step algorithm, which included escitalopram, sertraline, and desvenlafaxine in a prescribed sequence. Primary measures were the Hamilton Depression Rating Scale and the depression module of the Structured Clinical Interview for DSMIV Axis I Disorders, Research Version, Nonpatient Edition, administered by raters masked to treatment assignment, and the self-administered Insomnia Severity Index (ISI). Results: CBT-I was superior to CTRL in reducing insomnia severity (P=.028). The overall difference in depression remission between the treatments was not statistically significant (44% in CBT-I and 36% in CTRL; number needed to treat = 15). However, planned secondary analysis revealed that improvements in insomnia at week 6 mediated eventual remission from depression, with early change in ISI predicting depression remission in the CBT-I (P=.0002) but not in the CTRL arm (P=.26). Conclusions: CBT-I is an efficacious treatment for insomnia comorbid with MDD among patients treated with antidepressant medications. Improvement in insomnia may be related to the change in depression. Future studies should identify which patients are most likely to benefit from the addition of an insomnia-focused therapy to standard antidepressant treatments. (C) Copyright 2016 Physicians Postgraduate Press, Inc. C1 [Manber, Rachel; Trockel, Mickey; Kraemer, Helena C.] Stanford Univ, Dept Psychiat & Behav Sci, 401 Quarry Rd, Palo Alto, CA 94305 USA. [Buysse, Daniel J.; Kraemer, Helena C.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Edinger, Jack] Natl Jewish Hlth, Dept Med, Denver, CO USA. [Edinger, Jack; Krystal, Andrew] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA. [Luther, James F.; Wisniewski, Stephen R.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Thase, Michael E.] Univ Penn, Sch Med, Perelman Sch Med, Philadelphia, PA 19104 USA. [Thase, Michael E.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Manber, R (reprint author), Stanford Univ, Dept Psychiat & Behav Sci, 401 Quarry Rd, Palo Alto, CA 94305 USA. EM rmanber@stanford.edu FU US National Institutes of Health [MH078924, MH078961, MH079256] FX The study was supported by the following grants from the US National Institutes of Health: MH078924, MH078961, MH079256. Wyeth Pharmaceutical and Forest Laboratory donated medications to the study. NR 44 TC 1 Z9 1 U1 1 U2 1 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD OCT PY 2016 VL 77 IS 10 BP E1316 EP + DI 10.4088/JCP.15m10244 PG 15 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA EJ2DQ UT WOS:000393020500016 PM 27788313 ER PT J AU Post, RM Altshuler, LL Kupka, R McElroy, SL Frye, MA Rowe, M Grunze, H Suppes, T Keck, PE Leverich, GS Nolen, WA AF Post, Robert M. Altshuler, Lori L. Kupka, Ralph McElroy, Susan L. Frye, Mark A. Rowe, Michael Grunze, Heinz Suppes, Trisha Keck, Paul E., Jr. Leverich, Gabriele S. Nolen, Willem A. TI Age at Onset of Bipolar Disorder Related to Parental and Grandparental Illness Burden SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID ASTERISK-D-CHILD; UNITED-STATES; I DISORDER; PSYCHIATRIC-DISORDERS; MATERNAL DEPRESSION; SPECTRUM DISORDERS; MENTAL-DISORDERS; FOLLOW-UP; PSYCHOPATHOLOGY; RISK AB Objective: The age at onset of bipolar disorder varies greatly in different countries and continents. The association between load of family history of psychiatric illness and age at onset has not been adequately explored. Methods: 979 outpatients with bipolar disorder (from 4 sites in the United States and 3 in the Netherlands and Germany) gave informed consent and completed a questionnaire about their demographics, age at onset of illness, and family history of unipolar and bipolar disorder, alcohol and substance abuse comorbidity, suicide attempts, and "other" illnesses in their parents, 4 grandparents, and any offspring. We examined how the parental and grandparental burden of these illnesses related to the age at onset of the patients' bipolar disorder. Results: The burden of family psychiatric history was strongly related to an earlier age at onset of illness in both US and European patients (F-3,F-906 = 35.42, P<.0001). However, compared to the Europeans, patients in the United States had both more family history of most difficulties and notably earlier age at onset. Earlier age at onset was associated with a greater illness burden in the patient's offspring (t(568) = 4.1, P<.0001). Conclusions: More parental and grandparental psychiatric illness was associated with an earlier age at onset of bipolar disorder, which is earlier in the United States compared with Europe and is strongly related to a poor long-term prognosis. This apparent polygenic contribution to early onset deserves further study and therapeutic attempts at ameliorating the transgenerational impact. (C) Copyright 2016 Physicians Postgraduate Press, Inc. C1 [Post, Robert M.; Rowe, Michael; Leverich, Gabriele S.] Bipolar Collaborat Network, 5415 West Cedar Ln,Ste 201B, Bethesda, MD 20814 USA. [Post, Robert M.] George Washington Univ, Dept Psychiat & Behav Sci, Washington, DC USA. [Altshuler, Lori L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Behav Neurosci, Los Angeles, CA 90095 USA. [Altshuler, Lori L.] West Los Angeles Healthcare Ctr, VA Greater Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Kupka, Ralph; Keck, Paul E., Jr.] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA. [McElroy, Susan L.; Keck, Paul E., Jr.] Lindner Ctr HOPE, Mason, OH USA. [McElroy, Susan L.] Univ Cincinnati, Coll Med, Biol Psychiat Program, Cincinnati, OH USA. [Frye, Mark A.] Mayo Clin, Dept Psychiat, Rochester, MI USA. [Grunze, Heinz] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne, Tyne & Wear, England. [Suppes, Trisha] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Suppes, Trisha] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Nolen, Willem A.] Univ Groningen, Univ Med Ctr Groningen, NL-9700 AB Groningen, Netherlands. RP Post, RM (reprint author), Bipolar Collaborat Network, 5415 West Cedar Ln,Ste 201B, Bethesda, MD 20814 USA. EM robert.post@speakeasy.net OI Grunze, Heinz/0000-0003-4712-8979 FU Stanley Foundation FX The Stanley Foundation Bipolar Treatment Outcome Network was funded by the Stanley Foundation from 1995 to 2002 and patients were recruited and studied during this period. NR 48 TC 0 Z9 0 U1 2 U2 2 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD OCT PY 2016 VL 77 IS 10 BP E1309 EP E1315 DI 10.4088/JCP.15m09811 PG 7 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA EJ2DQ UT WOS:000393020500015 PM 27631141 ER PT J AU Edwards, B Sands, S Tavakkoli, A Corey, K Hamilton, G Brown, W Naughton, M White, D Wellman, A Malhotra, A AF Edwards, B. Sands, S. Tavakkoli, A. Corey, K. Hamilton, G. Brown, W. Naughton, M. White, D. Wellman, A. Malhotra, A. TI UNDERSTANDING THE MECHANISMS BY WHICH OBESITY CAUSES OBSTRUCTIVE SLEEP APNOEA SO JOURNAL OF SLEEP RESEARCH LA English DT Meeting Abstract C1 [Edwards, B.; Hamilton, G.; Brown, W.; Naughton, M.] Monash Univ, Melbourne, Vic, Australia. [Edwards, B.; Sands, S.; White, D.; Wellman, A.] Harvard Med Sch, Boston, MA USA. [Tavakkoli, A.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Corey, K.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Hamilton, G.] Monash Hlth, Melbourne, Vic, Australia. [Brown, W.; Naughton, M.] Alfred Hlth, Melbourne, Vic, Australia. [Malhotra, A.] Univ San Diego, San Diego, CA 92110 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0962-1105 EI 1365-2869 J9 J SLEEP RES JI J. Sleep Res. PD OCT PY 2016 VL 25 SU 2 SI SI MA 055 BP 19 EP 19 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EJ2IG UT WOS:000393032700038 ER PT J AU Al Efishat, M Attiyeh, M Lokshin, A Wolfgang, CL D'Angelica, MI DeMatteo, RP Kingham, P Jarnagin, WR Fernandez-del Castillo, C Allen, PJ AF Al Efishat, Mohammad Attiyeh, Marc Lokshin, Anna Wolfgang, Christopher L. D'Angelica, Michael I. DeMatteo, Ronald P. Kingham, Peter Jarnagin, William R. Fernandez-del Castillo, Carlos Allen, Peter J. TI A Multi-Institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-Grade Dysplasia in Intraductal Papillary Mucinous Neoplasms SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract C1 Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2016 VL 223 IS 4 SU 1 BP S138 EP S138 PG 1 WC Surgery SC Surgery GA EJ2YM UT WOS:000393077500258 ER PT J AU Bohnen, JD Mavros, MN Ramly, EP Chang, YC Yeh, DD Lee, J de Moya, M King, DR Velmahos, GC Kaafarani, HM AF Bohnen, Jordan D. Mavros, Michael N. Ramly, Elie P. Chang, Yuchiao Yeh, D. Dante Lee, Jarone de Moya, Marc King, David R. Velmahos, George C. Kaafarani, Haytham M. TI Intraoperative Adverse Events in Abdominal Surgery: What Happens in the Operating Room Does Not Stay in the Operating Room SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract C1 [Bohnen, Jordan D.; Mavros, Michael N.; Ramly, Elie P.; Chang, Yuchiao; Yeh, D. Dante; Lee, Jarone; de Moya, Marc; King, David R.; Velmahos, George C.; Kaafarani, Haytham M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2016 VL 223 IS 4 SU 1 BP S56 EP S56 PG 1 WC Surgery SC Surgery GA EJ2YM UT WOS:000393077500329 ER PT J AU Cauley, CE Lilley, EJ Weissman, J Bader, AM Hepner, DL Haynes, AB Cooper, Z AF Cauley, Christy E. Lilley, Elizabeth J. Weissman, Joel Bader, Angela M. Hepner, David L. Haynes, Alex B. Cooper, Zara TI Who Goes Home after Palliation? Utilization of Venting Percutaneous Endoscopic Gastrostomy in Malignant Bowel Obstruction SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract C1 [Cauley, Christy E.; Lilley, Elizabeth J.; Weissman, Joel; Bader, Angela M.; Hepner, David L.; Haynes, Alex B.; Cooper, Zara] Brigham & Womens Hosp, Massachusetts Gen Hosp, Ctr Surg & Publ Hlth, 75 Francis St, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2016 VL 223 IS 4 SU 1 BP S49 EP S50 PG 4 WC Surgery SC Surgery GA EJ2YM UT WOS:000393077500350 ER PT J AU Fong, ZV Bababekov, YJ Fernandez-del Castillo, CF Ferrone, CR Warshaw, AL Lillemoe, KD Chang, DC AF Fong, Zhi Ven Bababekov, Yanik J. Fernandez-del Castillo, Carlos F. Ferrone, Cristina R. Warshaw, Andrew L. Lillemoe, Keith D. Chang, David C. TI Are Patients Making Optimal Choices When Selecting Hospitals? SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract C1 [Fong, Zhi Ven; Bababekov, Yanik J.; Fernandez-del Castillo, Carlos F.; Ferrone, Cristina R.; Warshaw, Andrew L.; Lillemoe, Keith D.; Chang, David C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2016 VL 223 IS 4 SU 1 BP S106 EP S107 PG 4 WC Surgery SC Surgery GA EJ2YM UT WOS:000393077500188 ER PT J AU Goldstone, RN Khan, SI McCormack, M Salinas, H Meppelink, A Randolphs, MA Watkins, MT Rond, RW Austen, WG AF Goldstone, Robert N. Khan, Saiqa I. McCormack, Michael Salinas, Harry Meppelink, Amanda Randolphs, Mark A. Watkins, Michael T. Rond, Robert W. Austen, William G., Jr. TI Photochemical Reinforcement Reduces Intimal Hyperplasia in a Porcine Model of Arteriovenous Bypass Grafting SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract C1 [Goldstone, Robert N.; Khan, Saiqa I.; McCormack, Michael; Salinas, Harry; Meppelink, Amanda; Randolphs, Mark A.; Watkins, Michael T.; Rond, Robert W.; Austen, William G., Jr.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2016 VL 223 IS 4 SU 1 BP S25 EP S26 PG 4 WC Surgery SC Surgery GA EJ2YM UT WOS:000393077500048 ER PT J AU Lopez, J Juan, IC Wu, A Samaha, GJ Cho, B Soni, A Milton, J May, JW Tufaro, AP Dorafshar, AH AF Lopez, Joseph Juan, Ilona C. Wu, Adela Samaha, Georges J. Cho, Brian Soni, Ashwin Milton, Jacqueline May, James W., Jr. Tufaro, Anthony P. Dorafshar, Amir H. TI Financial Conflicts of Interest in Plastic Surgery: Are They All Created Equal? SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract C1 Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA. Univ Washington, Med Ctr, Seattle, WA 98195 USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2016 VL 223 IS 4 SU 1 BP S47 EP S47 PG 1 WC Surgery SC Surgery GA EJ2YM UT WOS:000393077500344 ER PT J AU Mehtsun, W Papanicolas, I Lillemoe, KD Jha, AK AF Mehtsun, Winta Papanicolas, Irene Lillemoe, Keith D. Jha, Ashish K. TI Trends in Readmission after Inpatient Surgery SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract C1 [Mehtsun, Winta; Papanicolas, Irene; Lillemoe, Keith D.; Jha, Ashish K.] Harvard TH Chan Sch Publ Hlth, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2016 VL 223 IS 4 SU 1 BP S120 EP S120 PG 1 WC Surgery SC Surgery GA EJ2YM UT WOS:000393077500218 ER PT J AU Mehtsun, W Orav, EJ Lillemoe, KD Jha, AK AF Mehtsun, Winta Orav, Endel J. Lillemoe, Keith D. Jha, Ashish K. TI Unintended Consequences of the 30-Day Mortality Measure: Fact or Fiction? SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract C1 [Mehtsun, Winta; Orav, Endel J.; Lillemoe, Keith D.; Jha, Ashish K.] Harvard Sch Publ Hlth, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2016 VL 223 IS 4 SU 1 BP S120 EP S121 PG 5 WC Surgery SC Surgery GA EJ2YM UT WOS:000393077500219 ER PT J AU Sachdeva, U Fong, ZV Wright, CD Wain, JC Lanuti, M Gaissert, HA Muniappan, A Chang, DC Mathisen, DJ Morse, CR AF Sachdeva, Uma Fong, Zhi Ven Wright, Cameron D. Wain, John C. Lanuti, Michael Gaissert, Henning A. Muniappan, Ashok Chang, David C. Mathisen, Douglas J. Morse, Christopher R. TI Pre-Existing Comorbidity Status Is a More Robust Predictor of Postoperative Complication Risk than Advanced Age in Patients Undergoing Esophagectomy SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract C1 [Sachdeva, Uma; Fong, Zhi Ven; Wright, Cameron D.; Wain, John C.; Lanuti, Michael; Gaissert, Henning A.; Muniappan, Ashok; Chang, David C.; Mathisen, Douglas J.; Morse, Christopher R.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2016 VL 223 IS 4 SU 1 BP S26 EP S27 PG 4 WC Surgery SC Surgery GA EJ2YM UT WOS:000393077500050 ER PT J AU Schwartz, D Nagy, N Cheng, LS Kitano, K Ott, HC Goldstein, AM AF Schwartz, Dana Nagy, Nandor Cheng, Lily S. Kitano, Kentaro Ott, Harald C. Goldstein, Allan M. TI Decellularized Intestinal Scaffolds Support the Survival, Migration, and Differentiation of Enteric Neuronal Progenitor Cells SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract C1 [Schwartz, Dana; Nagy, Nandor; Cheng, Lily S.; Kitano, Kentaro; Ott, Harald C.; Goldstein, Allan M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2016 VL 223 IS 4 SU 1 BP S146 EP S147 PG 4 WC Surgery SC Surgery GA EJ2YM UT WOS:000393077500280 ER PT J AU Shah, JA Rosales, IA Colvin, RB Markmann, JF Sachs, DH Vagefi, PA AF Shah, Jigesh A. Rosales, Ivy A. Colvin, Robert B. Markmann, James F. Sachs, David H. Vagefi, Parsia A. TI Baboon CD31 Endothelial Expression and Prolonged Survival after Pig-to-Baboon Liver Xenotransplantation SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract C1 [Shah, Jigesh A.; Rosales, Ivy A.; Colvin, Robert B.; Markmann, James F.; Sachs, David H.; Vagefi, Parsia A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2016 VL 223 IS 4 SU 1 BP S146 EP S146 PG 1 WC Surgery SC Surgery GA EJ2YM UT WOS:000393077500279 ER PT J AU Wahl, TS Graham, LA Richman, J Morris, MS Hollis, RH Jones, CE Copeland, LA Itani, KM Burns, EA Hawn, MT AF Wahl, Tyler S. Graham, Laura A. Richman, Joshua Morris, Melanie S. Hollis, Robert H. Jones, Caroline E. Copeland, Laurel A. Itani, Kamal M. Burns, Edith A. Hawn, Mary T. TI Modified Frailty Index is Associated with 30-Day Surgical Readmissions SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract C1 [Wahl, Tyler S.; Graham, Laura A.; Richman, Joshua; Morris, Melanie S.; Hollis, Robert H.; Jones, Caroline E.; Copeland, Laurel A.; Itani, Kamal M.; Burns, Edith A.; Hawn, Mary T.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2016 VL 223 IS 4 SU 1 BP S113 EP S113 PG 1 WC Surgery SC Surgery GA EJ2YM UT WOS:000393077500202 ER PT J AU Wojcik, BM Fong, ZV Chang, DC Petrusa, ER Mullen, J Phitayakorn, R AF Wojcik, Brandon M. Fong, Zhi Ven Chang, David C. Petrusa, Emil R. Mullen, John Phitayakorn, Roy TI Novel General Surgery Training Service That Increases Resident Operative Autonomy without Impacting Patient Outcomes: A Case-Control Study SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS LA English DT Meeting Abstract C1 [Wojcik, Brandon M.; Fong, Zhi Ven; Chang, David C.; Petrusa, Emil R.; Mullen, John; Phitayakorn, Roy] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1072-7515 EI 1879-1190 J9 J AM COLL SURGEONS JI J. Am. Coll. Surg. PD OCT PY 2016 VL 223 IS 4 SU 1 BP S123 EP S123 PG 1 WC Surgery SC Surgery GA EJ2YM UT WOS:000393077500224 ER PT J AU Saipetch, C Sachs, E Haneef, Z AF Saipetch, Chutima Sachs, Ezekiel Haneef, Zulfi TI Epilepsy Five new things SO NEUROLOGY-CLINICAL PRACTICE LA English DT Review ID TEMPORAL-LOBE EPILEPSY; STEREOTACTIC LASER AMYGDALOHIPPOCAMPOTOMY; INTERSTITIAL THERMAL THERAPY; MARIJUANA USE; TRIAL; STIMULATION; ABLATION; CANNABIDIOL; SEIZURES; ADULTS AB Purpose of review: Technological advance has revolutionized epilepsy management recently. Herein, we review some recent developments. Recent findings: Responsive neurostimulation (Food and Drug Administration [FDA]-approved 2013) works by continuous analysis of brain rhythms and direct brain stimulation on detecting patterns thought to be epileptogenic, thereby aborting seizures. Cardio-responsive vagus nerve stimulation (FDA-approved 2015) is an improvement over traditional vagus nerve stimulation systems, taking advantage of the fact that 80% of seizures are associated with tachycardia. Automated tachycardia detection leads to vagus nerve stimulation to abort seizures. In MRI-guided stereotactic laser ablation (developed 2012), a directed laser emitting fiberoptic catheter is used to ablate epileptogenic lesions. The procedure can be completed in 3 to 4 hours, potentially under local anesthesia and with next-day discharge. Perampanel (FDA-approved 2012) is a promising new class of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid)-antagonist antiseizure therapy. Meanwhile, a millennia-old remedy for epilepsy, cannabis, is staging a comeback with recent legal and social permissiveness accelerating research into this use. Summary: The coming years will demonstrate how these recent advances in device and drug management will improve the care of epilepsy. C1 [Saipetch, Chutima; Haneef, Zulfi] Baylor Coll Med, Houston, TX 77030 USA. [Sachs, Ezekiel] Emory Univ, Atlanta, GA 30322 USA. [Haneef, Zulfi] VA Med Ctr, Houston, TX 77030 USA. RP Haneef, Z (reprint author), Baylor Coll Med, Houston, TX 77030 USA.; Haneef, Z (reprint author), VA Med Ctr, Houston, TX 77030 USA. EM zulfi.haneef@bcm.edu NR 25 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2163-0402 EI 2163-0933 J9 NEUROL-CLIN PRACT JI Neurol.-Clin. Pract. PD OCT PY 2016 VL 6 IS 5 BP 444 EP 451 DI 10.1212/CPJ.0000000000000288 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA EJ3GX UT WOS:000393101700016 ER PT J AU Crnej, A Kheirkhah, A Ren, A Mullins, A Lavric, A Suri, K Hamrah, P Dana, R AF Crnej, Alja Kheirkhah, Ahmad Ren, Ai Mullins, Andrew Lavric, Alenka Suri, Kunal Hamrah, Pedram Dana, Reza TI Patients' Perspectives on Their Dry Eye Disease SO OCULAR SURFACE LA English DT Article DE disease perception; dry eye disease; patient satisfaction ID ILLNESS PERCEPTION QUESTIONNAIRE; PRIMARY SJOGRENS-SYNDROME; QUALITY-OF-LIFE; RHEUMATOID-ARTHRITIS; MYOCARDIAL-INFARCTION; COMMON-SENSE; DEPRESSION; BURDEN; PREVALENCE; DISABILITY AB Purpose: Although it has been known that patients' perspectives on their disease can significantly affect their level of functional disability as well as disease outcome, limited data are available on patients' perceptions of their dry eye disease (DED). The aim of this questionnaire-based study was to evaluate patients' perspectives on their DED. Methods: This cross-sectional study included 91 patients with DED. In addition to clinical evaluation, all patients completed a questionnaire to evaluate their perspectives on their DED. This included their satisfaction with understanding DED, their opinion on the easiness of following doctors' advice, their opinion on the effectiveness of the treatment, their satisfaction with the eye care, and their general outlook on DED. Results: This study included 75 (82%) women and 16 men (18%) with a mean age of 57 +/- 14 years who had been treated for DED for 5.2 +/- 5.4 years. 93% of the patients were satisfied with their understanding of DED, and 76% found it easy to follow their doctors' advice for DED management. Furthermore, 95% thought that the DED treatment had been helpful and 95% were satisfied with their eye care for DED. Forty-eight percent expressed optimism regarding the long-term prospects of their DED. Conclusions: Although the majority of DED patients have positive perspectives on their disease, close to half report a lack of optimism regarding the long-term outlook for their condition. C1 [Crnej, Alja; Kheirkhah, Ahmad; Ren, Ai; Mullins, Andrew; Lavric, Alenka; Suri, Kunal; Hamrah, Pedram; Dana, Reza] Harvard Med Sch, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA USA. RP Dana, R (reprint author), Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA. EM reza_dana@meei.harvard.edu NR 30 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1542-0124 EI 1937-5913 J9 OCUL SURF JI Ocul. Surf. PD OCT PY 2016 VL 14 IS 4 BP 440 EP 446 PG 7 WC Ophthalmology SC Ophthalmology GA EJ3RF UT WOS:000393128600004 PM 27395775 ER PT J AU Kumar, A Burger, IA Zhang, ZG Drill, EN Migliacci, JC Ng, A LaCasce, A Wall, D Witzig, TE Ristow, K Yahalom, J Moskowitz, CH Zelenetz, AD AF Kumar, Anita Burger, Irene A. Zhang, Zhigang Drill, Esther N. Migliacci, Jocelyn C. Ng, Andrea LaCasce, Ann Wall, Darci Witzig, Thomas E. Ristow, Kay Yahalom, Joachim Moskowitz, Craig H. Zelenetz, Andrew D. TI Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes SO HAEMATOLOGICA LA English DT Article ID MEDIASTINAL INVOLVEMENT; RADIATION-THERAPY; TRIAL; ABVD; CHEMOTHERAPY; RADIOTHERAPY; ADENOPATHY; MANAGEMENT; RISK AB Disease bulk is an important prognostic factor in early stage Hodgkin lymphoma, but its definition is unclear in the computed tomography era. This retrospective analysis investigated the prognostic significance of bulky disease measured in transverse and coronal planes on computed tomography imaging. Early stage Hodgkin lymphoma patients (n=185) treated with chemotherapy with or without radiotherapy from 2000-2010 were included. The longest diameter of the largest lymph node mass was measured in transverse and coronal axes on pre-treatment imaging. The optimal cut off for disease bulk was maximal diameter greater than 7 cm measured in either the transverse or coronal plane. Thirty patients with maximal transverse diameter of 7 cm or under were found to have bulk in coronal axis. The 4-year overall survival was 96.5% (CI: 93.3%, 100%) and 4-year relapse-free survival was 86.8% (CI: 81.9%, 92.1%) for all patients. Relapse-free survival at four years for bulky patients was 80.5% (CI: 73%, 88.9%) compared to 94.4% (CI: 89.1%, 100%) for non-bulky; Cox HR 4.21 (CI: 1.43, 12.38) (P=0.004). In bulky patients, relapse-free survival was not impacted in patients treated with chemoradiotherapy; however, it was significantly lower in patients treated with chemotherapy alone. In an independent validation cohort of 38 patients treated with chemotherapy alone, patients with bulky disease had an inferior relapse-free survival [at 4 years, 71.1% (CI: 52.1%, 97%) vs. 94.1% (CI: 83.6%, 100%), Cox HR 5.27 (CI: 0.62, 45.16); P=0.09]. Presence of bulky disease on multidimensional computed tomography imaging is a significant prognostic factor in early stage Hodgkin lymphoma. Coronal reformations may be included for routine Hodgkin lymphoma staging evaluation. In future, our definition of disease bulk may be useful in identifying patients who are most appropriate for chemotherapy alone. C1 [Kumar, Anita; Migliacci, Jocelyn C.; Moskowitz, Craig H.; Zelenetz, Andrew D.] Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA. [Burger, Irene A.] Univ Zurich Hosp, Dept Med Radiol, Zurich, Switzerland. [Zhang, Zhigang; Drill, Esther N.] Mem Sloan Kettering Canc Ctr, Biostat & Epidemiol, 1275 York Ave, New York, NY 10021 USA. [Ng, Andrea] Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA. [Ng, Andrea] Dana Farber Canc Inst, Boston, MA 02115 USA. [LaCasce, Ann] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Wall, Darci; Witzig, Thomas E.; Ristow, Kay] Mayo Clin, Dept Hematol, Rochester, MN USA. [Yahalom, Joachim] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1275 York Ave, New York, NY 10021 USA. RP Kumar, A (reprint author), Mem Sloan Kettering Canc Ctr, Dept Med, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA. EM kumara2@mskcc.org FU Lymphoma Research Foundation; NIH FX This research was supported by the Lymphoma Research Foundation and NIH. NR 27 TC 1 Z9 1 U1 1 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD OCT PY 2016 VL 101 IS 10 BP 1237 EP 1243 DI 10.3324/haematol.2016.141846 PG 7 WC Hematology SC Hematology GA EI5QF UT WOS:000392548700025 PM 27390360 ER PT J AU Nikiforow, S Kim, HT Daley, H Reynolds, C Jones, KT Armand, P Ho, VT Alyea, EP Cutler, CS Ritz, J Antin, JH Soiffer, RJ Koreth, J AF Nikiforow, Sarah Kim, Haesook T. Daley, Heather Reynolds, Carol Jones, Kyle Thomas Armand, Philippe Ho, Vincent T. Alyea, Edwin P., III Cutler, Corey S. Ritz, Jerome Antin, Joseph H. Soiffer, Robert J. Koreth, John TI A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation SO HAEMATOLOGICA LA English DT Article ID GRAFT-VERSUS-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; HOST-DISEASE; ADOPTIVE IMMUNOTHERAPY; MYELOGENOUS LEUKEMIA; PERIPHERAL-BLOOD; MULTIPLE-MYELOMA; SIBLING DONORS; GVHD; RESPONSES AB Donor lymphocyte infusions are used to treat relapse after allogeneic hematopoietic stem cell transplantation, but responses are inadequate. In addition to effector cells, infusions contain CD25(+) regulatory T cells (Treg) that may suppress graft-versus-tumor responses. We undertook a phase I study of donor lymphocyte infusions depleted of CD25(+) T cells in patients with hematologic malignancies who had relapsed after transplantation. Twenty-one subjects received CD25/Treg-depleted infusions following removal of CD25(+) cells using antibody-conjugated magnetic beads. Sixteen subjects received prior cytoreductive therapy. Four were in complete remission at the time of infusion. Two dose levels were administered: 1x10(7) (n=6) and 3x10(7) CD3(+) cells/kg (n=15). A median 2.3 log-depletion of CD4(+)CD25(+)FOXP3(+) Treg was achieved. Seven subjects (33%) developed clinically significant graft-versus-host disease by 1 year, including one patient who died. At dose level 1, five subjects had progressive disease and one had stable disease. At dose level 2, nine subjects (60%) achieved or maintained responses (8 complete responses, 1 partial response), including seven with active disease at the time of infusion. A shorter period between relapse and infusion was associated with response at dose level 2 (P=0.016). The 1-year survival rate was 53% among patients treated with dose level 2. Four of eight subjects with acute myeloid leukemia remained in remission at 1 year. When compared to unmodified donor lymphocyte infusions in 14 contemporaneous patients meeting study eligibility, CD25/Treg depletion was associated with a better response rate and improved event-free survival. Circulating naIve and central memory CD4(+) T cells increased after CD25/Treg-depleted infusion, but no immunophenotypic signature for response was noted. CD25/Tregdepleted donor infusion appears feasible and capable of inducing graft-versus-tumor responses without excessive graft-versus-host disease. (ClinicalTrials.gov NCT#00675831) C1 [Nikiforow, Sarah; Daley, Heather; Reynolds, Carol; Jones, Kyle Thomas; Armand, Philippe; Ho, Vincent T.; Alyea, Edwin P., III; Cutler, Corey S.; Ritz, Jerome; Antin, Joseph H.; Soiffer, Robert J.; Koreth, John] Dana Farber Canc Inst, Dept Med Oncol, Div Hematol Malignancies, Boston, MA 02115 USA. [Nikiforow, Sarah; Armand, Philippe; Ho, Vincent T.; Alyea, Edwin P., III; Cutler, Corey S.; Ritz, Jerome; Antin, Joseph H.; Soiffer, Robert J.; Koreth, John] Harvard Med Sch, Boston, MA 02115 USA. [Kim, Haesook T.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Kim, Haesook T.] Harvard Sch Publ Hlth, Boston, MA USA. RP Nikiforow, S (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Div Hematol Malignancies, Boston, MA 02115 USA.; Nikiforow, S (reprint author), Harvard Med Sch, Boston, MA 02115 USA. EM sarah_nikiforow@dfci.harvard.edu NR 50 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD OCT PY 2016 VL 101 IS 10 BP 1251 EP 1259 DI 10.3324/haematol.2015.141176 PG 9 WC Hematology SC Hematology GA EI5QF UT WOS:000392548700027 PM 27354021 ER PT J AU Kim, HT Zhang, MJ Woolfrey, AE St Martin, A Chen, JF Saber, W Perales, MA Armand, P Eapen, M AF Kim, Haesook T. Zhang, Mei-Jie Woolfrey, Ann E. St Martin, Andrew Chen, Junfang Saber, Wael Perales, Miguel-Angel Armand, Philippe Eapen, Mary TI Donor and recipient sex in allogeneic stem cell transplantation: what really matters SO HAEMATOLOGICA LA English DT Article ID EBMT RISK SCORE; VERSUS-HOST-DISEASE; COMORBIDITY INDEX; H-Y; LEUKEMIA; IMPACT; BLOOD AB We investigated whether and how recipient-donor sex affects transplantation outcomes of 11,797 patients transplanted between 2008 and 2010. Thirty-seven percent were male recipients with male donors, 21% male recipients with female donors, 25% female recipients with male donors, and 17% female recipients with female donors. In multivariable analyses, male recipients had inferior overall survival and progression-free survival compared to females regardless of donor sex, with an 11% relative increase in the hazard of death (P<0.0001) and a 10% relative increase in the hazard of death or relapse (P<0.0001). The detrimental effect of male recipients varied by donor sex. For male recipients with male donors, there was a 12% relative increase in the subdistribution hazard of relapse compared with female recipients with male donors (P=0.0036) and male recipients with female donors (P=0.0037). For male recipients with female donors, there was a 19% relative increase in the subdistribution hazard of non-relapse mortality compared with male recipients with male donors (P<0.0001) and a 22% relative increase compared with female recipients with male donors (P=0.0003). In addition, male recipients with female donors showed a 21% relative increase in the subdistribution hazard of chronic graft-versus-host disease (P<0.0001) compared with female recipients with male donors. Donor sex had no effect on outcomes for female recipients. Transplantation of grafts from male and female donors was associated with inferior overall survival and progression-free survival in male recipients with differing patterns of failure. Recipient sex is an important prognostic factor independent of donor sex. C1 [Kim, Haesook T.] Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA. [Zhang, Mei-Jie] Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA. [Woolfrey, Ann E.] Fred Hutchinson Canc Res Ctr, Dept Med, 1124 Columbia St, Seattle, WA 98104 USA. [St Martin, Andrew; Chen, Junfang; Saber, Wael; Eapen, Mary] Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Perales, Miguel-Angel] Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA. [Armand, Philippe] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Kim, HT (reprint author), Dana Farber Canc Inst, Biostat & Computat Biol, Boston, MA 02115 USA. EM htkimc@jimmy.harvard.edu FU NIAID [U19 AI 29530]; NHLBI from the NCI/NHLBI/ NIAID [PO1 HL 070149, U24-CA76518]; HRSA/DHHS [HHSH234200637015C]; NCI [P01 CA142106] FX This work was supported by U19 AI 29530 from NIAID, PO1 HL 070149 from NHLBI U24-CA76518 from the NCI/NHLBI/ NIAID, HHSH234200637015C (HRSA/DHHS) and P01 CA142106 from the NCI. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health or any other agency of the U.S. Government. NR 24 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD OCT PY 2016 VL 101 IS 10 BP 1260 EP 1266 DI 10.3324/haematol.2016.147645 PG 7 WC Hematology SC Hematology GA EI5QF UT WOS:000392548700028 PM 27354023 ER PT J AU Loschak, PM Degirmenci, A Tenzer, Y Tschabrunn, CM Anter, E Howe, RD AF Loschak, Paul M. Degirmenci, Alperen Tenzer, Yaroslav Tschabrunn, Cory M. Anter, Elad Howe, Robert D. TI A Four Degree of Freedom Robot for Positioning Ultrasound Imaging Catheters SO Journal of Mechanisms and Robotics-Transactions of the ASME LA English DT Article; Proceedings Paper CT 39th ASME Mechanisms and Robotics Conference CY AUG 02-05, 2015 CL Boston, MA SP Amer Soc Mech Engineers AB In this paper, we present the design, fabrication, and testing of a robot for automatically positioning ultrasound (US) imaging catheters. Our system will point US catheters to provide real-time imaging of anatomical structures and working instruments during minimally invasive procedures. Manually navigating US catheters is difficult and requires extensive training in order to aim the US imager at desired targets. Therefore, a four-degree-of-freedom (4DOF) robotic system was developed to automatically navigate US imaging catheters for enhanced imaging. A rotational transmission enables 3DOF for pitch, yaw, and roll of the imager. This transmission is translated by the 4DOF. An accuracy analysis calculated the maximum allowable joint motion error. Rotational joints must be accurate to within 1.5 deg, and the translational joint must be accurate within 1.4 mm. Motion tests then validated the accuracy of the robot. The average resulting errors in positioning of the rotational joints were 0.04-0.22 deg. The average measured backlash was 0.18-0.86 deg. Measurements of average translational positioning and backlash errors were negligible. The resulting joint motion errors were well within the required specifications for accurate robot motion. The output of the catheter was then tested to verify the effectiveness of the handle motions to transmit torques and translations to the catheter tip. The catheter tip was navigated to desired target poses with average error 1.3 mm and 0.71 deg. Such effective manipulation of US imaging catheters will enable better visualization in various procedures ranging from cardiac arrhythmia treatment to tumor removal in urological cases. C1 [Loschak, Paul M.; Degirmenci, Alperen; Tenzer, Yaroslav; Howe, Robert D.] Harvard Univ, Paulson Sch Engn & Appl Sci, Harvard Biorobot Lab, Cambridge, MA 02138 USA. [Tschabrunn, Cory M.; Anter, Elad] Beth Israel Deaconess Med Ctr, Div Cardiovasc Med, Expt Electrophysiol, Boston, MA 02215 USA. RP Loschak, PM (reprint author), Harvard Univ, Paulson Sch Engn & Appl Sci, Harvard Biorobot Lab, Cambridge, MA 02138 USA. EM loschak@seas.harvard.edu; adegirmenci@seas.harvard.edu; ytenzer@seas.harvard.edu; cory.tschabrunn@bidmc.harvard.edu; eanter@bidmc.harvard.edu; howe@seas.harvard.edu OI Loschak, Paul/0000-0003-2202-417X FU Harvard School of Engineering and Applied Sciences, American Heart Association [15PRE22710043]; NIH [1R21EB018938] FX This work was supported by the Harvard School of Engineering and Applied Sciences, American Heart Association Grant #15PRE22710043, and NIH Grant #1R21EB018938. NR 16 TC 0 Z9 0 U1 1 U2 1 PU ASME PI NEW YORK PA TWO PARK AVE, NEW YORK, NY 10016-5990 USA SN 1942-4302 EI 1942-4310 J9 J MECH ROBOT JI J. Mech. Robot. PD OCT PY 2016 VL 8 IS 5 SI SI AR 051016 DI 10.1115/1.4032249 PG 9 WC Engineering, Mechanical; Robotics SC Engineering; Robotics GA EI9ZZ UT WOS:000392869400018 ER PT J AU Mak, RH Hunt, D Efstathiou, JA Heney, NM Jones, CU Lukka, HR Bahary, JP Patel, M Balogh, A Nabid, A Leibenhaut, MH Hamstra, DA Roof, KS Lee, RJ Gore, EM Sandler, HM Shipley, WU AF Mak, Raymond H. Hunt, Daniel Efstathiou, Jason A. Heney, Niall M. Jones, Christopher U. Lukka, Himu R. Bahary, Jean-Paul Patel, Malti Balogh, Alexander Nabid, Abdenour Leibenhaut, Mark H. Hamstra, Daniel A. Roof, Kevin S. Lee, Robert Jeffrey Gore, Elizabeth M. Sandler, Howard M. Shipley, William U. TI Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01 SO UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS LA English DT Article DE Primary prostate cancer radiation therapy; Postprostatectomy radiation; Urinary toxicity ID CONFORMAL RADIOTHERAPY; LATE COMPLICATIONS; COMPETING RISK; 78 GY; CANCER; THERAPY; TRIAL; SEQUELAE; TOLERANCE; CARCINOMA AB Introduction: To estimate the contribution of the prostate gland and prostatic urethral inflammation to urinary symptoms after radiation therapy for prostate cancer, we performed a secondary analysis of urinary toxicity after primary radiation to an intact prostate vs. postprostatectomy radiation to the prostatic fossa in protocols RTOG 94-08 and 96-01, respectively. Materials and methods: Patients randomized to the radiation-alone arms (without hormone therapy) of the 2 trials were evaluated, including 104 men receiving primary prostate radiation to 68.4Gy on RTOG 94-08 and 371 men receiving 64.8Gy to the prostatic fossa on RTOG 96-01. Acute and late urinary toxicity were scored prospectively by RTOG scales. Chi-square test/logistic regression and cumulative incidence approach/Fine-Gray regression model were used for analyses of acute and late toxicity, respectively. Results: Grade >= 2 acute urinary toxicity was significantly higher after primary prostatic radiation compared with postprostatectomy radiation (30.8% vs. 14.0%; P < 0.001), but acute grade >= 3 toxicity did not differ (3.8% vs. 2.7%; P = 0.54). After adjusting for age, primary radiation resulted in significantly higher grade >= 2 acute urinary toxicity (odds ratio = 3.72; 95% CI: 1.65-8.37; P = 0.02). With median follow-up of 7.1 years, late urinary toxicity was not significantly different with primary vs. postprostatectomy radiation (5-year grade >= 2: 16.7% vs. 18.3%; P = 0.65; grade >= 3: 6.0% vs. 3.3%; P = 0.24). Conclusions: Primary radiation to an intact prostate resulted in higher grade=2 acute urinary toxicity than radiation to the prostatic fossa, with no difference in late urinary toxicity. Thus, a proportion of acute urinary toxicity in men with an intact prostate may be attributable to inflammation of the prostatic gland or urethra. Copyright (C) 2016 Elsevier Inc. All rights reserved. C1 [Mak, Raymond H.] Dana Farber Brigham & Womens Canc Ctr, Harvard Radiat Oncol Program, Boston, MA USA. [Hunt, Daniel] NRG Oncol Stat & Data Management Ctr, Philadelphia, PA USA. [Efstathiou, Jason A.; Shipley, William U.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. [Heney, Niall M.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Urol, Boston, MA USA. [Jones, Christopher U.; Leibenhaut, Mark H.] Sutter Canc Res Consortium, Roseville, CA USA. [Lukka, Himu R.; Patel, Malti] Hamilton Hlth Sci, Juravinski Canc Ctr, Div Radiat Oncol, Hamilton, ON, Canada. [Bahary, Jean-Paul] CHUM Hosp Notre Dame, Dept Radiat Oncol, Montreal, PQ, Canada. [Balogh, Alexander] Tom Baker Canc Clin, Div Radiat Oncol, Calgary, AB, Canada. [Nabid, Abdenour] Ctr Hosp Univ Sherbrooke Fleurimont, Dept Nucl Med & Radiobiol, Sherbrooke, PQ, Canada. [Hamstra, Daniel A.] Univ Michigan Hlth Syst, Canc Ctr, Dept Radiat Oncol, Ann Arbor, MI USA. [Roof, Kevin S.] Southeast Canc Control Consortium Inc, CCOP, Winston Salem, NC USA. [Lee, Robert Jeffrey] Intermt Med Ctr, Murray, UT USA. [Gore, Elizabeth M.] Froedtert, Dept Radiat Oncol, Milwaukee, WI USA. [Gore, Elizabeth M.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Sandler, Howard M.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Radiat Oncol, Los Angeles, CA 90048 USA. EM wshipley@partners.org FU National Cancer Institute (NCI), United States [U10CA21661, U10CA180868, U10CA18082]; AstraZeneca, United Kingdom [RTOG9601] FX This project was supported by Grant nos. U10CA21661, U10CA180868, and U10CA18082 from the National Cancer Institute (NCI), United States and AstraZeneca, United Kingdom (RTOG9601). NR 27 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1078-1439 EI 1873-2496 J9 UROL ONCOL-SEMIN ORI JI Urol. Oncol.-Semin. Orig. Investig. PD OCT PY 2016 VL 34 IS 10 DI 10.1016/j.urolonc.2016.04.015 PG 7 WC Oncology; Urology & Nephrology SC Oncology; Urology & Nephrology GA EI6XJ UT WOS:000392640600003 ER PT J AU Sheikhzadeh, P Sabet, H Ghadiri, H Geramifar, P Mahani, H Ghafarian, P Ay, M AF Sheikhzadeh, P. Sabet, H. Ghadiri, H. Geramifar, P. Mahani, H. Ghafarian, P. Ay, M. TI Performance characteristics of NeuroPET system using GATE Monte Carlo simulation SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING LA English DT Meeting Abstract CT Annual Congress of the European-Association-of-Nuclear-Medicine (EANM) CY OCT 15-19, 2016 CL Barcelona, SPAIN SP European Assoc Nucl Med C1 [Sheikhzadeh, P.; Ghadiri, H.; Ay, M.] Univ Tehran Med Sci, Dept Med Phys & Biomed Engn, Tehran, Iran. [Sheikhzadeh, P.; Ghadiri, H.; Mahani, H.; Ay, M.] Univ Tehran Med Sci, Res Ctr Mol & Cellular Imaging, Tehran, Iran. [Sabet, H.] Harvard Med Sch, Massachusetts Gen Hosp, Charlestown, MA USA. [Geramifar, P.] Univ Tehran Med Sci, Shariati Hosp, Res Ctr Nucl Med, Tehran, Iran. [Mahani, H.] Nucl Sci & Technol Res Inst, Radiat Applicat Res Sch, Tehran, Iran. [Ghafarian, P.] Shahid Beheshti Univ Med Sci, Natl Res Inst TB & Lung Dis NRITLD, Chron Resp Dis Res Ctr, Tehran, Iran. [Ghafarian, P.] Shahid Beheshti Univ Med Sci, Masih Daneshvari Hosp, PET CT & Cyclotron Ctr, Tehran, Iran. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1619-7070 EI 1619-7089 J9 EUR J NUCL MED MOL I JI Eur. J. Nucl. Med. Mol. Imaging PD OCT PY 2016 VL 43 SU 1 MA EP769 BP S512 EP S513 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EH5HF UT WOS:000391802500035 ER PT J AU Kamran, SC Jacene, HA Chen, YH Mauch, PM Ng, AK AF Kamran, S. C. Jacene, H. A. Chen, Y. -H. Mauch, P. M. Ng, A. K. TI CLINICAL OUTCOME OF PATIENTS WITH EARLY STAGE FAVORABLE HODGKIN LYMPHOMA TREATED WITH ABVDX2 CYCLES FOLLOWED BY PET/CT RESTAGING AND 20 GY OF INVOLVED-SITE RADIOTHERAPY SO HAEMATOLOGICA LA English DT Meeting Abstract CT 10th International Symposium on Hodgkin Lymphoma CY OCT 22-25, 2016 CL Cologne, GERMANY C1 [Kamran, S. C.] Brigham & Womens Hosp, Dana Farber Canc Inst, Harvard Radiat Oncol Program, 75 Francis St, Boston, MA 02115 USA. [Jacene, H. A.] Brigham & Womens Hosp, Dept Radiol, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. [Chen, Y. -H.] Brigham & Womens Hosp, Dept Biostat & Computat Biol, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. [Mauch, P. M.; Ng, A. K.] Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD OCT PY 2016 VL 101 SU 5 MA P051 BP 14 EP 14 PG 1 WC Hematology SC Hematology GA EI5QI UT WOS:000392549000036 ER PT J AU Pilichowska, M Pittaluga, S Ferry, JA Hemminger, J Gupta, G Kritharis, A Gascoyne, RD Evens, AM Jaffe, ES AF Pilichowska, M. Pittaluga, S. Ferry, J. A. Hemminger, J. Gupta, G. Kritharis, A. Gascoyne, R. D. Evens, A. M. Jaffe, E. S. TI GRAY ZONE LYMPHOMA WITH FEATURES INTERMEDIATE BETWEEN DIFFUSE LARGE B-CELL LYMPHOMA AND CLASSICAL HODGKIN LYMPHOMA: DIAGNOSTIC EXPERIENCES AND CHALLENGES FROM A MULTICENTER STUDY SO HAEMATOLOGICA LA English DT Meeting Abstract CT 10th International Symposium on Hodgkin Lymphoma CY OCT 22-25, 2016 CL Cologne, GERMANY C1 [Pilichowska, M.; Gupta, G.] Tufts Med Ctr, Dept Pathol, Boston, MA USA. [Pittaluga, S.; Jaffe, E. S.] NCI, Pathol Lab, Ctr Canc Res, Bethesda, MD 20892 USA. [Ferry, J. A.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Hemminger, J.] Ohio State Univ, Dept Pathol, Wexner Med Ctr, Columbus, OH 43210 USA. [Kritharis, A.; Evens, A. M.] Tufts Med Ctr, Div Hematol Oncol, Boston, MA USA. [Gascoyne, R. D.] British Columbia Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC, Canada. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD OCT PY 2016 VL 101 SU 5 MA P004 BP 21 EP 22 PG 2 WC Hematology SC Hematology GA EI5QI UT WOS:000392549000050 ER PT J AU Henderson, TO Parsons, SK Wroblewski, K Chen, L Hong, F Smith, S McNeer, J Advani, R Gascoyne, RD Constine, LS Horning, S Bartlett, NL Shah, B Connors, JM Leonard, J Kahl, BS Kelly, K Schwartz, CL Friedman, D Gordon, LI Evens, AM AF Henderson, T. O. Parsons, S. K. Wroblewski, K. Chen, L. Hong, F. Smith, S. McNeer, J. Advani, R. Gascoyne, R. D. Constine, L. S. Horning, S. Bartlett, N. L. Shah, B. Connors, J. M. Leonard, J. Kahl, B. S. Kelly, K. Schwartz, C. L. Friedman, D. Gordon, L. I. Evens, A. M. TI OUTCOMES IN ADOLESCENTS AND YOUNG ADULTS WITH HODGKIN LYMPHOMA TREATED ON US COOPERATIVE GROUP PROTOCOLS: AN ADULT INTERGROUP (E2496) AND CHILDREN'S ONCOLOGY GROUP (COG AHOD0031) COMPARATIVE ANALYSIS SO HAEMATOLOGICA LA English DT Meeting Abstract CT 10th International Symposium on Hodgkin Lymphoma CY OCT 22-25, 2016 CL Cologne, GERMANY C1 [Henderson, T. O.; McNeer, J.] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA. [Parsons, S. K.; Evens, A. M.] Tufts Univ, Sch Med, Tufts Med Ctr, Boston, MA 02111 USA. [Wroblewski, K.] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA. [Chen, L.] Childrens Oncol Grp, Acadia, CA USA. [Hong, F.] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA. [Smith, S.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA. [Advani, R.] Stanford Univ, Palo Alto, CA 94304 USA. [Gascoyne, R. D.; Connors, J. M.] BC Canc Agcy, Vancouver, BC, Canada. [Constine, L. S.] Univ Rochester, Dept Radiat Oncol, Rochester, NY USA. [Constine, L. S.] Univ Rochester, Dept Pediat, Rochester, NY USA. [Horning, S.] Genentech Inc, San Francisco, CA USA. [Bartlett, N. L.; Kahl, B. S.] Washington Univ, Sch Med, St Louis, MO USA. [Shah, B.] H Lee Moffitt Canc Ctr & Res Inst, Madison, WI USA. [Leonard, J.] Cornell Weill Sch Med, Dept Med, New York, NY USA. [Kelly, K.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Schwartz, C. L.] Univ Texas MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA. [Friedman, D.] Vanderbilt Univ, Dept Pediat, Nashville, TN USA. [Gordon, L. I.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD OCT PY 2016 VL 101 SU 5 MA T018 BP 34 EP 35 PG 2 WC Hematology SC Hematology GA EI5QI UT WOS:000392549000083 ER PT J AU Zinzani, PL Engert, A Younes, A Santoro, A Ansell, S Timmerman, J Collins, G Armand, P Savage, KJ Trneny, M Fanale, M Kuruvilla, J Cohen, JB Shipp, M Rodig, S Kato, K Sumbul, A Farsaci, BA Ratanatharathorn, V AF Zinzani, P. L. Engert, A. Younes, A. Santoro, A. Ansell, S. Timmerman, J. Collins, G. Armand, P. Savage, K. J. Trneny, M. Fanale, M. Kuruvilla, J. Cohen, J. B. Shipp, M. Rodig, S. Kato, K. Sumbul, A. Farsaci, B. A. Ratanatharathorn, V. TI CHECKMATE 205 COHORT C: NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA AFTER PRIOR BRENTUXIMAB VEDOTIN AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION SO HAEMATOLOGICA LA English DT Meeting Abstract CT 10th International Symposium on Hodgkin Lymphoma CY OCT 22-25, 2016 CL Cologne, GERMANY C1 [Zinzani, P. L.] Univ Bologna, Inst Hematol L&A Seragnoli, Bologna, Italy. [Engert, A.] Univ Hosp Cologne, Cologne, Germany. [Younes, A.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. [Santoro, A.] Humanitas Univ, Humanitas Canc Ctr, Rozzano, MI, Italy. [Ansell, S.] Mayo Clin, Rochester, MN USA. [Timmerman, J.] Univ Calif Los Angeles, Los Angeles, CA USA. [Collins, G.] Churchill Hosp, Oxford Canc & Haematol Ctr, Oxford, England. [Armand, P.; Shipp, M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Savage, K. J.] British Columbia Canc Agcy, Vancouver, BC, Canada. [Trneny, M.] Charles Univ Prague, Prague, Czech Republic. [Trneny, M.] Gen Univ Hosp Prague, Prague, Czech Republic. [Fanale, M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Kuruvilla, J.] Univ Toronto, Toronto, ON, Canada. [Kuruvilla, J.] Princess Margaret Canc Ctr, Toronto, ON, Canada. [Cohen, J. B.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA. [Rodig, S.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Kato, K.; Sumbul, A.; Farsaci, B. A.] Bristol Myers Squibb, Princeton, NJ USA. [Ratanatharathorn, V.] Barbara Ann Karmanos Canc Inst, Detroit, MI USA. FU BMS FX BMS. Medical writing: Caudex, funded by BMS. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD OCT PY 2016 VL 101 SU 5 MA T022 BP 43 EP 44 PG 2 WC Hematology SC Hematology GA EI5QI UT WOS:000392549000103 ER PT J AU Diefenbach, CSM Hong, F Ambinder, RF Cohen, JB Robertson, MJ Fenske, TS Advani, R Kahl, BS Ansell, S AF Diefenbach, C. S. M. Hong, F. Ambinder, R. F. Cohen, J. B. Robertson, M. J. Fenske, T. S. Advani, R. Kahl, B. S. Ansell, S. TI A PHASE I STUDY WITH AN EXPANSION COHORT OF THE COMBINATION OF IPILIMUMAB AND BRENTUXIMAB VEDOTIN IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A TRIAL OF THE ECOG-ACRIN CANCER RESEARCH GROUP (E4412) SO HAEMATOLOGICA LA English DT Meeting Abstract CT 10th International Symposium on Hodgkin Lymphoma CY OCT 22-25, 2016 CL Cologne, GERMANY C1 [Diefenbach, C. S. M.] NYU, Perlmutter Canc Ctr, New York, NY USA. [Hong, F.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Ambinder, R. F.] Johns Hopkins Univ, Baltimore, MD USA. [Cohen, J. B.] Emory Univ, Atlanta, GA 30322 USA. [Robertson, M. J.] Indiana Univ Hosp, 550 N Univ Blvd, Indianapolis, IN 46202 USA. [Fenske, T. S.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. [Advani, R.] Stanford Univ, Stanford, CA 94305 USA. [Kahl, B. S.] Washington Univ, St Louis, MO USA. [Ansell, S.] Mayo Clin, Rochester, MN USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD OCT PY 2016 VL 101 SU 5 MA P080 BP 44 EP 45 PG 2 WC Hematology SC Hematology GA EI5QI UT WOS:000392549000106 ER PT J AU Moskowitz, C Zinzani, PL Fanale, MA Armand, P Johnson, N Ribrag, V Radford, J von Tresckow, B Tomita, A Shipp, M Wang, Y Ricart, AD Balakumaran, A Chen, R AF Moskowitz, C. Zinzani, P. L. Fanale, M. A. Armand, P. Johnson, N. Ribrag, V. Radford, J. von Tresckow, B. Tomita, A. Shipp, M. Wang, Y. Ricart, A. D. Balakumaran, A. Chen, R. TI PEMBROLIZUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: MULTICOHORT, PHASE 2 KEYNOTE-087 STUDY SO HAEMATOLOGICA LA English DT Meeting Abstract CT 10th International Symposium on Hodgkin Lymphoma CY OCT 22-25, 2016 CL Cologne, GERMANY C1 [Moskowitz, C.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. [Zinzani, P. L.] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy. [Fanale, M. A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Armand, P.; Shipp, M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Johnson, N.] Jewish Gen Hosp, Montreal, PQ, Canada. [Ribrag, V.] Gustave Roussy, Villejuif, France. [Radford, J.] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England. [von Tresckow, B.] Uniklin Koln, Cologne, Germany. [Tomita, A.] Fujita Hlth Univ, Sch Med, Toyoake, Aichi, Japan. [Tomita, A.] Nagoya Univ, Toyoake, Aichi, Japan. [Wang, Y.; Ricart, A. D.; Balakumaran, A.] Merck & Co Inc, Kenilworth, NJ USA. [Chen, R.] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA. FU BMS FX BMS. Medical writing: Caudex, funded by BMS. NR 0 TC 0 Z9 0 U1 1 U2 1 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD OCT PY 2016 VL 101 SU 5 MA T023 BP 44 EP 44 PG 1 WC Hematology SC Hematology GA EI5QI UT WOS:000392549000104 ER PT J AU LaCasce, A Bociek, G Sawas, A Caimi, P Agura, E Matous, J Ansell, S Crosswell, H Islas-Ohlmayer, M Behler, C Cheung, E Forero-Torres, A Vose, J O'Connor, OA Josephson, N Advani, R AF LaCasce, A. Bociek, G. Sawas, A. Caimi, P. Agura, E. Matous, J. Ansell, S. Crosswell, H. Islas-Ohlmayer, M. Behler, C. Cheung, E. Forero-Torres, A. Vose, J. O'Connor, O. A. Josephson, N. Advani, R. TI BRENTUXIMAB VEDOTIN PLUS BENDAMUSTINE AS A SALVAGE TREATMENT REGIMEN FOR PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA SO HAEMATOLOGICA LA English DT Meeting Abstract CT 10th International Symposium on Hodgkin Lymphoma CY OCT 22-25, 2016 CL Cologne, GERMANY C1 [LaCasce, A.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bociek, G.; Vose, J.] Univ Nebraska Med Ctr, Omaha, NE USA. [Sawas, A.; O'Connor, O. A.] Columbia Univ, Med Ctr, New York, NY USA. [Caimi, P.] Univ Hosp Case Med Ctr, Cleveland, OH USA. [Agura, E.] Charles A Sammons Canc Ctr, Dallas, TX USA. [Matous, J.] Colorado Blood Canc Inst, Denver, CO USA. [Ansell, S.] Mayo Clin, Rochester, MN USA. [Crosswell, H.] St Francis Hosp, Greenville, SC USA. [Islas-Ohlmayer, M.] Jewish Hosp Mercy Hlth, Cincinnati, OH USA. [Behler, C.] Pacific Hematol Oncol Associates, San Francisco, CA USA. [Cheung, E.] Oncol Inst Hope & Innovat, Whittier, CA USA. [Forero-Torres, A.] Univ Alabama Birmingham, Birmingham, AL USA. [Josephson, N.] Seattle Genet Inc, Bothell, WA USA. [Advani, R.] Stanford Canc Inst, Stanford, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD OCT PY 2016 VL 101 SU 5 MA P082 BP 45 EP 46 PG 2 WC Hematology SC Hematology GA EI5QI UT WOS:000392549000108 ER PT J AU Ansell, S Armand, P Timmerman, J Shipp, M Mckiver, MP Zhu, L Lesokhin, AM AF Ansell, S. Armand, P. Timmerman, J. Shipp, M. Mckiver, M. Popa Zhu, L. Lesokhin, A. M. TI NIVOLUMAB RE-TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA: SAFETY AND EFFICACY OUTCOMES FROM A PHASE 1 CLINICAL TRIAL SO HAEMATOLOGICA LA English DT Meeting Abstract CT 10th International Symposium on Hodgkin Lymphoma CY OCT 22-25, 2016 CL Cologne, GERMANY C1 [Ansell, S.] Mayo Clin, Rochester, MN USA. [Armand, P.; Shipp, M.] Harvard Med Sch, Dana Faber Canc Inst, Boston, MA USA. [Timmerman, J.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, LA USA. [Mckiver, M. Popa; Zhu, L.] Bristol Myers Squibb Co, Princeton, NJ USA. [Lesokhin, A. M.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. [Lesokhin, A. M.] Weill Cornell Med Coll, New York, NY USA. FU Bristol-Myers Squibb FX Bristol-Myers Squibb. NR 3 TC 0 Z9 0 U1 0 U2 0 PU FERRATA STORTI FOUNDATION PI PAVIA PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY SN 0390-6078 J9 HAEMATOLOGICA JI Haematologica PD OCT PY 2016 VL 101 SU 5 MA P090 BP 49 EP 49 PG 1 WC Hematology SC Hematology GA EI5QI UT WOS:000392549000116 ER PT J AU Besner, S Scarcelli, G Pineda, R Yun, SH AF Besner, Sebastien Scarcelli, Giuliano Pineda, Roberto Yun, Seok-Hyun TI In Vivo Brillouin Analysis of the Aging Crystalline Lens SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE lens; biomechanics; Brillouin microscopy ID AGE-RELATED-CHANGES; REFRACTIVE-INDEX DISTRIBUTION; EYE LENS; MECHANICAL-PROPERTIES; OPTICAL MICROSCOPY; GAMMA-CRYSTALLINS; PRESBYOPIA; ACCOMMODATION; SPECTROSCOPY; SHAPE AB PURPOSE. To analyze the age dependence of the longitudinal modulus of the crystalline lens in vivo using Brillouin scattering data in healthy subjects. METHODS. Brillouin scans were performed along the crystalline lens in 56 eyes from 30 healthy subjects aged from 19 to 63 years. Longitudinal elastic modulus was acquired along the sagittal axis of the lens with a transverse and axial resolution of 4 and 60 mu m, respectively. The relative lens stiffness was computed, and correlations with age were analyzed. RESULTS. Brillouin axial profiles revealed nonuniform longitudinal modulus within the lens, increasing from a softer periphery toward a stiffer central plateau at all ages. The longitudinal modulus at the central plateau showed no age dependence in a range of 19 to 45 years and a slight decrease with age from 45 to 63 years. A significant intersubject variability was observed in an age-matched analysis. Importantly, the extent of the central stiff plateau region increased steadily over age from 19 to 63 years. The slope of change in Brillouin modulus in the peripheral regions were nearly age-invariant. CONCLUSIONS. The adult human lens showed no measurable age-related increase in the peak longitudinal modulus. The expansion of the stiff central region of the lens is likely to be the major contributing factor to age-related lens stiffening. Brillouin microscopy may be useful in characterizing the crystalline lens for the optimization of surgical or pharmacological treatments aimed at restoring accommodative power. C1 [Besner, Sebastien; Scarcelli, Giuliano; Yun, Seok-Hyun] Massachusetts Gen Hosp, Wellman Ctr Photomed, Cambridge, MA USA. [Besner, Sebastien; Scarcelli, Giuliano; Yun, Seok-Hyun] Harvard Med Sch, Dept Dermatol, Boston, MA USA. [Scarcelli, Giuliano] Univ Maryland, Fischell Dept Bioengn, College Pk, MD 20742 USA. [Pineda, Roberto] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA. [Yun, Seok-Hyun] Harvard MIT Hlth Sci & Technol, Cambridge, MA USA. RP Scarcelli, G; Yun, SH (reprint author), 65 Landsdowne St, Cambridge, MA 02139 USA. EM scarc@umd.edu; syun@hms.harvard.edu FU National Institutes of Health [R01EY025454, R21EY023043]; Harvard Catalyst Incubator program [UL1-RR025758]; National Science Foundation [CBET-1562863, CMMI-1537027]; MGH Research Scholar award program; Natural Sciences and Engineering Research Council of Canada (NSERC) postdoctoral fellowship FX Supported by the National Institutes of Health (R01EY025454 and R21EY023043), Harvard Catalyst Incubator program (UL1-RR025758), National Science Foundation (CBET-1562863 and CMMI-1537027), MGH Research Scholar award program, and the Natural Sciences and Engineering Research Council of Canada (NSERC) postdoctoral fellowship (to SB). NR 57 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD OCT PY 2016 VL 57 IS 13 BP 5093 EP 5100 DI 10.1167/iovs.16-20143 PG 8 WC Ophthalmology SC Ophthalmology GA EI4ND UT WOS:000392469600001 PM 27699407 ER PT J AU Nair, P Aiello, LP Gardner, TW Jampol, LM Ferris, FL AF Nair, Prashant Aiello, Lloyd Paul Gardner, Thomas W. Jampol, Lee M. Ferris, Frederick L., III TI Report From the NEI/FDA Diabetic Retinopathy Clinical Trial Design and Endpoints Workshop SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Editorial Material ID MACULAR EDEMA; INTRAVITREAL TRIAMCINOLONE; EXPLORATORY ANALYSIS; UNITED-STATES; BASE-LINE; PROGRESSION; RANIBIZUMAB; RISK; PREVALENCE; SEVERITY C1 [Aiello, Lloyd Paul] Joslin Diabet Ctr, Boston, MA 02215 USA. [Gardner, Thomas W.] Univ Michigan, Ann Arbor, MI 48109 USA. [Jampol, Lee M.] Northwestern Univ, Chicago, IL 60611 USA. [Ferris, Frederick L., III] NEI, Bethesda, MD 20892 USA. RP Ferris, FL (reprint author), NEI, NIH, Bethesda, MD 20892 USA. EM ferrisf@nei.nih.gov NR 22 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD OCT PY 2016 VL 57 IS 13 BP 5127 EP 5142 DI 10.1167/iovs.16-20356 PG 16 WC Ophthalmology SC Ophthalmology GA EI4ND UT WOS:000392469600005 PM 27699406 ER PT J AU Rosenthal, P Borsook, D Moulton, EA AF Rosenthal, Perry Borsook, David Moulton, Eric A. TI Oculofacial Pain: Corneal Nerve Damage Leading to Pain Beyond the Eye SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE neuropathic; keratomileusis; CNS; migraine; dry eye; referred pain ID CHRONIC DRY EYE; NEUROPATHIC PAIN; SUBNUCLEUS CAUDALIS; PHOTOPHOBIA; MIGRAINE; LIGHT; HYPERALGESIA; MECHANISMS; SYMPTOMS; PATHWAYS AB The cornea is supplied principally by the ophthalmic branch of the trigeminal nerve and is the most densely innervated organ in the human body. Under normal conditions, the corneal nerve terminals incorporate sensors that monitor the thickness and integrity of the tear film, which are essential for meaningful vision. A disrupted tear film or direct noxious stimulation of these corneal nerves can produce discomfort or pain limited to the affected surface. Damage to these nerves can sometimes lead to a chronic neuropathic condition, where pain persists months following the initial insult, long after the nerves appear to have healed in the cornea itself following treatment. Neuropathic pain appears to persist indefinitely in a few patients. C1 [Rosenthal, Perry] Boston EyePain Fdn, Chestnut Hill, MA USA. [Borsook, David; Moulton, Eric A.] Harvard Med Sch, McLean Hosp, Massachusetts Gen Hosp, Ctr Pain & Brain,Boston Childrens Hosp, Boston, MA USA. [Borsook, David; Moulton, Eric A.] Boston Childrens Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA. RP Rosenthal, P (reprint author), Boston Eye Fdn, 629 Hammond St,Suite 205E, Chestnut Hill, MA 02467 USA. EM prosenthal@bostoneyepain.org FU National Institutes of Health, Bethesda, Maryland, United States [5K24NS064050-09, 4R01NS075018-05, 5R01NS073997-06, 5R01NS095655-02, 5R21CA185870-02]; Migraine Research Foundation (New York, NY, USA); Mayday Foundation (New York, NY, USA); Boston EyePain Foundation (Boston, MA, USA) FX Supported by the National Institutes of Health, Bethesda, Maryland, United States (Grants 5K24NS064050-09, 4R01NS075018-05, 5R01NS073997-06, 5R01NS095655-02 [DB] and Grant 5R21CA185870-02 [EAM]) and by funding from the Migraine Research Foundation (New York, NY, USA), the Mayday Foundation (New York, NY, USA), and the Boston EyePain Foundation (Boston, MA, USA). NR 29 TC 0 Z9 0 U1 2 U2 2 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD OCT PY 2016 VL 57 IS 13 BP 5285 EP 5287 DI 10.1167/iovs.16-20557 PG 3 WC Ophthalmology SC Ophthalmology GA EI4ND UT WOS:000392469600025 PM 27723896 ER PT J AU Tsikata, E Lee, R Shieh, E Simavli, H Que, CJ Guo, R Khoueir, Z de Boer, J Chen, TC AF Tsikata, Edem Lee, Ramon Shieh, Eric Simavli, Huseyin Que, Christian J. Guo, Rong Khoueir, Ziad de Boer, Johannes Chen, Teresa C. TI Comprehensive Three-Dimensional Analysis of the Neuroretinal Rim in Glaucoma Using High-Density Spectral-Domain Optical Coherence Tomography Volume Scans SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE glaucoma; spectral-domain optical coherence tomography; optic disc; optic nerve; neuroretinal rim ID NERVE-FIBER LAYER; DIAGNOSTIC CAPABILITY; HEAD PARAMETERS; THICKNESS; REPRODUCIBILITY; ACCURACY; DESIGN; WIDTH; AREA; BIAS AB PURPOSE. To describe spectral-domain optical coherence tomography (OCT) methods for quantifying neuroretinal rim tissue in glaucoma and to compare these methods to the traditional retinal nerve fiber layer thickness diagnostic parameter. METHODS. Neuroretinal rim parameters derived from three-dimensional (3D) volume scans were compared with the two-dimensional (2D) Spectralis retinal nerve fiber layer (RNFL) thickness scans for diagnostic capability. This study analyzed one eye per patient of 104 glaucoma patients and 58 healthy subjects. The shortest distances between the cup surface and the OCT-based disc margin were automatically calculated to determine the thickness and area of the minimum distance band (MDB) neuroretinal rim parameter. Traditional 150-lm reference surface-based rim parameters (volume, area, and thickness) were also calculated. The diagnostic capabilities of these five parameters were compared with RNFL thickness using the area under the receiver operating characteristic (AUROC) curves. RESULTS. The MDB thickness had significantly higher diagnostic capability than the RNFL thickness in the nasal (0.913 vs. 0.818, P = 0.004) and temporal (0.922 vs. 0.858, P = 0.026) quadrants and the inferonasal (0.950 vs. 0.897, P = 0.011) and superonasal (0.933 vs. 0.868, P = 0.012) sectors. The MDB area and the three neuroretinal rim parameters based on the 150-mu m reference surface had diagnostic capabilities similar to RNFL thickness. CONCLUSIONS. The 3D MDB thickness had a high diagnostic capability for glaucoma and may be of significant clinical utility. It had higher diagnostic capability than the RNFL thickness in the nasal and temporal quadrants and the inferonasal and superonasal sectors. C1 [Tsikata, Edem; Simavli, Huseyin; Que, Christian J.; Khoueir, Ziad; Chen, Teresa C.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA. [Tsikata, Edem; Lee, Ramon; Shieh, Eric; Simavli, Huseyin; Que, Christian J.; Khoueir, Ziad; Chen, Teresa C.] Harvard Med Sch, Boston, MA USA. [Simavli, Huseyin] Pamukkale Univ Hastanesi, Denizli, Turkey. [Guo, Rong] Massachusetts Eye & Ear Infirm, Biostat, Boston, MA 02114 USA. [de Boer, Johannes] Vrije Univ Amsterdam, LaserLaB Amsterdam, Dept Phys & Astron, Amsterdam, Netherlands. [de Boer, Johannes] Vrije Univ Amsterdam, Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands. RP Chen, TC (reprint author), Massachusetts Eye & Ear Infirm, Glaucoma Serv, 243 Charles St, Boston, MA 02114 USA. EM teresa_chen@meei.harvard.edu OI Simavli, Huseyin/0000-0003-1657-9099 FU Fidelity Charitable Fund (Harvard University); Massachusetts Lions Eye Research Fund; American Glaucoma Society Mid-Career Award; National Institutes of Health [UL 1 RR025758] FX Funded by the Fidelity Charitable Fund (Harvard University), the Massachusetts Lions Eye Research Fund, an American Glaucoma Society Mid-Career Award, and National Institutes of Health UL 1 RR025758. NR 40 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD OCT PY 2016 VL 57 IS 13 BP 5498 EP 5508 DI 10.1167/iovs.16-19802 PG 11 WC Ophthalmology SC Ophthalmology GA EI4ND UT WOS:000392469600057 PM 27768203 ER PT J AU Iafe, NA Phasukkijwatana, N Chen, XJ Sarraf, D AF Iafe, Nicholas A. Phasukkijwatana, Nopasak Chen, Xuejing Sarraf, David TI Retinal Capillary Density and Foveal Avascular Zone Area Are Age-Dependent: Quantitative Analysis Using Optical Coherence Tomography Angiography SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Article DE foveal avascular zone; OCT angiography; OCTA; optical coherence tomography angiography; retinal capillary plexus ID ACUTE MIDDLE MACULOPATHY; MACULAR DEGENERATION; NONINVASIVE VISUALIZATION; FLUORESCEIN ANGIOGRAPHY; DIABETIC-RETINOPATHY; MOTION CORRECTION; VASCULAR DENSITY; NEOVASCULARIZATION; ISCHEMIA; SPECTRUM AB PURPOSE. The purpose of this study was to quantify retinal capillary density and the foveal avascular zone (FAZ) area in normal subjects according to age, using optical coherence tomography angiography (OCTA). METHODS. All eyes in this cross-sectional study underwent OCTA using RTVue XR Avanti with AngioVue. OCTA scans were analyzed and processed, and vessel density and FAZ dimensions were calculated. RESULTS. A total of 113 normal eyes from 70 subjects were included (30 males, 40 females; mean 48 +/- 20 years of age). The mean vessel density and FAZ dimensions were significantly smaller in the superficial retinal capillary plexus (SCP) than in the deep retinal capillary plexus (DCP), using quantitative OCTA analysis (all P<0.0001). With 3 x 3-mm scans, the mean vessel density was 13.431 +/- 1.758 mm(-1) in the SCP, 18.812 +/- 1.796 mm(-1) in the DCP, and 5.913 +/- 1.308 mm(-1) and 10.447 +/- 1.262 mm(-1) with 6 x 6-mm scans in the SCP and DCP, respectively. Mean FAZ areas were 0.289 +/- 0.108 mm(2) at the SCP and 0.614 +/- 0.200 mm(2) at the DCP. Age was a predictor of SCP and DCP vessel density and FAZ area in the SCP. Vessel density decreased 0.0393 mm(-1) (0.26%) per year in the SCP and 0.0574 mm(-1) (0.27%) per year in the DCP. FAZ areas increased 0.0014 mm(2) (0.63%) and 0.0011 mm(2) (0.20%) per year in the SCP and DCP, respectively. CONCLUSIONS. SCP and DCP vessel density decreased with increasing age, while FAZ area increased with age. Normal age-matched measurements provide important standardized values that may facilitate management of retinal vascular disorders. C1 [Iafe, Nicholas A.; Phasukkijwatana, Nopasak; Chen, Xuejing; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Los Angeles, CA 90095 USA. [Phasukkijwatana, Nopasak] Mahidol Univ, Siriraj Hosp, Dept Ophthalmol, Fac Med, Bangkok, Thailand. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Sarraf, D (reprint author), UCLA, David Geffen Sch Med, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM dsarraf@ucla.edu NR 39 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD OCT PY 2016 VL 57 IS 13 BP 5780 EP 5787 DI 10.1167/iovs.16-20045 PG 8 WC Ophthalmology SC Ophthalmology GA EI4ND UT WOS:000392469600094 PM 27792812 ER PT J AU Humar, M AF Humar, Matjaz TI Liquid-crystal-droplet optical microcavities SO LIQUID CRYSTALS LA English DT Article DE Liquid-crystal droplets; optical cavities; lasers; whispering-gallery modes; cholesteric lasers ID LABEL-FREE DETECTION; ANISOTROPIC FLUIDS; PHOTONIC CRYSTAL; MICRODROPLETS; LASERS; RESONATORS; LIGHT; DYE; MICROSPHERES; MICROLASERS AB The use of liquid-crystal droplets as optical microcavities and lasers is reviewed and possible applications are discussed. Liquid-crystal droplets are prepared by simple methods that enable scalable production since their internal structure is formed by self-assembly. Light is trapped in droplets due to total internal reflection on the surface due to refractive index mismatch or because of a photonic bandgap structure in cholesteric liquid crystals (CLCs). Light confinement gives rise to a variety of optical modes and by employing a fluorescent dye end external optical pumping, lasing can be achieved. Liquid-crystal-droplet cavities are largely tunable by applying an electric field or a temperature change. Such cavities can be used as temperature and chemical sensors, and tunable light sources and filters in future integrated soft photonic circuits. [GRAPHICS] . C1 [Humar, Matjaz] J Stefan Inst, Condensed Matter Dept, Ljubljana, Slovenia. [Humar, Matjaz] Harvard Med Sch, Cambridge, MA USA. [Humar, Matjaz] Massachusetts Gen Hosp, Wellman Ctr Photomed, Cambridge, MA USA. RP Humar, M (reprint author), Jozef Stefan Inst, Condensed Matter Dept, Jamova 39, Ljubljana 1000, Slovenia. EM matjaz.humar@ijs.si FU European Community [627274]; Slovenian Research Agency [P1-0099, PR-01557, J1-9728, J1-3612]; Directorate-General for Research and Innovation [627274] FX The work was supported by Marie Curie International Outgoing Fellowship Number 627274 within the 7th European Community Framework Programme and by the Slovenian Research Agency under the contracts P1-0099, PR-01557, J1-9728 and J1-3612; Directorate-General for Research and Innovation: [Grant Number 627274]; Slovenian Research Agency: [Grant Number P1-0099, PR-01557, J1-9728, J1-3612]. NR 85 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 0267-8292 EI 1366-5855 J9 LIQ CRYST JI Liq. Cryst. PD OCT-DEC PY 2016 VL 43 IS 13-15 SI SI BP 1937 EP 1950 DI 10.1080/02678292.2016.1221151 PG 14 WC Chemistry, Multidisciplinary; Crystallography; Materials Science, Multidisciplinary SC Chemistry; Crystallography; Materials Science GA EI1JD UT WOS:000392232300004 ER PT J AU Dong, YL Xu, ZP Huang, LN Zhang, YY Xie, ZC AF Dong, Yuanlin Xu, Zhipeng Huang, Lining Zhang, Yiying Xie, Zhongcong TI Peripheral surgical wounding may induce cognitive impairment through interlukin-6-dependent mechanisms in aged mice SO MEDICAL GAS RESEARCH LA English DT Article DE peripheral surgical wounding; interlukin-6; cognition; mice; fear conditioning system; neuroinflammation ID GENERAL-ANESTHESIA; NONCARDIAC SURGERY; PROTEIN-LEVELS; DYSFUNCTION; ISOFLURANE; MEMORY; ACCUMULATION; HIPPOCAMPUS; APOPTOSIS; DECLINE AB Post-operative cognitive dysfunction (POCD) is associated with morbidity, mortality and increased cost of medical care. However, the neuropathogenesis and targeted interventions of POCD remain largely to be determined. We have found that the peripheral surgical wounding induces an age-dependent A beta accumulation, neuroinflammation and cognitive impairment in aged mice. Pro-inflammatory cytokine interlukin-6 (IL-6) has been reported to be associated with cognitive impairment in rodents and humans. However, the role of IL-6 in the neuropathogenesis of POCD is unknown. We therefore employed pharmacological (IL-6 antibody) and genetic (knockout of IL-6) approach to investigate whether IL-6 contributed to the peripheral surgical wounding-induced cognitive impairment in aged mice. Abdominal surgery under local anesthesia (peripheral surgical wounding) was established in 18-month-old wild-type and IL-6 knockout mice (n = 6 to 10 in each group). Brain level of IL-6 and cognitive function in the mice were determined by western blot, ELISA at the end of procedure, and Fear Conditioning System at 7 days after the procedure. The peripheral surgical wounding increased the level of IL-6 in the hippocampus of aged wild-type, but not IL-6 knockout mice. IL-6 antibody ameliorated the peripheral surgical wounding-induced cognitive impairment in the aged wild-type mice. Finally, the peripheral surgical wounding did not induce cognitive impairment in the aged IL-6 knockout mice. These data suggested that IL-6 would be a required pro-inflammatory cytokine for the peripheral surgical wounding-induced cognitive impairment. Given this, further studies are warranted to investigate the role of IL-6 in the neuropathogenesis and targeted interventions of POCD. C1 [Dong, Yuanlin; Xu, Zhipeng; Huang, Lining; Zhang, Yiying; Xie, Zhongcong] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Geriatr Anesthesia Res Unit, Charlestown, MA 02129 USA. [Dong, Yuanlin; Xu, Zhipeng; Huang, Lining; Zhang, Yiying; Xie, Zhongcong] Harvard Med Sch, Charlestown, MA 02129 USA. [Huang, Lining] Hebei Med Univ, Hosp 2, Dept Anesthesiol, Shijiazhuang, Hebei Province, Peoples R China. RP Xie, ZC (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Geriatr Anesthesia Res Unit, Charlestown, MA 02129 USA.; Xie, ZC (reprint author), Harvard Med Sch, Charlestown, MA 02129 USA. EM zxie@mgh.harvard.edu FU National Institutes of Health, Bethesda, MD, USA [R01GM088801, R01AG041274, R01HD086977]; Investigator-initiated Research grant from Alzheimer's Association, Chicago, IL, USA FX This research was supported by R01GM088801, R01AG041274 and R01HD086977 from National Institutes of Health, Bethesda, MD, USA, and Investigator-initiated Research grant from Alzheimer's Association, Chicago, IL, USA (to ZX). NR 37 TC 0 Z9 0 U1 0 U2 0 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 2045-9912 J9 MED GAS RES JI Med. Gas Res. PD OCT-DEC PY 2016 VL 6 IS 4 BP 180 EP 186 DI 10.4103/2045-9912.196899 PG 7 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA EI4FW UT WOS:000392449500001 PM 28217289 ER PT J AU Yang, T Sun, Y Zhang, F AF Yang, Tuo Sun, Yang Zhang, Feng TI Anti-oxidative aspect of inhaled anesthetic gases against acute brain injury SO MEDICAL GAS RESEARCH LA English DT Review DE isoflurane; nuclear factor (erythroid-derived 2)-like 2; pre-conditioning; post-conditioning; sevoflurane; stroke; traumatic brain injury; xenon ID FOCAL CEREBRAL-ISCHEMIA; EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; VASCULAR COGNITIVE IMPAIRMENT; SUBARACHNOID HEMORRHAGE; RAT MODEL; OXIDATIVE STRESS; HEME OXYGENASE-1; HO-1 EXPRESSION; MURINE MODEL; NEUROPROTECTION AB Acute brain injury is a critical and emergent condition in clinical settings, which needs to be addressed urgently. Commonly acute brain injuries include traumatic brain injury, ischemic and hemorrhagic strokes. Oxidative stress is a key contributor to the subsequent injuries and impedes the reparative process after acute brain injury; therefore, facilitating an anti-oxidative approach is important in the care of those diseases. Readiness to deliver and permeability to blood brain barrier are essential for the use of this purpose. Inhaled anesthetic gases are a group of such agents. In this article, we discuss the anti-oxidative roles of anesthetic gases against acute brain injury. C1 [Yang, Tuo; Sun, Yang; Zhang, Feng] Univ Pittsburgh, Dept Neurol, Pittsburgh Inst Brain Disorders & Recovery, Pittsburgh, PA 15260 USA. [Zhang, Feng] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA. [Zhang, Feng] Taishan Med Univ, Key Lab Cerebral Microcirculat Univ Shandong, Tai An, Shandong, Peoples R China. RP Zhang, F (reprint author), Univ Pittsburgh, Dept Neurol, Pittsburgh Inst Brain Disorders & Recovery, Pittsburgh, PA 15260 USA.; Zhang, F (reprint author), Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA.; Zhang, F (reprint author), Taishan Med Univ, Key Lab Cerebral Microcirculat Univ Shandong, Tai An, Shandong, Peoples R China. EM zhanfx2@upmc.edu FU National Institutes of Health of USA [NS092810]; National Natural Science Foundation of China [81271276] FX This work was supported by grants from the National Institutes of Health of USA (No. NS092810 to FZ) and the National Natural Science Foundation of China (No. 81271276 to FZ). NR 55 TC 0 Z9 0 U1 1 U2 1 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 2045-9912 J9 MED GAS RES JI Med. Gas Res. PD OCT-DEC PY 2016 VL 6 IS 4 BP 223 EP 226 DI 10.4103/2045-9912.196905 PG 4 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA EI4FW UT WOS:000392449500007 PM 28217295 ER PT J AU Baratto, L Jegede, O Hong, F Kahl, B Evens, AM Quon, A AF Baratto, L. Jegede, O. Hong, F. Kahl, B. Evens, A. M. Quon, A. TI Comparison Between LUGANO, EORTC, PERCIST And IHP Criteria At Interim PET In Patients With Follicular Non-Hodgkin's Lymphoma SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING LA English DT Meeting Abstract CT Annual Congress of the European-Association-of-Nuclear-Medicine (EANM) CY OCT 15-19, 2016 CL Barcelona, SPAIN SP European Assoc Nucl Med C1 [Baratto, L.; Quon, A.] Stanford Univ, Div Nucl Med & Mol Imaging, Dept Radiol, Stanford, CA 94305 USA. [Jegede, O.; Hong, F.] Harvard Chan Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA USA. [Kahl, B.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA. [Evens, A. M.] Tufts Univ, Sch Med, Div Hematol Oncol, Tufts Canc Ctr,Tufts Med Ctr, Boston, MA 02111 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1619-7070 EI 1619-7089 J9 EUR J NUCL MED MOL I JI Eur. J. Nucl. Med. Mol. Imaging PD OCT PY 2016 VL 43 SU 1 MA OP082 BP S30 EP S31 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EH5GW UT WOS:000391801600053 ER PT J AU Sheikhzadeh, P Sabet, H Ghadiri, H Ghafarian, P Ay, M AF Sheikhzadeh, P. Sabet, H. Ghadiri, H. Ghafarian, P. Ay, M. TI Design and Performance evaluation of a Novel Brain PET Geometry Based on Partial Cylindrical Detector using Monte Carlo simulation SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING LA English DT Meeting Abstract CT Annual Congress of the European-Association-of-Nuclear-Medicine (EANM) CY OCT 15-19, 2016 CL Barcelona, SPAIN SP European Assoc Nucl Med C1 [Sheikhzadeh, P.; Ghadiri, H.; Ay, M.] Univ Tehran Med Sci, Dept Med Phys & Biomed Engn, Tehran, Iran. [Sheikhzadeh, P.; Ghadiri, H.; Ay, M.] Univ Tehran Med Sci, Res Ctr Mol & Cellular Imaging, Tehran, Iran. [Sabet, H.] Harvard Med Sch, Massachusetts Gen Hosp, Charlestown, MA USA. [Ghafarian, P.] Shahid Beheshti Univ Med Sci, Chron Resp Dis Res Ctr, NRITLD, Tehran, Iran. [Ghafarian, P.] Shahid Beheshti Univ Med Sci, PET CT & Cyclotron Ctr, Masih Daneshvari Hosp, Tehran, Iran. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1619-7070 EI 1619-7089 J9 EUR J NUCL MED MOL I JI Eur. J. Nucl. Med. Mol. Imaging PD OCT PY 2016 VL 43 SU 1 MA OP302 BP S94 EP S94 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EH5GW UT WOS:000391801600223 ER PT J AU Strosberg, J Wolin, E Chasen, B Kulke, M Bushnell, D Caplin, M Baum, RP Kunz, P Hobday, T Hendifar, A Oberg, K Sierra, ML Kwekkeboom, D Ruszniewski, P Krenning, E AF Strosberg, J. Wolin, E. Chasen, B. Kulke, M. Bushnell, D. Caplin, M. Baum, R. P. Kunz, P. Hobday, T. Hendifar, A. Oberg, K. Sierra, M. Lopera Kwekkeboom, D. Ruszniewski, P. Krenning, E. TI NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy and Safety Results SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING LA English DT Meeting Abstract CT Annual Congress of the European-Association-of-Nuclear-Medicine (EANM) CY OCT 15-19, 2016 CL Barcelona, SPAIN SP European Assoc Nucl Med C1 [Strosberg, J.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Wolin, E.] Univ Kentucky, Markey Canc Ctr, Lexington, KY USA. [Chasen, B.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Kulke, M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bushnell, D.] Univ Iowa, Iowa City, IA USA. [Caplin, M.] Royal Free Hosp, London, England. [Baum, R. P.] Zent Klin, Bad Berska, Germany. [Kunz, P.] Stanford Univ, Med Ctr, Stanford, CA USA. [Hobday, T.] Mayo Clin, Coll Med, Rochester, MN USA. [Hendifar, A.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Oberg, K.] Univ Hosp, Uppsala, Sweden. [Sierra, M. Lopera] Adv Accelerator Applicat, New York, NY USA. [Kwekkeboom, D.; Krenning, E.] Erasmus MC, Rotterdam, Netherlands. [Ruszniewski, P.] Hop Beaujon, Clichy, France. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1619-7070 EI 1619-7089 J9 EUR J NUCL MED MOL I JI Eur. J. Nucl. Med. Mol. Imaging PD OCT PY 2016 VL 43 SU 1 MA OP394 BP S121 EP S121 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EH5GW UT WOS:000391801600292 ER PT J AU Zhang, J Hall, NC Schoder, H Schwartz, LP Wilson, WH Kelloff, G Knopp, MV AF Zhang, J. Hall, N. C. Schoder, H. Schwartz, L. P. Wilson, W. H. Kelloff, G. Knopp, M. V. TI The Oncology Biomarker Qualification Initiative (OBQI): Multi-institutional Demonstration Using FDG-PET in Non-Hodgkin's Lymphoma SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING LA English DT Meeting Abstract CT Annual Congress of the European-Association-of-Nuclear-Medicine (EANM) CY OCT 15-19, 2016 CL Barcelona, SPAIN SP European Assoc Nucl Med C1 [Zhang, J.; Knopp, M. V.] Ohio State Univ, Columbus, OH 43210 USA. [Hall, N. C.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Schoder, H.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. [Schwartz, L. P.] Columbia Univ, New York, NY USA. [Wilson, W. H.] NIH, Bldg 10, Bethesda, MD 20892 USA. [Kelloff, G.] NCI, Bethesda, MD 20892 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1619-7070 EI 1619-7089 J9 EUR J NUCL MED MOL I JI Eur. J. Nucl. Med. Mol. Imaging PD OCT PY 2016 VL 43 SU 1 MA OP687 BP S204 EP S204 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EH5GW UT WOS:000391801600505 ER PT J AU Brunye, TT Ditman, T Giles, GE Holmes, A Taylor, HA AF Brunye, Tad T. Ditman, Tali Giles, Grace E. Holmes, Amanda Taylor, Holly A. TI Mentally Simulating Narrative Perspective Is Not Universal or Necessary for Language Comprehension SO JOURNAL OF EXPERIMENTAL PSYCHOLOGY-LEARNING MEMORY AND COGNITION LA English DT Article DE perspective-taking; discourse comprehension; individual differences; embodied cognition ID SENTENCE COMPREHENSION; EMBODIED LANGUAGE; WORKING-MEMORY; MOTOR SYSTEM; EMOTION; EMPATHY; TRANSPORTATION; ORIENTATION; COMPONENTS; REPRESENT AB Readers differentially adopt an agent's perspective as a function of pronouns encountered during reading. The present study assessed the reliability of this effect across narrative contexts and self-reported variation in levels of engagement during reading. Experiment 1 used an extended sample (N = 263) and replicated an interactive influence of pronouns on perspectives adopted during reading simple action sentences (e.g., You are peeling the cucumber.), with You promoting an agent's perspective, and He promoting an onlooker's external perspective. The magnitude of this effect was partially accounted for by individual differences in the tendency to get actively engaged during reading. Specifically, readers who self-reported greater empathic engagement during reading also showed a higher likelihood to adopt an agent's perspective when sentences used the pronoun You or I. Experiment 2 (N = 217) examined whether these influences of pronouns and individual differences would emerge with relatively realistic, extended narratives; effects were generally less robust than with single sentence scenarios, though empathic engagement still predicted adopting an agent's perspective with the pronoun You or I. Furthermore, even in the absence of perspective modulation in response to pronouns, comprehension was maintained. These results demonstrate that differentially adopting perspectives as a function of pronouns is not universal or necessary for comprehension, but rather influenced by narrative context and individuals' propensity to find themselves immersed in described events. Results are considered within the framework of embodied cognition, representational pluralism, individual differences, and high-powered replication projects. C1 [Brunye, Tad T.; Ditman, Tali; Giles, Grace E.; Holmes, Amanda; Taylor, Holly A.] Tufts Univ, Dept Psychol, Medford, MA 02155 USA. [Brunye, Tad T.; Giles, Grace E.; Holmes, Amanda; Taylor, Holly A.] Tufts Univ, Ctr Appl Brain & Cognit Sci, 200 Boston Ave,Suite 3000, Medford, MA 02155 USA. [Brunye, Tad T.] US Army NSRDEC, Cognit Sci Team, Natick, MA USA. [Ditman, Tali] Harvard Med Sch, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA USA. RP Brunye, TT (reprint author), Tufts Univ, Ctr Appl Brain & Cognit Sci, 200 Boston Ave,Suite 3000, Medford, MA 02155 USA. EM tbrunye@alumni.tufts.edu NR 72 TC 0 Z9 0 U1 2 U2 2 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0278-7393 EI 1939-1285 J9 J EXP PSYCHOL LEARN JI J. Exp. Psychol.-Learn. Mem. Cogn. PD OCT PY 2016 VL 42 IS 10 BP 1592 EP 1605 DI 10.1037/xlm0000250 PG 14 WC Psychology; Psychology, Experimental SC Psychology GA EH9TT UT WOS:000392114800006 PM 26889684 ER PT J AU Sheets, JN Iwanicki, M Liu, JF Howitt, BE Hirsch, MS Gubbels, JAA Drapkin, R Egland, KA AF Sheets, J. N. Iwanicki, M. Liu, J. F. Howitt, B. E. Hirsch, M. S. Gubbels, J. A. A. Drapkin, R. Egland, K. A. TI SUSD2 expression in high-grade serous ovarian cancer correlates with increased patient survival and defective mesothelial clearance SO ONCOGENESIS LA English DT Article ID EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR PROGRESSION; BREAST-CANCER; IN-VITRO; MOLECULAR-MECHANISMS; CELL-MIGRATION; CARCINOMA; INVASION; GENE; METASTASIS AB The cause of death among the majority of epithelial ovarian cancer (EOC) patients involves passive dissemination of cancer cells within the peritoneal cavity and subsequent implantation of cancer spheroids into adjacent organs. Thus, it is important to identify the factors that mediate EOC metastasis and implantation, including clearance of the mesothelium. Sushi domain containing 2 (SUSD2) encodes a type I transmembrane protein containing several functional domains inherent to adhesion molecules. Immunohistochemical analysis determined the presence of SUSD2 in several subtypes of EOC, with the strongest staining observed in high-grade serous ovarian carcinomas (HGSOCs). A high-density, clinically annotated HGSOC tissue microarray was stained with an anti-SUSD2 antibody. Patients with tumors that had a low percentage of SUSD2 staining cells had a shorter median survival (31.7 months) compared with patients who had tumors with extensive SUSD2 staining (49.1 months; P-value = 0.0083). To investigate the role of SUSD2 in HGSOCs, stable OVCAR3, OVSAHO and KURAMOCHI cell lines were established with knockdown (KD) or non-targeting (NT) of SUSD2. Boyden chamber and wound-healing assays demonstrated that OVCAR3, OVSAHO and KURAMOCHI SUSD2-KD cells migrated at significantly higher rates compared with their SUSD2 NT counterpart cell lines. Quantitative reverse transcription-PCR and western immunoblot analysis indicated an inverse relationship between SUSD2 and well-characterized mesenchymal proteins, including Twist-1, Zeb-1, N-cadherin, STEAP1, AHNAK, Snail-1, COL5A2 and Snail-3 in OVCAR3, OVSAHO and KURAMOCHI cell line models. In addition, OVCAR3 and KURAMOCHI SUSD2-KD spheroids displayed increased mesothelial clearance ability compared with cells that express endogenous levels of SUSD2. These data suggest that SUSD2 has a role in the inhibition of mesothelial clearance, which is required for metastasis. Altogether, our findings indicate that SUSD2 impedes migration, epithelial-to-mesenchymal transitional and mesothelial clearance of HGSOC cells, consistent with prolonged survival of patients with SUSD2-expressing tumors. C1 [Sheets, J. N.; Egland, K. A.] Univ South Dakota, Sanford Sch Med, Sanford Res, Canc Biol Res Ctr, 2301 East 60th St North, Sioux Falls, SD 57104 USA. [Iwanicki, M.] Dana Farber Canc Inst, Dept Cell Biol, Boston, MA 02115 USA. [Liu, J. F.] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA. [Howitt, B. E.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA. [Hirsch, M. S.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA. [Gubbels, J. A. A.] Augustana Coll, Dept Biol, Sioux Falls, SD USA. [Drapkin, R.] Univ Penn, Sch Med, Dept Obstet & Gynecol, Ovarian Canc Res Ctr, Philadelphia, PA 19104 USA. RP Egland, KA (reprint author), Univ South Dakota, Sanford Sch Med, Sanford Res, Canc Biol Res Ctr, 2301 East 60th St North, Sioux Falls, SD 57104 USA. EM kristi.egland@sanfordhealth.org FU NIH, NIGMS, Center of Biomedical Research Excellence (COBRE) [P20 GM103548]; NIH, NIGMS; COBRE Grants [P20 GM103548, P20 GM103620] FX We acknowledge Claire Evans, histologist, for the Sanford Research Molecular Pathology Core and for beautiful IHC staining of the TMAs. We thank Rick Evans for his assistance in generating the OVCAR3 stable cell lines. This research was supported by an NIH, NIGMS, Center of Biomedical Research Excellence (COBRE) grant number P20 GM103548. The Sanford Research Molecular Pathology Core, Flow Cytometry Core and Imaging Core are supported by the NIH, NIGMS and COBRE Grants P20 GM103548 and P20 GM103620. NR 42 TC 0 Z9 0 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 2157-9024 J9 ONCOGENESIS JI Oncogenesis PD OCT PY 2016 VL 5 AR e264 DI 10.1038/oncsis.2016.64 PG 12 WC Oncology SC Oncology GA EH7IZ UT WOS:000391947700005 PM 27775699 ER PT J AU Hall, NC Wright, CL Gortanla, N Nagar, V Zhang, J Knopp, MV AF Hall, N. C. Wright, C. L. Gortanla, N. Nagar, V. Zhang, J. Knopp, M. V. TI Matched Pair Validation of Ultra-low-dose CT Compared to Low-dose CT for Oncologic F-18-FDG PET/CT SO EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING LA English DT Meeting Abstract CT Annual Congress of the European-Association-of-Nuclear-Medicine CY OCT 15-19, 2016 CL Barcelona, SPAIN SP European Assoc Nucl Med C1 [Hall, N. C.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Wright, C. L.; Gortanla, N.; Nagar, V.; Zhang, J.; Knopp, M. V.] Ohio State Univ, Columbus, OH 43210 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1619-7070 EI 1619-7089 J9 EUR J NUCL MED MOL I JI Eur. J. Nucl. Med. Mol. Imaging PD OCT PY 2016 VL 43 SU 1 MA EP204 BP S322 EP S322 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EH5HE UT WOS:000391802400205 ER PT J AU Watson, C Tea, I Glezeva, N Zhou, S James, S Gallagher, J Januzzi, J Ledgwidge, M McDonald, K AF Watson, C. Tea, I. Glezeva, N. Zhou, S. James, S. Gallagher, J. Januzzi, J. Ledgwidge, M. McDonald, K. TI COMPARISON OF LONGITUDINAL CHANGE IN SOLUBLE ST2 VERSUS B-TYPE NATRIURETIC PEPTIDE TO PREDICT MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ASYMPTOMATIC PATIENTS IN THE COMMUNITY SO HEART LA English DT Meeting Abstract CT Annual Scientific Meeting and AGM of the Irish-Cardiac-Society CY OCT 06-08, 2016 CL Kilkenny, IRELAND SP Irish Cardiac Soc C1 [Watson, C.] Queens Univ Belfast, Belfast, Antrim, North Ireland. [Tea, I.] Lankenau Med Ctr, Wynnewood, PA USA. [Glezeva, N.] Univ Coll Dublin, Dublin, Ireland. [Zhou, S.; Gallagher, J.; Ledgwidge, M.; McDonald, K.] Heartbeat Trust, Crofton Terrace, Dublin, Ireland. [James, S.] St Vincents Univ Hosp, Dublin, Ireland. [Januzzi, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1355-6037 EI 1468-201X J9 HEART JI Heart PD OCT PY 2016 VL 102 SU 9 MA 55 BP A28 EP A29 DI 10.1136/heartjnl-2016-310523.55 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EG4QO UT WOS:000391029000056 ER PT J AU Tahir, U Yeh, RW AF Tahir, Usman Yeh, Robert W. TI Duration of dual antiplatelet therapy (DAPT): a call for personalized medicine SO JOURNAL OF THORACIC DISEASE LA English DT Editorial Material ID DRUG-ELUTING STENTS; GUIDELINE FOCUSED UPDATE; CORONARY-ARTERY-DISEASE; IMPLANTATION; TRIAL; CLOPIDOGREL; THROMBOSIS; EFFICACY; ASPIRIN; RISK C1 [Tahir, Usman; Yeh, Robert W.] Beth Israel Deaconess Med Ctr, Smith Ctr Outcomes Res Cardiol, Boston, MA 02215 USA. RP Tahir, U (reprint author), Beth Israel Deaconess Med Ctr, Div Cardiovasc Med, 185 Pilgrim Rd, Boston, MA 02215 USA. EM Utahir@bidmc.harvard.edu NR 18 TC 0 Z9 0 U1 0 U2 0 PU PIONEER BIOSCIENCE PUBL CO PI HONG KONG PA 9A GOLD SHINE TOWER, 346-348 QUEEN'S RD CENTRAL, SHEUNG WAN, HONG KONG, 00000, PEOPLES R CHINA SN 2072-1439 EI 2077-6624 J9 J THORAC DIS JI J. Thorac. Dis. PD OCT PY 2016 VL 8 IS 10 BP E1226 EP E1229 DI 10.21037/jtd.2016.10.05 PG 4 WC Respiratory System SC Respiratory System GA EG6QP UT WOS:000391171300017 PM 27867593 ER PT J AU Villar, J Kacmarek, RM AF Villar, Jesus Kacmarek, Robert M. TI The APPS: an outcome score for the acute respiratory distress syndrome SO JOURNAL OF THORACIC DISEASE LA English DT Editorial Material ID ACUTE LUNG INJURY; PLATEAU PRESSURE; PREDICT MORTALITY; CARE; ARDS; DEFINITION; SEVERITY; AGE C1 [Villar, Jesus] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain. [Villar, Jesus] Hosp Univ Dr Negrin, Res Unit, MODERN, Las Palmas Gran Canaria, Spain. [Kacmarek, Robert M.] Massachusetts Gen Hosp, Dept Resp Care, Boston, MA 02114 USA. [Kacmarek, Robert M.] Harvard Univ, Dept Anesthesiol, Boston, MA 02115 USA. RP Villar, J (reprint author), Hosp Univ Dr Negrin, Barranco de la Ballena S-N,4th Floor,South Wing, Las Palmas Gran Canaria 35019, Spain. EM jesus.villar54@gmail.com NR 25 TC 1 Z9 1 U1 0 U2 0 PU PIONEER BIOSCIENCE PUBL CO PI HONG KONG PA 9A GOLD SHINE TOWER, 346-348 QUEEN'S RD CENTRAL, SHEUNG WAN, HONG KONG, 00000, PEOPLES R CHINA SN 2072-1439 EI 2077-6624 J9 J THORAC DIS JI J. Thorac. Dis. PD OCT PY 2016 VL 8 IS 10 BP E1343 EP E1347 DI 10.21037/jtd.2016.10.76 PG 5 WC Respiratory System SC Respiratory System GA EG6QP UT WOS:000391171300047 PM 27867623 ER PT J AU Bar-Or, A Steinman, L Behne, JM Benitez-Ribas, D Chin, PS Clare-Salzler, M Healey, D Kim, JI Kranz, DM Lutterotti, A Martin, R Schippling, S Villoslada, P Wei, CH Weiner, HL Zamvil, SS Smith, TJ Yeaman, MR AF Bar-Or, Amit Steinman, Larry Behne, Jacinta M. Benitez-Ribas, Daniel Chin, Peter S. Clare-Salzler, Michael Healey, Donald Kim, James I. Kranz, David M. Lutterotti, Andreas Martin, Roland Schippling, Sven Villoslada, Pablo Wei, Cheng-Hong Weiner, Howard L. Zamvil, Scott S. Smith, Terry J. Yeaman, Michael R. CA Guthy-Jackson Charitable Fdn Int TI Restoring immune tolerance in neuromyelitis optica Part II SO NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION LA English DT Review ID REGULATORY T-CELLS; TRANSCRIPTION FACTOR FOXP3; B-CELLS; AUTOIMMUNE-DISEASE; MULTIPLE-SCLEROSIS; IN-VIVO; MICE; ACTIVATION; RESPONSES; DEPLETION AB Neuromyelitis optica spectrum disorder (NMO/SD) and its clinical variants have at their core the loss of immune tolerance to aquaporin-4 and perhaps other autoantigens. The characteristic phenotype is disruption of astrocyte function and demyelination of spinal cord, optic nerves, and particular brain regions. In this second of a 2-part article, we present further perspectives regarding the pathogenesis of NMO/SD and how this disease might be amenable to emerging technologies aimed at restoring immune tolerance to disease-implicated self-antigens. NMO/SD appears to be particularly well-suited for these strategies since aquaporin-4 has already been identified as the dominant autoantigen. The recent technical advances in reintroducing immune tolerance in experimental models of disease as well as in humans should encourage quantum leaps in this area that may prove productive for novel therapy. In this part of the article series, the potential for regulatory T and B cells is brought into focus, as are new approaches to oral tolerization. Finally, a road-map is provided to help identify potential issues in clinical development and guide applications in tolerization therapy to solving NMO/SD through the use of emerging technologies. Each of these perspectives is intended to shine new light on potential cures for NMO/SD and other autoimmune diseases, while sparing normal host defense mechanisms. C1 [Bar-Or, Amit] McGill Univ, Montreal Neurol Inst & Hosp, Neuroimmunol Unit, Montreal, PQ, Canada. [Bar-Or, Amit] McGill Univ, Montreal Neurol Inst & Hosp, Expt Therapeut Program, Montreal, PQ, Canada. [Steinman, Larry] Stanford Univ, Sch Med, Dept Neurol, Palo Alto, CA 94304 USA. [Behne, Jacinta M.] Guthy Jackson Charitable Fdn, San Diego, CA USA. [Benitez-Ribas, Daniel; Villoslada, Pablo] CIBERehd, Hosp Clin, Dept Gastroenterol, Barcelona, Spain. Inst Invest Biomed August Pi Sunyer, Ctr Neuroimmunol & Inflammatory Bowel Dis, Barcelona, Spain. [Chin, Peter S.] Genentech Inc, San Francisco, CA 94080 USA. [Clare-Salzler, Michael] Univ Florida, Dept Pathol, Sch Med, Gainesville, FL 32611 USA. [Healey, Donald] Opexa Therapeut, The Woodlands, TX USA. [Kim, James I.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Transplantat Sci, Dept Surg, Boston, MA USA. [Kranz, David M.] Univ Illinois, Dept Biochem, Urbana, IL 61801 USA. [Lutterotti, Andreas; Martin, Roland; Schippling, Sven] Univ Zurich, Univ Zurich Hosp, Dept Neurol, Neuroimmunol & MS Res, CH-8006 Zurich, Switzerland. [Weiner, Howard L.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurol, Ann Romney Ctr Neurol Dis, Boston, MA USA. [Zamvil, Scott S.] Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA 94143 USA. [Zamvil, Scott S.] Univ Calif San Francisco, Sch Med, Program Immunol, San Francisco, CA 94143 USA. [Smith, Terry J.] Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Sch Med, Ann Arbor, MI 48109 USA. Univ Michigan, Dept Internal Med, Sch Med, Div Metab Endocrine & Diabet, Ann Arbor, MI 48109 USA. [Yeaman, Michael R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Mol Med & Infect Dis, Los Angeles, CA 90095 USA. [Yeaman, Michael R.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA. [Yeaman, Michael R.] LABioMed Harbor UCLA Med Ctr, Torrance, CA USA. RP Smith, TJ (reprint author), Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Sch Med, Ann Arbor, MI 48109 USA. EM terrysmi@med.umich.edu FU Guthy-Jackson Charitable Foundation FX This work was supported in part by the Guthy-Jackson Charitable Foundation. NR 59 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2332-7812 J9 NEUROL-NEUROIMMUNOL JI Neurol.-Neuroimmunol. Neuroinflammation PD OCT PY 2016 VL 3 IS 5 AR e277 DI 10.1212/NXI.0000000000000277 PG 9 WC Neurosciences SC Neurosciences & Neurology GA EG6PU UT WOS:000391169200016 PM 27648464 ER PT J AU Regev, K Paul, A Healy, B von Glenn, F Diaz-Cruz, C Gholipour, T Mazzola, MA Raheja, R Nejad, P Glanz, BI Kivisakk, P Chitnis, T Weiner, HL Gandhi, R AF Regev, Keren Paul, Anu Healy, Brian von Glenn, Felipe Diaz-Cruz, Camilo Gholipour, Taha Mazzola, Maria Antonietta Raheja, Radhika Nejad, Parham Glanz, Bonnie I. Kivisakk, Pia Chitnis, Tanuja Weiner, Howard L. Gandhi, Roopali TI Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis SO NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION LA English DT Article ID CIRCULATING MICRORNAS; MESSENGER-RNAS; B-LYMPHOCYTES; EXPRESSION; CANCER; DISEASE; MIRNAS; DIFFERENTIATION; LESIONS; TH1 AB Objective: To identify circulating microRNAs (miRNAs) linked to disease stage and disability in multiple sclerosis (MS). Methods: Sera from 296 participants including patients with MS, other neurologic diseases (Alzheimer disease and amyotrophic lateral sclerosis), and inflammatory diseases (rheumatoid arthritis and asthma) and healthy controls (HCs) were tested. miRNA profiles were determined using LNA (locked nucleic acid)-based quantitative PCR. Patients with MS were categorized according to disease stage and disability. In the discovery phase, 652 miRNAs were measured in sera from 26 patients with MS and 20 HCs. Following this, significant miRNAs (p< 0.05) from the discovery set were validated using quantitative PCR in 58 patients with MS, 30 HCs, and in 74 samples from other disease controls (Alzheimer disease, amyotrophic lateral sclerosis, asthma, and rheumatoid arthritis). Results: We validated 7 miRNAs that differentiate patients with MS from HCs (p< 0.05 in both the discovery and validation phase); miR-320a upregulation was the most significantly changing serum miRNA in patients with MS. We also identified 2 miRNAs linked to disease progression, with miR-27a-3p being the most significant. Ten miRNAs correlated with the Expanded Disability Status Scale of which miR.199a.5p had the strongest correlation with disability. Of the 15 unique miRNAs we identified in the different group comparisons, 12 have previously been reported to be associated with MS but not in serum. Conclusions: Our findings identify circulating serum miRNAs as potential biomarkers to diagnose and monitor disease status in MS. C1 [Regev, Keren; Paul, Anu; Healy, Brian; von Glenn, Felipe; Mazzola, Maria Antonietta; Raheja, Radhika; Kivisakk, Pia; Chitnis, Tanuja; Weiner, Howard L.; Gandhi, Roopali] Harvard Med Sch, Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, Boston, MA 02115 USA. [Diaz-Cruz, Camilo; Gholipour, Taha; Nejad, Parham; Glanz, Bonnie I.; Chitnis, Tanuja; Weiner, Howard L.] Harvard Med Sch, Brigham & Womens Hosp, Partners MS Ctr, Boston, MA 02115 USA. [Healy, Brian] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA. RP Gandhi, R (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, Boston, MA 02115 USA. EM rgandhi@rics.bwh.harvard.edu FU NIH common funds via NCATS UH2/UH3 grant [TR000890] FX This study was funded by NIH common funds via NCATS UH2/UH3 grant TR000890. NR 42 TC 3 Z9 3 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2332-7812 J9 NEUROL-NEUROIMMUNOL JI Neurol.-Neuroimmunol. Neuroinflammation PD OCT PY 2016 VL 3 IS 5 AR e267 DI 10.1212/NXI.0000000000000267 PG 8 WC Neurosciences SC Neurosciences & Neurology GA EG6PU UT WOS:000391169200008 PM 27606352 ER PT J AU Steinman, L Bar-Or, A Behne, JM Benitez-Ribas, D Chin, PS Clare-Salzler, M Healey, D Kim, JI Kranz, DM Lutterotti, A Martin, R Schippling, S Villoslada, P Wei, CH Weiner, HL Zamvil, SS Yeaman, MR Smith, TJ AF Steinman, Larry Bar-Or, Amit Behne, Jacinta M. Benitez-Ribas, Daniel Chin, Peter S. Clare-Salzler, Michael Healey, Donald Kim, James I. Kranz, David M. Lutterotti, Andreas Martin, Roland Schippling, Sven Villoslada, Pablo Wei, Cheng-Hong Weiner, Howard L. Zamvil, Scott S. Yeaman, Michael R. Smith, Terry J. CA Guthy-Jackson Charitable Fdn Int TI Restoring immune tolerance in neuromyelitis optica Part I SO NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION LA English DT Review ID ANTIGEN-SPECIFIC TOLERANCE; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TOLEROGENIC DENDRITIC CELLS; TYPE-1 DIABETIC-PATIENTS; MYELIN BASIC-PROTEIN; CD4(+) T-CELLS; MULTIPLE-SCLEROSIS; PERIPHERAL TOLERANCE; INDUCTION; THERAPY AB Neuromyelitis optica (NMO) and spectrum disorder (NMO/SD) represent a vexing process and its clinical variants appear to have at their pathogenic core the loss of immune tolerance to the aquaporin-4 water channel protein. This process results in a characteristic pattern of astrocyte dysfunction, loss, and demyelination that predominantly affects the spinal cord and optic nerves. Although several empirical therapies are currently used in the treatment of NMO/SD, none has been proven effective in prospective, adequately powered, randomized trials. Furthermore, most of the current therapies subject patients to long-term immunologic suppression that can cause serious infections and development of cancers. The following is the first of a 2-part description of several key immune mechanisms in NMO/SD that might be amenable to therapeutic restoration of immune tolerance. It is intended to provide a roadmap for how potential immune tolerance restorative techniques might be applied to patients with NMO/SD. This initial installment provides a background rationale underlying attempts at immune tolerization. It provides specific examples of innovative approaches that have emerged recently as a consequence of technical advances. In several autoimmune diseases, these strategies have been reduced to practice. Therefore, in theory, the identification of aquaporin-4 as the dominant autoantigen makes NMO/SD an ideal candidate for the development of tolerizing therapies or cures for this increasingly recognized disease. C1 [Steinman, Larry] Stanford Univ, Sch Med, Dept Neurol, Palo Alto, CA 94304 USA. [Bar-Or, Amit] McGill Univ, Montreal Neurol Inst & Hosp, Neuroimmunol Unit, Montreal, PQ, Canada. [Bar-Or, Amit] McGill Univ, Montreal Neurol Inst & Hosp, Expt Therapeut Program, Montreal, PQ, Canada. [Behne, Jacinta M.] Guthy Jackson Charitable Fdn, San Diego, CA USA. [Benitez-Ribas, Daniel; Villoslada, Pablo] CIBERehd, Hosp Clin, Dept Gastroenterol, Barcelona, Spain. Inst Invest Biomed August Pi Sunyer IDIBAPS, Ctr Neuroimmunol & Inflammatory Bowel Dis, Barcelona, Spain. [Chin, Peter S.] Genentech Inc, San Francisco, CA 94080 USA. [Clare-Salzler, Michael] Univ Florida, Dept Pathol, Sch Med, Gainesville, FL 32611 USA. [Healey, Donald] Opexa Therapeut, The Woodlands, TX USA. [Kim, James I.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Transplantat Sci, Dept Surg, Boston, MA USA. [Kranz, David M.] Univ Illinois, Dept Biochem, Urbana, IL 61801 USA. [Lutterotti, Andreas; Martin, Roland; Schippling, Sven] Univ Zurich, Univ Zurich Hosp, Dept Neurol, Neuroimmunol & MS Res, CH-8006 Zurich, Switzerland. [Weiner, Howard L.] Forest Landing Court, Rockville, MD USA. [Zamvil, Scott S.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurol, Ann Romney Ctr Neurol Dis, Boston, MA USA. [Weiner, Howard L.] Univ Calif San Francisco, Sch Med, Dept Med, Dept Neurol, San Francisco, CA 94143 USA. [Weiner, Howard L.] Univ Calif San Francisco, Sch Med, Dept Med, Program Immunol, San Francisco, CA 94143 USA. [Zamvil, Scott S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Mol Med, Dept Med, Los Angeles, CA 90095 USA. [Zamvil, Scott S.] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Dept Med, Los Angeles, CA 90095 USA. [Yeaman, Michael R.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA. [Yeaman, Michael R.] LABioMed Harbor UCLA Med Ctr, Torrance, CA 90502 USA. [Smith, Terry J.] Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Sch Med, Ann Arbor, MI 48109 USA. [Smith, Terry J.] Univ Michigan, Dept Internal Med, Sch Med, Div Metab & Endocrine Dis, Ann Arbor, MI 48109 USA. RP Yeaman, MR (reprint author), Harbor UCLA Med Ctr, Torrance, CA 90509 USA.; Yeaman, MR (reprint author), LABioMed Harbor UCLA Med Ctr, Torrance, CA 90502 USA. EM MRYeaman@ucla.edu FU Guthy-Jackson Charitable Foundation FX This work was supported in part by the Guthy-Jackson Charitable Foundation. NR 58 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2332-7812 J9 NEUROL-NEUROIMMUNOL JI Neurol.-Neuroimmunol. Neuroinflammation PD OCT PY 2016 VL 3 IS 5 AR e276 DI 10.1212/NXI.0000000000000276 PG 10 WC Neurosciences SC Neurosciences & Neurology GA EG6PU UT WOS:000391169200015 PM 27648463 ER PT J AU Shinagare, AB Steele, E Braschi-Amirfarzan, M Tirumani, SH Ramaiya, NH AF Shinagare, Atul B. Steele, Erin Braschi-Amirfarzan, Marta Tirumani, Sree Harsha Ramaiya, Nikhil H. TI Sunitinib-associated Pancreatic Atrophy in Patients with Gastrointestinal Stromal Tumor: A Toxicity with Prognostic Implications Detected at Imaging SO RADIOLOGY LA English DT Article ID RENAL-CELL CARCINOMA; LUNG-CANCER; MANAGEMENT; SORAFENIB; THERAPY; TRIAL; RISK AB Purpose: To evaluate the effect and clinical importance of sunitinib on pancreatic volume in patients with gastrointestinal stromal tumor (GIST). Materials and Methods: This retrospective study was approved by the institutional review board and compliant with HIPAA. The requirement to obtain informed consent was waived. The authors evaluated 65 patients with GIST treated with oral sunitinib and a control group of 30 patients with GIST who did not receive any therapy (mean age: 56 years [range, 29-75 years] vs 60 years [range, 27-78 years], respectively; P =.11) seen at their institution from January 2002 through December 2008. Segmented pancreatic volumes of study and control groups were measured with computed tomography by using commercial software by two independent readers who were blinded to study group and the timing of the scan at a median of 6.2 and 6.1 months, respectively. Pre- and posttreatment volumes (Wilcoxon signed rank test) and rate of volume change per month (Wilcoxon rank sum test) were compared. Interobserver agreement was calculated. Associations and prognostic importance of pancreatic atrophy were studied by using multivariate linear regression and Cox proportional analysis, respectively. Results: Both readers recorded significant pancreatic volume loss in the study group (respective median pre- and posttreatment volume: 76.1 cm(3) and 58.4 cm(3) for reader 1 and 67.7 cm(3) and 59.0 cm(3) for reader 2; P < .0001 for both) but not in the control group (respective median pre- and posttreatment volume: 79.9 cm3 and 83.8 cm3 for reader 1 [P = .43] and 79.9 cm3 and 84.8 cm3 for reader 2 [P = .50]). The rate of volume loss per month was greater in the study group than in the control group (reader 1: 22.1% vs 20.1%, respectively, P = .003; reader 2: 22.0% vs 20.3%, P < .0001). Twenty- three of the 65 patients who received sunitinib (35%) showed at least 3% pancreatic volume loss per month, compared with only one of the 30 patients in the control group (3%). The concordance correlation coefficient for pre- and posttreatment measurements was 0.83 (95% confidence interval [CI]: 0.75, 0.89) and 0.91 (95% CI: 0.86, 0.94), respectively, and the mean relative difference was 0.04% and 1.2%. Sunitinib treatment was independently associated with pancreatic atrophy (P = .03; risk estimate: 2.64; 95% CI: 0.17, 5.11). At Cox proportional analysis within the study group, more than 3%, more than 5%, and more than 7% loss per month were independently associated with worse survival (P< .001, hazard ratio:.1.00 for all). Conclusion: Pancreatic atrophy is a sunitinib- associated toxicity detected at imaging. It may be a clinically important biomarker because a higher rate of pancreatic atrophy was independently associated with shorter survival. (C) RSNA, 2016 C1 [Shinagare, Atul B.; Braschi-Amirfarzan, Marta] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA. [Steele, Erin; Tirumani, Sree Harsha; Ramaiya, Nikhil H.] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA. RP Shinagare, AB (reprint author), Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA. EM ashinagare@partners.org FU RSNA Research and Educational Foundation Scholar Grant [RSCH1422] FX A.B.S. supported by RSNA Research and Educational Foundation Scholar Grant RSCH1422. NR 19 TC 2 Z9 2 U1 0 U2 0 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD OCT PY 2016 VL 281 IS 1 BP 140 EP 149 DI 10.1148/radiol.2016152547 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EG8NJ UT WOS:000391313600016 PM 27643769 ER PT J AU DeSalvo, MN Tanaka, N Douw, L Leveroni, CL Buchbinder, BR Greve, DN Stufflebeam, SM AF DeSalvo, Matthew N. Tanaka, Naoaki Douw, Linda Leveroni, Catherine L. Buchbinder, Bradley R. Greve, Douglas N. Stufflebeam, Steven M. TI Resting-State Functional MR Imaging for Determining Language Laterality in Intractable Epilepsy SO RADIOLOGY LA English DT Article ID SURFACE-BASED ANALYSIS; SPONTANEOUS FLUCTUATIONS; BRAIN; ACTIVATION; ASYMMETRY; FMRI AB Purpose: To measure the accuracy of resting-state functional magnetic resonance (MR) imaging in determining hemispheric language dominance in patients with medically intractable focal epilepsies against the results of an intracarotid amobarbital procedure (IAP). Materials and Methods: This study was approved by the institutional review board, and all subjects gave signed informed consent. Data in 23 patients with medically intractable focal epilepsy were retrospectively analyzed. All 23 patients were candidates for epilepsy surgery and underwent both IAP and resting-state functional MR imaging as part of presurgical evaluation. Language dominance was determined from functional MR imaging data by calculating a laterality index (LI) after using independent component analysis. The accuracy of this method was assessed against that of IAP by using a variety of thresholds. Sensitivity and specificity were calculated by using leave-one-out cross validation. Spatial maps of language components were qualitatively compared among each hemispheric language dominance group. Results: Measurement of hemispheric language dominance with resting-state functional MR imaging was highly concordant with IAP results, with up to 96% (22 of 23) accuracy, 96% (22 of 23) sensitivity, and 96% (22 of 23) specificity. Composite language component maps in patients with typical language laterality consistently included classic language areas such as the inferior frontal gyrus, the posterior superior temporal gyrus, and the inferior parietal lobule, while those of patients with atypical language laterality also included non-classical language areas such as the superior and middle frontal gyri, the insula, and the occipital cortex. Conclusion: Resting-state functional MR imaging can be used to measure language laterality in patients with medically intractable focal epilepsy. (C) RSNA, 2016 C1 [DeSalvo, Matthew N.; Tanaka, Naoaki; Douw, Linda; Greve, Douglas N.; Stufflebeam, Steven M.] Athinoula A Martinos Ctr Biomed Imaging, 149 Thirteenth St,Suite 2301, Charlestown, MA 02129 USA. [Leveroni, Catherine L.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Buchbinder, Bradley R.; Stufflebeam, Steven M.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP DeSalvo, MN (reprint author), Athinoula A Martinos Ctr Biomed Imaging, 149 Thirteenth St,Suite 2301, Charlestown, MA 02129 USA. EM mndesalvo@mgh.harvard.edu FU National Institutes of Health [P41-RR14075, 5R01-NS069696]; National Center for Research Resources [5P41-EB015896]; National Institutes of Health Human Connectome Project [5U01MH093765]; Mental Illness and Neuroscience Discovery Institute; NWO (Dutch Organization for Scientific Research) Rubicon grant; NOW Veni grant; Society in Science Branco Weiss Fellowship; Epilepsy Foundation; Japan Epilepsy Research Foundation; Radiological Society of North America Research Medical Student Grant FX Supported by the National Institutes of Health (grants P41-RR14075 [S.M.S.] and 5R01-NS069696 [C.L.L., L.D., D.N.G., S.M.S.]), the National Center for Research Resources (5P41-EB015896 [S.M.S.]), the National Institutes of Health Human Connectome Project (5U01MH093765 [S.M.S., D.N.G.]), the Mental Illness and Neuroscience Discovery Institute, the NWO (Dutch Organization for Scientific Research) Rubicon grant (L.D.), the NOW Veni grant, the Society in Science Branco Weiss Fellowship (L.D.), the Epilepsy Foundation, the Japan Epilepsy Research Foundation (N.T.), and the Radiological Society of North America Research Medical Student Grant (M.N.D.). NR 23 TC 0 Z9 0 U1 0 U2 0 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD OCT PY 2016 VL 281 IS 1 BP 264 EP 269 DI 10.1148/radiol.2016141010 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EG8NJ UT WOS:000391313600029 PM 27467465 ER PT J AU Ackman, JB Gaissert, HA Lanuti, M Digumarthy, SR Shepard, JAO Halpern, EF Wright, CD AF Ackman, Jeanne B. Gaissert, Henning A. Lanuti, Michael Digumarthy, Subba R. Shepard, Jo-Anne O. Halpern, Elkan F. Wright, Cameron D. TI Is it Time to Increase the Use of Nonvascular Thoracic MR Imaging in Clinical Practice in Lieu of CT? Response SO RADIOLOGY LA English DT Letter C1 [Ackman, Jeanne B.; Digumarthy, Subba R.; Shepard, Jo-Anne O.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Div Thorac Imaging & Intervent, 55 Fruit St,Founders House 202, Boston, MA 02114 USA. [Gaissert, Henning A.; Lanuti, Michael; Wright, Cameron D.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, 55 Fruit St,Founders House 202, Boston, MA 02114 USA. [Halpern, Elkan F.] Harvard Med Sch, Massachusetts Gen Hosp, Inst Technol Assessment, 55 Fruit St,Founders House 202, Boston, MA 02114 USA. RP Ackman, JB (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Div Thorac Imaging & Intervent, 55 Fruit St,Founders House 202, Boston, MA 02114 USA. EM jackman@mgh.harvard.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD OCT PY 2016 VL 281 IS 1 BP 321 EP 321 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EG8NJ UT WOS:000391313600036 ER PT J AU Davarpanah, AH AF Davarpanah, Amir H. TI Homogeneous T1 Hyperintense Renal Lesions with Smooth Borders Response SO RADIOLOGY LA English DT Letter C1 [Davarpanah, Amir H.] Massachusetts Gen Hosp, Dept Radiol, Div Abdominal Imaging, Boston, MA 02114 USA. RP Davarpanah, AH (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Abdominal Imaging, Boston, MA 02114 USA. EM adavarpanah@mgh.harvard.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD OCT PY 2016 VL 281 IS 1 BP 325 EP 325 PG 1 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EG8NJ UT WOS:000391313600042 ER PT J AU Mata, IF Davis, MY Lopez, AN Dorschner, MO Martinez, E Yearout, D Cholerton, BA Hu, SC Edwards, KL Bird, TD Zabetian, CP AF Mata, Ignacio F. Davis, Marie Y. Lopez, Alexis N. Dorschner, Michael O. Martinez, Erica Yearout, Dora Cholerton, Brenna A. Hu, Shu-Ching Edwards, Karen L. Bird, Thomas D. Zabetian, Cyrus P. TI The Discovery of LRRK2 p.R1441S, a Novel Mutation for Parkinson's Disease, Adds to the Complexity of a Mutational Hotspot SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS LA English DT Article DE movement disorders; genetics; neuropsychological ID R1441G MUTATION; KINASE-ACTIVITY; BASQUE COUNTRY; GENE; G2019S; PENETRANCE; VARIANTS; FAMILIES; CARRIERS; GTPASE AB Mutations in the LRRK2 gene result in autosomal dominant, late onset Parkinson's disease (PD). Three such mutations (p.R1441C, p.R1441G, and p.R1441H) are known to occur within codon 1441, and haplotype analyses indicate that each one has arisen independently on multiple occasions. We sequenced the entire coding region of 18 casual genes for PD or other parkinsonian neurodegenerative disorders in the proband of a family with autosomal dominant PD. We discovered a new missense mutation in the LRRK2 gene, c.4321C>A (p.R1441S). The mutation was predicted to be highly deleterious in silico (Combined Annotation Dependent Depletion score of 25.5) and segregated with disease in the pedigree. The clinical characteristics of affected family members were similar to those described in PD families with other mutations in LRRK2 codon 1441 and included resting tremor, rigidity, bradykinesia, unilateral onset, and a good response to levodopa. Age at onset ranged from 41 to 76. Two of the affected members of the pedigree underwent detailed, longitudinal neuropsychological testing, and both displayed evidence of mild cognitive deficits at or slightly preceding the onset of motor symptoms. LRRK2 p.R1441S represents the fourth pathogenic mutation observed within codon 1441 and its discovery adds to the remarkable complexity of a mutational hotspot within the ROC domain of the LRRK2 protein. (C) 2016 Wiley Periodicals, Inc. C1 [Mata, Ignacio F.; Davis, Marie Y.; Martinez, Erica; Yearout, Dora; Cholerton, Brenna A.; Hu, Shu-Ching; Bird, Thomas D.; Zabetian, Cyrus P.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Mata, Ignacio F.; Davis, Marie Y.; Yearout, Dora; Hu, Shu-Ching; Bird, Thomas D.; Zabetian, Cyrus P.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA. [Lopez, Alexis N.] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA. [Dorschner, Michael O.; Cholerton, Brenna A.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Dorschner, Michael O.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Edwards, Karen L.] Univ Calif Irvine, Dept Epidemiol, Irvine, CA USA. RP Zabetian, CP (reprint author), VA Puget Sound Hlth Care Syst, GRECC S-182,1660 South Columbian Way, Seattle, WA 98108 USA. EM zabetian@u.washington.edu FU Department of Veterans Affairs [1I01BX000531]; National Institutes of Health [R01 NS065070, P50 NS062684] FX Grant sponsor: Department of Veterans Affairs (Merit Award); Grant number: #1I01BX000531; Grant sponsor: National Institutes of Health; Grant numbers: R01 NS065070, P50 NS062684. NR 44 TC 2 Z9 2 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4841 EI 1552-485X J9 AM J MED GENET B JI Am. J. Med. Genet. B PD OCT PY 2016 VL 171 IS 7 BP 925 EP 930 DI 10.1002/ajmg.b.32452 PG 6 WC Genetics & Heredity; Psychiatry SC Genetics & Heredity; Psychiatry GA EF9PN UT WOS:000390662200002 PM 27111571 ER PT J AU Wu, CW Randolph, GW Lu, IC Chang, PY Chen, YT Hun, PC Lin, YC Dionigi, G Chiang, FY AF Wu, Che-Wei Randolph, Gregory W. Lu, I-Cheng Chang, Pi-Ying Chen, Yi-Ting Hun, Pao-Chu Lin, Yi-Chu Dionigi, Gianlorenzo Chiang, Feng-Yu TI Intraoperative neural monitoring in thyroid surgery: lessons learned from animal studies SO GLAND SURGERY LA English DT Review DE Intraoperative neural monitoring (IONM); recurrent laryngeal nerve (RLN); thyroid surgery; animal study; translation research ID RECURRENT LARYNGEAL NERVE; CONSTANT-VOLTAGE STIMULATION; PROSPECTIVE PORCINE MODEL; INVIVO CANINE MODEL; ENDOTRACHEAL-TUBE; ELECTROMYOGRAPHIC RESPONSE; THYROARYTENOID MUSCLES; NEUROPRAXIC INJURY; PHONATION; PARALYSIS AB Recurrent laryngeal nerve (RLN) injury remains a significant morbidity associated with thyroid and parathyroid surgery. In the past decade, surgeons have increasingly used intraoperative neural monitoring (IONM) as an adjunct technique for localizing and identifying the RLN, detecting RLN injury, and predicting the outcome of vocal cord function. In recent years, many animal studies have investigated common pitfalls and new applications of IONM. For example, the use of IONM technology in animal models has proven valuable in studies of the electrophysiology of RLN injury. The advent of animal studies has substantially improved understanding of IONM technology. Lessons learned from animal studies have immediate clinical applications in establishing reliable strategies for preventing intraoperative RLN injury. This article gives an overview of the research progress on IONM-relevant animal models. C1 [Wu, Che-Wei; Lin, Yi-Chu; Chiang, Feng-Yu] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Otolaryngol Head & Neck Surg, 100 TzYou 1st Rd, Kaohsiung 807, Taiwan. [Wu, Che-Wei; Lin, Yi-Chu; Chiang, Feng-Yu] Kaohsiung Med Univ, Coll Med, Fac Med, Kaohsiung, Taiwan. [Randolph, Gregory W.] Harvard Med Sch, Div Thyroid & Parathyroid Endocrine Surg, Dept Otol & Laryngol, Massachusetts Eye & Ear Infirm, Boston, MA USA. [Lu, I-Cheng; Chang, Pi-Ying] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Anesthesiol, Kaohsiung, Taiwan. [Chen, Yi-Ting] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Pathol, Kaohsiung, Taiwan. [Hun, Pao-Chu] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Lab Anim Ctr, Kaohsiung, Taiwan. [Dionigi, Gianlorenzo] Univ Insubria Como Varese, Div Surg 1, Res Ctr Endocrine Surg, Dept Surg Sci & Human Morphol, Varese, Italy. RP Wu, CW (reprint author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Otolaryngol Head & Neck Surg, 100 TzYou 1st Rd, Kaohsiung 807, Taiwan. EM cwwu@kmu.edu.tw FU Ministry of Science and Technology [MOST 105-2314-B-037-010]; Kaohsiung Medical University, Taiwan [KMU-TP105E, KMUH104-4R36] FX This study was supported by grants from the Ministry of Science and Technology (MOST 105-2314-B-037-010) and the Kaohsiung Medical University (KMU-TP105E; KMUH104-4R36), Taiwan. NR 56 TC 1 Z9 1 U1 0 U2 0 PU AME PUBL CO PI SHEUNG WAN PA ROOM 604 6-F HOLLYWOOD CENTER, 77-91, QUEENS ROAD, SHEUNG WAN, HONG KONG 00000, PEOPLES R CHINA SN 2227-684X EI 2227-8575 J9 GLAND SURG JI Gland Surg. PD OCT PY 2016 VL 5 IS 5 BP 473 EP 480 DI 10.21037/gs.2016.09.06 PN 1 PG 8 WC Surgery SC Surgery GA EG6BW UT WOS:000391129800004 PM 27867861 ER PT J AU Dionigi, G Wu, CW Kim, HY Liu, XL Liu, RB Randolph, GW Anuwong, A AF Dionigi, Gianlorenzo Wu, Che-Wei Kim, Hoon-Yub Liu, Xiaoli Liu, Renbin Randolph, Gregory W. Anuwong, Angkoon TI Safety of energy based devices for hemostasis in thyroid surgery SO GLAND SURGERY LA English DT Review DE Thyroid surgery; recurrent laryngeal nerve (RLN); continuous intraoperative neuromonitoring; safety; energy based devices (EBD); thyroidectomy ID RECURRENT LARYNGEAL NERVE; HARMONIC SCALPEL; PORCINE MODEL; CONVENTIONAL HEMOSTASIS; NETWORK METAANALYSIS; SURGICAL OUTCOMES; LIGASURE PRECISE; THERMAL-INJURY; FOCUS; TECHNOLOGIES AB Energy based devices (EBD) have been developed, implemented and increasingly applied in thyroid surgery because they can provide a combined dissection and haemostatic effect. In particular, advantages of EBD have been described in terms of efficacious haemostasis, reduction of procedure-associated time, reduced incision length, less operative blood loss and transfusion need, decreased postoperative drain, pain and hospital stay. In addition, EBD are essential for endoscopic procedures. On the contrary, a potential drawback is the increased health care costs. This paper reviews relevant medical literature published on the safety of new devices for achieving hemostasis and dissection around the recurrent laryngeal nerve (RLN). C1 [Dionigi, Gianlorenzo] Univ Insubria Como Varese, Div Surg 1, Res Ctr Endocrine Surg, Dept Surg Sci & Human Morphol, Varese, Italy. [Wu, Che-Wei] Kaohsiung Med Univ, Dept Otolaryngol Head & Neck Surg, Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan. [Kim, Hoon-Yub] Korea Univ, Coll Med, Korea Univ Hosp, KUMC Thyroid Ctr,Dept Surg, Seoul, South Korea. [Liu, Xiaoli] Jilin Univ, China Japan Union Hosp, Div Thyroid Surg, Jilin Prov Key Lab Surg Translat Med, Changchun 130031, Peoples R China. [Liu, Renbin] Sun Yat Sen Univ, Affiliated Hosp 3, Div Thyroid & Breast Surg, Guangzhou 510630, Guangdong, Peoples R China. [Randolph, Gregory W.] Harvard Med Sch, Div Thyroid & Parathyroid Endocrine Surg, Dept Otol & Laryngol, Massachusetts Eye & Ear Infirm, Boston, MA USA. [Anuwong, Angkoon] Police Gen Hosp, Dept Surg, Minimally Invas & Endocrine Surg Div, Bangkok, Thailand. RP Liu, XL (reprint author), Jilin Univ, Japan Union Hosp, Div Thyroid Surg, Jilin Prov Key Lab Surg Translat Med, Changchun 130031, Peoples R China. EM 13756304608@163.com NR 28 TC 1 Z9 1 U1 0 U2 0 PU AME PUBL CO PI SHEUNG WAN PA ROOM 604 6-F HOLLYWOOD CENTER, 77-91, QUEENS ROAD, SHEUNG WAN, HONG KONG 00000, PEOPLES R CHINA SN 2227-684X EI 2227-8575 J9 GLAND SURG JI Gland Surg. PD OCT PY 2016 VL 5 IS 5 BP 490 EP 494 DI 10.21037/gs.2016.09.01 PN 1 PG 5 WC Surgery SC Surgery GA EG6BW UT WOS:000391129800006 PM 27867863 ER PT J AU Lavazza, M Liu, XL Wu, CW Anuwong, A Kim, HY Liu, RB Randolph, GW Inversini, D Boni, L Rausei, S Frattini, F Dionigi, G AF Lavazza, Matteo Liu, Xiaoli Wu, Chewei Anuwong, Angkoon Kim, Hoon Yub Liu, Renbin Randolph, Gregory W. Inversini, Davide Boni, Luigi Rausei, Stefano Frattini, Francesco Dionigi, Gianlorenzo TI Indocyanine green-enhanced fluorescence for assessing parathyroid perfusion during thyroidectomy SO GLAND SURGERY LA English DT Review DE Indocyanine green (ICG); fluorescence; parathyroid; hypocalcemia; thyroidectomy ID LYMPH-NODE BIOPSY; ADVERSE-REACTIONS; BREAST-CANCER; LAPAROSCOPIC CHOLECYSTECTOMY; SURGERY; CHOLANGIOGRAPHY; ICG; TECHNOLOGIES; ANGIOGRAPHY; FOCUS AB Identification of the parathyroid glands during thyroid surgery may prevent their inadvertent surgical removal and thus provide a better postoperative quality of life. Nevertheless, the most common "technique" for intraoperative evaluation of perfusion of parathyroid gland tissues during thyroid surgery is visual inspection of the physical condition of tissues, e.g., their color and bleeding edges. Another technique is measurement of intact parathyroid hormone. Recently, indocyanine green-enhanced fluorescence has been used in various surgical techniques, particularly laparoscopic surgery, to improve visualization and to provide detailed anatomical information. Fluorescent optical guidance helps surgeons to avoid inadvertent tissue injury while enhancing procedural efficiency. This technique has potential use for evaluating perfusion of the parathyroid gland in real-time intraoperative angiography. C1 [Lavazza, Matteo; Inversini, Davide; Boni, Luigi; Rausei, Stefano; Frattini, Francesco; Dionigi, Gianlorenzo] Univ Insubria Varese Como, Div Gen Surg 1, Res Ctr Endocrine Surg, Dept Surg Sci & Human Morphol, Via Guicciardini 9, I-21100 Varese, Italy. [Liu, Xiaoli] Jilin Univ, Japan Union Hosp, Div Thyroid Surg, Jilin Prov Key Lab Surg Translat Med, Changchun 130033, Peoples R China. [Wu, Chewei] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Otolaryngol, Kaohsiung, Taiwan. [Anuwong, Angkoon] Siam Univ, Police Gen Hosp, Fac Med, Dept Surg, Bangkok, Thailand. [Kim, Hoon Yub] Korea Univ, KUMC Thyroid Ctr, Anam Hosp, Seoul, South Korea. [Liu, Renbin] Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou 510630, Guangdong, Peoples R China. [Randolph, Gregory W.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Div Thyroid & Parathyroid Surg, 243 Charles St, Boston, MA 02114 USA. [Randolph, Gregory W.] Harvard Med Sch, Boston, MA USA. RP Lavazza, M (reprint author), Univ Insubria Varese Como, Div Gen Surg 1, Res Ctr Endocrine Surg, Dept Surg Sci & Human Morphol, Via Guicciardini 9, I-21100 Varese, Italy. EM lavazza.matteo@gmail.com NR 41 TC 1 Z9 1 U1 0 U2 0 PU AME PUBL CO PI SHEUNG WAN PA ROOM 604 6-F HOLLYWOOD CENTER, 77-91, QUEENS ROAD, SHEUNG WAN, HONG KONG 00000, PEOPLES R CHINA SN 2227-684X EI 2227-8575 J9 GLAND SURG JI Gland Surg. PD OCT PY 2016 VL 5 IS 5 BP 512 EP 521 DI 10.21037/gs.2016.10.06 PN 1 PG 10 WC Surgery SC Surgery GA EG6BW UT WOS:000391129800009 PM 27867866 ER PT J AU Lonne, G Cha, TD AF Lonne, Greger Cha, Thomas D. TI MINIMALLY INVASIVE DECOMPRESSION IN LUMBAR SPINAL STENOSIS SO JBJS ESSENTIAL SURGICAL TECHNIQUES LA English DT Article ID X-STOP; BILATERAL DECOMPRESSION; UNILATERAL APPROACH; COST-EFFECTIVENESS; LAMINECTOMY; MULTICENTER; OUTCOMES; SURGERY; TRIAL C1 [Lonne, Greger; Cha, Thomas D.] Innlandet Hosp Trust, Lillehammer, Norway. [Lonne, Greger; Cha, Thomas D.] Hosp Alesund, Alesund, Norway. [Lonne, Greger; Cha, Thomas D.] Univ Hosp North Norway, Tromso, Norway. [Lonne, Greger; Cha, Thomas D.] Oslo Univ Hosp, Oslo, Norway. [Lonne, Greger; Cha, Thomas D.] St Olavs Hosp, Trondheim, Norway. [Lonne, Greger] Innlandet Hosp Trust, Dept Orthopaed Surg, Lillehammer, Norway. [Lonne, Greger; Cha, Thomas D.] Massachusetts Gen Hosp, Dept Orthopaed, Boston, MA 02114 USA. RP Lonne, G (reprint author), Innlandet Hosp Trust, Dept Orthopaed Surg, Lillehammer, Norway.; Lonne, G (reprint author), Massachusetts Gen Hosp, Dept Orthopaed, Boston, MA 02114 USA. EM greger.lonne@ntnu.no; TCHA@mgh.harvard.edu NR 15 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2160-2204 J9 JBJS ESSENT SURG TEC JI JBJS Essent. Surg. Tech. PD OCT-DEC PY 2016 VL 6 IS 4 AR e41 DI 10.2106/JBJS.ST.16.00029 PG 11 WC Surgery SC Surgery GA EG4RR UT WOS:000391031900008 ER PT J AU Faje, A Chunharojrith, P Nency, J Biller, BMK Swearingen, B Klibanski, A AF Faje, Alexander Chunharojrith, Paweena Nency, Joshipura Biller, Beverly M. K. Swearingen, Brooke Klibanski, Anne TI Dopamine Agonists Can Reduce Cystic Prolactinomas SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID SECRETING PITUITARY-ADENOMAS; CABERGOLINE TREATMENT; BROMOCRIPTINE; HYPERPROLACTINEMIA; MACROPROLACTINOMAS; DIAGNOSIS; SHRINKAGE; SOCIETY; SIZE AB Context: Cystic prolactinomas are considered resistant to volume reduction by dopamine agonists (DAs). Although several individual case reports and small case series have suggested that DAs may reduce these lesions, larger series using standardized imaging metrics are lacking. Objective: The objectives of the study were to assess the efficacy of DAs on cyst size in patients with predominantly cystic prolactinomas and to characterize the clinical course and treatment outcomes in these patients. Design: This study was a retrospective review. Setting: The study was conducted at a tertiary referral center. Subjects: The study comprised 30 adults with cystic prolactinomas treated at Massachusetts General Hospital. Intervention(s): The interventions included treatment with Das and transsphenoidal surgery. Main Outcome Measure(s): Cyst volume calculated by a commercial software and pituitary hormone function were measured. Results: Median age was 31.5 years (interquartile range [IR] 24.5-39.2), and 24 of 30 were female. Median length of follow-up was 3.05 years (IR 1.04-5.28). Twenty-three of 30 patients received initial treatment with DAs. Median cyst volume for these patients was 435 mm(3) (IR 255-1785). Persistent cyst reduction occurred in 20 of 22 patients after DA treatment. Median cyst volume reduction was 83.5% (IR 48.8-96.2). Median time to cyst reduction was 24.6 weeks (range 2.6-73). Chiasm compression resolved in four of five patients, and nongonadal anterior hypopituitarism improved in five of six. Transsphenoidal surgery was ultimately performed in 15 of 30 patients. Conclusions: Significant cyst reduction occurred in the majority of patients treated with DAs, including those with larger lesions and chiasm compression. This study is the first formal analysis of cyst reduction with DAs in patients with cystic prolactinomas, and contrary to long-held assumptions, our results suggest that medical therapy may be effective in many such patients. C1 [Faje, Alexander; Chunharojrith, Paweena; Biller, Beverly M. K.; Klibanski, Anne] Massachusetts Gen Hosp, Neuroendocrine Unit, BUL 457,55 Fruit St, Boston, MA 02114 USA. [Swearingen, Brooke] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Nency, Joshipura] Dana Farber Harvard Canc Ctr, Tumor Imaging Metr Core, Boston, MA 02114 USA. RP Faje, A (reprint author), Massachusetts Gen Hosp, Neuroendocrine Unit, BUL 457,55 Fruit St, Boston, MA 02114 USA. EM afaje@partners.org NR 18 TC 0 Z9 0 U1 0 U2 0 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD OCT PY 2016 VL 101 IS 10 BP 3709 EP 3715 DI 10.1210/jc.2016-2008 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EG2CI UT WOS:000390849800025 PM 27459530 ER PT J AU Chao, J Rubinow, KB Kratz, M Amory, JK Matsumoto, AM Page, ST AF Chao, Jing Rubinow, Katya B. Kratz, Mario Amory, John K. Matsumoto, Alvin M. Page, Stephanie T. TI Short-Term Estrogen Withdrawal Increases Adiposity in Healthy Men SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID ANDROGEN-DEPRIVATION THERAPY; REDUCES INSULIN SENSITIVITY; PROSTATE-CANCER; CARDIOVASCULAR-DISEASE; TESTOSTERONE THERAPY; METABOLIC SYNDROME; BODY-COMPOSITION; HEART-DISEASE; ADULT MEN; OLDER MEN AB Context: T deprivation increases risk of insulin resistance in men, but whether this risk is independent of changes in body composition is unknown. Further, the metabolic roles of T and its metabolite estradiol have not been clearly defined in men. Objective: This study sought to establish the effects of selective sex steroid withdrawal on insulin sensitivity in healthy men. Design, Setting, and Participants: This was a double-blinded, placebo-controlled, randomized trial at an academic medical center of 56 healthy men, 19-55 years of age. Interventions: Subjects received the GnRH antagonist acyline plus one of the following: placebo gel (Castrate), 1.25 g testosterone gel (Low T/E), 5 g testosterone gel (Normal T/E), or 5 g testosterone gel with letrozole (Normal T/Low E) daily for 4 weeks. Body composition and glucose tolerance were assessed at baseline and end of treatment. Main Outcome Measure: Insulin sensitivity was quantified by the Matsuda index. Results: Predicted circulating sex steroid concentrations were achieved in all treatment groups. The time-by-group interaction for Matsuda index did not achieve significance in overall repeated measures ANOVA (baseline vs week 4; P = .16). A significant time-by-group interaction was observed for fat mass (P = .003), with changes in fat mass attributable predominantly to estrogen exposure in linear regression analysis (P = .016). Atime-by-group interaction also was observed for lean mass (P = .03) and influenced by androgen exposure (P = .003). Conclusions: Short-term sex steroid withdrawal in healthy men causes adverse changes in body composition. These findings support the role of estradiol as a determinant of adiposity in men. C1 [Chao, Jing; Rubinow, Katya B.; Amory, John K.; Page, Stephanie T.] Univ Washington, Sch Med, Ctr Res Reprod & Contracept, Seattle, WA 98195 USA. [Rubinow, Katya B.; Page, Stephanie T.] Univ Washington, Sch Med, Inst Diabet, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. [Matsumoto, Alvin M.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA. [Kratz, Mario] Fred Hutchinson Canc Res Ctr, Seattle, WA 98108 USA. [Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. RP Page, ST (reprint author), Dept Med, Div Metab Endocrinol & Nutr, Hlth Sci, C-506,1959 NE Pacific St, Seattle, WA 98195 USA. EM page@uw.edu FU AbbVie Inc. (Chicago, IL); American Heart Association Clinical Research Program; Eunice Kennedy Shriver National Institute of Child Health and Development [6K12 HD053984, HD042454]; National Institute of Aging [RO1AG037603]; Robert McMillen Professorship in Lipid Research; National Institute of Diabetes and Digestive and Kidney Diseases [T32DK007247-37]; Department of Veterans Affairs FX Transdermal T gel and placebo gel were provided at no cost to the study by AbbVie Inc. (Chicago, IL), as an investigator-initiated grant. AbbVie Inc. had no input into the study design or conduct, data analyses, or manuscript preparation and provided no other financial support for the study. K.B.R. is supported by the American Heart Association Clinical Research Program and the Eunice Kennedy Shriver National Institute of Child Health and Development (6K12 HD053984). S.T.P. is supported by the Eunice Kennedy Shriver National Institute of Child Health and Development (HD042454), the National Institute of Aging (RO1AG037603), and the Robert McMillen Professorship in Lipid Research. J.C. received support through the National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007247-37). A.M.M. is supported by the Department of Veterans Affairs. NR 32 TC 0 Z9 0 U1 2 U2 2 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD OCT PY 2016 VL 101 IS 10 BP 3724 EP 3731 DI 10.1210/jc.2016-1482 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EG2CI UT WOS:000390849800027 PM 27482750 ER PT J AU Joffe, H Crawford, SL Freeman, MP White, DP Bianchi, MT Kim, S Economou, N Camuso, J Hall, JE Cohen, LS AF Joffe, Hadine Crawford, Sybil L. Freeman, Marlene P. White, David P. Bianchi, Matt T. Kim, Semmie Economou, Nicole Camuso, Julie Hall, Janet E. Cohen, Lee S. TI Independent Contributions of Nocturnal Hot Flashes and Sleep Disturbance to Depression in Estrogen-Deprived Women SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID MIDDLE-AGED WOMEN; MENOPAUSAL TRANSITION; VASOMOTOR SYMPTOMS; BREAST-CANCER; BAZEDOXIFENE/CONJUGATED ESTROGENS; PERIMENOPAUSAL WOMEN; MASS-SPECTROMETRY; RANDOMIZED-TRIAL; HORMONE AGONIST; MOOD AB Context: Women are at increased risk for mood disturbance during the menopause transition. Hot flashes (HFs), sleep disruption, and fluctuating estradiol levels correlate with menopause-associated depression but co-occur, making cause and effect relationships difficult to disentangle. Objective: Using a GnRH agonist (GnRHa) experimental model, we investigated whether depressive symptoms are associated with HFs and/or are explained by concomitant sleep fragmentation in the absence of estradiol fluctuation. Design and Intervention: Depressive symptoms, objective polysomnographic sleep parameters, subjective sleep quality, serum estradiol, and HFs were assessed before and 4 weeks after openlabel depot GnRHa (leuprolide 3.75-mg) administration. Setting: Academic medical center. Participants: Twenty-nine healthy nondepressed premenopausal volunteers (mean age, 27.3 years). Results: Serum estradiol was rapidly and uniformly suppressed. HFs developed in 69% of the subjects. Onunivariate analysis, worsening ofmoodwaspredicted by increases in time in light sleep (stage N1), number of transitions to wake, non-REM arousals, subjective sleep quality, and reductions in perceived sleep efficiency (all P < .045), as well as the number of nighttime (P = .006), but not daytime (P = .28), HFs reported. In adjusted models, the number of nighttime HFs reported, increases in non-REM arousals, time in stage N1, transitions to wake, and reduced sleep quality remained significant predictors of mood deterioration (P <= .05). Conclusions: Depressive symptoms emerged after estradiol withdrawal in association with objectively and subjectively measured sleep disturbance and the number of nighttime, but not daytime, HFs reported. Results suggest that sleep disruption and perceived nighttime HFs both contribute to vulnerability to menopause-associated depressive symptoms in hypoestrogenic women. C1 [Joffe, Hadine; Kim, Semmie; Camuso, Julie] Harvard Med Sch, Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA. [Joffe, Hadine] Harvard Med Sch, Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02215 USA. [Joffe, Hadine; Freeman, Marlene P.; Economou, Nicole; Cohen, Lee S.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Crawford, Sybil L.] Univ Massachusetts, Sch Med, Dept Med, Div Prevent & Behav Med, Worcester, MA 01655 USA. [White, David P.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Sleep Med, Boston, MA 02115 USA. [Bianchi, Matt T.] Harvard Med Sch, Massachusetts Gen Hosp, Sleep Div, Dept Neurol, Boston, MA 02114 USA. [Hall, Janet E.] Harvard Med Sch, Massachusetts Gen Hosp, Reprod Endocrine Unit, Dept Med, Boston, MA 02114 USA. [Hall, Janet E.] NIEHS, NIH, POB 12233, Res Triangle Pk, NC 27709 USA. RP Joffe, H (reprint author), Brigham & Womens Hosp, 75 Francis St,Thorn 1111, Boston, MA 02115 USA. EM hjoffe@partners.org OI Hall, Janet/0000-0003-4644-3061 FU National Institute of Mental Health [5R01MH082922] FX This work was supported by National Institute of Mental Health Grant 5R01MH082922 (to H.J.). NR 43 TC 1 Z9 1 U1 3 U2 3 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD OCT PY 2016 VL 101 IS 10 BP 3847 EP 3855 DI 10.1210/jc.2016-2348 PG 9 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EG2CI UT WOS:000390849800042 PM 27680875 ER PT J AU Ly, S Frates, MC Benson, CB Peters, HE Grant, FD Drubach, LA Voss, SD Feldman, HA Smith, JR Barletta, J Hollowell, M Cibas, ES Moore, FD Modi, B Shamberger, RC Huang, SA AF Ly, Samantha Frates, Mary C. Benson, Carol B. Peters, Hope E. Grant, Frederick D. Drubach, Laura A. Voss, Stephan D. Feldman, Henry A. Smith, Jessica R. Barletta, Justine Hollowell, Monica Cibas, Edmund S. Moore, Francis D., Jr. Modi, Biren Shamberger, Robert C. Huang, Stephen A. TI Features and Outcome of Autonomous Thyroid Nodules in Children: 31 Consecutive Patients Seen at a Single Center SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID MANAGEMENT GUIDELINES; FOLLICULAR VARIANT; TOXIC NODULE; CANCER; CARCINOMA; SURGERY; BENIGN; HYPERTHYROIDISM; ASSOCIATION; CYTOPATHOLOGY AB Context: Most thyroid nodules are benign and their accurate identification can avoid unnecessary procedures. In adult patients, documentation of nodule autonomy is accepted as reassurance of benign histology and as justification to forgo biopsy or thyroidectomy. In contrast, the negative predictive value of nodule autonomyin children is uncertain. Some recent publications recommend surgical resection as initial management, but few address the degree of TSH suppression or the specific scintigraphic criteria used to diagnose autonomy. Objective: The objective of the study was to study the presenting features and cancer risk of children with autonomous nodules. Design and Setting: Medical records of all 31 children diagnosed with autonomous nodules at our center from 2003 to 2014 were retrospectively reviewed. Patients and Results: All children met full diagnostic criteria for autonomous nodules, defined by both autonomous I-123 uptake into the nodule and the suppression of uptake in the normal thyroid parenchyma on scintigraphy performed during hypothyrotropinemia. The median age of presentation was 15 years (range 3-18 y) with a female to male ratio of 15: 1. Fifty-eight percent of patients had solitary nodules and 42% had multiple nodules. The median size of each patient's largest autonomous nodule was 39 mm (range 18-67 mm). Most of the children in this series (68%) had diagnostic biopsies and/ or operative pathology of their largest autonomous nodule, whichshowed benign cytology or histology in all cases. Conclusions: In this pediatric series, the cancer rate observed in biopsied or resected autonomous nodules was 0%. Whereas larger studies are needed to confirm our findings, these results agree with earlier reports suggesting that thyroid cancer is rare in rigorously defined autonomous nodules and support that conservativemanagementmaybe offered to selected childrenwhomeetstrict diagnostic criteria for autonomous nodules, deferring definitive therapies until adulthood when the risks of thyroidectomy and I-131 ablation are lower. C1 [Ly, Samantha; Grant, Frederick D.; Feldman, Henry A.; Smith, Jessica R.; Huang, Stephen A.] Boston Childrens Hosp, Thyroid Program, Div Endocrinol, 300 Longwood Ave, Boston, MA 02115 USA. [Feldman, Henry A.] Boston Childrens Hosp, Clin Res Ctr, Boston, MA 02115 USA. [Grant, Frederick D.; Drubach, Laura A.; Voss, Stephan D.; Huang, Stephen A.] Boston Childrens Hosp, Dept Radiol, Boston, MA 02115 USA. [Hollowell, Monica; Cibas, Edmund S.] Boston Childrens Hosp, Dept Pathol, Boston, MA 02115 USA. [Modi, Biren; Shamberger, Robert C.] Boston Childrens Hosp, Dept Surg, Boston, MA 02115 USA. [Huang, Stephen A.] Brigham & Womens Hosp, Thyroid Sect, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA. [Frates, Mary C.; Benson, Carol B.; Peters, Hope E.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA. [Barletta, Justine; Cibas, Edmund S.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Moore, Francis D., Jr.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA. [Huang, Stephen A.] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Huang, SA (reprint author), Boston Childrens Hosp, Thyroid Program, Div Endocrinol, 300 Longwood Ave, Boston, MA 02115 USA. EM stephen.huang@childrens.harvard.edu FU National Institutes of Health [DK076099] FX This work was supported by donations from the Evans family and the Murray family, the Pan-Mass Challenge, and Grant DK076099 from the National Institutes of Health. NR 34 TC 0 Z9 0 U1 1 U2 1 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD OCT PY 2016 VL 101 IS 10 BP 3856 EP 3862 DI 10.1210/jc.2016-1779 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EG2CI UT WOS:000390849800043 PM 27501280 ER PT J AU Nadkarni, NA Rajakumar, A Mokhashi, N Burke, SD Rana, S Salahuddin, S Dang, Q Thadhani, R Krishnan, R Stossel, TP Kaumanchi, SA AF Nadkarni, Neil A. Rajakumar, Augustine Mokhashi, Nikita Burke, Suzanne D. Rana, Sarosh Salahuddin, Saira Quynh Dang Thadhani, Ravi Krishnan, Ramaswamy Stossel, Thomas P. Kaumanchi, S. Ananth TI Gelsolin is an endogenous inhibitor of syncytiotrophoblast extracellular vesicle shedding in pregnancy SO PREGNANCY HYPERTENSION-AN INTERNATIONAL JOURNAL OF WOMENS CARDIOVASCULAR HEALTH LA English DT Article DE Preeclampsia; Syncytiotrophoblastic microparticle; shedding; Gelsolin; Dynamic stretch; sFlt1 ID INTRAUTERINE GROWTH RESTRICTION; PLASMA GELSOLIN; ANTIANGIOGENIC FACTORS; MATERNAL CIRCULATION; PREECLAMPSIA; ACTIN; MICROPARTICLES; PLACENTA; PATHOPHYSIOLOGY; EXPRESSION AB Background: Preeclampsia, a pregnancy-specific inflammatory disorder, is characterized by high levels of anti-angiogenic protein, soluble fms-like tyrosine kinase 1 (sFlt1), in the maternal circulation. sFlt1 producing molecular machinery is present in syncytiotrophoblast extracellular vesicles that are released by the placenta into maternal plasma during normal pregnancy, a process greatly accelerated in preeclampsia. We hypothesized that syncytiotrophoblast extracellular vesicles exposes cytoplasmic actin to plasma resulting in depletion of plasma gelsolin (pGSN), an abundant plasma protein that scavenges circulating actin and other pro-inflammatory mediators. Objective: To test whether pGSN levels would be lower in preeclampsia and to assess whether recombinant human plasma gelsolin (rhpGSN) may promote placental health by decreasing shedding of syncytiotrophoblast extracellular vesicles. Methods: We tested pGSN levels in third trimester plasma samples from women with preeclampsia and non-hypertensive pregnancies. We then assessed whether rhpGSN may act as a negative regulator of syncytial shedding in placental explant culture and dynamic mechanical stretch studies. Results: pGSN levels fall in late pregnancy and decline further in preeclampsia patients. Recombinant human pGSN (rhpGSN) at 100 mu g/ml limits spontaneous syncytiotrophoblast vesicle release and sFlt1 protein dissemination by normal placental explants. Higher rhpGSN doses (500 mu g/ml) also limit syncytiotrophoblast vesicle and sFlt1 dissemination from preeclamptic placental explants. rhpGSN also mitigates syncytiotrophoblast vesicle during dynamic mechanical stretch. Conclusions: 1) pGSN, an anti-inflammatory factor of maternal origin is reduced in preeclampsia and may contribute to disease progression and 2) exogenous rhpGSN supplementation can limit the dissemination of toxic syncytiotrophoblast vesicle that characterizes the disease state. (C) 2016 International Society for the Study of Hypertension in Pregnancy. Published by Elsevier B.V. All rights reserved. C1 [Nadkarni, Neil A.] McGaw Northwestern Mem Hosp, Dept Neurol, Chicago, IL USA. [Nadkarni, Neil A.; Rajakumar, Augustine; Mokhashi, Nikita; Burke, Suzanne D.; Rana, Sarosh; Salahuddin, Saira; Quynh Dang; Krishnan, Ramaswamy; Kaumanchi, S. Ananth] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Vasc Biol Res Ctr, Boston, MA USA. [Rajakumar, Augustine] Emory Univ, Sch Med, Dept Obstet & Gynecol, Atlanta, GA USA. [Burke, Suzanne D.; Salahuddin, Saira; Kaumanchi, S. Ananth] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA USA. [Rana, Sarosh] Univ Chicago, Dept Obstet & Gynecol, Div Maternal Fetal Med, Chicago, IL 60637 USA. [Rana, Sarosh; Salahuddin, Saira; Kaumanchi, S. Ananth] Harvard Med Sch, Beth Israel Med Ctr, Dept Obstet & Gynecol, Div Maternal Fetal Med, Boston, MA USA. [Quynh Dang; Krishnan, Ramaswamy] Harvard Med Sch, Beth Israel Med Ctr, Dept Emergency Med, Boston, MA USA. [Thadhani, Ravi] Harvard Med Sch, Massachusetts Gen Hosp, Div Nephrol, Boston, MA USA. [Stossel, Thomas P.] Harvard Med Sch, Brigham & Womens Hosp, Div Hematol, Boston, MA USA. RP Kaumanchi, SA (reprint author), Beth Israel Deaconess Med Ctr, 99 Brookline Ave, Boston, MA 02215 USA. EM sananth@bidmc.harvard.edu FU Howard Hughes Medical Institute; Howard Hughes Medical Institute Medical Student Research Fellowship FX This work was supported by Howard Hughes Medical Institute (S.A.K.), and Howard Hughes Medical Institute Medical Student Research Fellowship (N.A.N.). R.T. and S.A.K are co-inventors on patents related to preeclampsia biomarkers that are held at Massachusetts General Hospital and Beth Israel Deaconess Medical Center. R.T and S.A.K. have financial interest in Aggamin LLC and report serving as a consultant to Roche Diagnostics, Siemens and Thermofisher. T.S. is an inventor on issued and pending patents related to diagnostic and therapeutic aspects of gelsolin in infection, inflammatory and other diseases. He is a director of Velico Medical and of Bioaegis Therapeutics that is developing gelsolin diagnosis and therapy for use in disorders related to the aforementioned patents. All other authors report no conflict. NR 49 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2210-7789 J9 PREGNANCY HYPERTENS JI Pregnancy Hypertens. PD OCT PY 2016 VL 6 IS 4 BP 333 EP 339 DI 10.1016/j.preghy.2016.07.003 PG 7 WC Obstetrics & Gynecology; Peripheral Vascular Disease SC Obstetrics & Gynecology; Cardiovascular System & Cardiology GA EG1WT UT WOS:000390825400018 PM 27939478 ER PT J AU Wang, RX Chu, GCY Mrdenovic, S Annamalai, AA Hendifar, AE Nissen, NN Tomlinson, JS Lewis, M Palanisamy, N Tseng, HR Posadas, EM Freeman, MR Pandol, SJ Zhau, HE Chung, LWK AF Wang, Ruoxiang Chu, Gina C. Y. Mrdenovic, Stefan Annamalai, Alagappan A. Hendifar, Andrew E. Nissen, Nicholas N. Tomlinson, James S. Lewis, Michael Palanisamy, Nallasivam Tseng, Hsian-Rong Posadas, Edwin M. Freeman, Michael R. Pandol, Stephen J. Zhau, Haiyen E. Chung, Leland W. K. TI Cultured circulating tumor cells and their derived xenografts for personalized oncology SO ASIAN JOURNAL OF UROLOGY LA English DT Review DE Cancer metastasis; Peripheral blood; Circulating tumor cell; ex vivo culture ID COLON-CANCER CELLS; EX-VIVO CULTURE; IN-VITRO CULTURE; PROSTATE-CANCER; PANCREATIC-CANCER; BREAST-CANCER; LUNG-CANCER; MESENCHYMAL TRANSITION; GASTRIC-CANCER; EP-CAM AB Recent cancer research has demonstrated the existence of circulating tumor cells (CTCs) in cancer patient's blood. Once identified, CTC biomarkers will be invaluable tools for clinical diagnosis, prognosis and treatment. In this review, we propose ex vivo culture as a rational strategy for large scale amplification of the limited numbers of CTCs from a patient sample, to derive enough CTCs for accurate and reproducible characterization of the biophysical, biochemical, gene expressional and behavioral properties of the harvested cells. Because of tumor cell heterogeneity, it is important to amplify all the CTCs in a blood sample for a comprehensive understanding of their role in cancer metastasis. By analyzing critical steps and technical issues in ex vivo CTC culture, we developed a cost-effective and reproducible protocol directly culturing whole peripheral blood mononuclear cells, relying on an assumed survival advantage in CTCs and CTC-like cells over the normal cells to amplify this specified cluster of cancer cells. (C) 2016 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. C1 [Wang, Ruoxiang; Chu, Gina C. Y.; Mrdenovic, Stefan; Hendifar, Andrew E.; Posadas, Edwin M.; Pandol, Stephen J.; Zhau, Haiyen E.; Chung, Leland W. K.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Med, Urooncol Res, Los Angeles, CA 90048 USA. [Annamalai, Alagappan A.; Nissen, Nicholas N.; Freeman, Michael R.; Chung, Leland W. K.] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Surg, Urooncol Res, Los Angeles, CA 90048 USA. [Tomlinson, James S.] West Angeles VA Hosp, Greater Angeles Vet Affairs Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Lewis, Michael] West Los Angeles VA Hosp, Greater Los Angeles Vet Affairs Healthcare Syst, Dept Pathol, Los Angeles, CA USA. [Palanisamy, Nallasivam] Henry Ford Hlth Syst, Detroit, MI USA. [Tseng, Hsian-Rong] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA. RP Wang, RX (reprint author), Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Med, Urooncol Res, Los Angeles, CA 90048 USA. EM Ruoxiang.wang@cshs.org OI Palanisamy, Nallasivam/0000-0002-0633-9772 FU US NIH/NCI [2PO1CA098912, UO1CA198900]; Cedars-Sinai Medical Center Board of Governors Cancer Research Chair FX This work is supported by US NIH/NCI research grant (2PO1CA098912), Cedars-Sinai Medical Center Board of Governors Cancer Research Chair (LWKC), and US NIH/NCI (UO1CA198900) (HRT/EMP). NR 104 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SINGAPORE PTE LTD PI SINGAPORE PA 3 KILLINEY ROAD 08-01, WINSLAND HOUSE 1, SINGAPORE, 239519, SINGAPORE SN 2214-3882 EI 2214-3890 J9 ASIAN J UROL JI ASIAN J. UROL. PD OCT PY 2016 VL 3 IS 4 SI SI BP 240 EP 253 DI 10.1016/j.ajur.2016.08.005 PG 14 WC Urology & Nephrology SC Urology & Nephrology GA EG1VB UT WOS:000390819500010 ER PT J AU Fernandes, RS Ferreira, DD Ferreirac, CD Giammarile, F Rubello, D de Barros, ALB AF Fernandes, Renata Salgado Ferreira, Diego dos Santos Ferreirac, Carolina de Aguiar Giammarile, Francesco Rubello, Domenico Branco de Barros, Andre Luis TI Development of imaging probes for bone cancer in animal models. A systematic review SO BIOMEDICINE & PHARMACOTHERAPY LA English DT Review DE Bone metastasis; Bone tumor; Imaging probes; Diagnosis; Bone targeting ID HORMONE-RELATED PROTEIN; HUMAN PROSTATE-CANCER; POSITRON-EMISSION-TOMOGRAPHY; HUMAN BREAST-CANCER; MICRO-CT ANALYSIS; MOUSE MODEL; CANINE OSTEOSARCOMA; COMPUTED-TOMOGRAPHY; FOLLOW-UP; DEDIFFERENTIATED CHONDROSARCOMA AB Bone is a dynamic tissue that is constantly remodeled throughout the lifetime to ensure the integrity of the skeleton. Primary cancer cells disseminate into circulation, often extravasating to bone, where they interact with the bone marrow to grow and proliferate, disrupting the bone homeostasis. Although primary bone tumors account for less than 0.2% of all cancers, bone is a common site for the development of metastases, as its microenvironment provides the necessary conditions for the growth and proliferation of cancer cells. Metastases to the skeletal system are observed in up to 70% of all cancer patients and the growth of disseminated tumor metastases is a major cause of mortality. As widely known, a non-invasive diagnosis of bone tumors at early stages is of great importance to provide insights that will help on the decision of therapy regimen, improving treatment outcomes. Early diagnosis of bone metastases is also an important step for establishing palliative care as they may cause serious endocrine, hematologic, neurologic and orthopedic complications as well as intolerable pain. Therefore, development of new imaging techniques, imaging moieties, and animal models to mimic these bone conditions, play an important role in improving the clinical outcome of this disease. In this review, we will briefly describe the advantages and disadvantages of the currently available imaging techniques that aim at identifying bone tumors. In addition, we will provide an update on the animal models applicable at mimicking bone tumor characteristics, as well as describe recent advances on the development of new imaging probes, in the preclinical settings including targeted nanoparticles and radiopharmaceuticals. (C) 2016 Elsevier Masson SAS. All rights reserved. C1 [Fernandes, Renata Salgado; Branco de Barros, Andre Luis] Univ Fed Minas Gerais, Fac Pharm, Belo Horizonte, MG, Brazil. [Ferreira, Diego dos Santos] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Biomed Imaging, Boston, MA USA. [Ferreirac, Carolina de Aguiar] Univ Wisconsin, Dept Biomed Engn, Madison, WI USA. [Giammarile, Francesco] Univ Hosp Lyon, Dept Nucl Med, Lyon, France. [Rubello, Domenico] Rovigo Hosp, Dept Nucl Med, Radiol,Microbiol,Pathol, Intervent Radiol,NeuroRadiol,Med Phys,Clin Lab,, Rovigo, Italy. RP Rubello, D (reprint author), Rovigo Hosp, Dept Nucl Med, Radiol,Microbiol,Pathol, Intervent Radiol,NeuroRadiol,Med Phys,Clin Lab,, Rovigo, Italy. EM domenico.rubello@libero.it FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq-Brazil); Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG-Brazil); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES-Brazil) FX Authors would like to thank Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq-Brazil), Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG-Brazil), and Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES-Brazil) for their grants and fellowship. NR 170 TC 1 Z9 1 U1 8 U2 8 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0753-3322 EI 1950-6007 J9 BIOMED PHARMACOTHER JI Biomed. Pharmacother. PD OCT PY 2016 VL 83 BP 1253 EP 1264 DI 10.1016/j.biopha.2016.08.039 PG 12 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA EF6IC UT WOS:000390433400151 PM 27565848 ER PT J AU Liu, W Zhang, YK Xia, P Li, S Feng, XT Gao, Y Wang, K Song, Y Duan, ZF Yang, SH Shao, ZW Yang, C AF Liu, Wei Zhang, Yukun Xia, Ping Li, Shuai Feng, Xintong Gao, Yong Wang, Kun Song, Yu Duan, Zhenfeng Yang, Shuhua Shao, Zengwu Yang, Cao TI MicroRNA-7 regulates IL-1 beta-induced extracellular matrix degeneration by targeting GDF5 in human nucleus pulposus cells SO BIOMEDICINE & PHARMACOTHERAPY LA English DT Article DE Intervertebral disc degeneration; miR-7; GDF5; Nucleus pulposus; IL-1 beta ID HUMAN INTERVERTEBRAL DISC; DIFFERENTIATION FACTOR-5; IN-VITRO; EXPRESSION; GROWTH; INHIBITORS; PROTEIN AB The precise role of interleukin-1 beta (IL-1 beta)-induced extracellular matrix degeneration in the pathogenesis of intervertebral disc degeneration (IDD) is currently unknown. Recent evidence has revealed that microRNAs (miRNAs) are associated with IDD, but their function in the extracellular matrix degradation of nucleus pulposus (NP) tissues is also poorly understood. The aim of this study was to evaluate the expression and functional role of miR-7 in IL-1 beta-induced disc degeneration. The expression level of miR-7 was investigated in degenerative NP tissues and in IL-1 beta-induced NP cells using quantitative reverse transcription-polymerase chain reaction amplification analysis. A dual-luciferase reporter assay was then utilized to determine whether growth differentiation factor 5 (GDF5) is a target of miR-7. Finally, mRNA and protein levels of known matrix components and of matrix degradation enzymes were determined to elucidate the function of miR-7 in IL-1 beta-induced disc degeneration. In this study, we found that miR-7 is highly expressed in human degenerative NP tissues and in IL-1 beta stimulated NP cells compared to normal controls. We also determined that GDF5 was a target of miR-7. Functional analysis showed that the overexpression of miR-7 significantly enhanced the IL-1 beta-induced extracellular matrix degeneration, whereas inhibition of miR-7 function by antagomiR-7 prevented NP cell detrimental catabolic changes in response to IL-1 beta. Additionally, the prevention of IL-1 beta-induced NP extracellular matrix degeneration by miR-7 silencing was attenuated by GDF5 siRNA. These findings suggest that miR-7 contributes to an impaired ECM in intervertebral discs through targeting GDF5 and miR-7 might therefore represent a novel therapeutic target for the prevention of IDD. (C) 2016 Elsevier Masson SAS. All rights reserved. C1 [Liu, Wei; Zhang, Yukun; Li, Shuai; Feng, Xintong; Gao, Yong; Wang, Kun; Song, Yu; Yang, Shuhua; Shao, Zengwu; Yang, Cao] Huazhong Univ Sci & Technol, Union Hosp, Dept Orthoped, Tongji Med Coll, Jiefang Rd 1277, Wuhan 430022, Peoples R China. [Liu, Wei; Xia, Ping] First Hosp Wuhan, Dept Orthoped, Zhongshan Rd 215, Wuhan 430022, Peoples R China. [Duan, Zhenfeng] Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Sarcoma Biol Lab, 100 Blossom St, Boston, MA 02114 USA. RP Yang, C (reprint author), Huazhong Univ Sci & Technol, Union Hosp, Dept Orthoped, Tongji Med Coll, Jiefang Rd 1277, Wuhan 430022, Peoples R China. EM yangcao1971@sina.com FU National Natural Science Foundation of China [81272025] FX This work was supported by National Natural Science Foundation of China (grant no. 81272025). NR 31 TC 1 Z9 2 U1 2 U2 2 PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER PI PARIS PA 23 RUE LINOIS, 75724 PARIS, FRANCE SN 0753-3322 EI 1950-6007 J9 BIOMED PHARMACOTHER JI Biomed. Pharmacother. PD OCT PY 2016 VL 83 BP 1414 EP 1421 DI 10.1016/j.biopha.2016.08.062 PG 8 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA EF6IC UT WOS:000390433400169 PM 27583982 ER PT J AU Hermann, BA Meyer, EC Schnurr, PP Batten, SV Walser, RD AF Hermann, Barbara A. Meyer, Eric C. Schnurr, Paula P. Batten, Sonja V. Walser, Robyn D. TI Acceptance and commitment therapy for co-occurring PTSD and substance use: A manual development study SO JOURNAL OF CONTEXTUAL BEHAVIORAL SCIENCE LA English DT Article DE PTSD; Substance use; Acceptance and commitment therapy; Veterans ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; ACTION QUESTIONNAIRE-II; PSYCHOMETRIC PROPERTIES; EXPERIENTIAL AVOIDANCE; SMOKING-CESSATION; VETERANS; HEALTH; SCALE; DEPENDENCE AB We present the theoretical rationale for addressing comorbid posttraumatic stress disorder (PTSD) and substance use disorder (SUD) with Acceptance and Commitment Therapy (ACT). We then describe the development of a treatment manual of ACT for PTSD/SUD and the subsequent refinement to this manual following a feasibility study with a small sample of veterans. Treatment retention was similar to what has been observed in studies of other integrated treatments for PTSD/SUD. Overall treatment satisfaction was positive. Pilot outcomes are presented for descriptive purposes. We describe changes we made to the initial manual following the trial to bolster retention and improve the intervention. Revisions were based on feedback from therapists, consultants, and participants and examination of pilot outcome data. Additional strategies for adapting ACT to this challenging clinical presentation are offered. Published by Elsevier Inc. on behalf of Association for Contextual Behavioral Science. C1 [Hermann, Barbara A.; Schnurr, Paula P.] VA Med Ctr, Natl Ctr PTSD, Execut Div, 116D,215 North Main St, White River Jct, VT 05009 USA. [Hermann, Barbara A.; Schnurr, Paula P.] Geisel Sch Med, Dartmouth, NS, Canada. [Meyer, Eric C.] Waco VA Med Ctr, VA VISN Ctr Excellence Res Returning War Vet 17, 4800 Mem Dr 151C, Waco, TX 76711 USA. [Meyer, Eric C.] Texas A&M Hlth Sci Ctr, Coll Med, Temple, TX USA. [Batten, Sonja V.] Mental Hlth Serv 10P4M, VA Cent Off, 810 Vermont Ave,NW, Washington, DC 20420 USA. [Walser, Robyn D.] Palo Alto Hlth Care Syst NCPTSD 334, Disseminat & Training Div, Natl Ctr PTSD, 795 Willow Rd, Menlo Pk, CA 94025 USA. [Batten, Sonja V.] Booz Allen Hamilton, Washington, DC USA. RP Hermann, BA (reprint author), US Dept Vet Affairs, Burlington Community Based Outpatient Clin, 128 Lakeside Ave,Suite 260, Burlington, VT 05401 USA. EM Barbara.Hermann@va.gov; Eric.C.Meyer@va.gov; Paula.P.Schnurr@clartmouth.edu; sonjavbatten@gmail.com; Robyn.Walser@va.gov NR 57 TC 0 Z9 0 U1 7 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2212-1447 EI 2212-1455 J9 J CONTEXTUAL BEHAV S JI J. Contextual Behav. Sci. PD OCT PY 2016 VL 5 IS 4 BP 225 EP 234 DI 10.1016/j.jcbs.2016.07.001 PG 10 WC Psychology, Clinical SC Psychology GA EF8KK UT WOS:000390577500004 ER PT J AU Sitek, A Li, QZ El Fakhri, G Alpert, NM AF Sitek, Arkadiusz Li, Quanzheng El Fakhri, Georges Alpert, Nathaniel M. TI Validation of Bayesian analysis of compartmental kinetic models in medical imaging SO PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS LA English DT Article DE Bayesian inference; Dynamic nuclear imaging; Kinetic analysis ID POSITRON-EMISSION-TOMOGRAPHY; NONLINEAR-REGRESSION; PARAMETERS; GLUCOSE AB Introduction: Kinetic compartmental analysis is frequently used to compute physiologically relevant quantitative values from time series of images. In this paper, a new approach based on Bayesian analysis to obtain information about these parameters is presented and validated. Materials and methods: The closed-form of the posterior distribution of kinetic parameters is derived with a hierarchical prior to model the standard deviation of normally distributed noise. Markov chain Monte Carlo methods are used for numerical estimation of the posterior distribution. Computer simulations of the kinetics of F18-fluorodeoxyglucose (FDG) are used to demonstrate drawing statistical inferences about kinetic parameters and to validate the theory and implementation. Additionally, point estimates of kinetic parameters and covariance of those estimates are determined using the classical non-linear least squares approach. Results and discussion: Posteriors obtained using methods proposed in this work are accurate as no significant deviation from the expected shape of the posterior was found (one-sided P > 0.08). It is demonstrated that the results obtained by the standard non-linear least-square methods fail to provide accurate estimation of uncertainty for the same data set (P < 0.0001). Conclusions: The results of this work validate new methods for a computer simulations of FDG kinetics. Results show that in situations where the classical approach fails in accurate estimation of uncertainty, Bayesian estimation provides an accurate information about the uncertainties in the parameters. Although a particular example of FDG kinetics was used in the paper, the methods can be extended for different pharmaceuticals and imaging modalities. (C) 2016 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved. C1 Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA. Harvard Med Sch, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA. RP Sitek, A (reprint author), Philips Res North Amer, 2 Canal Pk, Cambridge, MA 02141 USA. EM sarkadiu@gmail.com FU National Institutes of Health [R21HL106474, R01CA165221, R01HL110241, S10RR031551] FX This work was supported by grants from the National Institutes of Health Nos. R21HL106474, R01CA165221, R01HL110241, and S10RR031551. NR 21 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1120-1797 EI 1724-191X J9 PHYS MEDICA JI Phys. Medica PD OCT PY 2016 VL 32 IS 10 BP 1252 EP 1258 DI 10.1016/j.ejmp.2016.09.010 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EF8QX UT WOS:000390595300008 PM 27692754 ER PT J AU Batteiger, T Tu, WZ Tong, Y Wang, J Hoover, S Dixon, B Arno, J AF Batteiger, Teresa Tu, Wanzhu Tong, Yan Wang, Jane Hoover, Sarah Dixon, Brian Arno, Janet TI AN EVALUATION OF STD SERVICE LOCATIONS USING AN INTEGRATED REGISTRY OF ELECTRONIC HEALTH RECORDS WITH COUNTY STD PROGRAM FILES SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Batteiger, Teresa] Indiana Univ Sch Med, Dept Internal Med, Div Infect Dis, Indianapolis, IN 46202 USA. [Tu, Wanzhu; Tong, Yan] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN 46202 USA. [Wang, Jane; Hoover, Sarah] Regenstrief Inst Hlth Care, Indianapolis, IN USA. [Dixon, Brian] US Dept Vet Affairs, Ctr Hlth Informat & Commun, Hlth Serv Res & Dev Serv, Indianapolis, IN USA. [Arno, Janet] Bell Flower Clin, Marion Cty Publ Hlth Dept, Indianapolis, IN USA. EM tbatteig@iu.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 10 BP S157 EP S157 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900118 ER PT J AU Dixon, B Tu, WZ Wang, J Batteiger, T Hoover, S Arno, J AF Dixon, Brian Tu, Wanzhu Wang, Jane Batteiger, Teresa Hoover, Sarah Arno, Janet TI A COMPREHENSIVE METROPOLITAN REGISTRY OF STD TESTING AND SERVICES FOR PRACTICE AND RESEARCH SO SEXUALLY TRANSMITTED DISEASES LA English DT Meeting Abstract CT Sexually Transmitted Diseases (STD) Prevention Conference CY SEP 20-23, 2016 CL Atlanta, GA C1 [Dixon, Brian] Hlth Serv Res & Dev Serv, Ctr Hlth Informat & Commun, US Dept Vet Affairs, Indianapolis, IN USA. [Tu, Wanzhu] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN 46202 USA. [Wang, Jane; Hoover, Sarah] Regenstrief Inst Hlth Care, Indianapolis, IN USA. [Batteiger, Teresa] Indiana Univ Sch Med, Dept Internal Med, Div Infect Dis, Indianapolis, IN 46202 USA. [Arno, Janet] Marion Cty Publ Hlth Dept, Bell Flower Clin, Indianapolis, IN USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD OCT PY 2016 VL 43 SU 2 MA WP 112 BP S186 EP S186 PG 1 WC Infectious Diseases SC Infectious Diseases GA EG0BO UT WOS:000390695900220 ER PT J AU Ferri, R Fulda, S Allen, RP Zucconi, M Bruni, O Chokroverty, S Ferini-Strambi, L Frauscher, B Garcia-Borreguero, D Hirshkowitz, M Hogl, B Inoue, Y Jahangir, A Manconi, M Marcus, CL Picchietti, DL Plazzi, G Winkelman, JW Zak, RS AF Ferri, R. Fulda, S. Allen, R. P. Zucconi, M. Bruni, O. Chokroverty, S. Ferini-Strambi, L. Frauscher, B. Garcia-Borreguero, D. Hirshkowitz, M. Hoegl, B. Inoue, Y. Jahangir, A. Manconi, M. Marcus, C. L. Picchietti, D. L. Plazzi, G. Winkelman, J. W. Zak, R. S. CA Int Restless Legs Syndrome Study G European Restless Legs Syndrome St TI World Association of Sleep Medicine (WASM) 2016 standards for recording and scoring leg movements in polysomnograms developed by a joint task force from the International and the European Restless Legs Syndrome Study Groups (IRLSSG and EURLSSG) SO SLEEP MEDICINE LA English DT Article DE Revised WASM standards; Periodic leg movements during sleep; Periodic leg movements during; wakefulness; Polysomnography; Electromyography ID PERIODIC LIMB MOVEMENTS; SICKLE-CELL-DISEASE; TIME STRUCTURE; MOTOR-ACTIVITY; CHILDREN; WAKEFULNESS; DISORDER; PLMS; NARCOLEPSY/CATAPLEXY; VARIABILITY AB This report presents the results of the work by a joint task force of the International and European Restless Legs Syndrome Study Groups and World Association of Sleep Medicine that revised and updated the current standards for recording and scoring leg movements (LM) in polysomnographic recordings (PSG). First, the background of the decisions made and the explanations of the new rules are reported and then specific standard rules are presented for recording, detecting, scoring and reporting LM activity in PSG. Each standard rule has been classified with a level of evidence. At the end of the paper, Appendix 1 provides algorithms to aid implementation of these new standards in software tools. There are two main changes introduced by these new rules: 1) Candidate LM (CLM), are any monolateral LM 0.5-10 s long or bilateral LM 0.5-15 s long; 2) periodic LM (PLM) are now defined by runs of at least four consecutive CLM with an intermovement interval >= 10 and <= 90 s without any CLM preceded by an interval <10 s interrupting the PLM series. There are also new options defining CLM associated with respiratory events. The PLM rate may now first be determined for all CLM not excluding any related to respiration (providing a consistent number across studies regardless of the rules used to define association with respiration) and, subsequently, the PLM rate should also be calculated without considering the respiratory related events. Finally, special considerations for pediatric studies are provided. The expert visual scoring of LM has only been altered by the new standards to require accepting all LM >0.5 s regardless of duration, otherwise the technician scores the LM as for the old standards. There is a new criterion for the morphology of LM that applies only to computerized LM detection to better match expert visual detection. Available automatic scoring programs will incorporate all the new rules so that the new standards should reduce technician burden for scoring PLMS. (C) 2016 Elsevier B.V. All rights reserved. C1 [Ferri, R.] Oasi Inst Res Mental Retardat & Brain Aging IRCCS, Dept Neurol IC, Sleep Res Ctr, Troina, Italy. [Fulda, S.; Manconi, M.] Civ Hosp EOC Lugano, Sleep & Epilepsy Ctr, Neuroctr Southern Switzerland, Lugano, Switzerland. [Allen, R. P.] Johns Hopkins Univ, Dept Neurol, Ctr Restless Legs Study, Baltimore, MD 21218 USA. [Zucconi, M.; Ferini-Strambi, L.] Univ Vita Salute San Raffaele, Inst Sci, Dept Neurol, Sleep Disorders Ctr, Milan, Italy. [Zucconi, M.; Ferini-Strambi, L.] Univ Vita Salute San Raffaele, Univ Osped San Raffaele, Milan, Italy. [Bruni, O.] Sapienza Univ, Dept Social & Dev Psychol, Rome, Italy. [Chokroverty, S.] JFK New Jersey Neurosci Inst, 65 James St, Edison, NJ USA. [Frauscher, B.] McGill Univ, Montreal Neurol Inst & Hosp, Montreal, PQ, Canada. [Frauscher, B.] Queens Univ, Dept Med, Kingston, ON, Canada. [Frauscher, B.] Queens Univ, Ctr Neurosci Studies, Kingston, ON, Canada. [Garcia-Borreguero, D.] Sleep Res Inst, Madrid, Spain. [Hirshkowitz, M.] Baylor Coll Med, Houston, TX 77030 USA. [Hoegl, B.] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria. [Inoue, Y.] Tokyo Med Univ, Dept Somnol, Tokyo, Japan. [Jahangir, A.] Aurora Univ, Wisconsin Med Grp, Aurora Hlth Care, Ctr Integrat Res Cardiovasc Aging, Milwaukee, WI USA. [Marcus, C. L.] Childrens Hosp Philadelphia, Sleep Ctr, Philadelphia, PA 19104 USA. [Marcus, C. L.] Univ Penn, Philadelphia, PA 19104 USA. [Picchietti, D. L.] Univ Illinois Sch Med Urbana Champaign, Urbana, IL USA. [Picchietti, D. L.] Carle Fdn Hosp, Urbana, IL USA. [Plazzi, G.] Univ Bologna, Dept Biomed & Neuromotor Sci DIBINEM, Bologna, Italy. [Plazzi, G.] IRCCS, Ist Sci Neurol, ASL Bologna, Bologna, Italy. [Winkelman, J. W.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA USA. [Zak, R. S.] Univ Calif San Francisco, Sleep Disorders Ctr, San Francisco, CA 94143 USA. RP Ferri, R (reprint author), Oasi Inst Res Mental Retardat & Brain Aging IRCCS, Dept Neurol IC, Sleep Res Ctr, Troina, Italy. EM rferri@oasi.en.it OI Ferri, Raffaele/0000-0001-6937-3065 FU International Restless Legs Syndrome Study Group; European Restless Legs Syndrome Study Group FX This work was supported by the International Restless Legs Syndrome Study Group and by the European Restless Legs Syndrome Study Group. We are indebted to Dr. Arthur S. Walters for his very helpful comments. NR 36 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1389-9457 EI 1878-5506 J9 SLEEP MED JI Sleep Med. PD OCT PY 2016 VL 26 BP 86 EP 95 DI 10.1016/j.sleep.2016.10.010 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA EG0KE UT WOS:000390720900018 PM 27890390 ER PT J AU Kernkamp, WA Li, GA Van de Velde, SK AF Kernkamp, Willem A. Li, Guoan Van de Velde, Samuel K. TI The anterolateral ligament: a closed chapter? SO ANNALS OF TRANSLATIONAL MEDICINE LA English DT Editorial Material ID ANTERIOR CRUCIATE LIGAMENT; VITRO ROBOTIC ASSESSMENT; BIOMECHANICAL ANALYSIS; SEGOND FRACTURE; LENGTH CHANGES; KNEE; RECONSTRUCTION; ANATOMY; INJURY C1 [Kernkamp, Willem A.; Li, Guoan] Harvard Med Sch, Massachusetts Gen Hosp, Bioengn Lab, Boston, MA USA. [Van de Velde, Samuel K.] Med Ctr Haaglanden & Bronovo Nebo, Focus Clin Orthoped Surg, The Hague, Netherlands. RP Van de Velde, SK (reprint author), Med Ctr Haaglanden, Lijnbaan 32, NL-2512 VA The Hague, Netherlands. EM svandevelde@post.harvard.edu NR 23 TC 0 Z9 0 U1 0 U2 0 PU AME PUBL CO PI SHEUNG WAN PA ROOM 604 6-F HOLLYWOOD CENTER, 77-91, QUEENS ROAD, SHEUNG WAN, HONG KONG 00000, PEOPLES R CHINA SN 2305-5839 EI 2305-5847 J9 ANN TRANSL MED JI ANN. TRANSL. MED. PD OCT PY 2016 VL 4 SU 1 AR S37 DI 10.21037/atm.2016.09.21 PG 4 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA EF0TP UT WOS:000390039200037 PM 27868005 ER PT J AU Sheth, K Elm, J Cheung, K Molyneaux, B Beslow, L Sze, G Ostwaldt, AC Kimberly, WT AF Sheth, K. Elm, J. Cheung, K. Molyneaux, B. Beslow, L. Sze, G. Ostwaldt, A. C. Kimberly, W. T. TI EXPLORATORY ANALYSIS FROM GLYBURIDE ADVANTAGE IN MALIGNANT EDEMA AND STROKE (GAMES-RP): BASIS FOR PHASE 3 TRIAL DESIGN AIMED AT IMPROVING OUTCOMES IN LARGE HEMISPHERIC INFARCTION SO INTERNATIONAL JOURNAL OF STROKE LA English DT Meeting Abstract C1 [Sheth, K.] Yale Sch Med, Neurol, New Haven, CT USA. [Elm, J.] Med Univ South Carolina, Dept Publ Hlth, Charleston, SC USA. [Cheung, K.] Columbia Univ, Biostat, New York, NY USA. [Molyneaux, B.] Univ Pittsburgh, Neurol, Pittsburgh, PA USA. [Beslow, L.] Yale Univ, Neurol, New Haven, CT USA. [Sze, G.] Yale Univ, Radiol, New Haven, CT USA. [Ostwaldt, A. C.; Kimberly, W. T.] Massachusetts Gen Hosp, Neurol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1747-4930 EI 1747-4949 J9 INT J STROKE JI Int. J. Stroke PD OCT PY 2016 VL 11 IS SUPP 3 MA 52 BP 22 EP 22 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA EA8TP UT WOS:000386912100054 ER PT J AU Gupta, L Pannu, A Pandian, J Sylaja, P Kaul, S Khurana, D Padma, V Thankachan, T Arora, D Singhal, A AF Gupta, L. Pannu, A. Pandian, J. Sylaja, P. Kaul, S. Khurana, D. Padma, V. Thankachan, T. Arora, D. Singhal, A. TI PREDICTORS OF STROKE RECURRENCE: DATA FROM INDO-USA ISCHEMIC STROKE REGISTRY SO INTERNATIONAL JOURNAL OF STROKE LA English DT Meeting Abstract C1 [Gupta, L.; Pannu, A.; Pandian, J.; Arora, D.] CMC LUDHIANA, Neurol, Ludhiana, Punjab, India. [Sylaja, P.] Sree Chitra Tirunal Inst Med Sci & Technol, Neurol, Trivandrum, Kerala, India. [Kaul, S.] Nizams Inst Med Sci, Neurol, Hyderabad, Andhra Pradesh, India. [Khurana, D.] Postgrad Inst Med Educ & Res, Neurol, Chandigarh, India. [Padma, V.] All India Inst Med Sci, Neurol, New Delhi, India. [Thankachan, T.; Singhal, A.] Massachusetts Gen Hosp, Neurol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1747-4930 EI 1747-4949 J9 INT J STROKE JI Int. J. Stroke PD OCT PY 2016 VL 11 IS SUPP 3 MA 88 BP 40 EP 40 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA EA8TP UT WOS:000386912100090 ER PT J AU Kumar, S Lioutas, V Selim, M Marchina, S Tarsia, J Catanese, L Caplan, L AF Kumar, S. Lioutas, V. Selim, M. Marchina, S. Tarsia, J. Catanese, L. Caplan, L. TI DOES INTUBATION PREVENT PNEUMONIAS AND DEATHS IN PATIENTS WITH SPONTANEOUS INTRACEREBRAL HEMORRHAGE? SO INTERNATIONAL JOURNAL OF STROKE LA English DT Meeting Abstract C1 [Kumar, S.; Lioutas, V.; Selim, M.; Marchina, S.; Tarsia, J.; Catanese, L.; Caplan, L.] Harvard Med Sch, BIDMC, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1747-4930 EI 1747-4949 J9 INT J STROKE JI Int. J. Stroke PD OCT PY 2016 VL 11 IS SUPP 3 MA 241 BP 100 EP 101 PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA EA8TP UT WOS:000386912100243 ER PT J AU Arora, D Pandian, JD Pannu, A Sylaja, PN Kaul, S Khurana, D Padma, MV Thankachan, T Singhal, AB AF Arora, D. Pandian, J. D. Pannu, A. Sylaja, P. N. Kaul, S. Khurana, D. Padma, M. V. Thankachan, T. Singhal, A. B. TI INFLUENCE OF RELIGION ON STROKE RISK FACTORS AND OUTCOME IN INDIA: DATA FROM INDO US STROKE REGISTRY SO INTERNATIONAL JOURNAL OF STROKE LA English DT Meeting Abstract C1 [Arora, D.; Pandian, J. D.; Pannu, A.] Christian Med Coll & Hosp, Neurol, Ludhiana, Punjab, India. [Sylaja, P. N.] Sree Chitra Tirunal Inst Med Sci & Technol, Neurol, Thiruvananthapuram, Kerala, India. [Kaul, S.] Nizams Inst Med Sci, Neurol, Hyderabad, Andhra Pradesh, India. [Khurana, D.] Postgrad Inst Med Educ & Res, Neurol, Chandigarh, India. [Padma, M. V.] All India Inst Med Sci, Neurol, New Delhi, India. [Thankachan, T.; Singhal, A. B.] Massachusetts Gen Hosp, Neurol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1747-4930 EI 1747-4949 J9 INT J STROKE JI Int. J. Stroke PD OCT PY 2016 VL 11 IS SUPP 3 MA 526 BP 207 EP 207 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA EA8TP UT WOS:000386912100528 ER PT J AU Arora, D Pandian, JD Pannu, A Sylaja, PN Kaul, S Khurana, D Padma, MV Thankachan, T Singhal, AB AF Arora, D. Pandian, J. D. Pannu, A. Sylaja, P. N. Kaul, S. Khurana, D. Padma, M. V. Thankachan, T. Singhal, A. B. TI ILLICIT DRUG USE AND STROKE IN INDIA: DATA FROM INDO-US STROKE REGISTRY SO INTERNATIONAL JOURNAL OF STROKE LA English DT Meeting Abstract C1 [Arora, D.; Pandian, J. D.; Pannu, A.] Christian Med Coll & Hosp, Neurol, Ludhiana, Punjab, India. [Sylaja, P. N.] Sree Chitra Tirunal Inst Med Sci & Technol, Neurol, Thiruvananthapuram, Kerala, India. [Kaul, S.] Nizams Inst Med Sci, Neurol, Hyderabad, Andhra Pradesh, India. [Khurana, D.] Postgrad Inst Med Educ & Res, Neurol, Chandigarh, India. [Padma, M. V.] All India Inst Med Sci, Neurol, New Delhi, India. [Thankachan, T.; Singhal, A. B.] Massachusetts Gen Hosp, Neurol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1747-4930 EI 1747-4949 J9 INT J STROKE JI Int. J. Stroke PD OCT PY 2016 VL 11 IS SUPP 3 MA 600 BP 234 EP 234 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA EA8TP UT WOS:000386912100602 ER PT J AU Chahal, A Pandian, JD Pannu, A Arora, D Sylaja, PN Kaul, S Khurana, D Padma, MV Thankachan, T Singhal, AB AF Chahal, A. Pandian, J. D. Pannu, A. Arora, D. Sylaja, P. N. Kaul, S. Khurana, D. Padma, M. V. Thankachan, T. Singhal, A. B. TI FACTORS PREDICTING RETURN TOWORK POST STROKE IN INDIA SO INTERNATIONAL JOURNAL OF STROKE LA English DT Meeting Abstract C1 [Chahal, A.; Pandian, J. D.; Pannu, A.; Arora, D.] Christian Med Coll & Hosp, Neurol, Ludhiana, Punjab, India. [Sylaja, P. N.] Sree Chitra Tirunal Inst Med Sci & Technol, Neurol, Thiruvananthapuram, Kerala, India. [Kaul, S.] Nizams Inst Med Sci, Neurol, Hyderabad, Andhra Pradesh, India. [Khurana, D.] Postgrad Inst Med Educ & Res, Neurol, Chandigarh, India. [Padma, M. V.] All India Inst Med Sci, Neurol, New Delhi, India. [Thankachan, T.; Singhal, A. B.] Massachusetts Gen Hosp, Neurol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1747-4930 EI 1747-4949 J9 INT J STROKE JI Int. J. Stroke PD OCT PY 2016 VL 11 IS SUPP 3 MA 603 BP 235 EP 235 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA EA8TP UT WOS:000386912100605 ER PT J AU Marquevich, V Ceciliano, A Pratesi, P Bueri, JA Schnitzler, E Villasante, F Navarro, F Moya, H Singhal, AB Musolino, PL AF Marquevich, V. Ceciliano, A. Pratesi, P. Bueri, J. A. Schnitzler, E. Villasante, F. Navarro, F. Moya, H. Singhal, A. B. Musolino, P. L. TI FEASIBILITY OF ENDOVASCULAR STROKE THERAPY IN ARGENTINA: CARE SERIES FOLLOWING STANDARDIZATION OF CLINICAL PRACTICE SO INTERNATIONAL JOURNAL OF STROKE LA English DT Meeting Abstract C1 [Marquevich, V.; Pratesi, P.; Schnitzler, E.] Hosp Univ Austral, Crit Care, Pilar, Buenos Aires, Argentina. [Ceciliano, A.; Villasante, F.; Navarro, F.; Moya, H.] Hosp Univ Austral, Neuroradiol, Pilar, Buenos Aires, Argentina. [Bueri, J. A.] Hosp Univ Austral, Neurol, Pilar, Buenos Aires, Argentina. [Singhal, A. B.; Musolino, P. L.] Massachusetts Gen Hosp, Neurol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1747-4930 EI 1747-4949 J9 INT J STROKE JI Int. J. Stroke PD OCT PY 2016 VL 11 IS SUPP 3 MA 691 BP 268 EP 268 PG 1 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA EA8TP UT WOS:000386912100693 ER PT J AU Hall, KS Gregg, J Bosworth, HB Beckham, JC Hoerster, KD Sloane, R Morey, MC AF Hall, Katherine S. Gregg, Jeffrey Bosworth, Hayden B. Beckham, Jean C. Hoerster, Katherine D. Sloane, Richard Morey, Miriam C. TI Physical activity counseling promotes physical and psychological resilience in older veterans with posttraumatic stress disorder SO MENTAL HEALTH AND PHYSICAL ACTIVITY LA English DT Article DE Clinical; PTSD; RCT; Quality of life; SF-36; Physical function ID RANDOMIZED CONTROLLED-TRIAL; MILITARY VETERANS; MENTAL-HEALTH; PTSD SYMPTOMS; ADULTS; EXERCISE; FITNESS; METAANALYSIS; CARE; ASSOCIATION AB Individuals with posttraumatic stress disorder (PTSD) have elevated rates of morbidity, and a sedentary lifestyle can cause and aggravate the physical health needs of adults with PTSD. The primary aim of this paper was to explore the impact of physical activity (PA) counseling (vs. usual care) on physical and psychological outcomes among individuals with PTSD. A secondary aim was to compare these arm effects between those with and without PTSD. Methods: Older (>60 years) overweight veterans with impaired glucose tolerance were randomly assigned to an intervention or a usual care control arm. Of the 302 participants who underwent randomization, 67 (22%) had PTSD. Participants in the intervention arm received one in-person activity counseling session followed by regular PA telephone counseling over 12 months. Physical and psychological outcomes were assessed at baseline, 3, and 12 months. Results: Primary Aim (intervention vs. usual care among those with PTSD): PA increased on average from 80 min/week to 161 min/week among participants in the intervention arm (p = 0.01). Large, clinically meaningful improvements in six-minute walk test and psychological health were observed over the course of the intervention (p < 0.01). Secondary Aim (PTSD/No PTSD, intervention/usual care): participants with PTSD responded equally well to the intervention compared to participants without PTSD, though we observed significantly greater improvements in vitality and six-minute walk compared to participants without PTSD (p < 0.05). Conclusions: Given the epidemic of comorbid psychological illness and lifestyle-related disease among persons with PTSD, our findings support development and implementation of targeted PA interventions in this high-risk population. Published by Elsevier Ltd. C1 [Hall, Katherine S.; Sloane, Richard; Morey, Miriam C.] Durham A Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Durham, NC USA. [Hall, Katherine S.; Bosworth, Hayden B.; Morey, Miriam C.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Hall, Katherine S.; Sloane, Richard; Morey, Miriam C.] Duke Univ, Med Ctr, Claude D Pepper Ctr Aging, Durham, NC USA. [Gregg, Jeffrey] Durham Vet Affairs Med Ctr, Mental Hlth Serv, Durham, NC USA. [Bosworth, Hayden B.] Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res & Dev, Durham, NC USA. [Beckham, Jean C.] Durham Vet Affairs Med Ctr, VA Res Serv, Vet Integrated Serv Network 6, Mental Illness Res Educ & Clin Ctr, Durham, NC USA. [Beckham, Jean C.] Duke Univ, Dept Psychiat & Behav Sci, Med Ctr, Durham, NC USA. [Hoerster, Katherine D.] VA Puget Sound Healthcare Syst, Mental Hlth Serv, Seattle, WA USA. [Hoerster, Katherine D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Hall, KS (reprint author), Durham VAMC GRECC 182, 508 Fulton St, Durham, NC 27705 USA. EM katherine.hall@duke.edu FU VA Health Services Research and Development grant [IIR-06-252-3]; National Institute on Aging [AG028716]; Department of Veterans Affairs Career Development Awards [RRD CDA 2RX001316, HSRD CDA 12-263]; Department of Veterans Affairs Career Scientist Award [HSRD 08-027] FX This study was funded by a VA Health Services Research and Development grant (IIR-06-252-3; BLINDED) and National Institute on Aging grant AG028716. Drs. Hall and Hoerster are supported by Department of Veterans Affairs Career Development Awards (RR&D CDA 2RX001316 and HSR&D CDA 12-263, respectively). Dr. Bosworth is supported by a Department of Veterans Affairs Career Scientist Award (HSR&D 08-027). The Duke Claude D. Pepper Older American Independence Center (NIA P30AG028716) contributed to the intellectual content of this work.. The funding sources had no involvement in study design; in the collection, analysis and interpretation of data; in the writing of the articles; and in the decision to submit it for publication. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. NR 40 TC 0 Z9 0 U1 6 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1755-2966 J9 MENT HEALTH PHYS ACT JI Ment. Health Phys. Act. PD OCT PY 2016 VL 11 BP 53 EP 59 DI 10.1016/j.mhpa.2016.10.001 PG 7 WC Psychiatry SC Psychiatry GA EF7MU UT WOS:000390514500008 ER PT J AU Spicer, AC Calfee, CS Zinter, MS Khemani, RG Lo, VP Alkhouli, MF Orwoll, BE Graciano, AL Boriosi, JP Howard, JP Flori, HR Matthay, MA Sapru, A AF Spicer, Aaron C. Calfee, Carolyn S. Zinter, Matthew S. Khemani, Robinder G. Lo, Victoria P. Alkhouli, Mustafa F. Orwoll, Benjamin E. Graciano, Ana L. Boriosi, Juan P. Howard, James P. Flori, Heidi R. Matthay, Michael A. Sapru, Anil TI A Simple and Robust Bedside Model for Mortality Risk in Pediatric Patients With Acute Respiratory Distress Syndrome SO PEDIATRIC CRITICAL CARE MEDICINE LA English DT Article DE acute lung injury; hospital mortality; intensive care units; pediatric; prognosis; respiratory distress syndrome; acute ID ACUTE LUNG INJURY; CONSENSUS CONFERENCE; INTENSIVE-CARE; CLINICAL-OUTCOMES; CHILDREN; FAILURE; MULTICENTER; TRIAL; VENTILATION; MANAGEMENT AB Objectives: Despite declining mortality, acute respiratory distress syndrome is still involved in up to one third of pediatric intensive care deaths. The recently convened Pediatric Acute Lung Injury Consensus Conference has outlined research priorities for the field, which include the need for accurate bedside risk stratification of patients. We aimed to develop a simple yet robust model of mortality risk among pediatric patients with acute respiratory distress syndrome to facilitate the targeted application of high-risk investigational therapies and stratification for enrollment in clinical trials. Design: Prospective, multicenter cohort. Setting: Five academic PICUs. Patients: Three hundred eight children greater than 1 month and less than or equal to 18 years old, admitted to the ICU, with bilateral infiltrates on chest radiograph and Pao(2)/Fio(2) ratio less than 300 in the clinical absence of left atrial hypertension. Interventions: None. Measurements and Main Results: Twenty clinical variables were recorded in the following six categories: demographics, medical history, oxygenation, ventilation, radiographic imaging, and multiple organ dysfunction. Data were measured 0-24 and 48-72 hours after acute respiratory distress syndrome onset (day 1 and 3) and examined for associations with hospital mortality. Among 308 enrolled patients, mortality was 17%. Children with a history of cancer and/or hematopoietic stem cell transplant had higher mortality ( 47% vs 11%; p < 0.001). Oxygenation index, the Pao(2)/Fio(2) ratio, extrapulmonary organ dysfunction, Pediatric Risk of Mortality-3, and positive cumulative fluid balance were each associated with mortality. Using two statistical approaches, we found that a parsimonious model of mortality risk using only oxygenation index and cancer/hematopoietic stem cell transplant history performed as well as other more complex models that required additional variables. Conclusions: In the PICU, oxygenation index and cancer/hematopoietic stem cell transplant history can be used on acute respiratory distress syndrome day 1 or day 3 to predict hospital mortality without the need for more complex models. These findings may simplify risk assessment for clinical trials, counseling families, and high-risk interventions such as extracorporeal life support. C1 [Spicer, Aaron C.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Calfee, Carolyn S.] Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA USA. [Calfee, Carolyn S.; Matthay, Michael A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Zinter, Matthew S.; Alkhouli, Mustafa F.; Orwoll, Benjamin E.; Sapru, Anil] Univ Calif San Francisco, Dept Pediat, Benioff Childrens Hosp San Francisco, Div Crit Care, San Francisco, CA 94143 USA. [Khemani, Robinder G.] Univ Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Dept Anesthesiol, Los Angeles, CA USA. [Khemani, Robinder G.] Univ Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Dept Crit Care Med, Los Angeles, CA USA. [Lo, Victoria P.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Graciano, Ana L.] Childrens Hosp Cent Calif, Dept Pediat, Fresno, CA USA. [Boriosi, Juan P.] Univ Wisconsin, Dept Pediat, Madison, WI USA. [Zinter, Matthew S.; Orwoll, Benjamin E.; Howard, James P.; Flori, Heidi R.] Univ Calif San Francisco, Div Pediat Crit Care, Benioff Childrens Hosp Oakland, Oakland, CA USA. [Sapru, Anil] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA. RP Sapru, A (reprint author), Univ Calif San Francisco, Dept Pediat, Benioff Childrens Hosp San Francisco, Div Crit Care, San Francisco, CA 94143 USA.; Sapru, A (reprint author), Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA. EM anil.sapru@ucsf.edu FU NIH [5T32H D049303-08, HL110969]; NHLBI [K23 HL085526, HL114484 (R01)]; National Institutes of Health (NIH); Boehringer Ingelheim; Glaxo Smith Kline; Department of Defense; RocheGenentec (Chair of DSMB); GlaxoSmithKline; Amgen FX Supported, in part, by NIH 5T32H D049303-08 (Dr. Spicer), HL110969 (Dr. Calfee), NHLBI K23 HL085526 (Dr. Sapru), and NHLBI HL114484 (R01) (Dr. Sapru).; Dr. Spicer received support for article research from the National Institutes of Health (NIH). His institution received funding from the NIH. Dr. Calfee disclosed other support (Member of Board of Directors of American Thoracic Society) and received funding from Boehringer Ingelheim. Her institution received funding from Glaxo Smith Kline. Dr. Zinter received support for article research from the NIH. Dr. Khemani's institution received funding from the NIH. Dr. Alkhouli received support for article research from the NIH. His institution received funding from the NIH. Dr. Boriosi received support for article research from the NIH. His institution received funding from the NIH. Dr. Flori disclosed other support (she received Department of Defense funding for clinical decision support systems and received honoraria from hospitals for giving educational lectures. None of these activities are related to the research involved in this publication) and received support for article research from the NIH. Dr. Matthay received support for article research from the NIH; received funding from RocheGenentec (Chair of DSMB for a clinical trial of asthma); and disclosed other support from GlaxoSmithKline (part of a DSMB for trial in critically ill patients), Cerus (consulting services), Biogen (consulting services), and Quark Pharmaceutical (consulting service). His institution received funding from GlaxoSmithKline (grant to study biomarkers of sepsis) and Amgen (grant to study lung injury in mice). Dr. Sapru received support for article research from the NIH. His institution received funding from the NIH. The remaining authors have disclosed that they do not have any potential conflicts of interest. NR 34 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1529-7535 EI 1947-3893 J9 PEDIATR CRIT CARE ME JI Pediatr. Crit. Care Med. PD OCT PY 2016 VL 17 IS 10 BP 907 EP 916 DI 10.1097/PCC.0000000000000865 PG 10 WC Critical Care Medicine; Pediatrics SC General & Internal Medicine; Pediatrics GA EF2EA UT WOS:000390136300007 PM 27487912 ER PT J AU Hu, KJ Zhang, TS Hutter, M Xu, WD Williams, Z AF Hu, Kejia Zhang, Tiansong Hutter, Matthew Xu, Wendong Williams, Ziv TI Thirty-Day Perioperative Adverse Outcomes After Peripheral Nerve Surgery: An Analysis of 2351 Patients in the American College of Surgeons National Surgical Quality Improvement Program Database SO WORLD NEUROSURGERY LA English DT Article DE ACS NSQIP; Nerve grafting; Peripheral nerve surgery; Short-term complications; Unplanned readmission ID COMMON PERONEAL NERVE; COMPLICATIONS; DECOMPRESSION; REPAIR; IMPACT; NSQIP AB BACKGROUND: Because peripheral nerve surgery has become more common in recent years, the pressure to increase this procedure's health care safety and cost-effectiveness has increased. Given our limited understanding, we evaluated prospectively identified and randomly sampled patients who underwent peripheral nerve surgery from 2005 to 2014 through the American College of Surgeons National Surgical Quality Improvement Program database. METHODS: We used bivariate testing and multivariate logistic regression analysis to identify patient-and surgery-related risk factors for postoperative complications and unplanned readmission in peripheral nerve surgery patients, and especially to estimate the impact of the nerve grafting procedure. RESULTS: Overall, 2351 patients underwent peripheral nerve surgery, 120 complications were identified in 100 patients (4.25%), and 103 patients (4.38%) received nerve grafting. Thirty-one of the 1593 patients (1.95%) underwent unplanned readmission. Nerve grafting procedures had no association with postoperative complications and unplanned readmission rates. Patients who experienced an inpatient procedure (odds ratio [OR], 2.54; P < 0.001), a longer operative time (OR, 1.00; P < 0.001), and worse wound classifications (OR, 1.83; P < 0.001) all had increased odds of postoperative complications. An inpatient procedure (OR, 2.74; P=0.014) and any complications (OR, 24.43; P < 0.001) were significantly associated with unplanned readmission. CONCLUSIONS: Our study confirms that peripheral nerve surgery and nerve graft procedures can be safely performed with low complication risks and low unplanned readmission rates. We also identified the risks associated with perioperative adverse outcomes, and these data may be used as an adjunct for risk stratification for patients under consideration for peripheral nerve surgery. This approach may enable the improved targeting of the most costly and harmful complications of preventive measures. C1 [Hu, Kejia; Xu, Wendong] Fudan Univ, Huashan Hosp, Dept Hand Surg, Shanghai, Peoples R China. [Hu, Kejia; Williams, Ziv] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA USA. [Hutter, Matthew] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Boston, MA USA. [Zhang, Tiansong] Fudan Univ, Dept Tradit Chinese Med, Jingan Dist Cent Hosp, Shanghai, Peoples R China. RP Xu, WD (reprint author), Fudan Univ, Huashan Hosp, Dept Hand Surg, Shanghai, Peoples R China.; Williams, Z (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA USA. EM wendongxu@fudan.edu.cn; zwilliams@mgh.harvard.edu NR 26 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1878-8750 EI 1878-8769 J9 WORLD NEUROSURG JI World Neurosurg. PD OCT PY 2016 VL 94 BP 409 EP 417 DI 10.1016/j.wneu.2016.07.023 PG 9 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA EF5EJ UT WOS:000390353200053 PM 27436210 ER PT J AU Li, C Neugroschl, J Umpierre, M Martin, J Huang, QY Zeng, XY Cai, DM Sano, M AF Li, Clara Neugroschl, Judith Umpierre, Mari Martin, Jane Huang, QiYing Zeng, Xiaoyi Cai, Dongming Sano, Mary TI Recruiting US Chinese Elders Into Clinical Research for Dementia SO ALZHEIMER DISEASE & ASSOCIATED DISORDERS LA English DT Article DE elderly Chinese Americans; clinical study; dementia; aging; recruitment; minority AB Purpose: This study described and evaluated the rapid recruitment of elderly Chinese into clinical research at the Mount Sinai Alzheimer's Disease Research Center (MSADRC). Design and Methods: Methods of publicizing the study included lectures to local senior centers/churches and publications in local Chinese newspapers. The amount of time and success of these methods were evaluated. A "go to them" model of evaluation was used to enable participants to complete the study visit at locations where they were comfortable. Results: From January to December 2015, we recruited 98 participants aged 65 years or older who primarily speak Mandarin/Cantonese and reside in New York. The mean age and years of education was 73.93 +/- 6.34 and 12.79 +/- 4.58, respectively. The majority of participants were female (65.3%) and primarily Mandarin speaking (53.1%). Of all enrollees, 54.1% were recruited from community lectures, 29.6% through newspapers, 10.2% through word of mouth, and 6.1% from our clinical services. About 40.8% of participants underwent evaluations at the MSADRC, 44.9% at local senior centers/churches, and 14.3% at home. Implications: Given that the majority of our participants had low English proficiency, the use of bilingual recruiters probably allowed us to overcome the language barrier, facilitating recruitment. Our "go to them" model of evaluation is another important factor contributing to our successful recruitment. C1 [Li, Clara; Neugroschl, Judith; Umpierre, Mari; Martin, Jane; Huang, QiYing; Zeng, Xiaoyi; Cai, Dongming; Sano, Mary] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Sano, Mary] James J Peters VA Med Ctr, Bronx, NY USA. RP Li, C (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, Alzheimers Dis Res Ctr, One Gustave L Levy Pl,POB 1230, New York, NY 10029 USA. EM clara.li@mssm.edu OI Cai, Dongming/0000-0002-0601-6826 FU NIH National Institute on Aging [P50AG05138] FX Supported by NIH National Institute on Aging grant (P50AG05138). NR 6 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0893-0341 J9 ALZ DIS ASSOC DIS JI Alzheimer Dis. Assoc. Dis. PD OCT-DEC PY 2016 VL 30 IS 4 BP 345 EP 347 DI 10.1097/WAD.0000000000000162 PG 3 WC Clinical Neurology; Pathology SC Neurosciences & Neurology; Pathology GA EE0IQ UT WOS:000389258200009 PM 27819841 ER PT J AU Brooks, GA Chen, EJ Murakami, MA Giannakis, M Baugh, CW Schrag, D AF Brooks, Gabriel A. Chen, Eddy J. Murakami, Marka A. Giannakis, Marios Baugh, Christopher W. Schrag, Deb TI An ED pilot intervention to facilitate outpatient acute care for cancer patients SO AMERICAN JOURNAL OF EMERGENCY MEDICINE LA English DT Article ID POTENTIALLY AVOIDABLE HOSPITALIZATIONS; EMERGENCY-DEPARTMENT; MEDICARE AB Introduction: Unplanned hospitalizations are common in patients with cancer, and most hospitalizations originate in the emergency department (ED). Methods: We implemented an ED-based pilot intervention designed to reduce hospitalizations among patients with solid tumors. The intervention, piloted at a single academic medical center, involved a medical oncologist embedded in the ED during evening hours. We used a quasiexperimental preimplementation/postimplementation study design to evaluate the proportion of ED visits that resulted in inpatient hospital admission, before and after pilot implementation. General estimating equations were used to evaluate the association between the intervention and hospital admission. Results: There were 390 ED visits by eligible cancer patients in the preintervention period and 418 visits in the intervention period. During the intervention period, 158 (38%) of 418 ED visits were identified by the embedded oncologist during the evening intervention shift. The proportion of ED visits leading to hospitalization was 70% vs 69% in the preintervention and intervention periods (odds ratio, 0.93 [95% confidence interval, 0.69-1.24]; P=.62). There were no differences between periods in ED length of stay or subsequent use of acute care. Among patients with initial ED presentation during the operating hours of the intervention, the proportion of ED visits leading to hospitalization was 77% vs 67% in the preintervention and intervention periods (odds ratio, 0.62 [0.36-1.08]; P=.08). Conclusion: Embedding an oncologist in the ED of an academic medical center did not significantly reduce hospital admissions. Novel approaches are needed to strengthen outpatient acute care for patients with cancer. (C) 2016 Elsevier Inc. All rights reserved. C1 [Brooks, Gabriel A.; Chen, Eddy J.; Murakami, Marka A.; Giannakis, Marios; Schrag, Deb] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA. [Brooks, Gabriel A.; Chen, Eddy J.; Murakami, Marka A.; Giannakis, Marios; Schrag, Deb] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA. [Baugh, Christopher W.] Brigham & Womens Hosp, Dept Emergency Med, Boston, MA 02115 USA. RP Brooks, GA (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM gabriel_brooks@dfci.harvard.edu FU Dana-Farber Cancer Institute Department of Medical Oncology; National Cancer Institute of the National Institutes of Health [T32-CA009172] FX This research was supported by an intramural grant to GAB from the Dana-Farber Cancer Institute Department of Medical Oncology. MAM acknowledges support from an institutional research training grant from the National Cancer Institute of the National Institutes of Health awarded to the Dana-Farber Cancer Institute Department of Medical Oncology (T32-CA009172). NR 20 TC 0 Z9 0 U1 2 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0735-6757 EI 1532-8171 J9 AM J EMERG MED JI Am. J. Emerg. Med. PD OCT PY 2016 VL 34 IS 10 BP 1934 EP 1938 DI 10.1016/j.ajem.2016.06.076 PG 5 WC Emergency Medicine SC Emergency Medicine GA EE3RL UT WOS:000389513800004 PM 27412915 ER PT J AU Schmidt, MG John, JJ Freeman, KD Sharpe, PA Estelle, AA Michels, HT AF Schmidt, Michael G. John, Joseph J., Jr. Freeman, Katherine D. Sharpe, Peter A. Estelle, Adam A. Michels, Harold T. TI Perspectives from the field in response to "It is time to revise our approach to registering antimicrobial agents for health care settings" SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Editorial Material ID RESISTANT STAPHYLOCOCCUS-AUREUS; COPPER SURFACES; SURVIVAL; ALLOYS; UNIT; INACTIVATION; NOROVIRUS; BACTERIA; REDUCE; STEEL C1 [Schmidt, Michael G.] Med Univ South Carolina, Dept Microbiol & Immunol, 173 Ashley Ave,MSC 504, Charleston, SC 29425 USA. [John, Joseph J., Jr.] Ralph H Johnson VA, Dept Med, Charleston, SC USA. [Freeman, Katherine D.] Extrapolate LLC, Delray Beach, FL USA. [Sharpe, Peter A.] Irwin P Sharpe & Associates, Westfield, NJ USA. [Estelle, Adam A.; Michels, Harold T.] Copper Dev Assoc, New York, NY USA. RP Schmidt, MG (reprint author), Med Univ South Carolina, Dept Microbiol & Immunol, 173 Ashley Ave,MSC 504, Charleston, SC 29425 USA. EM schm4647@gmail.com OI Schmidt, Michael G/0000-0002-7794-7265 NR 20 TC 1 Z9 1 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD OCT 1 PY 2016 VL 44 IS 10 BP 1187 EP 1189 DI 10.1016/j.ajic.2016.04.249 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA EE3QP UT WOS:000389510400029 PM 27520787 ER PT J AU Becerra, MB Shirley, D Safdar, N AF Becerra, Monideepa B. Shirley, Daniel Safdar, Nasia TI Prevalence, risk factors, and outcomes of idle intravenous catheters: An integrative review SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Review DE Bloodstream infection; Patient outcomes; Idle lines; CLABSI ID CENTRAL VENOUS CATHETER; BLOOD-STREAM INFECTION; INTENSIVE-CARE-UNIT; PREVENTION; GUIDELINES AB Objective: Complications of intravenous catheters remain a major contributor to health care costs and are a patient safety problem. An intravenous catheter not actively in use-an idle catheter-may increase the risk of infectious and noninfectious complications. We conducted an integrative review of the available literature to evaluate the prevalence, risk factors, and outcomes associated with idle intravenous catheters. Methods: Searches of multiple computerized databases were conducted to identify studies on idle intravenous catheters. Data on definitions of idle catheter, type of catheter, prevalence, risk factors, and patient outcomes were extracted. Results: Thirteen studies met inclusion criteria and were included in the review. The location and setting of the studies were diverse, including cross-sectional, retrospective, and prospective, and were conducted in varied geographic locations. The definition of an idle catheter was variable across studies. Although studies varied in terms of line-days or number of catheters placed, the primary definition of idle device was based on number of days or percent of devices left in situ without use. Four studies evaluated patient outcomes associated with idle catheters and found increased risk of infection, intensive care unit admission, and phlebitis. Conclusions: Idle intravenous catheters are common and are associated with adverse outcomes. Prospective studies incorporating uniform definitions of idle catheters to test interventions to reduce idle catheter use are urgently needed. Published by Elsevier Inc. on behalf of Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Becerra, Monideepa B.] Calif State Univ San Bernardino, Dept Hlth Sci & Human Ecol, San Bernardino, CA 92407 USA. [Shirley, Daniel; Safdar, Nasia] Univ Wisconsin, Dept Med, Div Infect Dis, Sch Med & Publ Hlth, Madison, WI USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Safdar, N (reprint author), Univ Wisconsin Madison, Dept Med, 1685 Highland Ave, Madison, WI 53792 USA. EM ns2@medicine.wisc.edu FU VA MERIT award; VA Patient Safety Center; Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service Quality Enhancement Research Initiative [PEC 15-248] FX NS is supported by a VA MERIT award and by the VA Patient Safety Center. The project reported here was also supported by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service Quality Enhancement Research Initiative (project No. PEC 15-248). The views expressed in this article are those of the author(s) and do not necessarily represent the views of the Department of Veterans Affairs. NR 31 TC 0 Z9 0 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD OCT 1 PY 2016 VL 44 IS 10 BP E167 EP E172 DI 10.1016/j.ajic.2016.03.073 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA EE3QP UT WOS:000389510400001 PM 27425008 ER PT J AU Nillni, YI Wesselink, AK Gradus, JL Hatch, EE Rothman, KJ Mikkelsen, EM Wise, LA AF Nillni, Yael I. Wesselink, Amelia K. Gradus, Jaimie L. Hatch, Elizabeth E. Rothman, Kenneth J. Mikkelsen, Ellen M. Wise, Lauren A. TI Depression, anxiety, and psychotropic medication use and fecundability SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article; Proceedings Paper CT Biennial Meeting of the North-American-Society-for-Psychosocial-Obstetrics-and-Gynecology CY APR 08-10, 2016 CL New York, NY SP N Amer Psychosocial Obstet & Gynecol DE anxiety; depression; fecundability; psychotropic medication ID WOMEN; INFERTILITY; INVENTORY; VALIDITY; DISORDER; STRESS; COHORT AB BACKGROUND: The literature regarding the associations between depression, anxiety, and fecundity is inconsistent. While cross-sectional studies suggest that depression and/or anxiety may adversely affect fecundity, the sole cohort study showed only a small association. OBJECTIVE: We sought to evaluate the association of self-reported depressive symptoms, self-reported diagnoses of depression and anxiety, and psychotropic medication use with fecundability in a prospective cohort study. STUDY DESIGN: Data were derived from Pregnancy Study Online (PRESTO), an Internet-based preconception cohort study of couples attempting to conceive in the United States and Canada. At baseline, female participants completed a survey that assessed demographic information, history of physician-diagnosed depression and anxiety, self-reported depressive symptoms (assessed by the Major Depression Inventory), and use of psychotropic medications. Women completed follow-up surveys every 8 weeks for up to 12 months or until reported conception to assess changes in exposures and pregnancy status. We estimated fecundability ratios and 95% confidence intervals using proportional probabilities regression models. The analysis was restricted to 2146 women who had been attempting to conceive for <= 6 cycles at study entry. RESULTS: Severe depressive symptoms at baseline, regardless of treatment, were associated with decreased fecundability compared with no or low depressive symptoms (fecundability ratio, 0.62; 95% confidence interval, 0.43-0.91). The fecundability ratio associated with a 10-unit increase in Major Depression Inventory score was 0.90 (95% confidence interval, 0.83-0.97). Women who reported moderate to severe depressive symptoms and had never received psychotropic medications (fecundability ratio, 0.69; 95% confidence interval, 0.48-0.99) or who were currently being treated with psychotropic medications (fecundability ratio, 0.72; 95% confidence interval, 0.44-1.20) had decreased fecundability relative to women who had no/mild depressive symptoms and had never used psychotropic medications. Former users of psychotropic medications had increased fecundability regardless of the presence of no/mild depressive symptoms (fecundability ratio, 1.22; 95% confidence interval, 1.06-1.39) or moderate to severe depressive symptoms (fecundability ratio, 1.18; 95% confidence interval, 0.80-1.76). CONCLUSION: We found an inverse association between depressive symptoms and fecundability, independent of psychotropic medication use. Use of psychotropic medications did not appear to harm fecundability. C1 [Nillni, Yael I.; Gradus, Jaimie L.] VA Boston Healthcare Syst, Womens Hlth Sci Div, Natl Ctr Posttraumat Stress Disorder, Boston, MA 02130 USA. [Nillni, Yael I.; Gradus, Jaimie L.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. [Wesselink, Amelia K.; Gradus, Jaimie L.; Hatch, Elizabeth E.; Rothman, Kenneth J.; Wise, Lauren A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Wise, Lauren A.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. [Rothman, Kenneth J.] RTI Hlth Solut, Durham, NC USA. [Mikkelsen, Ellen M.] Aarhus Univ, Dept Clin Epidemiol, Aarhus, Denmark. RP Nillni, YI (reprint author), VA Boston Healthcare Syst, Womens Hlth Sci Div, Natl Ctr Posttraumat Stress Disorder, Boston, MA 02130 USA.; Nillni, YI (reprint author), Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. EM yael.nillni@va.gov NR 26 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD OCT PY 2016 VL 215 IS 4 AR 453.e1-8 DI 10.1016/j.ajog.2016.04.022 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA EE3RJ UT WOS:000389513600014 PM 27131586 ER PT J AU Venkatesh, KK Nadel, H Blewett, D Freeman, MP Kaimal, AJ Riley, LE AF Venkatesh, Kartik K. Nadel, Hiyam Blewett, Dyan Freeman, Marlene P. Kaimal, Anjali J. Riley, Laura E. TI Implementation of universal screening for depression during pregnancy: feasibility and impact on obstetric care SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE depression; pregnancy; screening; EPDS; linkage to care ID PERINATAL DEPRESSION; POSTNATAL DEPRESSION; POSTPARTUM DEPRESSION; WOMEN; MANAGEMENT; OUTCOMES; SCALE; VALIDATION; PROGRAM AB BACKGROUND: Given the growing policy and public health interest in the identification and treatment of depression in pregnancy, an understanding of the feasibility, challenges, and implications for resource utilization of the implementation of a universal screening program is crucial. OBJECTIVE: The purpose of this study was to assess the feasibility of large-scale implementation of universal screening for depression in pregnancy and during the postpartum period with the use of the Edinburgh Postnatal Depression Scale. STUDY DESIGN: A prospective observational cohort study was conducted from July 2010 to June 2014 at a large academic medical center. Pregnant women were screened at 24-28 weeks gestation and again 6 weeks postpartum. An Edinburgh Postnatal Depression Scale score of >= 12 was the cutoff for referral to mental health services for diagnostic evaluation and treatment. RESULTS: Among 8985 women who were enrolled in prenatal care at the participating sites, 8840 women (98%) were screened for depression antepartum, and 7780 women (86%) were screened postpartum. A total of 576 women (6.5%) screened positive for probable depression; of these, 69% screened positive antepartum, and 31% screened positive postpartum (P < .01). All women who screened positive were referred for an evaluation by a mental health professional; 79% of the women were evaluated, which was more common antepartum than postpartum (83% vs 71%; P < .01). One hundred twenty-one women (21%) were not evaluated further after a positive screen; primary reasons included declining a mental health evaluation (30%) or transferring obstetric care 12%). Among women who underwent a mental health evaluation, 67% were diagnosed with major depression; 37% were diagnosed with an anxiety disorder; 28% were diagnosed concurrently with major depression and an anxiety disorder; 76% were diagnosed with either depression or anxiety, and 35% were treated with an antidepressant medication, which was more frequent during the postpartum period than during the antepartum period (54% vs 28%; P < .001). After adjustment for maternal age, parity, race, and household income, women who screened positive antepartum were significantly more likely to link to mental health services compared with women who screened positive postpartum (adjusted odds ratio, 2.09; 95% CI, 1.24-3.24; P = .001). CONCLUSION: This study demonstrates the feasibility of universal depression screening during both the antepartum and postpartum periods with the use of the Edinburgh Postnatal Depression Scale as an initial screen followed by mental health referral for further diagnostic evaluation and treatment. The population of women who screened positive and who accepted additional services differed at the 2 time points, which reinforces the utility of screening during both the antepartum and postpartum periods. Although universal screening for depression is feasible, further study of the barriers to mental health evaluation and treatment and the impact of treatment on obstetric outcomes are needed. C1 [Kaimal, Anjali J.; Riley, Laura E.] Massachusetts Gen Hosp, Div Maternal Fetal Med, Boston, MA 02114 USA. [Venkatesh, Kartik K.; Nadel, Hiyam; Kaimal, Anjali J.; Riley, Laura E.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA. [Blewett, Dyan] Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA. [Freeman, Marlene P.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Venkatesh, Kartik K.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. RP Venkatesh, KK (reprint author), Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA.; Venkatesh, KK (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. EM kvenkatesh@partners.org NR 32 TC 0 Z9 0 U1 7 U2 7 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD OCT PY 2016 VL 215 IS 4 AR 517.e1-8 DI 10.1016/j.ajog.2016.05.024 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA EE3RJ UT WOS:000389513600047 PM 27210067 ER PT J AU Gaggar, A Patel, RP AF Gaggar, Amit Patel, Rakesh P. TI There is blood in the water: hemolysis, hemoglobin, and heme in acute lung injury SO AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY LA English DT Article DE ARDS; heme; hemoglobin; inflammation; nitric oxide ID CELL-FREE HEMOGLOBIN; NITRIC-OXIDE; PULMONARY-HYPERTENSION; STORAGE LESION; HAPTOGLOBIN; DISEASE; MORTALITY; THERAPY; INFLAMMATION; HEMOPEXIN AB The major role of red blood cells (RBCs) is to deliver oxygen and remove carbon dioxide within organisms through the unique properties of hemoglobin. Although beneficial within RBCs, when outside hemoglobin and its breakdown products (heme, iron) induce proinflammatory responses affecting various cellular responses. Although these effects are considered to be prominent in disorders with increased hemolysis, recent evidence suggests that this process may be active in nonhemolytic disorders such as acute lung injury/acute respiratory distress syndrome. This perspectives article focuses on data related to red cell products in nonhemolytic disorders and the potential to target these factors in acute lung injury/acute respiratory distress syndrome. C1 [Gaggar, Amit] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Patel, Rakesh P.] Univ Alabama Birmingham, Dept Pathol, 901 19th St South,BMR 2,Rm 532, Birmingham, AL 35294 USA. [Patel, Rakesh P.] Univ Alabama Birmingham, Ctr Free Radical Biol, Birmingham, AL USA. [Gaggar, Amit] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA. RP Patel, RP (reprint author), Univ Alabama Birmingham, Dept Pathol, 901 19th St South,BMR 2,Rm 532, Birmingham, AL 35294 USA. EM rakeshpatel@uabmc.edu NR 39 TC 0 Z9 0 U1 5 U2 5 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1040-0605 EI 1522-1504 J9 AM J PHYSIOL-LUNG C JI Am. J. Physiol.-Lung Cell. Mol. Physiol. PD OCT 1 PY 2016 VL 311 IS 4 BP L714 EP L718 DI 10.1152/ajplung.00312.2016 PG 5 WC Physiology; Respiratory System SC Physiology; Respiratory System GA EE5IP UT WOS:000389640200004 PM 27542810 ER PT J AU Jacobs, JP He, X Mayer, JE Austin, EH Quintessenza, JA Karl, TR Vricella, L Mavroudis, C O'Brien, SM Pasquali, SK Hill, KD Husain, SA Overman, DM St Louis, JD Han, JM Shahian, DM Cameron, D Jacobs, ML AF Jacobs, Jeffrey P. He, Xia Mayer, John E., Jr. Austin, Erle H., III Quintessenza, James A. Karl, Tom R. Vricella, Luca Mavroudis, Constantine O'Brien, Sean M. Pasquali, Sara K. Hill, Kevin D. Husain, S. Adil Overman, David M. St Louis, James D. Han, Jane M. Shahian, David M. Cameron, Duke Jacobs, Marshall L. TI Mortality Trends in Pediatric and Congenital Heart Surgery: An Analysis of The Society of Thoracic Surgeons Congenital Heart Surgery Database SO ANNALS OF THORACIC SURGERY LA English DT Article ID EMPIRICALLY BASED TOOL; METHODOLOGY; OPERATIONS; OUTCOMES; DISEASE; EACTS AB Background. Previous analyses of The Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database have demonstrated a reduction over time of risk-adjusted operative mortality after coronary artery bypass grafting. The STS Congenital Heart Surgery Database (STS CHSD) was queried to assess multiinstitutional trends over time in discharge mortality and postoperative length of stay (PLOS). Methods. Since 2009, operations in the STS CHSD have been classified according to STAT (The Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery) Congenital Heart Surgery Mortality Categories. The five STAT Mortality Categories were chosen to be optimal with respect to minimizing variation within categories and maximizing variation between categories. For this study, all index cardiac operations from 1998 to 2014, inclusive, were grouped by STAT Mortality Category (exclusions: patent ductus arteriosus ligation in patients weighing less than or equal to 2.5 kg and operations that could not be assigned to a STAT Mortality Category). End points were discharge mortality and PLOS in survivors for the entire period and for 4-year epochs. The Cochran-Armitage trend test was used to test the null hypothesis that the mortality was the same across epochs, by STAT Mortality Category. Results. The analysis encompassed 202,895 index operations at 118 centers. The number of centers participating in STS CHSD increased in each epoch. Overall discharge mortality was 3.4% (6,959 of 202,895) for 1998 to 2014 and 3.1% (2,308 of 75,337) for 2011 to 2014. Statistically significant improvement in discharge mortality was seen in STAT Mortality Categories 2, 3, 4, and 5 (p values for STAT Mortality Categories 1 through 5 are 0.060, < 0.001, 0.015, < 0.001, and < 0.001, respectively). PLOS in survivors was relatively unchanged over the same time intervals. Sensitivity analyses reveal that the finding of declining risk-stratified rates of discharge mortality over time is not simply attributable to the addition of more centers to the cohort over time. Conclusions. This 16-year analysis of STS CHSD reveals declining discharge mortality over time, especially for more complex operations. (C) 2016 by The Society of Thoracic Surgeons C1 [Jacobs, Jeffrey P.; Quintessenza, James A.; Karl, Tom R.; Vricella, Luca; Mavroudis, Constantine; Cameron, Duke; Jacobs, Marshall L.] Johns Hopkins Univ, Sch Med, Div Cardiac Surg, Dept Surg, Baltimore, MD USA. [Jacobs, Jeffrey P.; Quintessenza, James A.; Karl, Tom R.; Vricella, Luca; Mavroudis, Constantine; Cameron, Duke; Jacobs, Marshall L.] Johns Hopkins All Childrens Hosp, Johns Hopkins All Childrens Heart Inst, Div Cardiovascular Surg, Dept Surg, Tampa, FL USA. Florida Hosp Children, Tampa, FL USA. [He, Xia; O'Brien, Sean M.; Hill, Kevin D.] Duke Univ, Durham, NC USA. [Mayer, John E., Jr.] Childrens Hosp Boston, Harvard Med Sch, Boston, MA 02215 USA. [Austin, Erle H., III] Univ Louisville, Kosair Childrens Hosp, Louisville, KY USA. [Karl, Tom R.] Univ Queensland, Sch Med, Brisbane, Qld, Australia. [Pasquali, Sara K.] Univ Michigan, C S Mott Childrens Hosp, Ann Arbor, MI USA. [Husain, S. Adil] Univ Texas Hlth Sci Ctr San Antonio, Univ Hlth Syst, San Antonio, TX 78229 USA. [Overman, David M.] Childrens Hosp & Clin Minnesota, Childrens Heart Clin, Minneapolis, MN 55415 USA. [St Louis, James D.] Univ Missouri Kansas City, Sch Med, Dept Surg, Kansas City, MO USA. [Han, Jane M.] Soc Thorac Surg, Chicago, IL 60611 USA. [Shahian, David M.] Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA USA. RP Jacobs, JP (reprint author), Johns Hopkins All Childrens Hosp, 601 Fifth St S Ste 607, St Petersburg, FL 33701 USA. EM jeffjacobs@msn.com NR 18 TC 1 Z9 1 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD OCT PY 2016 VL 102 IS 4 BP 1345 EP 1352 DI 10.1016/j.athoracsur.2016.01.071 PG 8 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA EE4AI UT WOS:000389543600074 PM 27590683 ER PT J AU Mihos, CG Pineda, AM Capoulade, R Santana, O AF Mihos, Christos G. Pineda, Andres M. Capoulade, Romain Santana, Orlando TI A Systematic Review of Mitral Valve Repair With Autologous Pericardial Leaflet Augmentation for Rheumatic Mitral Regurgitation SO ANNALS OF THORACIC SURGERY LA English DT Review ID VALVULAR HEART-DISEASE; REPLACEMENT; EXTENSION; GLUTARALDEHYDE AB A systematic review was conducted to assess the efficacy of mitral valve repair using glutaraldehyde-treated autologous pericardial leaflet augmentation for rheumatic mitral regurgitation (MR). Five retrospective studies were identified, which included 196 patients with moderate or greater MR. There was 1 operative death (0.5%). At a mean follow-up of 3.2 +/- 2.2 years, moderate or greater MR reoccurred in 22 patients (11.2%), reoperation was required in 9 (4.6%), and the cumulative survival was 98.9%. Finally, outcomes were similar between the patients who underwent augmentation of the anterior vs the posterior mitral leaflet. Pericardial leaflet augmentation is a viable technique for the treatment of rheumatic MR. (C) 2016 by The Society of Thoracic Surgeons C1 [Mihos, Christos G.] Harvard Med Sch, Massachusetts Gen Hosp, Cardiac Ultrasound Lab, 55 Fruit St, Boston, MA 02114 USA. Columbia Univ, Mt Sinai Heart Inst, Div Cardiol, Miami Beach, FL USA. RP Mihos, CG (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Cardiac Ultrasound Lab, 55 Fruit St, Boston, MA 02114 USA. EM cmihos@mgh.harvard.edu NR 27 TC 2 Z9 2 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0003-4975 EI 1552-6259 J9 ANN THORAC SURG JI Ann. Thorac. Surg. PD OCT PY 2016 VL 102 IS 4 BP 1400 EP 1405 DI 10.1016/j.athoracsur.2016.04.009 PG 6 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA EE4AI UT WOS:000389543600082 PM 27319989 ER PT J AU Katsiki, N Mantzoros, CS AF Katsiki, Niki Mantzoros, Christos S. TI Statins in relation to adiponectin: A significant association with clinical implications SO ATHEROSCLEROSIS LA English DT Editorial Material DE Statins; Adiponectin; Cardiovascular risk; Pleiotropic effects; New-onset diabetes ID RANDOMIZED CONTROLLED-TRIALS; FATTY LIVER-DISEASE; MOLECULAR-MECHANISMS; METAANALYSIS; RISK; PITAVASTATIN; THERAPY; DYSLIPIDEMIA; UPDATE; LEPTIN C1 [Katsiki, Niki] Aristotle Univ Thessaloniki, Hippocrat Hosp, Sch Med, Propedeut Dept Internal Med 2, Thessaloniki, Greece. [Mantzoros, Christos S.] Boston VA Healthcare Syst, Boston, MA USA. [Mantzoros, Christos S.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Internal Med, Div Endocrinol Diabet & Metab, Boston, MA USA. RP Katsiki, N (reprint author), 12 Dionyssiou St, Thessaloniki 54634, Greece. EM nikikatsiki@hotmail.com NR 57 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0021-9150 EI 1879-1484 J9 ATHEROSCLEROSIS JI Atherosclerosis PD OCT PY 2016 VL 253 BP 270 EP 272 DI 10.1016/j.atherosclerosis.2016.08.009 PG 3 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA EE2GG UT WOS:000389401200039 PM 27567030 ER PT J AU Yang, B Thrift, AP Figueiredo, JC Jenkins, MA Schumacher, FR Conti, DV Lin, Y Win, AK Limburg, PJ Berndt, SI Brenner, H Chan, AT Chang-Claude, J Hoffmeister, M Hudson, TJ Le Marchand, L Newcomb, PA Slattery, ML White, E Peters, U Casey, G Campbell, PT AF Yang, Baiyu Thrift, Aaron P. Figueiredo, Jane C. Jenkins, Mark A. Schumacher, Fredrick R. Conti, David V. Lin, Yi Win, Aung Ko Limburg, Paul J. Berndt, Sonja I. Brenner, Hermann Chan, Andrew T. Chang-Claude, Jenny Hoffmeister, Michael Hudson, Thomas J. Le Marchand, Loic Newcomb, Polly A. Slattery, Martha L. White, Emily Peters, Ulrike Casey, Graham Campbell, Peter T. TI Common variants in the obesity-associated genes FTO and MC4R are not associated with risk of colorectal cancer SO CANCER EPIDEMIOLOGY LA English DT Article DE Obesity; Genetic variants; Colorectal cancer; Case-control study ID METAANALYSIS; LOCI AB Background: Obesity is a convincing risk factor for colorectal cancer. Genetic variants in or near FTO and MC4R are consistently associated with body mass index and other body size measures, but whether they are also associated with colorectal cancer risk is unclear. Methods: In the discovery stage, we tested associations of 677 FTO and 323 MC4R single nucleotide polymorphisms (SNPs) 100 kb upstream and 300 kb downstream from each respective locus with risk of colorectal cancer in data from the Colon Cancer Family Registry (CCFR: 1960 cases; 1777 controls). Next, all SNPs that were nominally statistically significant (p < 0.05) in the discovery stage were included in replication analyses in data from the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO: 9716 cases; 9844 controls). Results: In the discovery stage, 43 FTO variants and 18 MC4R variants were associated with colorectal cancer risk (p < 0.05). No SNPs remained statistically significant in the replication analysis after accounting for multiple comparisons. Conclusion: We found no evidence that individual variants in or near the obesity-related genes FTO and MC4R are associated with risk of colorectal cancer. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Yang, Baiyu; Campbell, Peter T.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA. [Yang, Baiyu] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Thrift, Aaron P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Thrift, Aaron P.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA. [Figueiredo, Jane C.; Schumacher, Fredrick R.; Conti, David V.; Casey, Graham] Univ Southern Calif, Dept Prevent Med, Keck Sch Med, Los Angeles, CA USA. [Jenkins, Mark A.; Win, Aung Ko] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia. [Lin, Yi; Newcomb, Polly A.; White, Emily] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA. [Limburg, Paul J.] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA. [Berndt, Sonja I.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [Brenner, Hermann; Hoffmeister, Michael] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Heidelberg, Germany. [Brenner, Hermann] German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany. [Brenner, Hermann] German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany. [Brenner, Hermann] German Canc Res Ctr, Natl Ctr Tumor Dis NCT, Heidelberg, Germany. [Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. [Chan, Andrew T.] Harvard Med Sch, Boston, MA USA. [Chan, Andrew T.] Brigham & Womens Hosp, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Chang-Claude, Jenny] German Canc Res Ctr, Div Canc Epidemiol, Heidelberg, Germany. [Hudson, Thomas J.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada. [Hudson, Thomas J.] Ontario Inst Canc Res, Toronto, ON, Canada. [Hudson, Thomas J.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada. [Le Marchand, Loic] Univ Hawaii, Program Epidemiol, Ctr Canc, Honolulu, HI 96822 USA. [Newcomb, Polly A.; White, Emily; Peters, Ulrike] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Slattery, Martha L.] Univ Utah, Dept Internal Med, Hlth Sci Ctr, Salt Lake City, UT 84112 USA. RP Campbell, PT (reprint author), Amer Canc Soc, Natl Home Off, Epidemiol Res Program, 250 Williams St NW, Atlanta, GA 30303 USA. EM Peter.Campbell@cancer.org RI Brenner, Hermann/B-4627-2017; OI Brenner, Hermann/0000-0002-6129-1572; Win, Aung Ko/0000-0002-2794-5261; Hoffmeister, Michael/0000-0002-8307-3197 FU NCI NIH HHS [U24 CA074783, U24 CA074794, U24 CA074799, U01 CA074800, U24 CA074800, U24 CA074806, U24 CA097735, UM1 CA167551] NR 11 TC 1 Z9 1 U1 3 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1877-7821 EI 1877-783X J9 CANCER EPIDEMIOL JI Cancer Epidemiol. PD OCT PY 2016 VL 44 BP 1 EP 4 DI 10.1016/j.canep.2016.07.003 PG 4 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA EE3RU UT WOS:000389515700001 PM 27449576 ER PT J AU Kim, C Zhang, X Chan, AT Sesso, HD Rifai, N Stampfer, MJ Ma, J AF Kim, Chul Zhang, Xuehong Chan, Andrew T. Sesso, Howard D. Rifai, Nader Stampfer, Meir J. Ma, Jing TI Inflammatory biomarkers, aspirin, and risk of colorectal cancer: Findings from the physicians' health study SO CANCER EPIDEMIOLOGY LA English DT Article DE CRP; IL-6; TNFR-2; Colorectal cancer; Aspirin ID C-REACTIVE PROTEIN; INTERLEUKIN-6; METAANALYSIS; MARKERS; DISEASE; COHORT; WOMEN AB Background: Chronic inflammation has been implicated in colorectal carcinogenesis. However, the associations between plasma inflammatory markers and risk of colorectal cancer have been inconsistent. Methods: In a nested case-control study in the Physicians' Health Study, we prospectively investigated the associations of plasma C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor receptor 2 (TNFR-2) with risk of colorectal cancer, and whether aspirin modified these associations among 268 colorectal cancer patients and 446 age-and smoking-matched controls. Results: In multivariate-adjusted models, plasma levels of CRP, IL-6 and TNFR-2 were not significantly associated with risk of colorectal cancer, although a positive trend was observed for TNFR-2 (RRhighestvs. (lowestquartile) = 1.55; 95% CI = 0.95-2.54; P-trend = 0.05). We observed a statistically significant association between elevated TNFR-2 levels and colorectal cancer risk in the placebo arm (RRhighestvs.lowesttertile = 1.77; 95% CI = 1.02-3.06; P-trend = 0.02), but not in the aspirin arm (P-trend = 0.72). However, the interaction between TNFR-2 and aspirin was not statistically significant (P-interaction = 0.34). Conclusion: Plasma inflammatory markers were not significantly associated with colorectal cancer risk among men, though there was a statistically non-significant positive trend between TNFR-2 and colorectal cancer risk. More studies are required to understand the relationship between the role of TNF alpha pathway, aspirin, and colorectal cancer risk. Published by Elsevier Ltd. C1 [Kim, Chul] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA. [Kim, Chul] NCI, Med Oncol Serv, NIH, Bethesda, MD 20892 USA. [Zhang, Xuehong; Chan, Andrew T.; Stampfer, Meir J.; Ma, Jing] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Zhang, Xuehong; Chan, Andrew T.; Sesso, Howard D.; Stampfer, Meir J.; Ma, Jing] Harvard Med Sch, Boston, MA USA. [Chan, Andrew T.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA. [Sesso, Howard D.; Stampfer, Meir J.] Harvard Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Sesso, Howard D.] Brigham & Womens Hosp, Dept Med, Div Prevent Med, 75 Francis St, Boston, MA 02115 USA. [Rifai, Nader] Childrens Hosp Med Ctr, Dept Pathol, Boston, MA USA. [Stampfer, Meir J.] Harvard Sch Publ Hlth, Dept Nutr, Boston, MA USA. RP Kim, C (reprint author), Bldg 10,Room B2L312,10 Ctr Dr, Bethesda, MD 20814 USA.; Ma, J (reprint author), Brigham & Womens Hosp, Channing Div Network Med, 181 Longwood Ave, Boston, MA 02115 USA. EM kimc5@mail.nih.gov; jing.ma@channing.harvard.edu FU National Cancer Institute [CA42182, CA097193, CA019894, U54CA155626]; National Heart, Lung, and Blood Institute [HL26490, HL34595]; National Cancer Institute of Canada [019894]; National Institute of Health [R01 CA137178] FX This study was supported by Grant Numbers CA42182, CA097193, CA019894, U54CA155626 from the National Cancer Institute, by Grant Numbers HL26490 and HL34595 from the National Heart, Lung, and Blood Institute, and a grant (019894) from the National Cancer Institute of Canada. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Heart, Lung, and Blood Institute. This work was also supported by National Institute of Health grants R01 CA137178 (to A.T.C.). A.T.C. is a Damon Runyon Cancer Foundation Clinical Investigator. NR 26 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1877-7821 EI 1877-783X J9 CANCER EPIDEMIOL JI Cancer Epidemiol. PD OCT PY 2016 VL 44 BP 65 EP 70 DI 10.1016/j.canep.2016.07.012 PG 6 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA EE3RU UT WOS:000389515700009 PM 27504605 ER PT J AU Sistrunk, JR Nickerson, KP Chanin, RB Rasko, DA Faherty, CS AF Sistrunk, Jeticia R. Nickerson, Kourtney P. Chanin, Rachael B. Rasko, David A. Faherty, Christina S. TI Survival of the Fittest: How Bacterial Pathogens Utilize Bile To Enhance Infection SO CLINICAL MICROBIOLOGY REVIEWS LA English DT Review ID ENTERICA SEROVAR TYPHIMURIUM; ENTEROTOXIGENIC ESCHERICHIA-COLI; MULTIDRUG EFFLUX PUMP; CAMPYLOBACTER-JEJUNI RESPONSE; DIFFICILE SPORE GERMINATION; VIBRIO-CHOLERAE VIRULENCE; IN-VIVO COLONIZATION; SALMONELLA-ENTERICA; LISTERIA-MONOCYTOGENES; CLOSTRIDIUM-DIFFICILE AB Bacterial pathogens have coevolved with humans in order to efficiently infect, replicate within, and be transmitted to new hosts to ensure survival and a continual infection cycle. For enteric pathogens, the ability to adapt to numerous host factors under the harsh conditions of the gastrointestinal tract is critical for establishing infection. One such host factor readily encountered by enteric bacteria is bile, an innately antimicrobial detergent-like compound essential for digestion and nutrient absorption. Not only have enteric pathogens evolved to resist the bactericidal conditions of bile, but these bacteria also utilize bile as a signal to enhance virulence regulation for efficient infection. This review provides a comprehensive and up-to-date analysis of bile-related research with enteric pathogens. From common responses to the unique expression of specific virulence factors, each pathogen has overcome significant challenges to establish infection in the gastrointestinal tract. Utilization of bile as a signal to modulate virulence factor expression has led to important insights for our understanding of virulence mechanisms for many pathogens. Further research on enteric patho-gens exposed to this in vivo signal will benefit therapeutic and vaccine development and ultimately enhance our success at combating such elite pathogens. C1 [Sistrunk, Jeticia R.; Rasko, David A.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Inst Genome Sci, Baltimore, MD 21201 USA. [Nickerson, Kourtney P.; Chanin, Rachael B.; Faherty, Christina S.] Massachusetts Gen Hosp, Div Pediat Gastroenterol & Nutr, Mucosal Immunol & Biol Res Ctr, Boston, MA 02114 USA. [Nickerson, Kourtney P.; Chanin, Rachael B.; Faherty, Christina S.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA. RP Faherty, CS (reprint author), Massachusetts Gen Hosp, Div Pediat Gastroenterol & Nutr, Mucosal Immunol & Biol Res Ctr, Boston, MA 02114 USA.; Faherty, CS (reprint author), Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA. EM csfaherty@partners.org FU National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [T32 5T32AI095190-04, U19AI110820, 1K22AI104755-01] FX This project was funded in part by federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, from grants T32 5T32AI095190-04 (J.R.S.), U19AI110820 (D.A.R.), and 1K22AI104755-01 (C.S.F). NR 180 TC 0 Z9 0 U1 10 U2 10 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0893-8512 EI 1098-6618 J9 CLIN MICROBIOL REV JI Clin. Microbiol. Rev. PD OCT PY 2016 VL 29 IS 4 BP 819 EP 836 DI 10.1128/CMR.00031-16 PG 18 WC Microbiology SC Microbiology GA EE8UG UT WOS:000389901000006 PM 27464994 ER PT J AU Hofmann, G Haan, L Anderson, J AF Hofmann, Grace Haan, Lutana Anderson, Jeff TI Esophageal Pressure Measurements in Patients With Acute Respiratory Distress Syndrome SO CRITICAL CARE NURSE LA English DT Article ID PLEURAL PRESSURE; LUNG INJURY; VENTILATION; PARALYSIS AB Esophageal balloons are used in the respiratory monitoring of critical care patients. After the esophageal pressure is measured, the corresponding pleural pressure in the thorax can be projected, enabling lung-thorax compliance to be partitioned into chest-wall compliance and lung compliance. The esophageal balloon allows determination of transpulmonary pressures and a correspondingly individually tailored approach to respiratory care, such as patient-specific titration of positive end-expiratory pressure for patients with extrapulmonary acute respiratory distress syndrome. Esophageal balloon monitoring provides critical information for selecting ventilation strategies to use in patients with acute respiratory distress syndrome. C1 [Hofmann, Grace] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Haan, Lutana; Anderson, Jeff] Boise State Univ, Resp Care Program, Boise, ID 83725 USA. RP Haan, L (reprint author), Boise State Univ, Hlth Sci Riverside, HSR 116,950 Lusk, Boise, ID 83725 USA. EM lutanahaan@boisestate.edu NR 27 TC 0 Z9 0 U1 0 U2 0 PU AMER ASSOC CRITICAL CARE NURSES PI ALISO VIEJO PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA SN 0279-5442 EI 1940-8250 J9 CRIT CARE NURSE JI Crit. Care Nurse PD OCT PY 2016 VL 36 IS 5 BP 27 EP 35 DI 10.4037/ccn2016917 PG 9 WC Critical Care Medicine; Nursing SC General & Internal Medicine; Nursing GA EE5GP UT WOS:000389633900003 PM 27694355 ER PT J AU Yuen, KCJ Tritos, NA Samson, SL Hoffman, AR Katznelson, L AF Yuen, Kevin C. J. Tritos, Nicholas A. Samson, Susan L. Hoffman, Andrew R. Katznelson, Laurence TI AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: UPDATE ON GROWTH HORMONE STIMULATION TESTING AND PROPOSED REVISED CUT-POINT FOR THE GLUCAGON STIMULATION TEST IN THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY SO ENDOCRINE PRACTICE LA English DT Review ID INSULIN TOLERANCE-TEST; FATTY LIVER-DISEASE; BODY-MASS INDEX; GH DEFICIENCY; FACTOR-I; (GH)-RELEASING HORMONE; REPLACEMENT THERAPY; INDUCED HYPOGLYCEMIA; CORTISOL SECRETION; PITUITARY SURGERY AB Objective: The clinical features of adult GH deficiency (GHD) are nonspecific, and GH stimulation testing is often required to confirm the diagnosis. However, diagnosing adult GHD can be challenging due to the episodic and pulsatile GH secretion, concurrently modified by age, gender, and body mass index (BMI). Methods: PubMed searches were conducted to identify published data since 2009 on GH stimulation tests used to diagnose adult GHD. Relevant articles in English language were identified and considered for inclusion in the present document. Results: Testing for confirmation of adult GHD should only be considered if there is a high pretest probability, and the intent to treat if the diagnosis is confirmed. The insulin tolerance test (ITT) and glucagon stimulation test (GST) are the two main tests used in the United States. While the ITT has been accepted as the gold-standard test, its safety concerns hamper wider use. Previously, the GH-releasing hormone-arginine test, and more recently the GST, are accepted alternatives to the ITT. However, several recent studies have questioned the diagnostic accuracy of the GST when the GH cut-point of 3 mg/L is used and have suggested that a lower GH cut-point of 1 mg/L improved the sensitivity and specificity of this test in overweight/obese patients and in those with glucose intolerance. Conclusion: Until a potent, safe, and reliable test becomes available, the GST should remain as the alternative to the ITT in the United States. In order to reduce over-diagnosing adult GHD in overweight/obese patients with the GST, we propose utilizing a lower GH cut-point of 1 mg/L in these subjects. However, this lower GH cut-point still needs further evaluation for diagnostic accuracy in larger patient populations with varying BMIs and degrees of glucose tolerance. C1 [Yuen, Kevin C. J.] Swedish Neurosci Inst, Swedish Pituitary Ctr, Dept Neuroendocrinol, 550 17th Ave,Suite 400, Seattle, WA 98122 USA. [Yuen, Kevin C. J.] Swedish Neurosci Inst, Dept Neurosurg, 550 17th Ave,Suite 400, Seattle, WA 98122 USA. [Tritos, Nicholas A.] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA. [Tritos, Nicholas A.] Harvard Med Sch, Boston, MA USA. [Samson, Susan L.] Baylor Coll Med, Baylor St Lukes Med Ctr, Houston, TX 77030 USA. [Hoffman, Andrew R.] VA Palo Alto Hlth Care Serv, Dept Med, Palo Alto, CA USA. [Hoffman, Andrew R.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA. [Katznelson, Laurence] Stanford Univ, Dept Med, Sch Med, Div Endocrinol, Stanford, CA 94305 USA. [Katznelson, Laurence] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA. RP Yuen, KCJ (reprint author), Swedish Neurosci Inst, Dept Neurosurg, Swedish Pituitary Ctr, 550 17th Ave,Suite 400, Seattle, WA 98122 USA.; Yuen, KCJ (reprint author), Swedish Neurosci Inst, Dept Neurol, 550 17th Ave,Suite 400, Seattle, WA 98122 USA. EM kevin.yuen@swedish.org FU Pfizer; Novo Nordisk; Versartis; Ipsen; Novartis; OKPO Health FX K.C.J.Y. has received research grants from Pfizer, Novo Nordisk, and Versartis, and has served on the advisory boards for Pfizer, Novo Nordisk, Sandoz, and Versartis. N.A.T. has received research support from Ipsen, Pfizer, Novo Nordisk, and Novartis. A.R.H. has consulted for Ambrx, Versartis, Teva, Ascendis, and Genexine. S.L.S. has received research support from Novartis and OKPO Health, and has served on advisory boards for Chiasma and Novartis. L.K. has consulted for Versartis. NR 64 TC 1 Z9 1 U1 0 U2 0 PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS PI JACKSONVILLE PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA SN 1530-891X EI 1934-2403 J9 ENDOCR PRACT JI Endocr. Pract. PD OCT PY 2016 VL 22 IS 10 BP 1235 EP 1244 DI 10.4158/EP161407.DSCR PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EE7YZ UT WOS:000389842700012 PM 27409821 ER PT J AU Chuang, LS Villaverde, N Hui, KY Mortha, A Rahman, A Levine, AP Haritunians, T Ng, SME Zhang, W Hsu, NY Facey, JA Luong, T Fernandez-Hernandez, H Li, DL Rivas, M Schiff, ER Gusev, A Schumm, LP Bowen, BM Sharma, Y Ning, KD Remark, R Gnjatic, S Legnani, P George, J Sands, BE Stempak, JM Datta, LW Lipka, S Katz, S Cheifetz, AS Barzilai, N Pontikos, N Abraham, C Dubinsky, MJ Targan, S Taylor, K Rotter, JI Scherl, EJ Desnick, RJ Abreu, MT Zhao, HY Atzmon, G Pe'er, I Kugathasan, S Hakonarson, H McCauley, JL Lencz, T Darvasi, A Plagnol, V Silverberg, MS Muise, AM Brant, SR Daly, MJ Segal, AW Duerr, RH Merad, M McGovern, DPB Peter, I Cho, JH AF Chuang, Ling-Shiang Villaverde, Nicole Hui, Ken Y. Mortha, Arthur Rahman, Adeeb Levine, Adam P. Haritunians, Talin Ng, Sok Meng Evelyn Zhang, Wei Hsu, Nai-Yun Facey, Jody-Ann Luong, Tramy Fernandez-Hernandez, Heriberto Li, Dalin Rivas, Manuel Schiff, Elena R. Gusev, Alexander Schumm, L. Phillip Bowen, Beatrice M. Sharma, Yashoda Ning, Kaida Remark, Romain Gnjatic, Sacha Legnani, Peter George, James Sands, Bruce E. Stempak, Joanne M. Datta, Lisa W. Lipka, Seth Katz, Seymour Cheifetz, Adam S. Barzilai, Nir Pontikos, Nikolas Abraham, Clara Dubinsky, Marla J. Targan, Stephan Taylor, Kent Rotter, Jerome I. Scherl, Ellen J. Desnick, Robert J. Abreu, Maria T. Zhao, Hongyu Atzmon, Gil Pe'er, Itsik Kugathasan, Subra Hakonarson, Hakon McCauley, Jacob L. Lencz, Todd Darvasi, Ariel Plagnol, Vincent Silverberg, Mark S. Muise, Aleixo M. Brant, Steven R. Daly, Mark J. Segal, Anthony W. Duerr, Richard H. Merad, Miriam McGovern, Dermot P. B. Peter, Inga Cho, Judy H. TI A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling via GM-CSF SO GASTROENTEROLOGY LA English DT Article DE IBD; Inflammatory Bowel Disease; Risk Factor; Ethnic Variation ID INFLAMMATORY-BOWEL-DISEASE; COLONY-STIMULATING FACTOR; CYTOMETRY DATA; RECEPTOR; SUSCEPTIBILITY; ASSOCIATION; AUTOANTIBODIES; PROLIFERATION; ACTIVATION; EXPRESSION AB BACKGROUND & AIMS: Crohn's disease (CD) has the highest prevalence in Ashkenazi Jewish populations. We sought to identify rare, CD-associated frameshift variants of high functional and statistical effects. METHODS: We performed exome sequencing and array-based genotype analyses of 1477 Ashkenazi Jewish individuals with CD and 2614 Ashkenazi Jewish individuals without CD (controls). To validate our findings, we performed genotype analyses of an additional 1515 CD cases and 7052 controls for frameshift mutations in the colony-stimulating factor 2-receptor b common subunit gene (CSF2RB). Intestinal tissues and blood samples were collected from patients with CD; lamina propria leukocytes were isolated and expression of CSF2RB and granulocyte-macrophage colony-stimulating factor-responsive cells were defined by adenomatous polyposis coli (APC) time-of-flight mass cytometry (CyTOF analysis). Variants of CSF2RB were transfected into HEK293 cells and the expression and functions of gene products were compared. RESULTS: In the discovery cohort, we associated CD with a frameshift mutation in CSF2RB (P = 8.52 x 10(-4)); the finding was validated in the replication cohort (combined P = 3.42 x 10(-6)). Incubation of intestinal lamina propria leukocytes with granulocyte-macrophage colony-stimulating factor resulted in high levels of phosphorylation of signal transducer and activator of transcription (STAT5) and lesser increases in phosphorylation of extracellular signal-regulated kinase and AK straining transforming (AKT). Cells co-transfected with full-length and mutant forms of CSF2RB had reduced pSTAT5 after stimulation with granulocyte-macrophage colony-stimulating factor, compared with cells transfected with control CSF2RB, indicating a dominant-negative effect of the mutant gene. Monocytes from patients with CD who were heterozygous for the frameshift mutation (6% of CD cases analyzed) had reduced responses to granulocyte-macrophage colony-stimulating factor and markedly decreased activity of aldehyde dehydrogenase; activity of this enzyme has been associated with immune tolerance. CONCLUSIONS: In a genetic analysis of Ashkenazi Jewish individuals, we associated CD with a frameshift mutation in CSF2RB. Intestinal monocytes from carriers of this mutation had reduced responses to granulocyte-macrophage colony-stimulating factor, providing an additional mechanism for alterations to the innate immune response in individuals with CD. C1 [Chuang, Ling-Shiang; Villaverde, Nicole; Rahman, Adeeb; Hsu, Nai-Yun; Facey, Jody-Ann; Luong, Tramy; Fernandez-Hernandez, Heriberto; Desnick, Robert J.; Peter, Inga; Cho, Judy H.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. [Mortha, Arthur; Remark, Romain; Merad, Miriam] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA. [Gnjatic, Sacha] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol, New York, NY 10029 USA. [Legnani, Peter; George, James; Sands, Bruce E.; Dubinsky, Marla J.; Cho, Judy H.] Icahn Sch Med Mt Sinai, Div Gastroenterol, New York, NY 10029 USA. [Dubinsky, Marla J.] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA. [Cho, Judy H.] Icahn Sch Med Mt Sinai, Charles Bronfman Inst Personalized Med, New York, NY 10029 USA. [Hui, Ken Y.] Yale Univ, Program Computat Biol & Bioinformat, New Haven, CT USA. [Bowen, Beatrice M.] Yale Univ, Dept Genet, New Haven, CT USA. [Zhao, Hongyu] Yale Univ, Dept Biostat, New Haven, CT USA. [Hui, Ken Y.; Haritunians, Talin; Ng, Sok Meng Evelyn; Zhang, Wei; Sharma, Yashoda; Ning, Kaida; Abraham, Clara] Yale Univ, Sch Med, Dept Internal Med, Sect Digest Dis, New Haven, CT 06510 USA. [Levine, Adam P.; Schiff, Elena R.; Pontikos, Nikolas; Segal, Anthony W.] UCL, Ctr Mol Med, Div Med, London, England. [Plagnol, Vincent] UCL, Genet Inst, Div Biosci, London, England. [Li, Dalin; Targan, Stephan; McGovern, Dermot P. B.] Cedars Sinai Med Ctr, F Widjaja Fdn Inflammatory Bowel & Immunobiol Res, Los Angeles, CA 90048 USA. [Rivas, Manuel] Broad Inst, Dept Med & Populat Genet, Cambridge, MA USA. [Rivas, Manuel] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA. [Daly, Mark J.] Massachusetts Gen Hosp, Dept Med, Ctr Human Genet Res, Boston, MA 02114 USA. [Rivas, Manuel] Univ Oxford, Nuffield Dept Clin Med, Wellcome Trust Ctr Human Genet Res, Oxford, England. [Gusev, Alexander] Harvard Univ, Dept Epidemiol, Boston, MA 02115 USA. [Schumm, L. Phillip] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA. [Ning, Kaida] Univ Southern Calif, Dept Mol & Computat Biol, Los Angeles, CA USA. [Stempak, Joanne M.; Silverberg, Mark S.] Mt Sinai Hosp, Zane Cohen Ctr Digest Dis, Toronto, ON, Canada. [Stempak, Joanne M.; Silverberg, Mark S.] Univ Toronto, Dept Med, Toronto, ON, Canada. [Muise, Aleixo M.] Univ Toronto, Dept Pediat, Toronto, ON, Canada. [Datta, Lisa W.; Brant, Steven R.] Johns Hopkins Univ, Sch Med, Dept Med, Harvey M & Lyn P Meyerhoff Inflammatory Bowel Dis, Baltimore, MD 21205 USA. [Datta, Lisa W.; Brant, Steven R.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Lipka, Seth] Univ S Florida, Dept Internal Med, Tampa, FL USA. [Katz, Seymour] NYU, Sch Med, Dept Med, New York, NY USA. [Cheifetz, Adam S.] Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA. [Barzilai, Nir; Atzmon, Gil] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [Taylor, Kent; Rotter, Jerome I.] Harbor Univ Calif Los Angeles Med Ctr, Inst Translat Genom & Populat Sci, Div Genom Outcomes, Torrance, CA USA. [Scherl, Ellen J.] Cornell Univ, Div Gastroenterol & Hepatol, Sanford I Weill Coll, New York Presbyterian Hosp, New York, NY 10021 USA. [Abreu, Maria T.] Univ Miami, Miller Sch Med, Div Gastroenterol, Miami, FL 33136 USA. [McCauley, Jacob L.] Univ Miami, Miller Sch Med, John P Hussman Inst Human Genom, Miami, FL 33136 USA. [McCauley, Jacob L.] Univ Miami, Miller Sch Med, Dr John T Macdonald Fdn, Dept Human Genet, Miami, FL 33136 USA. [Pe'er, Itsik] Columbia Univ, Dept Comp Sci, New York, NY 10027 USA. [Kugathasan, Subra] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA. [Hakonarson, Hakon] Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA. [Hakonarson, Hakon] Univ Penn, Div Human Genet, Philadelphia, PA 19104 USA. [Lencz, Todd] North Shore Long Isl Jewish Hlth Syst, Feinstein Inst Med Res, Manhasset, NY USA. [Darvasi, Ariel] Hebrew Univ Jerusalem, Dept Genet, Jerusalem, Israel. [Muise, Aleixo M.] Hosp Sick Children, Inflammatory Bowel Dis Ctr, Toronto, ON, Canada. [Muise, Aleixo M.] Hosp Sick Children, Cell Biol Program, Toronto, ON, Canada. [Daly, Mark J.] Harvard Med Sch, Dept Genet, Boston, MA USA. [Duerr, Richard H.] Univ Pittsburgh, Sch Med, Dept Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA. RP Cho, JH (reprint author), 1468 Madison Ave,Box 10003, New York, NY 10029 USA. EM Judy.cho@mssm.edu OI katz, seymour/0000-0002-3492-9200; Chuang, Ling-shiang/0000-0001-5054-1305 FU National Institutes of Health [DK092235]; Inflammatory Bowel Disease Genetics Consortium [DK062429]; Genetic Research Center at the Icahn School of Medicine [DK062422]; New York Crohn's Foundation; Consortium ancillary [DK099097, DK062431]; Inflammatory Bowel Disease Genetic Research Chair [DK062420, CA141743]; Atran Foundation; Sanford J. Grossman Charitable Trust; Wellcome Trust; Charles Wolfson Charitable Trust; Irwin Joffe Memorial Fellowship; U.S. Public Health Service [DK046763]; Cedars-Sinai F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute Research Funds; Helmsley Charitable Trust; European Union; Crohn's and Colitis Foundation of America; Joshua L. and Lisa Z. Greer Chair in Inflammatory Bowel Disease Genetics; [DK062413]; [DK046763-19]; [AI067068]; [HS021747] FX Supported by the National Institutes of Health (DK092235), Inflammatory Bowel Disease Genetics Consortium (DK062429), Genetic Research Center at the Icahn School of Medicine (DK062422), New York Crohn's Foundation, Consortium ancillary RO1 (DK099097) and U01 (DK062431), Inflammatory Bowel Disease Genetic Research Chair, RO1 (DK062420) and RO1 (CA141743), the Atran Foundation, and the Sanford J. Grossman Charitable Trust. Researchers at University College of London were funded by the Wellcome Trust, Charles Wolfson Charitable Trust, and the Irwin Joffe Memorial Fellowship. Inflammatory bowel disease Research at Cedars-Sinai is supported by U.S. Public Health Service grant PO1 (DK046763) and the Cedars-Sinai F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute Research Funds. Project investigators are supported by The Helmsley Charitable Trust (D.P.B.M.), The European Union (D.P.B.M.), The Crohn's and Colitis Foundation of America (D.P.B.M.), The Joshua L. and Lisa Z. Greer Chair in Inflammatory Bowel Disease Genetics (D.P.B.M.), and grants DK062413, DK046763-19, AI067068, and HS021747 (D.P.B.M.). NR 37 TC 3 Z9 3 U1 2 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD OCT PY 2016 VL 151 IS 4 BP 710 EP + DI 10.1053/j.gastro.2016.06.045 PG 16 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EE4CE UT WOS:000389548500028 PM 27377463 ER PT J AU Li, DL Achkar, JP Haritunians, T Jacobs, JP Hui, KY D'Amato, M Brand, S Radford-Smith, G Halfvarson, J Niess, JH Kugathasan, S Buning, C Schumm, LP Klei, L Ananthakrishnan, A Aumais, G Baidoo, L Dubinsky, M Fiocchi, C Glas, J Milgrom, R Proctor, DD Regueiro, M Simms, LA Stempak, JM Targan, SR Torkvist, L Sharma, Y Devlin, B Borneman, J Hakonarson, H Xavier, RJ Daly, M Brant, SR Rioux, JD Silverberg, MS Cho, JH Braun, J McGovern, DPB Duerr, RH AF Li, Dalin Achkar, Jean-Paul Haritunians, Talin Jacobs, Jonathan P. Hui, Ken Y. D'Amato, Mauro Brand, Stephan Radford-Smith, Graham Halfvarson, Jonas Niess, Jan-Hendrik Kugathasan, Subra Buening, Carsten Schumm, L. Philip Klei, Lambertus Ananthakrishnan, Ashwin Aumais, Guy Baidoo, Leonard Dubinsky, Marla Fiocchi, Claudio Glas, Juergen Milgrom, Raquel Proctor, Deborah D. Regueiro, Miguel Simms, Lisa A. Stempak, Joanne M. Targan, Stephan R. Torkvist, Leif Sharma, Yashoda Devlin, Bernie Borneman, James Hakonarson, Hakon Xavier, Ramnik J. Daly, Mark Brant, Steven R. Rioux, John D. Silverberg, Mark S. Cho, Judy H. Braun, Jonathan McGovern, Dermot P. B. Duerr, Richard H. TI A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn's Disease and Human Gut Microbiome Composition SO GASTROENTEROLOGY LA English DT Article DE Genetics; Inflammatory Bowel Diseases; Microbiota ID INFLAMMATORY-BOWEL-DISEASE; ZINC TRANSPORTER; GENETIC-VARIANTS; SUSCEPTIBILITY LOCI; RISK; ZIP8; EXPRESSION; BACTERIA; CELLS; IBD AB BACKGROUND & AIMS: Genome-wide association studies have identified 200 inflammatory bowel disease (IBD) loci, but the genetic architecture of Crohn's disease (CD) and ulcerative colitis remain incompletely defined. Here, we aimed to identify novel associations between IBD and functional genetic variants using the Illumina ExomeChip (San Diego, CA). METHODS: Genotyping was performed in 10,523 IBD cases and 5726 non-IBD controls. There were 91,713 functional single-nucleotide polymorphism loci in coding regions analyzed. A novel identified association was replicated further in 2 independent cohorts. We further examined the association of the identified single-nucleotide polymorphism with microbiota from 338 mucosal lavage samples in the Mucosal Luminal Interface cohort measured using 16S sequencing. RESULTS: We identified an association between CD and a missense variant encoding alanine or threonine at position 391 in the zinc transporter solute carrier family 39, member 8 protein (SLC39A8 alanine 391 threonine, rs13107325) and replicated the association with CD in 2 replication cohorts (combined meta-analysis P = 5.55 x 10(-13)). This variant has been associated previously with distinct phenotypes including obesity, lipid levels, blood pressure, and schizophrenia. We subsequently determined that the CD risk allele was associated with altered colonic mucosal microbiome composition in both healthy controls (P =.009) and CD cases (P =.0009). Moreover, microbes depleted in healthy carriers strongly overlap with those reduced in CD patients (P = 9.24 x 10(-16)) and overweight individuals (P = 6.73 x 10(-16)). CONCLUSIONS: Our results suggest that an SLC39A8-dependent shift in the gut microbiome could explain its pleiotropic effects on multiple complex diseases including CD. C1 [Li, Dalin; Haritunians, Talin; Dubinsky, Marla; Targan, Stephan R.; McGovern, Dermot P. B.] Cedars Sinai Med Ctr, F Widjaja Fdn Inflammatory Bowel & Immunobiol Res, Los Angeles, CA 90048 USA. [Achkar, Jean-Paul] Cleveland Clin, Dept Gastroenterol & Hepatol, Cleveland, OH 44106 USA. [Fiocchi, Claudio] Cleveland Clin, Dept Pathol, Cleveland, OH 44106 USA. [Jacobs, Jonathan P.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis, Los Angeles, CA 90095 USA. [Braun, Jonathan] Univ Calif Los Angeles, David Geffen Sch Med, Pathol & Lab Med, Los Angeles, CA 90095 USA. [Hui, Ken Y.; Proctor, Deborah D.] Yale Univ, Dept Med, Div Gastroenterol, New Haven, CT 06520 USA. [D'Amato, Mauro] Karolinska Inst, Dept Biosci & Nutr, Stockholm, Sweden. [Torkvist, Leif] Karolinska Inst, Dept Clin Sci Intervent & Technol, Stockholm, Sweden. [D'Amato, Mauro] Biocruces Hlth Res Inst, Baracaldo, Bizkaia, Spain. [Brand, Stephan] Univ Hosp Munich Grosshadern, Dept Med 2, Munich, Germany. [Radford-Smith, Graham; Simms, Lisa A.] QIMR Berghofer Med Res Inst, Genet & Computat Biol, Inflammatory Bowel Dis, Brisbane, Qld, Australia. [Radford-Smith, Graham] Royal Brisbane & Womens Hosp, Dept Gastroenterol, Brisbane, Qld, Australia. [Radford-Smith, Graham] Univ Queensland, Sch Med, Brisbane, Qld, Australia. [Halfvarson, Jonas] Univ Orebro, Fac Med & Hlth, Dept Gastroenterol, Orebro, Sweden. [Niess, Jan-Hendrik] Univ Ulm, Dept Internal Med 1, Ulm, Germany. [Niess, Jan-Hendrik] Inselspital Bern, Dept Gastroenterol, Div Visceral Surg & Med, Bern, Switzerland. [Niess, Jan-Hendrik] Univ Basel Hosp, Gastroenterol & Hepatol, Basel, Switzerland. [Kugathasan, Subra] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA. [Kugathasan, Subra] Childrens Hlth Care Atlanta, Atlanta, GA USA. [Buening, Carsten] Krankenhaus Waldfriede, Internal Med, Berlin, Germany. [Schumm, L. Philip] Univ Chicago, Dept Publ Hlth Sci, Biostat Lab, Chicago, IL 60637 USA. [Klei, Lambertus] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Baidoo, Leonard; Regueiro, Miguel; Duerr, Richard H.] Univ Pittsburgh, Sch Med, Dept Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA. [Devlin, Bernie; Duerr, Richard H.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA. [Ananthakrishnan, Ashwin] Harvard Med Sch, Massachusetts Gen Hosp, Gastroenterol Unit, Boston, MA USA. [Daly, Mark] Harvard Med Sch, Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA USA. [Aumais, Guy; Rioux, John D.] Univ Montreal, Montreal, PQ, Canada. [Aumais, Guy] Hop Maison Neuve Rosemont, Montreal, PQ, Canada. [Dubinsky, Marla] Icahn Sch Med Mt Sinai, Dept Pediat, New York, NY 10029 USA. [Sharma, Yashoda; Cho, Judy H.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. [Cho, Judy H.] Icahn Sch Med Mt Sinai, Dept Med, Div Gastroenterol, New York, NY 10029 USA. [Glas, Juergen] Ludwig Maximilians Univ Munchen, Dept Prevent Dent & Periodontol, Munich, Germany. [Milgrom, Raquel] Univ Toronto, Mt Sinai Hosp, Zane Cohen Ctr Digest Dis, Toronto, ON, Canada. [Torkvist, Leif] Karolinska Univ Hosp, IBD Unit, Ctr Digest Dis, Stockholm, Sweden. [Borneman, James] Univ Calif Riverside, Dept Plant Pathol & Microbiol, Riverside, CA 92521 USA. [Hakonarson, Hakon] Childrens Hosp Philadelphia, Ctr Appl Genom, Philadelphia, PA 19104 USA. [Xavier, Ramnik J.; Daly, Mark] Broad Inst MIT & Harvard, Cambridge, MA USA. [Brant, Steven R.] Johns Hopkins Univ, Sch Med, Div Gastroenterol & Hepatol, Baltimore, MD USA. [Brant, Steven R.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Rioux, John D.] Montreal Heart Inst, Montreal, PQ, Canada. RP Duerr, RH (reprint author), Univ Pittsburgh, Sch Med, 200 Lothrop St,Biomed Sci Tower,Room BSTWR S704, Pittsburgh, PA 15213 USA. EM duerr@pitt.edu RI Niess, Jan /E-8361-2017; Rioux, John/A-9599-2015; OI Niess, Jan /0000-0001-6902-5650; Rioux, John/0000-0001-7560-8326; D'Amato, Mauro/0000-0003-2743-5197; Halfvarson, Jonas/0000-0003-0122-7234 FU National Institutes of Health [U01DK062413, U01DK062420, U01DK062422, U01DK062429, U01DK062423, U01DK062431, U01DK062432, F30DK098927, P01DK046763, P30CA016042, R01CA141743, R01DK087694, R01DK092235, R01DK098231, R01HS021747, T32DK007180, T32GM007205, U01AI067068, U54DE023798, UL1TR000124]; Crohn's and Colitis Foundation of America; Deutsche Forschungsgemeinschaft [DFG BR 1912/6-1, Ni575/7-1, Ni 575/4-1]; Else Kroner-Fresenius-Stiftung (Else Kroner Exzellenzstipendium) [2010_EKES.32]; Inflammatory Bowel Disease Genetic Research Chair at the University of Pittsburgh; Children's Hospital of Philadelphia; Orebro University Hospital Research Foundation; Royal Brisbane and Women's Hospital Research Foundation; Sanford J Grossman Charitable Trust; SUCCESS; Swedish Research Council [521-2011-2764, VR 2010-2976, VR 2013-3862]; Swiss National Science Foundation [146290]; Eli and Edythe Broad Foundation [IBD-0164R]; European Union; Kenneth Rainin Chair for Inflammatory Bowel Disease Research; Leona M and Harry B Helmsley Charitable Trust; National Health and Medical Research Council [APP498405] FX Funding for this work is acknowledged by the authors whose initials or names are in parentheses following each source of support. The National Institute of Diabetes and Digestive and Kidney Diseases Inflammatory Bowel Disease Genetics Consortium is supported by National Institutes of Health grants U01DK062413 (D.P.B.M. and J.Br.), U01DK062420 (R.H.D. and M.D.R.), U01DK062422 (J.H.C., K.Y.H., and D.D.P.), U01DK062429 (J.H.C., L.P.S., and Y.S.), U01DK062423 (M.S.S., R.M., and J.M.S.), U01DK062431 (S.R.B.), and U01DK062432 (J.D.R.). This work also was supported by National Institutes of Health grants F30DK098927 (K.Y.H.), P01DK046763 (S.R.T., J.Br., and D.P.B.M.), P30CA016042 (J.Br.), R01CA141743 (R.H.D.), R01DK087694 (S.K.), R01DK092235 (J.H.C. and K.Y.H.), R01DK098231 (S.K.), R01HS021747 (D.P.B.M.), T32DK007180 (J.P.J.), T32GM007205 (K.Y.H.), U01AI067068 (D.P.B.M.), U54DE023798 (J.Br.), and UL1TR000124 (J.Br.). Additional sources of support included the Crohn's and Colitis Foundation of America (J.Br. and H.H.), Deutsche Forschungsgemeinschaft (DFG BR 1912/6-1) (S.R.B.), Deutsche Forschungsgemeinschaft (projects Ni575/7-1 and Ni 575/4-1) (J.-H.N.), Else Kroner-Fresenius-Stiftung (Else Kroner Exzellenzstipendium 2010; 2010_EKES.32) (S.R.B.), Inflammatory Bowel Disease Genetic Research Chair at the University of Pittsburgh (R.H.D.), Institutional Development Fund from The Children's Hospital of Philadelphia (H.H.), Orebro University Hospital Research Foundation (J.H.), Royal Brisbane and Women's Hospital Research Foundation (G.R.-S.), Sanford J Grossman Charitable Trust (J.H.C.), SUCCESS (J.H.C.), Swedish Research Council grants 521-2011-2764 (J.H.), VR 2010-2976 (M.D.), and VR 2013-3862) (M.D.), Swiss National Science Foundation 146290 (J.-H.N.), The Eli and Edythe Broad Foundation, proposal IBD-0164R (C.B.), The European Union (D.P.B.M.), The Kenneth Rainin Chair for Inflammatory Bowel Disease Research (J.-P.A.), The Leona M and Harry B Helmsley Charitable Trust (D.P.B.M.), and The National Health and Medical Research Council (APP498405) (G.R.-S.). NR 54 TC 2 Z9 2 U1 7 U2 7 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD OCT PY 2016 VL 151 IS 4 BP 724 EP 732 DI 10.1053/j.gastro.2016.06.051 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EE4CE UT WOS:000389548500029 PM 27492617 ER PT J AU Wu, Y Xu, JX El-Jouni, W Lu, T Li, SY Wang, QY Tran, M Yu, WF Wu, MQ Barrera, IE Bonventre, JV Zhou, J Denker, BM Kong, TQ AF Wu, Yong Xu, Jen X. El-Jouni, Wassim Lu, Tzongshi Li, Suyan Wang, Qingyi Tran, Mei Yu, Wanfeng Wu, Maoqing Barrera, Ivan E. Bonventre, Joseph V. Zhou, Jing Denker, Bradley M. Kong, Tianqing TI G alpha 12 is required for renal cystogenesis induced by Pkd1 inactivation SO JOURNAL OF CELL SCIENCE LA English DT Article DE Polycystin-1; G proteins; Cadherin; Polycystic kidney diseases ID POLYCYSTIC KIDNEY-DISEASE; CELL-CELL ADHESION; EPITHELIAL-CELLS; E-CADHERIN; IN-VITRO; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; ADHERENS JUNCTIONS; LIVER-DISEASE; GENE-PRODUCT AB Mutation of PKD1, encoding the protein polycystin-1 (PC1), is themain cause of autosomal dominant polycystic kidney disease (ADPKD). The signaling pathways downstream of PC1 in ADPKD are still not fully understood. Here, we provide genetic evidence for the necessity of G alpha 12 (encoded by Gna12, hereafter G alpha 12) for renal cystogenesis induced by Pkd1 knockout. There was no phenotype in mice with deletion of Ga12 (Ga12(-/-)). Polyinosine-polycytosine (pI: pC)-induced deletion of Pkd1 (Mx1Cre(+)Pkd1(f/f)G alpha 12(+/+)) in 1-week-old mice resulted in multiple kidney cysts by 9 weeks, but the mice with double knockout of Pkd1 and Ga12 (Mx1Cre(+)Pkd1(f/f)G alpha 12(-/-)) had no structural and functional abnormalities in the kidneys. These mice could survive more than one year without kidney abnormalities except multiple hepatic cysts in some mice, which indicates that the effect of G alpha 12 on cystogenesis is kidney specific. Furthermore, Pkd1 knockout promoted G alpha 12 activation, which subsequently decreased cell-matrix and cell-cell adhesion by affecting the function of focal adhesion and E-cadherin, respectively. Our results demonstrate that G alpha 12 is required for the development of kidney cysts induced by Pkd1 mutation in mouse ADPKD. C1 [Wu, Yong; Xu, Jen X.; El-Jouni, Wassim; Lu, Tzongshi; Li, Suyan; Wang, Qingyi; Tran, Mei; Yu, Wanfeng; Wu, Maoqing; Barrera, Ivan E.; Bonventre, Joseph V.; Zhou, Jing; Kong, Tianqing] Harvard Med Sch, Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA. [Tran, Mei; Denker, Bradley M.] Beth Israel Deaconess Med Ctr, Div Renal, 330 Brookline Ave, Boston, MA 02215 USA. [Tran, Mei; Denker, Bradley M.] Harvard Med Sch, 330 Brookline Ave, Boston, MA 02215 USA. [Wu, Yong] Guangzhou Med Univ, Guangzhou, Guangdong, Peoples R China. [Xu, Jen X.] Harvard Univ, Cambridge, MA 02138 USA. [El-Jouni, Wassim] Massachusetts Gen Hosp, Div Nephrol, 55 Fruit St, Boston, MA 02114 USA. [Li, Suyan] McLean Hosp, Harvard Med Sch, Div Basic Neurosci, Belmont, MA 02478 USA. [Yu, Wanfeng] Northeastern Univ, Boston, MA 02115 USA. RP Kong, TQ (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA. EM tqkong@gmail.com FU National Institutes of Health [K01 DK080179, 3K01DK080179, DK096160, GM55223, R01DKD072381, R37DK039773, DK51050, DK099532]; Polycystic Kidney Center [P50 DK074030]; Baltimore Polycystic Kidney Disease Research and Clinical Core Center [P30DK090868] FX This work was supported by the National Institutes of Health [grant numbers K01 DK080179, 3K01DK080179 and DK096160 to T.K.; GM55223 to B.M.D.; R01DKD072381 and R37DK039773 to J.V.B.; DK51050 and DK099532 to J.Z.] and a grant from the Polycystic Kidney Center [P50 DK074030 to J.Z. and B.M.D.]. This project was also supported by the Baltimore Polycystic Kidney Disease Research and Clinical Core Center [grant number P30DK090868 to T.K.]. Deposited in PMC for release after 12 months. NR 62 TC 0 Z9 0 U1 0 U2 0 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 0021-9533 EI 1477-9137 J9 J CELL SCI JI J. Cell Sci. PD OCT 1 PY 2016 VL 129 IS 19 BP 3675 EP 3684 DI 10.1242/jcs.190496 PG 10 WC Cell Biology SC Cell Biology GA EE4SE UT WOS:000389594700015 PM 27505895 ER PT J AU Peacock, ZS Vakilian, P Caruso, P Resnick, CM Vangel, M Kaban, LB AF Peacock, Zachary S. Vakilian, Pouya Caruso, Paul Resnick, Cory M. Vangel, Mark Kaban, Leonard B. TI Quantifying Synovial Enhancement of the Pediatric Temporomandibular Joint SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article ID JUVENILE IDIOPATHIC ARTHRITIS; RHEUMATOID-ARTHRITIS; MANDIBULAR GROWTH; CLINICAL EXAMINATION; CHILDREN; MRI; INVOLVEMENT; SIGNS AB Purpose: The purposes of this study were to assess a novel method for quantifying temporomandibular joint (TMJ) synovial enhancement on gadolinium-enhanced magnetic resonance imaging (MRI) and to establish normative values to allow early detection of synovitis. Materials and Methods: This is a retrospective cohort study of pediatric patients (aged 0 to 16 years) without jawpathology who underwent MRI scanswith contrast that included the TMJs. Froma coronal T1weighted image, the signal intensity within the superior and inferior joint spaces was divided by the signal intensity of the longus capitis muscle to establish a ratio by age. Intrarater reliability and inter-rater reliability were assessed. A mixed-model regression analysis was used to determine the 95% specificity threshold for normal ratios. Results: Temporal and optic nerve MRI scans of 158 patients were included. Normative synovial enhancement ratios (95% specificity) thresholds were established: 1.52, 1.68, and 1.55 for superior joint space, inferior joint space, and average of both joint spaces, respectively. Intrarater and inter-rater agreement was excellent. Conclusions: A ratio of signal intensity of the TMJ synovium to the longus capitis is a reliable method to quantify enhancement controlling for time after contrast infusion and may be useful for diagnosis of TMJ synovitis. (C) 2016 American Association of Oral and Maxillofacial Surgeons. C1 [Peacock, Zachary S.; Kaban, Leonard B.] Harvard Sch Dent Med, Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA USA. [Vakilian, Pouya] Harvard Sch Dent Med, Boston, MA USA. [Caruso, Paul] Harvard Med Sch, Massachusetts Gen Hosp, Pediat Neuroradiol, Boston, MA USA. [Caruso, Paul; Vangel, Mark] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA. [Resnick, Cory M.] Harvard Sch Dent Med, Boston Childrens Hosp, Dept Plast & Oral Surg, Boston, MA USA. RP Peacock, ZS (reprint author), Massachusetts Gen Hosp, Warren 1201,55 Fruit St, Boston, MA 02114 USA. EM zpeacock@partners.org FU Harvard Medical School Scholars in Medicine Program; Massachusetts General Hospital Department of Oral and Maxillofacial Surgery Education and Research Fund FX This study was funded by the Harvard Medical School Scholars in Medicine Program and the Massachusetts General Hospital Department of Oral and Maxillofacial Surgery Education and Research Fund. NR 29 TC 1 Z9 1 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 EI 1531-5053 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD OCT PY 2016 VL 74 IS 10 BP 1937 EP 1945 DI 10.1016/j.joms.2016.03.010 PG 9 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA EE3QW UT WOS:000389511800008 PM 27067062 ER PT J AU Passeri, LA Choi, JG Kaban, LB Lahey, ET AF Passeri, Luis A. Choi, James G. Kaban, Leonard B. Lahey, Edward T. TI Morbidity and Mortality Rates After Maxillomandibular Advancement for Treatment of Obstructive Sleep Apnea SO JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY LA English DT Article ID ORTHOGNATHIC SURGERY; POSTOPERATIVE COMPLICATIONS; CARDIOVASCULAR RISK; AIRWAY ANALYSIS; GASTRIC BYPASS; WEIGHT-LOSS; MANAGEMENT; PATTERNS; ASSOCIATION; OBESITY AB Purpose: To compare morbidity and mortality rates in obstructive sleep apnea (OSA) versus dentofacial deformity (DFD) patients undergoing equivalent maxillofacial surgical procedures. Patients and Methods: Patients with OSA who underwent maxillomandibular advancement with genial tubercle advancement in the Massachusetts General Hospital Department of Oral and Maxillofacial Surgery from December 2002 to June 2011 were matched to patients with DFD undergoing similar maxillofacial procedures during the same period. They were compared regarding demographic variables, medical comorbidities, perioperative management, intraoperative complications, early and late postoperative complications, and mortality rate. Results: A study group of 28 patients with OSA and a control group of 26 patients with DFD were compared. The patients with OSA were older (41.9 +/- 12.5 years vs 21.7 +/- 8.6 years), had a higher American Society of Anesthesiologists classification (2.0 +/- 0.5 vs 1.3 +/- 0.6), and had a higher body mass index (29.6 +/- 4.7 kg/m(2) vs 23.0 +/- 3.1 kg/m(2)). They also had a greater number of medical comorbidities (2.4 +/- 2.3 vs 0.7 +/- 1.0). More OSA patients than DFD patients had complications (28 [100%] vs 19 [73%], P = .003), and the total number of complications in the OSA group was higher (108 vs 33, P < .001). Of the complications, 13.9% in the OSA group and 3.0% in the DFD group were classified as major. The absolute risk of a complication was 3.9 for the OSA group versus 1.3 for the DFD group. The relative risk of complications in OSA patients compared with DFD patients was 3.0. No difference in mortality rate was found. Conclusions: The patients in the OSA group were older, had more comorbidities, and ultimately had a greater number of early, late, minor, and major complications than those in the DFD group. The incidence of death in both groups was zero. Maxillomandibular advancement appears to be a safe procedure regarding mortality rate, but OSA patients should be counseled preoperatively regarding the relative increased risk of complications. (C) 2016 American Association of Oral and Maxillofacial Surgeons C1 [Passeri, Luis A.; Kaban, Leonard B.; Lahey, Edward T.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Warren 1201,55 Fruit St, Boston, MA 02114 USA. [Passeri, Luis A.; Kaban, Leonard B.; Lahey, Edward T.] Harvard Sch Dent Med, Boston, MA USA. [Passeri, Luis A.] Univ Estadual Campinas, Sch Med Sci, Dept Surg, Oral & Maxillofacial Surg, Campinas, SP, Brazil. [Choi, James G.] Hosp Univ Penn, Dept Oral & Maxillofacial Surg, 3400 Spruce St, Philadelphia, PA 19104 USA. [Lahey, Edward T.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Oral & Maxillofacial Surg, Boston, MA 02114 USA. RP Passeri, LA (reprint author), Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Warren 1201,55 Fruit St, Boston, MA 02114 USA. EM elahey@post.harvard.edu FU Harvard Catalyst-The Harvard Clinical and Translational Science Center (National Center for Research Resources); Harvard University; Massachusetts General Hospital Department of Oral and Maxillofacial Surgery Education and Research Fund; Brazilian National Council for Scientific and Technological Development (CNPq); Coordination for the Improvement of Higher Education Personnel (CAPES); Harvard Catalyst-The Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health) [UL1TR001102] FX This work was conducted with support from Harvard Catalyst-The Harvard Clinical and Translational Science Center (National Center for Research Resources and National Center for Advancing Translational Sciences, National Institutes of Health Award UL1TR001102) and financial contributions from Harvard University and its affiliated academic health care centers. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, or the National Institutes of Health. Support was also provided by the Massachusetts General Hospital Department of Oral and Maxillofacial Surgery Education and Research Fund, Brazilian National Council for Scientific and Technological Development (CNPq), and Coordination for the Improvement of Higher Education Personnel (CAPES). NR 39 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0278-2391 EI 1531-5053 J9 J ORAL MAXIL SURG JI J. Oral Maxillofac. Surg. PD OCT PY 2016 VL 74 IS 10 BP 2033 EP 2043 DI 10.1016/j.joms.2016.04.005 PG 11 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA EE3QW UT WOS:000389511800020 PM 27181624 ER PT J AU Kachooei, AR Mellema, JJ Tarabochia, MA Chen, N van Dijk, CN Ring, D AF Kachooei, Amir Reza Mellema, Jos J. Tarabochia, Matthew A. Chen, Neal van Dijk, C. Niek Ring, David TI Involvement of the lesser sigmoid notch in elbow fracture dislocations SO JOURNAL OF SHOULDER AND ELBOW SURGERY LA English DT Article DE Mayo; lesser sigmoid notch; coronoid; Q3DCT; elbow fracture; Monteggia; terrible triad; varus posteromedial instability ID COMPUTED-TOMOGRAPHY; PATTERNS; INSTABILITY; HEAD AB Background: This study addressed the primary null hypothesis that there is no difference in the articular surface area of the lesser sigmoid notch involved among Mayo classes. Secondarily, we analyzed the fracture line location and the pattern of lesser sigmoid notch articular surface involvement among Mayo classes. Methods: Using quantitative 3-dimensional computed tomography, we reconstructed and analyzed fractures involving the lesser sigmoid notch articular surface in 52 patients. Further, we assessed the surface area involved in the fracture, the number of fracture fragments, and the location and direction of the fracture lines. Coronoid fractures were classified according to Mayo types. Results: There was no significant difference between Mayo types 1 and 2 in any characteristic of the involvement of the lesser sigmoid notch articular surface, whereas Mayo type 3 was significantly different from both Mayo types 1 and 2 in the area involved in the fracture (42% in Mayo type 3 vs. 9% in Mayo types 1 and 2), the number of articular fragments (>3 fragments in type 3 vs. 2 fragments in types 1 and 2), and the direction of fracture line (both horizontal and vertical lines in type 3 vs. only horizontal line in types 1 and 2). Conclusion: Mayo type III results in a more complex fracture, which might need to be addressed directly or indirectly during open reduction with internal fixation of olecranon fracture dislocations because changes in the geometry of lesser sigmoid notch may affect the radioulnar joint if it remains incongruent. (C) 2016 Journal of Shoulder and Elbow Surgery Board of Trustees. All rights reserved. C1 [Kachooei, Amir Reza; Mellema, Jos J.; Tarabochia, Matthew A.; Chen, Neal; Ring, David] Massachusetts Gen Hosp, Harvard Med Sch, Hand & Upper Extrem Serv, Boston, MA USA. [Kachooei, Amir Reza] Mashhad Univ Med Sci, Orthoped Res Ctr, Mashhad, Iran. [van Dijk, C. Niek] Acad Med Ctr Amsterdam, Dept Orthopaed Surg, Amsterdam, Netherlands. RP Ring, D (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Hand & Upper Extrem Serv, Boston, MA USA. EM david.ring@austin.utexas.edu OI Kachooei, Amir Reza/0000-0001-7795-1830; Ring, David/0000-0002-6506-4879 NR 12 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 1058-2746 J9 J SHOULDER ELB SURG JI J. Shoulder Elbow Surg. PD OCT PY 2016 VL 25 IS 10 BP 1571 EP 1576 DI 10.1016/j.jse.2016.02.013 PG 6 WC Orthopedics; Sport Sciences; Surgery SC Orthopedics; Sport Sciences; Surgery GA EE6DB UT WOS:000389697800010 PM 27233485 ER PT J AU Perri, J Nolan, B Goodney, P DeMartino, R Brooke, B Arya, S Conrad, M Cronenwett, J AF Perri, Jennifer Nolan, Brian Goodney, Philip DeMartino, Randall Brooke, Benjamin Arya, Shipra Conrad, Mark Cronenwett, Jack TI Factors Affecting Operative Time and Outcome of Carotid Endarterectomy in the Vascular Quality Initiative SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Annual Meeting of the New-England-Society-for-Vascular-Surgery CY SEP 23-25, 2015 CL Stowe, VT SP New England Soc Vasc Surg C1 [Perri, Jennifer; Nolan, Brian; Goodney, Philip; Cronenwett, Jack] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. [DeMartino, Randall] Mayo Clin, Rochester, MN USA. [Brooke, Benjamin] Univ Utah, Salt Lake City, UT USA. [Arya, Shipra] Emory Univ, Sch Med, Atlanta, GA USA. [Conrad, Mark] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD OCT PY 2016 VL 64 IS 4 BP 1177 EP 1177 PG 1 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA EE3RI UT WOS:000389513400054 ER PT J AU Schwartz, SI Clouse, WD Patel, VI Cambria, RP Conrad, MF AF Schwartz, Samuel I. Clouse, William D. Patel, Virendra I. Cambria, Richard P. Conrad, Mark F. TI Predictors of Delayed Aortic Repair in Uncomplicated Type B Aortic Dissection SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Annual Meeting of the New-England-Society-for-Vascular-Surgery CY SEP 23-25, 2015 CL Stowe, VT SP New England Soc Vasc Surg C1 [Schwartz, Samuel I.; Clouse, William D.; Patel, Virendra I.; Cambria, Richard P.; Conrad, Mark F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD OCT PY 2016 VL 64 IS 4 BP 1179 EP 1179 PG 1 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA EE3RI UT WOS:000389513400059 ER PT J AU Clouse, WD Ergul, E Patel, VI Lancaster, RT LaMuraglia, GM Cambria, RP Conrad, MF AF Clouse, W. Darrin Ergul, Emel Patel, Virendra I. Lancaster, R. Todd LaMuraglia, Glenn M. Cambria, Richard P. Conrad, Mark F. TI Characterization of Perioperative Contralateral Stroke After Carotid Endarterectomy SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Annual Meeting of the New-England-Society-for-Vascular-Surgery CY SEP 23-25, 2015 CL Stowe, VT SP New England Soc Vasc Surg C1 [Clouse, W. Darrin; Ergul, Emel; Patel, Virendra I.; Lancaster, R. Todd; LaMuraglia, Glenn M.; Cambria, Richard P.; Conrad, Mark F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD OCT PY 2016 VL 64 IS 4 BP 1183 EP 1183 PG 1 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA EE3RI UT WOS:000389513400065 ER PT J AU Twerdahl, EH Aranson, NJ Yeo, AL Lancaster, RT Ergul, EA Conrad, MF Kwolek, CJ Patel, VI AF Twerdahl, Eric H., Jr. Aranson, Nathan J. Yeo, Alexander L. Lancaster, Robert T. Ergul, Emel A. Conrad, Mark F. Kwolek, Christopher J. Patel, Virendra I. TI Clinical Outcomes of a Staged Approach to Axillosubclavian Deep Venous Thrombosis Caused by Thoracic Outlet Syndrome SO JOURNAL OF VASCULAR SURGERY LA English DT Meeting Abstract CT Annual Meeting of the New-England-Society-for-Vascular-Surgery CY SEP 23-25, 2015 CL Stowe, VT SP New England Soc Vasc Surg C1 [Twerdahl, Eric H., Jr.] Naval Med Ctr Portsmouth, Portsmouth, VA USA. [Aranson, Nathan J.] Virginia Mason Med Ctr, Seattle, WA USA. [Yeo, Alexander L.] Bon Secours Baltimore, Baltimore, MD USA. [Lancaster, Robert T.; Ergul, Emel A.; Conrad, Mark F.; Kwolek, Christopher J.; Patel, Virendra I.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD OCT PY 2016 VL 64 IS 4 BP 1185 EP 1185 PG 1 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA EE3RI UT WOS:000389513400070 ER PT J AU Stoffel, EM Yurgelun, MB AF Stoffel, Elena M. Yurgelun, Matthew B. TI Genetic predisposition to colorectal cancer: Implications for treatment and prevention SO SEMINARS IN ONCOLOGY LA English DT Review DE Colorectal cancer; Genetics; Hereditary cancer; Microsatellite instability ID MISMATCH REPAIR DEFICIENCY; SOCIETY-TASK-FORCE; LYNCH-SYNDROME; GERMLINE MUTATIONS; AMERICAN SOCIETY; MICROSATELLITE INSTABILITY; ADENOMATOUS POLYPOSIS; SERRATED PATHWAY; FAMILY-HISTORY; COLON-CANCER AB Colorectal cancer (CRC) is the third most common cancer diagnosed in men and women and approximately 5% of cases are associated with identifiable germline mutations associated with hereditary cancer syndromes. Lifetime risks for CRC can approach 50%-80% for mutation carriers in the absence of endoscopic and/or surgical intervention, and early identification of at-risk individuals can guide clinical interventions for cancer prevention and treatment. Personal and family history and molecular phenotype of CRC tumors are used in determining which patients should be referred for clinical genetic evaluation. Outcomes of genetic testing performed using next-generation sequencing (NGS) multigene panels suggest there can be significant overlap in clinical features among the various hereditary cancer syndromes. This review summarizes new developments in diagnosis and management of patients with genetic predisposition to CRC. (C) 2016 Elsevier Inc. All rights reserved. C1 [Stoffel, Elena M.] Univ Michigan Hlth Syst, Canc Ctr 2150A, Ann Arbor, MI 48109 USA. [Yurgelun, Matthew B.] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA. RP Stoffel, EM (reprint author), Univ Michigan Hlth Syst, Canc Ctr 2150A, Ann Arbor, MI 48109 USA. EM estoffel@med.umich.edu NR 58 TC 1 Z9 1 U1 5 U2 5 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0093-7754 EI 1532-8708 J9 SEMIN ONCOL JI Semin. Oncol. PD OCT PY 2016 VL 43 IS 5 BP 536 EP 542 DI 10.1053/j.seminoncol.2016.08.002 PG 7 WC Oncology SC Oncology GA EE8HH UT WOS:000389865800003 PM 27899184 ER PT J AU Anderson, TA Kang, JW Gubin, T Dasari, RR So, PTC AF Anderson, T. Anthony Kang, Jeon Woong Gubin, Tatyana Dasari, Ramachandra R. So, Peter T. C. TI Raman Spectroscopy Differentiates Each Tissue from the Skin to the Spinal Cord A Novel Method for Epidural Needle Placement? SO ANESTHESIOLOGY LA English DT Article ID MORBIDLY OBESE PARTURIENTS; NEUROLOGICAL COMPLICATIONS; NEURAXIAL BLOCKADE; STEROID INJECTIONS; CONFOCAL RAMAN; DURAL PUNCTURE; META-ANALYSIS; LUMBAR SPINE; FOLLOW-UP; IN-VIVO AB Background: Neuraxial anesthesia and epidural steroid injection techniques require precise anatomical targeting to ensure successful and safe analgesia. Previous studies suggest that only some of the tissues encountered during these procedures can be identified by spectroscopic methods, and no previous study has investigated the use of Raman, diffuse reflectance, and fluorescence spectroscopies. The authors hypothesized that real-time needle-tip spectroscopy may aid epidural needle placement and tested the ability of spectroscopy to distinguish each of the tissues in the path of neuraxial needles. Methods: For comparison of detection methods, the spectra of individual, dissected ex vivo paravertebral and neuraxial porcine tissues were collected using Raman spectroscopy (RS), diffuse reflectance spectroscopy, and fluorescence spectroscopy. Real-time spectral guidance was tested using a 2-mm inner-diameter fiber-optic probe-in-needle device. Raman spectra were collected during the needle's passage through intact paravertebral and neuraxial porcine tissue and analyzed afterward. The RS tissue signatures were verified as mapping to individual tissue layers using histochemical staining and widefield microscopy. Results: RS revealed a unique spectrum for all ex vivo paravertebral and neuraxial tissue layers; diffuse reflectance spectroscopy and fluorescence spectroscopy were not distinct for all tissues. Moreover, when accounting for the expected order of tissues, real-time Raman spectra recorded during needle insertion also permitted identification of each paravertebral and neuraxial porcine tissue. Conclusions: This study demonstrates that RS can distinguish the tissues encountered during epidural needle insertion. This technology may prove useful during needle placement by providing evidence of its anatomical localization. C1 [Anderson, T. Anthony] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St,GRB 444, Boston, MA 02114 USA. [Kang, Jeon Woong; Dasari, Ramachandra R.] MIT, Dept Chem, Cambridge, MA 02139 USA. [Gubin, Tatyana] MIT, Dept Mech Engn, Cambridge, MA 02139 USA. [So, Peter T. C.] MIT, Dept Mech & Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA. RP Anderson, TA (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St,GRB 444, Boston, MA 02114 USA. EM tanderson9@mgh.harvard.edu FU National Science Foundation (Arlington, Virginia) [1549613]; National Institutes of Health (Bethesda. Maryland) [9P41EB015871-28]; Massachusetts Institute of Technology (MIT) SkolTech initiative (Cambridge, Massachusetts); Samsung Advanced Institute of Technology (Seoul, South Korea) [DP3-DK101024 01, 1-U01-NS090438-01, 1-R01-EY017656-06A1, 1R21NS091982-01, 1-R01-HL121386-01A1, 1U01CA202177-01]; Singapore-MIT Alliance 2 (Cambridge, Massachusetts); Biosym IRG of Singapore-MIT Alliance Research and Technology Center (Cambridge, Massachusetts); MIT SkolTech initiative; Hamamatsu Corporation (Hamamatsu City, Japan); Koch institute for Integrative Cancer Research Bridge Initiative (Cambridge, Massachusetts); Connecticut: Children's Medical Center (Hartford, Connecticut) FX Supported by the National Science Foundation 1549613 (Arlington, Virginia); funded research time from Jeanine Wiener-Kronish. M.D., Anesthetist-in-Chief, Massachusetts General Hospital Department of Anesthesia, Critical Care and Pain Medicine (Boston, Massachusetts; to Dr. Anderson); National Institutes of Health 9P41EB015871-28 (Bethesda, Maryland; to Drs. Kang, Dasari, and So); Massachusetts Institute of Technology (MIT) SkolTech initiative (Cambridge, Massachusetts; to Drs. Rang, Dasari. and So); Samsung Advanced Institute of Technology (Seoul, South Korea; to Drs. Kang, Dasari, and So); DP3-DK101024 01, 1-U01-NS090438-01, 1-R01-EY017656-06A1, 1R21NS091982-01. 1-R01-HL121386-01A1, and 1U01CA202177-01 (to Dr. So); the Singapore-MIT Alliance 2 (Cambridge, Massachusetts; to Dr. So); the Biosym IRG of Singapore-MIT Alliance Research and Technology Center (Cambridge, Massachusetts; to Dr. So); MIT SkolTech initiative (to Dr. So): Hamamatsu Corporation (Hamamatsu City, Japan: to Dr. So): the Koch institute for Integrative Cancer Research Bridge Initiative (Cambridge, Massachusetts; to Dr. So); and Connecticut: Children's Medical Center (Hartford, Connecticut; to Dr. So). NR 61 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-3022 EI 1528-1175 J9 ANESTHESIOLOGY JI Anesthesiology PD OCT PY 2016 VL 125 IS 4 BP 793 EP 804 DI 10.1097/ALN.0000000000001249 PG 12 WC Anesthesiology SC Anesthesiology GA ED3KE UT WOS:000388747200027 PM 27466032 ER PT J AU Garcia-Solache, M Lebreton, F McLaughlin, RE Whiteaker, JD Gilmore, MS Rice, LB AF Garcia-Solache, Monica Lebreton, Francois McLaughlin, Robert E. Whiteaker, James D. Gilmore, Michael S. Rice, Louis B. TI Homologous Recombination within Large Chromosomal Regions Facilitates Acquisition of beta-Lactam and Vancomycin Resistance in Enterococcus faecium SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID MOBILE GENETIC ELEMENTS; SUBSYSTEMS TECHNOLOGY; TRANSPOSON TN1549; FAECALIS; VANB; DETERMINANT; STRAINS; TN5382; PBP5; DNA AB The transfer of DNA between Enterococcus faecium strains has been characterized both by the movement of well-defined genetic elements and by the large-scale transfer of genomic DNA fragments. In this work, we report on the whole-genome analysis of transconjugants resulting from mating events between the vancomycin-resistant E. faecium C68 strain and the vancomycin-susceptible D344RRF strain to discern the mechanism by which the transferred regions enter the recipient chromosome. Vancomycin-resistant transconjugants from five independent matings were analyzed by whole-genome sequencing. In all cases but one, the penicillin binding protein 5 (pbp5) gene and the Tn5382 vancomycin resistance transposon were transferred together and replaced the corresponding pbp5 region of D344RRF. In one instance, Tn5382 inserted independently downstream of the D344RRF pbp5 gene. Single nucleotide variant (SNV) analysis suggested that entry of donor DNA into the recipient chromosome occurred by recombination across regions of homology between donor and recipient chromosomes, rather than through insertion sequence-mediated transposition. The transfer of genomic DNA was also associated with the transfer of C68 plasmid pLRM23 and another putative plasmid. Our data are consistent with the initiation of transfer by cointegration of a transferable plasmid with the donor chromosome, with subsequent circularization of the plasmid-chromosome cointegrant in the donor prior to transfer. Entry into the recipient chromosome most commonly occurred across regions of homology between donor and recipient chromosomes. C1 [Garcia-Solache, Monica; Rice, Louis B.] Brown Univ, Rhode Isl Hosp, Dept Med, Warren Alpert Med Sch, Providence, RI 02903 USA. [Lebreton, Francois; Gilmore, Michael S.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA USA. [Lebreton, Francois; Gilmore, Michael S.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Microbiol & Immunol, Boston, MA USA. [McLaughlin, Robert E.; Whiteaker, James D.] AstraZeneca R&D Boston, Infect Biosci, Waltham, MA USA. RP Garcia-Solache, M (reprint author), Brown Univ, Rhode Isl Hosp, Dept Med, Warren Alpert Med Sch, Providence, RI 02903 USA. EM monica.garciasolache@cantab.net FU HHS \ NIH \ National Institute of Allergy and Infectious Diseases (NIAID) [AI045626] FX This work, including the efforts of Louis B. Rice, was funded by HHS vertical bar NIH vertical bar National Institute of Allergy and Infectious Diseases (NIAID) (AI045626). NR 45 TC 2 Z9 2 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD OCT PY 2016 VL 60 IS 10 BP 5777 EP 5786 DI 10.1128/AAC.00488-16 PG 10 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA ED7PD UT WOS:000389059800018 PM 27431230 ER PT J AU Bhatnagar, B Eisfeld, AK Nicolet, D Mrozek, K Blachly, JS Orwick, S Lucas, DM Kohlschmidt, J Blum, W Kolitz, JE Stone, RM Bloomfield, CD Byrd, JC AF Bhatnagar, Bhavana Eisfeld, Ann-Kathrin Nicolet, Deedra Mrozek, Krzysztof Blachly, James S. Orwick, Shelley Lucas, David M. Kohlschmidt, Jessica Blum, William Kolitz, Jonathan E. Stone, Richard M. Bloomfield, Clara D. Byrd, John C. TI Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia SO BRITISH JOURNAL OF HAEMATOLOGY LA English DT Article DE acute myeloid leukaemia; DNA (cytosine-5)-methyltransferase 3 alpha; mutation clearance; survival; prognosis ID HEMATOPOIETIC STEM-CELLS; GROUP-B; ADULT PATIENTS; PROGNOSTIC-SIGNIFICANCE; CLONAL HEMATOPOIESIS; EUROPEAN LEUKEMIANET; FRENCH ASSOCIATION; DOSE CYTARABINE; AGE 60; CANCER AB Somatic mutation of the DNMT3A gene at the arginine R882 site is common in acute myeloid leukaemia (AML). The prognostic significance of DNMT3A R882 mutation clearance, using traditional diagnostic next generation sequencing (NGS) methods, during complete remission (CR) in AML patients is controversial. We examined the impact of clearing DNMT3A R882 mutations at diagnosis to the detectable threshold of ?3% during CR on outcome in 56 adult AML patients. Mutational remission, defined as clearance of pre-treatment DNMT3A R882 and all other AML-associated mutations to a variant allele frequency ?3%, occurred in 14 patients whereas persistent DNMT3A R882 mutations were observed in 42 patients. There were no significant differences in disease-free or overall survival between patients with and without DNMT3A R882 mutation clearance. Patients with persistent DNMT3A R882 who cleared all other AML mutations and did not acquire new mutations (n=30), trended towards longer disease-free survival (16 vs. 06years, P=006) than patients with persistence of DNMT3A R882, in addition to other mutations or acquisition of new AML-associated mutations, such as those in TET2, JAK2, ASXL1 and TP53 (n=12). These data demonstrate that DNMT3A R882 mutations, as assessed by traditional NGS methods, persist in the majority of AML patients in CR. C1 [Bhatnagar, Bhavana; Blachly, James S.; Orwick, Shelley; Lucas, David M.; Blum, William; Bloomfield, Clara D.; Byrd, John C.] Ohio State Univ, Div Hematol, Dept Internal Med, Comprehens Canc Ctr, Columbus, OH USA. [Bhatnagar, Bhavana; Eisfeld, Ann-Kathrin; Nicolet, Deedra; Mrozek, Krzysztof; Orwick, Shelley; Kohlschmidt, Jessica; Bloomfield, Clara D.; Byrd, John C.] Ohio State Univ, Ctr Comprehens Canc, 300 West 10th. Ave,B307 Starling Loving Hall, Columbus, OH 43210 USA. [Nicolet, Deedra; Kohlschmidt, Jessica] Mayo Clin, Alliance Clin Trials Oncol Stat & Data Ctr, Rochester, MN USA. [Kolitz, Jonathan E.] Hofstra North Shore Long Isl Jewish Sch Med, Monter Canc Ctr, Lake Success, NY USA. [Stone, Richard M.] Dana Farber Canc Inst, Boston, MA USA. RP Bhatnagar, B; Byrd, JC (reprint author), Ohio State Univ, Ctr Comprehens Canc, 300 West 10th. Ave,B307 Starling Loving Hall, Columbus, OH 43210 USA. EM Bhavana.Bhatnagar@osumc.edu; john.byrd@osumc.edu FU National Institutes of Health (NIH) [R35 CA197734, 5P30 CA016058, U10 CA180861, CA101140, CA140158, CA196171, CA180821, CA180882, CA077658]; Coleman Leukemia Research Foundation; Pelotonia Fellowship Program; D Warren Brown Foundation; NCCN Foundation FX The authors are grateful to the patients who consented to participate in these clinical trials and the families who supported them; to Donna Bucci and the CALGB/Alliance Leukemia Tissue Bank at The Ohio State University Comprehensive Cancer Center, Columbus, OH, for sample processing and storage services and Lisa J. Sterling and Chris Finks for data management. This research was supported by National Institutes of Health (NIH) grants R35 CA197734, 5P30 CA016058, U10 CA180861, CA101140, CA140158, CA196171, CA180821, CA180882, and CA077658, the Coleman Leukemia Research Foundation (A.-K.E.), the Pelotonia Fellowship Program (A.-K.E.), the D Warren Brown Foundation, the NCCN Foundation (J.S.B.) and by an allocation of computing resources from The Ohio Supercomputer Center. NR 44 TC 3 Z9 3 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-1048 EI 1365-2141 J9 BRIT J HAEMATOL JI Br. J. Haematol. PD OCT PY 2016 VL 175 IS 2 BP 226 EP 236 DI 10.1111/bjh.14254 PG 11 WC Hematology SC Hematology GA DZ3QH UT WOS:000385763400007 PM 27476855 ER PT J AU Rogal, S Mankaney, G Udawatta, V Good, CB Chinman, M Zickmund, S Bielefeldt, K Jonassaint, N Jazwinski, A Shaikh, O Hughes, C Humar, A DiMartini, A Fine, MJ AF Rogal, Shari Mankaney, Gautham Udawatta, Viyan Good, Chester B. Chinman, Matthew Zickmund, Susan Bielefeldt, Klaus Jonassaint, Naudia Jazwinski, Alison Shaikh, Obaid Hughes, Christopher Humar, Abhinav DiMartini, Andrea Fine, Michael J. TI Association between opioid use and readmission following liver transplantation SO CLINICAL TRANSPLANTATION LA English DT Article DE narcotics; pain; rehabilitation; rehospitalization ID PALLIATIVE CARE; KIDNEY-TRANSPLANTATION; PAIN; DISEASE; VALIDATION; MANAGEMENT; CIRRHOSIS; ADULTS AB The aim of this study was to assess the independent association between pre-transplant prescription opioid use and readmission following liver transplantation. We reviewed the medical records of all patientsat a single medical center undergoing primary, single-organ, liver transplantation from 2004 to 2014. We assessed factors associated with hospital readmission 30days and 1year after hospital discharge using multivariable competing risk regression models. Among 1056 transplant recipients, 49 (4.6%) were prescribed pre-transplant prescription opioids. Readmission occurred in 421 (40%) patients within 30days and 689 (65%) within 1year. Patients with pre-transplant opioid use had a significantly higher risk of readmission at 30days (HR 1.7; 95% CI 1.1-2.5) and a non-significantly elevated risk at 1year (HR 1.4; 95% CI 1.0-1.9) when controlling for other potential confounders. Although pain was the major reason for readmission in only 12 (3%) patients at 30days and 33 (6%) patients at 1year, pre-transplant opioid use was significantly associated with pain-related readmission at both time points. In conclusion, prescription opioid use pre-transplantation was significantly associated with all-cause 30-day readmissions and pain-related readmissions at 30 days and 1 year. C1 [Rogal, Shari; Good, Chester B.; Zickmund, Susan; Fine, Michael J.] VA Pittsburgh Hlthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15261 USA. [Rogal, Shari; Jonassaint, Naudia; Hughes, Christopher; Humar, Abhinav; DiMartini, Andrea] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA. [Rogal, Shari; Shaikh, Obaid] VA Pittsburgh Hlthcare Syst, Div Gastroenterol, Pittsburgh, PA USA. [Mankaney, Gautham; Udawatta, Viyan; Good, Chester B.; Zickmund, Susan; Fine, Michael J.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Chinman, Matthew] VA Pittsburgh Hlthcare Syst, VISN Mental Illness Res & Clin Ctr 4, Pittsburgh, PA USA. [Chinman, Matthew] RAND Corp, Pittsburgh, PA USA. [Rogal, Shari; Bielefeldt, Klaus; Jonassaint, Naudia; Jazwinski, Alison; Shaikh, Obaid] Univ Pittsburgh, Sch Med, Div Gastroenterol Hepatol & Nut, Pittsburgh, PA USA. [DiMartini, Andrea] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. RP Rogal, S (reprint author), VA Pittsburgh Hlthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15261 USA. EM rogalss@upmc.edu FU Gilead Sciences FX The authors of this manuscript have no conflict of interests to disclose as described by the American Journal of Transplantation. Although there are not any potential conflict of interests relevant to this manuscript, Drs. Rogal, Zickmund and Jonassaint report a grant (to the institution) from Gilead Sciences for projects related to hepatitis. NR 29 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0902-0063 EI 1399-0012 J9 CLIN TRANSPLANT JI Clin. Transplant. PD OCT PY 2016 VL 39 IS 10 BP 1222 EP 1229 DI 10.1111/ctr.12806 PG 8 WC Surgery; Transplantation SC Surgery; Transplantation GA DZ3OT UT WOS:000385758800006 ER PT J AU Nassan, FL Coull, BA Skakkebaek, NE Williams, MA Dadd, R Minguez-Alarcon, L Krawetz, SA Hait, EJ Korzenik, JR Moss, AC Ford, JB Hauser, R AF Nassan, Feiby L. Coull, Brent A. Skakkebaek, Niels E. Williams, Michelle A. Dadd, Ramace Minguez-Alarcon, Lidia Krawetz, Stephen A. Hait, Elizabeth J. Korzenik, Joshua R. Moss, Alan C. Ford, Jennifer B. Hauser, Russ TI A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and semen quality in men with inflammatory bowel disease SO ENVIRONMENT INTERNATIONAL LA English DT Article DE Phthalates; Mesalamine; Inflammatory bowel disease (IBD); Semen quality ID N-BUTYL PHTHALATE; SPRAGUE-DAWLEY RATS; IN-UTERO EXPOSURE; MONO-(2-ETHYLHEXYL) PHTHALATE; DI(N-BUTYL) PHTHALATE; URINARY CONCENTRATIONS; REPRODUCTIVE TOXICITY; ULCERATIVE-COLITIS; BENZYL PHTHALATE; SPERM MORPHOLOGY AB Background: Phthalates are widely used chemicals with ubiquitous exposure. Dibutyl-phthalate (DBP), a male reproductive toxicant in animals, is understudied in humans. Some mesalamine medications used to treat inflammatory bowel disease (IBD) have DBP in their coating, whereas other mesalamine formulations do not. Objectives: Taking advantage of differences in mesalamine formulations, we investigated whether high-DBP exposure from mesalamine medications was associated with decreased semen parameters. Methods: 73 men with IBD taking mesalamine participated in a crossover-crossback prospective study. Men taking non-DBP containing mesalamine at baseline i.e., background exposure, crossed-over for four months to high-DBP mesalamine and then crossed-back for four months to their non-DBP mesalamine (B1HB2-arm;Backgroundi-High-Backgrounds) and vice versa for men taking high-DBP mesalamine at baseline (H1BH2-arm;High(1)-Background-High(2)). Men provided up to six semen samples (2: baseline, 2: crossover and 2: crossback). Results: We estimated crossover, crossback and carryover effects using linear mixed models adjusted for abstinence time, age, season and duration on high-DBP mesalamine at baseline. Semen parameters in B1HB2-arm (26 men, 133 samples) decreased after high-DBP mesalamine exposure (crossover versus baseline), especially motility parameters, and continued to decrease further even after crossback to non-DBP mesalamine (crossback versus crossover). The cumulative carryover effect of high-DBP (crossback versus baseline) was a decrease of % total sperm motility by 7.61(CI: -13.1, -2.15), % progressive sperm motility by 4.23(Cl: -8.05, -0.4) and motile sperm count by 26.0% (CI: -46.2%,1.7%). However, H1BH2-arm (47 men, 199 samples) had no significant change during crossover or crossback. Conclusions: Men newly exposed to high-DBP mesalamine for four months had a cumulative reduction in several semen parameters, primarily sperm motility, that was more pronounced and statistically significant even after exposure ended for four months. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Nassan, Feiby L.; Dadd, Ramace; Minguez-Alarcon, Lidia; Ford, Jennifer B.; Hauser, Russ] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave,Bldg 1,Room 1406, Boston, MA 02115 USA. [Coull, Brent A.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Skakkebaek, Niels E.] Rigshosp, Univ Dept Growth & Reprod, Copenhagen, Denmark. [Williams, Michelle A.; Hauser, Russ] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Krawetz, Stephen A.] Wayne State Univ, Dept Obstet & Gynecol, Ctr Mol Med & Genet, Detroit, MI USA. [Hait, Elizabeth J.] Harvard Med Sch, Childrens Hosp Boston, Div Gastroenterol, Boston, MA USA. [Korzenik, Joshua R.] Harvard Med Sch, Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, Boston, MA USA. [Moss, Alan C.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Inflammatory Bowel Dis, Boston, MA USA. [Hauser, Russ] Massachusetts Gen Hosp, Vincent Obstet & Gynecol, Boston, MA 02114 USA. [Hauser, Russ] Harvard Med Sch, Boston, MA USA. RP Nassan, FL (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave,Bldg 1,Room 1406, Boston, MA 02115 USA. EM fen769@mail.harvard.edu OI Nassan, Feiby/0000-0002-3204-0694 FU National Institute of Environmental Health Sciences (NIEHS) [R01ES017285, P30ES000002]; Leslie Silverman Industrial Hygiene Fund; Benjamin Greely Ferris Jr. Fellowship in Environmental Epidemiology; Cyprus Endowment for the Environment and Public Health at the Harvard T.H. Chan School of Public Health FX This work was supported by National Institute of Environmental Health Sciences (NIEHS) [grants R01ES017285 and P30ES000002] and support for Feiby L. Nassan during her doctoral studies from the Leslie Silverman Industrial Hygiene Fund, Benjamin Greely Ferris Jr. Fellowship in Environmental Epidemiology, and Cyprus Endowment for the Environment and Public Health at the Harvard T.H. Chan School of Public Health. NR 81 TC 0 Z9 0 U1 2 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0160-4120 EI 1873-6750 J9 ENVIRON INT JI Environ. Int. PD OCT PY 2016 VL 95 BP 120 EP 130 DI 10.1016/j.envint.2016.08.006 PG 11 WC Environmental Sciences SC Environmental Sciences & Ecology GA DY0LY UT WOS:000384789500014 PM 27575365 ER PT J AU Anwar, MA Vorkas, PA Li, J Adesina-Georgiadis, KN Reslan, OM Raffetto, JD Want, EJ Khalil, RA Holmes, E Davies, AH AF Anwar, M. A. Vorkas, P. A. Li, J. Adesina-Georgiadis, K. N. Reslan, O. M. Raffetto, J. D. Want, E. J. Khalil, R. A. Holmes, E. Davies, A. H. TI Prolonged Mechanical Circumferential Stretch Induces Metabolic Changes in Rat Inferior Vena Cava SO EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY LA English DT Article DE Vascular biology; Varicose veins; Circumferential stretch; Metabonomics ID VARICOSE-VEINS; TISSUE; METABONOMICS; NMR; SPECTROSCOPY; EXTRACTION; EXPRESSION; URINE AB Objective/Background: Circumferential stretch on the vein wall has been suggested as a potential etiological factor in the development of varicose veins. However, the influence of vein wall stretch on vein metabolism has not yet been explored. The aim of this study was to investigate the effect of short and prolonged mechanical stretch on vein wall metabolism. Methods: Circular segments of inferior vena cava from male Sprague Dawley rats were exposed to normal 0.5-g (nonstretched) or high 2-g (stretched) tension for short (4 h) or prolonged (18 h) duration (five vein segments per group). Contraction response to phenylephrine (10(-5) M) and KCI (96 mM) was elicited to observe the effect of circumferential stretch on vein function. The polar and organic metabolites in vein tissue were extracted using a bilayer extraction method. Aqueous and organic extracts were analyzed using nuclear magnetic resonance spectroscopy and ultra performance liquid chromatography coupled to mass spectrometry, respectively. Data acquired from both analytical platforms were analyzed using mathematical modeling. Results: Increased concentrations of valine (p=.02) and choline (p=.03) metabolites and triglyceride moieties (p=.03) were observed in veins stretched for 18 h compared with the nonstretched/18 h group. Discussion: Increased concentrations of branched chain amino acid valine and cell membrane constituent choline indicate increased muscle breakdown and increased metabolism of membrane phospholipids under stretch in an ex-vivo model. Increased intensities of triglyceride moieties in stretched vein segments for 18 h suggest that high pressure may induce an inflammatory response. Conclusion: This study has shown that prolonged mechanical circumferential stretch (18 h) alters the metabolic profile of rat inferior vena cava. (C) 2016 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved. C1 [Anwar, M. A.; Davies, A. H.] Imperial Coll, Dept Surg & Canc, Acad Sect Vasc Surg, London, England. [Vorkas, P. A.; Li, J.; Adesina-Georgiadis, K. N.; Want, E. J.; Holmes, E.] Imperial Coll, Dept Surg & Canc, Sect Biomol Med Computat & Syst Med, London, England. [Reslan, O. M.; Raffetto, J. D.; Khalil, R. A.] Brigham & Womens Hosp, Div Vasc & Endovasc Surg, 75 Francis St, Boston, MA 02115 USA. [Raffetto, J. D.] VA Boston Healthcare Syst, Div Vasc Surg, West Roxbury, MA USA. [Raffetto, J. D.; Khalil, R. A.] Harvard Med Sch, Boston, MA USA. RP Anwar, MA (reprint author), Imperial Coll, Dept Surg & Canc, Acad Sect Vasc Surg, London, England. EM m.anwar@imperial.ac.uk FU Graham Dixon Charitable Trust; European Venous Forum; Imperial College London Healthcare NHS Charitable Trust; Royal Society of Chemistry; National Heart, Lung and Blood Institute [HL-65998, HL-111775] FX The authors acknowledge the Graham Dixon Charitable Trust, the European Venous Forum, and Imperial College London Healthcare NHS Charitable Trust for their funding in carrying out this research project. P.A.V. acknowledges the Royal Society of Chemistry for funding his PhD studentship. This work was partly supported by grants from National Heart, Lung and Blood Institute (HL-65998, HL-111775) to R.A. Khalil. NR 23 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 1078-5884 EI 1532-2165 J9 EUR J VASC ENDOVASC JI Eur. J. Vasc. Endovasc. Surg. PD OCT PY 2016 VL 52 IS 4 BP 544 EP 552 DI 10.1016/j.ejvs.2016.07.002 PG 9 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA EA6KP UT WOS:000386738400025 PM 27523725 ER PT J AU Liow, MHL Tsai, TY Dimitriou, D Li, G Kwon, YM AF Liow, Ming Han Lincoln Tsai, Tsung-Yuan Dimitriou, Dimitris Li, Guoan Kwon, Young-Min TI Does 3-Dimensional In Vivo Component Rotation Affect Clinical Outcomes in Unicompartmental Knee Arthroplasty? SO JOURNAL OF ARTHROPLASTY LA English DT Article DE unicompartmental knee arthroplasty; biplanar radiograph; component rotational position; alignment; functional scores ID PATIENT-REPORTED OUTCOMES; NAVIGATION SYSTEM; TIBIAL COMPONENT; LIMB ALIGNMENT; EARLY FAILURE; CT-SCAN; REPLACEMENT; RELIABILITY; IMPLANT; SURVIVORSHIP AB Background: Unicompartmental knee arthroplasty (UKA) is an effective treatment for single-compartment osteoarthritis. Limited studies have examined the relationship between component rotation and functional outcomes, with no existing consensus to guide "optimal" UKA component rotation. Our study aims to study the effect of 3-dimensional (3D) in vivo UKA component axial rotation on functional outcomes by determining (1) how much component axial rotation variability exists in UKA? and (2) does 3D in vivo UKA component axial rotation affect functional outcomes? Methods: Sixty-six UKAs from 58 consecutive patients (36 male [62.1%], age 63.7 +/- 9.2 years, body mass index 28.2 +/- 4.9 kg/m(2), and mean follow-up time 49.2 months) were imaged in weight-bearing standing position using biplanar radiography. We performed multiple comparisons to analyze the relationship between 3D UKA component alignment and European Quality of Life-5 Dimensions (EQ-5D), UCLA activity score, and Knee Injury and Osteoarthritis Outcome Scores. Results: Significant improvements in EQ-5D, EQ-5D (United States adjusted), and Knee Injury and Osteoarthritis Outcome Scores (Sport/Rec) scores were noted postoperatively. However, high variability in 3D UKA femoral (6.2 degrees +/- 6.5 degrees) and tibial (4.6 degrees +/- 6.4 degrees) component positioning was observed. A trend toward better outcome scores in lower angles of femoral (<2.7 degrees external rotation [ER]) and tibial (2.7 degrees ER to 2.4 degrees internal rotation [IR]) component rotation was noted, with better functional scores observed at mean femoral and tibial rotation angles of 3 degrees ER to 3 degrees IR. Conclusion: Patients with UKA femoral and/or tibial component rotation angles within 3 degrees ER to 3 degrees IR of neutral component alignment reported better functional outcomes. Surgeons should be cognizant of the high variability noted in UKA component axial rotation and its potential correlation with functional scores. (C) 2016 Elsevier Inc. All rights reserved. C1 [Liow, Ming Han Lincoln; Tsai, Tsung-Yuan; Dimitriou, Dimitris; Li, Guoan; Kwon, Young-Min] Harvard Med Sch, Massachusetts Gen Hosp, Dept Orthopaed Surg, 55 Fruit St,YAW 3700, Boston, MA 02114 USA. RP Kwon, YM (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Orthopaed Surg, 55 Fruit St,YAW 3700, Boston, MA 02114 USA. FU Zimmer FX Partial funding from Zimmer. NR 47 TC 0 Z9 0 U1 1 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0883-5403 EI 1532-8406 J9 J ARTHROPLASTY JI J. Arthroplast. PD OCT PY 2016 VL 31 IS 10 BP 2167 EP 2172 DI 10.1016/j.arth.2016.03.003 PG 6 WC Orthopedics SC Orthopedics GA EA6OF UT WOS:000386747800015 PM 27067168 ER PT J AU Dwyer, MK AF Dwyer, Maureen K. TI Response to Letter to the Editor on "Cartilage Status at Time of Arthroscopy Predicts Failure in Patients With Hip Dysplasia" Reply SO JOURNAL OF ARTHROPLASTY LA English DT Letter C1 [Dwyer, Maureen K.] Newton Wellesley Hosp, Kaplan Joint Ctr, Newton, MA 02462 USA. [Dwyer, Maureen K.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA. RP Dwyer, MK (reprint author), Newton Wellesley Hosp, Kaplan Joint Ctr, Newton, MA 02462 USA.; Dwyer, MK (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0883-5403 EI 1532-8406 J9 J ARTHROPLASTY JI J. Arthroplast. PD OCT PY 2016 VL 31 IS 10 BP 2372 EP 2372 DI 10.1016/j.arth.2016.03.032 PG 1 WC Orthopedics SC Orthopedics GA EA6OF UT WOS:000386747800054 PM 27426029 ER PT J AU Weinrauch, LA Bayliss, G Segal, AR Liu, JK Wisniewski, E D'Elia, JA AF Weinrauch, Larry A. Bayliss, George Segal, Alissa R. Liu, Jiankang Wisniewski, Eric D'Elia, John A. TI Treating Hypertension in Diabetic Patients With Advanced Chronic Kidney Disease: What Should We Have in Mind? SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Letter ID RESISTANT HYPERTENSION C1 [Weinrauch, Larry A.; Bayliss, George; Segal, Alissa R.; Wisniewski, Eric; D'Elia, John A.] Joslin Diabet Ctr, Kidney & Hypertens Sect, Boston, MA 02215 USA. [Weinrauch, Larry A.; Liu, Jiankang; Wisniewski, Eric] Brigham & Womens Hosp, Cardiovasc Div, Clin End Points Sect, 75 Francis St, Boston, MA 02115 USA. [Weinrauch, Larry A.; Liu, Jiankang; Wisniewski, Eric; D'Elia, John A.] Harvard Med Sch, Boston, MA USA. [Bayliss, George; Wisniewski, Eric] Brown Univ, Alpert Med Sch, Rhode Isl Hosp, Div Kidney Dis & Hypertens, Providence, RI 02912 USA. [Segal, Alissa R.] MCPHS Univ, Boston, MA USA. RP Weinrauch, LA (reprint author), Joslin Diabet Ctr, Kidney & Hypertens Sect, Boston, MA 02215 USA.; Weinrauch, LA (reprint author), Brigham & Womens Hosp, Cardiovasc Div, Clin End Points Sect, 75 Francis St, Boston, MA 02115 USA.; Weinrauch, LA (reprint author), Harvard Med Sch, Boston, MA USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1524-6175 EI 1751-7176 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD OCT PY 2016 VL 18 IS 10 BP 1077 EP 1078 DI 10.1111/jch.12839 PG 2 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DZ3QN UT WOS:000385764100021 PM 27170522 ER PT J AU Danek, BA Karatasakis, A Karmpaliotis, D Alaswad, K Yeh, RW Jaffer, FA Patel, MP Mahmud, E Lombardi, WL Wyman, MR Grantham, JA Doing, A Kandzari, DE Lembo, NJ Garcia, S Toma, C Moses, JW Kirtane, AJ Parikh, MA Ali, ZA Karacsonyi, J Rangan, BV Thompson, CA Banerjee, S Brilakis, ES AF Danek, Barbara Anna Karatasakis, Aris Karmpaliotis, Dimitri Alaswad, Khaldoon Yeh, Robert W. Jaffer, Farouc A. Patel, Mitul P. Mahmud, Ehtisham Lombardi, William L. Wyman, Michael R. Grantham, J. Aaron Doing, Anthony Kandzari, David E. Lembo, Nicholas J. Garcia, Santiago Toma, Catalin Moses, Jeffrey W. Kirtane, Ajay J. Parikh, Manish A. Ali, Ziad A. Karacsonyi, Judit Rangan, Bavana V. Thompson, Craig A. Banerjee, Subhash Brilakis, Emmanouil S. TI Development and Validation of a Scoring System for Predicting Periprocedural Complications During Percutaneous Coronary Interventions of Chronic Total Occlusions: The Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (PROGRESS CTO) Complications Score SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE chronic total occlusion; complication; outcome; percutaneous coronary intervention; risk stratification ID MULTICENTER US REGISTRY; LONG-TERM OUTCOMES; HYBRID APPROACH; MYOCARDIAL-INFARCTION; PROCEDURAL OUTCOMES; INSIGHTS; SUCCESS; IMPACT; REVASCULARIZATION; RECANALIZATION AB Background-High success rates are achievable for chronic total occlusion (CTO) percutaneous coronary intervention (PCI) using the hybrid approach, but periprocedural complications remain of concern. Although scores estimating success and efficiency in CTO PCI have been developed, there is currently no available score for estimation of the risk for periprocedural complications. We sought to develop a scoring tool for prediction of periprocedural complications during CTO PCI. Methods and Results-We analyzed data from 1569 CTO PC's in the Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (PROGRESS CTO) using a derivation and validation sampling ratio of 2:1. Variables independently associated with periprocedural complications in multivariable analysis in the derivation set were assigned points based on their respective odds ratios. Forty-four (2.8%) patients experienced complications. Three factors were independent predictors of complications and were included in the score: patient age >65 years, +3 points (odds ratio, OR=4.85, Cl 1.82-1677); lesion length >= 23 mm, +2 points (OR=3.22, CI 1.08-13.89); and use of the retrograde approach +1 point (OR=2.41, CI 1.04-6.05). The resulting score showed good calibration and discriminatory capacity in the derivation (Hosmer-Lemeshow chi(2) 6.271, P=0.281, receiver-operating characteristic [ROC] area-0.758) and validation (Hosmer-Lemeshow chi(2) 4.551, P=0.473, ROC area=0.793) sets. Score values of 0 to 2, 3 to 4, and >= 5 were defined as low, intermediate, and high risk of complications (derivation cohort 0.4%, 1.8%, 6.5%, P<0.001; validation cohort 0.0%, 2.5%, 6.8%, P<0.001). Conclusions-The PROGRESS CTO complication score is a useful tool for prediction of periprocedural complications in CTO PCI. C1 [Danek, Barbara Anna; Karatasakis, Aris; Karacsonyi, Judit; Rangan, Bavana V.; Banerjee, Subhash; Brilakis, Emmanouil S.] VA North Texas Healthcare Syst, Dallas, TX USA. [Danek, Barbara Anna; Karatasakis, Aris; Karacsonyi, Judit; Rangan, Bavana V.; Banerjee, Subhash; Brilakis, Emmanouil S.] UT Southwestern Med Ctr, Dallas, TX USA. [Karmpaliotis, Dimitri; Moses, Jeffrey W.; Kirtane, Ajay J.; Parikh, Manish A.; Ali, Ziad A.] Columbia Univ, New York, NY USA. [Alaswad, Khaldoon] Henry Ford Hosp, Detroit, MI 48202 USA. [Yeh, Robert W.; Jaffer, Farouc A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Yeh, Robert W.; Jaffer, Farouc A.] Harvard Med Sch, Boston, MA USA. [Patel, Mitul P.; Mahmud, Ehtisham] VA San Diego Healthcare Syst, San Diego, CA USA. [Patel, Mitul P.; Mahmud, Ehtisham] Univ Calif San Diego, San Diego, CA 92103 USA. [Lombardi, William L.] Univ Washington, Seattle, WA 98195 USA. [Wyman, Michael R.] Torrance Mem Med Ctr, Torrance, CA USA. [Grantham, J. Aaron] Mid Amer Heart Inst, Kansas City, MO USA. [Doing, Anthony] Med Ctr Rockies, Loveland, CO USA. [Kandzari, David E.; Lembo, Nicholas J.] Piedmont Haan Inst, Atlanta, GA USA. [Garcia, Santiago] Minneapolis VA Healthcare Syst, Minneapolis, MN USA. [Garcia, Santiago] Univ Minnesota, Minneapolis, MN USA. [Toma, Catalin] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Thompson, Craig A.] Boston Sci, Natick, MA USA. RP Brilakis, ES (reprint author), Dallas VA Med Ctr 111A, 4500 South Lancaster Rd, Dallas, TX 75216 USA. EM esbrilakis@gmail.com FU National Center for Advancing Translational Sciences of the National Institutes of Health [UL1-RR024982] FX Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1-RR024982. The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH. NR 34 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD OCT PY 2016 VL 5 IS 10 AR e004272 DI 10.1161/JAHA.116.004272 PG 13 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EA6OM UT WOS:000386748500051 ER PT J AU Eisen, A Bhatt, DL Steg, PG Eagle, KA Goto, S Guo, JP Smith, SC Ohman, EM Scirica, BM AF Eisen, Alon Bhatt, Deepak L. Steg, P. Gabriel Eagle, Kim A. Goto, Shinya Guo, Jianping Smith, Sidney C. Ohman, E. Magnus Scirica, Benjamin M. CA REACH Registry Investigators TI Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE angina; cardiovascular events; coronary artery disease ID HEART-DISEASE; CLINICAL-OUTCOMES; MYOCARDIAL-ISCHEMIA; CLARIFY REGISTRY; OUTPATIENTS; SYMPTOMS; PECTORIS; RATES; SOUL; RISK AB Background-The extent to which angina is associated with future cardiovascular events in patients with coronary artery disease has long been debated. Methods and Results-Included were outpatients with established coronary artery disease who were enrolled in the REACH registry and were followed for 4 years. Angina at baseline was defined as necessitating episodic or permanent antianginal treatment. The primary end point was the composite of cardiovascular death, myocardial infarction, or stroke. Secondary end points included heart failure, cardiovascular hospitalizations, and coronary revascularization. The independent association between angina and first/total events was examined using Cox and logistic regression models. Out of 26 159 patients with established coronary artery disease, 13 619 (52%) had angina at baseline. Compared with patients without angina, patients with angina were more likely to be older, female, and had more heart failure and polyvascular disease (P<0.001 for each). Compared with patients without angina, patients with angina had higher rates of first primary end-point event (14.2% versus 16.3%, unadjusted hazard ratio 1.19, CI 1.11-1.27, P<0.001; adjusted hazard ratio 1.06, CI 0.99-1.14, P=0.11), and total primary end-point events (adjusted risk ratio 1.08, CI 1.01-1.16, P=0.03). Patients with angina were at increased risk for heart failure (adjusted odds ratio 1.17, CI 1.06-1.28, P=0.002), cardiovascular hospitalizations (adjusted odds ratio 1.29, CI 1.21-1.38, P<0.001), and coronary revascularization (adjusted odds ratio 1.23, CI 1.13-1.34, P<0.001). Conclusions-Patients with stable coronary artery disease and angina have higher rates of future cardiovascular events compared with patients without angina. After adjustment, angina was only weakly associated with cardiovascular death, myocardial infarction, or stroke, but significantly associated with heart failure, cardiovascular hospitalization, and coronary revascularization. C1 [Eisen, Alon; Bhatt, Deepak L.; Guo, Jianping; Scirica, Benjamin M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Eisen, Alon; Bhatt, Deepak L.; Guo, Jianping; Scirica, Benjamin M.] Harvard Med Sch, 75 Francis St, Boston, MA 02115 USA. [Steg, P. Gabriel] Univ Paris Diderot, Sorbonne Pails Cite, Dept Hosp Univ FIRE Fibrosis Inflammat Remodeling, Paris, France. [Steg, P. Gabriel] Hop Bichat Claude Bernard, AP HP, FACT French Alliance Cardiovasc Clin Trials, Paris, France. [Steg, P. Gabriel] INSERM, U1148, Paris, France. [Steg, P. Gabriel] Imperial Coll, Royal Brompton Hosp, Natl Heart & Lung Inst, London, England. [Eagle, Kim A.] Univ Michigan Hlth Syst, Ann Arbor, MI USA. [Goto, Shinya] Tokai Univ, Sch Med, Dept Med, Isehara, Kanagawa, Japan. [Smith, Sidney C.] Univ N Carolina, Heart & Vasc Ctr, Chapel Hill, NC USA. [Ohman, E. Magnus] Duke Univ, Med Ctr, Durham, NC USA. RP Scirica, BM (reprint author), Harvard Med Sch, 75 Francis St, Boston, MA 02115 USA.; Scirica, BM (reprint author), Brigham & Womens Hosp, Cardiovasc Div, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA. EM bscirica@partners.org RI Statsenko, Mikhail/N-7573-2015; OI Statsenko, Mikhail/0000-0002-3306-0312; Galyavich, Albert/0000-0002-4510-6197; Climent, Vicente/0000-0001-7362-1922; Santoso, Teguh/0000-0003-0367-4564; Karpov, Yuri/0000-0003-1480-0458 FU Sanofi-Aventis; Bristol-Myers Squibb; Waksman Foundation (Tokyo, Japan) FX The REACH Registry was sponsored by Sanofi-Aventis, Bristol-Myers Squibb, and the Waksman Foundation (Tokyo, Japan) and is endorsed by the World Heart Federation. NR 24 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD OCT PY 2016 VL 5 IS 10 AR e004080 DI 10.1161/JAHA.116.004080 PG 23 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EA6OM UT WOS:000386748500035 ER PT J AU Hess, PL Ho, PM AF Hess, Paul L. Ho, P. Michael TI Hypertension Management: Ripe for Disruption SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Editorial Material DE Editorials; hypertension; intensification; quality of care ID PERFORMANCE C1 [Hess, Paul L.; Ho, P. Michael] VA Eastern Colorado Hlth Care Syst, Cardiol Sect, Denver, CO USA. [Hess, Paul L.; Ho, P. Michael] Univ Colorado, Dept Med, Anschutz Med Campus, Aurora, CO USA. RP Hess, PL (reprint author), Denver VA Med Ctr, Cardiol Sect 111B, 1055 Clermont St, Denver, CO 80220 USA. EM paul.hess@ucdenver.edu NR 6 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD OCT PY 2016 VL 5 IS 10 AR e004681 DI 10.1161/JAHA.116.004681 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EA6OM UT WOS:000386748500058 ER PT J AU Hira, RS Bhatt, DL Fonarow, GC Heidenreich, PA Ju, C Virani, SS Bozkurt, B Petersen, LA Hernandez, AF Schwamm, LH Eapen, ZJ Albert, MA Liang, L Matsouaka, RA Peterson, ED Jneid, H AF Hira, Ravi S. Bhatt, Deepak L. Fonarow, Gregg C. Heidenreich, Paul A. Ju, Christine Virani, Salim S. Bozkurt, Biykem Petersen, Laura A. Hernandez, Adrian F. Schwamm, Lee H. Eapen, Zubin J. Albert, Michelle A. Liang, Li Matsouaka, Roland A. Peterson, Eric D. Jneid, Hani TI Temporal Trends in Care and Outcomes of Patients Receiving Fibrinolytic Therapy Compared to Primary Percutaneous Coronary Intervention: Insights From the Get With The Guidelines Coronary Artery Disease (GWTG-CAD) Registry SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE fibrinolysis; myocardial infarction; outcome and process assessment; primary percutaneous coronary intervention ID ELEVATION MYOCARDIAL-INFARCTION; ASSOCIATION TASK-FORCE; REQUIRING INTERHOSPITAL TRANSFER; CARDIOVASCULAR DATA REGISTRY; TO-BALLOON TIMES; HEART-ASSOCIATION; ST-ELEVATION; AMERICAN-COLLEGE; PERFORMANCE-MEASURES; PRIMARY ANGIOPLASTY AB Background-Timely reperfusion after ST-elevation myocardial infarction (STEMI) improves survival. Guidelines recommend primary percutaneous coronary intervention (PPCI) within 90 minutes of arrival at a PCI-capable hospital. The alternative is fibrinolysis within 30 minutes for those in those for whom timely transfer to a PCI-capable hospital is not feasible. Methods and Results-We identified STEMI patients receiving reperfusion therapy at 229 hospitals participating in the Get With the Guidelines-Coronary Artery Disease (GWTG-CAD) database (January 1, 2003 through December 31, 2008). Temporal trends in the use of fibrinolysis and PPCI, its timeliness, and in-hospital mortality outcomes were assessed. We also assessed predictors of fibrinolysis versus PPCI and compliance with performance measures. Defect-free care was defined as 100% compliance with all performance measures. We identified 29 190 STEMI patients, of whom 2441 (8.4%) received fibrinolysis; 38.2% of these patients achieved door-to-needle times <= 30 minutes. Median door-to-needle times increased from 36 to 60 minutes (P=0.005) over the study period. Among PPCI patients, median door-to-balloon times decreased from 94 to 64 minutes (P<0.0001) over the same period. In-hospital mortality was higher with fibrinolysis than with PPCI (4.6% vs 3.3%, P=0.001) and did not change significantly over time. Patients receiving fibrinolysis were less likely to receive defect-free care compared with their PPCI counterparts. Conclusions-Use of fibrinolysis for STEMI has decreased over time with concomitant worsening of door-to-needle times. Over the same time period, use of PPCI increased with improvement in door-to-balloon times. In-hospital mortality was higher with fibrinolysis than with PPCI. As reperfusion for STEMI continues to shift from fibrinolysis to PPCI, it will be critical to ensure that door-to-needle times and outcomes do not worsen. C1 [Hira, Ravi S.] Univ Washington, Div Cardiol, Seattle, WA 98195 USA. [Bhatt, Deepak L.] Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA. [Bhatt, Deepak L.] Harvard Med Sch, Boston, MA USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Los Angeles, CA USA. [Heidenreich, Paul A.] Vet Adm Palo Alto Healthcare Syst, Palo Alto, CA USA. [Heidenreich, Paul A.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Ju, Christine; Hernandez, Adrian F.; Eapen, Zubin J.; Liang, Li; Matsouaka, Roland A.; Peterson, Eric D.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA. [Virani, Salim S.; Bozkurt, Biykem; Jneid, Hani] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Virani, Salim S.; Bozkurt, Biykem; Jneid, Hani] Baylor Coll Med, Dept Med, Div Cardiol, Houston, TX 77030 USA. [Virani, Salim S.; Petersen, Laura A.] Baylor Coll Med, Dept Med, Sect Hlth Serv Res, Houston, TX 77030 USA. [Virani, Salim S.; Petersen, Laura A.] Michael E DeBakey VA Med Ctr, Hlth Serv Res & Dev Ctr Innovat, Houston, TX USA. [Schwamm, Lee H.] TeleStroke & Acute Stroke Serv, Dept Neurol, Boston, MA USA. [Schwamm, Lee H.] Massachusetts Gen Hosp, Inst Heart Vasc & Stroke Care, Boston, MA 02114 USA. [Schwamm, Lee H.] Harvard Med Sch, Dept Neurol, Boston, MA USA. [Albert, Michelle A.] Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA. RP Hira, RS (reprint author), 325 Ninth Ave,Box 359748, Seattle, WA 98104 USA. EM hira@uw.edu FU American Heart Association Council on Clinical Cardiology FX Hira was the recipient of a Database Research Seed Grant from the American Heart Association Council on Clinical Cardiology. NR 26 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD OCT PY 2016 VL 5 IS 10 AR e004113 DI 10.1161/JAHA.116.004113 PG 18 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EA6OM UT WOS:000386748500038 ER PT J AU Ladapo, JA Hoffmann, U Lee, KL Coles, A Huang, M Mark, DB Dolor, RJ Pelberg, RA Budoff, M Sigurdsson, G Severance, HW Douglas, PS AF Ladapo, Joseph A. Hoffmann, Udo Lee, Kerry L. Coles, Adrian Huang, Megan Mark, Daniel B. Dolor, Rowena J. Pelberg, Robert A. Budoff, Matthew Sigurdsson, Gardar Severance, Harry W. Douglas, Pamela S. TI Changes in Medical Therapy and Lifestyle After Anatomical or Functional Testing for Coronary Artery Disease SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE angina; coronary disease; diagnosis; prevention ID COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CT ANGIOGRAPHY; CHEST-PAIN; COST-EFFECTIVENESS; MYOCARDIAL-PERFUSION; CLINICAL-OUTCOMES; UNITED-STATES; RISK-FACTORS; TRIAL; INDIVIDUALS AB Background-Diagnostic testing in the care of patients newly presenting with symptoms suggestive of coronary artery disease may influence risk factor management, independent of test type or test results. However, little is known about changes in medications and lifestyle after anatomical or functional testing. Methods and Results-We examined what factors influenced preventive medical therapy and lifestyle practices at 60 days among 10 003 symptomatic patients (53% women; mean age 61 years) randomly assigned to anatomical testing with coronary computed tomographic angiography or functional testing (NCT01174550). We also assessed the association of preventive changes with major cardiovascular events. There were no differences in medications/lifestyle at baseline. At 60 days, relative to baseline, the computed tomographic angiography strategy was associated with a higher proportion of patients newly initiating aspirin (11.8% versus 7.8%), statins (12.7% versus 6.2%), and beta-blockers (8.1% versus 5.3%), compared to functional testing (P<0.0001 for each). No significant differences between computed tomographic angiography and functional testing strategies were observed for initiation of exercise, quitting smoking, or weight loss in overweight/obese patients, though overall prevalence of healthy eating was higher after computed tomographic angiography (P=0.002) while obese/overweight status was lower (P=0.040). Positive initial test results and revascularization demonstrated stronger associations with preventive medications and lifestyle than test type. Medication initiation was not associated with fewer cardiovascular events. Conclusions-Positive initial test results and revascularization are primary drivers of changes in preventive medical and lifestyle practices, with test type making secondary contributions. However, substantial opportunities exist to further reduce cardiovascular risk. C1 [Ladapo, Joseph A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Ladapo, Joseph A.] NYU, Sch Med, Dept Med, New York, NY USA. [Ladapo, Joseph A.] NYU, Sch Med, Dept Populat Hlth, New York, NY USA. [Hoffmann, Udo] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Lee, Kerry L.; Coles, Adrian; Huang, Megan; Mark, Daniel B.; Dolor, Rowena J.; Douglas, Pamela S.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA. [Pelberg, Robert A.] Lindner Clin Trial Ctr, Cincinnati, OH USA. [Budoff, Matthew] Los Angeles Biomed Res Inst, Torrance, CA USA. [Sigurdsson, Gardar] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA. [Severance, Harry W.] Erlanger Inst Clin Res, Chattanooga, TN USA. RP Ladapo, JA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, 911 Broxton Ave, Los Angeles, CA 90024 USA. EM jladapo@mednet.ucla.edu OI Ladapo, Joseph/0000-0002-8518-4800 FU National Heart, Lung, and Blood Institute [R01 HL098237, R01 HL098236, R01 HL098305, R01 HL098235] FX The PROMISE trial was funded by National Heart, Lung, and Blood Institute grants R01 HL098237, R01 HL098236, R01 HL098305, and R01 HL098235. NR 25 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD OCT PY 2016 VL 5 IS 10 AR e003807 DI 10.1161/JAHA.116.003807 PG 21 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EA6OM UT WOS:000386748500012 ER PT J AU Murthy, VL Abbasi, SA Siddique, J Colangelo, LA Reis, J Venkatesh, BA Carr, JJ Terry, JG Camhi, SM Jerosch-Herold, M de Ferranti, S Das, S Freedman, J Carnethon, MR Lewis, CE Lima, JAC Shah, RV AF Murthy, Venkatesh L. Abbasi, Siddique A. Siddique, Juned Colangelo, Laura A. Reis, Jared Venkatesh, Bharath A. Carr, J. Jeffrey Terry, James G. Camhi, Sarah M. Jerosch-Herold, Michael de Ferranti, Sarah Das, Saumya Freedman, Jane Carnethon, Mercedes R. Lewis, Cora E. Lima, Joao A. C. Shah, Ravi V. TI Transitions in Metabolic Risk and Long-Term Cardiovascular Health: Coronary Artery Risk Development in Young Adults (CARDIA) Study SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE epidemiology; metabolic syndrome; obesity; risk factor ID CHILDHOOD OBESITY; ABDOMINAL OBESITY; BLOOD-PRESSURE; HEART-FAILURE; ASSOCIATION CONFERENCE; ADIPOSE-TISSUE; MIDDLE-AGE; ECHOCARDIOGRAPHY; ATHEROSCLEROSIS; POPULATION AB Background-Despite evidence suggesting that early metabolic dysfunction impacts cardiovascular disease risk, current guidelines focus on risk assessments later in life, missing early transitions in metabolic risk that may represent opportunities for averting the development of cardiovascular disease. Methods and Results-In 4420 young adults in the Coronary Artery Risk Development in Young Adults (CARDIA) study, we defined a "metabolic" risk score based on components of the Third Report of the Adult Treatment Panel's definition of metabolic syndrome. Using latent class trajectory analysis adjusted for sex, race, and time-dependent body mass index, we identified 6 distinct metabolic trajectories over time, specified by initial and final risk: low-stable, low-worsening, high-stable, intermediate-worsening, intermediate-stable, and high-worsening. Overall, individuals gained weight over time in CARDIA with statistically but not clinically different body mass index trend over time. Dysglycemia and dyslipidemia over time were highest in initially high or worsening trajectory groups. Divergence in metabolic trajectories occurred in early adulthood (before age 40), with 2 of 3 individuals experiencing an increase in metabolic risk over time. Membership in a higher-risk trajectory (defined as initially high or worsening over time) was associated with greater prevalence and extent of coronary artery calcification, left ventricular mass, and decreased left ventricular strain at year 25. Importantly, despite similar rise in body mass index across trajectories over 25 years, coronary artery calcification and left ventricular structure and function more closely tracked risk factor trajectories. Conclusions-Transitions in metabolic risk occur early in life. Obesity-related metabolic dysfunction is related to subclinical cardiovascular phenotypes independent of evolution in body mass index, including coronary artery calcification and myocardial hypertrophy and dysfunction. C1 [Murthy, Venkatesh L.] Univ Michigan, Dept Med, Cardiovasc Med Div, Ann Arbor, MI 48109 USA. [Murthy, Venkatesh L.] Univ Michigan, Dept Radiol, Div Nucl Med, Ann Arbor, MI 48109 USA. [Abbasi, Siddique A.] Brown Univ, Alpert Med Sch, Providence VA Med Ctr, Providence, RI 02912 USA. [Abbasi, Siddique A.] Brown Univ, Alpert Med Sch, Cardiovasc Inst, Providence, RI 02912 USA. [Siddique, Juned; Colangelo, Laura A.] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Carnethon, Mercedes R.] Northwestern Univ, Dept Preventat Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Reis, Jared] NHLBI, Div Cardiovasc Sci, Bethesda, MD USA. [Venkatesh, Bharath A.; Lima, Joao A. C.] Johns Hopkins Univ, Dept Med, Div Cardiol, Johns Hopkins Med Inst, Baltimore, MD USA. [Carr, J. Jeffrey; Terry, James G.] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA. [Camhi, Sarah M.] Univ Massachusetts, Exercise & Hlth Sci Depaitment, Coll Nursing & Hlth Sci, Boston, MA 02125 USA. [Jerosch-Herold, Michael] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Noninvas Cardiovasc Imaging Sect, Boston, MA 02115 USA. [Jerosch-Herold, Michael] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA. [de Ferranti, Sarah] Boston Childrens Hosp, Preventat Cardiol, Boston, MA USA. [Das, Saumya] Beth Israel Deaconess Med Ctr, Dept Med, Div Cardiovasc, Boston, MA 02215 USA. [Freedman, Jane] Univ Massachusetts, Dept Med, Worcester, MA 01605 USA. [Lewis, Cora E.] Univ Alabama Birmingham, Div Preventat Med, Birmingham, AL USA. [Shah, Ravi V.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Shah, RV (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.; Murthy, VL (reprint author), Univ Michigan, Dept Med Cardiol, Ann Arbor, MI 48109 USA. EM vlmurthy@med.umich.edu; rvshah@partners.org OI Carr, John/0000-0002-4398-8237 FU National Heart, Lung, and Blood Institute (NHLBI) [N01 HC 95159, N01 HC 95160, N01 HC 95161, N01 HC 95162, N01 HC 95163, N01 HC 95164, N01 HC 95165, N01 HC 95166, N01 HC 95168, N01 HC 95169, HL098445-05]; NCRR [UL1-TR-000040, UL1-RR-025005]; American Heart Association; Thrasher Research Foundation; NHLBI, the Intramural Research Program of the National Institute on Aging (NIA) [HHSN268201300025C, HHSN268201300026C, HHSN268201300027C, HHSN268201300028C, HHSN268201300029C, HHSN268200900041C]; NIA [AG0005]; NHLBI [AG0005] FX This research was supported by contracts N01 HC 95159, N01 HC 95160, N01 HC 95161, N01 HC 95162, N01 HC 95163, N01 HC 95164, N01 HC 95165, N01 HC 95166, N01 HC 95168, N01 HC 95169, and HL098445-05 (to Carr) from the National Heart, Lung, and Blood Institute (NHLBI) and by grants UL1-TR-000040 and UL1-RR-025005 from NCRR. Dr Shah is supported by an American Heart Association Fellow-to-Faculty Award and the Thrasher Research Foundation. The CARDIA study is supported by contracts HHSN268201300025C, HHSN268201300026C, HHSN268201300027C, HHSN268201300028C, HHSN268201300029C, and HHSN268200900041C from the NHLBI, the Intramural Research Program of the National Institute on Aging (NIA), and an intra-agency agreement between NIA and NHLBI (AG0005). NR 37 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD OCT PY 2016 VL 5 IS 10 AR e003934 DI 10.1161/JAHA.116.003934 PG 14 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EA6OM UT WOS:000386748500028 ER PT J AU Secemsky, EA Butala, NM Kartoun, U Mahmood, S Wasfy, JH Kennedy, KF Shaw, SY Yeh, RW AF Secemsky, Eric A. Butala, Neel M. Kartoun, Uri Mahmood, Sadiqa Wasfy, Jason H. Kennedy, Kevin F. Shaw, Stanley Y. Yeh, Robert W. TI Use of Chronic Oral Anticoagulation and Associated Outcomes Among Patients Undergoing Percutaneous Coronary Intervention SO JOURNAL OF THE AMERICAN HEART ASSOCIATION LA English DT Article DE anticoagulant; bleeding; mortality; percutaneous coronary intervention; readmission ID ATRIAL-FIBRILLATION PATIENTS; ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR DATA REGISTRY; LONG-TERM MORTALITY; ANTITHROMBOTIC THERAPY; ANTIPLATELET TREATMENT; NATIONAL TRENDS; OLDER PATIENTS; MANAGEMENT; IMPACT AB Background-Contemporary rates of oral anticoagulant (OAC) therapy and associated outcomes among patients undergoing percutaneous coronary intervention (PCI) have been poorly described. Methods and Results-Using data from an integrated health care system from 2009 to 2014, we identified patients on OACs within 30 days of PCI. Outcomes included in-hospital bleeding and mortality. Of 9566 PCIs, 837 patients (8.8%) were on OACs, and of these, 7.9% used non vitamin K antagonist agents. OAC use remained stable during the study (8.1% in 2009, 9.0% in 2014; P-0.11), whereas use of non vitamin K antagonist agents in those on OACs increased (0% in 2009, 16% in 2014; P<0.01). Following PCI, OAC-treated patients had higher crude rates of major bleeding (11% versus 6.5%; P<0.01), access-site bleeding (2.3% versus 1.3%; P=0.017), and non access-site bleeding (8.2% versus 5.2%; P<0.01) but similar crude rates of in-hospital stent thrombosis (0.4% versus 0.3%; P=0.85), myocardial infarction (2.5% versus 3.0%; P=0.40), and stroke (0.48% versus 0.52%; P=0.88). In addition, prior to adjustment. OAC-treated patients had longer hospitalizations (3.9 +/- 5.5 versus 2.8 +/- 4.6 days; more transfusions (7.2% versus 4.2%; P<0.01), and higher 90-day readmission rates (22.1% versus 13.1%; P<0.01). In adjusted models. OAC use was associated with increased risks of in-hospital bleeding (odds ratio 1.50; P<0.01), 90-day readmission (odds ratio 1.40; P<0.01), and long-term mortality (hazard ratio 1.36; P<0.01). Conclusions-Chronic OAC therapy is frequent among contemporary patients undergoing PCI. After adjustment for potential confounders. OAC-treated patients experienced greater in-hospital bleeding, more readmissions, and decreased long-term survival following PCI. Efforts are needed to reduce the occurrence of adverse events in this population. C1 [Secemsky, Eric A.; Wasfy, Jason H.; Shaw, Stanley Y.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA. [Kartoun, Uri; Shaw, Stanley Y.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Kartoun, Uri; Shaw, Stanley Y.] Massachusetts Gen Hosp, CATCH, Boston, MA 02114 USA. [Secemsky, Eric A.; Butala, Neel M.; Kartoun, Uri; Wasfy, Jason H.; Shaw, Stanley Y.; Yeh, Robert W.] Harvard Med Sch, Boston, MA USA. [Secemsky, Eric A.; Yeh, Robert W.] Beth Israel Deaconess Med Ctr, Dept Med, Smith Ctr Outcomes Res Cardiol, 375 Longwood Ave,4th Floor, Boston, MA 02215 USA. [Butala, Neel M.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Mahmood, Sadiqa] Partners HealthCare, Dept Qual Safety & Value, Boston, MA USA. [Kennedy, Kevin F.] St Lukes Midamer Heart Inst, Kansas City, MO USA. RP Yeh, RW (reprint author), Beth Israel Deaconess Med Ctr, Dept Med, Smith Ctr Outcomes Res Cardiol, 375 Longwood Ave,4th Floor, Boston, MA 02215 USA. EM ryeh@bidmc.harvard.edu FU Corrigan Minehan Heart Center at the Massachusetts General Hospital FX The work was funded, in part, by a SPARK Award from the Corrigan Minehan Heart Center at the Massachusetts General Hospital. NR 34 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2047-9980 J9 J AM HEART ASSOC JI J. Am. Heart Assoc. PD OCT PY 2016 VL 5 IS 10 AR e004310 DI 10.1161/JAHA.116.004310 PG 20 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EA6OM UT WOS:000386748500053 ER PT J AU Lazar, HL Salm, TV Engelman, R Orgill, D Gordon, S AF Lazar, Harold L. Salm, Thomas Vander Engelman, Richard Orgill, Dennis Gordon, Steven TI Prevention and management of sternal wound infections SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Review DE guidelines; prevention; sternal wound infection; treatment ID IODINE MEDIASTINAL IRRIGATION; SURGICAL-SITE INFECTIONS; VACUUM-ASSISTED CLOSURE; PRACTICE GUIDELINE SERIES; LONG-TERM SURVIVAL; STAPHYLOCOCCUS-AUREUS BACTEREMIA; GENTAMICIN-COLLAGEN SPONGE; TIGHT GLYCEMIC CONTROL; BYPASS GRAFT-SURGERY; OPEN-HEART-SURGERY C1 [Lazar, Harold L.] Boston Med Ctr, Div Cardiac Surg, 88 East Newton St,B402, Boston, MA 02118 USA. [Salm, Thomas Vander] Massachusetts Gen Hosp, Div Cardiac Surg, Boston, MA 02114 USA. [Engelman, Richard] Baystate Med Ctr, Div Cardiac Surg, Springfield, MA USA. [Orgill, Dennis] Brigham & Womens Hosp, Div Plast Surg, 75 Francis St, Boston, MA 02115 USA. [Gordon, Steven] Cleveland Clin, Div Infect Dis, Cleveland, OH 44106 USA. RP Lazar, HL (reprint author), Boston Med Ctr, Div Cardiac Surg, 88 East Newton St,B402, Boston, MA 02118 USA. EM harold.l.lazar@gmail.com NR 101 TC 1 Z9 1 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD OCT PY 2016 VL 152 IS 4 BP 962 EP 972 DI 10.1016/j.jtcvs.2016.01.060 PG 11 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA EA6OO UT WOS:000386748700018 PM 27555340 ER PT J AU Ahmed, MI Guichard, JL Rajasekaran, NS Ahmad, S Mariappan, N Litovsky, S Gupta, H Lloyd, SG Denney, TS Powell, PC Aban, I Collawn, JF Davies, JE McGiffin, DC Dell'Italia, LJ AF Ahmed, Mustafa I. Guichard, Jason L. Rajasekaran, Namakkal S. Ahmad, Shama Mariappan, Nithya Litovsky, Silvio Gupta, Himanshu Lloyd, Steven G. Denney, Thomas S. Powell, Pamela Cox Aban, Inmaculada Collawn, James F. Davies, James E. McGiffin, David C. Dell'Italia, Louis J. TI Disruption of desmin-mitochondrial architecture in patients with regurgitant mitral valves and preserved ventricular function SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article DE heart failure; mitochondria; cardiomyocyte; mitral regurgitation ID ALPHA-B-CRYSTALLIN; OXIDATIVE STRESS; IN-VIVO; INTERMEDIATE-FILAMENTS; EJECTION FRACTION; HEART-ASSOCIATION; CARDIOMYOPATHY; EXPRESSION; DYSFUNCTION; BLOCKADE AB Objective: Recent studies have demonstrated improved outcomes in patients receiving early surgery for degenerative mitral regurgitation ( MR) rather than adhering to conventional guidelines for surgical intervention. However, studies providing a mechanistic basis for these findings are limited. Methods: Left ventricular ( LV) myocardium from 22 patients undergoing mitral valve repair for American Heart Association class I indications was evaluated for desmin, the voltage-dependent anion channel, alpha-B-crystallin, and alpha, beta-unsaturated aldehyde 4-hydroxynonenal by fluorescence microscopy. The same was evaluated in 6 normal control LV autopsy specimens. Cardiomyocyte ultrastructure was examined by transmission electron microscopy. Magnetic resonance imaging with tissue tagging was performed in 55 normal subjects and 22 MR patients before and 6 months after mitral valve repair. Results: LV end-diastolic volume was 1.5-fold ( P<. 0001) higher and LV mass-to-volume ratio was lower in MR ( P =.004) hearts versus normal hearts and showed improvement 6 months after mitral valve surgery. However, LV ejection fraction decreased from 65% +/- 7% to 52% +/- 9% ( P<. 0001) and LV circumferential ( P<. 0001) and longitudinal strain decreased significantly below normal values ( P <.002) after surgery. Hearts with MR had a 53% decrease in desmin ( P<. 0001) and a 2.6-fold increase in desmin aggregates ( P<. 0001) versus normal, along with substantial, intense perinuclear staining of alpha, beta-unsaturated aldehyde 4-hydroxynonenal in areas of mitochondrial breakdown and clustering. Transmission electron microscopy demonstrated numerous electron-dense deposits, myofibrillar loss, Z-disc abnormalities, and extensive granulofilamentous debris identified as desmin-positive by immunogold transmission electron microscopy. Conclusions: Despite well-preserved preoperative LV ejection fraction, severe oxidative stress and disruption of cardiomyocyte desmin-mitochondrial sarcomeric architecture may explain postoperative LV functional decline and further supports the move toward earlier surgical intervention. C1 [Ahmed, Mustafa I.; Guichard, Jason L.; Gupta, Himanshu; Lloyd, Steven G.; Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA. [Rajasekaran, Namakkal S.; Litovsky, Silvio] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Ahmad, Shama; Mariappan, Nithya] Univ Alabama Birmingham, Dept Anesthesiol & Perioperat Med, Birmingham, AL USA. [Aban, Inmaculada] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA. [Collawn, James F.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL USA. [Davies, James E.] Univ Alabama Birmingham, Dept Surg, Div Thorac & Cardiovasc Surg, Birmingham, AL 35294 USA. [Gupta, Himanshu; Lloyd, Steven G.; Powell, Pamela Cox; Davies, James E.; Dell'Italia, Louis J.] Dept Vet Affairs Med Ctr, Birmingham, AL USA. [Denney, Thomas S.] Auburn Univ, MRI Res Ctr, Auburn, AL 36849 USA. RP Dell'Italia, LJ (reprint author), Birmingham VA Med Ctr, 700 S 19th St, Birmingham, AL 35233 USA. EM louis.dellitalia@va.gov FU National Heart, Lung, and Blood Institute; Specialized Centers of Clinically Oriented Research [P50HL077100]; Department of Veterans Affairs Merit Review Award [1CX000993-01]; National Institutes of Health [P01 HL051952]; National Heart, Lung, and Blood Institute [5-T32-HL-072757, R01HL118067] FX This work was supported by the National Heart, Lung, and Blood Institute and the Specialized Centers of Clinically Oriented Research (grant No. P50HL077100 to L.J.D.) in cardiac dysfunction; by a Department of Veterans Affairs Merit Review Award (grant No. 1CX000993-01 to L.J.D.); by National Institutes of Health grant No. P01 HL051952 (to L.J.D.); and National Heart, Lung, and Blood Institute Training Grant Nos. 5-T32-HL-072757 (to J.L.G) and R01HL118067 (to R.N.S.). NR 35 TC 1 Z9 1 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD OCT PY 2016 VL 152 IS 4 BP 1059 EP + DI 10.1016/j.jtcvs.2016.06.017 PG 14 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA EA6OO UT WOS:000386748700040 PM 27464577 ER PT J AU Whitton, JP Hancock, KE Shannon, JM Polley, DB AF Whitton, Jonathon P. Hancock, Kenneth E. Shannon, Jeffrey M. Polley, Daniel B. TI Validation of a Self-Administered Audiometry Application: An Equivalence Study SO LARYNGOSCOPE LA English DT Article DE Telehealth; mobile health; audiology; automation; diagnostics; audiometry; speech; auditory processing ID PURE-TONE AUDIOMETRY; HEARING-LOSS; IMPAIRED HEARING; SCREENING-TESTS; TELEPHONE; NOISE; INTERNET; VALIDITY; ADULTS AB Objectives/Hypothesis: To compare hearing measurements made at home using self-administered audiometric software against audiological tests performed on the same subjects in a clinical setting Study Design: Prospective, crossover equivalence study Methods: In experiment 1, adults with varying degrees of hearing loss (N = 19) performed air-conduction audiometry, frequency discrimination, and speech recognition in noise testing twice at home with an automated tablet application and twice in sound-treated clinical booths with an audiologist. The accuracy and reliability of computer-guided home hearing tests were compared to audiologist administered tests. In experiment 2, the reliability and accuracy of pure-tone audiometric results were examined in a separate cohort across a variety of clinical settings (N - 21). Results: Remote, automated audiograms were statistically equivalent to manual, clinic-based testing from 500 to 8,000 Hz (P <= 02); however, 250 Hz thresholds were elevated when collected at home. Remote and sound-treated booth testing of frequency discrimination and speech recognition thresholds were equivalent (P <= 5 x 10(-5)). In the second experiment, remote testing was equivalent to manual sound-booth testing from 500 to 8,000 Hz (P <= .02) for a different cohort who received clinic-based testing in a variety of settings. Conclusion: These data provide a proof of concept that several self-administered, automated hearing measurements are statistically equivalent to manual measurements made by an audiologist in the clinic. The demonstration of statistical equivalency for these basic behavioral hearing tests points toward the eventual feasibility of monitoring progressive or fluctuant hearing disorders outside of the clinic to increase the efficiency of clinical information collection. C1 [Whitton, Jonathon P.; Hancock, Kenneth E.; Polley, Daniel B.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA USA. [Hancock, Kenneth E.; Polley, Daniel B.] Harvard Med Sch, Dept Otol & Laryngol, Boston, MA USA. [Shannon, Jeffrey M.] Harvard MIT Div Hlth Sci & Technol, Program Speech Hearing Biosci & Technol, Cambridge, MA USA. [Shannon, Jeffrey M.] Hudson Valley Audiol Ctr, Pomona, NY USA. RP Whitton, JP (reprint author), Mass Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM Jonathon_Whitton@meei.harvard.edu FU Mass. Eye, and Ear Curing Kids Award; One Fund Boston research award FX Human research was supported by a Mass. Eye, and Ear Curing Kids Award and a One Fund Boston research award (D.B.P). The Bose Corporation donated the headphones that were used in this study and Microsoft Corporation donated the tablets. The authors have no other funding, financial relationships, or conflicts of interest to disclose. NR 47 TC 1 Z9 1 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0023-852X EI 1531-4995 J9 LARYNGOSCOPE JI Laryngoscope PD OCT PY 2016 VL 126 IS 10 BP 2382 EP 2388 DI 10.1002/lary.25988 PG 7 WC Medicine, Research & Experimental; Otorhinolaryngology SC Research & Experimental Medicine; Otorhinolaryngology GA EA8ZZ UT WOS:000386930800040 PM 27140227 ER PT J AU Cho, H Wivagg, CN Kapoor, M Barry, Z Rohs, PDA Suh, H Marto, JA Garner, EC Bernhardt, TG AF Cho, Hongbaek Wivagg, Carl N. Kapoor, Mrinal Barry, Zachary Rohs, Patricia D. A. Suh, Hyunsuk Marto, Jarrod A. Garner, Ethan C. Bernhardt, Thomas G. TI Bacterial cell wall biogenesis is mediated by SEDS and PBP polymerase families functioning semi-autonomously SO Nature Microbiology LA English DT Article ID PENICILLIN-BINDING PROTEINS; SINGLE-MOLECULE MICROSCOPY; BETA-LACTAM ANTIBIOTICS; ESCHERICHIA-COLI K-12; PEPTIDOGLYCAN SYNTHESIS; SYNTHESIS MACHINERY; STREPTOCOCCUS-PNEUMONIAE; BACILLUS-SUBTILIS; IMAGE-ANALYSIS; LIVE-CELL AB Multi-protein complexes organized by cytoskeletal proteins are essential for cell wall biogenesis in most bacteria. Current models of the wall assembly mechanism assume that class A penicillin-binding proteins (aPBPs), the targets of penicillinlike drugs, function as the primary cell wall polymerases within these machineries. Here, we use an in vivo cell wall polymerase assay in Escherichia coli combined with measurements of the localization dynamics of synthesis proteins to investigate this hypothesis. We find that aPBP activity is not necessary for glycan polymerization by the cell elongation machinery, as is commonly believed. Instead, our results indicate that cell wall synthesis is mediated by two distinct polymerase systems, shape, elongation, division, sporulation (SEDS)-family proteins working within the cytoskeletal machines and aPBP enzymes functioning outside these complexes. These findings thus necessitate a fundamental change in our conception of the cell wall assembly process in bacteria. C1 [Cho, Hongbaek; Rohs, Patricia D. A.; Bernhardt, Thomas G.] Harvard Med Sch, Dept Microbiol & Immunobiol, Boston, MA 02115 USA. [Wivagg, Carl N.; Kapoor, Mrinal; Barry, Zachary; Garner, Ethan C.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA. [Suh, Hyunsuk; Marto, Jarrod A.] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Marto, Jarrod A.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA. [Marto, Jarrod A.] Dana Farber Canc Inst, Blais Prote Ctr, Boston, MA 02215 USA. RP Bernhardt, TG (reprint author), Harvard Med Sch, Dept Microbiol & Immunobiol, Boston, MA 02115 USA.; Garner, EC (reprint author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA. EM egarner@g.harvard.edu; thomas_bernhardt@hms.harvard.edu OI Garner, Ethan/0000-0003-0141-3555; Wivagg, Carl/0000-0001-9617-7625 FU National Institutes of Health [R01AI083365, AI099144, CETR U19 AI109764, DP2AI117923]; Smith Family Award; Searle Scholar Fellowship; CHIR; Dana-Farber Strategic Research Initiative FX The authors thank all members of the Bernhardt, Rudner and Garner laboratories for advice and discussions. The authors thank P. de Boer and C. Hale for the gift of the mreB:: galK strain for constructing sandwich fusions and L. Lavis for his gift of JF dyes. This work was supported by the National Institutes of Health (R01AI083365 to T.G.B., AI099144 to T.G.B., CETR U19 AI109764 to T.G.B. and DP2AI117923 to E.C.G.). E.C.G. was also supported by a Smith Family Award and a Searle Scholar Fellowship. P.D.A.R. was supported in part by a pre-doctoral fellowship from CHIR. J.A.M. was supported by the Dana-Farber Strategic Research Initiative. NR 39 TC 6 Z9 6 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2058-5276 J9 NAT MICROBIOL JI NAT. MICROBIOL PD OCT PY 2016 VL 1 IS 10 AR 16172 DI 10.1038/NMICROBIOL.2016.172 PG 8 WC Microbiology SC Microbiology GA ED8RS UT WOS:000389139200017 ER PT J AU Ayus, JC Fuentes, NA Negri, AL Moritz, ML Giunta, DH Kalantar-Zadeh, K Nigwekar, SU Thadhani, RI Go, AS De Quiros, FGB AF Carlos Ayus, Juan Angelica Fuentes, Nora Luis Negri, Armando Moritz, Michael L. Hernan Giunta, Diego Kalantar-Zadeh, Kamyar Nigwekar, Sagar U. Thadhani, Ravi I. Go, Alan S. Gonzalez Bernaldo De Quiros, Fernan TI Mild prolonged chronic hyponatremia and risk of hip fracture in the elderly SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE bone; falls; hip fracture; hyponatremia; osteoporosis ID NONCARDIOGENIC PULMONARY-EDEMA; ORGANIC OSMOLYTES; MORTALITY; WOMEN; ENCEPHALOPATHY; OSTEOPOROSIS; POPULATION; ASSOCIATION; VASOPRESSIN AB Hip fractures are among the most serious bone fractures in the elderly, producing significant morbidity and mortality. Several observational studies have found that mild hyponatremia can adversely affect bone, with fractures occurring as a potential complication. We examined if there is an independent association between prolonged chronic hyponatremia (> 90 days duration) and risk of hip fracture in the elderly. We performed a retrospective cohort study in adults > 60 years of age from a prepaid health maintenance organization who had two or more measurements of plasma sodium between 2005 and 2012. The incidence of hip fractures was assessed in a very restrictive population: subjects with prolonged chronic hyponatremia, defined as plasma sodium values < 135 mmol/L, lasting > 90 days. Multivariable Cox regression was performed to determine the hazard ratio (HR) for hip fracture risk associated with prolonged chronic hyponatremia after adjustment for the propensity to have hyponatremia, fracture risk factors and relevant baseline characteristics. Among 31 527 eligible patients, only 228 (0.9%) had prolonged chronic hyponatremia. Mean plasma sodium was 132 +/- 5 mmol/L in hyponatremic patients and 139 +/- 3 mmol/L in normonatremic patients (P < 0.001). The absolute risk for hip fracture was 7/282 in patients with prolonged chronic hyponatremia and 411/313 299 in normonatremic patients. Hyponatremic patients had a substantially elevated rate of hip fracture [adjusted HR 4.52 (95% CI 2.14-9.6)], which was even higher in those with moderate hyponatremia (< 130 mmol/L) [adjusted HR 7.61 (95% CI 2.8-20.5)]. Mild prolonged chronic hyponatremia is independently associated with hip fracture risk in the elderly population, although the absolute risk is low. However, proof that correcting hyponatremia will result in a reduction of hip fractures is lacking. C1 [Carlos Ayus, Juan] Renal Consultants Houston, Houston, TX USA. [Carlos Ayus, Juan] Hosp Italiano Buenos Aires, Nephrol Sect, Buenos Aires, DF, Argentina. [Angelica Fuentes, Nora; Hernan Giunta, Diego; Gonzalez Bernaldo De Quiros, Fernan] Internal Med Hosp Italiano Buenos Aires, Internal Med Res Unit, Buenos Aires, DF, Argentina. [Luis Negri, Armando] Univ Salvador, Inst Invest Metab, Buenos Aires, DF, Argentina. [Moritz, Michael L.] Univ Pittsburgh, Sch Med, Dept Pediat, Div Nephrol,Childrens Hosp Pittsburgh UPMC, Pittsburgh, PA 15261 USA. [Kalantar-Zadeh, Kamyar] Univ Calif Irvine, Div Nephrol & Hypertens, Irvine, CA USA. [Kalantar-Zadeh, Kamyar; Go, Alan S.] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA. [Nigwekar, Sagar U.; Thadhani, Ravi I.] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA. [Go, Alan S.] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA. [Go, Alan S.] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA. [Go, Alan S.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Go, Alan S.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA. RP Ayus, JC (reprint author), Renal Consultants Houston, Houston, TX USA.; Ayus, JC (reprint author), Hosp Italiano Buenos Aires, Nephrol Sect, Buenos Aires, DF, Argentina. EM carlosayus@yahoo.com NR 34 TC 0 Z9 0 U1 1 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 EI 1460-2385 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD OCT PY 2016 VL 31 IS 10 BP 1662 EP 1669 DI 10.1093/ndt/gfw029 PG 8 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA DZ8YT UT WOS:000386159700022 PM 27190372 ER PT J AU Franceschini, N Deng, Y Flessner, MF Eckfeldt, JH Kramer, HJ Lash, JP Lee, DJ Melamed, ML Moncrieft, AE Ricardo, AC Rosas, SE Kaplan, RC Raij, L Cai, JW AF Franceschini, Nora Deng, Yu Flessner, Michael F. Eckfeldt, John H. Kramer, Holly J. Lash, James P. Lee, David J. Melamed, Michal L. Moncrieft, Ashley E. Ricardo, Ana C. Rosas, Sylvia E. Kaplan, Robert C. Raij, Leopoldo Cai, Jianwen TI Smoking patterns and chronic kidney disease in US Hispanics: Hispanic Community Health Study/Study of Latinos SO NEPHROLOGY DIALYSIS TRANSPLANTATION LA English DT Article DE chronic kidney disease; Hispanics; Latinos; intermittent smoking ID GLOMERULAR-FILTRATION-RATE; CIGARETTE-SMOKING; RISK-FACTOR; TOBACCO USE; COLLABORATIVE METAANALYSIS; POPULATION COHORTS; HIGHER ALBUMINURIA; SUPEROXIDE ANION; UNITED-STATES; PROGRESSION AB Intermittent smoking is prevalent among Hispanics, but little is known about whether this smoking pattern associates with increased chronic kidney disease (CKD) risk in this population. The objective of the present study is to identify patterns of exposure associated with CKD in US Hispanics. We used cross-sectional data on 15 410 participants of the Hispanics Community Health Study/the Study of Latinos, a population-based study of individuals aged 18-74 years, recruited in 2008 to 2011 from four US field centers (Bronx, NY; Chicago, IL; Miami, FL; San Diego, CA). Smoking exposure was obtained through a questionnaire. CKD was defined by an estimated glomerular filtration rate of < 60 mL/min/1.73 m(2) or a urine albumin-to-creatinine ratio of a parts per thousand yen30 mg/g. Approximately 14% of individuals were daily and 7% were intermittent smokers, and 16% were past smokers. There was a significant interaction between smoking status and pack-years of exposure (P = 0.0003). In adjusted models, there was an increased odds of CKD among daily, intermittent and past smokers by pack-years compared with never smokers. The association of intermittent smokers was significant at 10 pack-years [odds ratio (OR) = 1.38, 95% confidence intervals (CI) 1.06, 1.81], whereas for daily smokers this association was observed at 40 pack-years (OR = 1.43, 95% CI 1.09, 1.89). Our findings of increased risk of CKD among Hispanics who are intermittent smokers support screening and smoking cessation interventions targeted to this population for the prevention of CKD. It also suggests novel mechanistic pathways for kidney toxicity that should be further explored in future studies. C1 [Franceschini, Nora] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27514 USA. [Deng, Yu; Cai, Jianwen] Univ North Carolina Chapel Hill, Dept Biostat, Collaborat Studies Coordinating Ctr, Chapel Hill, NC USA. [Flessner, Michael F.] NIDDK, Bethesda, MD USA. [Eckfeldt, John H.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA. [Kramer, Holly J.] Loyola Univ, Div Nephrol, Maywood, IL 60153 USA. [Lash, James P.; Ricardo, Ana C.] Univ Illinois, Dept Med, Chicago, IL USA. [Lee, David J.; Moncrieft, Ashley E.; Raij, Leopoldo] Univ Miami, Miami, FL USA. [Melamed, Michal L.; Kaplan, Robert C.] Albert Einstein Coll Med, New York, NY USA. [Rosas, Sylvia E.] Harvard Univ, Joslin Diabet Ctr, Boston, MA 02115 USA. RP Franceschini, N (reprint author), Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27514 USA. EM noraf@unc.edu FU National Heart, Lung, and Blood Institute (NHLBI) [N01-HC65233]; University of Miami [N01-HC65234]; Albert Einstein College of Medicine [N01-HC65235]; Northwestern University [N01-HC65236]; San Diego State University [N01-HC65237]; National Institute of Diabetes and Digestive and Kidney Diseases [K23 DK094829, K24 DK092290]; National Institutes of Health [R21HL123677-01] FX The HCHS/SOL was carried out as a collaborative study supported by contracts from the National Heart, Lung, and Blood Institute (NHLBI) to the University of North Carolina (N01-HC65233), University of Miami (N01-HC65234), Albert Einstein College of Medicine (N01-HC65235), Northwestern University (N01-HC65236) and San Diego State University (N01-HC65237). The following institutes, centers or offices contribute to the HCHS/SOL through a transfer of funds to the NHLBI: National Center on Minority Health and Health Disparities, the National Institute on Deafness and Other Communications Disorders, the National Institute of Dental and Craniofacial Research, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Neurological Disorders and Stroke, and the Office of Dietary Supplements. A.C.R. and J.P.L. are funded by the National Institute of Diabetes and Digestive and Kidney Diseases (K23 DK094829, A.C.R.; K24 DK092290, J.P.L.). N.F. and J.C. had full access to the data and take responsibility for the integrity of the data and the accuracy of the data analysis. N.F. is supported by the National Institutes of Health grant R21HL123677-01. NR 45 TC 1 Z9 1 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0931-0509 EI 1460-2385 J9 NEPHROL DIAL TRANSPL JI Nephrol. Dial. Transplant. PD OCT PY 2016 VL 31 IS 10 BP 1670 EP 1676 DI 10.1093/ndt/gfw210 PG 7 WC Transplantation; Urology & Nephrology SC Transplantation; Urology & Nephrology GA DZ8YT UT WOS:000386159700023 PM 27257272 ER PT J AU Ciolino, JB Ross, AE Tulsan, R Watts, AC Wang, RF Zurakowski, D Serle, JB Kohane, DS AF Ciolino, Joseph B. Ross, Amy E. Tulsan, Rehka Watts, Amy C. Wang, Rong-Fang Zurakowski, David Serle, Janet B. Kohane, Daniel S. TI Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys SO OPHTHALMOLOGY LA English DT Article ID INTRAOCULAR-PRESSURE; MEDICATION ADHERENCE; CYNOMOLGUS MONKEY; DRUG-DELIVERY; DOSE REGIMENS; EYE; INSTILLATION; XALATAN; VISION; PHXA41 AB Purpose: To assess the ability of latanoprost-eluting contact lenses to lower the intraocular pressure (IOP) of glaucomatous eyes of cynomolgus monkeys. Design: Preclinical efficacy study of 3 treatment arms in a crossover design. Participants: Female cynomolgus monkeys with glaucoma induced in 1 eye by repeated argon laser trabeculoplasty. Methods: Latanoprost-eluting low-dose contact lenses (CLLO) and high-dose contact lenses (CLHI) were produced by encapsulating a thin latanoprost-polymer film within the periphery of a methafilcon hydrogel, which was lathed into a contact lens. We assessed the IOP-lowering effect of CLLO, CLHI, or daily latanoprost ophthalmic solution in the same monkeys. Each monkey consecutively received 1 week of continuous-wear CLLO, 3 weeks without treatment, 5 days of latanoprost drops, 3 weeks without treatment, and 1 week of continuous-wear CLHI. On 2 consecutive days before initiation of each study arm, the IOP was measured hourly over 7 consecutive hours to establish the baseline IOP. Two-tailed Student t tests and repeated-measures analysis of variance were used for statistical analysis. Main Outcome Measures: Intraocular pressure. Results: Latanoprost ophthalmic solution resulted in IOP reduction of 5.4 +/- 1.0 mmHg on day 3 and peak IOP reduction of 6.6 +/- 1.3 mmHg on day 5. The CLLO reduced IOP by 6.3 +/- 1.0, 6.7 +/- 0.3, and 6.7 +/- 0.3 mmHg on days 3, 5, and 8, respectively. The CLHI lowered IOP by 10.5 +/- 1.4, 11.1 +/- 4.0, and 10.0 +/- 2.5 mmHg on days 3, 5, and 8, respectively. For the CLLO and CLHI, the IOP was statistically significantly reduced compared with the untreated baseline at most time points measured. The CLHI demonstrated greater IOP reduction than latanoprost ophthalmic solution on day 3 (P = 0.001) and day 5 (P = 0.015), and at several time points on day 8 (P < 0.05). Conclusions: Sustained delivery of latanoprost by contact lenses is at least as effective as delivery with daily latanoprost ophthalmic solution. More research is needed to determine the optimal continuous-release dose that would be well tolerated and maximally effective. Contact lens drug delivery may become an option for the treatment of glaucoma and a platform for ocular drug delivery. (C) 2016 by the American Academy of Ophthalmology. C1 [Ciolino, Joseph B.; Ross, Amy E.; Tulsan, Rehka; Watts, Amy C.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA USA. [Ciolino, Joseph B.; Ross, Amy E.; Tulsan, Rehka] Harvard Med Sch, Lab Biomat & Drug Delivery, Dept Anesthesiol, Div Crit Care Med,Boston Childrens Hosp, Boston, MA USA. [Ciolino, Joseph B.; Ross, Amy E.; Tulsan, Rehka; Zurakowski, David; Kohane, Daniel S.] Harvard Med Sch, Boston Childrens Hosp, Dept Anesthesia, Boston, MA USA. [Ciolino, Joseph B.; Ross, Amy E.; Tulsan, Rehka; Kohane, Daniel S.] Harvard Med Sch, Boston Childrens Hosp, Dept Surg, Boston, MA USA. [Wang, Rong-Fang; Serle, Janet B.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. RP Ciolino, JB (reprint author), Massachusetts Eye & Ear Infirm, Dept Ophthalmol, 325 Charles St, Boston, MA 02114 USA.; Kohane, DS (reprint author), Boston Childrens Hosp, Dept Anesthesiol, 300 Longwood Ave, Boston, MA 02115 USA. EM Joseph_Ciolino@meei.harvard.edu; daniel.kohane@childrens.harvard.edu FU National Eye Institute [1K08EY019686-01]; Boston Children's Hospital; Research to Prevent Blindness, Inc., New York, New York FX Funded by the National Eye Institute 1K08EY019686-01 (J.B.C.), Technology Development Grant from Boston Children's Hospital (J.B.C., D.S.K.), and a Career Development Award from Research to Prevent Blindness, Inc., New York, New York (J.B.C.). Supported in part by an unrestricted grant from Research to Prevent Blindness Inc., New York, New York (J.B.S.). This study was made possible by funding from a Technology Development Grant from Boston Children's Hospital. NR 26 TC 1 Z9 1 U1 7 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 EI 1549-4713 J9 OPHTHALMOLOGY JI Ophthalmology PD OCT PY 2016 VL 123 IS 10 BP 2085 EP 2092 DI 10.1016/j.ophtha.2016.06.038 PG 8 WC Ophthalmology SC Ophthalmology GA EE3QI UT WOS:000389509100007 PM 27586444 ER PT J AU Sarraf, D London, NJS Khurana, RN Dugel, PU Gune, S Hill, L Tuomi, L AF Sarraf, David London, Nikolas J. S. Khurana, Rahul N. Dugel, Pravin U. Gune, Shamika Hill, Lauren Tuomi, Lisa TI Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration Post Hoc Analysis of the HARBOR Study SO OPHTHALMOLOGY LA English DT Article; Proceedings Paper CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology CY MAY, 2016 CL Seattle, WA SP Assoc Res Vis & Ophthalmol ID OPTICAL COHERENCE TOMOGRAPHY; OCCULT CHOROIDAL NEOVASCULARIZATION; 2.0 MG RANIBIZUMAB; VISUAL-ACUITY; AFLIBERCEPT; THERAPY; MORPHOLOGY; EYES; VERTEPORFIN; RELEVANT AB Purpose: To analyze the effect of baseline presence and height of pigment epithelial detachments (PEDs) on visual and anatomic outcomes at 24 months in patients with neovascular age-related macular degeneration (AMD) treated with ranibizumab. Design: Post hoc analysis of HARBOR, a 24-month, phase III, randomized, multicenter, double-masked, active treatment-controlled study (clinicaltrials. gov identifier, NCT00891735). Participants: One thousand ninety-seven patients with neovascular AMD. Methods: Intravitreal ranibizumab 0.5 mg or 2.0 mg monthly or pro re nata (PRN) after 3 monthly loading doses. Main Outcome Measures: We evaluated the effect of presence and height of baseline PED on several outcomes at 24 months, including best-corrected visual acuity (BCVA), change in PED height, resolution of PED, and number of injections in the PRN arms. Development of macular atrophy at month 24 by presence or absence of PED was evaluated. Results: Five hundred ninety-eight (54.5%) patients showed PED at baseline. In the ranibizumab 0.5-mg PRN group, mean numbers of injections were similar for patients with PED present or absent at baseline (14.0 vs. 12.5). Mean BCVA gains from baseline to 24 months were seen in all treatment groups and were comparable in patients with or without PED at baseline treated with ranibizumab 0.5 mg monthly (PED present at baseline, +9.0 letters; PED absent at baseline, +11.3 letters), 0.5 mg PRN (present, +8.4; absent, +7.9), 2.0 mg monthly (present, +7.1; absent, +11.1), or 2.0 mg PRN (present, +7.2; absent, +8.8). When analyzed by baseline PED height, mean BCVA gains were demonstrated and comparable in all treatment groups at 24 months except for patients treated with ranibizumab 2.0 mg monthly in the extra-large group (PEDs >= 352 mu m; mean BCVA change, -0.8 letters). At 24 months, 53.2% (0.5 mg monthly), 44.5% (0.5 mg PRN), 70.4% (2.0 mg monthly), and 57.3% (2.0 mg PRN) of patients showed complete resolution of PED. Conclusions: Ranibizumab 0.5 mg given monthly or PRN effectively treated PEDs in patients with neovascular AMD, and significant vision gains resulted regardless of PED status and height at baseline. In this analysis, there was no additional vision benefit with a higher dose of ranibizumab (2.0 mg). (C) 2016 by the American Academy of Ophthalmology. C1 [Sarraf, David] Univ Calif Los Angeles, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [London, Nikolas J. S.] Retina Consultants San Diego, Poway, CA USA. [Khurana, Rahul N.] Northern Calif Retina Vitreous Associates, Mountain View, CA USA. [Khurana, Rahul N.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA. [Dugel, Pravin U.] Retinal Consultants Arizona, Retinal Res Inst, Phoenix, AZ USA. [Dugel, Pravin U.] Univ Southern Calif, Keck Sch Med, USC Roski Eye Inst, Los Angeles, CA USA. [Gune, Shamika; Hill, Lauren; Tuomi, Lisa] Genentech Inc, San Francisco, CA 94080 USA. RP Sarraf, D (reprint author), Univ Calif Los Angeles, Stein Eye Inst, 200 Stein Plaza, Los Angeles, CA 90095 USA. EM dsarraf@ucla.com NR 36 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 EI 1549-4713 J9 OPHTHALMOLOGY JI Ophthalmology PD OCT PY 2016 VL 123 IS 10 BP 2213 EP 2224 DI 10.1016/j.ophtha.2016.07.007 PG 12 WC Ophthalmology SC Ophthalmology GA EE3QI UT WOS:000389509100020 PM 27566855 ER PT J AU da Cruz, L Dorn, JD Humayun, MS Dagnelie, G Handa, J Barale, PO Sahel, JA Stanga, PE Hafezi, F Safran, AB Salzmann, J Santos, A Birch, D Spencer, R Cideciyan, AV de Juan, E Duncan, JL Eliott, D Fawzi, A de Koo, LCO Ho, AC Brown, G Haller, J Regillo, C Del Priore, LV Arditi, A Greenberg, RJ AF da Cruz, Lyndon Dorn, Jessy D. Humayun, Mark S. Dagnelie, Gislin Handa, James Barale, Pierre-Olivier Sahel, Jose-Alain Stanga, Paulo E. Hafezi, Farhad Safran, Avinoam B. Salzmann, Joel Santos, Arturo Birch, David Spencer, Rand Cideciyan, Artur V. de Juan, Eugene Duncan, Jacque L. Eliott, Dean Fawzi, Amani de Koo, Lisa C. Olmos Ho, Allen C. Brown, Gary Haller, Julia Regillo, Carl Del Priore, Lucian V. Arditi, Aries Greenberg, Robert J. CA Argus II Study Grp TI Five-Year Safety and Performance Results from the Argus II Retinal Prosthesis System Clinical Trial SO OPHTHALMOLOGY LA English DT Article ID BLIND SUBJECTS AB Purpose: The Argus II Retinal Prosthesis System (Second Sight Medical Products, Inc, Sylmar, CA) was developed to restore some vision to patients blind as a result of retinitis pigmentosa (RP) or outer retinal degeneration. A clinical trial was initiated in 2006 to study the long-term safety and efficacy of the Argus II System in patients with bare or no light perception resulting from end-stage RP. Design: Prospective, multicenter, single-arm clinical trial. Within-patient controls included the non-implanted fellow eye and patients' native residual vision compared with their vision with the Argus II. Participants: Thirty participants in 10 centers in the United States and Europe. Methods: The worse-seeing eye of blind patients was implanted with the Argus II. Patients wore glasses mounted with a small camera and a video processor that converted images into stimulation patterns sent to the electrode array on the retina. Main Outcome Measures: The primary outcome measures were safety (the number, seriousness, and relatedness of adverse events) and visual function, as measured by 3 computer-based, objective tests. Secondary measures included functional vision performance on objectively scored real-world tasks. Results: Twenty-four of 30 patients remained implanted with functioning Argus II Systems at 5 years after implantation. Only 1 additional serious adverse event was experienced after the 3-year time point. Patients performed significantly better with the Argus II on than off on all visual function tests and functional vision tasks. Conclusions: The 5-year results of the Argus II trial support the long-term safety profile and benefit of the Argus II System for patients blind as a result of RP. The Argus II is the first and only retinal implant to have market approval in the European Economic Area, the United States, and Canada. (C) 2016 by the American Academy of Ophthalmology. C1 [da Cruz, Lyndon] NHS Fdn Trust, Moorfields Eye Hosp, NIHR Moorfields Biomed Res Ctr, Dept Vitreoretinal Surg, London, England. [da Cruz, Lyndon] UCL, Dept Brain Sci, London WC1E 6BT, England. [Dorn, Jessy D.; Greenberg, Robert J.] Second Sight Med Prod Inc, Sylmar, CA USA. [Humayun, Mark S.; Hafezi, Farhad; Eliott, Dean; Fawzi, Amani; de Koo, Lisa C. Olmos] Univ Southern Calif, Los Angeles, CA USA. [Dagnelie, Gislin; Handa, James; Haller, Julia] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA. [Barale, Pierre-Olivier; Sahel, Jose-Alain] Ctr Hosp Natl Ophtalmol Quinze Vingts, Paris, France. [Sahel, Jose-Alain; Safran, Avinoam B.] UPMC Paris 06, Sorbonne Univ, Paris, France. [Sahel, Jose-Alain; Safran, Avinoam B.] Inst Vis, Paris, France. [Sahel, Jose-Alain] Rothschild Ophthalmol Fdn, Paris, France. [Hafezi, Farhad] ELZA Inst, Zurich, Switzerland. [Stanga, Paulo E.] Univ Manchester, Manchester Royal Eye Hosp, Manchester Vis Regenerat MVR Lab, NIHR,Wellcome Trust Manchester CRF, Manchester, Lancs, England. [Stanga, Paulo E.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England. [Stanga, Paulo E.] Univ Manchester, Ctr Ophthalmol & Vis Res, Inst Human Dev, Manchester, Lancs, England. [Hafezi, Farhad; Safran, Avinoam B.; Salzmann, Joel] Hop Univ Geneve, Geneva, Switzerland. [Santos, Arturo] Ctr Retina Med & Quirurg SC, Guadalajara, Jalisco, Mexico. [Santos, Arturo] Tecnol Monterrey, Guadalajara, Jalisco, Mexico. [Birch, David] Retina Fdn Southwest, Dallas, TX USA. [Spencer, Rand] Texas Retina Associates, Dallas, TX USA. [Cideciyan, Artur V.] Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA. [de Juan, Eugene; Duncan, Jacque L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Eliott, Dean] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Boston, MA USA. [Fawzi, Amani] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Ho, Allen C.; Brown, Gary; Haller, Julia; Regillo, Carl] Wills Eye Hosp & Res Inst, Philadelphia, PA USA. [Del Priore, Lucian V.] Columbia Univ, New York, NY USA. [Del Priore, Lucian V.] Storm Eye Inst, 171 Ashley Ave, Charleston, SC 29425 USA. [Arditi, Aries] Lighthouse Guild, New York, NY USA. [Arditi, Aries] Visibil Metr LLC, Chappaqua, NY USA. RP Dorn, JD (reprint author), Second Sight Med Prod, Clin & Sci Res, 12744 San Fernando Rd, Sylmar, CA 91342 USA. EM jdorn@secondsight.com RI Sahel, Jose-Alain/F-3172-2017; OI Dagnelie, Gislin/0000-0001-6707-9735 FU National Institutes of Health, Bethesda, Maryland [5R01EY012893, 07, 1RC3EY020778]; Second Sight Medical Products, Inc., Sylmar, California FX Supported by the National Institutes of Health, Bethesda, Maryland ( grant nos.: 5R01EY012893 [R.J.G., principal investigator], 07, and 1RC3EY020778 [R.J.G., principal investigator]). The clinical trial was sponsored by Second Sight Medical Products, Inc., Sylmar, California. The sponsor participated in the design and conduct of the study; data management, analysis, and interpretation; and preparation and review of the manuscript. NR 11 TC 4 Z9 4 U1 9 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 EI 1549-4713 J9 OPHTHALMOLOGY JI Ophthalmology PD OCT PY 2016 VL 123 IS 10 BP 2248 EP 2254 DI 10.1016/j.ophtha.2016.06.049 PG 7 WC Ophthalmology SC Ophthalmology GA EE3QI UT WOS:000389509100023 PM 27453256 ER PT J AU Campochiaro, PA Aiello, LP Rosenfeld, PJ AF Campochiaro, Peter A. Aiello, Lloyd Paul Rosenfeld, Philip J. TI Antie-Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease From Bench to Bedside SO OPHTHALMOLOGY LA English DT Article ID DIABETIC MACULAR EDEMA; INTRAVITREAL AFLIBERCEPT INJECTION; OCCLUSION 12-MONTH OUTCOMES; BEVACIZUMAB AVASTIN THERAPY; LONG-TERM OUTCOMES; 2.0 MG RANIBIZUMAB; VEGF TRAP-EYE; VEIN OCCLUSION; CHOROIDAL NEOVASCULARIZATION; PERMEABILITY FACTOR AB The association of retinal hypoxia with retinal neovascularization has been recognized for decades, causing Michaelson to postulate in 1948 that a factor secreted by hypoxic retina was involved. The isolation of vascular endothelial growth factor (VEGF), characterization of its angiogenic activity, and demonstration that its expression was increased in hypoxic tissue made it a prime candidate. Intraocular levels of VEGF are elevated in patients with retinal or iris neovascularization, and VEGF-specific antagonists markedly suppress retinal neovascularization in mice and primates with ischemic retinopathy. Vascular endothelial growth factor antagonists also suppress choroidal neovascularization, and transgenic expression of VEGF in the retina of mice causes subretinal neovascularization. Clinical trials using a VEGF antagonist that blocks all isoforms of VEGF-A in patients with neovascular age-related macular degeneration (nAMD) demonstrated dramatic benefit. Similar results have been obtained with 2 other VEGF antagonists. Retinal hypoxia also contributes to diabetic macular edema (DME), and because of the absence of good animal models, small clinical trials were used to test the role of VEGF. The results clearly implicated VEGF as a major contributor to DME and have been confirmed by several large multicenter trials. A similar strategy demonstrated that VEGF is a major contributor to macular edema resulting from retinal vein occlusion, also confirmed in multicenter trials. Secondary outcomes in these large clinical trials have shown that VEGF inhibition improves retinal hemorrhages, retinal vessel closure, and progression of nonproliferative diabetic retinopathy. Anti-VEGF agents also provide therapeutic benefits in proliferative diabetic retinopathy. Thus, the development of VEGF antagonists has revolutionized the treatment of nAMD, diabetic retinopathy, and other ischemic retinopathies, but in many patients, the upregulation of VEGF is prolonged. Although the molecular signaling by which hypoxia and some other insults lead to upregulation of VEGF has been elucidated, it has not yet led to a treatment that reliably reduces the production of VEGF, necessitating continued neutralization by repeated intraocular injections of VEGF antagonists in many patients. The next horizon in the evolution of anti-VEGF therapy is the development of longer-acting agents or delivery platforms that provide sustained neutralization with fewer injections. (C) 2016 by the American Academy of Ophthalmology. C1 [Campochiaro, Peter A.] Johns Hopkins Univ, Wilmer Eye Inst, Sch Med, Baltimore, MD 21218 USA. [Aiello, Lloyd Paul] Harvard Med Sch, Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA USA. [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA. RP Campochiaro, PA (reprint author), Johns Hopkins Univ, Wilmer Eye Inst, 600 North Wolfe St,Maunenee 815, Baltimore, MD 21287 USA. EM pcampo@jhmi.edu FU AbbVie (North Chicago, IL); Allergan (Irvine, CA); Genentech/Roche; Genzyme (Cambridge, MA); GlaxoSmithKline (Philadelphia, PA); Oxford Biomedica (Oxford, UK); Regeneron; RegenX; Rxi Pharmaceuticals; Kalvista (Southampton, UK); Genentech; Merck; Apellis (Crestwood, KY); Carl Zeiss Meditec (Dublin, CA); Genentech/Roche GlaxoSmithKline; Neurotech (Cumberland, RI); Ocata Therapeutics; Acucela FX The author(s) have made the following disclosure(s): P.A.C.: Consultant - Alimera (Alpharetta, GA); Applied Genetic Technologies (Gainesville, FL); Eleven Biotherapeutics (Cambridge, MA); AsclipiX (Baltimore, MD); Genentech/Roche (South San Francisco, CA); Kala Pharmaceuticals (Waltham, MA); Rxi Pharmaceuticals (Marlborough, MA); Aerpio (Cincinnati, OH); Regeneron (Tarrytown, NY); Allegro (San Juan Capistrano, CA); Intrexon (Germantown, MD); RegenX (Rockville, MD); Merck (Kenilworth, NJ); Financial support - AbbVie (North Chicago, IL); Allergan (Irvine, CA); Genentech/Roche; Genzyme (Cambridge, MA); GlaxoSmithKline (Philadelphia, PA); Oxford Biomedica (Oxford, UK); Regeneron; RegenX; Rxi Pharmaceuticals; Royalties - Graybug (Baltimore, MD); Equity owner - Alimera; Allegro; Graybug; L.P.A.: Financial support - Kalvista (Southampton, UK); Genentech; Merck; Patents - 8,841,259 (Compositions and Methods for Treating Vascular Permeability); 8,658,685 (Methods for Treatment of Kallikrein-Related Disorders); 6,114,320 (Therapeutic Treatment for VEGF-Related Ocular Diseases); P.J.R.: Consultant - Achillion Pharmaceuticals (New Haven, CT); Acucela (Seattle, WA); Alcon (Fort Worth, TX); Boehringer-Ingelheim (Ridgefield, CT); Cell Cure Neurosciences (Jerusalem, Israel); Chengdu Kanghong Biotech (Chengdu, China); CoDa Therapeutics (San Diego, CA); Genentech/Roche Healios (Brewster, MA); MacRegen Inc. (Seoul, South Korea); NGM Biopharmaceuticals (South San Francisco, CA); Ocata Therapeutics (Marlborough, MA); Ocudyne (Plano, TX); Regeneron, Stealth BioTherapeutics (Newton, MA); Tyrogenex (Needham Heights, MA); Vision Medicine (Cambridge, MA); Financial support - Acucela, Apellis (Crestwood, KY); Carl Zeiss Meditec (Dublin, CA); Genentech/Roche GlaxoSmithKline; Neurotech (Cumberland, RI); Ocata Therapeutics, Tyrogenex Equity owner - Apellis, Digisight (Portola Valley, CA). NR 93 TC 2 Z9 2 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0161-6420 EI 1549-4713 J9 OPHTHALMOLOGY JI Ophthalmology PD OCT PY 2016 VL 123 IS 10 SU S BP S78 EP S88 DI 10.1016/j.ophtha.2016.04.056 PG 11 WC Ophthalmology SC Ophthalmology GA EE3QJ UT WOS:000389509400004 ER PT J AU Dobalian, A Stein, JA Radcliff, TA Riopelle, D Brewster, P Hagigi, F Der-Martirosian, C AF Dobalian, Aram Stein, Judith A. Radcliff, Tiffany A. Riopelle, Deborah Brewster, Pete Hagigi, Farhad Der-Martirosian, Claudia TI Developing Valid Measures of Emergency Management Capabilities within US Department of Veterans Affairs Hospitals SO PREHOSPITAL AND DISASTER MEDICINE LA English DT Article DE disasters; emergency preparedness; hospitals; quality improvement; United States Department of Veterans Affairs ID SURGE CAPACITY; DISASTER PREPAREDNESS; MASS CASUALTY; CARE; PERFORMANCE; MODEL AB Introduction Hospitals play a critical role in providing health care in the aftermath of disasters and emergencies. Nonetheless, while multiple tools exist to assess hospital disaster preparedness, existing instruments have not been tested adequately for validity. Hypothesis/Problem This study reports on the development of a preparedness assessment tool for hospitals that are part of the US Department of Veterans Affairs (VA; Washington, DC USA). Methods The authors evaluated hospital preparedness in six Mission Areas (MAs: Program Management; Incident Management; Safety and Security; Resiliency and Continuity; Medical Surge; and Support to External Requirements), each composed of various observable hospital preparedness capabilities, among 140 VA Medical Centers (VAMCs). This paper reports on two successive assessments (Phase I and Phase II) to assess the MAs' construct validity, or the degree to which component capabilities relate to one another to represent the associated domain successfully. This report describes a two-stage confirmatory factor analysis (CFA) of candidate items for a comprehensive survey implemented to assess emergency preparedness in a hospital setting. Results The individual CFAs by MA received acceptable fit statistics with some exceptions. Some individual items did not have adequate factor loadings within their hypothesized factor (or MA) and were dropped from the analyses in order to obtain acceptable fit statistics. The Phase II modified tool was better able to assess the pre-determined MAs. For each MA, except for Resiliency and Continuity (MA 4), the CFA confirmed one latent variable. In Phase I, two sub-scales (seven and nine items in each respective sub-scale) and in Phase II, three sub-scales (eight, four, and eight items in each respective sub-scale) were confirmed for MA 4. The MA 4 capabilities comprise multiple sub-domains, and future assessment protocols should consider re-classifying MA 4 into three distinct MAs. Conclusion The assessments provide a comprehensive and consistent, but flexible, approach for ascertaining health system preparedness. This approach can provide an organization with a clear understanding of areas for improvement and could be adapted into a standard for hospital readiness. C1 [Dobalian, Aram; Stein, Judith A.; Radcliff, Tiffany A.; Riopelle, Deborah; Hagigi, Farhad; Der-Martirosian, Claudia] US Dept Vet Affairs, Vet Emergency Management Evaluat Ctr, North Hills, CA USA. [Dobalian, Aram] Univ Calif Los Angeles, Dept Hlth Policy & Management, Fielding Sch Publ Hlth, Los Angeles, CA USA. [Dobalian, Aram] Univ Calif Los Angeles, Sch Nursing, Los Angeles, CA 90024 USA. [Dobalian, Aram; Riopelle, Deborah] US Dept Vet Affairs, Ctr Study Healthcare Innovat Implementat & Policy, North Hills, CA USA. [Radcliff, Tiffany A.] Texas A&M Univ, Dept Hlth Policy & Management, Sch Publ Hlth, College Stn, TX USA. [Brewster, Pete] US Dept Vet Affairs, Off Emergency Management, Vet Hlth Adm, Martinsburg, WV USA. [Hagigi, Farhad] Univ Calif Los Angeles, Dept Family Med, Geffen Sch Med, Los Angeles, CA USA. RP Dobalian, A (reprint author), VEMEC, 16111 Plummer St MS-152, North Hills, CA 91343 USA. EM aram.dobalian@va.gov NR 31 TC 2 Z9 2 U1 1 U2 1 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1049-023X EI 1945-1938 J9 PREHOSPITAL DISASTER JI Prehospital Disaster Med. PD OCT PY 2016 VL 31 IS 5 BP 475 EP 484 DI 10.1017/S1049023X16000625 PG 10 WC Emergency Medicine SC Emergency Medicine GA DZ2IR UT WOS:000385666000004 PM 27492572 ER PT J AU Blonigen, DM Bui, L Britt, JY Thomas, KM Timko, C AF Blonigen, Daniel M. Bui, Leena Britt, Jessica Y. Thomas, Katherine M. Timko, Christine TI Internalizing and Externalizing Personality Subtypes Predict Differences in Functioning and Outcomes Among Veterans in Residential Substance Use Disorder Treatment SO PSYCHOLOGICAL ASSESSMENT LA English DT Article DE substance use disorders; residential treatment; subtypes; internalizing; externalizing ID POSTTRAUMATIC-STRESS-DISORDER; SELF-EFFICACY; MILITARY VETERANS; MENTAL-DISORDERS; ALCOHOL-PROBLEMS; ABUSE TREATMENT; MODEL; VALIDATION; PTSD; QUESTIONNAIRE AB There is a long history of using personality to subtype patients in treatment for substance use disorders (SUD). However, no one has validated a typology of SUD patients using a structural model of normal-range personality, particularly indicating whether subtypes differ on treatment processes and outcomes. We developed a personality-based typology among 196 military veterans enrolled in residential SUD treatment at a Veterans Affairs medical center. Patients were assessed at treatment entry, 1 month into treatment, and at discharge from treatment. Personality was assessed using the Multidimensional Personality Questionnaire-Brief Form at treatment entry. Latent profile analyses identified a 3-group solution consisting of low pathology, internalizing, and externalizing groups. The internalizing group scored lowest on measures of functioning at treatment entry, whereas the externalizing group scored more poorly on treatment processes and outcomes over the course of their residential stay (e. g., more stressful relationships with other residents, lower program alliance). These findings support a clinically meaningful typology of SUD patients based on a 3-factor model of personality and can serve as a guide for future efforts aimed at developing targeted interventions that can address the individual differences of patients in this population. C1 [Blonigen, Daniel M.; Bui, Leena; Timko, Christine] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Britt, Jessica Y.] Palo Alto Univ, Palo Alto, CA USA. [Thomas, Katherine M.] San Francisco VA Med Ctr, San Francisco, CA USA. [Timko, Christine] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Thomas, Katherine M.] Purdue Univ, Dept Psychol, W Lafayette, IN 47907 USA. RP Blonigen, DM (reprint author), Vet Affairs Palo Alto Hlth Care Syst, Hlth Serv Res & Dev Ctr Innovat Implementat, 795 Willow Rd 152, Menlo Pk, CA 94025 USA. EM dmblonigen@gmail.com FU VA Clinical Science Research Development [CDA-2-008-10S]; VA Health Services Research Development [RCS-00-001] FX Dr. Blonigen was supported by a Career Development Award (CDA-2-008-10S) from VA Clinical Science Research & Development. Christine Timko was supported by a Research Career Scientist Award (RCS-00-001) from VA Health Services Research & Development. The views expressed are the authors' and do not necessarily reflect those of the VA. No conflicts of interest are reported by any of the authors listed on this article. NR 68 TC 0 Z9 0 U1 11 U2 11 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1040-3590 EI 1939-134X J9 PSYCHOL ASSESSMENT JI Psychol. Assess. PD OCT PY 2016 VL 28 IS 10 BP 1186 EP 1197 DI 10.1037/pas0000250 PG 12 WC Psychology, Clinical SC Psychology GA EE0YX UT WOS:000389307700006 PM 26619089 ER PT J AU Climov, M Matar, AJ Farkash, EA Medeiros, E Qiao, JZ Harrington, E Gusha, A Al-Musa, A Sachs, DH Randolph, M Bollenbach, TJ Huang, CA AF Climov, Mihail Matar, Abraham J. Farkash, Evan A. Medeiros, Erika Qiao, Jizeng Harrington, Edward Gusha, Ashley Al-Musa, Ahmad Sachs, David H. Randolph, Mark Bollenbach, Thomas J. Huang, Christene A. TI Survival of Allogeneic Self-Assembled Cultured Skin SO TRANSPLANTATION LA English DT Article ID MAJOR HISTOCOMPATIBILITY COMPLEX; HLA-DR ANTIGENS; MINIATURE SWINE; T-CELLS; ALLOGRAFT SURVIVAL; Y-CHROMOSOME; IN-VITRO; TRANSPLANTATION; KERATINOCYTES; REJECTION AB Background Deficiency of autologous skin for reconstruction of severe wounds is a major problem in plastic surgery. Autologous substitutes can provide additional coverage, but due to the duration of production, treatment is significantly delayed. The allogeneic approach offers a potential of having an off-the-shelf solution for the immediate application. Methods In this study, we assess the engraftment and immunogenicity of allogeneic bilayered bioengineered skin prepared by a self-assembly method. Bioengineered skin has the potential immunological advantage of lacking passenger leukocytes including antigen-presenting cells. The skin constructs were transplanted across major histocompatibility complex (MHC) barriers in a porcine animal model. Animals received a second grafting of the same skin construct 7 weeks after the first set of grafts together with MHC-matched constructs to assess for clinical sensitization. Results All alloconstructs successfully engrafted with histologic evidence of neovascularization by day 4. Complete cellular rejection and tissue loss occurred by day 8 for most grafts. After the second application, accelerated rejection (<4 days) took place with the development of swine MHC-specific cytotoxic alloantibody. Conclusions These data demonstrate preclinically that self-assembled allogeneic constructs engraft and reject similar to allogeneic skin despite the absence of professional donor antigen-presenting cells. C1 [Climov, Mihail; Matar, Abraham J.; Farkash, Evan A.; Harrington, Edward; Gusha, Ashley; Al-Musa, Ahmad; Sachs, David H.; Huang, Christene A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Transplantat Biol Res Ctr, Boston, MA 02115 USA. [Farkash, Evan A.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Medeiros, Erika; Qiao, Jizeng; Bollenbach, Thomas J.] Organogenesis Inc, Preclin Res & Dev Lab, Canton, MA 02021 USA. [Randolph, Mark] Massachusetts Gen Hosp, Plast Surg Res Lab, Boston, MA 02114 USA. RP Huang, CA (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Transplantat Biol Res Ctr, Boston, MA 02115 USA.; Bollenbach, TJ (reprint author), Organogenesis Inc, Preclin Res & Dev Lab, Canton, MA 02021 USA. EM tbollenb@gmail.com; cahuang@mgh.harvard.edu FU Organogenesis Inc FX The study was supported in part by Organogenesis Inc, E.M., J.Q., and T.B. were employees of Organogenesis Inc. All the other authors declare no conflicts of interest. NR 43 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD OCT PY 2016 VL 100 IS 10 BP 2071 EP 2078 DI 10.1097/TP.0000000000001353 PG 8 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA DZ2GV UT WOS:000385661200024 PM 27479166 ER PT J AU Greenland, JR Wong, CM Ahuja, R Wang, AS Uchida, C Golden, JA Hays, SR Leard, LE Rajalingam, R Singer, JP Kukreja, J Wolters, PJ Caughey, GH Tang, QZ AF Greenland, John R. Wong, Charissa M. Ahuja, Rahul Wang, Angelia S. Uchida, Chiyo Golden, Jeffrey A. Hays, Steven R. Leard, Lorriana E. Rajalingam, Raja Singer, Jonathan P. Kukreja, Jasleen Wolters, Paul J. Caughey, George H. Tang, Qizhi TI Donor-Reactive Regulatory T Cell Frequency Increases During Acute Cellular Rejection of Lung Allografts SO TRANSPLANTATION LA English DT Article ID INTERNATIONAL SOCIETY; ADULT LUNG; TRANSPLANT RECIPIENTS; MESSENGER-RNA; HEART; REGISTRY; DIAGNOSIS; RESPONSES; BLOCKADE; THERAPY AB Background Acute cellular rejection is a major cause of morbidity after lung transplantation. Because regulatory T (Treg) cells limit rejection of solid organs, we hypothesized that donor-reactive Treg increase after transplantation with development of partial tolerance and decrease relative to conventional CD4(+) (Tconv) and CD8(+) T cells during acute cellular rejection. Methods To test these hypotheses, we prospectively collected 177 peripheral blood mononuclear cell specimens from 39 lung transplant recipients at the time of transplantation and during bronchoscopic assessments for acute cellular rejection. We quantified the proportion of Treg, CD4(+) Tconv, and CD8(+) T cells proliferating in response to donor-derived, stimulated B cells. We used generalized estimating equation-adjusted regression to compare donor-reactive T cell frequencies with acute cellular rejection pathology. Results An average of 16.5 9.0% of pretransplantation peripheral blood mononuclear cell Treg cell were donor-reactive, compared with 3.8% +/- 2.9% of CD4(+) Tconv and 3.4 +/- 2.6% of CD8(+) T cells. These values were largely unchanged after transplantation. Donor-reactive CD4(+) Tconv and CD8(+) T cell frequencies both increased 1.5-fold (95% confidence interval [95% CI], 1.3-1.6; P < 0.001 and 95% CI, 1.2-1.6; P = 0.007, respectively) during grade A2 rejection compared with no rejection. Surprisingly, donor-reactive Treg frequencies increased by 1.7-fold (95% CI, 1.4-1.8; P < 0.001). Conclusions Contrary to prediction, overall proportions of donor-reactive Treg cells are similar before and after transplantation and increase during grade A2 rejection. This suggests how A2 rejection can be self-limiting. The observed increases over high baseline proportions in donor-reactive Treg were insufficient to prevent acute lung allograft rejection. C1 [Greenland, John R.; Ahuja, Rahul; Caughey, George H.] Vet Affairs Med Ctr, Med Serv, San Francisco, CA 94121 USA. [Greenland, John R.; Golden, Jeffrey A.; Hays, Steven R.; Leard, Lorriana E.; Singer, Jonathan P.; Wolters, Paul J.; Caughey, George H.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Wong, Charissa M.; Wang, Angelia S.; Golden, Jeffrey A.; Rajalingam, Raja; Kukreja, Jasleen; Tang, Qizhi] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA. [Uchida, Chiyo] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA. [Caughey, George H.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA USA. RP Greenland, JR (reprint author), San Francisco VA Med Ctr, Mail Stop 111D,4150 Clement St, San Francisco, CA 94121 USA. EM john.greenland@ucsf.edu OI Greenland, John/0000-0003-1422-8367 FU Nina Ireland Program in Lung Health; NIH [HL024136]; CSR&D Service of the VA Office of Research and Development [IK2CX001034]; NIH, through the UCSF Career Development Program in Omics of Lung Diseases [K12HL119997] FX This work was primarily funded by a grant from the Nina Ireland Program in Lung Health (QT), with additional support from NIH HL024136 (GHC). JRG was supported the CSR&D Service of the VA Office of Research and Development (IK2CX001034) and the NIH, through the UCSF Career Development Program in Omics of Lung Diseases (K12HL119997). NR 40 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD OCT PY 2016 VL 100 IS 10 BP 2090 EP 2098 DI 10.1097/TP.0000000000001191 PG 9 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA DZ2GV UT WOS:000385661200026 PM 27077597 ER PT J AU Viehman, JA Clancy, CJ Clarke, L Shields, RK Silveira, FP Kwak, EJ Vergidis, P Hughes, C Humar, A Nguyen, MH AF Viehman, J. Alexander Clancy, Cornelius J. Clarke, Lloyd Shields, Ryan K. Silveira, Fernanda P. Kwak, Eun J. Vergidis, Pascalis Hughes, Christopher Humar, Abhinav Nguyen, M. Hong TI Surgical Site Infections After Liver Transplantation: Emergence of Multidrug-Resistant Bacteria and Implications for Prophylaxis and Treatment Strategies SO TRANSPLANTATION LA English DT Article ID SOLID-ORGAN TRANSPLANTATION; BLOOD-STREAM INFECTIONS; RISK-FACTORS; KLEBSIELLA-PNEUMONIAE; INTRAABDOMINAL INFECTIONS; RECIPIENTS; SUSCEPTIBILITY; OUTCOMES; COLONIZATION; EPIDEMIOLOGY AB Background Perioperative antimicrobial prophylaxis is administered to liver transplant (LTx) recipients to prevent surgical site infections (SSIs), but regimens are not standardized, and there are limited effectiveness data. Prevention and treatment of SSIs have been complicated by the emergence of multidrug-resistant (MDR) pathogens. Methods We retrospectively reviewed SSIs among 331 LTx recipients at our center in 2010 to 2014. Results Culture-proven superficial and deep SSIs occurred in 3% and 15% of patients, respectively, at median 12.5 and 13.5 days post-LTx. Recipients with superficial SSIs and those without SSIs were similar in demographics, clinical characteristics, length of hospital stay, and mortality. Deep SSIs included abscesses (58%), peritonitis (28%), deep incisional infections (8%), and cholangitis (6%). Rates of deep SSIs were comparable among patients receiving prophylaxis with ampicillin-sulbactam, aztreonam and vancomycin, or tigecycline (P = 0.61). Independent risk factors for deep SSIs were bile leak (P < 0.001) and operative time (P < 0.001). Enterobacteriaceae (42%), Enterococcus spp. (24%), and Candida spp. (15%) were predominant pathogens. Fifty-three percent of bacteria were MDR, including 95% of Enterococcus faecium and 55% of Enterobacteriaceae; 82% of deep SSIs were caused by bacteria resistant to antimicrobials used for prophylaxis, and 58% of patients were treated with an inactive empiric regimen. Deep SSIs were associated with longer lengths of stay (P < 0.001), and higher 90-day and long-term mortality rates (P < 0.001). Conclusions Deep SSIs, including those caused by MDR bacteria, were common after LTx despite prophylaxis with broad-spectrum antimicrobials. Rather than altering prophylaxis regimens, programs should devise empiric treatment regimens that are directed against the most common local pathogens. C1 [Viehman, J. Alexander; Silveira, Fernanda P.; Kwak, Eun J.; Vergidis, Pascalis; Nguyen, M. Hong] Univ Pittsburgh, Med Ctr, Div Infect Dis, Falk Med Bldg,3601 Fifth Ave,7th Floor, Pittsburgh, PA 15213 USA. [Viehman, J. Alexander; Clancy, Cornelius J.; Shields, Ryan K.; Silveira, Fernanda P.; Kwak, Eun J.; Vergidis, Pascalis; Nguyen, M. Hong] Univ Pittsburgh, Sch Med, Div Infect Dis, Pittsburgh, PA USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Infect Dis Sect, Pittsburgh, PA USA. [Clarke, Lloyd; Shields, Ryan K.; Nguyen, M. Hong] Univ Pittsburgh, Med Ctr, Antibiot Management Program, Pittsburgh, PA USA. [Clarke, Lloyd] Univ Pittsburgh, Dept Pharm, Med Ctr, Pittsburgh, PA USA. [Hughes, Christopher; Humar, Abhinav] Univ Pittsburgh, Thomas E Starzl Transplantat Inst, Pittsburgh, PA USA. [Hughes, Christopher; Humar, Abhinav] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA. RP Viehman, JA (reprint author), Univ Pittsburgh, Med Ctr, Div Infect Dis, Falk Med Bldg,3601 Fifth Ave,7th Floor, Pittsburgh, PA 15213 USA. EM viehmanja@upmc.edu FU NIAID NIH HHS [K08 AI114883] NR 36 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD OCT PY 2016 VL 100 IS 10 BP 2107 EP 2114 DI 10.1097/TP.0000000000001356 PG 8 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA DZ2GV UT WOS:000385661200028 PM 27479167 ER PT J AU Cheloha, RW Watanabe, T Dean, T Gellman, SH Gardella, TJ AF Cheloha, Ross W. Watanabe, Tomoyuki Dean, Thomas Gellman, Samuel H. Gardella, Thomas J. TI Backbone Modification of a Parathyroid Hormone Receptor-1 Antagonist/Inverse Agonist SO ACS CHEMICAL BIOLOGY LA English DT Article ID PROTEIN-COUPLED RECEPTORS; ALPHA-HELIX MIMICRY; ACTION IN-VIVO; METAPHYSEAL CHONDRODYSPLASIA; PROTEOLYTIC-ENZYMES; PEPTIDE RECEPTOR; LIGAND-BINDING; PTH; RAT; PHARMACOKINETICS AB A backbone-modified peptide derived from parathyroid hormone (PTH) is shown to function as an inhibitor and inverse agonist of parathyroid hormone receptor-1 (PTHR1) signaling. This receptor acts to regulate calcium and phosphate homeostasis, as well as bone turnover and development. PTH is a natural agonist of PTHR1, and PTH(1-34) displays full activity relative to the natural 84-residue hormone. PTH(1-34) is used clinically to treat osteoporosis. N-terminally truncated derivatives of PTH(1-34), such as PTH(7-34), are known to bind to PTHR1 without initiating intracellular signaling and can thus act as competitive antagonists of PTH-induced signaling at PTHR1. In some cases, N-terminally truncated PTH derivatives also act as inverse agonists of PTHR1 variants that display pathologically high levels of signaling in the absence of PTH. Many analogues of PTH, however, are rapidly degraded by proteases, which may limit biomedical application. We show that backbone modification via periodic replacement of a-amino acid residues with homologous beta-amino acid residues leads to an alpha/beta-PTH(7-34) peptide that retains the antagonist and inverse agonist activities of the prototype alpha-peptide while exhibiting enhanced stability in the presence of aggressive proteases. These findings highlight the value of backbone-modified peptides derived from PTH as tools for investigating determinants of PTH metabolism and provide guidance for designing therapeutic agents for diseases arising from excessive ligand-dependent or ligand-independent PTHR1 activity. C1 [Cheloha, Ross W.; Gellman, Samuel H.] Univ Wisconsin, Dept Chem, 1101 Univ Ave, Madison, WI 53706 USA. [Watanabe, Tomoyuki; Dean, Thomas; Gardella, Thomas J.] Massachusetts Gen Hosp, Endocrine Unit, 50 Blossom St, Boston, MA 02114 USA. RP Gellman, SH (reprint author), Univ Wisconsin, Dept Chem, 1101 Univ Ave, Madison, WI 53706 USA.; Gardella, TJ (reprint author), Massachusetts Gen Hosp, Endocrine Unit, 50 Blossom St, Boston, MA 02114 USA. EM Gellman@chem.wisc.edu; gardella@helix.mgh.harvard.edu FU National Institutes of Health (NIH) [P01-DK11794, R01 GM-056414]; NIGMS [T32 GM008349] FX This research was supported by National Institutes of Health (NIH) P01-DK11794 (T.J.G) and R01 GM-056414 (S.H.G.). R.W.C. was supported in part by a Biotechnology Training Grant from NIGMS (T32 GM008349). NR 63 TC 0 Z9 0 U1 5 U2 5 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1554-8929 EI 1554-8937 J9 ACS CHEM BIOL JI ACS Chem. Biol. PD OCT PY 2016 VL 11 IS 10 BP 2752 EP 2762 DI 10.1021/acschembio.6b00404 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DZ9IE UT WOS:000386187700011 PM 27533344 ER PT J AU Tolstunov, L Brickeen, M Kamanin, V Susarla, SM Selvie, F AF Tolstunov, Len Brickeen, Marshall Kamanin, Vladislav Susarla, Srinivas M. Selvie, Firat TI Is the angulation of mandibular third molars associated with the thickness of lingual bone? SO BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY LA English DT Article DE lingual bone; third molar; angulation; thickness; lingual nerve ID NERVE INJURY; SURGERY; PLACEMENT; REGION; TOMOGRAPHY; EXTRACTION; SITES; RISK AB To find out whether the angulation of mandibular third molars is associated with the thickness of the bone at the site of impaction, and if so, which particular angulation affects the protective mechanism of the nerve, we retrospectively studied the thickness of lingual bone at the sites of impaction of 200 mandibular third molars in 149 patients using coronal, sagittal, and axial slices of cone-beam computed tomograms (CT). We measured the bone at the cementoenamel junction of the mandibular second molar, at the mid-root of the third molar, and at the apex of the root. Bone less than 1 mm thick was defined as "thinning". We correlated these measurements with the angulation of the tooth based on the position of the second molar and the occlusal plane in 3 dimensions: vertical, mesiobuccal, and buccolingual. The primary outcome was the thickness of the bone around the third molar. A total of 102 teeth were on the left (51%), and 125 were angulated with an occlusal plane of <85 degrees (63%). The mean (SD) thickness of bone at the cementoenamel junction of the second molar was 1.40 (0.87) mm, at mid-root 1.07 (1.03) mm, and at the apex 1.07 (1.30) mm When the horizontal and mesioangular angulations of teeth were <85 degrees, the thickness of bone at the mid-root differed significantly from that when the vertical and distoangular angulations were 85 degrees or more (p<0.001). Correlations between the thickness of the bone and the buccolingual angulations were significantly associated with perforation of the bone at mid-root and apex (p<0.003). The bone around horizontal and mesioangular impactions was 3.6 times more likely to be "thin" than that at mid-root of vertical and distoangular third molars. A buccolingual angulation was also associated with perforation of the lingual cortex (p<0.003). As the bone was thinner at the mid-root of horizontally and mesioangularly impacted teeth, it seemed to compromise the integrity of the lingual plate, which is the natural protective barrier of the lingual nerve. These findings could be of prognostic value. (C) 2016 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved. C1 [Tolstunov, Len] Univ Pacific, Arthur A Dugoni Sch Dent, Dept Oral & Maxillofacial Surg, Stockton, CA 95211 USA. [Tolstunov, Len] Univ Calif San Francisco, Dept Oral & Maxillofacial Surg, San Francisco, CA 94143 USA. [Brickeen, Marshall] Reveal Diagnost CBCT Imaging Ctr, San Francisco, CA USA. [Susarla, Srinivas M.] Johns Hopkins Univ Hosp, Dept Plast Reconstruct & Maxillofacial Surg, Baltimore, MD 21287 USA. [Susarla, Srinivas M.] Johns Hopkins Sch Med, Baltimore, MD USA. [Selvie, Firat] Harvard Sch Dent Med, Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA USA. [Selvie, Firat] Istanbul Univ, Sch Dent, Dept Oral Surg, Istanbul, Turkey. RP Tolstunov, L (reprint author), Univ Pacific, Arthur A Dugoni Sch Dent, Dept Oral & Maxillofacial Surg, Stockton, CA 95211 USA.; Tolstunov, L (reprint author), Univ Calif San Francisco, Dept Oral & Maxillofacial Surg, San Francisco, CA 94143 USA. EM Tolstunov@yahoo.com NR 29 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 0266-4356 EI 1532-1940 J9 BRIT J ORAL MAX SURG JI Br. J. Oral Maxillofac. Surg. PD OCT PY 2016 VL 54 IS 8 BP 914 EP 919 DI 10.1016/j.bjoms.2016.06.005 PG 6 WC Dentistry, Oral Surgery & Medicine; Surgery SC Dentistry, Oral Surgery & Medicine; Surgery GA ED7EG UT WOS:000389024300014 PM 27381746 ER PT J AU Anstey, DE Li, S Thomas, L Wang, TY Wiviott, SD AF Anstey, D. Edmund Li, Shuang Thomas, Laine Wang, Tracy Y. Wiviott, Stephen D. TI Race and Sex Differences in Management and Outcomes of Patients After ST-Elevation and Non-ST-Elevation Myocardial Infarct: Results From the NCDR SO CLINICAL CARDIOLOGY LA English DT Article DE Acute coronary syndrome; Gender; Disparities in Care; Race; STEMI; NSTEMI ID ACUTE CORONARY SYNDROMES; ASSOCIATION TASK-FORCE; QUALITY-OF-CARE; RAPID RISK STRATIFICATION; SUPPRESS ADVERSE OUTCOMES; AMERICAN-COLLEGE; UNSTABLE ANGINA; WHITE PATIENTS; CARDIAC-CATHETERIZATION; EARLY IMPLEMENTATION AB Background: Race and sex have been shown to affect management of myocardial infarction (MI); however, it is unclear if such disparities exist in contemporary care of ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI). Hypothesis: Disparities in care will be less prevalent in more heavily protocol-driven management of STEMI than the less algorithmic care of NSTEMI. Methods: Data were collected from the ACTION Registry-GWTG database to assess care differences related to race and sex of patients presenting with NSTEMI or STEMI. For key treatments and outcomes, adjustments were made including patient demographics, baseline comorbidities, and markers of socioeconomic status. Results: Key demographic variables demonstrate significant differences in baseline comorbidities; black patients had higher incidences of hypertension and diabetes, and women more frequently had diabetes. With few exceptions, rates of acute and discharge medical therapy were similar by race in any sex category in both STEMI and NSTEMI populations. Rates of catheterization were similar by race for STEMI but not for NSTEMI, where both black men and women had lower rates of invasive therapy. Rates of revascularization were significantly lower for black patients in both the STEMI and NSTEMI groups regardless of sex. Rates of adverse events differed by sex, with disparities for death and major bleeding; after adjustment, rates were similar by race within sex comparisons. Conclusions: In this contemporary cohort, although there are differences by race in presentation and management of MI, heavily protocol-driven processes seem to show fewer racial disparities. C1 [Anstey, D. Edmund; Wiviott, Stephen D.] Brigham & Womens Hosp, Dept Med, Cardiovasc Div, 350 Longwood Ave,First Off Floor Boston, Boston, MA 02114 USA. [Anstey, D. Edmund; Wiviott, Stephen D.] Harvard Med Sch, Boston, MA USA. [Li, Shuang; Thomas, Laine; Wang, Tracy Y.] Duke Univ, Duke Clin Res Inst, Dept Med, Cardiovasc Div, Durham, NC USA. RP Wiviott, SD (reprint author), Brigham & Womens Hosp, TIMI Study Grp, 350 Longwood Ave,First Off Floor, Boston, MA 02114 USA. EM swiviott@partners.org NR 33 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0160-9289 EI 1932-8737 J9 CLIN CARDIOL JI Clin. Cardiol. PD OCT PY 2016 VL 39 IS 10 BP 585 EP 595 DI 10.1002/clc.22570 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC8AP UT WOS:000388362600005 ER PT J AU Ono, N Kronenberg, HM AF Ono, Noriaki Kronenberg, Henry M. TI Bone repair and stem cells SO CURRENT OPINION IN GENETICS & DEVELOPMENT LA English DT Article ID OSTEOBLAST DIFFERENTIATION; MARROW; PRECURSORS; PERIOSTEUM; CARTILAGE; OSTERIX; CBFA1; SOX9; MICE AB Bones are an important component of vertebrates; they grow explosively in early life and maintain their strength throughout life. Bones also possess amazing capabilities to repair - the bone is like new without a scar after complete repair. In recent years, a substantial progress has been made in our understanding on mammalian bone stem cells. Mouse genetic models are powerful tools to understand the cell lineage, giving us better insights into stem cells that regulate bone growth, maintenance and repair. Recent findings about these stem cells raise new questions that require further investigations. C1 [Ono, Noriaki] Univ Michigan, Dept Orthodont & Pediat Dent, Sch Dent, Ann Arbor, MI 48109 USA. [Kronenberg, Henry M.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA. [Kronenberg, Henry M.] Harvard Med Sch, Boston, MA 02114 USA. RP Ono, N (reprint author), Univ Michigan, Dept Orthodont & Pediat Dent, Sch Dent, Ann Arbor, MI 48109 USA.; Kronenberg, HM (reprint author), Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.; Kronenberg, HM (reprint author), Harvard Med Sch, Boston, MA 02114 USA. EM noriono@umich.edu; hkronenberg@mgh.harvard.edu FU National Institutes of Health [DE022564, DK011794] FX These authors gratefully acknowledge the support from National Institutes of Health Grants DE022564 to N.O. and DK011794 to H.M.K. NR 28 TC 2 Z9 2 U1 3 U2 3 PU CURRENT BIOLOGY LTD PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0959-437X EI 1879-0380 J9 CURR OPIN GENET DEV JI Curr. Opin. Genet. Dev. PD OCT PY 2016 VL 40 BP 103 EP 107 DI 10.1016/j.gde.2016.06.012 PG 5 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA ED5WM UT WOS:000388923400015 PM 27399886 ER PT J AU Vargas, AJ Quackenbush, J Glass, K AF Vargas, Ashley J. Quackenbush, John Glass, Kimberly TI Diet-induced weight loss leads to a switch in gene regulatory network control in the rectal mucosa SO GENOMICS LA English DT Article DE Weight loss; Colorectal cancer; Colorectum; Diet; Gene network; Gene regulation; Diet ID OBESITY-RELATED CANCERS; BODY-MASS INDEX; COLORECTAL-CANCER; COLON-CANCER; C-MYC; HEALTH-PROFESSIONALS; RISK; EXPRESSION; TRANSCRIPTION; METAANALYSIS AB Background: Weight loss may decrease risk of colorectal cancer in obese individuals, yet its effect in the colorectum is not well understood. We used integrative network modeling, Passing Attributes between Networks for Data Assimilation, to estimate transcriptional regulatory network models from mRNA expression levels from rectal mucosa biopsies measured pre- and post-weight loss in 10 obese, pre-menopausal women. Results: We identified significantly greater regulatory targeting of glucose transport pathways in the post-weight loss regulatory network, including "regulation of glucose transport" (FDR = 0.02), "hexose transport" (FDR = 0.06), "glucose transport" (FDR = 0.06) and "monosaccharide transport" (FDR = 0.08). These findings were not evident by gene expression analysis alone. Network analysis also suggested a regulatory switch from NFKB1 to MAX control of MYC post-weight loss. Conclusions: These network-based results expand upon standard gene expression analysis by providing evidence for a potential mechanistic alteration caused by weight loss. (C) 2016 The Authors. Published by Elsevier Inc. C1 [Vargas, Ashley J.; Quackenbush, John] Harvard Univ, Harvard Sch Publ Hlth, Boston, MA USA. [Vargas, Ashley J.] NCI, Canc Prevent Fellowship Program, Rockville, MD USA. [Quackenbush, John; Glass, Kimberly] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Glass, Kimberly] Brigham & Womens Hosp, Channing Div Network Med, 181 Longwood Ave,Rm 577, Boston, MA 02115 USA. RP Glass, K (reprint author), Brigham & Womens Hosp, Channing Div Network Med, 181 Longwood Ave,Rm 577, Boston, MA 02115 USA. EM rekrg@channing.harvard.edu FU Cancer Prevention Fellowship Program, National Cancer Institute; National Heart, Lung, and Blood Institute of the US National Institutes of Health [1R01 HL111759] FX AV was supported by the Cancer Prevention Fellowship Program, National Cancer Institute. JQ and KG were supported by a grant from the National Heart, Lung, and Blood Institute of the US National Institutes of Health (1R01 HL111759) NR 49 TC 0 Z9 0 U1 1 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0888-7543 EI 1089-8646 J9 GENOMICS JI Genomics PD OCT PY 2016 VL 108 IS 3-4 BP 126 EP 133 DI 10.1016/j.ygeno.2016.08.001 PG 8 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA ED1CD UT WOS:000388580500003 PM 27524493 ER PT J AU Barkati, M King, B Fortin, I Portelance, L Viswanathan, AN Fyles, TW Beriwal, S Alfieri, J Lim, KS Harkenrider, MM Small, W Klopp, AH Stewart, A Yashar, CM Bosch, WR Jhingran, A Jolicoeur, M Gaffney, DK AF Barkati, M. King, B. Fortin, I. Portelance, L. Viswanathan, A. N. Fyles, T. W. Beriwal, S. Alfieri, J. Lim, K. S. Harkenrider, M. M. Small, W., Jr. Klopp, A. H. Stewart, A. Yashar, C. M. Bosch, W. R. Jhingran, A. Jolicoeur, M. Gaffney, D. K. TI Intensity Modulated Radiation Therapy for Vulvar Carcinoma: Changes in Practice Over 5 Years SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Barkati, M.; Fortin, I.] Ctr Hosp Univ Montreal, Montreal, PQ, Canada. [King, B.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia. [Portelance, L.] Univ Miami, Dept Radiat Oncol, Sylvester Comprehens Canc Ctr, Miami, FL USA. [Viswanathan, A. N.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Fyles, T. W.] Princess Margaret Canc Ctr, Toronto, ON, Canada. [Beriwal, S.] Univ Pittsburgh, Dept Radiat Oncol, Inst Canc, Pittsburgh, PA USA. [Alfieri, J.] McGill Univ, Ctr Hlth, Montreal, PQ, Canada. [Lim, K. S.] Liverpool Ctr, Sydney, NSW, Australia. [Lim, K. S.] Macarthur Canc Therapy Ctr, Sydney, NSW, Australia. [Lim, K. S.] Ingham Inst, Sydney, NSW, Australia. [Harkenrider, M. M.; Small, W., Jr.] Loyola Univ Chicago, Stritch Sch Med, Maywood, IL USA. [Klopp, A. H.; Jhingran, A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Stewart, A.] Royal Surrey Cty Hosp NHS Fdn Trust, Guildford, Surrey, England. [Yashar, C. M.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Bosch, W. R.] Washington Univ, Sch Med, St Louis, MO USA. [Jolicoeur, M.] Hop Charles LeMoyne, Longueuil, PQ, Canada. [Gaffney, D. K.] Huntsman Canc Hosp, Salt Lake City, UT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2723 BP E295 EP E296 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655803040 ER PT J AU Braunstein, LZ Taghian, AG Niemierko, A Salama, LW Capuco, A Wong, JS Punglia, RS Bellon, JR MacDonald, S Harris, JR AF Braunstein, L. Z. Taghian, A. G. Niemierko, A. Salama, L. W. Capuco, A. Wong, J. S. Punglia, R. S. Bellon, J. R. MacDonald, S. Harris, J. R. TI Breast Cancer Subtype, Lymph Node Involvement, and Age As Predictors of Isolated Local-Regional Recurrence Following Breast-Conserving Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Braunstein, L. Z.] Harvard Radiat Oncol Program, Boston, MA USA. [Taghian, A. G.; Niemierko, A.; MacDonald, S.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Salama, L. W.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Capuco, A.; Wong, J. S.; Punglia, R. S.; Bellon, J. R.; Harris, J. R.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2089 BP E37 EP E37 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802090 ER PT J AU Brivio, D Nguyen, PL Sajo, E Ngwa, W Zygmanski, P AF Brivio, D. Nguyen, P. L. Sajo, E. Ngwa, W. Zygmanski, P. TI Radiosensitization of Prostate With Simultaneous Rectal Dose Sparing Via Radiation Trapping by Gold Nanoparticles in I-125 Prostate Brachytherapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Brivio, D.; Nguyen, P. L.; Ngwa, W.; Zygmanski, P.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. [Brivio, D.; Nguyen, P. L.; Ngwa, W.; Zygmanski, P.] Harvard Med Sch, Boston, MA USA. [Sajo, E.; Ngwa, W.] Univ Massachusetts Lowell, Lowell, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2630 BP E259 EP E260 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802628 ER PT J AU Buscariollo, D Cronin, A Bleicher, RJ Cohen, A Hassett, MJ Javid, S Kumar, S Moy, B Niland, J Wolff, A Punglia, RS AF Buscariollo, D. Cronin, A. Bleicher, R. J. Cohen, A. Hassett, M. J. Javid, S. Kumar, S. Moy, B. Niland, J. Wolff, A. Punglia, R. S. TI Association Between the 21-Gene Recurrence Score and Isolated Local-Regional Recurrence in Hormone Receptor-Positive Breast Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Buscariollo, D.; Cronin, A.; Hassett, M. J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Buscariollo, D.] Harvard Radiat Oncol Program, Boston, MA USA. [Bleicher, R. J.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Cohen, A.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA. [Javid, S.] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, 1124 Columbia St, Seattle, WA 98104 USA. [Kumar, S.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Moy, B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Niland, J.] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA. [Wolff, A.] John Hopkins Canc Ctr, Baltimore, MD USA. [Punglia, R. S.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2031 BP E13 EP E13 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802032 ER PT J AU Cagney, DN Van Dijk, KR Horvath, MC Christianson, L Weiss, SE Mak, RH Aizer, AA Arvold, ND Buckner, RL Alexander, BM AF Cagney, D. N. Van Dijk, K. R. Horvath, M. C. Christianson, L. Weiss, S. E. Mak, R. H. Aizer, A. A. Arvold, N. D. Buckner, R. L. Alexander, B. M. TI Cortical Structural Changes in Patients Receiving Whole-Brain Radiation Therapy (WBRT) SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Cagney, D. N.; Horvath, M. C.; Christianson, L.; Mak, R. H.; Arvold, N. D.; Alexander, B. M.] Brigham & Womens Canc Ctr, Dana Farber Canc Inst, Boston, MA USA. [Van Dijk, K. R.; Buckner, R. L.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA USA. [Van Dijk, K. R.; Buckner, R. L.] Harvard Univ, Dept Psychol, Ctr Brain Sci, 33 Kirkland St, Cambridge, MA 02138 USA. [Weiss, S. E.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Aizer, A. A.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2173 BP E71 EP E72 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802174 ER PT J AU Dyer, MA McDonnell, EI Yeap, BY Depauw, N Wolfgang, JA Wo, JY DeLaney, TF Ben-Josef, E Crane, CH Zhu, AX Hong, TI AF Dyer, M. A. McDonnell, E. I. Yeap, B. Y. Depauw, N. Wolfgang, J. A. Wo, J. Y. DeLaney, T. F. Ben-Josef, E. Crane, C. H. Zhu, A. X. Hong, T. I. TI Change in Platelet Count and Normal Liver Dosimetry in Patients Receiving Proton Radiation Therapy for Unresectable Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Dyer, M. A.] Harvard Radiat Oncol Program, Boston, MA USA. [McDonnell, E. I.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Yeap, B. Y.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA. [Depauw, N.; Wolfgang, J. A.; Wo, J. Y.; Zhu, A. X.; Hong, T. I.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [DeLaney, T. F.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Ben-Josef, E.] Univ Penn, Philadelphia, PA 19104 USA. [Crane, C. H.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2426 BP E174 EP E175 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802425 ER PT J AU Feng, FY Karnes, JR Ashab, HADM Trock, B Ross, AE Tsai, H Tosoian, J Erho, NG Alshalafa, M Choeurng, V Yousefi, K Abdollah, F Klein, EA Nguyen, PL Dicker, AP Den, RB Davicioni, E Jenkins, RB Lotan, T Schaeffer, EM AF Feng, F. Y. Karnes, J. R. Ashab, H. A. D. M. Trock, B. Ross, A. E. Tsai, H. Tosoian, J. Erho, N. G. Alshalafa, M. Choeurng, V. Yousefi, K. Abdollah, F. Klein, E. A. Nguyen, P. L. Dicker, A. P. Den, R. B. Davicioni, E. Jenkins, R. B. Lotan, T. Schaeffer, E. M. TI Development and Validation of Genomic Signature That Predicts Androgen Deprivation Therapy Treatment Failure SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Feng, F. Y.] Univ Michigan, Ann Arbor, MI 48109 USA. [Karnes, J. R.] Mayo Clin, Dept Urol, Rochester, MN USA. [Ashab, H. A. D. M.; Erho, N. G.; Alshalafa, M.; Yousefi, K.; Davicioni, E.] GenomeDx Biosci, Vancouver, BC, Canada. [Trock, B.; Tosoian, J.] Johns Hopkins Univ Hosp, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA. [Ross, A. E.; Schaeffer, E. M.] Johns Hopkins Univ, Baltimore, MD USA. [Tsai, H.] JHMI, Baltimore, MD USA. [Choeurng, V.] GenomeDx Biosci Inc, Vancouver, BC, Canada. [Abdollah, F.] Henry Ford Hosp, Vattikuti Urol Inst, Detroit, MI 48202 USA. [Klein, E. A.] Cleveland Clin, Cleveland, OH 44106 USA. [Nguyen, P. L.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Nguyen, P. L.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Dicker, A. P.] Thomas Jefferson Univ, Dept Radiat Oncol, Philadelphia, PA 19107 USA. [Den, R. B.] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA. [Jenkins, R. B.] Mayo Clin, Rochester, MN USA. [Lotan, T.] Johns Hopkins Sch Med, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2540 BP E221 EP E221 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802539 ER PT J AU Keane, FK Wo, JY Ferrone, CR Clark, JW Blaszkowsky, LS Allen, JN Kwak, EL Ryan, DP Lillemoe, KD Fernandez-del Castillo, C Hong, TI AF Keane, F. K. Wo, J. Y. Ferrone, C. R. Clark, J. W. Blaszkowsky, L. S. Allen, J. N. Kwak, E. L. Ryan, D. P. Lillemoe, K. D. Fernandez-del Castillo, C. Hong, T. I. TI Intraoperative Radiation Therapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiation Therapy for Pancreatic Adenocarcinoma SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Keane, F. K.] Harvard Med Sch, Harvard Radiat Oncol Program, Boston, MA USA. [Wo, J. Y.; Hong, T. I.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Ferrone, C. R.; Lillemoe, K. D.; Fernandez-del Castillo, C.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Clark, J. W.; Blaszkowsky, L. S.; Allen, J. N.; Kwak, E. L.; Ryan, D. P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2512 BP E209 EP E210 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802511 ER PT J AU Kim, DW Niemierko, A Hwang, W Stemmer-Rachamimov, AO Curry, WT Barker, FG Martuza, R Loeffler, JS Oh, KS Shih, HA AF Kim, D. W. Niemierko, A. Hwang, W. Stemmer-Rachamimov, A. O. Curry, W. T. Barker, F. G., II Martuza, R. Loeffler, J. S. Oh, K. S. Shih, H. A. TI Histopathologic Prognostic Factors of Recurrence Following Surgery and Radiation Therapy for Atypical and Malignant Meningiomas SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Kim, D. W.; Hwang, W.] Harvard Med Sch, Boston, MA USA. [Niemierko, A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Biostat, Boston, MA USA. [Stemmer-Rachamimov, A. O.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Curry, W. T.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Barker, F. G., II; Martuza, R.; Shih, H. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Loeffler, J. S.; Oh, K. S.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2194 BP E80 EP E80 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802195 ER PT J AU Kishan, AU Shaikh, T Wang, J Reiter, R Said, J Raghavan, G Nickols, N Aronson, W Sadeghi, A Kamrava, M Demanes, DJ Steinberg, ML Horwitz, EM Kupelian, PA King, CR AF Kishan, A. U. Shaikh, T. Wang, J. Reiter, R. Said, J. Raghavan, G. Nickols, N. Aronson, W. Sadeghi, A. Kamrava, M. Demanes, D. J. Steinberg, M. L. Horwitz, E. M. Kupelian, P. A. King, C. R. TI Clinical Outcomes for Patients With Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiation Therapy or Radical Prostatectomy: A Comparative Analysis SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Kishan, A. U.; Wang, J.; Reiter, R.; Said, J.; Raghavan, G.; Aronson, W.; Kamrava, M.; Demanes, D. J.; King, C. R.] Univ Calif Los Angeles, Los Angeles, CA USA. [Shaikh, T.; Horwitz, E. M.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Nickols, N.] CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA. [Sadeghi, A.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Steinberg, M. L.; Kupelian, P. A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2559 BP E229 EP E229 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802558 ER PT J AU Mihalcik, SA Rawal, B Braunstein, LZ Capuco, A Wong, JS Punglia, RS Bellon, JR Harris, JR AF Mihalcik, S. A. Rawal, B. Braunstein, L. Z. Capuco, A. Wong, J. S. Punglia, R. S. Bellon, J. R. Harris, J. R. TI The Impact of Re-Excision and Residual Disease on Local Recurrence Following Breast-Conserving Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Mihalcik, S. A.; Braunstein, L. Z.] Harvard Radiat Oncol Program, Boston, MA USA. [Rawal, B.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Capuco, A.; Wong, J. S.; Punglia, R. S.; Bellon, J. R.; Harris, J. R.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2030 BP E12 EP E13 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802031 ER PT J AU Mitra, D Hong, TI Horick, N Rose, B Drapek, LC Blaszkowsky, L Allen, JN Kwak, EL Murphy, JE Ryan, DP Cusack, JC Bordeianou, L Berger, DL Wo, JY AF Mitra, D. Hong, T. I. Horick, N. Rose, B. Drapek, L. C. Blaszkowsky, L. Allen, J. N. Kwak, E. L. Murphy, J. E. Ryan, D. P. Cusack, J. C. Bordeianou, L. Berger, D. L. Wo, J. Y. TI Long-Term Outcomes and Toxicity of Anal Cancer Patients Treated Per Radiation Therapy Oncology Group 0529 SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Mitra, D.; Horick, N.; Drapek, L. C.; Blaszkowsky, L.; Allen, J. N.; Kwak, E. L.; Murphy, J. E.; Ryan, D. P.; Cusack, J. C.; Bordeianou, L.; Berger, D. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mitra, D.; Rose, B.] Harvard Radiat Oncol Program, Boston, MA USA. [Hong, T. I.; Wo, J. Y.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2408 BP E167 EP E167 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802407 ER PT J AU Muralidhar, V Nezolosky, MD Chen, YW Martin, NE Beard, CJ Orio, PF Nguyen, PL AF Muralidhar, V. Nezolosky, M. D. Chen, Y. W. Martin, N. E. Beard, C. J. Orio, P. F., III Nguyen, P. L. TI Association with Distance to Treatment Facility and Treatment Trends: Implications for Radiation Reimbursement Policies SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Muralidhar, V.; Beard, C. J.] Harvard Med Sch, Boston, MA USA. [Nezolosky, M. D.; Orio, P. F., III; Nguyen, P. L.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Chen, Y. W.] Harvard Sch Publ Hlth, Boston, MA USA. [Martin, N. E.; Nguyen, P. L.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2639 BP E263 EP E263 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802637 ER PT J AU Muralidhar, V Nezolosky, MD Chen, YW Martin, NE Beard, CJ Orio, PF Nguyen, PL AF Muralidhar, V. Nezolosky, M. D. Chen, Y. W. Martin, N. E. Beard, C. J. Orio, P. F., III Nguyen, P. L. TI Adverse Pathologic Features Following Prostatectomy for Favorable High-Risk Versus Other High-Risk Prostate Cancer: Implications for Choice of Local Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Muralidhar, V.; Beard, C. J.] Harvard Med Sch, Boston, MA USA. [Nezolosky, M. D.; Orio, P. F., III; Nguyen, P. L.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Chen, Y. W.] Harvard Sch Publ Hlth, Boston, MA USA. [Martin, N. E.; Nguyen, P. L.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2622 BP E256 EP E256 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802620 ER PT J AU Muralidhar, V Nezolosky, MD Chen, YW Martin, NE Beard, CJ Orio, PF Nguyen, PL AF Muralidhar, V. Nezolosky, M. D. Chen, Y. W. Martin, N. E. Beard, C. J. Orio, P. F., III Nguyen, P. L. TI National Trends in Androgen Deprivation Therapy Use for Prostate Cancer After Versus Before the Controversy Surrounding Cardiovascular Toxicity SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Muralidhar, V.; Beard, C. J.] Harvard Med Sch, Boston, MA USA. [Nezolosky, M. D.; Orio, P. F., III; Nguyen, P. L.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Chen, Y. W.] Harvard Sch Publ Hlth, Boston, MA USA. [Martin, N. E.; Nguyen, P. L.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2589 BP E241 EP E242 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802587 ER PT J AU Nakamura, A Prichard, HA Wo, JY Wolfgang, JA Hong, TI AF Nakamura, A. Prichard, H. A. Wo, J. Y. Wolfgang, J. A. Hong, T. I. TI Elective Nodal Irradiation With Simultaneous Integrated Boost Stereotactic Body Radiation Therapy for Pancreatic Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Nakamura, A.; Prichard, H. A.; Wo, J. Y.; Wolfgang, J. A.; Hong, T. I.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2513 BP E210 EP E210 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802512 ER PT J AU Padilla, O Botticello, T Winey, B Niemierko, A Shin, J Oh, KS AF Padilla, O. Botticello, T. Winey, B. Niemierko, A. Shin, J. Oh, K. S. TI Feasibility of Simultaneous Integrated Boost (SIB) to Gross Disease in Spine Radiosurgery SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Padilla, O.] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Botticello, T.; Niemierko, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Winey, B.; Oh, K. S.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Shin, J.] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2263 BP E107 EP E108 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802264 ER PT J AU Rahman, R Catalano, PJ Arvold, ND Aizer, AA Weiss, SE Pinnell, N Horvath, MC Christianson, L Reardon, DA Lee, EQ Nayak, L Rinne, M Dunn, IF Golby, AJ Johnson, MD Claus, EB Ligon, KL Wen, P Alexander, BM AF Rahman, R. Catalano, P. J. Arvold, N. D. Aizer, A. A. Weiss, S. E. Pinnell, N. Horvath, M. C. Christianson, L. Reardon, D. A. Lee, E. Q. Nayak, L. Rinne, M. Dunn, I. F. Golby, A. J. Johnson, M. D. Claus, E. B. Ligon, K. L. Wen, P. Alexander, B. M. TI Chemoradiation-Related Lymphopenia Is Common Among Glioblastoma Patients and Is Associated With Worse Progression-Free and Overall Survival SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Rahman, R.] Harvard Radiat Oncol Program, Boston, MA USA. [Catalano, P. J.; Pinnell, N.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Arvold, N. D.; Horvath, M. C.; Christianson, L.; Reardon, D. A.; Lee, E. Q.; Nayak, L.; Rinne, M.; Dunn, I. F.; Golby, A. J.; Johnson, M. D.; Claus, E. B.; Ligon, K. L.; Wen, P.; Alexander, B. M.] Dana Farber Canc Inst, Brigham & Womens Canc Ctr, Boston, MA 02115 USA. [Aizer, A. A.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. [Weiss, S. E.] Fox Chase Canc Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2300 BP E123 EP E123 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802300 ER PT J AU Rodin, D Andersen, LW Buscariollo, D Drumm, MR Clayman, RH Galland, S Eidelman, A Feldman, AS Lee, RJ Dahl, DM McGovern, FJ Olumi, A Niemierko, A Shipley, WU Zietman, AL Efstathiou, JA AF Rodin, D. Andersen, L. W. Buscariollo, D. Drumm, M. R. Clayman, R. H. Galland, S. Eidelman, A. Feldman, A. S. Lee, R. J. Dahl, D. M. McGovern, F. J. Olumi, A. Niemierko, A. Shipley, W. U. Zietman, A. L. Efstathiou, J. A. TI Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long- Term Results of a Large Institutional Experience SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Rodin, D.] Univ Toronto, Dept Radiat Oncol, Toronto, ON, Canada. [Andersen, L. W.] Aarhus Univ Hosp, Dept Anesthesiol, Aarhus, Denmark. [Buscariollo, D.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Drumm, M. R.; Clayman, R. H.; Eidelman, A.; Lee, R. J.; Shipley, W. U.; Zietman, A. L.; Efstathiou, J. A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA. [Galland, S.] Bordeaux Hosp Univ, Bordeaux, France. [Feldman, A. S.; Dahl, D. M.; McGovern, F. J.; Olumi, A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Urol, Boston, MA USA. [Niemierko, A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Biostat, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2605 BP E249 EP E249 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802603 ER PT J AU Rose, B Jee, KW Niemierko, A Murphy, JE Blaszkowsky, LS Allen, JN Lee, LK Wang, Y Drapek, LC Hong, TI Wo, JY AF Rose, B. Jee, K. W. Niemierko, A. Murphy, J. E. Blaszkowsky, L. S. Allen, J. N. Lee, L. K. Wang, Y. Drapek, L. C. Hong, T. I. Wo, J. Y. TI Irradiation of Anatomically Defined Pelvic Bone Marrow Subsites and Acute Hematologic Toxicity in Anal Cancer Patients Undergoing Chemoradiation SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Rose, B.] Harvard Radiat Oncol Program, Boston, MA USA. [Jee, K. W.; Murphy, J. E.; Blaszkowsky, L. S.; Allen, J. N.; Lee, L. K.; Drapek, L. C.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Niemierko, A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Biostat, Boston, MA USA. [Wang, Y.; Hong, T. I.; Wo, J. Y.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2487 BP E198 EP E199 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802486 ER PT J AU Royce, TJ Gray, PJ Lin, CC Shipley, WU Jemal, A Efstathiou, JA AF Royce, T. J. Gray, P. J. Lin, C. C. Shipley, W. U. Jemal, A. Efstathiou, J. A. TI Treatment Patterns and Outcomes of Nonurothelial Cell Carcinoma of the Bladder: Results From the National Cancer Data Base SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Royce, T. J.; Gray, P. J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Royce, T. J.] Harvard Radiat Oncol Program, Boston, MA USA. [Lin, C. C.; Jemal, A.] Amer Canc Soc, Atlanta, GA 30329 USA. [Shipley, W. U.; Efstathiou, J. A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2575 BP E236 EP E236 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802574 ER PT J AU Royce, TJ Nachtigall, LB Daartz, J Fullerton, BC Oh, KS Loeffler, JS Shih, HA AF Royce, T. J. Nachtigall, L. B. Daartz, J. Fullerton, B. C. Oh, K. S. Loeffler, J. S. Shih, H. A. TI Neuroendocrine Function Following Proton Therapy for Low-Grade Gliomas: Results From a Prospective Trial SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Royce, T. J.; Nachtigall, L. B.; Fullerton, B. C.; Shih, H. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Royce, T. J.] Harvard Radiat Oncol Program, Boston, MA USA. [Daartz, J.; Oh, K. S.; Loeffler, J. S.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2169 BP E70 EP E70 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802170 ER PT J AU Salama, LW Vieira, BL Braunstein, LZ Horick, N Asdourian, MS Skolny, M Tighe, MP Taghian, NR MacDonald, S Colwell, AS Winograd, JM Gadd, MA Specht, M Smith, BL AF Salama, L. W. Vieira, B. Lavajo Braunstein, L. Z. Horick, N. Asdourian, M. S. Skolny, M. Tighe, M. P. Taghian, N. R. MacDonald, S. Colwell, A. S. Winograd, J. M. Gadd, M. A. Specht, M. Smith, B. L. TI Radiation Therapy-Dependent Predictors of Adverse Breast Reconstruction Outcomes SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Salama, L. W.; Asdourian, M. S.; Skolny, M.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Vieira, B. Lavajo] AROME Assoc Radiotherapy & Oncol Mediterranean Ar, Paris, France. [Vieira, B. Lavajo] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Braunstein, L. Z.] Harvard Radiat Oncol Program, Boston, MA USA. [Horick, N.; Tighe, M. P.; Taghian, N. R.; MacDonald, S.; Smith, B. L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Colwell, A. S.; Winograd, J. M.] Massachusetts Gen Hosp, Div Plast Surg, Boston, MA 02114 USA. [Gadd, M. A.; Specht, M.; Smith, B. L.] Massachusetts Gen Hosp, Div Surg Oncol, Gillette Ctr Womens Canc, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2064 BP E27 EP E27 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802065 ER PT J AU Sanford, NN Chen, MH Loffredo, M Renshaw, A Kantoff, PW D'Amico, AV AF Sanford, N. N. Chen, M. H. Loffredo, M. Renshaw, A. Kantoff, P. W. D'Amico, A. V. TI Duration of the Anti-Androgen in Men Undergoing 6 Months of an LHRH Agonist and Radiation Therapy for Unfavorable-Risk Prostate Cancer and the Risk of Death SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Sanford, N. N.] Harvard Radiat Oncol Program, Boston, MA USA. [Chen, M. H.] Univ Connecticut, Storrs, CT USA. [Loffredo, M.; D'Amico, A. V.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Loffredo, M.; D'Amico, A. V.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Renshaw, A.] Miami Baptist Hosp, Miami, FL USA. [Kantoff, P. W.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2553 BP E226 EP E227 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802552 ER PT J AU Sinha, S Muralidhar, V Nguyen, PL AF Sinha, S. Muralidhar, V. Nguyen, P. L. TI Characteristics and National Trends of Patients Receiving Prostate or Pelvic Radiation for Metastatic Prostate Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Sinha, S.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Sinha, S.; Muralidhar, V.; Nguyen, P. L.] Harvard Med Sch, Boston, MA USA. [Nguyen, P. L.] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2571 BP E234 EP E235 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802570 ER PT J AU Syed, N Chang, H Schwartzberg, B Bremner, A Bhatnagar, A Vito, C Lopez-Penalver, C Ivanov, O Rahman, S Golder, S Proulx, GM Ellenhorn, J Boylan, S Chan, LW AF Syed, N. Chang, H. Schwartzberg, B. Bremner, A. Bhatnagar, A. Vito, C. Lopez-Penalver, C. Ivanov, O. Rahman, S. Golder, S. Proulx, G. M. Ellenhorn, J. Boylan, S. Chan, L. W. TI Early Results of a Multicenter Trial of Intraoperative Radiation Therapy Using Electronic Brachytherapy at the Time of Breast Conservation Surgery for Early-Stage Breast Cancer SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Syed, N.] Long Beach Mem Med Ctr, Todd Canc Inst, Long Beach, CA USA. [Chang, H.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Schwartzberg, B.] Rose Med Ctr, Sarah Canc Res Inst, Denver, CO USA. [Bremner, A.] Breastlink, Murietta, CA USA. [Bhatnagar, A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Vito, C.] City Hope Natl Med Ctr, Duarte, CA USA. [Lopez-Penalver, C.] Baptist Hlth South Florida, Miami, FL USA. [Ivanov, O.] Florida Hosp Celebrat Hlth, Celebration, FL USA. [Rahman, S.] Diablo Valley Hematol Oncol, Pleasant Hill, CA USA. [Golder, S.] Parkridge Med Ctr, Chattanooga, TN USA. [Proulx, G. M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Ellenhorn, J.] Tower Outpatient Surg Ctr, Los Angeles, CA USA. [Boylan, S.] Sentara Northern Virginia, Norfolk, VA USA. [Chan, L. W.] Long Beach Mem Radiat Oncol, Long Beach, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2134 BP E55 EP E56 PG 2 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802135 ER PT J AU Wang, Y Oh, KS Loeffler, JS Shih, HA Mahmood, U AF Wang, Y. Oh, K. S. Loeffler, J. S. Shih, H. A. Mahmood, U. TI C11 Methionine Positron Emission Tomography (MET-PET) Imaging of Glioblastoma for Detecting Postoperative Residual Disease and Response to Chemoradiation Therapy SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Wang, Y.; Oh, K. S.; Loeffler, J. S.; Mahmood, U.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Shih, H. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2226 BP E93 EP E93 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802227 ER PT J AU Wilkinson, B Morgan, H Gondi, V Larson, GL Hartsell, WF Laramore, GE Halasz, LM Vargas, C Keole, SR Grosshans, DR Shih, HA Mehta, MP AF Wilkinson, B. Morgan, H. Gondi, V. Larson, G. L. Hartsell, W. F. Laramore, G. E. Halasz, L. M. Vargas, C. Keole, S. R. Grosshans, D. R. Shih, H. A. Mehta, M. P. TI Low Levels of Acute Toxicity Associated With Proton Therapy for Low-Grade Glioma: A Proton Collaborative Group Study SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Meeting Abstract CT 58th Annual Meeting of the American-Society-for-Radiation-Oncology CY SEP 25-28, 2016 CL Boston, MA SP Amer Soc Radiat Oncol C1 [Wilkinson, B.] Willis Knighton Canc Ctr, Shreveport, LA USA. [Morgan, H.] LSU Hlth Sci Ctr Shreveport, Shreveport, LA USA. [Gondi, V.; Hartsell, W. F.] Northwestern Med Chicago Proton Ctr, Warrenville, IL USA. [Larson, G. L.] ProCure Proton Therapy Ctr, Oklahoma City, OK USA. [Laramore, G. E.; Halasz, L. M.] Univ Washington, Dept Radiat Oncol, Seattle, WA 98195 USA. [Vargas, C.; Keole, S. R.] Mayo Clin Arizona, Phoenix, AZ USA. [Grosshans, D. R.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA. [Shih, H. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Mehta, M. P.] Baptist Hlth South Florida, Miami Canc Inst, Miami, FL USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0360-3016 EI 1879-355X J9 INT J RADIAT ONCOL JI Int. J. Radiat. Oncol. Biol. Phys. PD OCT 1 PY 2016 VL 96 IS 2 SU S MA 2329 BP E135 EP E135 PG 1 WC Oncology; Radiology, Nuclear Medicine & Medical Imaging SC Oncology; Radiology, Nuclear Medicine & Medical Imaging GA EB8QL UT WOS:000387655802329 ER PT J AU Karatasakis, A Danek, BA Karmpaliotis, D Alaswad, K Jaffer, FA Yeh, RW Patel, MP Bahadorani, JN Wyman, RM Lombardi, WL Grantham, JA Kandzari, DE Lembo, NJ Doing, AH Moses, JW Kirtane, AJ Garcia, S Parikh, MA Ali, ZA Karacsonyi, J Kalra, S Rangan, BV Kalsaria, P Thompson, CA Banerjee, S Brilakis, ES AF Karatasakis, Aris Danek, Barbara A. Karmpaliotis, Dimitri Alaswad, Khaldoon Jaffer, Farouc A. Yeh, Robert W. Patel, Mitul P. Bahadorani, John N. Wyman, R. Michael Lombardi, William L. Grantham, J. Aaron Kandzari, David E. Lembo, Nicholas J. Doing, Anthony H. Moses, Jeffrey W. Kirtane, Ajay J. Garcia, Santiago Parikh, Manish A. Ali, Ziad A. Karacsonyi, Judit Kalra, Sanjog Rangan, Bavana V. Kalsaria, Pratik Thompson, Craig A. Banerjee, Subhash Brilakis, Emmanouil S. TI Impact of Proximal Cap Ambiguity on Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Multicenter US Registry SO JOURNAL OF INVASIVE CARDIOLOGY LA English DT Article DE chronic total occlusion; percutaneous coronary intervention; techniques; outcomes ID HYBRID APPROACH; PROCEDURAL OUTCOMES; EFFICACY; SCORE AB Objectives. We sought to determine the impact of proximal cap ambiguity on procedural techniques and outcomes for coronary chronic total occlusion (CTO) percutaneous coronary intervention (PCI). Methods. We examined the clinical and angiographic characteristics and outcomes of 1021 CTO-PCIs performed between 2012 and 2015 at 11 United States centers. Results. Proximal cap ambiguity was present in 31% of target lesions and was associated with increased clinical and angiographic complexity (prior coronary artery bypass graft surgery: 43% vs 33%; P=.01; moderate/severe calcification 66% vs 51%; P<.001) and lower technical success (85% vs 93%; P<.001) and procedural success (84% vs 91%; P=.01), but similar incidence of major adverse cardiac events (3.2% vs 2.9%; P=.77). A retrograde approach was more commonly utilized among cases with proximal cap ambiguity (68% vs 33%; P<.001), and was more likely to be the initial (39% vs 13%; P<.001) and successful approach (42% vs 20%; P<.001). Proximal cap ambiguity was associated with increased use of intravascular ultrasound (49% vs 36%; P=.01) and contrast (281 mL vs 250 mL; P<.001), higher air kerma radiation dose (4.0 Gy vs 3.0 Gy; P<.001), and longer procedure time (161 min vs 119 min; P<.001). Conclusions. Proximal cap ambiguity is present in one-third of CTO-PCI target lesions and is associated with lower success rates, higher utilization of the retrograde approach, and lower procedural efficiency, but no significant difference in the incidence of major adverse cardiac events. C1 [Karatasakis, Aris; Danek, Barbara A.; Karacsonyi, Judit; Rangan, Bavana V.; Kalsaria, Pratik; Banerjee, Subhash; Brilakis, Emmanouil S.] VA North Texas Hlth Care Syst, Dallas, TX USA. [Karatasakis, Aris; Danek, Barbara A.; Karacsonyi, Judit; Rangan, Bavana V.; Kalsaria, Pratik; Banerjee, Subhash; Brilakis, Emmanouil S.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. [Karmpaliotis, Dimitri; Moses, Jeffrey W.; Kirtane, Ajay J.; Parikh, Manish A.; Ali, Ziad A.; Kalra, Sanjog] Columbia Univ, New York, NY USA. [Alaswad, Khaldoon] Henry Ford Hosp, Detroit, MI 48202 USA. [Jaffer, Farouc A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Yeh, Robert W.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Patel, Mitul P.; Bahadorani, John N.] VA San Diego Healthcare Syst, La Jolla, CA USA. [Patel, Mitul P.; Bahadorani, John N.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Wyman, R. Michael] Torrance Mem Med Ctr, Torrance, CA USA. [Lombardi, William L.] PeaceHlth St Joseph Med Ctr, Bellingham, WA USA. [Grantham, J. Aaron] Mid Amer Heart Inst, Kansas City, MO USA. [Kandzari, David E.; Lembo, Nicholas J.] Piedmont Heart Inst, Atlanta, GA USA. [Doing, Anthony H.] Med Ctr Rockies, Loveland, CO USA. [Garcia, Santiago] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA. [Garcia, Santiago] Univ Minnesota, Minneapolis, MN USA. [Thompson, Craig A.] Boston Sci, Natick, MA USA. RP Brilakis, ES (reprint author), Dallas VA Med Ctr 111A, 4500 South Lancaster Rd, Dallas, TX 75216 USA. EM esbrilakis@gmail.com FU Clinical and Translational Science Awards Program of the National Institutes of Health, (Bethesda, Maryland, USA) [UL1-RR024982] FX Research reported in this publication was supported by the Clinical and Translational Science Awards Program of the National Institutes of Health, (Bethesda, Maryland, USA) under grant number UL1-RR024982. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. NR 16 TC 0 Z9 0 U1 1 U2 1 PU H M P COMMUNICATIONS PI MALVERN PA 83 GENERAL WARREN BLVD, STE 100, MALVERN, PA 19355 USA SN 1042-3931 EI 1557-2501 J9 J INVASIVE CARDIOL JI J. Invasive Cardiol. PD OCT PY 2016 VL 28 IS 10 BP 391 EP 396 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA ED2HX UT WOS:000388665700005 PM 27705889 ER PT J AU Chen, W Gao, B Hao, L Zhu, G Jules, J MacDougall, MJ Wang, J Han, X Zhou, X Li, YP AF Chen, W. Gao, B. Hao, L. Zhu, G. Jules, J. MacDougall, M. J. Wang, J. Han, X. Zhou, X. Li, Y. -P. TI The silencing of cathepsin K used in gene therapy for periodontal disease reveals the role of cathepsin K in chronic infection and inflammation SO JOURNAL OF PERIODONTAL RESEARCH LA English DT Article DE adeno-associated virus; alveolar bone loss; cathepsin K; gene therapy; periodontal diseases ID PORPHYROMONAS-GINGIVALIS; BONE DESTRUCTION; IMMUNE CELL; EXPRESSION; OSTEOCLASTS; MOUSE; MICE; ARTHRITIS; DIFFERENTIATION; PYCNODYSOSTOSIS AB Background and Objective: Periodontitis is a severe chronic inflammatory disease and one of the most prevalent non-communicable chronic diseases that affects the majority of the world's adult population. While great efforts have been devoted toward understanding the pathogenesis of periodontitis, there remains a pressing need for developing potent therapeutic strategies for targeting this dreadful disease. In this study, we utilized adeno-associated virus (AAV) expressing cathepsin K (Ctsk) small hairpin (sh) RNA (AAV-sh-Ctsk) to silence Ctsk in vivo and subsequently evaluated its impact in periodontitis as a potential therapeutic strategy for this disease. Material and Methods: We used a known mouse model of periodontitis, in which wild-type BALB/cJ mice were infected with Porphyromonas gingivalis W50 in the maxillary and mandibular periodontium to induce the disease. AAV-sh-Ctsk was then administrated locally into the periodontal tissues in vivo, followed by analyses to assess progression of the disease. Results: AAV-mediated Ctsk silencing drastically protected mice (>80%) from P. gingivalis-induced bone resorption by osteoclasts. In addition, AAV-sh-Ctsk administration drastically reduced inflammation by impacting the expression of many inflammatory cytokines as well as T-cell and dendritic cell numbers in periodontal lesions. Conclusion: AAV-mediated Ctsk silencing can simultaneously target both the inflammation and bone resorption associated with periodontitis through its inhibitory effect on immune cells and osteoclast function. Thereby, AAV-sh-Ctsk administration can efficiently protect against periodontal tissue damage and alveolar bone loss, establishing this AAV-mediated local silencing of Ctsk as an important therapeutic strategy for effectively treating periodontal disease. C1 [Chen, W.; Gao, B.; Hao, L.; Zhu, G.; Jules, J.; Wang, J.; Li, Y. -P.] Univ Alabama Birmingham, Dept Pathol, SHEL 810,1825 Univ Blvd, Birmingham, AL 35294 USA. [Gao, B.; Hao, L.; Zhou, X.] Sichuan Univ, West China Coll Stomatol, State Key Lab Oral Dis, Chengdu, Sichuan, Peoples R China. [MacDougall, M. J.] Univ Alabama Birmingham, Sch Dent, Inst Oral Hlth Res, Birmingham, AL 35294 USA. [Han, X.] Forsyth Inst, Dept Immunol & Infect Dis, Cambridge, MA USA. RP Li, YP (reprint author), Univ Alabama Birmingham, Dept Pathol, SHEL 810,1825 Univ Blvd, Birmingham, AL 35294 USA.; Zhou, X (reprint author), Sichuan Univ, West China Coll Stomatol, State Key Lab Oral Dis, Chengdu, Sichuan, Peoples R China. EM zhouxd@scu.edu.cn; ypli@uab.edu FU UAB Department of Pathology; [R01DE023813] FX We thank Ms. Christie Paulson for her excellent assistance with this manuscript. We appreciate the assistance of the Center for Metabolic Bone Disease at The University of Alabama at Birmingham (P30 AR046031). We are also grateful for the assistance of the Small Animal Phenotyping Core (P30 DK079626), Metabolism Core, and Neuroscience Molecular Detection Core Laboratory at the University of Alabama at Birmingham (P30 NS0474666). This work was supported by R01DE023813 (Y.P.L.) and UAB Department of Pathology Start-Up funding (Wei Chen). NR 49 TC 0 Z9 0 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3484 EI 1600-0765 J9 J PERIODONTAL RES JI J. Periodont. Res. PD OCT PY 2016 VL 51 IS 5 BP 647 EP 660 DI 10.1111/jre.12345 PG 14 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA ED7DX UT WOS:000389023400011 PM 26754272 ER PT J AU Shih, SL Zafonte, R Bates, DW Gerrard, P Goldstein, R Mix, J Niewczyk, P Greysen, SR Kazis, L Ryan, CM Schneider, JC AF Shih, Shirley L. Zafonte, Ross Bates, David W. Gerrard, Paul Goldstein, Richard Mix, Jacqueline Niewczyk, Paulette Greysen, S. Ryan Kazis, Lewis Ryan, Colleen M. Schneider, Jeffrey C. TI Functional Status Outperforms Comorbidities as a Predictor of 30-Day Acute Care Readmissions in the Inpatient Rehabilitation Population SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE Readmission; functional status; rehabilitation; patient outcomes ID POST-ACUTE CARE; HOSPITAL READMISSION; DISCHARGE; PERFORMANCE; MORTALITY; VALIDATION; MODELS AB Objectives: Functional status is associated with patient outcomes, but is rarely included in hospital readmission risk models. The objective of this study was to determine whether functional status is a better predictor of 30-day acute care readmission than traditionally investigated variables including demographics and comorbidities. Design: Retrospective database analysis between 2002 and 2011. Setting: 1158 US inpatient rehabilitation facilities. Participants: 4,199,002 inpatient rehabilitation facility admissions comprising patients from 16 impairment groups within the Uniform Data System for Medical Rehabilitation database. Measurements: Logistic regression models predicting 30-day readmission were developed based on age, gender, comorbidities (Elixhauser comorbidity index, Deyo-Charlson comorbidity index, and Medicare comorbidity tier system), and functional status [Functional Independence Measure (FIM)]. We hypothesized that (1) function-based models would outperform demographic-and comorbidity-based models and (2) the addition of demographic and comorbidity data would not significantly enhance function-based models. For each impairment group, Function Only Models were compared against Demographic-Comorbidity Models and Function Plus Models (Function-Demographic-Comorbidity Models). The primary outcome was 30-day readmission, and the primary measure of model performance was the c-statistic. Results: All-cause 30-day readmission rate from inpatient rehabilitation facilities to acute care hospitals was 9.87%. C-statistics for the Function Only Models were 0.64 to 0.70. For all 16 impairment groups, the Function Only Model demonstrated better c-statistics than the Demographic-Comorbidity Models (c-statistic difference: 0.03-0.12). The best-performing Function Plus Models exhibited negligible improvements in model performance compared to Function Only Models, with c-statistic improvements of only 0.01 to 0.05. Conclusion: Readmissions are currently used as a marker of hospital performance, with recent financial penalties to hospitals for excessive readmissions. Function-based readmission models outperform models based only on demographics and comorbidities. Readmission risk models would benefit from the inclusion of functional status as a primary predictor. (C) 2016 AMDA - The Society for Post-Acute and Long-Term Care Medicine. C1 [Shih, Shirley L.; Zafonte, Ross; Goldstein, Richard; Schneider, Jeffrey C.] Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA. [Shih, Shirley L.; Zafonte, Ross; Schneider, Jeffrey C.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Phys Med & Rehabil, Boston, MA USA. [Bates, David W.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Gen Internal Med & Primary Care, Boston, MA USA. [Bates, David W.] Harvard Sch Publ Hlth, Boston, MA USA. [Gerrard, Paul] New England Rehabil Hosp Portland, Portland, ME USA. [Mix, Jacqueline; Niewczyk, Paulette] Uniform Data Syst Med Rehabil, Amherst, NY USA. [Niewczyk, Paulette] Daemen Coll, Hlth Care Studies Dept, Amherst, NY USA. [Greysen, S. Ryan] Univ Calif San Francisco, Div Hosp Med, San Francisco, CA 94143 USA. [Kazis, Lewis] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Ryan, Colleen M.] Massachusetts Gen Hosp, Sumner Redstone Burn Ctr, Surg Serv, Boston, MA 02114 USA. [Ryan, Colleen M.] Shriners Hosp Childrene Boston, Boston, MA USA. RP Schneider, JC (reprint author), 300 1st Ave, Charlestown, MA 02129 USA. EM jcschneider@partners.org NR 39 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 EI 1538-9375 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD OCT 1 PY 2016 VL 17 IS 10 BP 921 EP 926 DI 10.1016/j.jamda.2016.06.003 PG 6 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA ED7PO UT WOS:000389061400011 PM 27424092 ER PT J AU Chang, E Ruder, T Setodji, C Saliba, D Hanson, M Zingmond, DS Wenger, NS Ganz, DA AF Chang, Emiley Ruder, Teague Setodji, Claude Saliba, Debra Hanson, Mark Zingmond, David S. Wenger, Neil S. Ganz, David A. TI Differences in Nursing Home Quality Between Medicare Advantage and Traditional Medicare Patients SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION LA English DT Article DE Medicare Advantage; nursing homes; quality measures ID FEE-FOR-SERVICE; POST-ACUTE CARE; HEALTH MAINTENANCE ORGANIZATIONS; ACUTE MYOCARDIAL-INFARCTION; MANAGED CARE; OF-CARE; ELDERLY-PATIENTS; DUAL ELIGIBLES; HOSPICE USE; BENEFICIARIES AB Background: Medicare Advantage (MA) enrollment is steadily growing, but little is known about the quality of nursing home (NH) care provided to MA enrollees compared to enrollees in traditional fee-for-service (FFS) Medicare. Objectives: To compare MA and FFS enrollees' quality of NH care. Design: Cross-sectional. Setting: US nursing homes. Participants: 2.17 million Medicare enrollees receiving care at an NH during 2011. Measurements: CMS methodology was used to calculate the 18 Nursing Home Compare quality measures as applicable for each enrollee. Results: Among Medicare enrollees using NH in 2011, 17% were in MA plans. Most quality scores were similar between MA and FFS. After adjusting for facility, beneficiary age and gender, CMS Hierarchical Condition Category score, and geographic region, short-stay MA enrollees had statistically significantly lower rates of new or worsening pressure ulcers [relative risk (RR) = 0.76, 95% confidence interval (CI) = 0.71-0.82] and new antipsychotic use (RR = 0.82, 95% CI = 0.80-0.83) but higher rates of moderate to severe pain (RR = 1.09, 95% CI = 1.07-1.12), compared with short-stay FFS enrollees. MA long-stay enrollees had lower rates of antipsychotic use (RR = 0.94, 95% CI = 0.93-0.96) but had higher rates of incontinence (RR = 1.08, 95% CI = 1.06-1.09) and urinary catheterization (RR = 1.10, 95% CI = 1.06-1.13), compared with long-stay FFS enrollees. Conclusion: Overall, we found few differences in NH quality scores between MA and FFS Medicare enrollees. MA enrollment was associated with better scores for pressure ulcers and antipsychotic use but worse scores for pain control, incontinence, and urinary catheterization. Results may be limited by residual case-mix differences between MA and FFS patients or by the small number of short-stay measures reported. (C) 2016 AMDA - The Society for Post-Acute and Long-Term Care Medicine. C1 [Chang, Emiley; Saliba, Debra; Zingmond, David S.; Wenger, Neil S.; Ganz, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Ruder, Teague; Setodji, Claude; Saliba, Debra; Hanson, Mark; Wenger, Neil S.; Ganz, David A.] RAND Corp, Santa Monica, CA USA. [Saliba, Debra; Ganz, David A.] VA Greater Los Angeles HSR&D Ctr Innovat, Sepulveda, CA USA. [Saliba, Debra; Ganz, David A.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Saliba, Debra] Univ Calif Los Angeles, Borun Ctr Gerontol Res, Los Angeles, CA USA. [Saliba, Debra] Los Angeles Jewish Home, Los Angeles, CA USA. RP Chang, E (reprint author), 911 Broxton Ave, Los Angeles, CA 90024 USA. EM emileychang@mednet.ucla.edu FU National Research Service - National Institutes of Health; Geriatric Training for Physicians, Dentists, and Behavioral and Mental Health Providers fellowship - Bureau of Health Professions; Centers for Medicare & Medicaid Services; Centers for Medicare & Medicaid Services, Department of Health and Human Services [HHSM-500-2005-00028I, HHSM-500-T0004]; Centers for Medicare and Medicaid Services; Health Services Advisory Group; SCAN Health Plan FX Dr. Chang is currently supported by the National Research Service Award fellowship sponsored by the National Institutes of Health; she was previously supported by the Geriatric Training for Physicians, Dentists, and Behavioral and Mental Health Providers fellowship sponsored by the Bureau of Health Professions. The Centers for Medicare & Medicaid Services provided data and financial support for the study. The analyses upon which this publication is based were performed under HHSM-500-2005-00028I, Task Order Number HHSM-500-T0004 funded by the Centers for Medicare & Medicaid Services, Department of Health and Human Services. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does the mention of trade names, commercial products, or organizations imply endorsement by the US Government. The author assumes full responsibility for the accuracy and completeness of the ideas presented.; Dr. Chang has received an honorarium from SCAN Health Plan. Dr. Ganz is or recently has been part of the project team on contracts awarded to RAND from the Centers for Medicare and Medicaid Services and Health Services Advisory Group, and a contract awarded to UCLA from SCAN Health Plan. Dr. Wenger has been part of the project team on a contract awarded to RAND from the Centers for Medicare and Medicaid Services. The other authors have no conflicts of interest to declare. NR 50 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1525-8610 EI 1538-9375 J9 J AM MED DIR ASSOC JI J. Am. Med. Dir. Assoc. PD OCT 1 PY 2016 VL 17 IS 10 AR UNSP 960.e9 DI 10.1016/j.jamda.2016.07.017 PG 6 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA ED7PO UT WOS:000389061400023 ER PT J AU Ruiz-Arguelles, GJ Steensma, DP AF Ruiz-Arguelles, Guillermo J. Steensma, David P. TI Staunching the rising costs of haematological health care SO LANCET HAEMATOLOGY LA English DT Editorial Material ID CANCER DRUGS; MEXICO; CML C1 [Ruiz-Arguelles, Guillermo J.] Ctr Hematol & Med Interna Puebla, Puebla 72530, Mexico. [Steensma, David P.] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA. RP Ruiz-Arguelles, GJ (reprint author), Ctr Hematol & Med Interna Puebla, Puebla 72530, Mexico. EM gruiz1@clinicaruiz.com NR 7 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2352-3026 J9 LANCET HAEMATOL JI Lancet Haematol. PD OCT PY 2016 VL 3 IS 10 BP E455 EP E455 PG 1 WC Hematology SC Hematology GA ED7SL UT WOS:000389070400006 PM 27692304 ER PT J AU Davids, M Schad, LR Wald, LL Guerin, B AF Davids, Mathias Schad, Lothar R. Wald, Lawrence L. Guerin, Bastien TI Fast Three-Dimensional Inner Volume Excitations Using Parallel Transmission and Optimized k-Space Trajectories SO MAGNETIC RESONANCE IN MEDICINE LA English DT Article DE Parallel transmit; spatially selective excitation; inner volume excitation; B0 robustness; k-space trajectory optimization ID GRADIENT WAVE-FORMS; RF PULSES; DESIGN; ECHOES; BRAIN AB Purpose: To design short parallel transmission (pTx) pulses for excitation of arbitrary three-dimensional (3D) magnetization patterns. Methods: We propose a joint optimization of the pTx radiofrequency (RF) and gradient waveforms for excitation of arbitrary 3D magnetization patterns. Our optimization of the gradient waveforms is based on the parameterization of k-space trajectories (3D shells, stack-of-spirals, and cross) using a small number of shape parameters that are well-suited for optimization. The resulting trajectories are smooth and sample k-space efficiently with few turns while using the gradient system at maximum performance. Within each iteration of the k-space trajectory optimization, we solve a small tip angle least-squares RF pulse design problem. Our RF pulse optimization framework was evaluated both in Bloch simulations and experiments on a 7T scanner with eight transmit channels. Results: Using an optimized 3D cross (shells) trajectory, we were able to excite a cube shape (brain shape) with 3.4% (6.2%) normalized root-mean-square error in less than 5 ms using eight pTx channels and a clinical gradient system (G(max) = 40 mT/m, S-max = 150 T/m/s). This compared with 4.7% (41.2%) error for the unoptimized 3D cross (shells) trajectory. Incorporation of B-0 robustness in the pulse design significantly altered the k-space trajectory solutions. Conclusion: Our joint gradient and RF optimization approach yields excellent excitation of 3D cube and brain shapes in less than 5 ms, which can be used for reduced field of view imaging and fat suppression in spectroscopy by excitation of the brain only. (C) 2015 Wiley Periodicals, Inc. C1 [Davids, Mathias; Schad, Lothar R.] Heidelberg Univ, Med Fac Mannheim, Comp Assisted Clin Med, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, BW, Germany. [Davids, Mathias; Wald, Lawrence L.; Guerin, Bastien] Massachusetts Gen Hosp, Dept Radiol, AA Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Wald, Lawrence L.] Harvard MIT, Div Hlth Sci & Technol, Cambridge, MA USA. [Wald, Lawrence L.; Guerin, Bastien] Harvard Med Sch, Boston, MA USA. RP Davids, M (reprint author), Heidelberg Univ, Med Fac Mannheim, Comp Assisted Clin Med, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, BW, Germany. EM mathias.davids@medma.uni-heidel-berg.de FU NIBIB NIH HHS [K99 EB019482, P41 EB015896, R01 EB006847] NR 31 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0740-3194 EI 1522-2594 J9 MAGN RESON MED JI Magn. Reson. Med. PD OCT PY 2016 VL 76 IS 4 BP 1170 EP 1182 DI 10.1002/mrm.26021 PG 13 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA ED1PW UT WOS:000388618400014 PM 26527590 ER PT J AU Gaudin, RA Jowett, N Banks, CA Knox, CJ Hadlock, TA AF Gaudin, Robert A. Jowett, Nathan Banks, Caroline A. Knox, Christopher J. Hadlock, Tessa A. TI Bilateral Facial Paralysis: A 13-Year Experience SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article ID MELKERSSON-ROSENTHAL SYNDROME; BELL PALSY; NERVE DECOMPRESSION; LYME-DISEASE; SYNKINESIS; REANIMATION; MANAGEMENT; MUSCLE AB Background: Bilateral facial palsy is a rare clinical entity caused by myriad disparate conditions requiring different treatment paradigms. Lyme disease, Guillain-Barre syndrome, and leukemia are several examples. In this article, the authors describe the cause, the initial diagnostic approach, and the management of long-term sequelae of bilateral paralysis that has evolved in the authors' center over the past 13 years. Methods: A chart review was performed to identify all patients diagnosed with bilateral paralysis at the authors' center between January of 2002 and January of 2015. Demographics, signs and symptoms, diagnosis, initial medical treatment, interventions for facial reanimation, and outcomes were reviewed. Results: Of the 2471 patients seen at the authors' center, 68 patients (3-percent) with bilateral facial paralysis were identified. Ten patients (15 percent) presented with bilateral facial paralysis caused by Lyme disease, nine (13-percent) with Mobius syndrome, nine (13 percent) with neurofibromatosis type 2, five (7 percent) with bilateral facial palsy caused by brain tumor, four (6 percent) with Melkersson-Rosenthal syndrome, three (4 percent) with bilateral temporal bone fractures, two (3 percent) with Guillain-Barre syndrome, one (2 percent) with central nervous system lymphoma, one (2 percent) with human immunodeficiency virus infection, and 24 (35 percent) with presumed Bell palsy. Treatment included pharmacologic therapy, physical therapy, chemodenervation, and surgical interventions. Conclusions: Bilateral facial palsy is a rare medical condition, and treatment often requires a multidisciplinary approach. The authors outline diagnostic and therapeutic algorithms of a tertiary care center to provide clinicians with a systematic approach to managing these complicated patients. C1 [Hadlock, Tessa A.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. Harvard Med Sch, Boston, MA USA. RP Hadlock, TA (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM tessa_hadlock@meei.harvard.edu NR 37 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0032-1052 EI 1529-4242 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD OCT PY 2016 VL 138 IS 4 BP 879 EP 887 DI 10.1097/PRS.0000000000002599 PG 9 WC Surgery SC Surgery GA ED7HI UT WOS:000389033000063 PM 27307336 ER PT J AU Guerrero, EN Wang, HB Mitra, J Hegde, PM Stowell, SE Liachko, NF Kraemer, BC Garruto, RM Rao, KS Hegde, ML AF Guerrero, Erika N. Wang, Haibo Mitra, Joy Hegde, Pavana M. Stowell, Sara E. Liachko, Nicole F. Kraemer, Brian C. Garruto, Ralph M. Rao, K. S. Hegde, Muralidhar L. TI TDP-43/FUS in motor neuron disease: Complexity and challenges SO PROGRESS IN NEUROBIOLOGY LA English DT Review DE TDP-43; FUS/TLS; Amyotrophic lateral sclerosis; RNA processing; Genome damage/repair ID AMYOTROPHIC-LATERAL-SCLEROSIS; FRONTOTEMPORAL LOBAR DEGENERATION; RNA-BINDING PROTEINS; PARKINSONISM-DEMENTIA COMPLEX; PRION-LIKE DOMAINS; LENGTH POLYGLUTAMINE EXPANSIONS; ARGININE METHYLTRANSFERASE 1; C9ORF72 REPEAT EXPANSION; HUMAN MYELOID-LEUKEMIA; NUCLEAR FACTOR TDP-43 AB Amyotrophic lateral sclerosis (ALS), a common motor neuron disease affecting two per 100,000 people worldwide, encompasses at least five distinct pathological subtypes, including, ALS-SOD1, ALS-C9orf72, ALS-TDP-43, ALS-FUS and Guam-ALS. The etiology of a major subset of ALS involves toxicity of the TAR DNA-binding protein-43 (TDP-43). A second RNA/DNA binding protein, fused in sarcoma/translocated in liposarcoma (FUS/TLS) has been subsequently associated with about 1% of ALS patients. While mutations in TDP-43 and FUS have been linked to ALS, the key contributing molecular mechanism(s) leading to cell death are still unclear. One unique feature of TDP-43 and FUS pathogenesis in ALS is their nuclear clearance and simultaneous cytoplasmic aggregation in affected motor neurons. Since the discoveries in the last decade implicating TDP-43 and FUS toxicity in ALS, a majority of studies have focused on their cytoplasmic aggregation and disruption of their RNA-binding functions. However, TDP-43 and FUS also bind to DNA, although the significance of their DNA binding in disease-affected neurons has been less investigated. A recent observation of accumulated genomic damage in TDP-43 and FUS-linked ALS and association of FUS with neuronal DNA damage repair pathways indicate a possible role of deregulated DNA binding function of TDP-43 and FUS in ALS. In this review, we discuss the different ALS disease subtypes, crosstalk of etiopathologies in disease progression, available animal models and their limitations, and recent advances in understanding the specific involvement of RNA/DNA binding proteins, TDP-43 and FUS, in motor neuron diseases. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Guerrero, Erika N.; Wang, Haibo; Mitra, Joy; Hegde, Pavana M.; Hegde, Muralidhar L.] Houston Methodist Res Inst, Dept Radiat Oncol, Houston, TX 77030 USA. [Guerrero, Erika N.; Rao, K. S.] Inst Sci Res & Technol Serv INDICASAT AIP, Ctr Neurosci, City Of Knowledge, Panama. [Guerrero, Erika N.; Rao, K. S.] Acharya Nagarjuna Univ, Dept Biotechnol, Guntur, India. [Stowell, Sara E.; Garruto, Ralph M.] SUNY Binghamton, Dept Anthropol, Binghamton, NY USA. [Garruto, Ralph M.] SUNY Binghamton, Dept Biol Sci, Binghamton, NY USA. [Liachko, Nicole F.; Kraemer, Brian C.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Hegde, Muralidhar L.] Houston Methodist Neurol Inst, Houston, TX 77030 USA. [Hegde, Muralidhar L.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA. RP Hegde, ML (reprint author), 6550 Fannin St,Smith 8-05, Houston, TX 77030 USA. EM mlhegde@houstonmethodist.org OI Hegde, Muralidhar/0000-0001-7333-8123; Guerrero, Erika/0000-0002-9838-3577 FU National Institutes of Health USPHS [R01 NS 088645]; Muscular Dystrophy Association [MDA 294842]; ALS Association [15-IIP-204]; Alzheimer's Association [NIRG-12-242135]; Melo Brain Funds; Institute for Training and Development of Human resources of Panama (IFARHU); National Secretariat for Science, Technology, and Innovation of Panama (SENACYT); National System on Investigation (SNI) grant of SENACYT; Department of Veterans Affairs [I01BX002619]; National Institutes of Health [R01NS064131]; Career Development Award 2 from the Department of Veterans Affairs [I01BX007080] FX The research in the Hegde laboratory is supported by grants from the National Institutes of Health USPHS R01 NS 088645, Muscular Dystrophy Association (MDA 294842), ALS Association (15-IIP-204), Alzheimer's Association (NIRG-12-242135) to M.L.H. and Melo Brain Funds (M.L.H. and K.S.R.). E.N.G. is supported by a Doctoral Scholarship granted by the Institute for Training and Development of Human resources of Panama (IFARHU) and the National Secretariat for Science, Technology, and Innovation of Panama (SENACYT). K.S.R. is supported by the National System on Investigation (SNI) grant of SENACYT. B.C.K. is supported by grants from the Department of Veterans Affairs [Merit Review Grant #I01BX002619] and National Institutes of Health [R01NS064131]. N.L. is supported by a Career Development Award 2 from the Department of Veterans Affairs [#I01BX007080]. The authors thank other members of the Hegde laboratory for their assistance. NR 295 TC 1 Z9 1 U1 5 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0301-0082 J9 PROG NEUROBIOL JI Prog. Neurobiol. PD OCT-NOV PY 2016 VL 145 BP 78 EP 97 DI 10.1016/j.pneurobio.2016.09.004 PG 20 WC Neurosciences SC Neurosciences & Neurology GA ED3WT UT WOS:000388779900004 PM 27693252 ER PT J AU Mulder, FJ Mellema, JJ Ring, D AF Mulder, Frans J. Mellema, Jos J. Ring, David TI Proximity of Vital Structures to the Clavicle: Comparison of Fractured and Non-fractured Side SO ARCHIVES OF BONE AND JOINT SURGERY-ABJS LA English DT Article DE Clavicle; Computed tomography; Distance; Fracture; Vital structures ID BRACHIAL-PLEXUS; INJURY AB Background: Previous anatomic and radiological studies have described the relationship of the clavicle to major neurovascular structures in healthy subjects. We were curious about this relationship in patients with a clavicle fracture and if it is different from non-fractured clavicles. Methods: We retrospectively identified all patients with a clavicle fracture between July 2001 and October 2013 in two level 1 trauma centers. Patients aged 18 years or greater with an acute unilateral clavicle fracture and a chest CT scan in the supine position displaying both clavicles and the complete fracture were included. Seventy patients were available for study. The distance was measured from the fracture site and from the closest clavicular cortex to the closest major artery, major vein, and inner surface of the thoracic cavity. CT data was evaluated in OsiriX DICOM viewer software with the use of three-dimensional Multiplanar Reconstruction. Results: Compared to the fractured side, the clavicle was significantly closer to the artery and vein on the non-fractured side (P<0.001 and P=0.0025 respectively). There was a significant difference in the median distance of the fracture site to the artery, vein, and inner surface of thoracic cavity between the different types of fractures (P<0.001). A post-hoc comparison showed significant differences in all distances between fracture types, except for the distance of proximal third compared to middle third fractures to the closest artery (P=0.41). There was no significant difference in distance when the arm is up overhead compared to down by the side of the body in computed tomography (CT) scans. Conclusions: A fracture of the clavicle changes the relationship of the clavicle to major vital structures. The minimum distance of the clavicle to the closest artery and vein is significantly less on the non-fractured side, compared to the fractured side. C1 [Mulder, Frans J.; Mellema, Jos J.; Ring, David] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Ring, D (reprint author), Univ Texas Austin, Dept Surg & Perioperat Care, Dell Med Sch, 1400 Barbara Jordan Blvd,Suite 2-834,MC R1800, Austin, TX 78723 USA. EM david.ring@austin.utexas.edu NR 16 TC 0 Z9 0 U1 0 U2 0 PU MASHHAD UNIV MED SCIENCES PI MASHHAD PA VICE-CHANCELLOR FOR RES CTR OFF IJBMS, DANESHGAH ST, PO BOX 9138813944 - 445, MASHHAD, 00000, IRAN SN 2345-4644 EI 2345-461X J9 ARCH BONE JT SURG-AB JI Arch. Bone Jt. Surg.-ABJS PD OCT PY 2016 VL 4 IS 4 BP 318 EP 322 PG 5 WC Orthopedics SC Orthopedics GA EC4LE UT WOS:000388100200006 PM 27847843 ER PT J AU Drijkoningen, T Knotter, R Coerkamp, EG Koning, AHJ Rhemrev, SJ Beeres, FJ AF Drijkoningen, Tessa Knotter, Robert Coerkamp, Emile G. Koning, Anton H. J. Rhemrev, Steven J. Beeres, Frank J. TI Inter-observer agreement between 2-dimensional CT versus 3-dimensional I-Space model in the Diagnosis of Occult Scaphoid Fractures SO ARCHIVES OF BONE AND JOINT SURGERY-ABJS LA English DT Article DE 3D Imaging; Occult fracture; Scaphoid; Virtual Reality ID VIRTUAL-REALITY; COMPUTED-TOMOGRAPHY; RELIABILITY; VOLUME AB Background: The I-Space is a radiological imaging system in which Computed Tomography (CT)-scans can be evaluated as a three dimensional hologram. The aim of this study is to analyze the value of virtual reality (I-Space) in diagnosing acute occult scaphoid fractures. Methods: A convenient cohort of 24 patients with a CT-scan from prior studies, without a scaphoid fracture on radiograph, yet high clinical suspicion of a fracture, were included in this study. CT-scans were evaluated in the I-Space by 7 observers of which 3 observers assessed the scans in the I-Space twice. The observers in this study assessed in the I-Space whether the patient had a scaphoid fracture. The kappa value was calculated for inter-and intra-observer agreement. Results: The Kappa value varied from 0.11 to 0.33 for the first assessment. For the three observers who assessed the CT-scans twice; observer 1 improved from a kappa of 0.33 to 0.50 (95% CI 0.26-0.74, P=0.01), observer 2 from 0.17 to 0.78 (95% CI 0.36-1.0, P< 0.001), and observer 3 from 0.11 to 0.24 (95% CI 0.0-0.77, P=0.24). Conclusion: Following our findings the I-Space has a fast learning curve and has a potential place in the diagnostic modalities for suspected scaphoid fractures. C1 [Drijkoningen, Tessa; Knotter, Robert; Coerkamp, Emile G.; Koning, Anton H. J.; Rhemrev, Steven J.; Beeres, Frank J.] Med Ctr Haaglanden, Dept Surg, The Hague, Netherlands. RP Drijkoningen, T (reprint author), Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA. EM tessa.drijkoningen@gmail.com NR 12 TC 0 Z9 0 U1 0 U2 0 PU MASHHAD UNIV MED SCIENCES PI MASHHAD PA VICE-CHANCELLOR FOR RES CTR OFF IJBMS, DANESHGAH ST, PO BOX 9138813944 - 445, MASHHAD, 00000, IRAN SN 2345-4644 EI 2345-461X J9 ARCH BONE JT SURG-AB JI Arch. Bone Jt. Surg.-ABJS PD OCT PY 2016 VL 4 IS 4 BP 343 EP 347 PG 5 WC Orthopedics SC Orthopedics GA EC4LE UT WOS:000388100200010 PM 27847847 ER PT J AU Doring, AC Overbeek, CL Teunis, T Becker, SJE Ring, D AF Doring, Anne-Carolin Overbeek, Celeste L. Teunis, Teun Becker, Stephanie J. E. Ring, David TI A Slightly Dorsally Tilted Lunate on MRI can be Considered Normal SO ARCHIVES OF BONE AND JOINT SURGERY-ABJS LA English DT Article DE Capitolunate angle; Lunate bone; MRI; Radiolunate angle ID CARPAL BONE ANGLES; LATERAL WRIST RADIOGRAPHS AB Background: Abnormal angulation of the lunate can be an indication of intercarpal pathology. On magnetic resonance images (MRIs) the lunate often looks dorsally angulated, even in healthy wrists. The tilt on individual slices can also be different and might be misinterpreted as pathological, contributing to inaccurate diagnoses and unnecessary surgery. The primary aim of this study was to determine the average radiolunate angle on sagittal wrist MRI images as well as the radiolunate angle in the most radial, central and most ulnar part of the lunate; also the interobserver reliability was determined. Methods: 140 MRIs from adult, non-pregnant patients presenting to the outpatient hand and upper extremity service between 2010 and 2013 with wrist pain were used for this retrospective study. One author measured the radiolunate and capitolunate angle (i.e., tangential and axial method) in all MRIs. Additionally, two authors measured the same angles independently in 46 MRIs to analyze interobserver reliability. Results: The average radiolunate angle was 8.7 degrees dorsal. There were no significant differences in the radiolunate angles between the different parts of the lunate. A very good interrater agreement was measured considering the radiolunate angle and capitolunate angle (tangential and axial method). Conclusions: Our study showed that the lunate appears slightly dorsally angulated on an MRI of a healthy wrist. Regarding the radiolunate angle, 10 to 15 degrees of dorsal tilt can be considered normal. This study provides reference information of normal anatomy for carpal axial alignment that may facilitate diagnoses of wrist pathology. C1 [Doring, Anne-Carolin; Overbeek, Celeste L.; Teunis, Teun; Becker, Stephanie J. E.; Ring, David] Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Boston, MA 02114 USA. RP Ring, D (reprint author), Univ Texas Austin, Dell Med Sch, Dept Surg & Perioperat Care, Austin, TX 78712 USA. EM dring@mgh.harvard.edu NR 10 TC 0 Z9 0 U1 0 U2 0 PU MASHHAD UNIV MED SCIENCES PI MASHHAD PA VICE-CHANCELLOR FOR RES CTR OFF IJBMS, DANESHGAH ST, PO BOX 9138813944 - 445, MASHHAD, 00000, IRAN SN 2345-4644 EI 2345-461X J9 ARCH BONE JT SURG-AB JI Arch. Bone Jt. Surg.-ABJS PD OCT PY 2016 VL 4 IS 4 BP 348 EP 352 PG 5 WC Orthopedics SC Orthopedics GA EC4LE UT WOS:000388100200011 PM 27847848 ER PT J AU Hageman, MGJS Doring, AC Spit, SA Guitton, TG Ring, D AF Hageman, Michiel G. J. S. Doring, Anne-Carolin Spit, Silke A. Guitton, Thierry G. Ring, David CA Sci Variation Grp TI Assessment of Decisional Conflict about the Treatment of Trigger Finger, Comparing Patients and Physicians SO ARCHIVES OF BONE AND JOINT SURGERY-ABJS LA English DT Article DE Assessment of Needs; Decisional Conflict Scale; Shared decision making; Trigger Finger ID PAIN; VALIDATION; QUESTIONNAIRE; DISABILITY; FRAMEWORK; BEHAVIOR; SUPPORT; SCALE; CARE AB Background: As an early step in the development of a decision aid for idiopathic trigger finger (TF) we were interested in the level of decisional conflict experienced by patients and hand surgeons. This study tested the null hypothesis that there is no difference in decisional conflict between patients with one or more idiopathic trigger fingers and hand surgeons. Secondary analyses address the differences between patients and surgeons regarding the influence of the DCS-subcategories on the level of decisional conflict, as well as the influence of patient and physician demographics, the level of self-efficacy, and satisfaction with care on decisional conflict. Methods: One hundred and five hand surgeon-members of the Science of Variation Group (SOVG) and 84 patients with idiopathic TF completed the survey regarding the Decisional Conflict Scale. Patients also filled out the Pain Self-efficacy Questionnaire (PSEQ) and the Patient Doctor Relationship Questionnaire (PDRQ-9). Results: On average, patients had decisional conflict comparable to physicians, but by specific category patients felt less informed and supported than physicians. The only factors associated with greater decisional conflict was the relationship between the patient and doctor. Conclusions: There is a low, but measurable level of decisional conflict among patients and surgeons regarding idiopathic trigger finger. Studies testing the ability of decision aids to reduce decisional conflict and improve patient empowerment and satisfaction with care are merited. C1 [Hageman, Michiel G. J. S.; Doring, Anne-Carolin; Spit, Silke A.; Guitton, Thierry G.; Ring, David; Sci Variation Grp] Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Boston, MA 02114 USA. RP Ring, D (reprint author), Univ Texas Austin, Dell Med Sch, Dept Surg & Perioperat Care, Austin, TX 78712 USA. EM Dring@partners.org NR 24 TC 0 Z9 0 U1 4 U2 4 PU MASHHAD UNIV MED SCIENCES PI MASHHAD PA VICE-CHANCELLOR FOR RES CTR OFF IJBMS, DANESHGAH ST, PO BOX 9138813944 - 445, MASHHAD, 00000, IRAN SN 2345-4644 EI 2345-461X J9 ARCH BONE JT SURG-AB JI Arch. Bone Jt. Surg.-ABJS PD OCT PY 2016 VL 4 IS 4 BP 353 EP 358 PG 6 WC Orthopedics SC Orthopedics GA EC4LE UT WOS:000388100200012 PM 27847849 ER PT J AU Hermanussen, HH Menendez, ME Chen, NC Ring, D Vranceanu, AM AF Hermanussen, Hugo H. Menendez, Mariano E. Chen, Neal C. Ring, David Vranceanu, Ana-Maria TI Predictors of Upper-Extremity Physical Function in Older Adults SO ARCHIVES OF BONE AND JOINT SURGERY-ABJS LA English DT Article DE Diet; Exercise; Pain intensity; Pain interference; Upper-extremity physical function AB Background: Little is known about the influence of habitual participation in physical exercise and diet on upper-extremity physical function in older adults. To assess the relationship of general physical exercise and diet to upper-extremity physical function and pain intensity in older adults. Methods: A cohort of 111 patients 50 or older completed a sociodemographic survey, the Rapid Assessment of Physical Activity (RAPA), an 11-point ordinal pain intensity scale, a Mediterranean diet questionnaire, and three Patient-Reported Outcomes Measurement Information System (PROMIS) based questionnaires: Pain Interference to measure inability to engage in activities due to pain, Upper-Extremity Physical Function, and Depression. Multivariable linear regression modeling was used to characterize the association of physical activity, diet, depression, and pain interference to pain intensity and upper-extremity function. Results: Higher general physical activity was associated with higher PROMIS Upper-Extremity Physical Function and lower pain intensity in bivariate analyses. Adherence to the Mediterranean diet did not correlate with PROMIS Upper-Extremity Physical Function or pain intensity in bivariate analysis. In multivariable analyses factors associated with higher PROMIS Upper-Extremity Physical Function were male sex, non-traumatic diagnosis and PROMIS Pain Interference, with the latter accounting for most of the observed variability (37%). Factors associated with greater pain intensity in multivariable analyses included fewer years of education and higher PROMIS Pain Interference. Conclusions: General physical activity and diet do not seem to be as strongly or directly associated with upper-extremity physical function as pain interference. C1 [Hermanussen, Hugo H.; Menendez, Mariano E.; Chen, Neal C.; Ring, David; Vranceanu, Ana-Maria] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Ring, D (reprint author), Univ Texas Austin, Dell Med Sch, Dept Surg & Perioperat Care, Austin, TX 78712 USA. EM dring@partners.org NR 15 TC 0 Z9 0 U1 0 U2 0 PU MASHHAD UNIV MED SCIENCES PI MASHHAD PA VICE-CHANCELLOR FOR RES CTR OFF IJBMS, DANESHGAH ST, PO BOX 9138813944 - 445, MASHHAD, 00000, IRAN SN 2345-4644 EI 2345-461X J9 ARCH BONE JT SURG-AB JI Arch. Bone Jt. Surg.-ABJS PD OCT PY 2016 VL 4 IS 4 BP 359 EP 365 PG 7 WC Orthopedics SC Orthopedics GA EC4LE UT WOS:000388100200013 PM 27847850 ER PT J AU Pitman, MB AF Pitman, Martha Bishop TI Cancer Cytopathology: 20 Years of Advancing the Field of Pancreaticobiliary Cytopathology SO CANCER CYTOPATHOLOGY LA English DT Editorial Material ID FINE-NEEDLE-ASPIRATION; CYTOLOGIC DIAGNOSTIC CATEGORY; PAPILLARY MUCINOUS NEOPLASMS; ULTRASOUND-GUIDED FNA; ONE INSTITUTIONS EXPERIENCE; ATYPICAL EPITHELIAL-CELLS; IN-SITU HYBRIDIZATION; CYST FLUID ANALYSIS; ENDOSCOPIC ULTRASOUND; PREOPERATIVE DIAGNOSIS C1 [Pitman, Martha Bishop] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St, Boston, MA 02114 USA. RP Pitman, MB (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St, Boston, MA 02114 USA. EM mpitman@partners.org NR 69 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1934-662X EI 1934-6638 J9 CANCER CYTOPATHOL JI Cancer Cytopathol. PD OCT PY 2016 VL 124 IS 10 BP 690 EP 694 DI 10.1002/cncy.21773 PG 5 WC Oncology; Pathology SC Oncology; Pathology GA EC0CK UT WOS:000387765100004 PM 27740727 ER PT J AU Manchikanti, L Hirsch, JA Pampati, V Boswell, MV AF Manchikanti, Laxmaiah Hirsch, Joshua A. Pampati, Vidyasagar Boswell, Mark V. TI Utilization of Facet Joint and Sacroiliac Joint Interventions in Medicare Population from 2000 to 2014: Explosive Growth Continues! SO CURRENT PAIN AND HEADACHE REPORTS LA English DT Review DE Facet joint interventions; Sacroiliac joint injections; Chronic spinal pain; Patterns of utilization ID LOW-BACK-PAIN; CHRONIC SPINAL PAIN; MANAGEMENT SPECIFIC INSTRUMENT; MANAGING CHRONIC PAIN; DOUBLE-BLIND TRIAL; 2-YEAR FOLLOW-UP; RADIOFREQUENCY DENERVATION; UNITED-STATES; EPIDURAL INJECTIONS; RANDOMIZED-TRIAL AB Increasing utilization of interventional techniques in managing chronic spinal pain, specifically facet joint interventions and sacroiliac joint injections, is a major concern of healthcare policy makers. We analyzed the patterns of utilization of facet and sacroiliac joint interventions in managing chronic spinal pain. The results showed significant increase of facet joint interventions and sacroiliac joint injections from 2000 to 2014 in Medicare FFS service beneficiaries. Overall, the Medicare population increased 35 %, whereas facet joint and sacroiliac joint interventions increased 313.3 % per 100,000 Medicare population with an annual increase of 10.7 %. While the increases were uniform from 2000 to 2014, there were some decreases noted for facet joint interventions in 2007, 2010, and 2013, whereas for sacroiliac joint injections, the decreases were noted in 2007 and 2013. The increases were for cervical and thoracic facet neurolysis at 911.5 % compared to lumbosacral facet neurolysis of 567.8 %, 362.9 % of cervical and thoracic facet joint blocks, 316.9 % of sacroiliac joints injections, and finally 227.3 % of lumbosacral facet joint blocks. C1 [Manchikanti, Laxmaiah; Pampati, Vidyasagar] Pain Management Ctr Paducah, 2831 Lone Oak Rd, Paducah, KY 42003 USA. [Manchikanti, Laxmaiah; Boswell, Mark V.] Univ Louisville, Dept Anesthesiol & Perioperat Med, 530 S Jackson St,Room C2A01, Louisville, KY 40202 USA. [Hirsch, Joshua A.] Massachusetts Gen Hosp, 55 Blossom St,Gray 241B, Boston, MA 02114 USA. [Hirsch, Joshua A.] Harvard Med Sch, 55 Blossom St,Gray 241B, Boston, MA 02114 USA. RP Manchikanti, L (reprint author), Pain Management Ctr Paducah, 2831 Lone Oak Rd, Paducah, KY 42003 USA.; Manchikanti, L (reprint author), Univ Louisville, Dept Anesthesiol & Perioperat Med, 530 S Jackson St,Room C2A01, Louisville, KY 40202 USA. EM drlm@thepainmd.com; hirsch@snisonline.org; sagar@thepainmd.com; boswellmv@earthlink.net FU Carefusion FX Joshua A. Hirsch declares he is a consultant for Medtronic and declares personal fees for teaching a single course for Carefusion. NR 82 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1531-3433 EI 1534-3081 J9 CURR PAIN HEADACHE R JI Curr. Pain Headache Rep. PD OCT PY 2016 VL 20 IS 10 AR 58 DI 10.1007/s11916-016-0588-2 PG 15 WC Clinical Neurology SC Neurosciences & Neurology GA EC7AT UT WOS:000388288700003 PM 27646014 ER PT J AU Gutner, CA Galovski, T Bovin, MJ Schnurr, PP AF Gutner, Cassidy A. Galovski, Tara Bovin, Michelle J. Schnurr, Paula P. TI Emergence of Transdiagnostic Treatments for PTSD and Posttraumatic Distress SO CURRENT PSYCHIATRY REPORTS LA English DT Review DE Posttraumatic stress disorder; Transdiagnostic; Treatment; Psychotherapy ID COGNITIVE-BEHAVIOR THERAPY; NATIONAL COMORBIDITY SURVEY; EMOTIONAL DISORDERS; UNIFIED PROTOCOL; STRESS-DISORDER; PANIC DISORDER; MENTAL-HEALTH; ANXIETY DISORDERS; CONTROLLED-TRIAL; DEPRESSION AB Both theoretical and empirical findings have demonstrated similarities across diagnoses, leading to a growing interest in transdiagnostic interventions. Most of the evidence supporting transdiagnostic treatment has accumulated for depression, anxiety, and eating disorders, with minimal attention given to posttraumatic stress disorder and other reactions to traumatic stressors. Although single-diagnosis protocols are effective for posttraumatic stress disorder (PTSD) and other trauma-related disorders, in principle, transdiagnostic approaches may have beneficial applications within a traumatized population. This paper defines different types of transdiagnostic treatments, reviews transdiagnostic approaches used in related disorders, and discusses their applicability to PTSD. Examples are drawn from existing transdiagnostic treatments in order to provide a framework for the application of such interventions to the field of traumatic stress. Implications for implementation and dissemination are also discussed. C1 [Gutner, Cassidy A.; Galovski, Tara] Boston Univ, Sch Med, Natl Ctr PTSD, Womens Hlth Sci Div, 150 South Huntington Ave,116B-3, Boston, MA 02130 USA. [Bovin, Michelle J.] Boston Univ, Sch Med, Natl Ctr PTSD, Behav Sci Div, 150 South Huntington Ave,116B-3, Boston, MA 02130 USA. [Schnurr, Paula P.] VA Med Ctr 116D, Natl Ctr PTSD, Execut Div, 215 North Main St, White River Jct, VT 05009 USA. [Schnurr, Paula P.] Geisel Sch Med Dartmouth, Hanover, NH 03755 USA. RP Gutner, CA (reprint author), Boston Univ, Sch Med, Natl Ctr PTSD, Womens Hlth Sci Div, 150 South Huntington Ave,116B-3, Boston, MA 02130 USA. EM cassidy.gutner@va.gov; tara.galovski@va.gov; michelle.bovin@va.gov; paula.p.schnurr@dartmouth.edu FU National Institute of Mental Health [1K23MH103396-01A1] FX Dr. Gutner was supported by a National Institute of Mental Health grant (1K23MH103396-01A1). NR 61 TC 0 Z9 0 U1 4 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3812 EI 1535-1645 J9 CURR PSYCHIAT REP JI Curr. Psychiatry Rep. PD OCT PY 2016 VL 18 IS 10 AR 95 DI 10.1007/s11920-016-0734-x PG 7 WC Psychiatry SC Psychiatry GA EC5IG UT WOS:000388167300007 PM 27604362 ER PT J AU Walford, GA Gustafsson, S Rybin, D Stancakova, A Chen, H Liu, CT Hong, JY Jensen, RA Rice, K Morris, AP Magi, R Tonjes, A Prokopenko, I Kleber, ME Delgado, G Silbernagel, G Jackson, AU Appel, EV Grarup, N Lewis, JP Montasser, ME Landenvall, C Staiger, H Luan, J Frayling, TM Weedon, MN Xie, WJ Morcillo, S Martinez-Larrad, MT Biggs, ML Chen, YDI Corbaton-Anchuelo, A Faerch, K Gomez-Zumaquero, JM Goodarzi, MO Kizer, JR Koistinen, HA Leong, A Lind, L Lindgren, C Machicao, F Manning, AK Martin-Nunez, GM Rojo-Martinez, G Rotter, JI Siscovick, DS Zmuda, JM Zhang, ZY Serrano-Rios, M Smith, U Soriguer, F Hansen, T Jorgensen, TJ Linnenberg, A Pedersen, O Walker, M Langenberg, C Scott, RA Wareham, NJ Fritsche, A Haring, HU Stefan, N Groop, L O'Connell, JR Boehnke, M Bergman, RN Collins, FS Mohlke, KL Tuomilehto, J Marz, W Kovacs, P Stumvoll, M Psaty, BM Kuusisto, J Laakso, M Meigs, JB Dupuis, J Ingelsson, E Florez, JC AF Walford, Geoffrey A. Gustafsson, Stefan Rybin, Denis Stancakova, Alena Chen, Han Liu, Ching-Ti Hong, Jaeyoung Jensen, Richard A. Rice, Ken Morris, Andrew P. Magi, Reedik Toenjes, Anke Prokopenko, Inga Kleber, Marcus E. Delgado, Graciela Silbernagel, Guenther Jackson, Anne U. Appel, Emil V. Grarup, Niels Lewis, Joshua P. Montasser, May E. Landenvall, Claes Staiger, Harald Luan, Jian'an Frayling, Timothy M. Weedon, Michael N. Xie, Weijia Morcillo, Sonsoles Teresa Martinez-Larrad, Maria Biggs, Mary L. Chen, Yii-Der Ida Corbaton-Anchuelo, Arturo Faerch, Kristine Miguel Gomez-Zumaquero, Juan Goodarzi, Mark O. Kizer, Jorge R. Koistinen, Heikki A. Leong, Aaron Lind, Lars Lindgren, Cecilia Machicao, Fausto Manning, Alisa K. Maria Martin-Nunez, Gracia Rojo-Martinez, Gemma Rotter, Jerome I. Siscovick, David S. Zmuda, Joseph M. Zhang, Zhongyang Serrano-Rios, Manuel Smith, Ulf Soriguer, Federico Hansen, Torben Jorgensen, Torben J. Linnenberg, Allan Pedersen, Oluf Walker, Mark Langenberg, Claudia Scott, Robert A. Wareham, Nicholas J. Fritsche, Andreas Haering, Hans-Ulrich Stefan, Norbert Groop, Leif O'Connell, Jeff R. Boehnke, Michael Bergman, Richard N. Collins, Francis S. Mohlke, Karen L. Tuomilehto, Jaakko Maerz, Winfried Kovacs, Peter Stumvoll, Michael Psaty, Bruce M. Kuusisto, Johanna Laakso, Markku Meigs, James B. Dupuis, Josee Ingelsson, Erik Florez, Jose C. TI Genome-Wide Association Study of the Modified Stumvoll Insulin Sensitivity Index Identifies BCL2 and FAM19A2 as Novel Insulin Sensitivity Loci SO DIABETES LA English DT Article ID GLUCOSE-TOLERANCE TEST; EUGLYCEMIC CLAMP; GLYCEMIC TRAITS; METAANALYSIS; GENE; PATHOPHYSIOLOGY; HERITABILITY; RESISTANCE; RELEASE; SNP AB Genome-wide association studies (GWAS) have found few common variants that influence fasting measures of insulin sensitivity. We hypothesized that a GWAS of an integrated assessment of fasting and dynamic measures of insulin sensitivity would detect novel common variants. We performed a GWAS of the modified Stumvoll Insulin Sensitivity Index (ISI) within the Meta-Analyses of Glucose and Insulin-Related Traits Consortium. Discovery for genetic association was performed in 16,753 individuals, and replication was attempted for the 23 most significant novel loci in 13,354 independent individuals. Association with ISI was tested in models adjusted for age, sex, and BMI and in a model analyzing the combined influence of the genotype effect adjusted for BMI and the interaction effect between the genotype and BMI on ISI (model 3). In model 3, three variants reached genome-wide significance: rs13422522 (NYAP2; P = 8.87 x 10(-11)), rs12454712 (BCL2; P = 2.7 x 10(-8)), and rs10506418 (FAM19A2; P = 1.9 x 10(-8)). The association at NYAP2 was eliminated by conditioning on the known IRS1 insulin sensitivity locus; the BCL2 and FAM19A2 associations were independent of known cardiometabolic loci. In conclusion, we identified two novel loci and replicated known variants associated with insulin sensitivity. Further studies are needed to clarify the causal variant and function at the BCL2 and FAM19A2 loci. C1 [Walford, Geoffrey A.; Florez, Jose C.] Massachusetts Gen Hosp, Diabet Unit, Diabet Res Ctr, Boston, MA 02114 USA. [Walford, Geoffrey A.; Manning, Alisa K.; Florez, Jose C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Walford, Geoffrey A.; Leong, Aaron; Manning, Alisa K.; Meigs, James B.; Florez, Jose C.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA. [Gustafsson, Stefan; Lind, Lars] Uppsala Univ, Dept Med Sci, Uppsala, Sweden. [Rybin, Denis] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA USA. [Stancakova, Alena] Univ Eastern Finland, Kuopio, Finland. [Stancakova, Alena; Kuusisto, Johanna; Laakso, Markku] Kuopio Univ Hosp, Kuopio, Finland. [Chen, Han; Liu, Ching-Ti; Hong, Jaeyoung; Dupuis, Josee] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Chen, Han] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Jensen, Richard A.; Biggs, Mary L.; Siscovick, David S.; Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA. [Jensen, Richard A.; Siscovick, David S.; Psaty, Bruce M.] Univ Washington, Dept Med, Seattle, WA USA. [Rice, Ken; Biggs, Mary L.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Morris, Andrew P.] Univ Liverpool, Dept Biostat, Liverpool, Merseyside, England. [Morris, Andrew P.; Prokopenko, Inga; Lindgren, Cecilia] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England. [Magi, Reedik] Univ Tartu, Estonian Genome Ctr, Tartu, Estonia. [Toenjes, Anke; Stumvoll, Michael] Univ Leipzig, Dept Med, Leipzig, Germany. [Prokopenko, Inga] Imperial Coll London, Dept Genom Common Dis, London, England. [Prokopenko, Inga] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford, England. [Kleber, Marcus E.; Delgado, Graciela; Maerz, Winfried] Heidelberg Univ, Med Fac Mannheim, Dept Med 5, Heidelberg, Germany. [Silbernagel, Guenther] Med Univ Graz, Dept Internal Med, Div Angiol, Graz, Austria. [Jackson, Anne U.; Boehnke, Michael] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA. [Jackson, Anne U.; Boehnke, Michael] Univ Michigan, Ctr Stat Genet, Ann Arbor, MI 48109 USA. [Appel, Emil V.; Grarup, Niels; Hansen, Torben; Pedersen, Oluf] Univ Copenhagen, Fac Hlth & Med Sci, Ctr Basic Metab Res, Novo Nordisk Fdn, Copenhagen, Denmark. [Lewis, Joshua P.; Montasser, May E.; O'Connell, Jeff R.] Univ Maryland, Sch Med, Div Endocrinol Diabet & Nutr, Baltimore, MD 21201 USA. [Lewis, Joshua P.; Montasser, May E.; O'Connell, Jeff R.] Univ Maryland, Sch Med, Program Personalized & Genom Med, Baltimore, MD 21201 USA. [Landenvall, Claes; Groop, Leif] Lund Univ, Ctr Diabet, Dept Clin Sci Diabet & Endocrinol, Malmo, Sweden. [Landenvall, Claes] Uppsala Univ, Sci Life Lab, Dept Immunol Genet & Pathol, Uppsala, Sweden. [Staiger, Harald; Fritsche, Andreas; Haering, Hans-Ulrich; Stefan, Norbert] Univ Tubingen Hosp, Div Endocrinol & Diabetol Angiol Nephrol & Clin C, Dept Internal Med, Tubingen, Germany. [Staiger, Harald; Machicao, Fausto; Fritsche, Andreas; Haering, Hans-Ulrich; Stefan, Norbert] German Ctr Diabet Res DZD, Tubingen, Germany. [Staiger, Harald; Machicao, Fausto; Fritsche, Andreas; Haering, Hans-Ulrich; Stefan, Norbert] Univ Tubingen, Helmholtz Ctr Munich, Inst Diabet Res & Metab Dis, Tubingen, Germany. [Luan, Jian'an; Langenberg, Claudia; Scott, Robert A.; Wareham, Nicholas J.] Univ Cambridge, Sch Clin Med, MRC Epidemiol Unit, Cambridge, England. [Frayling, Timothy M.; Weedon, Michael N.; Xie, Weijia] Univ Exeter, Sch Med, Exeter, Devon, England. [Morcillo, Sonsoles] CIBER Pathophysiol Obes & Nutr, Madrid, Spain. [Morcillo, Sonsoles; Rojo-Martinez, Gemma; Soriguer, Federico] Hosp Reg Univ Malaga, Dept Endocrinol & Nutr, Malaga, Spain. [Teresa Martinez-Larrad, Maria; Corbaton-Anchuelo, Arturo; Serrano-Rios, Manuel] Hosp Clin San Carlos IdISSC, Spanish Biomed Res Ctr Diabet & Associated Metab, Inst Invest Sanitaria, Madrid, Spain. [Chen, Yii-Der Ida; Rotter, Jerome I.] Harbor UCLA Med Ctr, Dept Pediat, Inst Translat Genom & Populat Sci, Torrance, CA 90509 USA. [Chen, Yii-Der Ida; Rotter, Jerome I.] Harbor UCLA Med Ctr, Dept Med, LABioMed, Torrance, CA 90509 USA. [Faerch, Kristine] Steno Diabet Ctr, Gentofte, Denmark. [Miguel Gomez-Zumaquero, Juan; Rojo-Martinez, Gemma; Soriguer, Federico] Inst Invest Biomed Malaga IBIMA, Malaga, Spain. [Miguel Gomez-Zumaquero, Juan] Hosp Carlos Haya Malaga, Sequencing & Genotyping Platform, Malaga, Spain. [Goodarzi, Mark O.] Cedars Sinai Med Ctr, Div Endocrinol Diabet & Metab, Los Angeles, CA 90048 USA. [Kizer, Jorge R.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA. [Kizer, Jorge R.] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA. [Kizer, Jorge R.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA. [Koistinen, Heikki A.] Natl Inst Hlth & Welf, Dept Hlth, Helsinki, Finland. [Koistinen, Heikki A.] Minerva Fdn, Inst Med Res, Biomedicum 2U, Helsinki, Finland. [Koistinen, Heikki A.] Univ Helsinki, Dept Med, Helsinki, Finland. [Koistinen, Heikki A.] Univ Helsinki, Abdominal Ctr Endocrinol, Helsinki, Finland. [Koistinen, Heikki A.] Univ Helsinki, Cent Hosp, Helsinki, Finland. [Leong, Aaron; Meigs, James B.] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA. [Lindgren, Cecilia; Manning, Alisa K.; Meigs, James B.] Broad Inst Massachusetts Inst Technol & Harvard U, Cambridge, MA USA. [Maria Martin-Nunez, Gracia] Hosp Reg Univ & Virgen de la Victoria Malaga, Dept Endocrinol & Nutr, Malaga, Spain. [Rojo-Martinez, Gemma; Soriguer, Federico] CIBER Diabet & Enfermedades Metab Asociadas CIBER, Madrid, Spain. [Siscovick, David S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Siscovick, David S.] New York Acad Med, New York, NY USA. [Zmuda, Joseph M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA. [Zhang, Zhongyang] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. [Zhang, Zhongyang] Icahn Sch Med Mt Sinai, Icahn Inst Genom & Multiscale Biol, New York, NY 10029 USA. [Smith, Ulf] Univ Gothenburg, Sahlgrenska Acad, Dept Mol & Clin Med, Lundberg Lab Diabet Res, Gothenburg, Sweden. [Jorgensen, Torben J.] Univ Copenhagen, Fac Hlth & Med Sci, Dept Publ Hlth, Copenhagen, Denmark. [Jorgensen, Torben J.] Aalborg Univ, Fac Med, Aalborg, Denmark. [Jorgensen, Torben J.; Linnenberg, Allan] Res Ctr Prevent & Hlth, Copenhagen, Denmark. [Linnenberg, Allan] Rigshosp, Dept Clin Expt Res, Glostrup, Denmark. [Linnenberg, Allan] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark. [Walker, Mark] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England. [Groop, Leif] Univ Helsinki, Finnish Inst Mol Med, Helsinki, Finland. [Bergman, Richard N.] Cedars Sinai Med Ctr, Diabet & Obes Res Inst, Los Angeles, CA USA. [Collins, Francis S.] NHGRI, Med Genom & Metab Genet Branch, NIH, Bethesda, MD 20892 USA. [Mohlke, Karen L.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA. [Tuomilehto, Jaakko] Natl Inst Hlth & Welf, Chron Dis Prevent Unit, Helsinki, Finland. [Tuomilehto, Jaakko] Danube Univ Krems, Ctr Vasc Prevent, Krems, Austria. [Tuomilehto, Jaakko] King Abdulaziz Univ, Diabet Res Grp, Jeddah, Saudi Arabia. [Tuomilehto, Jaakko] Dasman Diabet Inst, Dasman, Kuwait. [Maerz, Winfried] Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, Graz, Austria. [Maerz, Winfried] Synlab Serv GmbH, Synlab Acad, Mannheim, Germany. [Maerz, Winfried] Synlab Serv GmbH, Synlab Acad, Augsburg, Germany. [Kovacs, Peter] Univ Leipzig, Integrated Res & Treatment IFB Ctr AdiposityDis, Leipzig, Germany. [Psaty, Bruce M.] Univ Washington, Epidemiol & Hlth Serv, Seattle, WA 98195 USA. [Psaty, Bruce M.] Grp Hlth Res Inst, Seattle, WA USA. [Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Seattle, WA USA. [Kuusisto, Johanna; Laakso, Markku] Univ Eastern Finland, Dept Med, Kuopio, Finland. [Dupuis, Josee] NHLBI, Framingham Heart Study, Framingham, MA USA. [Ingelsson, Erik] Uppsala Univ, Dept Med Sci, Mol Epidemiol & Sci Life Lab, Uppsala, Sweden. [Ingelsson, Erik] Stanford Univ, Dept Med, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA. RP Walford, GA (reprint author), Massachusetts Gen Hosp, Diabet Unit, Diabet Res Ctr, Boston, MA 02114 USA.; Walford, GA (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.; Walford, GA (reprint author), Harvard Med Sch, Dept Med, Boston, MA 02115 USA. EM gwalford@partners.org RI Grarup, Niels/K-2807-2015; OI Grarup, Niels/0000-0001-5526-1070; Koistinen, Heikki/0000-0001-7870-070X; Staiger, Harald/0000-0002-9507-5333; Chen, Han/0000-0002-9510-4923; Jorgensen, Torben/0000-0001-9453-2830; Stefan, Norbert/0000-0002-2186-9595 FU National Institutes of Health [DK099249]; Academy of Finland [77299, 124243]; German Research Council (DFG) [SFB 1052, SPP 1629 TO 718/2-1]; German Diabetes Association; Diabetes Hilfs-und Forschungsfonds Deutschland (DHFD); Federal Ministry of Education and Research (BMBF), Germany, Federal Ministry of Education and Research (BMBF), Germany, FKZ [01EO1501, AD2-060E]; Boehringer Ingelheim Foundation; National Heart, Lung, and Blood Institute [N02-HL-6-4278, N01-HC-25195, HL084756, HHSN268201500001I, HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, U01HL080295, HL105756, HL120393]; National Institute of Diabetes and Digestive and Kidney Diseases [R01 DK078616, U01-DK085526, 2R01 DK078616, K24 DK080140]; Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine; Boston Medical Center; American Diabetes Association Research Foundation [7-12-MN-02]; National Institute of Neurological Disorders and Stroke; National Institute on Aging (NIA) [R01AG023629]; Knut and Alice Wallenberg Foundation; European Research Council (ERC Starting Grant); Swedish Diabetes Foundation [2013-024]; Swedish Research Council [2012-1397]; Swedish Heart-Lung Foundation [20120197]; Nordic Center of Excellence in Disease Genetics [WT098017]; 7th Framework Program of the European Union [201668, 305739]; INTERREG-IV-Oberrhein-Program [A28]; European Regional Development Fund (ERDF); Wissenschaftsoffensive; German Federal Ministry of Education and Research as part of the Competence Cluster of Nutrition and Cardiovascular Health (nutriCARD); Danish Research Council; Danish Centre for Health Technology Assessment; Novo Nordisk; Research Foundation of Copenhagen County; Ministry of Internal Affairs and Health of Denmark; Danish Heart Foundation; Danish Pharmaceutical Association; Augustinus Foundation; Ib Henriksen Foundation; Becket Foundation; the Danish Diabetes Association; National Human Genome Research Institute [ZIA-HG000024]; National Institutes of Health from National Institute of General Medical Sciences [K23GM102678]; National Institutes of Health from National Heart, Lung, and Blood Institute [HL084756]; Sigrid Juselius Foundation; Folkhalsan Research Foundation; Nordic Center of Excellence in Disease Genetics; European Union [GA FP6 2004-005272]; Signe and Ane Gyllenberg Foundation; Swedish Cultural Foundation in Finland; Finnish Diabetes Research Foundation; Foundation for Life and Health in Finland; Finnish Medical Society; Paavo Nurmi Foundation; Helsinki University Central Hospital Research Foundation; Perklen Foundation; Ollqvist Foundation; Narpes Health Care Foundation; Ahokas Foundation; Ministry of Education in Finland; Municipal Health Care Center and Hospital in Jakobstad; Health Care Centers in Vasa, Narpes, and Korsholm; German Federal Ministry of Education and Research; Medical Research Council [MC_UU_12015/1, MC_U106179471]; Diabetes UK; Medical Research Council-GlaxoSmithKline pilot program grant [G0701863]; Novo Nordisk Foundation Center for Basic Metabolic Research, an independent research center at the University of Copenhagen - the Novo Nordisk Foundation; Instituto de Salud Carlos III [PI11/00880, PS09/02117]; Fondo Europeo para el Desarrollo Regional, Red de Centros RCMN [C03/08, FEDER 2FD 1997/2309]; Instituto de Salud Carlos III-RETIC, Madrid, Spain [RD06/0015/0012, FIS 03/1618]; CIBER in Diabetes and Associated Metabolic Disorders (Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion); Madrid Autonomous Community [MOIR S2010/BMD-2423]; Eli Lilly Lab, Spain; Bayer Pharmaceutical Co., Spain; Fundacion Mutua Madrilena, Spain FX This work was supported by National Institutes of Health grant DK099249 (to G.A.W.). Grant support was provided to cohorts. For METSIM, the study was funded by the Academy of Finland (grants 77299 and 124243). For Sorbs, the work was supported by grants from the German Research Council (DFG-SFB 1052, "Obesity mechanisms," A01, C01, B03, and SPP 1629 TO 718/2-1), the German Diabetes Association, and the Diabetes Hilfs-und Forschungsfonds Deutschland (DHFD). This work was further supported by the Federal Ministry of Education and Research (BMBF), Germany, FKZ (01EO1501, AD2-060E to P.K.), and by the Boehringer Ingelheim Foundation. For FHS, the study was supported by the National Heart, Lung, and Blood Institute (contract nos. N02-HL-6-4278 [supporting its contract with Affymetrix, Inc., for genotyping services], N01-HC-25195, HL084756, and HHSN268201500001I) and the National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK078616 to J.D., U01-DK085526 to H.C. and J.D., 2R01 DK078616 and K24 DK080140 to J.M.). A portion of this research utilized the Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center. A.K.M. was supported by American Diabetes Association Research Foundation (grant 7-12-MN-02). For CHS, research was supported by National Heart, Lung, and Blood Institute contract nos. HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, and N01HC85086 and grant nos. U01HL080295, HL105756, and HL120393, with additional contribution from the National Institute of Neurological Disorders and Stroke. Additional support was provided by R01AG023629 from the National Institute on Aging (NIA). For ULSAM, the project was supported by the Knut and Alice Wallenberg Foundation (Wallenberg Academy Fellow), the European Research Council (ERC Starting Grant), the Swedish Diabetes Foundation (grant 2013-024), the Swedish Research Council (grant 2012-1397), and the Swedish Heart-Lung Foundation (20120197). A.P.M. is a Wellcome Trust Senior Fellow in Basic Biomedical Science (grant WT098017 from the Nordic Center of Excellence in Disease Genetics). For LURIC, the study was supported by the 7th Framework Program (AtheroRemo, grant agreement no. 201668, and RiskyCAD, grant agreement no. 305739) of the European Union and by the INTERREG-IV-Oberrhein-Program (Project A28, Genetic mechanisms of cardiovascular diseases) with support from the European Regional Development Fund (ERDF) and the Wissenschaftsoffensive. M.E.K. and W.M. are supported by the German Federal Ministry of Education and Research as part of the Competence Cluster of Nutrition and Cardiovascular Health (nutriCARD). For Inter99, the study was financially supported by research grants from the Danish Research Council, the Danish Centre for Health Technology Assessment, Novo Nordisk, the Research Foundation of Copenhagen County, Ministry of Internal Affairs and Health of Denmark, the Danish Heart Foundation, the Danish Pharmaceutical Association, the Augustinus Foundation, the Ib Henriksen Foundation, the Becket Foundation, and the Danish Diabetes Association. For FUSION, the study was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (DK093757, DK072193, DK062370) and the National Human Genome Research Institute (ZIA-HG000024). H.A.K. has received funding from the Academy of Finland (support for clinical research careers, grant no. 258753).; Work on the Amish Studies was supported by National Institutes of Health awards K23GM102678 (from National Institute of General Medical Sciences) to J.P.L. and HL084756 (from National Heart, Lung, and Blood Institute) to J.R.O. The Botnia study has been financially supported by grants from the Sigrid Juselius Foundation, the Folkhalsan Research Foundation, the Nordic Center of Excellence in Disease Genetics, a European Union grant (EXGENESIS, GA FP6 2004-005272), the Signe and Ane Gyllenberg Foundation, the Swedish Cultural Foundation in Finland, the Finnish Diabetes Research Foundation, the Foundation for Life and Health in Finland, the Finnish Medical Society, the Paavo Nurmi Foundation, the Helsinki University Central Hospital Research Foundation, the Perklen Foundation, the Ollqvist Foundation, the Narpes Health Care Foundation, and the Ahokas Foundation. The DGI study was further supported by a Swedish Research Council Linne grant (2006-237) and by the Ministry of Education in Finland, the Municipal Health Care Center and Hospital in Jakobstad, and the Health Care Centers in Vasa, Narpes, and Korsholm. The Tubingen study was supported in part by a grant from the German Federal Ministry of Education and Research to the German Center for Diabetes Research (DZD e.V.). For the Ely Study, J.L., C. Lang, R.A.S., and N.J.W. acknowledge support from the Medical Research Council (MC_UU_12015/1). The Ely Study was funded by the Medical Research Council (MC_U106179471) and Diabetes UK. Genotyping in the Ely and Fenland studies was supported in part by a Medical Research Council-GlaxoSmithKline pilot program grant (G0701863). For the Birth Cohort 1936 and Inter99 studies, work was support by the Novo Nordisk Foundation Center for Basic Metabolic Research, an independent research center at the University of Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation (www.metabol.ku.dk). Work on the Pizarra study was support by Instituto de Salud Carlos III PI11/00880 and Instituto de Salud Carlos III PS09/02117. For Segovia, this work was supported by the Fondo Europeo para el Desarrollo Regional, Red de Centros RCMN (C03/08) grants FEDER 2FD 1997/2309, the Instituto de Salud Carlos III-RETIC RD06/0015/0012, Madrid, Spain (FIS 03/1618); CIBER in Diabetes and Associated Metabolic Disorders (Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion); and the Madrid Autonomous Community (MOIR S2010/BMD-2423), and by educational grants from Eli Lilly Lab, Spain; Bayer Pharmaceutical Co., Spain; and the Fundacion Mutua Madrilena 2008, Spain. NR 26 TC 2 Z9 2 U1 8 U2 8 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD OCT PY 2016 VL 65 IS 10 BP 3200 EP 3211 DI 10.2337/db16-0199 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EC8EJ UT WOS:000388372900037 PM 27416945 ER PT J AU Dal-Bianco, JP Bartko, PE Levine, RA AF Dal-Bianco, Jacob P. Bartko, Philipp E. Levine, Robert A. TI The power of ultrasound: treating secondary MR with sound waves SO EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING LA English DT Editorial Material ID ISCHEMIC MITRAL REGURGITATION; CHORDAE TENDINEAE; ADAPTATION; VALVE; HISTOTRIPSY; MECHANISM; INSIGHTS; REPAIR C1 [Dal-Bianco, Jacob P.; Bartko, Philipp E.; Levine, Robert A.] Harvard Med Sch, Massachusetts Gen Hosp, Cardiac Ultrasound Lab, 55 Fruit St,Yawkey 5B, Boston, MA 02114 USA. RP Levine, RA (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Cardiac Ultrasound Lab, 55 Fruit St,Yawkey 5B, Boston, MA 02114 USA. EM rlevine@partners.org FU NHLBI NIH HHS [R01 HL128099] NR 22 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 2047-2404 EI 2047-2412 J9 EUR HEART J-CARD IMG JI Eur. Heart J.-Cardiovasc. Imaging PD OCT 1 PY 2016 VL 17 IS 10 BP 1108 EP 1109 DI 10.1093/ehjci/jew154 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC8DA UT WOS:000388369300004 PM 27550662 ER PT J AU Iannaccone, M Quadri, G Taha, S D'Ascenzo, F Montefusco, A Omede', P Jang, IK Niccoli, G Souteyrand, G Chen, YD Toutouzas, K Benedetto, S Barbero, U Annone, U Lonni, E Imori, Y Biondi-Zoccai, G Templin, C Moretti, C Luscher, TF Gaita, F AF Iannaccone, Mario Quadri, Giorgio Taha, Salma D'Ascenzo, Fabrizio Montefusco, Antonio Omede', Pierluigi Jang, Ik-Kyung Niccoli, Giampaolo Souteyrand, Geraud Chen Yundai Toutouzas, Konstantinos Benedetto, Sara Barbero, Umberto Annone, Umberto Lonni, Enrica Imori, Yoichi Biondi-Zoccai, Giuseppe Templin, Christian Moretti, Claudio Luscher, Thomas F. Gaita, Fiorenzo TI Prevalence and predictors of culprit plaque rupture at OCT in patients with coronary artery disease: a meta-analysis SO EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING LA English DT Article DE Optical coherence tomography; Plaque rupture; Thin cap; Acute coronary syndrome ID OPTICAL COHERENCE TOMOGRAPHY; ACUTE MYOCARDIAL-INFARCTION; THIN-CAP FIBROATHEROMA; INTRAVASCULAR ULTRASOUND; STENT IMPLANTATION; VULNERABLE PLAQUE; VASCULAR-RESPONSE; ANGINA-PECTORIS; STABLE ANGINA; LESIONS AB Aims The prevalence of plaque rupture at the culprit lesion identified by optical coherence tomography (OCT) in different clinical subset of patients undergoing coronary angiography and its clinical predictors remain to be defined. Methods All studies including patients with OCT evaluation of the culprit coronary plaque were included. The prevalence of culprit plaque rupture (CPR) and thin-cap fibro-atheroma (TCFA) were the primary endpoints. The factors associated with these findings were studied in a subset of patients with different clinical presentations [ST-elevation myocardial (STEMI) vs. nonST-elevation myocardial infarction (NSTEMI) vs. unstable angina (UA) vs. stable angina pectoris (SAP)]. Results One hundred and fifty citations were initially appraised at the abstract level and 23 full-text studies were assessed. The mean prevalence of CPR and TCFA was 48.1% (40.5-55.8) and 48.7% (37.4-60.1), respectively. The prevalence of CPR and TCFA were higher in STEMI (70.4 and 76.6%) than in NSTEMI (55.6 and 56.3%) and UA (39.1 and 52.9%) or SAP (6.2 and 22.8%). In the overall population at meta-regression analysis, TCFA and current smoking were the only predictors of CPR (B 3.6:2.0-5.1, P < 0.001 and 0.06:0.02-0.1, P = 0.002, respectively). The factors associated with CPR were different depending on clinical presentation. Hypertension was the only clinical predictor for STEMI (B 3.3:1.2.-5.3 P = 0.001), while advanced age (B 0.12:0.02-0.22, P = 0.021), diabetes mellitus (B 0.04:0.01-0.08, P = 0.012), and hyperlipidaemia (B 0.07:0.02-0.11, P = 0.005) were the predictors in NSTEMI and UA. No clinical predictor was found in SA. Conclusions Our analysis showed high rates of CPR and TCFA detected by OCT in CAD patients, especially in those with ACS, although their prevalence is not negligible in stable patients. TCFA seems to be a strong predictor of CPR in all the ACS scenarios. C1 [Iannaccone, Mario; Quadri, Giorgio; Taha, Salma; D'Ascenzo, Fabrizio; Montefusco, Antonio; Omede', Pierluigi; Benedetto, Sara; Barbero, Umberto; Annone, Umberto; Lonni, Enrica; Moretti, Claudio; Gaita, Fiorenzo] Citta Salute & Sci, Div Cardiol, Dipartimento Sci Med, Turin, Italy. [Jang, Ik-Kyung] Harvard Med Sch, Massachusetts Gen Hosp, Div Cardiol, Boston, MA USA. [Niccoli, Giampaolo] Cattolica Sacro Cuore, Div Cardiol, Rome, Italy. [Souteyrand, Geraud] Ctr Hosp Univ Clermont Ferrant, Pole Cardiol, Clermont Ferrand, France. [Chen Yundai] Chinese Peoples Liberat Army Gen Hosp, Dept Cardiol, Beijing, Peoples R China. [Toutouzas, Konstantinos] Hippokrateion Hosp, Athens Med Sch, Athens, Greece. [Imori, Yoichi] Tsuchiura Kyodo Gen Hosp, Tsuchiura, Ibaraki, Japan. [Imori, Yoichi; Templin, Christian; Luscher, Thomas F.] Univ Zurich Hosp, Zurich, Switzerland. [Biondi-Zoccai, Giuseppe] Sapienza Univ Rome, Dept Medicosurg Sci & Biotechnol, Latina, Italy. RP Iannaccone, M (reprint author), Citta Salute & Sci, Div Cardiol, Dipartimento Sci Med, Turin, Italy. EM mario.iannaccone@hotmail.it OI Iannaccone, Mario/0000-0003-0571-3918 NR 49 TC 14 Z9 14 U1 2 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 2047-2404 EI 2047-2412 J9 EUR HEART J-CARD IMG JI Eur. Heart J.-Cardiovasc. Imaging PD OCT 1 PY 2016 VL 17 IS 10 BP 1128 EP 1137 DI 10.1093/ehjci/jev283 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC8DA UT WOS:000388369300008 PM 26508517 ER PT J AU Vinue, L Hooper, DC AF Vinue, Laura Hooper, David C. TI A simple technique for suppressor detection in Escherichia coli SO FEMS MICROBIOLOGY LETTERS LA English DT Article DE UAG mutations; Escherichia coli J53; gyrA Ser83Stop; tRNA suppressor ID NONSENSE MUTATIONS; GENOME SEQUENCE; CODONS; AMBER; OPAL; MUTANTS; STRAIN; OCHRE; UAG AB To study the viability of a gyrA S83 stop mutation found in an Escherichia coli J53 ciprofloxacin-resistant strain ( J53 CipR27), a pBR322 derivative was constructed with a TAG mutation in the bla gene knocking out ampicillin resistance. Ampicillin resistance was restored, suggesting that the strain contains tRNA suppressor activity able to suppress the UAG codon gyrA and allow viability. The method was applied to 22 unique clinical E. coli isolates, and all were found to have low-level suppressor activity. C1 [Vinue, Laura; Hooper, David C.] Harvard Med Sch, Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St, Boston, MA 02114 USA. RP Vinue, L (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Div Infect Dis, 55 Fruit St, Boston, MA 02114 USA. EM lvinue-santolalla@mgh.harvard.edu FU National Institutes of Health, U.S. Public Health Service [R01 AI057576] FX This work was supported by grant R01 AI057576 (to DCH) from the National Institutes of Health, U.S. Public Health Service. NR 14 TC 0 Z9 0 U1 3 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0378-1097 EI 1574-6968 J9 FEMS MICROBIOL LETT JI FEMS Microbiol. Lett. PD OCT PY 2016 VL 363 IS 19 AR fnw228 DI 10.1093/femsle/fnw228 PG 3 WC Microbiology SC Microbiology GA EC8HI UT WOS:000388381800014 ER PT J AU Finger, A Teunis, T Hageman, MG Thornton, ER Neuhaus, V Ring, D AF Finger, Abigail Teunis, Teun Hageman, Michiel G. Thornton, Emily R. Neuhaus, Valentin Ring, David TI Do patients prefer optional follow-up for simple upper extremity fractures: A pilot study SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED LA English DT Article DE Arm fracture; Disability; Follow-up ID NECK FRACTURES AB Introduction: We aimed to evaluate the results of offering patients optional follow-up for simple upper extremity fractures. Specifically this study tested if there is a difference in (1) upper extremity disability, (2) return to work, and (3) satisfaction with delivered care at 2-6 months after enrollment between patients who choose and do not choose a return visit for an adequately aligned metacarpal, distal radius, or radial head fracture. Additionally we assessed if there was a difference in overall evaluation of the visit at enrollment between those patients and what factors were associated with returning after initially choosing not to schedule a follow-up visit. Patients and methods: We prospectively enrolled all adult patients (n = 120) with adequately aligned metacarpal fractures, non-or minimally displaced distal radius fractures, and isolated non-or minimally displaced radial head fractures of whom 82 (68%) were available at 2-6 months after enrollment. Subjects chose to have a scheduled (n = 56) or optional (n = 64) return visit. Subsequently, we recorded patient demographics and overall evaluation of the visit. Between two and six months after enrollment we measured QuickDASH, satisfaction with care, and current employment status. Results: Accounting for potential differences in baseline characteristics by multivariable analysis, return choice was not associated with QuickDASH (beta regression coefficient [beta] -0.53, 95% confidence interval [CI] -7.4 to 6.4, standard error [SE] 3.5, P = 0.88), return to work (odds ratio [OR] -1.3, 95% CI - 3.5 to 0.95, SE 1.1, P = 0.26), satisfaction with care (beta -0.084, 95% CI -0.51 to 0.35, SE 0.22, P = 0.70), or overall evaluation of the initial visit (b 0.18, 95% CI -0.38 to 0.73, SE 0.28, P = 0.53). Of the 64 people choosing optional follow-up, 11 patients returned (17%). The only factor independently associated with returning after initially not choosing to return was greater disability at enrollment (OR 1.05, 95% CI 1.0050-1.098, SE 0.024, P = 0.029). Conclusions: A majority of patients prefer optional follow-up for simple upper extremity fractures with a good prognosis. Hand surgeons can consider offering patients with low-risk hand fractures an optional second visit. Eliminating unnecessary visits, tests and imaging could lower the cost of care. Level of evidence: Therapeutic level II. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Finger, Abigail; Teunis, Teun; Hageman, Michiel G.; Thornton, Emily R.; Neuhaus, Valentin; Ring, David] Harvard Med Sch, Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Boston, MA USA. RP Ring, D (reprint author), Univ Texas Austin, Dell Med Sch, Comprehens Care, 1400 Barbara Jordan Blvd Suite 2-834 MC R1800, Austin, TX 78723 USA.; Ring, D (reprint author), Univ Texas Austin, Dell Med Sch, Surg, 1400 Barbara Jordan Blvd Suite 2-834 MC R1800, Austin, TX 78723 USA. EM David.ring@austin.utexas.edu OI Ring, David/0000-0002-6506-4879; Neuhaus, Valentin/0000-0003-4012-5628 NR 18 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0020-1383 EI 1879-0267 J9 INJURY JI Injury-Int. J. Care Inj. PD OCT PY 2016 VL 47 IS 10 BP 2276 EP 2282 DI 10.1016/j.injury.2016.06.029 PG 7 WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery GA EC5IB UT WOS:000388166500039 PM 27418457 ER PT J AU Antoci, V Patel, SP Weaver, MJ Kwon, JY AF Antoci, Valentin, Jr. Patel, Shaun P. Weaver, Michael J. Kwon, John Y. TI Relevance of adjacent joint imaging in the evaluation of ankle fractures SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED LA English DT Article DE Ankle fracture; Trauma; Radiography; X-Ray; Utilization ID TERTIARY TRAUMA SURVEY; CLINICAL DECISION RULES; MISSED INJURIES; EMERGENCY AB Background: Routinely obtaining adjacent joint radiographs when evaluating patients with ankle fractures may be of limited clinical utility and an unnecessary burden, particularly in the absence of clinical suspicion for concomitant injuries. Methods: One thousand, three hundred and seventy patients who sustained ankle fractures over a 5-year period presenting to two level 1 trauma centers were identified. Medical records were retrospectively reviewed for demographics, physical examination findings, and radiographic information. Analyses included descriptive statistics along with sensitivity and predictive value calculations for the presence of adjacent joint fracture. Results: Adjacent joint imaging (n = 1045 radiographs) of either the knee or foot was obtained in 873 patients (63.7%). Of those, 75/761 patients (9.9%) demonstrated additional fractures proximal to the ankle joint, most commonly of the proximal fibula. Twenty-two of 284 (7.7%) demonstrated additional fractures distal to the ankle joint, most commonly of the metatarsals. Tenderness to palpation demonstrated sensitivities of 0.92 and 0.77 and positive predictive values of 0.94 and 0.89 for the presence of proximal and distal fractures, respectively. Additionally, 19/22 (86.4%) of patients sustaining foot fractures had their injury detectable on initial ankle X-rays. Overall, only 5.5% (75/ 1370) of patients sustained fractures proximal to the ankle and only 0.2% (3/1370) of patients had additional foot fractures not evident on initial ankle X-rays. Conclusion: The addition of adjacent joint imaging for the evaluation of patients sustaining ankle fractures is low yield. As such, patient history, physical examination, and clinical suspicion should direct the need for additional X-rays. (C) 2016 Elsevier Ltd. All rights reserved. C1 [Antoci, Valentin, Jr.] Brown Univ, Dept Orthopaed Surg, Providence, RI 02912 USA. [Patel, Shaun P.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA. [Weaver, Michael J.] Brigham & Womens Hosp, Dept Orthopaed Surg, 75 Francis St, Boston, MA 02115 USA. [Kwon, John Y.] Beth Israel Deaconess Med Ctr, Dept Orthopaed Surg, Boston, MA 02215 USA. RP Patel, SP (reprint author), Massachusetts Gen Hosp, 55 Fruit St,WHT 535, Boston, MA 02114 USA. EM shaun.p.patel@gmail.com NR 23 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0020-1383 EI 1879-0267 J9 INJURY JI Injury-Int. J. Care Inj. PD OCT PY 2016 VL 47 IS 10 BP 2366 EP 2369 DI 10.1016/j.injury.2016.07.025 PG 4 WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery GA EC5IB UT WOS:000388166500054 PM 27465987 ER PT J AU Jacobs, J Bleier, BS Hopkins, C Hwang, P Poetker, D Schlosser, R Stewart, M Varshney, R AF Jacobs, Joseph Bleier, Benjamin S. Hopkins, Claire Hwang, Peter Poetker, David Schlosser, Rodney Stewart, Michael Varshney, Rickul TI Response to: The "RACE" national database for recurrent acute rhinosinusitis may need a relook SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY LA English DT Letter C1 [Jacobs, Joseph] NYU, Langone Med Ctr, New York, NY USA. [Jacobs, Joseph] ARS, RACE Database Execut Comm, Bethesda, MD USA. [Bleier, Benjamin S.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Boston, MA USA. [Hopkins, Claire] Guys Hosp, ENT Dept, London, England. [Hwang, Peter] Stanford Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Stanford, CA 94305 USA. [Poetker, David] Med Coll Wisconsin, Dept Otolaryngol Head & Neck Surg, Milwaukee, WI 53226 USA. [Schlosser, Rodney] Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC USA. [Stewart, Michael] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, Div Rhinol & Sinus Surg, Portland, OR 97201 USA. [Varshney, Rickul] McGill Univ, Dept Otolaryngol Head & Neck Surg, Montreal, PQ, Canada. RP Bleier, BS (reprint author), 243 Charles St, Boston, MA 02114 USA. EM benjamin_bleier@meei.harvard.edu OI jacobs, joseph/0000-0003-1729-4378 NR 4 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2042-6976 EI 2042-6984 J9 INT FORUM ALLERGY RH JI Int. Forum Allergy Rhinol. PD OCT PY 2016 VL 6 IS 10 BP 1100 EP 1100 DI 10.1002/alr.21815 PG 1 WC Otorhinolaryngology SC Otorhinolaryngology GA EC7IE UT WOS:000388309600018 PM 27383827 ER PT J AU Wilkoff, BL Fauchier, L Stiles, MK Morillo, CA Al-Khatib, SM Almendral, J Aguinaga, L Berger, RD Cuesta, A Daubert, JP Dubner, S Ellenbogen, KA Estes, NAM Fenelon, G Garcia, FC Gasparini, M Haines, DE Healey, JS Hurtwitz, JL Keegan, R Kolb, C Kuck, KH Marinskis, G Martinelli, M McGuire, M Molina, LG Okumura, K Proclemer, A Russo, AM Singh, JP Swerdlow, CD Teo, WS Uribe, W Viskin, S Wang, CC Zhang, S AF Wilkoff, Bruce L. Fauchier, Laurent Stiles, Martin K. Morillo, Carlos A. Al-Khatib, Sana M. Almendral, Jesoes Aguinaga, Luis Berger, Ronald D. Cuesta, Alejandro Daubert, James P. Dubner, Sergio Ellenbogen, Kenneth A. Estes, N. A. Mark, III Fenelon, Guilherme Garcia, Fermin C. Gasparini, Maurizio Haines, David E. Healey, Jeff S. Hurtwitz, Jodie L. Keegan, Roberto Kolb, Christof Kuck, Karl-Heinz Marinskis, Germanas Martinelli, Martino McGuire, Mark Molina, Luis G. Okumura, Ken Proclemer, Alessandro Russo, Andrea M. Singh, Jagmeet P. Swerdlow, Charles D. Teo, Wee Siong Uribe, William Viskin, Sami Wang, Chun-Chieh Zhang, Shu TI 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing (vol 32, pg 1, 2016) SO JOURNAL OF ARRHYTHMIA LA English DT Correction C1 [Wilkoff, Bruce L.] Cleveland Clin, Cleveland, OH 44106 USA. [Fauchier, Laurent] CHU Trousseau, Tours, France. [Stiles, Martin K.] Waikato Hosp, Hamilton, New Zealand. [Morillo, Carlos A.; Healey, Jeff S.] McMaster Univ, Populat Hlth Res Inst, Div Cardiol, Dept Med, Hamilton, ON, Canada. [Al-Khatib, Sana M.; Daubert, James P.] Duke Univ, Med Ctr, Durham, NC USA. [Almendral, Jesoes] Univ CEU San Pablo, Grp HM Hosp, Madrid, Spain. [Aguinaga, Luis] Ctr Privado Cardiol, San Miguel De Tucuman, Argentina. [Berger, Ronald D.] Johns Hopkins Univ, Baltimore, MD USA. [Cuesta, Alejandro] Inst Cardiol Infantil, Serv Arritmias, Montevideo, Uruguay. [Dubner, Sergio] Clin & Maternidad Suizo Argentina, Buenos Aires, DF, Argentina. [Ellenbogen, Kenneth A.] Virginia Commonwealth Univ, Med Ctr, Richmond, VA USA. [Estes, N. A. Mark, III] Tufts Univ New England Med Ctr, 750 Washington St, Boston, MA 02111 USA. [Fenelon, Guilherme] Univ Fed Sao Paulo, Sao Paulo, Brazil. [Garcia, Fermin C.] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA. [Gasparini, Maurizio] Humanitas Res Hosp, Milan, Italy. [Haines, David E.] William Beaumont Hosp, Div Cardiol, Royal Oak, MI 48072 USA. [Hurtwitz, Jodie L.] North Texas Heart Ctr, Dallas, TX USA. [Keegan, Roberto] Hosp Privado Sur, Bahia Blanca, Buenos Aires, Argentina. [Kolb, Christof] Deutsch Herzzentrum Munich, Munich, Germany. [Kuck, Karl-Heinz] Allgemeines Krankenhaus St Georg, Hamburg, Germany. [Marinskis, Germanas] Vilnius Univ, Clin Cardiac & Vasc Dis, Vilnius, Lithuania. [Martinelli, Martino] Univ Sao Paulo, Inst Coracao, Sao Paulo, Brazil. [McGuire, Mark] Royal Prince Alfred Hosp, Sydney, NSW, Australia. [Molina, Luis G.] Mexicos Natl Univ, Mexicos Gen Hosp, Mexico City, DF, Mexico. [Okumura, Ken] Hirosaki Univ, Grad Sch Med, Hirosaki, Aomori, Japan. [Proclemer, Alessandro] Azienda Osped Univ S Maria Misericordia Udine, Udine, Italy. [Russo, Andrea M.] Cooper Univ Hosp, Camden, NJ USA. [Singh, Jagmeet P.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Swerdlow, Charles D.] Cedars Sinai Med Ctr, Beverly Hills, CA USA. [Teo, Wee Siong] Natl Heart Ctr Singapore, Singapore, Singapore. [Uribe, William] CES Cardiol, Medellin, Colombia. [Uribe, William] San Vicente Fdn, Ctr Especializados, Medellin, Colombia. [Uribe, William] CES Cardiol, Rionegro, Colombia. [Uribe, William] San Vicente Fdn, Ctr Especializados, Rionegro, Colombia. [Viskin, Sami] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel. [Viskin, Sami] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel. [Wang, Chun-Chieh] Chang Gung Mem Hosp, Taipei, Taiwan. [Zhang, Shu] Peking Union Med Coll, Natl Ctr Cardiovasc Dis, Beijing, Peoples R China. [Zhang, Shu] Peking Union Med Coll, Beijing Fu Wai Hosp, Beijing, Peoples R China. [Zhang, Shu] China Acad Med Sci, Beijing, Peoples R China. [Dubner, Sergio] De Los Arcos Sanatorio, Buenos Aires, DF, Argentina. RP Wilkoff, BL (reprint author), Cleveland Clin, Cleveland, OH 44106 USA. NR 1 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1880-4276 EI 1883-2148 J9 J ARRYTHM JI J. Arrythm. PD OCT PY 2016 VL 32 IS 5 BP 441 EP 442 DI 10.1016/j.joa.2016.08.001 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC3ND UT WOS:000388032000017 PM 27761170 ER PT J AU Gora, MJ Simmons, LH Queneherve, L Grant, CN Carruth, RW Lu, WN Tiernan, A Dong, J Walker-Corkery, B Soomro, A Rosenberg, M Metlay, JP Tearney, GJ AF Gora, Michalina J. Simmons, Leigh H. Queneherve, Lucille Grant, Catriona N. Carruth, Robert W. Lu, Weina Tiernan, Aubrey Dong, Jing Walker-Corkery, Beth Soomro, Amna Rosenberg, Mireille Metlay, Joshua P. Tearney, Guillermo J. TI Tethered capsule endomicroscopy: from bench to bedside at a primary care practice SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE optical coherence tomography; digestive system; clinical translation ID OPTICAL COHERENCE TOMOGRAPHY; BARRETTS-ESOPHAGUS; GASTROINTESTINAL-TRACT; ADENOCARCINOMA; OCT; DYSPLASIA; CANCER; SCALE AB Due to the relatively high cost and inconvenience of upper endoscopic biopsy and the rising incidence of esophageal adenocarcinoma, there is currently a need for an improved method for screening for Barrett's esophagus. Ideally, such a test would be applied in the primary care setting and patients referred to endoscopy if the result is suspicious for Barrett's. Tethered capsule endomicroscopy (TCE) is a recently developed technology that rapidly acquires microscopic images of the entire esophagus in unsedated subjects. Here, we present our first experience with clinical translation and feasibility of TCE in a primary care practice. The acceptance of the TCE device by the primary care clinical staff and patients shows the potential of this device to be useful as a screening tool for a broader population. (C) 2016 Society of Photo-Optical Instrumentation Engineers (SPIE) C1 [Gora, Michalina J.; Queneherve, Lucille; Grant, Catriona N.; Carruth, Robert W.; Lu, Weina; Tiernan, Aubrey; Dong, Jing; Soomro, Amna; Rosenberg, Mireille; Tearney, Guillermo J.] Massachusetts Gen Hosp, Wellman Ctr Photomed, 55 Fruit St, Boston, MA 02114 USA. [Gora, Michalina J.; Simmons, Leigh H.; Dong, Jing; Rosenberg, Mireille; Tearney, Guillermo J.] Harvard Med Sch, 25 Shattuck St, Boston, MA 02115 USA. [Gora, Michalina J.] Strasbourg Univ, CNRS, ICube Lab, 1 Pl Hop, F-67091 Strasbourg, France. [Simmons, Leigh H.; Walker-Corkery, Beth; Metlay, Joshua P.] Massachusetts Gen Hosp, Div Gen Internal Med, 55 Fruit St, Boston, MA 02114 USA. [Queneherve, Lucille] CHU Nantes, Hotel Dieu, Inst Malad Appareil Digestif, Pl Alexis Ricordeau, F-44000 Nantes, France. [Tearney, Guillermo J.] Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St, Boston, MA 02114 USA. [Tearney, Guillermo J.] Harvard MIT Div Hlth Sci Technol, 77 Massachusetts Ave, Cambridge, MA 02139 USA. RP Tearney, GJ (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 55 Fruit St, Boston, MA 02114 USA.; Tearney, GJ (reprint author), Harvard Med Sch, 25 Shattuck St, Boston, MA 02115 USA.; Tearney, GJ (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St, Boston, MA 02114 USA.; Tearney, GJ (reprint author), Harvard MIT Div Hlth Sci Technol, 77 Massachusetts Ave, Cambridge, MA 02139 USA. EM gtearney@mgh.harvard.edu FU US National Institutes of Health [NIH R01CA103769, 1 R01 DK100569-01A1]; MGH Research Scholars program; University Hospital of Nantes (France); SanteDige Foundation FX This work was supported in part (development of certain elements of TCE technology) by the US National Institutes of Health grants NIH R01CA103769 (G.J.T.) and 1 R01 DK100569-01A1 (G.J.T.). The authors also gratefully acknowledge John and Dottie Remondi and the MGH Research Scholars program for their generous funding that enabled this work. Lucille Queneherve thanks the DHU 2020 (hospital and academic department-Personalized medicine for chronic diseases) of University Hospital of Nantes (France) and the SanteDige Foundation for their funding. The authors thank Katrina Armstrong from the Department of Medicine at MGH for her valuable advice and support of the study; Cynthia Ann Yeo, Kaitlyn Kelley, and Arlene Byrnes from the Internal Medicine Associate at MGH for administrative support of the study, as well as Thomas Cerruto and his team at the MGH GI unit. NR 29 TC 1 Z9 1 U1 2 U2 2 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 EI 1560-2281 J9 J BIOMED OPT JI J. Biomed. Opt. PD OCT PY 2016 VL 21 IS 10 AR 104001 DI 10.1117/1.JBO.21.10.104001 PG 7 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA EC5YN UT WOS:000388213300016 PM 27689919 ER PT J AU Zani, SR Moss, K Shibli, JA Teixeira, ER Mairink, RD Onuma, T Feres, M Teles, RP AF Zani, Sabrina Rebollo Moss, Kevin Shibli, Jamil Awad Teixeira, Eduardo Rolim Mairink, Renata de Oliveira Onuma, Tatiana Feres, Magda Teles, Ricardo Palmier TI Peri-implant crevicular fluid biomarkers as discriminants of peri-implant health and disease SO JOURNAL OF CLINICAL PERIODONTOLOGY LA English DT Article DE biomarkers; cytokines; dental implant; peri-implantitis ID ANTIINFECTIVE MECHANICAL THERAPY; NECROSIS-FACTOR-ALPHA; TNF-ALPHA; PROINFLAMMATORY CYTOKINES; PERIODONTAL-DISEASE; EXPRESSION; GINGIVAL; IL-1-BETA; DIAGNOSIS; MARKERS AB Aim: The objective of this cross-sectional study was to examine the potential of peri-implant crevicular fluid (PICF) analytes to discriminate between peri-implant health and disease using a multi-biomarker approach. Methods: We collected PICF samples from the mesio-buccal site of every implant (n = 145) from 52 subjects with peri-implantitis and measured the levels of 20 biomarkers using Luminex. We grouped implants and subjects based on the clinical characteristic of the sampled sites and implants into: healthy sites from healthy implants (HH), diseased sites from diseased implants (DD) and healthy sites from diseased implants (HD). The significance of the differences between the HH and DD groups was determined using general linear models controlling for false discovery rate. We used logistic regression to determine the best multi-biomarker models that could distinguish HH from DD subjects and HH from HD subjects. Results: There were statistically significant differences between HH and DD groups for 12/20 biomarkers. Logistic regression resulted in a 6-biomarker model (Flt-3L, GM-CSF, IL-10, sCD40L, IL-17 and TNF alpha) that discriminated HH from DD subjects (AUC = 0.93) and a 3-biomarker model (IL-17, IL-1ra and vascular endothelial growth factor) that distinguished HH from DD subjects (AUC = 0.90). Conclusion: PICF biomarkers might help discriminate peri-implant health from disease. C1 [Zani, Sabrina Rebollo; Teixeira, Eduardo Rolim] Pontificia Univ Catolica Rio Grande do Sul, Dept Prosthodont, Porto Alegre, RS, Brazil. [Moss, Kevin] Univ North Carolina Chapel Hill, Sch Dent, Dept Dent Ecol, Chapel Hill, NC USA. [Shibli, Jamil Awad; Mairink, Renata de Oliveira; Onuma, Tatiana; Feres, Magda] Univ Guarulhos, Dent Res Div, Dept Periodontol, Guarulhos, SP, Brazil. [Teles, Ricardo Palmier] Univ North Carolina Chapel Hill, Sch Dent, Dept Periodontol, Chapel Hill, NC USA. [Teles, Ricardo Palmier] Forsyth Inst, Dept Appl Oral Sci, Cambridge, MA USA. RP Teles, RP (reprint author), UNC Sch Dent, Dept Periodontol, Koury Hlth Sci Bldg,385 S Columbia St,Room 3506, Chapel Hill, NC 27599 USA. EM rteles@email.unc.edu FU National Institute of Dental and Craniofacial Research [DE021127-01]; MEC/CAPES (Brazilian Federal Agency for Support and Evaluation of Graduate Education); PROBOLSAS (Pontifical Catholic University of Rio Grande do Sul) FX This study was supported by research grant DE021127-01 from the National Institute of Dental and Craniofacial Research. Sabrina Rebollo Zani was supported by scholarships from MEC/CAPES (Brazilian Federal Agency for Support and Evaluation of Graduate Education) and from PROBOLSAS (Pontifical Catholic University of Rio Grande do Sul Master and PhD Scholarship Program). NR 35 TC 0 Z9 0 U1 5 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0303-6979 EI 1600-051X J9 J CLIN PERIODONTOL JI J. Clin. Periodontol. PD OCT PY 2016 VL 43 IS 10 BP 825 EP 832 DI 10.1111/jcpe.12586 PG 8 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA EC7YL UT WOS:000388357000003 PM 27279264 ER PT J AU Boudreau, KJ Guinan, EC Lakhani, KR Riedl, C AF Boudreau, Kevin J. Guinan, Eva C. Lakhani, Karim R. Riedl, Christoph TI Looking Across and Looking Beyond the Knowledge Frontier: Intellectual Distance, Novelty, and Resource Allocation in Science SO MANAGEMENT SCIENCE LA English DT Article DE innovation; project selection; bounded rationality; knowledge frontier; novelty; intellectual distance ID CUMULATIVE INNOVATION; COMMERCIAL SUCCESS; RANDOMIZED-TRIAL; GRANT PROPOSALS; BIAS; AGREEMENT; REVIEWERS; VALIDITY; QUALITY; SEARCH AB Selecting among alternative projects is a core management task in all innovating organizations. In this paper, we focus on the evaluation of frontier scientific research projects. We argue that the "intellectual distance" between the knowledge embodied in research proposals and an evaluator's own expertise systematically relates to the evaluations given. To estimate relationships, we designed and executed a grant proposal process at a leading research university in which we randomized the assignment of evaluators and proposals to generate 2,130 evaluator-proposal pairs. We find that evaluators systematically give lower scores to research proposals that are closer to their own areas of expertise and to those that are highly novel. The patterns are consistent with biases associated with boundedly rational evaluation of new ideas. The patterns are inconsistent with intellectual distance simply contributing "noise" or being associated with private interests of evaluators. We discuss implications for policy, managerial intervention, and allocation of resources in the ongoing accumulation of scientific knowledge. C1 [Boudreau, Kevin J.] London Business Sch, London NW1 4SA, England. [Boudreau, Kevin J.; Lakhani, Karim R.] Harvard Sch Business, Boston, MA 02163 USA. [Guinan, Eva C.] Dana Farber Harvard Canc Ctr, Boston, MA 02215 USA. [Riedl, Christoph] Northeastern Univ, DAmore McKim Sch Business, Boston, MA 02115 USA. RP Boudreau, KJ (reprint author), London Business Sch, London NW1 4SA, England.; Boudreau, KJ (reprint author), Harvard Sch Business, Boston, MA 02163 USA. EM kboudreau@hbs.edu; eva_guinan@dfci.harvard.edu; klakhani@hbs.edu; c.riedl@neu.edu FU London Business School's Deloitte Institute on Innovation and Entrepreneurship; London Business School RAMD; NASA Tournament Laboratory; German Research Foundation [RI 2185/1-1]; Harvard Catalyst; National Institutes of Health National Center for Advancing Translational Sciences [UL1TR000170, UL1TR001102S]; National Center for Research Resources [UL1RR025758-02S4] FX The authors are indebted to administrators at an anonymous granting organization and host university for their invaluable support. They also thank executives at Inno-Centive who assisted with platform and information technology design and support. They would also like to acknowledge Thomas Astebro, Michael Bikard, Amy Edmonson, Dan Elfenbein, Alfonso Gambardella, Yigal Gerchak, Shane Greenstein, Ben Hallen, Danielle Li, Lars Bo Jeppesen, Gary Pisano, Anisa Shyti, Eric von Hippel, Keyvan Valkili, and participants at presentations at Bocconi University, Cambridge University, INSEAD, London Business School, National Bureau of Economic Research (NBER), the Roundtable for Engineering Entrepreneurship Research (REER), University of Maryland, and Washington University at St. Louis for useful comments. The authors acknowledge support from the London Business School's Deloitte Institute on Innovation and Entrepreneurship, London Business School RAMD, the NASA Tournament Laboratory, German Research Foundation [Grant RI 2185/1-1], Harvard Catalyst, and the National Institutes of Health National Center for Advancing Translational Sciences [Grants UL1TR000170 and UL1TR001102S] and National Center for Research Resources [UL1RR025758-02S4]. Eric Lonstein provided excellent research support. Griffin Weber assisted in selecting evaluators. Eric Lin provided access to the PubMed citation data. All errors are the authors' own. NR 69 TC 7 Z9 7 U1 41 U2 41 PU INFORMS PI CATONSVILLE PA 5521 RESEARCH PARK DR, SUITE 200, CATONSVILLE, MD 21228 USA SN 0025-1909 EI 1526-5501 J9 MANAGE SCI JI Manage. Sci. PD OCT PY 2016 VL 62 IS 10 BP 2765 EP 2783 DI 10.1287/mnsc.2015.2285 PG 19 WC Management; Operations Research & Management Science SC Business & Economics; Operations Research & Management Science GA EC9CR UT WOS:000388441900001 PM 27746512 ER PT J AU Faulkner, HR Colwell, AS Liao, EC Winograd, JM Austen, WG AF Faulkner, Heather R. Colwell, Amy S. Liao, Eric C. Winograd, Jonathan M. Austen, William G., Jr. TI Thermal Injury to Reconstructed Breasts from Commonly Used Warming Devices: A Risk for Reconstructive Failure SO PLASTIC AND RECONSTRUCTIVE SURGERY-GLOBAL OPEN LA English DT Article ID HOT-WATER BOTTLE; BURN INJURY; SUBCUTANEOUS MASTECTOMY; PROSTHESIS; FLAPS AB Background: Sensation is decreased or absent after breast reconstruction. This leaves reconstructed breasts vulnerable to injury from common household thermal sources such as heating pads and hot water bottles. We sought to categorize these injuries, provide a treatment plan, and prevent these injuries in the future. Methods: A retrospective review of patients who had sustained burns to reconstructed breasts with household devices was performed at a single institution. A PubMed search was performed to identify and summarize articles cataloguing patients who had suffered burns to breast reconstructions. Results: Five patients in our practice were affected. Fifteen articles were identified in the literature search. A total of 40 patients had sustained thermal injury to reconstructed breasts, with the majority being full thickness burns (67.5%). Patients who sustained full thickness burns to reconstructed breasts were more likely to require an operative procedure compared with patients who sustained partial thickness burns (P = 0.0076). Conclusions: Reconstructed breasts are at risk for injury from commonly used household warming devices and ambient heat from the sun. As a result, patients should be counseled about these risks accordingly, to avoid injury or loss of -reconstruction. These injuries require immediate vigilant treatment. C1 [Faulkner, Heather R.; Colwell, Amy S.; Liao, Eric C.; Winograd, Jonathan M.; Austen, William G., Jr.] Harvard Med Sch, Div Plast & Reconstruct Surg, Massachusetts Gen Hosp, Boston, MA USA. RP Faulkner, HR (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Surgery, Div Plast & Reconstruct Surg, 104 Endicott St,Suite 200, Danvers, MA 01923 USA. EM hrfaulkner@partners.org NR 21 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2169-7574 J9 PRS-GLOB OPEN JI PRS-GLOB. OPEN PD OCT PY 2016 VL 4 IS 10 AR e1033 DI 10.1097/GOX.0000000000001033 PG 5 WC Surgery SC Surgery GA EC8BD UT WOS:000388364000008 PM 27826463 ER PT J AU Sharifi, M Sequist, TD Rifas-Shiman, SL Melly, SJ Duncan, DT Horan, CM Smith, RL Marshall, R Taveras, EM AF Sharifi, Mona Sequist, Thomas D. Rifas-Shiman, Sheryl L. Melly, Steven J. Duncan, Dustin T. Horan, Christine M. Smith, Renata L. Marshall, Richard Taveras, Elsie M. TI The role of neighborhood characteristics and the built environment in understanding racial/ethnic disparities in childhood obesity SO PREVENTIVE MEDICINE LA English DT Article DE Childhood obesity; BMI; Disparities; Built environment; Socioeconomic risk factors; Electronic health records ID BODY-MASS INDEX; ETHNIC DISPARITIES; PHYSICAL-ACTIVITY; HEALTH DISPARITIES; US CHILDREN; CARE; PREVALENCE; YOUTH; EPIDEMIC; WEIGHT AB Background. Childhood obesity prevalence remains high and racial/ ethnic disparities may bewidening. Studies have examined the role of health behavioral differences. Less is known regarding neighborhood and built environment mediators of disparities. The objective of this study was to examine the extent to which racial/ ethnic disparities in elevated child body mass index (BMI) are explained by neighborhood socioeconomic status (SES) and built environment. Methods. We collected and analyzed race/ ethnicity, BMI, and geocoded address from electronic health records of 44,810 children 4 to 18 years-old seen at 14 Massachusetts pediatric practices in 2011-2012. Main outcomes were BMI z-score and BMI z-score change over time. We used multivariable linear regression to examine associations between race/ ethnicity and BMI z-score outcomes, sequentially adjusting for neighborhood SES and the food and physical activity environment. Results. Among 44,810 children, 13.3% were black, 5.7% Hispanic, and 65.2% white. Compared to white children, BMI z-scores were higher among black (0.43 units [95% CI: 0.40-0.45]) and Hispanic (0.38 [0.34-0.42]) children; black (0.06 [0.04-0.08]), but not Hispanic, children also had greater increases in BMI z-score over time. Adjusting for neighborhood SES substantially attenuated BMI z-score differences among black (0.30 [0.27-0.34]) and Hispanic children (0.28 [0.23-0.32]), while adjustment for food and physical activity environments attenuated the differences but to a lesser extent than neighborhood SES. Conclusions. Neighborhood SES and the built environment may be important drivers of childhood obesity disparities. To accelerate progress in reducing obesity disparities, interventions must be tailored to the neighborhood contexts in which families live. (C) 2016 Elsevier Inc. All rights reserved. C1 [Sharifi, Mona; Horan, Christine M.; Taveras, Elsie M.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pediat, Div Gen Acad Pediat, Boston, MA 02114 USA. [Sequist, Thomas D.] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med, 75 Francis St, Boston, MA 02115 USA. [Sequist, Thomas D.; Smith, Renata L.] Harvard Med Sch, Dept Hlth Care Policy, Boston, AL USA. [Sequist, Thomas D.] Partners HealthCare Syst Inc, Boston, MA USA. [Rifas-Shiman, Sheryl L.] Harvard Med Sch, Dept Populat Med, Obes Prevent Program, Boston, MA USA. [Rifas-Shiman, Sheryl L.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Melly, Steven J.] Harvard Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA. [Duncan, Dustin T.] NYU, Sch Med, Dept Populat Hlth, New York, NY USA. [Marshall, Richard] Harvard Vanguard Med Associates, Boston, MA USA. [Taveras, Elsie M.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA. RP Sharifi, M (reprint author), Yale Univ, Sch Med, Dept Pediat, Sect Gen Pediat, 330 Cedar St, New Haven, CT 06510 USA. EM mona.sharifi@yale.edu FU Academic Pediatric Association Young Investigator Award; Harvard Catalyst \ The Harvard Clinical and Translational Science Center [UL1 TR001102]; Harvard University; AHRQ Mentored Career Development Award for Child and Family Centered Outcomes Research [1 K12 HS 022986-01]; National Institute of Diabetes and Digestive and Kidney Diseases [K24 DK10589] FX This study was conducted with support from an Academic Pediatric Association Young Investigator Award (PI: Sharifi) and the Harvard Catalyst vertical bar The Harvard Clinical and Translational Science Center (UL1 TR001102) and financial contributions from Harvard University and its affiliated academic healthcare centers. Dr. Sharifi is supported by an AHRQ Mentored Career Development Award for Child and Family Centered Outcomes Research (1 K12 HS 022986-01). Dr. Taveras is supported by grant K24 DK10589 from the National Institute of Diabetes and Digestive and Kidney Diseases. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic health care centers, the NIH, AHRQ or the Academic Pediatric Association. NR 34 TC 0 Z9 0 U1 3 U2 3 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD OCT PY 2016 VL 91 BP 103 EP 109 DI 10.1016/j.ypmed.2016.07.009 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EC7ME UT WOS:000388322800016 PM 27404577 ER PT J AU Sorensen, G McLellan, DL Sabbath, EL Dennerlein, JT Nagler, EM Hurtado, DA Pronk, NP Wagner, GR AF Sorensen, Glorian McLellan, Deborah L. Sabbath, Erika L. Dennerlein, Jack T. Nagler, Eve M. Hurtado, David A. Pronk, Nicolaas P. Wagner, Gregory R. TI Integrating worksite health protection and health promotion: A conceptual model for intervention and research SO PREVENTIVE MEDICINE LA English DT Article DE Worker safety; Occupational health and safety; Health promotion; Conceptual model; Workplace health ID PATIENT-CARE WORKERS; REPORTED MUSCULOSKELETAL DISORDERS; RANDOMIZED CONTROLLED-TRIAL; CROSS-SECTIONAL SURVEY; BLUE-COLLAR WORKERS; LOW-BACK-PAIN; SAFETY CLIMATE; BEHAVIOR-CHANGE; RISK-FACTORS; CANCER PREVENTION AB There is increasing recognition of the value added by integrating traditionally separate efforts to protect and promote worker safety and health. This paper presents an innovative conceptual model to guide research on determinants of worker safety and health and to inform the design, implementation and evaluation of integrated approaches to promoting and protecting worker health. This model is rooted in multiple theories and the premise that the conditions of work are important determinants of individual safety and health outcomes and behaviors, and outcomes important to enterprises such as absence and turnover. Integrated policies, programs and practices simultaneously address multiple conditions of work, including the physical work environment and the organization of work (e.g., psychosocial factors, job tasks and demands). Findings from two recent studies conducted in Boston and Minnesota (2009-2015) illustrate the application of this model to guide social epidemiological research. This paper focuses particular attention on the relationships of the conditions of work to worker health-related behaviors, musculoskeletal symptoms, and occupational injury; and to the design of integrated interventions in response to specific settings and conditions of work of small and medium size manufacturing businesses, based on a systematic assessment of priorities, needs, and resources within an organization. This model provides an organizing framework for both research and practice by specifying the causal pathways through which work may influence health outcomes, and for designing and testing interventions to improve worker safety and health that are meaningful for workers and employers, and responsive to that setting's conditions of work. (C) 2016 Elsevier Inc. All rights reserved. C1 [Sorensen, Glorian; McLellan, Deborah L.; Nagler, Eve M.] Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. [Sorensen, Glorian; McLellan, Deborah L.; Dennerlein, Jack T.; Nagler, Eve M.; Pronk, Nicolaas P.; Wagner, Gregory R.] Harvard TH Chan Sch Publ Hlth, 677 Huntington Ave, Boston, MA 02115 USA. [Sabbath, Erika L.] Boston Coll, Sch Social Work, 140 Commonwealth Ave, Chestnut Hill, AL 02467 USA. [Dennerlein, Jack T.] Northeastern Univ, Bouve Coll Hlth Sci, 360 Huntington Ave, Boston, MA USA. [Pronk, Nicolaas P.] HealthPartners Inc, 8170 33rd Ave S, Bloomington, MN 55425 USA. [Wagner, Gregory R.] Natl Inst Occupat Safety & Hlth, 395 E St,SW, Washington, DC 20201 USA. [Hurtado, David A.] Oregon Hlth & Sci Univ, Oregon Inst Occupat Hlth Sci, 3181 SW Sam Jackson Pk Rd,L606, Portland, OR 97239 USA. RP Sorensen, G (reprint author), Dana Farber Canc Inst, Ctr Conununity Based Res, 450 Brookline Ave, Boston, MA 02215 USA. EM glorian_sorensen@dfci.harvard.edu FU National Institute for Occupational Safety and Health [U19 OH008861]; National Institutes of Health [K05 CA124415] FX This work was supported by a grant from the National Institute for Occupational Safety and Health (U19 OH008861) for the Harvard T.H. Chan School of Public Health Center for Work, Health and Well-being and by a grant from the National Institutes of Health (K05 CA124415). NR 150 TC 0 Z9 0 U1 12 U2 12 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 EI 1096-0260 J9 PREV MED JI Prev. Med. PD OCT PY 2016 VL 91 BP 188 EP 196 DI 10.1016/j.ypmed.2016.08.005 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA EC7ME UT WOS:000388322800029 PM 27527576 ER PT J AU Park, SG Chang, BH Mueller, L Resnick, SG Eisen, SV AF Park, Stephanie Grace Chang, Bei-Hung Mueller, Lisa Resnick, Sandra G. Eisen, Susan V. TI Predictors of Employment Burnout Among VHA Peer Support Specialists SO PSYCHIATRIC SERVICES LA English DT Article ID MENTAL-HEALTH WORKERS; CONSUMER-PROVIDERS; JOB-SATISFACTION; SERVICES; ILLNESS; STRESS; CARE; METAANALYSIS; MECHANISMS; CHALLENGES AB Objective: This study evaluated three domains of job burnout (emotional exhaustion, depersonalization, and personal accomplishment) and factors associated with burnout in a national sample of peer specialists (PSs) employed at 138 Veterans Health Administration (VHA) health care systems in 49 states. Methods: Data were drawn from an observational study in which participants (N=152) completed online, self-report surveys about their mental health recovery, quality of life, and employment experiences at baseline, six months, and 12 months. Levels of burnout were analyzed at each time point, and regression analyses that controlled for baseline levels identified potential predictors of burnout (demographic, clinical, and employment characteristics) at six and 12 months. Results: Compared with previously published burnout levels of other mental health workers in the VHA, PSs reported similar levels of emotional exhaustion, depersonalization, and personal accomplishment. At baseline, increased burnout was correlated with white race, fewer hours providing direct services, greater psychiatric symptoms, and lower self-efficacy. However, analyses did not reveal strong predictors of burnout scores at six or 12 months. Conclusions: In the first study to prospectively examine job burnout among PSs employed by the VHA, results illustrate the nuanced experience of burnout over a 12-month period and suggest the need for replication and further research on employment experiences of this emerging workforce. C1 [Park, Stephanie Grace] Vet Integrated Serv Network VISN 5, Vet Affairs VA Capitol Hlth Care Network, MIRECC, Baltimore, MD USA. [Park, Stephanie Grace] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA. [Park, Stephanie Grace] Rockville Internal Med Grp, Rockville, MD USA. [Chang, Bei-Hung] VA Boston Healthcare Syst, Boston, MA USA. [Chang, Bei-Hung] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA. [Mueller, Lisa] Edith Nourse Rogers Mem ENRM Vet Hosp, VISN MIRECC 1, Bedford, MA USA. [Eisen, Susan V.] Edith Nourse Rogers Mem ENRM Vet Hosp, Ctr Healthcare Org & Implementat Res, Bedford, MA USA. [Eisen, Susan V.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Resnick, Sandra G.] VISN 1 MIRECC, West Haven, CT USA. [Resnick, Sandra G.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. RP Park, SG (reprint author), Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA. EM spark@priviamedicalgroup.com FU VA Health Services Research and Development grant [IIR 10-332]; Office of Academic Affiliations, VA Advanced Fellowship Program in Mental Illness Research and Treatment; VA Capitol Health Care Network (VISN 5) MIRECC; ENRM Veterans Hospital FX This work was supported by VA Health Services Research and Development grant IIR 10-332; the Office of Academic Affiliations, VA Advanced Fellowship Program in Mental Illness Research and Treatment; the VA Capitol Health Care Network (VISN 5) MIRECC; and the ENRM Veterans Hospital. NR 46 TC 0 Z9 0 U1 2 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD OCT 1 PY 2016 VL 67 IS 10 BP 1108 EP 1114 DI 10.1176/appi.ps.201500239 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA EC6TC UT WOS:000388268600021 ER PT J AU Rosenheck, RA Leslie, DL Sint, KJ Lin, HQ Li, Y McEvoy, JP Byerly, MJ Hamer, RM Swartz, MS Stroup, TS AF Rosenheck, Robert A. Leslie, Douglas L. Sint, Kyaw J. Lin, Haiqun Li, Yue McEvoy, Joseph P. Byerly, Matthew J. Hamer, Robert M. Swartz, Marvin S. Stroup, T. Scott TI Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia SO PSYCHIATRIC SERVICES LA English DT Article ID RANDOMIZED CLINICAL-TRIAL; SCHIZOAFFECTIVE DISORDER; ORAL ANTIPSYCHOTICS; RELAPSE PREVENTION; OPEN-LABEL; RISPERIDONE; 2ND-GENERATION; UNCERTAINTY; OLANZAPINE; FRAMEWORK AB Objective: This study assessed the relative cost-effectiveness of haloperidol decanoate (HD), a first-generation long-acting injectable (LAI) antipsychotic, and paliperidone palmitate (PP), a second-generation LAI antipsychotic. Methods: A double-blind, randomized 18-month clinical trial conducted at 22 clinical research sites in the United States compared the cost-effectiveness of HD and PP among 311 adults with schizophrenia or schizoaffective disorder who had been clinically assessed as likely to benefit from an LAI antipsychotic. Patients were randomly assigned to monthly intramuscular injections of HD (25-200 mg) or PP (39-234 mg) for up to 24 months. Quality-adjusted life years (QALYs) were measured by a schizophrenia-specific algorithm based on the Positive and Negative Syndrome Scale and side-effect assessments; total health care costs were assessed from the perspective of the health system. Results: Mixed-model analysis showed that PP was associated with .0297 greater QALYs over 18 months (p=.03) and with $ 2,100 more in average costs per quarter for inpatient and outpatient services and medication compared with HD (p<.001). Bootstrap analysis with 5,000 replications showed an incremental cost-effectiveness ratio for PP of $ 508,241 per QALY (95% confidence interval=$122,390-$1,582,711). Net health benefits analysis showed a .98 probability of greater cost-effectiveness for HD compared with PP at an estimated value of $ 150,000 per QALY and a .50 probability of greater cost-effectiveness at $ 500,000 per QALY. Conclusions: HD was more cost-effective than PP, suggesting that PP's slightly greater benefits did not justify its markedly higher costs, which are likely to fall once the medication's patent expires. C1 [Rosenheck, Robert A.] Yale Med Sch, Dept Psychiat, New Haven, CT 06510 USA. [Rosenheck, Robert A.] US Dept Vet Affairs, New England Mental Illness Res Educ & Clin Ctr, West Haven, CT 06516 USA. [Leslie, Douglas L.] Penn State Univ, Coll Med, Dept Publ Hlth Sci & Psychiat, Hershey, PA USA. [Sint, Kyaw J.; Lin, Haiqun; Li, Yue] Yale Sch Publ Hlth, New Haven, CT USA. [McEvoy, Joseph P.] Georgia Regents Univ, Med Coll Georgia, Augusta, GA USA. [Byerly, Matthew J.] Univ Texas Southwestern Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA. [Hamer, Robert M.] Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC USA. [Swartz, Marvin S.] Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA. [Stroup, T. Scott] Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA. RP Rosenheck, RA (reprint author), Yale Med Sch, Dept Psychiat, New Haven, CT 06510 USA.; Rosenheck, RA (reprint author), US Dept Vet Affairs, New England Mental Illness Res Educ & Clin Ctr, West Haven, CT 06516 USA. EM robert.rosenheck@yale.edu FU National Institute of Mental Health (NIMH); NIMH; AstraZeneca; Janssen Pharmaceutica; Otsuka; Wyeth Pharmaceuticals; Alkermes, Inc.; Alkermes; Auspex; Avanir; BoehringerIngelheim; Eli Lilly; Forum; GlaxoSmithKline; Hoffman LaRoche; Merck; Sunovion; University of North Carolina; Abbott; Acadia; Allergan; Alpharma; Cenerx; Corcept; EnabledMD; Epix; Johnson and Johnson; Novartis; Pfizer; PureTech-Ventures; Sanofi-Aventis; Schwartz; Takeda; Wyeth; Eli Lilly and Co; Genentech; Auspex Pharmaceuticals FX The study was funded by grants from the National Institute of Mental Health (NIMH) to Dr. McEvoy and Dr. Stroup and is registered as clinical trial NCT01136772. NIMH grant funds paid for all study medications. The following investigators conducted the study: Lawrence Adler, M.D., Glen Burnie, Maryland; Peter Buckley, M.D., Augusta, Georgia; Matthew Byerly, M.D., Dallas; Stanley Caroff, M.D., Philadelphia; Cherilyn DeSouza, M.D., Kansas City, Missouri; Dale D'Mello, M.D., Lansing, Michigan; Deepak D'Souza, M.D., New Haven, Connecticut; Fred Jarskog, M.D., Chapel Hill, North Carolina; Venkata Jasty, M.D., Detroit; Eric Konicki, M.D., Cleveland; Matthew Macaluso, M.D., Wichita, Kansas; J. Steven Lamberti, M.D., Rochester, New York; Joshua Kantrowitz, M.D., New York; Joseph McEvoy, M.D., Butner, North Carolina; Del Miller, M.D., Iowa City, Iowa; Robert Millet, M.D., Durham, North Carolina; Max Schubert, M.D., Waco, Texas; Martin Strassnig, M.D., Miami; Sriram Ramaswamy, M.D., Omaha; Andre Tapp, M.D., Tacoma, Washington; and Sarah Yasmin, M.D., Palo Alto, California. NIMH had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; and in the preparation, review, or approval of the manuscript. The funder had no role in the decision to submit the manuscript for publication.; Dr. Rosenheck has received research support from or been a consultant to AstraZeneca, Janssen Pharmaceutica, Otsuka, and Wyeth Pharmaceuticals and was testifying expert in Jones ex rel the State of Texas v Janssen Phamaceutica et al. Dr. Leslie has received research grant funding from Alkermes, Inc. Dr. McEvoy receives speaking honoraria, consultation and honorarium fees for educational lectures, advisory fees, or research grants from Alkermes, Auspex, Avanir, BoehringerIngelheim, Eli Lilly, Forum, GlaxoSmithKline, Hoffman LaRoche, Merck, Otsuka, and Sunovion. Dr. Byerly reports receiving consulting fees and research support from Otsuka. Prior to his death, Dr. Hamer had received advisory or consulting fees from, served on a data and safety monitoring board and an advisory board for, or was involved in a contract by the University of North Carolina involving Abbott, Acadia, Allergan, Alpharma, AstraZeneca, Cenerx, Corcept, Eli Lilly, EnabledMD, Epix, Johnson and Johnson, Novartis, Pfizer, PureTech-Ventures, Sanofi-Aventis, Schwartz, Takeda, and Wyeth. Dr. Hamer also had served as an expert witness in lawsuits involving Anesta, Barr, Caraco, Cephalon, Eurand, Forest, Lundbeck, Mylan, Sun, and Teva. Dr. Swartz reports having received research funding from Eli Lilly and Co. Dr. Stroup has participated in continuing medical education activities funded by Genentech and is an investigator in a clinical trial sponsored by Auspex Pharmaceuticals. The other authors report no financial relationships with commercial interests. NR 37 TC 0 Z9 0 U1 1 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD OCT 1 PY 2016 VL 67 IS 10 BP 1123 EP 1129 DI 10.1176/appi.ps.201500447 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA EC6TC UT WOS:000388268600023 ER PT J AU Chang, CY Rosenthal, DI Mitchell, DM Handa, A Kattapuram, SV Huang, AJ AF Chang, Connie Y. Rosenthal, Daniel I. Mitchell, Deborah M. Handa, Atsuhiko Kattapuram, Susan V. Huang, Ambrose J. TI Imaging Findings of Metabolic Bone Disease SO RADIOGRAPHICS LA English DT Article ID LONG-TERM HEMODIALYSIS; OF-THE-ART; RENAL-TRANSPLANTATION; OSTEOPOROSIS; HYPOPARATHYROIDISM; PREVALENCE; WOMEN; HYPERPARATHYROIDISM; HYPOPHOSPHATASIA; MANIFESTATIONS AB Metabolic bone diseases are a diverse group of diseases that result in abnormalities of (a) bone mass, (b) structure mineral homeostasis, (c) bone turnover, or (d) growth. Osteoporosis, the most common metabolic bone disease, results in generalized loss of bone mass and deterioration in the bone microarchitecture. Impaired chondrocyte development and failure to mineralize growth plate cartilage in rickets lead to widened growth plates and frayed metaphyses at sites of greatest growth. Osteomalacia is the result of impaired mineralization of newly formed osteoid, which leads to characteristic Looser zones. Hypophosphatasia is a congenital condition of impaired bone mineralization with wide phenotypic variability. Findings of hyperparathyroidism are the result of bone resorption, most often manifesting as subperiosteal resorption in the hand. Renal osteodystrophy is the collection of skeletal findings observed in patients with chronic renal failure and associated secondary hyperparathyroidism and can include osteopenia, osteosclerosis, and "rugger jersey spine." Hypoparathyroidism is most commonly due to iatrogenic injury, and radiographic findings of hypoparathyroidism reflect an overall increase in bone mass. Thyroid hormone regulates endochondral bone formation; and congenital hypothyroidism, when untreated, leads to delayed bone age and absent, irregular, or fragmented distal femoral and proximal tibial epiphyses. Soft-tissue proliferation of thyroid acropachy is most often observed in the hands and feet. The findings of acromegaly are due to excess growth hormone secretion and therefore proliferation of the bones and soft tissues. Vitamin C deficiency, or scurvy, impairs posttranslational collagen modification, leading to subperiosteal hemorrhage and fractures. (C) RSNA, 2016 C1 [Chang, Connie Y.; Rosenthal, Daniel I.; Kattapuram, Susan V.; Huang, Ambrose J.] Massachusetts Gen Hosp, Dept Radiol, Div Musculoskeletal Imaging & Intervent, 55 Fruit St,Yawkey 6E, Boston, MA 02114 USA. [Mitchell, Deborah M.] Massachusetts Gen Hosp, Dept Pediat, Pediat Endocrine Div, 55 Fruit St,Yawkey 6E, Boston, MA 02114 USA. [Handa, Atsuhiko] St Lukes Int Hosp, Dept Radiol, Tokyo, Japan. RP Chang, CY (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Musculoskeletal Imaging & Intervent, 55 Fruit St,Yawkey 6E, Boston, MA 02114 USA. EM cychang@mgh.harvard.edu OI Mitchell, Deborah/0000-0003-0364-9107 NR 57 TC 0 Z9 0 U1 3 U2 3 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0271-5333 J9 RADIOGRAPHICS JI Radiographics PD OCT PY 2016 VL 36 IS 6 BP 1871 EP 1887 DI 10.1148/rg.2016160004 PG 17 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EC9BJ UT WOS:000388438200016 PM 27726750 ER PT J AU Limkakeng, AT Monte, AA Kabrhel, C Puskarich, M Heitsch, L Tsalik, EL Shapiro, NI AF Limkakeng, Alexander T., Jr. Monte, Andrew A. Kabrhel, Christopher Puskarich, Michael Heitsch, Laura Tsalik, Ephraim L. Shapiro, Nathan I. TI Systematic Molecular Phenotyping: A Path Toward Precision Emergency Medicine? SO ACADEMIC EMERGENCY MEDICINE LA English DT Article ID CORONARY-ARTERY-DISEASE; PERSONALIZED MEDICINE; ISCHEMIC-STROKE; SEPTIC SHOCK; SEPSIS; ASSOCIATION; PERSPECTIVE; VARIANTS; FUTURE; MODEL AB Precision medicine is an emerging approach to disease treatment and prevention that considers variability in patient genes, environment, and lifestyle. However, little has been written about how such research impacts emergency care. Recent advances in analytical techniques have made it possible to characterize patients in a more comprehensive and sophisticated fashion at the molecular level, promising highly individualized diagnosis and treatment. Among these techniques are various systematic molecular phenotyping analyses (e.g., genomics, transcriptomics, proteomics, and metabolomics). Although a number of emergency physicians use such techniques in their research, widespread discussion of these approaches has been lacking in the emergency care literature and many emergency physicians may be unfamiliar with them. In this article, we briefly review the underpinnings of such studies, note how they already impact acute care, discuss areas in which they might soon be applied, and identify challenges in translation to the emergency department (ED). While such techniques hold much promise, it is unclear whether the obstacles to translating their findings to the ED will be overcome in the near future. Such obstacles include validation, cost, turnaround time, user interface, decision support, standardization, and adoption by end-users. (C) 2016 by the Society for Academic Emergency Medicine C1 [Limkakeng, Alexander T., Jr.] Duke Univ, Div Emergency Med, Durham, NC 27708 USA. [Monte, Andrew A.] Univ Colorado Denver, Div Med Toxicol, Dept Emergency Med, Aurora, CO USA. [Monte, Andrew A.] Denver Hlth & Hosp Author, Rocky Mt Poison & Drug Ctr, Denver, CO USA. [Kabrhel, Christopher] Massachusetts Gen Hosp, Ctr Vasc Emergencies, Dept Emergency Med, Boston, MA 02114 USA. [Kabrhel, Christopher; Shapiro, Nathan I.] Harvard Med Sch, Boston, MA USA. [Puskarich, Michael] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA. [Heitsch, Laura] Washington Univ, Dept Emergency Med, St Louis, MO USA. [Tsalik, Ephraim L.] Durham Vet Affairs Med Ctr, Emergency Med Serv, Durham, NC USA. [Tsalik, Ephraim L.] Duke Univ, Ctr Appl Genom & Precis Med, Durham, NC USA. [Tsalik, Ephraim L.] Duke Univ, Dept Med, Div Infect Dis & Int Hlth, Durham, NC USA. [Shapiro, Nathan I.] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA. [Shapiro, Nathan I.] Beth Israel Deaconess Med Ctr, Vasc Biol Res Ctr, Boston, MA 02215 USA. RP Limkakeng, AT (reprint author), Duke Univ, Div Emergency Med, Durham, NC 27708 USA. EM alexander.limkakeng@duke.edu FU Duke University PDC; National Institutes of Health [HL 116854, K23 GM113041-01, K23 GM110516, UL1 TR000154] FX We acknowledge the following grant support: Dr. Limkakeng's work was supported by an internal grant from the Duke University PDC. Dr. Kabrhel's work was supported by National Institutes of Health Grant HL 116854. Dr. Puskarich's work was supported by National Institutes of Health Grant K23 GM113041-01. Dr. Monte's work was supported by National Institutes of Health Grants K23 GM110516 and UL1 TR000154 (AAM). NR 40 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1069-6563 EI 1553-2712 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD OCT PY 2016 VL 23 IS 10 BP 1097 EP 1106 DI 10.1111/acem.13027 PG 10 WC Emergency Medicine SC Emergency Medicine GA EB8AL UT WOS:000387613000001 PM 27288269 ER PT J AU Yun, BJ Hunink, MGM Prabhakar, AM Heng, M Liu, SW Qudsi, R Raja, AS AF Yun, Brian J. Hunink, M. G. Myriam Prabhakar, Anand M. Heng, Marilyn Liu, Shan W. Qudsi, Rameez Raja, Ali S. TI Diagnostic Imaging Strategies for Occult Hip Fractures: A Decision and Cost-Effectiveness Analysis SO ACADEMIC EMERGENCY MEDICINE LA English DT Article ID EMERGENCY-DEPARTMENT PATIENTS; PROXIMAL FEMUR; COMPUTED-TOMOGRAPHY; OPERATIVE DELAY; OLDER PATIENTS; MRI; MORTALITY; HEALTH; HEMIARTHROPLASTY; METAANALYSIS AB Objective: Hip fractures cause significant morbidity and mortality. Determining the optimal diagnostic strategy for the subset of patients with potential occult hip fracture remains challenging. We determined the most cost-effective strategy for the diagnosis of occult hip fractures from the choices of performing only computed tomography (CT), performing only magnetic resonance imaging (MRI), performing CT and if negative performing MRI (MRI-selective strategy) or discharging the patient without advanced imaging. Methods: We developed a decision-analytic model to compare outcomes and costs of different diagnostic strategies for the diagnosis of an occult hip fracture from a societal perspective. Model inputs were derived from charge data, Medicare reimbursements, and the literature. Strategies with an incremental cost-effectiveness ratio (ICER) below $100,000 per quality-adjusted life-year (QALY) gained were considered cost-effective. We tested the robustness of our results using probabilistic sensitivity analysis. Results: Compared to a CT strategy, MRI provides an additional 0.05 QALY at an incremental cost of $1,227 and ICER of $25,438/QALY. For facilities without MRI capability, if the cost of transfer is below $1,228, transferring the patient to a MRI-capable facility is the most cost-effective strategy. Above this cost, employing a CT and if negative transfer to a MRI-capable facility strategy was more cost-effective. When the cost of a transfer reached more than $4,039, it became more cost-effective to only obtain a CT. Conclusion: MRI is a cost-effective strategy for the diagnosis of an occult hip fracture. For facilities without MRI capability, the most cost-effective strategy depends on the cost of the interfacility transfer. (C) 2016 by the Society for Academic Emergency Medicine C1 [Yun, Brian J.; Liu, Shan W.; Raja, Ali S.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Hunink, M. G. Myriam] Erasmus Univ, Med Ctr, Dept Radiol, Rotterdam, Netherlands. [Hunink, M. G. Myriam] Erasmus Univ, Med Ctr, Dept Epidemiol, Rotterdam, Netherlands. [Hunink, M. G. Myriam] Harvard TH Chan Sch Publ Hlth, Ctr Hlth Decis Sci, Boston, MA USA. [Prabhakar, Anand M.] Dept Radiol, Div Cardiovasc Imaging, Boston, MA USA. [Prabhakar, Anand M.] Dept Radiol, Div Emergency Imaging, Boston, MA USA. [Heng, Marilyn; Qudsi, Rameez] Dept Orthopaed Surg, Boston, MA USA. [Heng, Marilyn] Harvard Orthopaed Trauma Initiat, Boston, MA USA. [Raja, Ali S.] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA. [Yun, Brian J.; Prabhakar, Anand M.; Heng, Marilyn; Liu, Shan W.; Qudsi, Rameez; Raja, Ali S.] Harvard Med Sch, Boston, MA 02115 USA. RP Yun, BJ (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.; Yun, BJ (reprint author), Harvard Med Sch, Boston, MA 02115 USA. EM byun@partners.org NR 47 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1069-6563 EI 1553-2712 J9 ACAD EMERG MED JI Acad. Emerg. Med. PD OCT PY 2016 VL 23 IS 10 BP 1161 EP 1169 DI 10.1111/acem.13026 PG 9 WC Emergency Medicine SC Emergency Medicine GA EB8AL UT WOS:000387613000009 PM 27286291 ER PT J AU Kuzu, G Keskin, O Nussinov, R Gursoy, A AF Kuzu, Guray Keskin, Ozlem Nussinov, Ruth Gursoy, Attila TI PRISM-EM: template interface-based modelling of multi-protein complexes guided by cryo-electron microscopy density maps SO ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY LA English DT Article DE multimolecular protein complexes; modelling protein assemblies; PRISM-EM; three-dimensional electron microscopy; protein structure prediction ID FITTING ATOMIC MODELS; ELECTRON-MICROSCOPY; MACROMOLECULAR ASSEMBLIES; WEB SERVER; I-TASSER; DOCKING; PREDICTION; SEGMENTATION; SCALE; TOOL AB The structures of protein assemblies are important for elucidating cellular processes at the molecular level. Three-dimensional electron microscopy (3DEM) is a powerful method to identify the structures of assemblies, especially those that are challenging to study by crystallography. Here, a new approach, PRISM-EM, is reported to computationally generate plausible structural models using a procedure that combines crystallographic structures and density maps obtained from 3DEM. The predictions are validated against seven available structurally different crystallographic complexes. The models display mean deviations in the backbone of <5 angstrom. PRISM-EM was further tested on different benchmark sets; the accuracy was evaluated with respect to the structure of the complex, and the correlation with EM density maps and interface predictions were evaluated and compared with those obtained using other methods. PRISM-EM was then used to predict the structure of the ternary complex of the HIV-1 envelope glycoprotein trimer, the ligand CD4 and the neutralizing protein m36. C1 [Kuzu, Guray; Keskin, Ozlem] Koc Univ, Ctr Computat Biol & Bioinformat, TR-34450 Istanbul, Turkey. [Kuzu, Guray; Keskin, Ozlem] Koc Univ, Coll Engn, TR-34450 Istanbul, Turkey. [Keskin, Ozlem] Koc Univ, Coll Engn, Chem & Biol Engn, TR-34450 Istanbul, Turkey. [Nussinov, Ruth] NCI, Canc & Inflammat Program, Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA. [Nussinov, Ruth] Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, Sackler Inst Mol Med, IL-69978 Tel Aviv, Israel. [Gursoy, Attila] Koc Univ, Comp Engn, TR-34450 Istanbul, Turkey. [Kuzu, Guray] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. RP Keskin, O (reprint author), Koc Univ, Ctr Computat Biol & Bioinformat, TR-34450 Istanbul, Turkey.; Keskin, O (reprint author), Koc Univ, Coll Engn, TR-34450 Istanbul, Turkey.; Keskin, O (reprint author), Koc Univ, Coll Engn, Chem & Biol Engn, TR-34450 Istanbul, Turkey.; Gursoy, A (reprint author), Koc Univ, Comp Engn, TR-34450 Istanbul, Turkey. EM okeskin@ku.edu.tr; agursoy@ku.edu.tr RI Gursoy, Attila/E-9565-2015 OI Gursoy, Attila/0000-0002-2297-2113 FU TUBITAK (The Scientific and Technological Research Council of Turkey) fellowship; TUBITAK Research Grant [114M196]; National Cancer Institute, National Institutes of Health [HHSN261200800001E]; Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research FX We thank Drs Sriram Subramaniam, Erin E. H. Tran and Lesley A. Earl for guidance relating to the incorporation of the 3DEM information and for critical reading of this manuscript, insight and discussions. GK was supported by a TUBITAK (The Scientific and Technological Research Council of Turkey) fellowship. This work was supported by TUBITAK Research Grant No. 114M196. It was also funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health under contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government. This research was supported (in part) by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. NR 66 TC 0 Z9 0 U1 2 U2 2 PU INT UNION CRYSTALLOGRAPHY PI CHESTER PA 2 ABBEY SQ, CHESTER, CH1 2HU, ENGLAND SN 2059-7983 J9 ACTA CRYSTALLOGR D JI Acta Crystallogr. Sect. D-Struct. Biol. PD OCT PY 2016 VL 72 BP 1137 EP 1148 DI 10.1107/S2059798316013541 PN 10 PG 12 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Biophysics; Crystallography SC Biochemistry & Molecular Biology; Biophysics; Crystallography GA EB7TE UT WOS:000387592700007 PM 27710935 ER PT J AU Mounessa, J Qin, R Dunnick, CA Dellavalle, RP AF Mounessa, Jessica Qin, Rosie Dunnick, Cory A. Dellavalle, Robert P. TI Chemoprevention of Keratinocyte Carcinomas: An Updated Review SO AMERICAN JOURNAL OF CLINICAL DERMATOLOGY LA English DT Review ID NONMELANOMA SKIN-CANCER; RENAL-TRANSPLANT RECIPIENTS; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; PHASE-I CHEMOPREVENTION; HUMAN ACTINIC KERATOSES; PERILLYL ALCOHOL CREAM; BASAL-CELL CARCINOMA; DNA-REPAIR ENZYMES; DOUBLE-BLIND AB A well-established link between ultraviolet exposure and the carcinogenesis of keratinocyte carcinomas exists. Despite increased sun protection efforts, skin cancer remains the most common cancer in the USA. Numerous studies on the topic of chemoprevention investigate alternative topical, oral, and injectable agents to reduce skin cancer incidence in those at risk. Such agents include sunscreen, numerous vitamins and minerals, difluoromethylornithine, non-steroidal anti-inflammatory drugs, various peptides, field therapy, statins, and polyphenols. In this focused review, we discuss the risks and benefits of chemoprotective agents reported in clinical studies conducted in humans. We report several agents that may reduce skin cancer incidence in those at risk. C1 [Mounessa, Jessica] SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA. [Mounessa, Jessica; Dunnick, Cory A.; Dellavalle, Robert P.] Univ Colorado Hosp, Dept Dermatol, Aurora, CO 80045 USA. [Qin, Rosie] Duke Univ, Sch Med, 8 Duke Univ Med Ctr Greenspace, Durham, NC USA. [Dunnick, Cory A.; Dellavalle, Robert P.] Denver VA Med Ctr, Dept Dermatol, 1055 Clermont St 165, Denver, CO 80220 USA. RP Dellavalle, RP (reprint author), Univ Colorado Hosp, Dept Dermatol, Aurora, CO 80045 USA.; Dellavalle, RP (reprint author), Denver VA Med Ctr, Dept Dermatol, 1055 Clermont St 165, Denver, CO 80220 USA. EM Robert.Dellavalle@ucdenver.edu NR 74 TC 0 Z9 0 U1 2 U2 2 PU ADIS INT LTD PI NORTHCOTE PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND SN 1175-0561 EI 1179-1888 J9 AM J CLIN DERMATOL JI Am. J. Clin. Dermatol. PD OCT PY 2016 VL 17 IS 5 BP 475 EP 484 DI 10.1007/s40257-016-0208-2 PG 10 WC Dermatology SC Dermatology GA EC0UZ UT WOS:000387818000005 PM 27372106 ER PT J AU Hess, EJ Moody, KA Geffrey, AL Pollack, SF Skirvin, LA Bruno, PL Paolini, JL Thiele, EA AF Hess, Evan J. Moody, Kirsten A. Geffrey, Alexandra L. Pollack, Sarah F. Skirvin, Lauren A. Bruno, Patricia L. Paolini, Jan L. Thiele, Elizabeth A. TI Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex SO EPILEPSIA LA English DT Article DE Tuberous sclerosis complex; Cannabidiol; Efficacy; Tolerability; Seizures ID PARTIAL SEIZURES; RATS; MICE; CANNABINOIDS AB Objective: Tuberous sclerosis complex (TSC) is an autosomal-dominant genetic disorder with highly variable expression. The most common neurologic manifestation of TSC is epilepsy, which affects approximately 85% of patients, 63% of whom develop treatment-resistant epilepsy. Herein, we evaluate the efficacy, safety, and tolerability of cannabidiol (CBD), a nonpsychoactive compound derived from the marijuana plant, as an adjunct to current antiepileptic drugs in patients with refractory seizures in the setting of TSC. Methods: Eighteen of the 56 patients who have enrolled in our current expandedaccess study of cannabidiol for patients with treatment-resistant epilepsy carry a diagnosis of TSC. After an initial baseline period of 1 month, patients began treatment with CBD. The initial dose of 5 mg/kg/day was increased by 5 mg/kg/day every week up to a maximum dose of 50 mg/kg/day, if tolerated. Weekly seizure frequencies, percent change in seizure frequencies, and responder rates were calculated during the 2nd, 3rd, 6th, 9th, and 12th month of treatment with CBD. Results: The median weekly seizure frequency during the baseline period was 22.0 (interquartile range [IQR] 14.8-57.4), which decreased to 13.3 (IQR 5.1-22.1) after 3 months of treatment with cannabidiol. The median percent change in total weekly seizure frequency was -48.8% (IQR -69.1% to -11.1%) after 3 months of treatment. The 50% responder rates over the course of the study were 50%, 50%, 38.9%, 50%, and 50% after 2, 3, 6, 9, and 12 months of treatment with CBD, respectively. In patients taking clobazam concurrently with CBD (n = 12), the responder rate after 3 months of treatment was 58.3%, compared to 33.3% in patients not taking clobazam (n = 6). Twelve (66.7%) of 18 patients in this study experienced at least one adverse event thought possibly related to CBD; the most common adverse events were drowsiness (n = 8, 44.4%), ataxia (n = 5, 27.8%), and diarrhea (n = 4, 22.2%). Significance: Although double-blind, placebo-controlled trials are still necessary, these findings suggest that cannabidiol may be an effective and well-tolerated treatment option for patients with refractory seizures in TSC. C1 [Hess, Evan J.; Moody, Kirsten A.; Geffrey, Alexandra L.; Pollack, Sarah F.; Skirvin, Lauren A.; Bruno, Patricia L.; Paolini, Jan L.; Thiele, Elizabeth A.] Massachusetts Gen Hosp, 175 Cambridge St,Suite 340, Boston, MA 02114 USA. RP Thiele, EA (reprint author), Massachusetts Gen Hosp, 175 Cambridge St,Suite 340, Boston, MA 02114 USA. EM ethiele@partners.org FU Herscot Center for Tuberous Sclerosis Complex FX Thank you to GW Pharmaceuticals for providing the study drug and to the Herscot Center for Tuberous Sclerosis Complex for financial support. NR 23 TC 2 Z9 2 U1 14 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0013-9580 EI 1528-1167 J9 EPILEPSIA JI Epilepsia PD OCT PY 2016 VL 57 IS 10 BP 1617 EP 1624 DI 10.1111/epi.13499 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA EB8QV UT WOS:000387656800011 PM 27696387 ER PT J AU Choi, JE Kim, JH Song, NY Suh, J Kim, DH Kim, SJ Na, HK Nadas, J Dong, ZG Cha, YN Surh, YJ AF Choi, Jee-Eun Kim, Jung-Hyun Song, Na-Young Suh, Jinyoung Kim, Do-Hee Kim, Su-Jung Na, Hye-Kyung Nadas, Janos Dong, Zigang Cha, Young-Nam Surh, Young-Joon TI 15-Deoxy-Delta(12,14)-prostaglandin J(2) stabilizes hypoxia inducible factor-1 alpha through induction of heme oxygenase-1 and direct modification ofprolyl-4-hydroxylase 2 SO FREE RADICAL RESEARCH LA English DT Article; Proceedings Paper CT 7th Biennial Meeting of Society-for-Free-Radical-Research-Asia (SFRR-Asia) CY 2015 CL Chiang Mai, THAILAND SP Soc Free Rad Res Asia DE 15-Deoxy-Delta(12,14)-prostaglandin J(2); hypoxia inducible factor-1 alpha; heme oxygenase-1; prolyl-4-hydroxylase 2; MCF-7 cells; cyclopentenone prostaglandin ID BREAST-CANCER CELLS; ENDOTHELIAL GROWTH-FACTOR; TUMOR-SUPPRESSOR PROTEIN; PROLYL HYDROXYLASE; FACTOR PROLYL-4-HYDROXYLASE; HIF-ALPHA; PROLINE HYDROXYLATION; COX-2 EXPRESSION; CARBON-MONOXIDE; DNA-BINDING AB 15-Deoxy-(12,14)-prostaglandin J(2) (15d-PGJ(2)), a representative J-series cyclopentenone prostaglandin, has biphasic roles in cell proliferation and apoptosis. Hypoxia inducible factor-1 (HIF-1) regulates expression of various genes involved in tumor growth and angiogenesis. In the present study, treatment of human breast cancer (MCF-7) cells with 15d-PGJ(2) resulted in the accumulation of the -subunit of HIF-1. Pretreatment with zinc protoporphyrin IX, a pharmacological inhibitor of heme oxygenase-1 (HO-1), as well as siRNA knockdown of HO-1 gene in MCF-7 cells attenuated 15d-PGJ(2)-mediated HIF-1 accumulation. 15d-PGJ(2) treatment increased intracellular production of reactive oxygen species (ROS), which was mediated by HO-1 induction. Preincubation of MCF-7 cells with trolox, a water-soluble form of vitamin E, attenuated 15d-PGJ(2)-induced HIF-1 expression although HO-1 expression was unchanged. This finding suggests that ROS accumulated as a consequence of HO-1 up-regulation can enhance HIF-1 expression in MCF-7 cells treated with 15d-PGJ(2). Alternatively, 15d-PGJ(2) was found to covalently bind to HIF-1 prolyl-4-hydroxylase 2 (PHD2) in MCF-7 cells, which hampers the proline hydroxylation of HIF-1, thereby disrupting ubiquitin-dependent proteasomal degradation of this transcription factor. Pretreatment with thiol reducing agents blunted 15d-PGJ(2)-induced HIF-1 stabilization, indicative of a cysteine residue as a direct target of 15d-PGJ(2). Molecular docking analysis suggests that 15d-PGJ(2) preferentially binds to PHD2 in the vicinity of the Cys(201) residue based on binding energies and carbon-sulfur distances. In summary, 15d-PGJ(2) stabilizes HIF-1 in MCF-7 cells through HO-1 induction with subsequent ROS generation and also through direct modification of PHD2. C1 [Choi, Jee-Eun; Kim, Jung-Hyun; Song, Na-Young; Suh, Jinyoung; Kim, Do-Hee; Surh, Young-Joon] Pharmaceut Sci Res Inst, Coll Pharm, Seoul, South Korea. [Kim, Su-Jung; Dong, Zigang; Surh, Young-Joon] Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul, South Korea. [Na, Hye-Kyung] Sungshin Womens Univ, Dept Food & Nutr, Seoul, South Korea. [Nadas, Janos; Dong, Zigang] Univ Minnesota, Hormel Inst, Austin, MN USA. [Cha, Young-Nam] Inha Univ, Coll Med, Inchon, South Korea. [Surh, Young-Joon] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea. Harvard Med Sch, Biol & Biomed Sci Grad program, Boston, MA 02115 USA. [Choi, Jee-Eun] Harvard Med Sch, Massachusetts Gen Hosp Canc Ctr, Boston, MA 02114 USA. [Kim, Jung-Hyun] Natl Inst Hlth, Div Intractable Dis, Ctr Biomed Sci, Chungcheongbuk Do, South Korea. RP Surh, YJ (reprint author), Pharmaceut Sci Res Inst, Coll Pharm, Seoul, South Korea.; Surh, YJ (reprint author), Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul, South Korea.; Surh, YJ (reprint author), Seoul Natl Univ, Canc Res Inst, Seoul, South Korea.; Surh, YJ (reprint author), Seoul Natl Univ, Coll Pharm, 1 Gwanak Ro, Seoul 08826, South Korea. EM surh@snu.ac.kr NR 70 TC 1 Z9 1 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1071-5762 EI 1029-2470 J9 FREE RADICAL RES JI Free Radic. Res. PD OCT PY 2016 VL 50 IS 10 BP 1140 EP 1152 DI 10.1080/10715762.2016.1219352 PG 13 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA EC2EH UT WOS:000387922000011 PM 27598034 ER PT J AU Kass, JI Giraldez, L Gooding, W Choby, G Kim, S Miles, B Teng, M Sikora, AG Johnson, JT Myers, EN Duvvuri, U Genden, EM Ferris, RL AF Kass, Jason I. Giraldez, Laureano Gooding, William Choby, Garret Kim, Seungwon Miles, Brett Teng, Marita Sikora, Andrew G. Johnson, Jonas T. Myers, Eugene N. Duvvuri, Umamaheswar Genden, Eric M. Ferris, Robert L. TI Oncologic outcomes of surgically treated early-stage oropharyngeal squamous cell carcinoma SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK LA English DT Article DE oropharyngeal squamous cell carcinoma; transoral robotic surgery; oncologic outcomes ID TRANSORAL ROBOTIC SURGERY; QUALITY-OF-LIFE; HUMAN-PAPILLOMAVIRUS; LASER-MICROSURGERY; CANCER; HEAD; CHEMORADIATION; RADIATION; SURVIVAL AB Background. The purpose of this study was to characterize oncologic outcomes in early (T1-T2, N0) and intermediate (T1-T2, N1) oropharyngeal squamous cell carcinoma (SCC) after surgery. Methods. Patients with oropharyngeal SCC treated with surgery were identified from 2 academic institutions. Results. Of 188 patients, 143 met the inclusion criteria. Eighty-six (60%) had T1 to T2 N0 and 57 (40%) had T1 to T2 N1 disease. Sixty-five patients (45%) underwent a robotic-assisted resection, whereas the remaining had transoral (n = 60; 42%), mandible-splitting (n = 11; 8%), or transhyoid approaches (n = 7; 5%). Human papillomavirus (HPV) status was known for 97 patients (68%), and 54 (55%) were HPV positive. Three-year recurrence-free survival (RFS) was 82% (95% confidence interval [CI] = 0.75-0.89). Since 2008, HPV infection was protective of recurrence (log-rank p =.0334). A single node did not increase the risk of recurrence (p =.467) or chance of a second primary (p =.175). Conclusion. Complete surgical resection is effective therapy for early and intermediate oropharyngeal SCC. HPV-negative patients were at increased risk for locoregional recurrence or second primary disease. (C) 2016 Wiley Periodicals, Inc. C1 [Kass, Jason I.; Choby, Garret; Kim, Seungwon; Johnson, Jonas T.; Myers, Eugene N.; Duvvuri, Umamaheswar; Ferris, Robert L.] Univ Pittsburgh, Med Ctr, Dept Otolaryngol, 200 Lothrop St,EEI 500, Pittsburgh, PA 15213 USA. [Kass, Jason I.; Giraldez, Laureano; Miles, Brett; Teng, Marita; Genden, Eric M.] Icahn Sch Med Mt Sinai, Dept Otolaryngol, New York, NY 10029 USA. [Gooding, William] Univ Pittsburgh, Inst Canc, Biostat Facil, 200 Lothrop St,EEI 500, Pittsburgh, PA 15213 USA. [Sikora, Andrew G.] Baylor Coll Med, Dept Otolaryngol, Houston, TX 77030 USA. [Duvvuri, Umamaheswar] Vet Affairs Pittsburgh Hlth Syst, Pittsburgh, PA USA. RP Ferris, RL (reprint author), Univ Pittsburgh, Med Ctr, Dept Otolaryngol, 200 Lothrop St,EEI 500, Pittsburgh, PA 15213 USA. EM ferrisrl@upmc.edu FU University of Pittsburgh Cancer Institute Biostatistics Facility [P30CA047904] FX Contract grant sponsor: This project was conducted using the University of Pittsburgh Cancer Institute Biostatistics Facility that is supported in part by award P30CA047904. NR 25 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1043-3074 EI 1097-0347 J9 HEAD NECK-J SCI SPEC JI Head Neck-J. Sci. Spec. Head Neck PD OCT PY 2016 VL 38 IS 10 BP 1467 EP 1471 DI 10.1002/hed.24456 PG 5 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA EC7JM UT WOS:000388313600008 PM 27080244 ER PT J AU Macias, AA Eappen, S Malikin, I Goldfarb, J Kujawa, S Konowitz, PM Kamani, D Randolph, GW AF Macias, Alvaro A. Eappen, Sunil Malikin, Ilya Goldfarb, Jeremy Kujawa, Sharon Konowitz, Paul M. Kamani, Dipti Randolph, Gregory W. TI Successful intraoperative electrophysiologic monitoring of the recurrent laryngeal nerve, a multidisciplinary approach: The Massachusetts Eye and Ear Infirmary monitoring collaborative protocol with experience in over 3000 cases SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK LA English DT Article DE anesthesia; recurrent laryngeal nerve; neuromuscular agents; thyroid; intraoperative nerve monitoring (IONM) ID THYROID ASSOCIATION GUIDELINES; VOCAL FOLD PARALYSIS; QUALITY-OF-LIFE; INTUBATING CONDITIONS; PARATHYROID SURGERY; STATEMENT; MANAGEMENT; IMPACT; VOICE; IDENTIFICATION AB Background. Although intraoperative nerve monitoring (IONM) is utilized increasingly, the information on the related anesthesia technique is limited. This study presents an up-to-date clinical algorithm, including setup and troubleshooting of an IONM system, endotracheal tube placement, and anesthetic parameters. To our knowledge, this is the first interdisciplinary collaborative protocol for monitored neck surgery based on the published evidence and clinical experience. Methods. The Departments of Otolaryngology Head and Neck Surgery, Anesthesiology, and Audiology collaboratively developed a protocol for IONM of the recurrent laryngeal nerve (RLN) based on published evidence and our experience with 3000 patients over a 16-year period. Results. No complications related to monitoring or endotracheal tube placement were noted when the IONM protocol was implemented at Massachusetts Eye and Ear Infirmary (MEEI). The IONM protocol has proven to be vital in standardizing care and in avoiding intraoperative errors. Conclusion. An IONM system entails an anesthesiologist who understands the challenges posed by this technique; muscle relaxation must be minimized/eliminated to optimize IONM. (C) 2016 Wiley Periodicals, Inc. C1 [Macias, Alvaro A.; Eappen, Sunil; Malikin, Ilya; Goldfarb, Jeremy] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Anesthesia, Boston, MA USA. [Kujawa, Sharon] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Audiol, Boston, MA USA. [Konowitz, Paul M.; Kamani, Dipti; Randolph, Gregory W.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Div Thyroid & Parathyroid Surg, Boston, MA USA. RP Randolph, GW (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Div Thyroid & Parathyroid Surg, 243 Charles St, Boston, MA 02114 USA. EM Gregory_Randolph@meei.harvard.edu FU John and Claire Bertucci Thyroid Research Fund FX Contract grant sponsor: This research was supported by The John and Claire Bertucci Thyroid Research Fund. NR 57 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1043-3074 EI 1097-0347 J9 HEAD NECK-J SCI SPEC JI Head Neck-J. Sci. Spec. Head Neck PD OCT PY 2016 VL 38 IS 10 BP 1487 EP 1494 DI 10.1002/hed.24468 PG 8 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA EC7JM UT WOS:000388313600011 PM 27062311 ER PT J AU Keane, FK Chen, YH Tishler, RB Schoenfeld, JD Haddad, RI Goguen, LA Catalano, P Neville, BA Margalit, DN AF Keane, Florence K. Chen, Yu-Hui Tishler, Roy B. Schoenfeld, Jonathan D. Haddad, Robert I. Goguen, Laura A. Catalano, Paul Neville, Bridget A. Margalit, Danielle N. TI Population-based validation of the recursive partitioning analysis-based staging system for oropharyngeal cancer SO HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK LA English DT Article DE oropharyngeal squamous cell cancer; head and neck cancer staging; American Joint Committee on Cancer (AJCC) staging system; human papillomavirus (HPV)-related cancer; recursive partitioning analysis-based staging ID SQUAMOUS-CELL CARCINOMA; HUMAN-PAPILLOMAVIRUS; NECK-CANCER; PROGNOSTIC-FACTORS; UNITED-STATES; INCREASED RISK; MARITAL-STATUS; TOBACCO USE; HEAD; SURVIVAL AB Background. The American Joint Committee on Cancer (AJCC) staging system does not adequately distinguish prognostic groups in the era of human papillomavirus (HPV)-related oropharyngeal cancer. The purpose of this study was to validate a recursive partitioning analysis (RPA)-based stage grouping on a population-wide level. Methods. We identified 8427 patients in Surveillance, Epidemiology, and End Results (SEER) with nonmetastatic oropharyngeal cancer with unknown HPV-status diagnosed from 2004 to 2008. We estimated the overall survival (OS) and head and neck cancer-specific mortality by RPA stage and AJCC stage and compared the predictive power of the systems. Results. RPA stage was significantly associated with OS and head and neck cancer-specific mortality (p <.0001) with 5-year OS of 70% for RPA-I, 55.6% for RPA-II, and 44.3% for RPA-III. AJCC stage failed to divide patients into distinct subgroups. RPA stage had significantly improved predictive ability versus AJCC stage for OS (c-statistic: 0.60 = RPA vs 0.54 = AJCC) and head and neck cancer-specific mortality (c-statistic: 0.62 = RPA vs 0.55 = AJCC). Conclusion. The RPA-based stage grouping divided patients into prognostically distinct cohorts and provided superior prediction of OS and head and neck cancer-specific mortality compared to AJCC staging. (C) 2016 Wiley Periodicals, Inc. C1 [Keane, Florence K.] Harvard Med Sch, Harvard Radiat Oncol Program, 450 Brookline Ave, Boston, MA 02115 USA. [Chen, Yu-Hui; Catalano, Paul] Dana Farber Harvard Canc Ctr, Boston, MA USA. [Tishler, Roy B.; Schoenfeld, Jonathan D.; Margalit, Danielle N.] Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. [Haddad, Robert I.] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02115 USA. [Haddad, Robert I.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. [Goguen, Laura A.] Brigham & Womens Hosp, Dept Surg, Div Otolaryngol, 75 Francis St, Boston, MA 02115 USA. [Neville, Bridget A.] Ariadne Labs, Boston, MA USA. RP Margalit, DN (reprint author), Harvard Med Sch, Dana Farber Canc Inst, Dept Radiat Oncol, 450 Brookline Ave, Boston, MA USA. EM dmargalit@lroc.harvard.edu NR 31 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1043-3074 EI 1097-0347 J9 HEAD NECK-J SCI SPEC JI Head Neck-J. Sci. Spec. Head Neck PD OCT PY 2016 VL 38 IS 10 BP 1530 EP 1538 DI 10.1002/hed.24470 PG 9 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA EC7JM UT WOS:000388313600017 PM 27080700 ER PT J AU Lobach, DF Johns, EB Halpenny, B Saunders, TA Brzozowski, J Del Fiol, G Berry, DL Braun, IM Finn, K Wolfe, J Abrahm, JL Cooley, ME AF Lobach, David F. Johns, Ellis B. Halpenny, Barbara Saunders, Toni-Ann Brzozowski, Jane Del Fiol, Guilherme Berry, Donna L. Braun, Ilana M. Finn, Kathleen Wolfe, Joanne Abrahm, Janet L. Cooley, Mary E. TI Increasing Complexity in Rule-Based Clinical Decision Support: The Symptom Assessment and Management Intervention SO JMIR MEDICAL INFORMATICS LA English DT Article DE rule-based clinical decision support; clinical algorithms; Web services; software as a service; symptom management; patient-reported outcomes; lung cancer ID CELL LUNG-CANCER; QUALITY-OF-LIFE; PALLIATIVE CARE; BEHAVIORAL INTERVENTION; GERIATRIC-PATIENTS; PREVALENCE; DEPRESSION; DISTRESS; TIME; PREDICTORS AB Background: Management of uncontrolled symptoms is an important component of quality cancer care. Clinical guidelines are available for optimal symptom management, but are not often integrated into the front lines of care. The use of clinical decision support (CDS) at the point-of-care is an innovative way to incorporate guideline-based symptom management into routine cancer care. Objective: The objective of this study was to develop and evaluate a rule-based CDS system to enable management of multiple symptoms in lung cancer patients at the point-of-care. Methods: This study was conducted in three phases involving a formative evaluation, a system evaluation, and a contextual evaluation of clinical use. In Phase 1, we conducted iterative usability testing of user interface prototypes with patients and health care providers (HCPs) in two thoracic oncology clinics. In Phase 2, we programmed complex algorithms derived from clinical practice guidelines into a rules engine that used Web services to communicate with the end-user application. Unit testing of algorithms was conducted using a stack-traversal tree-spanning methodology to identify all possible permutations of pathways through each algorithm, to validate accuracy. In Phase 3, we evaluated clinical use of the system among patients and HCPs in the two clinics via observations, structured interviews, and questionnaires. Results: In Phase 1, 13 patients and 5 HCPs engaged in two rounds of formative testing, and suggested improvements leading to revisions until overall usability scores met a priori benchmarks. In Phase 2, symptom management algorithms contained between 29 and 1425 decision nodes, resulting in 19 to 3194 unique pathways per algorithm. Unit testing required 240 person-hours, and integration testing required 40 person-hours. In Phase 3, both patients and HCPs found the system usable and acceptable, and offered suggestions for improvements. Conclusions: A rule-based CDS system for complex symptom management was systematically developed and tested. The complexity of the algorithms required extensive development and innovative testing. The Web service-based approach allowed remote access to CDS knowledge, and could enable scaling and sharing of this knowledge to accelerate availability, and reduce duplication of effort. Patients and HCPs found the system to be usable and useful. C1 [Lobach, David F.] Duke Univ, Sch Med, Dept Community & Family Med, Durham, NC USA. [Lobach, David F.] Klesis Healthcare, Durham, NC USA. [Johns, Ellis B.] Family Med Albemarle, Charlottesville, VA USA. [Johns, Ellis B.] Medengineers Informat, Charlottesville, VA USA. [Halpenny, Barbara; Saunders, Toni-Ann; Berry, Donna L.; Cooley, Mary E.] Dana Farber Canc Inst, Phyllis F Cantor Ctr, Boston, MA 02115 USA. [Del Fiol, Guilherme] Univ Utah, Dept Biomed Informat, Salt Lake City, UT USA. [Braun, Ilana M.; Wolfe, Joanne; Abrahm, Janet L.] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA. [Finn, Kathleen] City Hope Natl Med Ctr, Clin Trials Off, Duarte, CA USA. RP Lobach, DF (reprint author), Duke Univ, Med Ctr, Dept Community & Family Med, Sch Med, Box 3886, Durham, NC 22710 USA. EM David.Lobach@klesishealthcare.com OI Del Fiol, Guilherme/0000-0001-9954-6799 FU NCI NIH HHS [R01 CA125256] NR 45 TC 1 Z9 1 U1 5 U2 5 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 2291-9694 J9 JMIR MED INF JI JMIR Med. Inf. PD OCT-DEC PY 2016 VL 4 IS 4 BP 62 EP 75 AR e36 DI 10.2196/medinform.5728 PG 14 WC Medical Informatics SC Medical Informatics GA EC2XO UT WOS:000387988000006 PM 27826132 ER PT J AU Haun, JN Chavez, M Nazi, KM Antinori, N AF Haun, Jolie N. Chavez, Margeaux Nazi, Kim M. Antinori, Nicole TI Developing a Health Information Technology Systems Matrix: A Qualitative Participatory Approach SO JOURNAL OF MEDICAL INTERNET RESEARCH LA English DT Article DE veterans; patient-centered care; information resources; patient preferences; integrated delivery system; health information technology ID RECOMMENDATIONS; ORGANIZATIONS AB Background: The US Department of Veterans Affairs (VA) has developed various health information technology (HIT) resources to provide accessible veteran-centered health care. Currently, the VA is undergoing a major reorganization of VA HIT to develop a fully integrated system to meet consumer needs. Although extensive system documentation exists for various VA HIT systems, a more centralized and integrated perspective with clear documentation is needed in order to support effective analysis, strategy, planning, and use. Such a tool would enable a novel view of what is currently available and support identifying and effectively capturing the consumer's vision for the future. Objective: The objective of this study was to develop the VA HIT Systems Matrix, a novel tool designed to describe the existing VA HIT system and identify consumers' vision for the future of an integrated VA HIT system. Methods: This study utilized an expert panel and veteran informant focus groups with self-administered surveys. The study employed participatory research methods to define the current system and understand how stakeholders and veterans envision the future of VA HIT and interface design (eg, look, feel, and function). Directed content analysis was used to analyze focus group data. Results: The HIT Systems Matrix was developed with input from 47 veterans, an informal caregiver, and an expert panel to provide a descriptive inventory of existing and emerging VA HIT in four worksheets: (1) access and function, (2) benefits and barriers, (3) system preferences, and (4) tasks. Within each worksheet is a two-axis inventory. The VA's existing and emerging HIT platforms (eg, My HealtheVet, Mobile Health, VetLink Kiosks, Telehealth), My HealtheVet features (eg, Blue Button, secure messaging, appointment reminders, prescription refill, vet library, spotlight, vitals tracker), and non-VA platforms (eg, phone/mobile phone, texting, non-VA mobile apps, non-VA mobile electronic devices, non-VA websites) are organized by row. Columns are titled with thematic and functional domains (eg, access, function, benefits, barriers, authentication, delegation, user tasks). Cells for each sheet include descriptions and details that reflect factors relevant to domains and the topic of each worksheet. Conclusions: This study provides documentation of the current VA HIT system and efforts for consumers' vision of an integrated system redesign. The HIT Systems Matrix provides a consumer preference blueprint to inform the current VA HIT system and the vision for future development to integrate electronic resources within VA and beyond with non-VA resources. The data presented in the HIT Systems Matrix are relevant for VA administrators and developers as well as other large health care organizations seeking to document and organize their consumer-facing HIT resources. C1 [Haun, Jolie N.; Chavez, Margeaux; Antinori, Nicole] US Dept Vet Affairs, HSR&D Ctr Innovat Disabil & Rehabil Res, James A Haley VA Hosp, 8900 Grand Oak Circle,118M, Tampa, FL 33637 USA. [Haun, Jolie N.] Univ S Florida, Coll Publ Hlth, Dept Community & Family Hlth, Tampa, FL USA. [Nazi, Kim M.] Dept Vet Affairs, Vet Hlth Adm, Vet & Consumers Hlth Informat Off, Albany, NY USA. RP Haun, JN (reprint author), US Dept Vet Affairs, HSR&D Ctr Innovat Disabil & Rehabil Res, James A Haley VA Hosp, 8900 Grand Oak Circle,118M, Tampa, FL 33637 USA. EM joliehaun@gmail.com OI Nazi, Kim/0000-0002-0966-5602 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service; National eHealth Quality Enhancement Research Initiative (QUERI) Coordinating Center [RRP 12-495]; Center of Innovation for Disability and Rehabilitation Research at the James A. Haley Veterans Hospital FX The Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development Service, and National eHealth Quality Enhancement Research Initiative (QUERI) Coordinating Center (RRP 12-495) supported this study. This study was also supported in part by the Center of Innovation for Disability and Rehabilitation Research at the James A. Haley Veterans Hospital. The contents of this paper do not represent the views of the Department of Veterans Affairs or the US Government. The authors would like to acknowledge the efforts of the VA Human Factors team, including Nancy Wilck, Abigail Noonan, and Ashley Cook, for their significant contribution to the success of this project. We would also like to thank Susan Woods and Jeffrey Sartori for their generosity of time and consultation throughout the conceptualization and implementation of this project. NR 13 TC 0 Z9 0 U1 2 U2 2 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 1438-8871 J9 J MED INTERNET RES JI J. Med. Internet Res. PD OCT PY 2016 VL 18 IS 10 BP 111 EP 119 AR e266 DI 10.2196/jmir.6499 PG 9 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA EC2WT UT WOS:000387985700009 PM 27713112 ER PT J AU Besser, LM Alosco, ML Gomez, LR Zhou, XH McKee, AC Stern, RA Gunstad, J Schneider, JA Chui, H Kukull, WA AF Besser, Lilah M. Alosco, Michael L. Gomez, Liliana Ramirez Zhou, Xiao-Hua McKee, Ann C. Stern, Robert A. Gunstad, John Schneider, Julie A. Chui, Helena Kukull, Walter A. TI Late-Life Vascular Risk Factors and Alzheimer Disease Neuropathology in Individuals with Normal Cognition SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY LA English DT Article DE Alzheimer disease; Asymptomatic; Body mass index; Heart rate; Neuropathology; Normal cognition; Vascular risk factor ID BODY-MASS INDEX; RESTING HEART-RATE; MIDLIFE BLOOD-PRESSURE; PULSE PRESSURE; CARDIOVASCULAR-DISEASE; OLDER-ADULTS; CEREBROVASCULAR-DISEASE; RATE-VARIABILITY; SENILE DEMENTIA; WEIGHT-LOSS AB Vascular risk factors (VRFs) have been associated with clinically diagnosed Alzheimer disease (AD), but few studies have examined the association between VRF and AD neuropathology (ADNP) in cognitively normal individuals. We used longitudinal data from the National Alzheimer's Disease Center's Uniform Data Set and Neuropathology Data Set to examine the association between VRF and ADNP (moderate to frequent neuritic plaques; Braak stage III-VI) in those with normal cognition. Our sample included 53 participants with ADNP and 140 without ADNP. Body mass index (BMI), resting heart rate (HR), and pulse pressure (PP) were measured at each visit; values were averaged across participant visits and examined annual change in BMI, PP, and HR. Hypertension, diabetes, and hypercholesterolemia were self-reported. In the multivariable logistic regression analyses, average BMI and HR were associated with lower odds of ADNP, and annual increases in HR and BMI were associated with higher odds of ADNP. A previously experienced decline in BMI or HR in late-life (therefore, currently low BMI and low HR) as well as a late-life increase in BMI and HR may indicate underlying AD pathology. Additional clinicopathological research is needed to elucidate the role of changes in late-life VRF and AD pathogenesis. C1 [Besser, Lilah M.; Zhou, Xiao-Hua; Kukull, Walter A.] Univ Washington, Natl Alzheimers Coordinating Ctr, 4311 11th Ave NE,Suite 300, Seattle, WA 98105 USA. [Alosco, Michael L.; McKee, Ann C.; Stern, Robert A.] Boston Univ, Sch Med, Boston Univ Alzheimers Dis, Boston, MA 02118 USA. [Alosco, Michael L.; McKee, Ann C.; Stern, Robert A.] Boston Univ, Sch Med, CTE Ctr, Boston, MA 02118 USA. [Alosco, Michael L.; McKee, Ann C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA. [Gomez, Liliana Ramirez] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [McKee, Ann C.] US Dept Vet Affairs, VA Boston Healthcare Syst, Boston, MA USA. [McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA. [McKee, Ann C.] Dept Vet Affairs Med Ctr, Bedford, MA USA. [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg & Anat & Neurobiol, Boston, MA 02118 USA. [Gunstad, John] Kent State Univ, Dept Psychol Sci, Kent, OH 44242 USA. [Schneider, Julie A.] Rush Univ, Rush Alzheimers Dis Ctr, Dept Pathol, Chicago, IL 60612 USA. [Schneider, Julie A.] Rush Univ, Rush Alzheimers Dis Ctr, Dept Neurol Sci, Chicago, IL 60612 USA. [Chui, Helena] Univ Southern Calif, Los Angeles, CA USA. RP Besser, LM (reprint author), Univ Washington, Natl Alzheimers Coordinating Ctr, 4311 11th Ave NE,Suite 300, Seattle, WA 98105 USA. EM lmbesser@uw.edu FU NIA NIH HHS [P50 AG005142, P50 AG005136, P50 AG005133, P30 AG019610, P30 AG010124, P30 AG008051, P50 AG033514, P30 AG010161, P30 AG012300, P30 AG013854, P30 AG028383, P30 AG035982, P50 AG005131, U01 AG016976, P50 AG005134, P50 AG005146, P50 AG016570, P50 AG016573, P50 AG025688, P50 AG016574, P50 AG008702, P50 AG005681, P50 AG005138, P30 AG013846, P30 AG010129, P30 AG008017, P01 AG003991, P50 AG023501, P30 AG010133]; NIAAA NIH HHS [R01 AA022336]; NINDS NIH HHS [F32 NS096803] NR 63 TC 0 Z9 0 U1 3 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-3069 EI 1554-6578 J9 J NEUROPATH EXP NEUR JI J. Neuropathol. Exp. Neurol. PD OCT PY 2016 VL 75 IS 10 BP 955 EP 962 DI 10.1093/jnen/nlw072 PG 8 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA EC3ET UT WOS:000388009200005 PM 27516116 ER PT J AU Kinney, HC Poduri, AH Cryan, JB Haynes, RL Teot, L Sleeper, LA Holm, IA Berry, GT Prabhu, SP Warfield, SK Brownstein, C Abram, HS Kruer, M Kemp, WL Hargitai, B Gastrang, J Mena, OJ Haas, EA Dastjerdi, R Armstrong, DD Goldstein, RD AF Kinney, Hannah C. Poduri, Annapurna H. Cryan, Jane B. Haynes, Robin L. Teot, Lisa Sleeper, Lynn A. Holm, Ingrid A. Berry, Gerald T. Prabhu, Sanjay P. Warfield, Simon K. Brownstein, Catherine Abram, Harry S. Kruer, Michael Kemp, Walter L. Hargitai, Beata Gastrang, Joanne Mena, Othon J. Haas, Elisabeth A. Dastjerdi, Roya Armstrong, Dawna D. Goldstein, Richard D. TI Hippocampal Formation Maldevelopment and Sudden Unexpected Death across the Pediatric Age Spectrum SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY LA English DT Article DE Dentate gyrus; Febrile seizures; Granule cell dispersion; Sudden unexplained death in childhood (SUDC); Sudden infant death syndrome (SIDS); Sudden unexplained death in epilepsy (SUDEP); Sudden unexpected death in pediatrics with hippocampal formation maldevelopment (SUDP-HFM) ID GRANULE CELL DISPERSION; BRAIN-STEM ABNORMALITIES; NORTHERN PLAINS INDIANS; TEMPORAL-LOBE EPILEPSY; DENTATE GYRUS; ARCUATE NUCLEUS; EARLY-CHILDHOOD; RISK-FACTORS; HUMAN INFANT; SEIZURES AB Sudden infant death syndrome (SIDS) and sudden unexplained death in childhood (SUDC) are defined as sudden death in a child remaining unexplained despite autopsy and death scene investigation. They are distinguished from each other by age criteria, i.e. with SIDS under 1 year and SUDC over 1 year. Our separate studies of SIDS and SUDC provide evidence of shared hippocampal abnormalities, specifically focal dentate bilamination, a lesion classically associated with temporal lobe epilepsy, across the 2 groups. In this study, we characterized the clinicopathologic features in a retrospective case series of 32 children with sudden death and hippocampal formation (HF) maldevelopment. The greatest frequency of deaths was between 3 weeks and 3 years (81%, 26/32). Dentate anomalies were found across the pediatric age spectrum, supporting a common vulnerability that defies the 1-year age cutoff between SIDS and SUDC. Twelve cases (38%) had seizures, including 7 only with febrile seizures. Subicular anomalies were found in cases over 1 year of age and were associated with increased risk of febrile seizures. Sudden death associated with HF maldevelopment reflects a complex interaction of intrinsic and extrinsic factors that lead to death at different pediatric ages, and may be analogous to sudden unexplained death in epilepsy. C1 [Kinney, Hannah C.; Haynes, Robin L.; Teot, Lisa; Dastjerdi, Roya] Boston Childrens Hosp, Dept Pathol, Enders 1112,61 Binney St, Boston, MA 02115 USA. [Kinney, Hannah C.; Poduri, Annapurna H.; Haynes, Robin L.; Teot, Lisa; Sleeper, Lynn A.; Holm, Ingrid A.; Berry, Gerald T.; Prabhu, Sanjay P.; Warfield, Simon K.; Brownstein, Catherine; Dastjerdi, Roya; Goldstein, Richard D.] Harvard Med Sch, Boston, MA USA. [Poduri, Annapurna H.] Boston Childrens Hosp, FM Kirby Neurobiol Ctr, Dept Neurol, Epilepsy Genet Program, Boston, MA USA. [Cryan, Jane B.] Beaumont Hosp, Div Neuropathol, Dublin, Ireland. [Sleeper, Lynn A.] Boston Childrens Hosp, Dept Cardiol, Boston, MA USA. [Holm, Ingrid A.; Berry, Gerald T.; Brownstein, Catherine] Boston Childrens Hosp, Dept Genet & Genom Med, Boston, MA USA. [Prabhu, Sanjay P.; Warfield, Simon K.] Boston Childrens Hosp, Dept Radiol, Boston, MA USA. [Abram, Harry S.] Nemours Childrens Specialty Care, Div Child Neurol, Jacksonville, FL USA. [Kruer, Michael] Univ Arizona, Coll Med, Phoenix Childrens Hosp, Barrow Neurol Inst,Dept Child Hlth, Phoenix, AZ USA. [Kemp, Walter L.] Univ North Dakota, Sch Med & Hlth Sci, Dept Pathol, Grand Forks, ND 58201 USA. [Hargitai, Beata] Birmingham Womens Hosp, Dept Cellular Pathol, Birmingham, W Midlands, England. [Gastrang, Joanne] Univ Warwick, Div Mental Hlth & Wellbeing, Coventry, W Midlands, England. [Gastrang, Joanne] Coventry & Warwickshire Partnership NHS Trust, Coventry, W Midlands, England. [Mena, Othon J.] Off Med Examiner, County Of San Diego, CA USA. [Haas, Elisabeth A.] Rady Childrens Hosp, Dept Pathol, San Diego, CA USA. [Armstrong, Dawna D.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA. [Armstrong, Dawna D.] Baylor Coll Med, Pathol, Houston, TX 77030 USA. [Goldstein, Richard D.] Boston Childrens Hosp, Dana Farber Canc Inst, Dept Med, Dept Psychosocial Oncol & Palliat Care, Boston, MA USA. RP Kinney, HC (reprint author), Boston Childrens Hosp, Dept Pathol, Enders 1112,61 Binney St, Boston, MA 02115 USA. EM Hannah.Kinney@childrens.harvard.edu FU NICHD NIH HHS [U54 HD090255, P01 HD036379] NR 71 TC 0 Z9 0 U1 2 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-3069 EI 1554-6578 J9 J NEUROPATH EXP NEUR JI J. Neuropathol. Exp. Neurol. PD OCT PY 2016 VL 75 IS 10 BP 981 EP 997 DI 10.1093/jnen/nlw075 PG 17 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA EC3ET UT WOS:000388009200008 PM 27612489 ER PT J AU Molina, G Neville, BA Lipsitz, SR Gibbons, L Childers, AK Gawande, AA Berry, WR Haynes, AB AF Molina, George Neville, Bridget A. Lipsitz, Stuart R. Gibbons, Lorri Childers, Ashley Kay Gawande, Atul A. Berry, William R. Haynes, Alex B. TI Postoperative acute care use after freestanding ambulatory surgery SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE Freestanding ambulatory surgery centers; Ambulatory surgery; Postoperative acute care ID RETURN HOSPITAL VISITS; FOLLOW-UP; MORBIDITY; DISCHARGE; READMISSIONS; INPATIENT; PROGRAM; COSTS AB Background: Surgical procedures in the United States are increasingly performed in the ambulatory setting, including freestanding ambulatory surgery centers (ASCs). However, there is a lack of research and tracking of surgical outcomes in this setting. Materials and methods: We analyzed data from a state all-payer claims database to produce a retrospective cohort study on the rate of acute care use (emergency department [ED] visits and inpatient admissions) within 7 d after operations performed in freestanding ASCs in South Carolina. Two-level reliability-adjusted generalized linear mixed models accounting for random facility-level effects were used to adjust for patient-level and facility-level characteristics. Results: A total of 1,328,708 procedures were performed in 86 freestanding ASCs in South Carolina from 2006-2013. The overall rate of postoperative acute care per 1000 procedures within 7 d was 17.3 (95% confidence interval [CI], 15.3-19.5). Patient characteristics associated with the highest postoperative acute care use within 7 d included Medicaid insurance (adjusted odds ratio [aOR], 1.79; 95% CI, 1.70-1.90), lowest median household income (aOR, 1.36; 95% CI, 1.30-1.43), and preoperative Charlson Comorbidity Index (CCI) score 3+ (aOR, 4.14; 95% CI, 3.95-4.34). Total charges for postoperative ED visits (n = 14,682) and inpatient admissions (n = 8945) within 7 d were approximately $51.4 and $361.1 million, respectively from 2006-2013. Conclusions: Acute care use within 7 d was commonly >= 10 per 1000 procedures performed in freestanding ASCs in South Carolina. These measures may be targets for quality and cost improvement and innovation. Patients at risk for acute care utilization may benefit from improvements in postoperative follow-up after procedures in ASCs. (C) 2016 Elsevier Inc. All rights reserved. C1 [Molina, George; Neville, Bridget A.; Lipsitz, Stuart R.; Gawande, Atul A.; Berry, William R.; Haynes, Alex B.] Brigham & Womens Hosp, Ariadne Labs, 75 Francis St, Boston, MA 02115 USA. [Molina, George; Neville, Bridget A.; Lipsitz, Stuart R.; Gawande, Atul A.; Berry, William R.; Haynes, Alex B.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA. [Molina, George; Haynes, Alex B.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Gibbons, Lorri; Childers, Ashley Kay] South Carolina Hosp Assoc, Columbia, SC USA. [Childers, Ashley Kay] Clemson Univ, Dept Ind Engn, Clemson, SC USA. RP Haynes, AB (reprint author), Ariadne Labs, 401 Pk Dr,Third Floor East, Boston, MA 02215 USA. EM abhaynes@mgh.harvard.edu NR 22 TC 1 Z9 1 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 EI 1095-8673 J9 J SURG RES JI J. Surg. Res. PD OCT PY 2016 VL 205 IS 2 BP 331 EP 340 DI 10.1016/j.jss.2016.06.084 PG 10 WC Surgery SC Surgery GA EC2VG UT WOS:000387981700011 PM 27664881 ER PT J AU Mason, MC Garcia, JM Sansgiry, S Walder, A Berger, DH Anaya, DA AF Mason, Meredith C. Garcia, Jose M. Sansgiry, Shubhada Walder, Annette Berger, David H. Anaya, Daniel A. TI Preoperative cancer cachexia and short-term outcomes following surgery SO JOURNAL OF SURGICAL RESEARCH LA English DT Article DE Cachexia; Postoperative complications; Surgical oncology; BMI ID QUALITY-OF-LIFE; WEIGHT-LOSS; COLORECTAL-CANCER; SURGICAL COMPLICATIONS; DOUBLE-BLIND; SURVIVAL; CHEMOTHERAPY; ASSOCIATION; DEFINITION; MECHANISMS AB Background: Cancer cachexia is an important measure of physiologic reserve associated with worse survival and represents an actionable factor for the cancer population. However, the incidence of cachexia in surgical cancer patients and its impact on postoperative outcomes are currently unknown. Methods: A prospective cohort study enrolling patients having elective cancer surgery (2012-2014) at a Veterans Affairs tertiary referral center. Preoperative cancer cachexia (weight loss >= 5% over 6-mo period before surgery) was the predictor of interest. The primary outcome was 60-d postoperative complications (VA Surgical Quality Improvement Program). Patients were grouped by body mass index (BMI) category (< 25, 25-29.9, >= 30), and interaction between cachexia and BMI was tested for the primary outcome. Multivariate logistic regression was used to examine the association between preoperative cachexia and postoperative complications. Results: Of 253 patients, 16.6% had preoperative cachexia, and 51.8% developed >= 1 postoperative complications. Complications were more common in cachectic patients (64.3% versus 49.3%, P = 0.07). This association varied by BMI category, and interaction analysis was significant for those with normal or underweight BMI (BMI < 25, P = 0.03). After multivariate modeling, in patients with normal or underweight BMI, preoperative cachexia was associated with higher odds of postoperative complications (odds ratios, 5.08 [95% confidence intervals, 1.18-21.88]; P = 0.029). Additional predictors of complications included major surgery (3.19 [1.24-8.21], P = 0.01), ostomy (4.43 [1.68-11.72], P = 0.003), and poor baseline performance status (2.31 [1.05-5.08], P = 0.03). Conclusions: Cancer cachexia is common in surgical patients, and is an important predictor of postoperative complications, though its effect varies by BMI. As a modifiable predictor of worse outcomes, future studies should examine the role of cachexia treatment before cancer surgery. (C) 2016 Elsevier Inc. All rights reserved. C1 [Mason, Meredith C.; Sansgiry, Shubhada; Walder, Annette; Berger, David H.] Michael E DeBakey VA Med Ctr, Houston VA Ctr Innovat Qual Effectiveness & Safet, Dept Med, Houston, TX USA. [Mason, Meredith C.; Berger, David H.; Anaya, Daniel A.] Baylor Coll Med, Michael E DeBakey Dept Surg, Houston, TX 77030 USA. [Garcia, Jose M.] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Dept Med, Seattle, WA USA. [Garcia, Jose M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Garcia, Jose M.] Michael E DeBakey VA Med Ctr, Ctr Translat Res Inflammatory Dis, Dept Med, Houston, TX USA. [Garcia, Jose M.] Baylor Coll Med, Houston, TX 77030 USA. [Anaya, Daniel A.] H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, Tampa, FL USA. RP Anaya, DA (reprint author), H Lee Moffitt Canc Ctr & Res Inst, Sect Hepatobiliary Tumors, Dept Gastrointestinal Oncol, 12902 Magnolia Dr FOB2, Tampa, FL 33612 USA. EM Daniel.Anaya@moffitt.org FU Conquer Cancer Foundation of ASCO Career Development Award; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development (MERIT grant) [BX000507, CX000174]; Center for Innovations in Quality, Effectiveness and Safety [CIN 13-413] FX This work was funded by a Conquer Cancer Foundation of ASCO Career Development Award (D.A.A.). This material is also based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development (MERIT grants BX000507 and CX000174 to J.M.G.), and the Center for Innovations in Quality, Effectiveness and Safety (CIN 13-413). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs, Baylor College of Medicine, American Society of Clinical Oncology or the Conquer Cancer Foundation. This source had no role in the preparation, review, or approval of the manuscript. NR 33 TC 0 Z9 0 U1 1 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0022-4804 EI 1095-8673 J9 J SURG RES JI J. Surg. Res. PD OCT PY 2016 VL 205 IS 2 BP 398 EP 406 DI 10.1016/j.jss.2016.06.076 PG 9 WC Surgery SC Surgery GA EC2VG UT WOS:000387981700019 PM 27664889 ER PT J AU Pilic, L Pedlar, CR Mavrommatis, Y AF Pilic, Leta Pedlar, Charles R. Mavrommatis, Yiannis TI Salt-sensitive hypertension: mechanisms and effects of dietary and other lifestyle factors SO NUTRITION REVIEWS LA English DT Review DE blood pressure; diet; hypertension; salt sensitivity ID RENAL BLOOD-FLOW; NERVOUS-SYSTEM ACTIVITY; NITRIC-OXIDE PRODUCTION; PLASMA-RENIN ACTIVITY; L-ARGININE UPTAKE; AFRICAN-AMERICANS; ANGIOTENSIN-II; SODIUM-INTAKE; DAHL RATS; ASYMMETRICAL DIMETHYLARGININE AB Salt sensitivity, which is an increase in blood pressure in response to high dietary salt intake, is an independent risk factor for cardiovascular disease and mortality. It is associated with physiological, environmental, demographic, and genetic factors. This review focuses on the physiological mechanisms of salt sensitivity in populations at particular risk, along with the associated dietary factors. The interplay of mechanisms such as the renin-angiotensin aldosterone system, endothelial dysfunction, ion transport, and estrogen decrease in women contributes to development of salt sensitivity. Because of their effects on these mechanisms, higher dietary intakes of potassium, calcium, vitamin D, antioxidant vitamins, and proteins rich in L-arginine, as well as adherence to dietary patterns similar to the DASH (Dietary Approaches to Stop Hypertension) diet, can be beneficial to salt-sensitive populations. In contrast, diets similar to the typical Western diet, which is rich in saturated fats, sucrose, and fructose, together with excessive alcohol consumption, may exacerbate salt-sensitive changes in blood pressure. Identifying potential mechanisms of salt sensitivity in susceptible populations and linking them to protective or harmful dietary and lifestyle factors can lead to more specific guidelines for the prevention of hypertension and cardiovascular disease. C1 [Pilic, Leta; Pedlar, Charles R.; Mavrommatis, Yiannis] St Marys Univ, Sch Sport Hlth & Appl Sci, London, England. [Pedlar, Charles R.] Massachusetts Gen Hosp, Cardiovasc Performance Program, Boston, MA 02114 USA. RP Pilic, L (reprint author), St Marys Univ, Sch Sport Hlth & Appl Sci, Waldegrave Rd,Strawberry Hill, Twickenham TW1 4SX, England. EM leta.pilic@stmarys.ac.uk NR 113 TC 2 Z9 2 U1 12 U2 12 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0029-6643 EI 1753-4887 J9 NUTR REV JI Nutr. Rev. PD OCT 1 PY 2016 VL 74 IS 10 BP 645 EP 658 DI 10.1093/nutrit/nuw028 PG 14 WC Nutrition & Dietetics SC Nutrition & Dietetics GA EB7TC UT WOS:000387592500005 PM 27566757 ER PT J AU Matsuo, K Machida, H Shoupe, D Melamed, A Muderspach, LI Roman, LD Wright, JD AF Matsuo, Koji Machida, Hiroko Shoupe, Donna Melamed, Alexander Muderspach, Laila I. Roman, Lynda D. Wright, Jason D. TI Ovarian Conservation and Overall Survival in Young Women With Early-Stage Low-Grade Endometrial Cancer SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID CARDIOVASCULAR-DISEASE; PREMENOPAUSAL WOMEN; MANAGEMENT; RISK; PRESERVATION; OOPHORECTOMY; SAFETY; TERM AB OBJECTIVE:To characterize contributing factors for ovarian conservation during surgical treatment for endometrial cancer and to examine the association of ovarian conservation on survival of young women with early-stage, low-grade tumors.METHODS:This was a population-based study using the Surveillance, Epidemiology, and End Results program to identify surgically treated stage I type I (grade 1-2 endometrioid histology) endometrial cancer cases diagnosed between 1983 and 2012 (N=86,005). Multivariable models were used to identify independent factors for ovarian conservation. Survival outcomes and cause of death were examined for women aged younger than 50 with stage I type I endometrial cancer who underwent ovarian conservation (1,242 among 12,860 women [9.7%]).RESULTS:On multivariable analysis, age younger than 50 years, grade 1 endometrioid histology, and tumor size 2.0 cm or less were noted to be independent factors for ovarian conservation (all, P<.001). For 9,110 women aged younger than 50 years with stage I grade 1 tumors, cause-specific survival was similar between ovarian conservation and oophorectomy cases (20-year rates 98.9% compared with 97.7%, P=.31), whereas overall survival was significantly higher in ovarian conservation cases than oophorectomy cases (88.8% compared with 82.0%, P=.011). On multivariable analysis, ovarian conservation remained an independent prognostic factor for improved overall survival (adjusted hazard ratio 0.73, 95% confidence interval [CI] 0.54-0.98, P=.036) and was independently associated with a lower cumulative risk of death resulting from cardiovascular disease compared with oophorectomy (20-year rates, 2.3% compared with 3.7%, adjusted hazard ratio 0.40, 95% CI 0.17-0.91, P=.029). Contrary, cause-specific survival (20-year rates 94.6% compared with 96.1%, P=.68) and overall survival (81.0% compared with 80.6%, P=.91) were similar between ovarian conservation and oophorectomy among 3,750 women aged younger than 50 years with stage I grade 2 tumors.CONCLUSION:Ovarian conservation is performed in less than 10% of young women with stage I type I endometrial cancer. Ovarian conservation is associated with decreased mortality in young women with stage I grade 1 tumors. C1 [Matsuo, Koji] Univ Southern Calif, Div Gynecol Oncol, Dept Obstet & Gynecol, Los Angeles Cty Med Ctr, 2020 Zonal Ave,IRD520, Los Angeles, CA 90089 USA. Univ Southern Calif, Div Reprod Endocrinol & Infertil, Dept Obstet & Gynecol, Los Angeles Cty Med Ctr, Los Angeles, CA 90089 USA. Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA. Harvard Med Sch, Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA USA. Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. Columbia Univ Coll Phys & Surg, Dept Obstet & Gynecol, New York, NY 10032 USA. RP Matsuo, K (reprint author), Univ Southern Calif, Div Gynecol Oncol, Dept Obstet & Gynecol, Los Angeles Cty Med Ctr, 2020 Zonal Ave,IRD520, Los Angeles, CA 90089 USA. EM koji.matsuo@med.usc.edu OI Melamed, Alexander/0000-0002-0654-0863 FU Ensign Endowment for Gynecologic Cancer Research FX Supported by the Ensign Endowment for Gynecologic Cancer Research (Koji Matsuo). NR 26 TC 2 Z9 2 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD OCT PY 2016 VL 128 IS 4 BP 761 EP 770 DI 10.1097/AOG.0000000000001647 PG 10 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DX6VT UT WOS:000384523600012 PM 27607873 ER PT J AU Penn, CA Morgan, DM Rice, LW Harris, JA Rauh-Hain, JA Uppal, S AF Penn, Courtney A. Morgan, Daniel M. Rice, Laurel W. Harris, John A. Rauh-Hain, J. Alejandro Uppal, Shitanshu TI Timing of and Reasons for Unplanned 30-Day Readmission After Hysterectomy for Benign Disease SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID HOSPITAL READMISSION; HEART-FAILURE; UNITED-STATES; SURGERY; QUALITY; PROGRAM; CARE AB OBJECTIVE:To characterize timing and reasons associated with unplanned 30-day readmissions after hysterectomy for benign indications.METHODS:We performed a retrospective analysis of the American College of Surgeons National Surgical Quality Improvement Project database files from 2012 to 2013. We identified patterns of 30-day readmission after benign hysterectomy for all surgical approaches (abdominal, laparoscopic, vaginal). Readmission timing was determined from discharge date and readmission diagnoses were tabulated. Statistical analyses included (2) tests and multivariable logistic regression.RESULTS:The 30-day readmission rate was 2.8% (1,118/40,580 hysterectomies). Readmissions complicated 3.7% (361/9,869) of abdominal, 2.6% (576/22,266) of laparoscopic, and 2.1% (181/8,445) of vaginal hysterectomies. Readmissions were more likely when hysterectomy was performed abdominally (adjusted odds ratio [OR] 1.45, 95% confidence interval [CI] 1.2-1.76) but not laparoscopically (adjusted OR 1.1, 95% CI 0.9-1.4) compared with a vaginal approach. Eighty-two percent of readmissions occurred within 15 days of discharge. The shortest median time to readmission was associated with pain (3 days), and the longest was associated with noninfectious wound complications (10 days). Surgical site infection was the most common diagnosis (abdominal 36.6%, laparoscopic 28.3%, vaginal 32.6%). Surgical site infections, surgical injuries, and wound complications combined accounted for 51.5% of abdominal, 51.9% of laparoscopic, and 50.8% of vaginal hysterectomy readmissions. Medical complications such as cardiovascular events and venous thromboembolism were responsible for 5.8% of abdominal, 6.9% of laparoscopic, and 8.8% of vaginal hysterectomy readmissions. Surgical injuries were responsible for more readmissions after laparoscopic (unadjusted OR 2.3, 95% CI 1.48-3.65) and vaginal hysterectomies (unadjusted OR 2.3, 95% CI 1.29-3.97) than abdominal cases.CONCLUSION:Readmissions after hysterectomy tend to occur shortly after discharge. Most readmissions are related to surgical issues, most commonly surgical site infection. Medical complications, including venous thromboembolism, account for less than 10% of readmissions. Readmission reduction efforts should focus on early postdischarge follow-up, preventing infectious complications, and determining preventability of surgical-related reasons for readmission. C1 Univ Michigan Hlth Syst, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA. Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA. Univ Wisconsin Hosp & Clin, Dept Obstet & Gynecol, Madison, WI 53792 USA. Massachusetts Gen Hosp, Vincent Dept Obstet & Gynecol, Boston, MA 02114 USA. [Uppal, Shitanshu] Univ Michigan Hlth Syst, Dept Obstet & Gynecol, Womens Hosp L3601, SPC 5276,1500 East Med Ctr Dr, Ann Arbor, MI 48109 USA. RP Uppal, S (reprint author), Univ Michigan Hlth Syst, Dept Obstet & Gynecol, Womens Hosp L3601, SPC 5276,1500 East Med Ctr Dr, Ann Arbor, MI 48109 USA. EM uppal@med.umich.edu NR 23 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD OCT PY 2016 VL 128 IS 4 BP 889 EP 897 DI 10.1097/AOG.0000000000001599 PG 9 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DX6VT UT WOS:000384523600028 PM 27607868 ER PT J AU Greene, ME Rolfson, O Gordon, M Annerbrink, K Malchau, H Garellick, G AF Greene, Meridith E. Rolfson, Ola Gordon, Max Annerbrink, Kristina Malchau, Henrik Garellick, Goren TI Is the use of antidepressants associated with patient-reported outcomes following total hip replacement surgery? SO ACTA ORTHOPAEDICA LA English DT Article ID NATIONAL COMORBIDITY SURVEY; PRIMARY-CARE PATIENTS; MAJOR DEPRESSION; ARTHROPLASTY REGISTER; JAMTLAND COUNTY; OSTEOARTHRITIS; ANXIETY; PREVALENCE; POPULATION; MEDICATION AB Background and purpose - Patients with anxiety and/or depression tend to report less pain reduction and less satisfaction with surgical treatment. We hypothesized that the use of antidepressants would be correlated to patient-reported outcomes (PROs) 1 year after total hip replacement (THR), where increased dosage or discontinuation would be associated with worse outcomes. Patients and methods - THR cases with pre- and postoperative patient-reported outcome measures (PROMs) were selected from the Swedish Hip Arthroplasty Register (n = 9,092; women: n = 5,106). The PROMs were EQ-5D, visual analog scale (VAS) for pain, Charnley class, and VAS for satisfaction after surgery. These cases were merged with a national database of prescription purchases to determine the prevalence of antidepressant purchases. Regression analyses were performed where PROs were dependent variables and sex, age, Charnley class, preoperative pain, preoperative health-related quality of life (HRQoL), patient-reported anxiety/depression, and antidepressant use were independent variables. Results - Antidepressants were used by 10% of the cases (n = 943). Patients using antidepressants had poorer HRQoL and higher levels of pain before and after surgery and they experienced less satisfaction. Preoperative antidepressant use was independently associated with PROs 1 year after THR regardless of patient-reported anxiety/depression. Interpretation - Antidepressant usage before surgery was associated with reduced PROs after THR. Cases at risk of poorer outcomes may be identified through review of the patient's medical record. Clinicians are encouraged to screen for antidepressant use preoperatively, because their use may be associated with PROs after THR. C1 [Greene, Meridith E.; Rolfson, Ola; Malchau, Henrik] Massachusetts Gen Hosp, Harris Orthopaed Lab, Boston, MA 02114 USA. [Greene, Meridith E.; Rolfson, Ola; Malchau, Henrik; Garellick, Goren] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Orthopaed, Gothenburg, Sweden. [Gordon, Max] Karolinska Inst, Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden. [Annerbrink, Kristina] Sahlgrens Univ Hosp, Dept Psychiat, Gothenburg, Sweden. RP Greene, ME (reprint author), Massachusetts Gen Hosp, Harris Orthopaed Lab, Boston, MA 02114 USA.; Greene, ME (reprint author), Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Orthopaed, Gothenburg, Sweden. EM megreene@partners.org OI Gordon, Max/0000-0002-8080-5815 FU Felix Neubergh Foundation; Goran Bauer Grant; Swedish Society of Medicine; Wangstedt Foundation; Harris Orthopaedic Laboratory; Swedish Hip Arthroplasty Register FX We thank Szliard Nemes for his guidance with the statistical part of the work. The study was funded by the Harris Orthopaedic Laboratory and the Swedish Hip Arthroplasty Register. OR received funding through grants from the Felix Neubergh Foundation, the Goran Bauer Grant, the Swedish Society of Medicine, and the Wangstedt Foundation. NR 37 TC 1 Z9 1 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1745-3674 EI 1745-3682 J9 ACTA ORTHOP JI Acta Orthop. PD OCT PY 2016 VL 87 IS 5 BP 444 EP 451 DI 10.1080/17453674.2016.1216181 PG 8 WC Orthopedics SC Orthopedics GA EB6WM UT WOS:000387526300003 PM 27482877 ER PT J AU Hussey, DK Madanat, R Donahue, GS Rolfson, O Muratoglu, OK Malchau, H AF Hussey, Daniel K. Madanat, Rami Donahue, Gabrielle S. Rolfson, Ola Muratoglu, Orhun K. Malchau, Henrik TI Worse health-related quality of life and hip function in female patients with elevated chromium levels A prospective study of 659 patients with a recalled THR metal-on-metal implant SO ACTA ORTHOPAEDICA LA English DT Article ID ION LEVELS; FOLLOW-UP; ARTHROPLASTY; ASR; REPLACEMENT; COBALT; BLOOD; OSTEOARTHRITIS; INCLINATION; BEARINGS AB Background and purpose - Blood metal ion levels can be an indicator for detecting implant failure in metal-on-metal (MoM) hip arthroplasties. Little is known about the effect of bilateral MoM implants on metal ion levels and patient-reported outcomes. We compared unilateral patients and bilateral patients with either an ASR hip resurfacing (HR) or an ASR XL total hip replacement (THR) and investigated whether cobalt or chromium was associated with a broad spectrum of patient outcomes. Patients and methods - From a registry of 1,328 patients enrolled in a multicenter prospective follow-up of the ASR Hip System, which was recalled in 2010, we analyzed data from 659 patients (311 HR, 348 THR) who met our inclusion criteria. Cobalt and chromium blood metal ion levels were measured and a 21-item patient-reported outcome measures (PROMs) questionnaire was used mean 6 years after index surgery. Results - Using a minimal threshold of >= 7 ppb, elevated chromium ion levels were found to be associated with worse health related quality of life (HRQoL) (p < 0.05) and hip function (p < 0.05) in women. These associations were not observed in men. Patients with a unilateral ASR HR had lower levels of cobalt ions than bilateral ASR HR patients (p < 0.001) but similar levels of chromium ions (p = 0.09). Unilateral ASR XL THR patients had lower chromium and cobalt ion levels (p < 0.005) than bilateral ASR XL THR patients. Interpretation - Chromium ion levels of > 7 ppb were associated with reduced functional outcomes in female MoM patients. C1 [Hussey, Daniel K.; Madanat, Rami; Donahue, Gabrielle S.; Rolfson, Ola; Muratoglu, Orhun K.; Malchau, Henrik] Massachusetts Gen Hosp, Harris Orthopaed Lab, Boston, MA 02114 USA. [Madanat, Rami; Rolfson, Ola; Muratoglu, Orhun K.; Malchau, Henrik] Harvard Med Sch, Dept Orthopaed Surg, Boston, MA 02115 USA. [Rolfson, Ola] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Orthopaed, Gothenburg, Sweden. RP Malchau, H (reprint author), Massachusetts Gen Hosp, Harris Orthopaed Lab, Boston, MA 02114 USA.; Malchau, H (reprint author), Harvard Med Sch, Dept Orthopaed Surg, Boston, MA 02115 USA. EM hmalchau@mgh.harvard.edu FU DePuy Orthopaedics, Warsaw, Indiana; Orion-Farmos Research Foundation FX This study was supported by DePuy Orthopaedics, Warsaw, Indiana. The publication of these results was not contingent on the sponsor's approval. RM received research support from the Orion-Farmos Research Foundation. The authors have no relevant competing interests to disclose. NR 27 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1745-3674 EI 1745-3682 J9 ACTA ORTHOP JI Acta Orthop. PD OCT PY 2016 VL 87 IS 5 BP 485 EP 491 DI 10.1080/17453674.2016.1213596 PG 7 WC Orthopedics SC Orthopedics GA EB6WM UT WOS:000387526300009 PM 27459602 ER PT J AU Koo, H Lee, JH Bao, K Wu, YS El Fakhri, G Henary, M Yun, SH Choi, HS AF Koo, Heebeom Lee, Jeong Heon Bao, Kai Wu, Yunshan El Fakhri, Georges Henary, Maged Yun, Seok Hyun Choi, Hak Soo TI Site-Specific In Vivo Bioorthogonal Ligation via Chemical Modulation SO ADVANCED HEALTHCARE MATERIALS LA English DT Article ID NEAR-INFRARED FLUOROPHORES; CHEMISTRY; ANTIBODY; CELLS; CYCLOADDITIONS; NANOPARTICLES; CYCLOOCTENE; BINDING AB A critical limitation of bioorthogonal click chemistry for in vivo applications has been its low reaction efficiency due to the pharmacokinetic barriers, such as blood distribution, circulation, and elimination in living organisms. To identify key factors that dominate the efficiency of click chemistry, here a rational design of near-infrared fluorophores containing tetrazine as a click moiety is proposed. Using trans-cyclooctene-modified cells in live mice, it is found that the in vivo click chemistry can be improved by subtle changes in lipophilicity and surface charges of intravenously administered moieties. By controlling pharmacokinetics, biodistribution, and clearance of click moieties, it is proved that the chemical structure dominates the fate of in vivo click ligation. C1 [Koo, Heebeom; Yun, Seok Hyun] Massachusetts Gen Hosp, Wellman Ctr Photomed, 65 Landsdowne St,UP 5, Cambridge, MA 02139 USA. [Koo, Heebeom; Yun, Seok Hyun] Harvard Med Sch, 65 Landsdowne St,UP 5, Cambridge, MA 02139 USA. [Koo, Heebeom] Catholic Univ Korea, Coll Med, Dept Med Lifesci, Seoul 06591, South Korea. [Lee, Jeong Heon; Bao, Kai; El Fakhri, Georges; Choi, Hak Soo] Massachusetts Gen Hosp, Gordon Ctr Med Imaging, Div Nucl Med & Mol Imaging, Dept Radiol, Boston, MA 02114 USA. [Lee, Jeong Heon; Bao, Kai; El Fakhri, Georges; Choi, Hak Soo] Harvard Med Sch, Boston, MA 02114 USA. [Wu, Yunshan; Henary, Maged] Georgia State Univ, Dept Chem, Ctr Diagnost & Therapeut, Atlanta, GA 30303 USA. RP Yun, SH (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 65 Landsdowne St,UP 5, Cambridge, MA 02139 USA.; Yun, SH (reprint author), Harvard Med Sch, 65 Landsdowne St,UP 5, Cambridge, MA 02139 USA.; Choi, HS (reprint author), Massachusetts Gen Hosp, Gordon Ctr Med Imaging, Div Nucl Med & Mol Imaging, Dept Radiol, Boston, MA 02114 USA.; Choi, HS (reprint author), Harvard Med Sch, Boston, MA 02114 USA.; Henary, M (reprint author), Georgia State Univ, Dept Chem, Ctr Diagnost & Therapeut, Atlanta, GA 30303 USA. EM mhenary1@gsu.edu; syun@hms.harvard.edu; hchoi12@mgh.harvard.edu FU NIH: NIBIB [R01-EB-011523, R01-EB017699]; NIH: NCI [R01-CA-192878]; Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [2016R1C1B3013951] FX H.K. and J.H.L. contributed equally to this work. This study was supported by the following grants from NIH: NIBIB #R01-EB-011523 (H.S.C.) and #R01-EB017699 (H.S.C.), NCI #R01-CA-192878 (S.H.Y.), and the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2016R1C1B3013951) (H.K.). NR 28 TC 0 Z9 0 U1 7 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2192-2640 EI 2192-2659 J9 ADV HEALTHC MATER JI Adv. Healthc. Mater. PD OCT PY 2016 VL 5 IS 19 BP 2510 EP 2516 DI 10.1002/adhm.201600574 PG 7 WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials Science, Biomaterials SC Engineering; Science & Technology - Other Topics; Materials Science GA EB2AK UT WOS:000387158500006 PM 27568818 ER PT J AU Khalili, H AF Khalili, Hamed TI Statins for Inflammatory Bowel Disease: Expanding the Scope of Prevention SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Editorial Material ID C-REACTIVE PROTEIN; CROHNS-DISEASE; ULCERATIVE-COLITIS; RISK; ROSUVASTATIN; THERAPY; MARKERS AB In addition to cholesterol depletion, statins also significantly decrease systemic inflammation as measured by C-reactive protein. In this issue of American Journal of Gastroenterology, Ungaro et al. present their results on the associations between statin prescriptions and risk of Crohn's disease (CD) and ulcerative colitis (UC). Using a national medical claims and pharmacy database created by Symphony Health Solutions LLC (SHA), they show that any use of statin is protective against diagnosis of CD and UC. The protective effect against CD appears strongest among older populations (>60 years old). These findings offer intriguing insights into inflammatory pathways that could be modulated by cholesterol lowering drugs. In addition, if replicated in other cohorts, these results provide further rationale for investigating the use of statins in broader preventive efforts, including healthy patients at risk of developing inflammatory bowel disease. C1 [Khalili, Hamed] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. [Khalili, Hamed] Harvard Med Sch, Boston, MA USA. [Khalili, Hamed] Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Boston, MA 02114 USA. RP Khalili, H (reprint author), Massachusetts Gen Hosp, Digest Healthcare Ctr, Crohns & Colitis Ctr, 165 Cambridge St,9th Floor, Boston, MA 02114 USA. EM hkhalili@mgh.harvard.edu FU NIDDK [K23DK099681] FX H.K. is funded by NIDDK K23DK099681. NR 18 TC 1 Z9 1 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD OCT PY 2016 VL 111 IS 10 BP 1424 EP 1426 DI 10.1038/ajg.2016.338 PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EB2BY UT WOS:000387163200017 PM 27694857 ER PT J AU Barta, SK Li, HL Hochster, HS Hong, FX Weller, E Gascoyne, RD Habermann, TM Gordon, LI Colocci, N Bengtson, EM Horning, SJ Kahl, BS AF Barta, Stefan K. Li, Hailun Hochster, Howard S. Hong, Fangxin Weller, Edie Gascoyne, Randy D. Habermann, Thomas M. Gordon, Leo I. Colocci, Natalia Bengtson, Elizabeth M. Horning, Sandra J. Kahl, Brad S. TI Randomized Phase 3 Study in Low-Grade Lymphoma Comparing Maintenance Anti-CD20 Antibody With Observation After Induction Therapy: A Trial of the ECOG-ACRIN Cancer Research Group (E1496) SO CANCER LA English DT Article DE follicular lymphoma; indolent lymphoma; non-Hodgkin lymphoma; rituximab; rituximab maintenance ID NON-HODGKIN-LYMPHOMA; DETUDE DES LYMPHOMES; TERM-FOLLOW-UP; FOLLICULAR LYMPHOMA; RITUXIMAB MAINTENANCE; SIGNIFICANTLY INCREASES; COST-EFFECTIVENESS; INDOLENT LYMPHOMA; ADVANCED-STAGE; FREE SURVIVAL AB BACKGROUND: In an ECOG-ACRIN Cancer Research Group study (E1496), maintenance rituximab (MR) was reported to prolong progression-free survival (PFS) in comparison with observation (OBS) alone in patients with indolent lymphoma after induction chemotherapy. Here the long-term follow-up of the same patient cohort is presented. METHODS: Patients with indolent lymphoma received induction chemotherapy with cyclophosphamide, vincristine, and prednisone (CVP). Patients with stable disease or a better response were then randomized to weekly rituximab (375 mg/m(2) x 4 doses) every 6 months for 2 years (MR) or to OBS. The primary endpoint was PFS; the secondary endpoints were overall survival (OS), response rate, and toxicities. RESULTS: Of the 387 patients who initially received CVP induction, 158 were randomized to MR, and 153 were randomized to OBS. After a median follow-up of 11.5 years, patients on MR had longer median PFS (4.8 years) than patients on OBS (1.3 years; hazard ratio [HR], 0.49; P < .0001). However, there was no difference in OS between MR and OBS (10-year OS, 67% vs 59%; median OS, 13.5 years vs not reached; HR, 0.91; P = .69). Other than MR, only minimal residual disease after induction therapy was significantly associated with PFS on multivariate analysis (HR, 0.71; P = .02). A low initial tumor burden, minimal residual disease, follicular histology, a low Follicular Lymphoma International Prognostic Index score, and female sex were associated with longer OS. There was no increase in the rate of second primary malignancies with MR vs OBS. CONCLUSIONS: With long-term follow-up, MR did not influence OS. The PFS benefit was maintained. MR should be considered optional for patients with indolent B-cell lymphoma. (C) 2016 American Cancer Society. C1 [Barta, Stefan K.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Li, Hailun; Hong, Fangxin; Weller, Edie] Dana Farber Canc Inst, Boston, MA 02115 USA. [Hochster, Howard S.] Yale Univ, New Haven, CT USA. [Gascoyne, Randy D.] British Columbia Canc Agcy, Vancouver, BC, Canada. [Habermann, Thomas M.] Mayo Clin, Rochester, MN USA. [Gordon, Leo I.] Northwestern Univ, Chicago, IL 60611 USA. [Colocci, Natalia] Palo Alto Med Fdn, Palo Alto, CA USA. [Bengtson, Elizabeth M.] Dartmouth Canc Med Ctr, Lebanon, NH USA. [Horning, Sandra J.] Genentech Inc, San Francisco, CA 94080 USA. [Kahl, Brad S.] Washington Univ, 660 South Euclid Ave,Campus Box 8056, St Louis, MO USA. RP Kahl, BS (reprint author), Washington Univ, Sch Med, Div Oncol, 660 South Euclid Ave,Campus Box 8056, St Louis, MO 63110 USA. EM bkahl@wustl.edu FU Public Health Service [CA180794, CA180820, CA180826, CA180790, CA180816, CA180799, CA180821]; National Cancer Institute (National Institutes of Health, US Department of Health and Human Services) FX This study was coordinated by the ECOG-ACRIN Cancer Research Group (Robert L. Comis, MD, and Mitchell D Schnall, MD, PhD, group cochairs) and was supported in part by the Public Health Service (grants CA180794, CA180820, CA180826, CA180790, CA180816, CA180799, and CA180821) and the National Cancer Institute (National Institutes of Health, US Department of Health and Human Services). The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute. NR 28 TC 1 Z9 1 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD OCT 1 PY 2016 VL 122 IS 19 BP 2996 EP 3004 DI 10.1002/cncr.30137 PG 9 WC Oncology SC Oncology GA EB5KN UT WOS:000387413300012 PM 27351685 ER PT J AU Deol, A Sengsayadeth, S Ahn, KW Wang, HL Aljurf, M Antin, JH Battiwalla, M Bornhauser, M Cahn, JY Camitta, B Chen, YB Cutler, CS Gale, RP Ganguly, S Hamadani, M Inamoto, Y Jagasia, M Kamble, R Koreth, J Lazarus, HM Liesveld, J Litzow, MR Marks, DI Nishihori, T Olsson, RF Reshef, R Rowe, JM Saad, AA Sabloff, M Schouten, HC Shea, TC Soiffer, RJ Uy, GL Waller, EK Wiernik, PH Wirk, B Woolfrey, AE Bunjes, D Devine, S de Lima, M Sandmaier, BM Weisdorf, D Khoury, HJ Saber, W AF Deol, Abhinav Sengsayadeth, Salyka Ahn, Kwang Woo Wang, Hai-Lin Aljurf, Mahmoud Antin, Joseph Harry Battiwalla, Minoo Bornhauser, Martin Cahn, Jean-Yves Camitta, Bruce Chen, Yi-Bin Cutler, Corey S. Gale, Robert Peter Ganguly, Siddhartha Hamadani, Mehdi Inamoto, Yoshihiro Jagasia, Madan Kamble, Rammurti Koreth, John Lazarus, Hillard M. Liesveld, Jane Litzow, Mark R. Marks, David I. Nishihori, Taiga Olsson, Richard F. Reshef, Ran Rowe, Jacob M. Saad, Ayman A. Sabloff, Mitchell Schouten, Harry C. Shea, Thomas C. Soiffer, Robert J. Uy, Geoffrey L. Waller, Edmond K. Wiernik, Peter H. Wirk, Badeep Woolfrey, Ann E. Bunjes, Donald Devine, Steven de Lima, Marcos Sandmaier, Brenda M. Weisdorf, Dan Khoury, Hanna Jean Saber, Wael TI Does FLT3 Mutation Impact Survival After Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis SO CANCER LA English DT Article DE acute myeloid leukemia; allogeneic stem cell transplantation; FMS-like tyrosine kinase 3 (FLT3); 1 more ID MINIMAL RESIDUAL DISEASE; ALLOGENEIC TRANSPLANTATION; TANDEM DUPLICATIONS; COMPLETE REMISSION; 12 TRIALS; AML; PROGNOSIS; GENE; CYTOGENETICS; DISTINCT AB BACKGROUND: Patients with FMS like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML) have a poor prognosis and are referred for early allogeneic hematopoietic stem cell transplantation (HCT). METHODS: Data from the Center for International Blood and Marrow Transplant Research (CIBMTR) were used to evaluate 511 adult patients with de novo AML who underwent HCT during 2008 through 2011 to determine whether FLT3 mutations had an impact on HCT outcomes. RESULTS: In total, 158 patients (31%) had FLT3 mutations. Univariate and multivariate analyses revealed an increased risk of relapse at 3 years in the FLT3 mutated group compared with the wild-type (WT) group (38% [95% confidence interval (CI), 30%-45%] vs 28% [95% CI, 24%-33%]; P = .04; relative risk, 1.60 [95% CI, 1.15-2.22]; P = .0048). However, FLT3 mutation status was not significantly associated with nonrelapse mortality, leukemia-free survival, or overall survival. Although more patients in the FLT3 mutated group died from relapsed primary disease compared with those in the WT group (60% vs 46%), the 3-year overall survival rate was comparable for the 2 groups (mutated group: 49%; 95% CI, 40%-57%; WT group: 55%, 95% CI, 50%-60%; P = .20). CONCLUSIONS: The current data indicate that FLT3 mutation status did not adversely impact overall survival after HCT, and about 50% of patients with this mutation who underwent HCT were long-term survivors. (C) 2016 American Cancer Society. C1 [Deol, Abhinav] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, 4100 John R,4 HWCRC, Detroit, MI 48201 USA. [Sengsayadeth, Salyka; Jagasia, Madan] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Ahn, Kwang Woo; Wang, Hai-Lin; Hamadani, Mehdi; Saber, Wael] Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA. [Ahn, Kwang Woo] Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA. [Aljurf, Mahmoud] King Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riyadh, Saudi Arabia. [Antin, Joseph Harry; Cutler, Corey S.; Koreth, John; Soiffer, Robert J.] Dana Farber Canc Inst, Dept Med Oncol, Ctr Hematol Oncol, Boston, MA 02115 USA. [Battiwalla, Minoo] NHLBI, Hematol Branch, Bethesda, MD 20892 USA. [Bornhauser, Martin] Carl Gustav Carus Univ Hosp, Dresden, Germany. [Cahn, Jean-Yves] Univ Hosp, Dept Hematol, Grenoble, France. [Camitta, Bruce] Med Coll Wisconsin, Midwest Ctr Canc & Blood Disorders, Milwaukee, WI 53226 USA. [Camitta, Bruce] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA. [Chen, Yi-Bin] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. [Gale, Robert Peter] Imperial Coll London, Dept Med, Div Expt Med, Hematol Res Ctr, London, England. [Ganguly, Siddhartha] Univ Kansas, Med Ctr, Div Hematol & Oncol, Blood & Marrow Transplantat, Kansas City, KS 66103 USA. [Inamoto, Yoshihiro] Natl Canc Ctr, Div Hematopoiet Stem Cell Transplantat, Tokyo, Japan. [Kamble, Rammurti] Baylor Coll Med, Ctr Cell & Gene Therapy, Div Hematol & Oncol, Houston, TX 77030 USA. [Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA. [Liesveld, Jane] Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA. [Litzow, Mark R.] Mayo Clin, Div Hematol, Rochester, NY USA. [Litzow, Mark R.] Mayo Clin, Transplant Ctr, Rochester, NY USA. [Marks, David I.] Univ Hosp Bristol Natl Hlth Serv Trust, Pediat Bone Marrow Transplant, Bristol, Avon, England. [Nishihori, Taiga] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA. [Olsson, Richard F.] Karolinska Inst, Div Therapeut Immunol, Dept Lab Med, Stockholm, Sweden. [Olsson, Richard F.] Uppsala Univ, Ctr Clin Res Sormland, Uppsala, Sweden. [Reshef, Ran] Columbia Univ, Med Ctr, Blood & Marrow Transplantat Program, New York, NY USA. [Reshef, Ran] Columbia Univ, Med Ctr, Columbia Ctr Translat Immunol, New York, NY USA. [Rowe, Jacob M.] Shaare Zedek Med Ctr, Dept Hematol, Jerusalem, Israel. [Saad, Ayman A.] Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA. [Sabloff, Mitchell] Univ Ottawa, Dept Med, Div Hematol, Ottawa, ON, Canada. [Sabloff, Mitchell] Ottawa Hosp, Res Inst, Ottawa, ON, Canada. [Schouten, Harry C.] Acad Hosp Maastricht, Dept Hematol, Maastricht, Netherlands. [Shea, Thomas C.] Univ North Carolina Hlth Care, Dept Med, Div Hematol & Oncol, Chapel Hill, NC USA. [Uy, Geoffrey L.] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA. [Waller, Edmond K.; Khoury, Hanna Jean] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA. [Wiernik, Peter H.] Our Lady Mercy Med Ctr, Bronx, NY USA. [Wirk, Badeep] Seattle Canc Care Alliance, Div Bone Marrow Transplant, Seattle, WA USA. [Woolfrey, Ann E.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Bunjes, Donald] Ulm Univ Hosp, Dept Internal Med 3, Ulm, Germany. [Devine, Steven] Ohio State Univ, Dept Internal Med, Comprehens Canc Ctr James, Columbus, OH 43210 USA. [de Lima, Marcos] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Dept Med, Cleveland, OH USA. [Sandmaier, Brenda M.] Univ Washington, Div Med Oncol, Seattle, WA 98195 USA. [Sandmaier, Brenda M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA. [Weisdorf, Dan] Natl Marrow Donor Program Be Match, Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA. RP Deol, A (reprint author), Wayne State Univ, Karmanos Canc Inst, Dept Oncol, 4100 John R,4 HWCRC, Detroit, MI 48201 USA. EM deola@karmanos.org OI Saad, Ayman /0000-0003-0003-0130 FU Public Health Service grant from the National Cancer Institute (NCI) [5U24-CA076518]; National Heart, Lung, and Blood Institute (NHLBI); National Institute of Allergy and Infectious Diseases (NIAID); NHLIB; NCI [5U10HL069294]; Health Resources and Services Administration/Department of Health and Human Services from the Office of Naval Research [HHSH250201200016C, N00014-13-1-0039, N00014-14-1-0028]; Alexion; Amgen, Inc; Be the Match Foundation; Bristol-Myers Squibb Oncology; Celgene Corporation; Chimeric, Inc; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd; Genentech, Inc; Genzyme Corporation; Gilead Sciences, Inc; Health Research, Inc; Roswell Park Cancer Institute; HistoGenetics, Inc; Incyte Corporation; Jazz Pharmaceuticals, Inc; Jeff Gordon Children's Foundation; Leukemia and Lymphoma Society; Medical College of Wisconsin; Merck and Company, Inc; Mesoblast; Millennium: The Takeda Oncology Company; Miltenyi Biotec, Inc; National Marrow Donor Program; Neovii Biotech NA, Inc; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals; Optum Health Care Solutions, Inc; Otsuka America Pharmaceutical, Inc; Otsuka Pharmaceutical Company, Ltd-Japan; Oxford Immunotec; Perkin Elmer, Inc; Pharmacyclics; Sanofi US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Spectrum Pharmaceuticals, Inc; St Baldrick's Foundation; Sunesis Pharmaceuticals, Inc; Swedish Orphan Biovitrum, Inc; Telomere Diagnostics, Inc; TerumoBCT; Therakos, Inc; University of Minnesota; Wellpoint, Inc FX The Center for International Blood and Marrow Transplant Research (CIBMTR) is supported by a Public Health Service grant (cooperative agreement 5U24-CA076518) from the National Cancer Institute (NCI), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute of Allergy and Infectious Diseases (NIAID); by the NHLIB and the NCI (grant/cooperative agreement 5U10HL069294); by the Health Resources and Services Administration/Department of Health and Human Services (contract HHSH250201200016C; grants N00014-13-1-0039 and N00014-14-1-0028) from the Office of Naval Research; by an anonymous donation to the Medical College of Wisconsin; and by grants from Alexion; Amgen, Inc (a corporate member); Be the Match Foundation; Bristol-Myers Squibb Oncology (a corporate member); Celgene Corporation (a corporate member); Chimeric, Inc (a corporate member); the Fred Hutchinson Cancer Research Center; Gamida Cell Ltd; Genentech, Inc; Genzyme Corporation; Gilead Sciences, Inc (a corporate member); Health Research, Inc; the Roswell Park Cancer Institute; HistoGenetics, Inc; Incyte Corporation; Jazz Pharmaceuticals, Inc (a corporate member); Jeff Gordon Children's Foundation; The Leukemia and Lymphoma Society; The Medical College of Wisconsin; Merck and Company, Inc; Mesoblast; Millennium: The Takeda Oncology Company; Miltenyi Biotec, Inc (a corporate member); the National Marrow Donor Program; Neovii Biotech NA, Inc; Novartis Pharmaceuticals Corporation; Onyx Pharmaceuticals; Optum Health Care Solutions, Inc; Otsuka America Pharmaceutical, Inc; Otsuka Pharmaceutical Company, Ltd-Japan; Oxford Immunotec; Perkin Elmer, Inc; Pharmacyclics; Sanofi US (a corporate member); Seattle Genetics; Sigma-Tau Pharmaceuticals; Spectrum Pharmaceuticals, Inc (a corporate member); St Baldrick's Foundation; Sunesis Pharmaceuticals, Inc (a corporate member); Swedish Orphan Biovitrum, Inc; Telomere Diagnostics, Inc; TerumoBCT; Therakos, Inc; the University of Minnesota; and Wellpoint, Inc (a corporate member). NR 24 TC 1 Z9 2 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD OCT 1 PY 2016 VL 122 IS 19 BP 3005 EP 3014 DI 10.1002/cncr.30140 PG 10 WC Oncology SC Oncology GA EB5KN UT WOS:000387413300013 PM 27315441 ER PT J AU Carrizzo, A Damato, A Ambrosio, M Falco, A Rosati, A Capunzo, M Madonna, M Turco, MC Januzzi, JL De Laurenzi, V Vecchione, C AF Carrizzo, Albino Damato, Antonio Ambrosio, Mariateresa Falco, Antonia Rosati, Alessandra Capunzo, Mario Madonna, Michele Turco, Maria C. Januzzi, James L. De Laurenzi, Vincenzo Vecchione, Carmine TI The prosurvival protein BAG3: a new participant in vascular homeostasis SO CELL DEATH & DISEASE LA English DT Article ID CHRONIC HEART-FAILURE; BLOOD-PRESSURE; TUMOR-GROWTH; EXPRESSION; PATHWAY; TARGET AB Bcl2-associated athanogene 3 (BAG3), is constitutively expressed in a few normal cell types, including myocytes, peripheral nerves and in the brain, and is also expressed in certain tumors. To date, the main studies about the role of BAG3 are focused on its pro-survival effect in tumors through various mechanisms that vary according to cellular type. Recently, elevated concentrations of a soluble form of BAG3 were described in patients affected by advanced stage of heart failure (HF), identifying BAG3 as a potentially useful biomarker in monitoring HF progression. Despite the finding of high levels of BAG3 in the sera of HF patients, there are no data on its possible role on the modulation of vascular tone and blood pressure levels. The aim of this study was to investigate the possible hemodynamic effects of BAG3 performing both in vitro and in vivo experiments. Through vascular reactivity studies, we demonstrate that BAG3 is capable of evoking dose-dependent vasorelaxation. Of note, BAG3 exerts its vasorelaxant effect on resistance vessels, typically involved in the blood pressure regulation. Our data further show that the molecular mechanism through which BAG3 exerts this effect is the activation of the PI3K/Akt signalling pathway leading to nitric oxide release by endothelial cells. Finally, we show that in vivo BAG3 administration is capable of regulating blood pressure and that this is dependent on eNOS regulation since this ability is lost in eNOS KO animals. C1 [Carrizzo, Albino; Damato, Antonio; Ambrosio, Mariateresa; Madonna, Michele; Vecchione, Carmine] IRCCS Neuromed, Pozzilli, IS, Italy. [Falco, Antonia; Rosati, Alessandra; Turco, Maria C.; De Laurenzi, Vincenzo] Univ Salerno, Biouniversa Srl, Vasc Pathophysiol Unit, Fisciano, SA, Italy. [Falco, Antonia] Univ Salerno, Dept Pharm, Fisciano, SA, Italy. [Rosati, Alessandra; Capunzo, Mario; Turco, Maria C.; Vecchione, Carmine] Univ Salerno, Dept Med & Surg, Via S Allende, I-84081 Baronissi, SA, Italy. [Januzzi, James L.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Januzzi, James L.] Harvard Med Sch, Boston, MA USA. [De Laurenzi, Vincenzo] Univ G DAnnunzio Chieti & Pescara, CeSI, Dipartimento Sci Med Orali & Biotecnol, Pescara, Italy. RP Vecchione, C (reprint author), Univ Salerno, Dept Med & Surg, Via S Allende, I-84081 Baronissi, SA, Italy.; De Laurenzi, V (reprint author), Univ Salerno, Biouniversa Srl, Univ G DAnnunzio Chieti Pescara CeSI Chieti, Dept Biochem Sci, I-66100 Fisciano, Italy.; Vecchione, C (reprint author), IRCCS Neuromed, Vasc Physiopathol Unit, I-86077 Pozzilli, IS, Italy. EM delaurenzi@unich.it; cvecchione@unisa.it NR 27 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-4889 J9 CELL DEATH DIS JI Cell Death Dis. PD OCT PY 2016 VL 7 DI 10.1038/cddis.2016.321 PG 6 WC Cell Biology SC Cell Biology GA EB4QU UT WOS:000387358800031 PM 27763645 ER PT J AU Papaioannou, G Mirzamohammadi, F Kobayashi, T AF Papaioannou, Garyfallia Mirzamohammadi, Fatemeh Kobayashi, Tatsuya TI Ras signaling regulates osteoprogenitor cell proliferation and bone formation SO CELL DEATH & DISEASE LA English DT Article ID SKELETAL DEVELOPMENT; STEM-CELLS; OSTEOBLAST DIFFERENTIATION; SOMATIC ACTIVATION; TRABECULAR BONE; TGF-BETA; GROWTH; MAINTENANCE; EXPRESSION; ONCOGENE AB During endochondral bone development, osteoblasts are continuously differentiated from locally residing progenitor cells. However, the regulation of such endogenous osteoprogenitor cells is still poorly understood mainly due to the difficulty in identifying such cells in vivo. In this paper, we genetically labeled different cell populations of the osteoblast linage using stage-specific, tamoxifen-inducible Cre transgenic mice to investigate their responses to a proliferative stimulus. We have found that overactivation of Kras signaling in type II collagen-positive, immature osteoprogenitor cells, but not in mature osteoblasts, substantially increases the number of their descendant stromal cells and mature osteoblasts, and subsequently increases bone mass. This effect was mediated by both, the extracellular signal-regulated kinase (ERK) and phosphoinositide 3 kinase (PI3K), pathways. Thus we demonstrate that Ras signaling stimulates proliferation of immature osteoprogenitor cells to increase the number of their osteoblastic descendants in a cell-autonomous fashion. C1 [Papaioannou, Garyfallia; Mirzamohammadi, Fatemeh; Kobayashi, Tatsuya] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Papaioannou, Garyfallia; Mirzamohammadi, Fatemeh; Kobayashi, Tatsuya] Harvard Med Sch, Thier 1101,50 Blossom St, Boston, MA 02114 USA. RP Kobayashi, T (reprint author), Harvard Med Sch, Thier 1101,50 Blossom St, Boston, MA 02114 USA.; Kobayashi, T (reprint author), Massachusetts Gen Hosp, Med, Thier 1101,50 Blossom St, Boston, MA 02114 USA. EM Kobayash@helix.mgh.harvard.edu FU National Institutes of Health [AR056645]; Harvard Stem Cell Institute [SG-0090-13] FX We thank Jacqueline Lees and Simona Nedelcu for valuable discussion and the Center for Skeletal Research Core (NIH P30 AR066261) for histological analysis. This work was supported by the National Institutes of Health (AR056645 to T.K.) and Harvard Stem Cell Institute (SG-0090-13 to T.K.). NR 32 TC 0 Z9 0 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-4889 J9 CELL DEATH DIS JI Cell Death Dis. PD OCT PY 2016 VL 7 AR e2405 DI 10.1038/cddis.2016.314 PG 9 WC Cell Biology SC Cell Biology GA EB4QU UT WOS:000387358800024 PM 27735946 ER PT J AU Fukuda, S Song, JK Mahara, K Kuwaki, H Jang, JY Takeuchi, M Sun, BJ Kim, YJ Miyamoto, T Oginosawa, Y Sonoda, S Eto, M Nishimura, Y Takanashi, S Levine, RA Otsuji, Y AF Fukuda, Shota Song, Jae-Kwan Mahara, Keitaro Kuwaki, Hiroshi Jang, Jeong Yoon Takeuchi, Masaaki Sun, Byung Joo Kim, Yun Jeong Miyamoto, Tetsu Oginosawa, Yasushi Sonoda, Shinjo Eto, Masataka Nishimura, Yosuke Takanashi, Shuichiro Levine, Robert A. Otsuji, Yutaka TI Basal Left Ventricular Dilatation and Reduced Contraction in Patients With Mitral Valve Prolapse Can Be Secondary to Annular Dilatation: Preoperative and Postoperative Speckle-Tracking Echocardiographic Study on Left Ventricle and Mitral Valve Annulus Interaction SO CIRCULATION-CARDIOVASCULAR IMAGING LA English DT Article DE dilatation; echocardiography; left ventricle; mitral valve; prolapse ID 3-DIMENSIONAL ECHOCARDIOGRAPHY; REAL-TIME; LEAFLET PROLAPSE; REGURGITATION; REPAIR; RECOMMENDATIONS; ANNULOPLASTY; ASSOCIATION; MECHANISM; GEOMETRY AB Background Prominent mitral valve (MV) annular dilatation with only modest left ventricular (LV) dilatation in patients with MV prolapse (MVP) suggests predominant dilatation in adjacent basal LV, which may augment regional wall tension and attenuate contraction by Laplace's law. We hypothesized that MV annular dilatation in patients with MVP is associated with the basal predominance of LV dilatation and attenuated contraction, which can be altered by surgical MV plasty with annulus reduction. Methods and Results Echocardiography with speckle-tracking analysis to assess regional cross-sectional short-axis area and longitudinal contraction (strain) of basal, middle, and apical LV was performed in 30 controls and 130 patients with MVP. The basal value/averaged middle and apical values (B/MA ratio) of LV cross-sectional area and strain were obtained. Patients with MVP showed significantly greater MV annular area (6.41.6 versus 3.7 +/- 0.6 cm(2)/m(2)), increased B/MA LV area ratio (2.4 +/- 0.5 versus 1.8 +/- 0.2), and reduced B/MA LV strain ratio (0.83 +/- 0.14 versus 0.96 +/- 0.09) than controls (P<0.001). Multivariable analyses identified that MV annular dilatation was independently associated with increased B/MA LV area ratio (=0.60, P<0.001), which was associated with reduced B/MA LV strain ratio (=-0.32, P<0.001). In 35 patients with MVP, B/MA LV area and strain ratio significantly altered after surgical MV plasty with annulus reduction (2.5 +/- 0.5-1.8 +/- 0.3 and 0.73 +/- 0.10-0.89 +/- 0.17, P<0.001, respectively). Conclusions In patients with MVP, MV annular dilatation was associated with the basal predominance of LV dilatation and reduced contraction, which can be altered by surgical MV plasty with annulus reduction, suggesting unfavorable influence from MV annular dilatation on basal LV. C1 [Fukuda, Shota; Kuwaki, Hiroshi; Miyamoto, Tetsu; Oginosawa, Yasushi; Sonoda, Shinjo; Otsuji, Yutaka] Univ Occupat & Environm Hlth, Dept Internal Med 2, Kitakyushu, Fukuoka, Japan. [Takeuchi, Masaaki] Univ Occupat & Environm Hlth, Dept Lab & Transfus Med, Kitakyushu, Fukuoka, Japan. [Eto, Masataka; Nishimura, Yosuke] Univ Occupat & Environm Hlth, Dept Cardiovasc Surg, Kitakyushu, Fukuoka, Japan. [Song, Jae-Kwan; Jang, Jeong Yoon; Sun, Byung Joo; Kim, Yun Jeong] Asan Med Ctr Heart Inst, Cardiac Imaging Ctr, Seoul, South Korea. [Mahara, Keitaro; Takanashi, Shuichiro] Sakakibara Heart Inst, Dept Cardiol, Fuchu, Tokyo, Japan. [Mahara, Keitaro; Takanashi, Shuichiro] Sakakibara Heart Inst, Dept Cardiovasc Surg, Fuchu, Tokyo, Japan. [Levine, Robert A.] Massachusetts Gen Hosp, Cardiac Ultrasound Lab, Boston, MA 02114 USA. RP Otsuji, Y (reprint author), Univ Occupat & Environm Hlth, Dept Internal Med 2, Kitakyushu, Fukuoka, Japan. EM otsujiy@med.uoeh-u.ac.jp FU Japan Society of the Promotion of Science [15K10226]; National Institutes of Health, Bethesda, MD [R01 HL109506, HL128099] FX Drs Fukuda, Mahara, Takeuchi, Eto, Nishimura, Takanashi, and Otsuji were supported by Grants-in-aid for Scientific Research from the Japan Society of the Promotion of Science (15K10226 for Drs Fukuda, Mahara, Takeuchi, Eto, Nishimura, Takanashi, and Otsuji). Dr Levine was supported by by grants R01 HL109506 and HL128099 from the National Institutes of Health, Bethesda, MD. NR 28 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-9651 EI 1942-0080 J9 CIRC-CARDIOVASC IMAG JI Circ.-Cardiovasc. Imaging PD OCT PY 2016 VL 9 IS 10 AR e005113 DI 10.1161/CIRCIMAGING.115.005113 PG 9 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA EA8SK UT WOS:000386908700009 ER PT J AU Safi, LM Wood, MJ AF Safi, Lucy M. Wood, Malissa J. TI Aortic Root Size in Elite Athletes: When No Change Matters SO CIRCULATION-CARDIOVASCULAR IMAGING LA English DT Editorial Material DE Editorials; aorta; athletes; dilatation; vascular remodeling ID ETHNIC-DIFFERENCES; METAANALYSIS; HEART C1 [Safi, Lucy M.; Wood, Malissa J.] Massachusetts Gen Hosp, Div Cardiol, Yawkey 5,55 Fruit St, Boston, MA 02114 USA. RP Wood, MJ (reprint author), Massachusetts Gen Hosp, Div Cardiol, Yawkey 5,55 Fruit St, Boston, MA 02114 USA. EM MWood@MGH.HARVARD.edu NR 13 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-9651 EI 1942-0080 J9 CIRC-CARDIOVASC IMAG JI Circ.-Cardiovasc. Imaging PD OCT PY 2016 VL 9 IS 10 AR e005575 DI 10.1161/CIRCIMAGING.116.005575 PG 2 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA EA8SK UT WOS:000386908700019 ER PT J AU Dunlay, SM Strand, JJ Wordingham, SE Stulak, JM Luckhardt, AJ Swetz, KM AF Dunlay, Shannon M. Strand, Jacob J. Wordingham, Sara E. Stulak, John M. Luckhardt, Angela J. Swetz, Keith M. TI Dying With a Left Ventricular Assist Device as Destination Therapy SO CIRCULATION-HEART FAILURE LA English DT Article DE end-of-life care; heart failure; left ventricular assist device; morbidity; mortality ID OF-LIFE CARE; HEART-FAILURE; MEDICARE BENEFICIARIES; END; OUTCOMES; PLACE; PERSPECTIVES; IMPLANTATION; SUPPORT; HEALTH AB Background Despite the ability of left ventricular assist device as destination therapy (DT-LVAD) to prolong survival for many patients with advanced heart failure, little is known about the eventual end-of-life care that patients with DT-LVAD receive. Methods and Results All patients undergoing DT-LVAD at the Mayo Clinic in Rochester, Minnesota, from January 1, 2007, to September 30, 2014, who subsequently died before July 1, 2015, were included. Information about end-of-life care was obtained from documentation in the electronic medical record. Of 89 patients who died with a DT-LVAD, the median (25th-75th percentile) time from left ventricular assist device implantation to death was 14 (4-31) months. The most common causes of death were multiorgan failure (26%), hemorrhagic stroke (24%), and progressive heart failure (21%). Nearly half (46%) of the patients saw palliative care within 1 month before death; however, only 13 (15%) patients enrolled in hospice a median 11 (range 1-315) days before death. Most patients (78%) died in the hospital, of which 88% died in the intensive care unit. In total, 49 patients had their left ventricular assist device deactivated before death, with all but 3 undergoing deactivation in the hospital. Most patients died within an hour of left ventricular assist device deactivation and all within 26 hours. Conclusions In contrast to the general heart failure population, most patients with DT-LVAD die in the hospital and few use hospice. Further work is needed to understand these differences and to determine whether patients with DT-LVAD are receiving optimal end-of-life care. C1 [Dunlay, Shannon M.] Mayo Clin, Dept Cardiovasc Dis, Rochester, MN 55905 USA. [Dunlay, Shannon M.] Mayo Clin, Div Hlth Care Policy & Res, Dept Hlth Sci Res, Rochester, MN 55905 USA. [Strand, Jacob J.] Mayo Clin, Div Gen Internal Med, Dept Med, Rochester, MN 55905 USA. [Stulak, John M.; Luckhardt, Angela J.] Mayo Clin, Dept Surg, Div Cardiovasc Surg, Rochester, MN 55905 USA. [Wordingham, Sara E.] Mayo Clin, Dept Internal Med, Div Hematol & Med Oncol, Phoenix, AZ USA. [Swetz, Keith M.] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA. [Swetz, Keith M.] Univ Alabama Birmingham, Ctr Palliat & Support Care, Birmingham, AL USA. [Swetz, Keith M.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Dunlay, SM (reprint author), Mayo Clin, 200 First St SW, Rochester, MN 55905 USA. EM dunlay.shannon@mayo.edu FU National Institutes of Health (NIH) [K23 HL116643] FX Dr Dunlay is supported by a National Institutes of Health (NIH) Career Development Award (K23 HL116643). NR 21 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD OCT PY 2016 VL 9 IS 10 AR e003096 DI 10.1161/CIRCHEARTFAILURE.116.003096 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EA8SW UT WOS:000386909900003 ER PT J AU Yung, RL Ligibel, JA AF Yung, Rachel L. Ligibel, Jennifer A. TI Obesity and Breast Cancer: Risk, Outcomes, and Future Considerations SO CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY LA English DT Article DE Breast cancer; obesity; weight loss intervention ID BODY-MASS INDEX; WEIGHT-LOSS INTERVENTION; POSTMENOPAUSAL WOMEN REANALYSIS; RANDOMIZED-TRIAL; LIFE-STYLE; METAANALYSIS; INSULIN; RECONSTRUCTION; INFLAMMATION; BIOMARKERS AB The proportion of adults who are obese has increased dramatically in the United States over the last 30 years. Obesity has been linked to an increased risk of developing a number of malignancies, including postmenopausal breast cancer. Evidence also suggests that obesity at the time of breast cancer diagnosis is linked to an increased risk of breast cancer-specific and overall mortality in both premenopausal and postmenopausal women with early-stage breast cancer. Obesity is linked to an increased risk of secondary malignancies in women with early breast cancer, and studies suggest that weight gain after diagnosis increases overall mortality. Despite the data linking obesity to poor outcomes in women with early breast cancer, there are currently no data from randomized trials testing the impact of weight loss on breast cancer outcomes. A number of recent randomized controlled trials have shown that weight loss interventions are feasible in obese survivors of breast cancer, yielding loss of 5% to 6% of body weight, and several ongoing randomized phase 3 clinical trials are evaluating the effect of weight loss interventions on breast cancer outcomes. These studies will help define the role of weight loss in the management of obese women with early breast cancer. C1 [Yung, Rachel L.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Yung, Rachel L.; Ligibel, Jennifer A.] Harvard Med Sch, Med, Boston, MA USA. [Ligibel, Jennifer A.] Dana Farber Canc Inst, Adult Oncol, Boston, MA 02215 USA. RP Ligibel, JA (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA. EM Jennifer_Ligibel@dfci.harvard.edu NR 34 TC 0 Z9 0 U1 5 U2 5 PU MILLENNIUM MEDICAL PUBLISHING, INC PI NEW YORK PA 611 BROADWAY, STE 310, NEW YORK, NY 10012 USA SN 1543-0790 J9 CLIN ADV HEMATOL ONC JI Clin. Adv. Hematol. Oncol. PD OCT PY 2016 VL 14 IS 10 BP 790 EP 797 PG 8 WC Oncology SC Oncology GA EB4KF UT WOS:000387339700012 PM 27930630 ER PT J AU Kleinsteuber, K Corleis, B Rashidi, N Nchinda, N Lisanti, A Cho, JL Medoff, BD Kwon, D Walker, BD AF Kleinsteuber, Katja Corleis, Bjoern Rashidi, Narges Nchinda, Nzuekoh Lisanti, Antonella Cho, Josalyn L. Medoff, Benjamin D. Kwon, Douglas Walker, Bruce D. TI Standardization and quality control for high-dimensional mass cytometry studies of human samples SO CYTOMETRY PART A LA English DT Article DE Mass cytometry; CyTOF; HIV; clinical studies; human immunology ID SINGLE-CELL TECHNOLOGIES; T-CELLS; EXPRESSION; IMMUNE; PROGRESSION; EXHAUSTION; CONTINUUM; RESPONSES; SYSTEM; KI-67 AB Mass cytometry (CyTOF), a mass spectrometry-based single cell phenotyping technology, allows utilization of over 35 antibodies in a single sample and is a promising tool for translational human immunology studies. Although several analysis tools are available to interpret the complex data sets generated, a robust method for standardization and quality control within and across studies is needed. Here we report an efficient and easily adaptable method to monitor quality of individual samples in human immunology studies and to facilitate reproducible data analysis. Samples to be assessed are spiked with a defined amount of reference peripheral blood mononuclear cells from a healthy donor, derived from a single large blood draw. The presence of known standardized numbers and phenotypic profiles of these reference cells greatly facilitates sample analysis by allowing for: 1) quality control for consistent staining of each antibody in the panel, 2) identification of potential batch effects, and 3) implementation of a robust gating strategy. We demonstrate the utility of this method using peripheral blood and bronchoalveolar lavage samples from HIV+ patients by characterizing their CD8(+) T-cell phenotypes and cytokine expression, respectively. Our results indicate that this method allows quality control of experimental conditions and results in highly reproducible population frequencies through a robust gating strategy. (c) 2016 International Society for Advancement of Cytometry C1 [Kleinsteuber, Katja; Corleis, Bjoern; Rashidi, Narges; Nchinda, Nzuekoh; Lisanti, Antonella; Kwon, Douglas; Walker, Bruce D.] MIT & Harvard, Ragon Inst MGH, 400 Technol Sq, Cambridge, MA 02139 USA. [Kleinsteuber, Katja; Nchinda, Nzuekoh; Walker, Bruce D.] Howard Hughes Med Inst HHMI Chevy Chase, Chevy Chase, MD 20815 USA. [Kleinsteuber, Katja] Heinrich Pette Inst Expt Virol, Hamburg, Germany. [Cho, Josalyn L.; Medoff, Benjamin D.] Massachusetts Gen Hosp, Div Pulm & Crit Care Med, Boston, MA USA. [Cho, Josalyn L.; Medoff, Benjamin D.] Harvard Med Sch, Boston, MA USA. [Cho, Josalyn L.; Medoff, Benjamin D.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA USA. [Kwon, Douglas; Walker, Bruce D.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA USA. RP Walker, BD (reprint author), MIT & Harvard, Ragon Inst MGH, 400 Technol Sq, Cambridge, MA 02139 USA.; Walker, BD (reprint author), Howard Hughes Med Inst HHMI Chevy Chase, Chevy Chase, MD 20815 USA. EM bwalker@mgh.harvard.edu FU U.S. National Institutes of Health (NIH) Scripps Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery grant (CHAVI-ID) [1UM1-AI100663]; NIH [P30 AI060354]; NIAID; NCI; NICHD; NHLBI; NIDA; NIMH; NIA; FIC; OAR; U.S. National Institute of Allergy and Infectious Diseases [5U01HL121827-03]; European Research Council Marie Curie fellowship [628359] FX Grant sponsor: U.S. National Institutes of Health (NIH) Scripps Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery grant (CHAVI-ID), Grant number: 1UM1-AI100663; Grant sponsor: Harvard University Center for AIDS Research (CFAR), an NIH-funded program (P30 AI060354) which is supported by NIH co-funding and participating institutes and centers, including the NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, FIC, and OAR; Grant sponsor: U.S. National Institute of Allergy and Infectious Diseases, Grant number: 5U01HL121827-03; Grant sponsor: European Research Council Marie Curie fellowship, Grant number: 628359 NR 28 TC 2 Z9 2 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1552-4922 EI 1552-4930 J9 CYTOM PART A JI Cytom. Part A PD OCT PY 2016 VL 89A IS 10 BP 903 EP 913 DI 10.1002/cyto.a.22935 PG 11 WC Biochemical Research Methods; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA EB2UH UT WOS:000387217600006 PM 27575385 ER PT J AU Lambert, LJ Challa, AK Niu, AD Zhou, LH Tucholski, J Johnson, MS Nagy, TR Eberhardt, AW Estep, PN Kesterson, RA Grams, JM AF Lambert, Laura J. Challa, Anil K. Niu, Aidi Zhou, Lihua Tucholski, Janusz Johnson, Maria S. Nagy, Tim R. Eberhardt, Alan W. Estep, Patrick N. Kesterson, Robert A. Grams, Jayleen M. TI Increased trabecular bone and improved biomechanics in an osteocalcin-null rat model created by CRISPR/Cas9 technology SO DISEASE MODELS & MECHANISMS LA English DT Article DE Osteocalcin; Bone strength; Bone structure; Genetic animal models; Osteocalcin knockout ID CLEIDOCRANIAL DYSPLASIA; GENE; INHIBITION; EXPRESSION; DIFFERENTIATION; OSTEOPOROSIS; ADIPONECTIN; PROMOTER; PROTEIN; SYSTEM AB Osteocalcin, also known as bone gamma-carboxyglutamate protein (Bglap), is expressed by osteoblasts and is commonly used as a clinical marker of bone turnover. A mouse model of osteocalcin deficiency has implicated osteocalcin as a mediator of changes to the skeleton, endocrine system, reproductive organs and central nervous system. However, differences between mouse and human osteocalcin at both the genome and protein levels have challenged the validity of extrapolating findings from the osteocalcin-deficient mouse model to human disease. The rat osteocalcin (Bglap) gene locus shares greater synteny with that of humans. To further examine the role of osteocalcin in disease, we created a rat model with complete loss of osteocalcin using the CRISPR/Cas9 system. Rat osteocalcin was modified by injection of CRISPR/Cas9 mRNA into the pronuclei of fertilized single cell Sprague-Dawley embryos, and animals were bred to homozygosity and compound heterozygosity for the mutant alleles. Dual-energy X-ray absorptiometry (DXA), glucose tolerance testing (GTT), insulin tolerance testing (ITT), microcomputed tomography (mu CT), and a three-point break biomechanical assay were performed on the excised femurs at 5 months of age. Complete loss of osteocalcin resulted in bones with significantly increased trabecular thickness, density and volume. Cortical bone volume and density were not increased in null animals. The bones had improved functional quality as evidenced by an increase in failure load during the biomechanical stress assay. Differences in glucose homeostasis were observed between groups, but there were no differences in body weight or composition. This rat model of complete loss of osteocalcin provides a platform for further understanding the role of osteocalcin in disease, and it is a novel model of increased bone formation with potential utility in osteoporosis and osteoarthritis research. C1 [Lambert, Laura J.; Challa, Anil K.; Kesterson, Robert A.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA. [Niu, Aidi; Zhou, Lihua; Tucholski, Janusz; Grams, Jayleen M.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA. [Johnson, Maria S.; Nagy, Tim R.] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Eberhardt, Alan W.; Estep, Patrick N.] Univ Alabama Birmingham, Dept Biomed Engn, Birmingham, AL 35294 USA. [Grams, Jayleen M.] Birmingham VA Med Ctr, Dept Surg, Birmingham, AL 35233 USA. RP Grams, JM (reprint author), Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA.; Grams, JM (reprint author), Birmingham VA Med Ctr, Dept Surg, Birmingham, AL 35233 USA. EM jgrams@uab.edu FU Society for Surgery of the Alimentary Tract; Society of University Surgeons Foundation; University of Alabama at Birmingham (UAB) Comprehensive Arthritis, Musculoskeletal, Bone, and Autoimmunity Center; Department of Surgery; Department of Genetics; National Institutes of Health [P30CA13148, P30AR048311, P30DK074038, P30DK05336, P60DK079626]; National Institutes of Health Nutrition and Obesity Research Center [P30DK056336]; Diabetes Research Center [P30DK079626] FX This work was supported by the Society for Surgery of the Alimentary Tract; the Society of University Surgeons Foundation; and the University of Alabama at Birmingham (UAB) Comprehensive Arthritis, Musculoskeletal, Bone, and Autoimmunity Center, the Department of Surgery, and Department of Genetics. Services obtained from the UAB Transgenic and Genetically Engineered Model Systems Core Facility (R.A.K.) in this publication are supported by awards from the National Institutes of Health [grant numbers P30CA13148, P30AR048311, P30DK074038, P30DK05336, P60DK079626]. Services obtained from the UAB Small Animal Phenotyping Core (M.S.J. and T.R.N.) are supported by the National Institutes of Health Nutrition and Obesity Research Center [grant number P30DK056336] and the Diabetes Research Center [grant number P30DK079626]. NR 38 TC 3 Z9 3 U1 2 U2 2 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND SN 1754-8403 EI 1754-8411 J9 DIS MODEL MECH JI Dis. Model. Mech. PD OCT 1 PY 2016 VL 9 IS 10 BP 1169 EP 1179 DI 10.1242/dmm.025247 PG 11 WC Cell Biology; Pathology SC Cell Biology; Pathology GA EB7OX UT WOS:000387579100011 PM 27483347 ER PT J AU Watanabe, Y Iwamura, A Shimada, YJ Wakai, K Tamakoshi, A Iso, H AF Watanabe, Yuko Iwamura, Akira Shimada, Yuichi J. Wakai, Kenji Tamakoshi, Akiko Iso, Hiroyasu CA JACC Study Grp TI Transforming Growth Factor-beta 1 as a Predictor for the Development of Hepatocellular Carcinoma: A Nested Case-Controlled Study SO EBIOMEDICINE LA English DT Article DE Hepatocellular carcinoma; Nested case-controlled study; Predictor; TGF-beta 1 ID GROWTH-FACTOR-BETA; TGF-BETA; CANCER PROGRESSION; JACC AB Background: Transforming growth factor-beta 1 (TGF-beta 1) reportedly acts as a tumor suppressor in tumorigenesis. However, little is known as to how TGF-beta 1 concentrations change prior to the development of hepatocellular carcinoma (HCC) in humans. We examined the association between the serum TGF-beta 1 concentrations and death from HCC to determine whether the serum TGF-beta 1 can be a predictor of incident HCC. Methods: We conducted a nested case-controlled study of participants in the Japan Collaborative Cohort Study for Evaluation of Cancer Risk. We used a conditional logistic regression analysis to estimate the adjusted relative risks (aRRs) of death from HCC according to the serum TGF-beta 1 concentrations among 1940 participants including 83 patients with HCC and 1857 controls matched for age, sex, and hepatitis C virus (HCV)-antibody seropositivity. Findings: When serum TGF-beta 1 was modelled as a continuous variable, the aRR of death from HCC associated with a decrement of 7.9 ng/mL (one standard deviation) in the serum TGF-beta 1 concentrations was 2.3 (95% CI 1.7-3.0, P < 0.001) for all the subjects. The area under the receiver operating characteristic curve for the serum TGF-beta 1 concentrations was 0.78 (P < 0.05). Interpretation: Our finding suggests that TGF-beta 1 serves as a predictor for HCC. (C) 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). C1 [Watanabe, Yuko; Iwamura, Akira; Iso, Hiroyasu] Osaka Univ, Grad Sch Med, Dept Social Med, Publ Hlth, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan. [Shimada, Yuichi J.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Wakai, Kenji] Nagoya Univ, Grad Sch Med, Dept Prevent Med, Nagoya, Aichi, Japan. [Tamakoshi, Akiko] Hokkaido Univ, Grad Sch Med, Dept Prevent Med, Publ Hlth, Sapporo, Hokkaido, Japan. RP Iso, H (reprint author), Osaka Univ, Grad Sch Med, Dept Social Med, Publ Hlth, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan. EM iso@pbhel.med.osaka-u.ac.jp NR 18 TC 2 Z9 2 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2352-3964 J9 EBIOMEDICINE JI EBioMedicine PD OCT PY 2016 VL 12 BP 68 EP 71 DI 10.1016/j.ebiom.2016.09.001 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA EA8IM UT WOS:000386878500021 PM 27614396 ER PT J AU Bradley, T Trama, A Tumba, N Gray, E Lu, XZ Madani, N Jahanbakhsh, F Eaton, A Xia, SM Parks, R Lloyd, KE Sutherland, LL Scearce, RM Bowman, CM Barnett, S Abdool-Karim, SS Boyd, SD Melillo, B Smith, AB Sodroski, J Kepler, TB Alam, SM Gao, F Bonsignori, M Liao, HX Moody, MA Montefiori, D Santra, S Morris, L Haynes, BF AF Bradley, Todd Trama, Ashley Tumba, Nancy Gray, Elin Lu, Xiaozhi Madani, Navid Jahanbakhsh, Fatemeh Eaton, Amanda Xia, Shi-Mao Parks, Robert Lloyd, Krissey E. Sutherland, Laura L. Scearce, Richard M. Bowman, Cindy M. Barnett, Susan Abdool-Karim, Salim S. Boyd, Scott D. Melillo, Bruno Smith, Amos B., III Sodroski, Joseph Kepler, Thomas B. Alam, S. Munir Gao, Feng Bonsignori, Mattia Liao, Hua-Xin Moody, M. Anthony Montefiori, David Santra, Sampa Morris, Lynn Haynes, Barton F. TI Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity SO EBIOMEDICINE LA English DT Article ID EXTERNAL REGION; MONOCLONAL-ANTIBODIES; TYPE-1 GP41; ENVELOPE GLYCOPROTEINS; IMMUNE PRESSURE; CELL RESPONSES; FOUNDER VIRUS; BINDING-SITE; INFECTION; EPITOPE AB Most HIV-1 vaccines elicit neutralizing antibodies that are active against highly sensitive (tier-1) viruses or rare cases of vaccine-matched neutralization-resistant (tier-2) viruses, but no vaccine has induced antibodies that can broadly neutralize heterologous tier-2 viruses. In this study, we isolated antibodies from an HIV-1-infected individual that targeted the gp41 membrane-proximal external region (MPER) that may have selected single-residue changes in viral variants in the MPER that resulted in neutralization sensitivity to antibodies targeting distal epitopes on the HIV-1 Env. Similarly, a single change in the MPER in a second virus from another infected-individual also conferred enhanced neutralization sensitivity. These gp41 single-residue changes thus transformed tier-2 viruses into tier-1 viruses that were sensitive to vaccine-elicited tier-1 neutralizing antibodies. These data demonstrate that Env amino acid changes within the MPER bnAb epitope of naturally-selected escape viruses can increase neutralization sensitivity to multiple types of neutralizing antibodies, and underscore the critical importance of the MPER for maintaining the integrity of the tier-2 HIV-1 trimer. (C) 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). C1 [Bradley, Todd; Trama, Ashley; Lu, Xiaozhi; Eaton, Amanda; Xia, Shi-Mao; Parks, Robert; Lloyd, Krissey E.; Sutherland, Laura L.; Scearce, Richard M.; Bowman, Cindy M.; Alam, S. Munir; Gao, Feng; Bonsignori, Mattia; Liao, Hua-Xin; Moody, M. Anthony; Montefiori, David; Haynes, Barton F.] Duke Univ, Med Ctr, Duke Human Vaccine Inst, Durham, NC 27710 USA. [Tumba, Nancy; Gray, Elin; Morris, Lynn] Natl Inst Communicable Dis, ZA-2131 Johannesburg, South Africa. [Madani, Navid; Jahanbakhsh, Fatemeh; Sodroski, Joseph] Dana Farber Canc Inst, Boston, MA 02215 USA. [Madani, Navid; Sodroski, Joseph] Harvard Med Sch, Boston, MA 02115 USA. [Barnett, Susan] Novartis Vaccines & Diagnost Inc, Cambridge, MA USA. [Abdool-Karim, Salim S.; Morris, Lynn] Univ KwaZulu Natal, Ctr AIDS Program Res South Africa, ZA-4013 Durban, South Africa. [Abdool-Karim, Salim S.] Columbia Univ, New York, NY 10032 USA. [Boyd, Scott D.] Stanford Univ, Palo Alto, CA 94305 USA. [Melillo, Bruno; Smith, Amos B., III] Univ Penn, Philadelphia, PA 19104 USA. [Kepler, Thomas B.] Boston Univ, Boston, MA 02118 USA. [Santra, Sampa] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA. [Morris, Lynn] Univ Witwatersrand, Fac Hlth Sci, ZA-2131 Johannesburg, South Africa. RP Bradley, T; Haynes, BF (reprint author), Duke Univ, Med Ctr, Duke Human Vaccine Inst, Durham, NC 27710 USA. EM todd.bradley@duke.edu; barton.haynes@duke.edu OI Gray, Elin/0000-0002-8613-3570 FU NIAID NIH HHS [P30 AI064518, R01 AI124982, UM1 AI100645] NR 59 TC 3 Z9 3 U1 2 U2 2 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2352-3964 J9 EBIOMEDICINE JI EBioMedicine PD OCT PY 2016 VL 12 BP 196 EP 207 DI 10.1016/j.ebiom.2016.08.045 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA EA8IM UT WOS:000386878500036 PM 27612593 ER PT J AU Richard, J Pacheco, B Gohain, N Veillette, M Ding, SL Alsahafi, N Tolbert, WD Prevost, J Chapleau, JP Coutu, M Jia, MX Brassard, N Park, J Courter, JR Melillo, B Martin, L Tremblay, C Hahn, BH Kaufmanna, DE Wu, XL Smith, AB Sodroski, J Pazgier, M Finzi, A AF Richard, Jonathan Pacheco, Beatriz Gohain, Neelakshi Veillette, Maxime Ding, Shilei Alsahafi, Nirmin Tolbert, William D. Prevost, Jeremie Chapleau, Jean-Philippe Coutu, Mathieu Jia, Manxue Brassard, Nathalie Park, Jongwoo Courter, Joel R. Melillo, Bruno Martin, Loic Tremblay, Cecile Hahn, Beatrice H. Kaufmanna, Daniel E. Wu, Xueling Smith, Amos B., III Sodroski, Joseph Pazgier, Marzena Finzi, Andres TI Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins SO EBIOMEDICINE LA English DT Article DE HIV-1; Envelope glycoproteins; CD4; Non-neutralizing antibodies; ADCC; CD4-mimetics ID DEPENDENT CELLULAR CYTOTOXICITY; VACCINE EFFICACY TRIAL; GP120 INNER DOMAIN; MEDIATED CYTOTOXICITY; DISEASE PROGRESSION; MONOCLONAL-ANTIBODIES; EFFECTOR FUNCTION; RECEPTOR-BINDING; DENDRITIC CELLS; CD4 BINDING AB Human immunodeficiency virus type 1 (HIV-1) has evolved a sophisticated strategy to conceal conserved epitopes of its envelope glycoproteins (Env) recognized by antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies. These antibodies, which are present in the sera of most HIV-1-infected individuals, preferentially recognize Env in its CD4-bound conformation. Accordingly, recent studies showed that small CD4-mimetics (CD4mc) able to "push" Env into this conformation sensitize HIV-1-infected cells to ADCC mediated by HIV+ sera. Here we test whether CD4mc also expose epitopes recognized by anti-cluster A monoclonal antibodies such as A32, thought to be responsible for the majority of ADCC activity present in HIV+ sera and linked to decreased HIV-1 transmission in the RV144 trial. We made the surprising observation that CD4mc are unable to enhance recognition of HIV-1-infected cells by this family of antibodies in the absence of antibodies such as 17b, which binds a highly conserved CD4-induced epitope overlapping the co-receptor binding site (CoRBS). Our results indicate that CD4mc initially open the trimeric Env enough to allow the binding of CoRBS antibodies but not anti-cluster A antibodies. CoRBS antibody binding further opens the trimeric Env, allowing anti-cluster A antibody interaction and sensitization of infected cells to ADCC. Therefore, ADCC responses mediated by cluster A antibodies in HIV-positive sera involve a sequential opening of the Env trimer on the surface of HIV-1-infected cells. The understanding of the conformational changes required to expose these vulnerable Env epitopes might be important in the design of new strategies aimed at fighting HIV-1. (C) 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). C1 [Richard, Jonathan; Pacheco, Beatriz; Veillette, Maxime; Ding, Shilei; Alsahafi, Nirmin; Prevost, Jeremie; Chapleau, Jean-Philippe; Coutu, Mathieu; Brassard, Nathalie; Tremblay, Cecile; Kaufmanna, Daniel E.; Finzi, Andres] Ctr Rech CHUM, Montreal, PQ H2X 0A9, Canada. [Richard, Jonathan; Veillette, Maxime; Ding, Shilei; Prevost, Jeremie; Chapleau, Jean-Philippe; Tremblay, Cecile; Finzi, Andres] Univ Montreal, Dept Microbiol Infectiol & Immunol, Montreal, PQ H2X 0A9, Canada. [Gohain, Neelakshi; Tolbert, William D.; Pazgier, Marzena] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Inst Human Virol, Baltimore, MD 21201 USA. [Alsahafi, Nirmin; Finzi, Andres] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada. [Jia, Manxue; Wu, Xueling] Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 1230 York Ave, New York, NY 10021 USA. [Park, Jongwoo; Courter, Joel R.; Melillo, Bruno; Smith, Amos B., III] Univ Penn, Sch Arts & Sci, Dept Chem, Philadelphia, PA 19104 USA. [Martin, Loic] CEA, IBiTecS, Serv Ingn Mol Prot, Gif Sur Yvette, France. [Hahn, Beatrice H.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA. [Hahn, Beatrice H.] Univ Penn, Perelman Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA. [Kaufmanna, Daniel E.] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Cambridge, MA 02139 USA. [Kaufmanna, Daniel E.] Univ Montreal, Dept Med, Montreal, PQ H3C 3T5, Canada. [Kaufmanna, Daniel E.] Scripps Res Inst, Ctr HIV AIDS Vaccine Immunol & Immunogen Discover, La Jolla, CA 92037 USA. [Sodroski, Joseph] Harvard Med Sch, Div Aids, Dept Microbiol & Immunol, Dept Canc Immunol & Virol,Dana Farber Canc Inst, Boston, MA 02115 USA. [Sodroski, Joseph] Harvard Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA. RP Richard, J; Finzi, A (reprint author), Univ Montreal, Dept Microbiol Infectiol & Immunol, Montreal, PQ H2X 0A9, Canada. EM jonathan.richard.1@umontreal.ca; andres.finzi@umontreal.ca FU NIAID NIH HHS [UM1 AI100645, R01 AI116274] NR 58 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2352-3964 J9 EBIOMEDICINE JI EBioMedicine PD OCT PY 2016 VL 12 BP 208 EP 218 DI 10.1016/j.ebiom.2016.09.004 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA EA8IM UT WOS:000386878500037 PM 27633463 ER PT J AU Battistella, G Fuertinger, S Fleysher, L Ozelius, LJ Simonyan, K AF Battistella, G. Fuertinger, S. Fleysher, L. Ozelius, L. J. Simonyan, K. TI Cortical sensorimotor alterations classify clinical phenotype and putative genotype of spasmodic dysphonia SO EUROPEAN JOURNAL OF NEUROLOGY LA English DT Article DE dystonia; imaging marker; resting-state networks ID FOCAL HAND DYSTONIA; INDEPENDENT COMPONENT ANALYSIS; STATE FUNCTIONAL CONNECTIVITY; PARIETAL CORTEX; BOTULINUM TOXIN; BRAIN NETWORKS; CERVICAL DYSTONIA; WRITERS CRAMP; MOTOR CORTEX; ACTIVATION AB Background and purpose: Spasmodic dysphonia (SD), or laryngeal dystonia, is a task-specific isolated focal dystonia of unknown causes and pathophysiology. Although functional and structural abnormalities have been described in this disorder, the influence of its different clinical phenotypes and genotypes remains scant, making it difficult to explain SD pathophysiology and to identify potential biomarkers. Methods: We used a combination of independent component analysis and linear discriminant analysis of resting-state functional magnetic resonance imaging data to investigate brain organization in different SD phenotypes (abductor versus adductor type) and putative genotypes (familial versus sporadic cases) and to characterize neural markers for genotype/phenotype categorization. Results: We found abnormal functional connectivity within sensorimotor and frontoparietal networks in patients with SD compared with healthy individuals as well as phenotype-and genotype-distinct alterations of these networks, involving primary somatosensory, premotor and parietal cortices. The linear discriminant analysis achieved 71% accuracy classifying SD and healthy individuals using connectivity measures in the left inferior parietal and sensorimotor cortices. When categorizing between different forms of SD, the combination of measures from the left inferior parietal, premotor and right sensorimotor cortices achieved 81% discriminatory power between familial and sporadic SD cases, whereas the combination of measures from the right superior parietal, primary somatosensory and premotor cortices led to 71% accuracy in the classification of adductor and abductor SD forms. Conclusions: Our findings present the first effort to identify and categorize isolated focal dystonia based on its brain functional connectivity profile, which may have a potential impact on the future development of biomarkers for this rare disorder. C1 [Battistella, G.; Fuertinger, S.; Simonyan, K.] Icahn Sch Med Mt Sinai, Dept Neurol, One Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. [Fleysher, L.] Icahn Sch Med Mt Sinai, Dept Radiol, New York, NY 10029 USA. [Ozelius, L. J.] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA. [Simonyan, K.] Icahn Sch Med Mt Sinai, Dept Otolaryngol, New York, NY 10029 USA. RP Simonyan, K (reprint author), Icahn Sch Med Mt Sinai, Dept Neurol, One Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. EM kristina.simonyan@mssm.edu OI Simonyan, Kristina/0000-0001-7444-0437; Fuertinger, Stefan/0000-0002-8118-036X FU National Institute on Deafness and Other Communication Disorders, National Institutes of Health [R01DC01805] FX We thank Estee Rubien-Thomas, BA, and Heather Alexander, BA, for patient recruitment and imaging data acquisition. We thank Andrew Blitzer, MD, DDS, and Steven Frucht, MD, for patient referrals. This work was supported by R01DC01805 grant to K.S. from the National Institute on Deafness and Other Communication Disorders, National Institutes of Health. NR 65 TC 0 Z9 0 U1 3 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-5101 EI 1468-1331 J9 EUR J NEUROL JI Eur. J. Neurol. PD OCT PY 2016 VL 23 IS 10 BP 1517 EP 1527 DI 10.1111/ene.13067 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EB4SR UT WOS:000387364300006 PM 27346568 ER PT J AU Antonini, A Chaudhuri, KR Boroojerdi, B Asgharnejad, M Bauer, L Grieger, F Weintraub, D AF Antonini, A. Chaudhuri, K. R. Boroojerdi, B. Asgharnejad, M. Bauer, L. Grieger, F. Weintraub, D. TI Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis SO EUROPEAN JOURNAL OF NEUROLOGY LA English DT Article DE clinical trial; dopamine agonists; impulse control disorders; long-term treatment; Parkinson's disease; rotigotine transdermal patch ID PARKINSONS-DISEASE PATIENTS; RESTLESS LEGS SYNDROME; OPEN-LABEL EXTENSION; TRANSDERMAL SYSTEM; DOPAMINE AGONISTS; SYMPTOMS; TOLERABILITY; ASSOCIATION; MULTICENTER; PREVALENCE AB Background and purpose: Dopamine agonists in Parkinson's disease (PD) are associated with impulse control disorders (ICDs) and other compulsive behaviours (together called ICD behaviours). The frequency of ICD behaviours reported as adverse events (AEs) in long-term studies of rotigotine transdermal patch in PD was evaluated. Methods: This was a post hoc analysis of six open-label extension studies up to 6 years in duration. Analyses included patients treated with rotigotine for at least 6 months and administered the modified Minnesota Impulse Disorders Interview. ICD behaviours reported as AEs were identified and categorized. Results: For 786 patients, the mean (+/- SD) exposure to rotigotine was 49.4 +/- 17.6 months. 71 (9.0%) patients reported 106 ICD AEs cumulatively. Occurrence was similar across categories: 2.5% patients reported 'compulsive sexual behaviour', 2.3% 'buying disorder', 2.0% 'compulsive gambling', 1.7% 'compulsive eating' and 1.7% 'punding behaviour'. Examining at 6-month intervals, the incidence was relatively low during the first 30 months; it was higher over the next 30 months, peaking in the 54-60-month period. No ICD AEs were serious, and 97% were mild or moderate in intensity. Study discontinuation occurred in seven (9.9%) patients with ICD AEs; these then resolved in five patients. Dose reduction occurred for 23 AEs, with the majority (73.9%) resolving. Conclusions: In this analysis of >750 patients with PD treated with rotigotine, the frequency of ICD behaviour AEs was 9.0%, with a specific incidence time-line observed. Active surveillance as duration of treatment increases may help early identification and management; once ICD behaviours are present rotigotine dose reduction may be considered. C1 [Antonini, A.] IRCCS Hosp San Camillo, Parkinson Unit, Venice, Italy. [Chaudhuri, K. R.] Kings Coll Hosp London, Kings Coll, Natl Parkinson Fdn Int Ctr Excellence, London, England. [Boroojerdi, B.; Bauer, L.; Grieger, F.] UCB Pharma, Monheim, Germany. [Asgharnejad, M.] UCB Pharma, Raleigh, NC USA. [Weintraub, D.] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA. [Weintraub, D.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA. [Weintraub, D.] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis & Mental Illness Res Educ & Clin C, Philadelphia, PA USA. [Weintraub, D.] Philadelphia Vet Affairs Med Ctr, MIRECC, Philadelphia, PA USA. RP Antonini, A (reprint author), IRCCS Hosp San Camillo, Parkinson Unit, Venice, Italy. EM angelo3000@yahoo.com FU UCB Pharma, Brussels, Belgium; UCB Pharma, Monheim am Rhein, Germany FX The authors thank the patients and their caregivers in addition to the investigators and their teams who contributed to the studies included in these analyses. The authors also acknowledge Emily Thompson, PhD, CMPP (Evidence Scientific Solutions, London, UK), for writing assistance which was funded by UCB Pharma, Brussels, Belgium; Cedric Laloyaux, PhD, CMPP (Strategic Publication Lead Neurology, UCB Pharma, Brussels, Belgium), for publication coordination; Elisabeth Dohin, MD (UCB Pharma, Brussels, Belgium), for scientific and medical input into the data analyses and interpretation; and Marc Derycke, MSc (UCB Pharma, Monheim am Rhein, Germany), for his contributions to the specifications and programming of the post hoc analyses. This post hoc analysis was supported by UCB Pharma, Monheim am Rhein, Germany. NR 32 TC 1 Z9 1 U1 4 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1351-5101 EI 1468-1331 J9 EUR J NEUROL JI Eur. J. Neurol. PD OCT PY 2016 VL 23 IS 10 BP 1556 EP 1565 DI 10.1111/ene.13078 PG 10 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EB4SR UT WOS:000387364300011 PM 27425586 ER PT J AU Matulonis, U Herrstedt, J Oza, A Mahner, S Redondo, A Fabbro, M Ledermann, J Lorusso, D Vergote, I Rosengarten, O Reinthaller, A Madry, R Monk, BJ Dorum, A Tinker, AV DuBois, A Martin, AG Follana, P Berek, JS Gilbert, L Benigno, B Rosenberg, P Rimel, BJ Buscema, J Balser, J Agarwal, S Mirza, MR AF Matulonis, U. Herrstedt, J. Oza, A. Mahner, S. Redondo, A. Fabbro, M. Ledermann, J. Lorusso, D. Vergote, I. Rosengarten, O. Reinthaller, A. Madry, R. Monk, B. J. Dorum, A. Tinker, A. V. DuBois, A. Gonzalez Martin, A. Follana, P. Berek, J. S. Gilbert, L. Benigno, B. Rosenberg, P. Rimel, B. J. Buscema, J. Balser, J. Agarwal, S. Mirza, M. R. TI ENGOT-OV16/NOVA: A MAINTENANCE STUDY WITH NIRAPARIB VERSUS PLACEBO IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER LA English DT Meeting Abstract C1 [Matulonis, U.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Herrstedt, J.] NSGO, Odense, Denmark. [Herrstedt, J.] Odense Univ Hosp, Odense, Denmark. [Oza, A.] Univ Hlth Network, Toronto, ON, Canada. [Mahner, S.] AGO, Munich, Germany. [Mahner, S.] Univ Munich, Munich, Germany. [Redondo, A.] GEICO, Madrid, Spain. [Redondo, A.] Hosp Univ La Paz, Madrid, Spain. [Fabbro, M.] GINECO, Montpellier, France. [Fabbro, M.] Inst Canc Montpellier, Montpellier, France. [Ledermann, J.] UCL, NCRI, London, England. [Ledermann, J.] UCL, UCL Canc Inst, London, England. [Lorusso, D.] MITO MaNGO, Milan, Italy. [Lorusso, D.] Fdn IRCCS Natl Canc Inst, Milan, Italy. [Vergote, I.] BGOG, Leuven, Belgium. [Vergote, I.] Univ Leuven, Leuven, Belgium. [Rosengarten, O.] ISGO, Jerusalem, Israel. [Rosengarten, O.] Shaare Zedek Med Ctr, Jerusalem, Israel. [Reinthaller, A.] AGO Austria, Vienna, Austria. [Reinthaller, A.] Med Univ Vienna, Vienna, Austria. [Madry, R.] CEEGOG, Poznan, Poland. [Madry, R.] Uniwersytet Med Poznaniu, Poznan, Poland. [Monk, B. J.] Univ Arizona, Canc Ctr Phoenix, Phoenix, AZ USA. [Dorum, A.] Oslo Univ Hosp, Dept Gynecol Oncol, Oslo, Norway. [Tinker, A. V.] British Columbia Canc Agcy, Vancouver, BC, Canada. [DuBois, A.] AGO, Essen, Germany. [DuBois, A.] Kliniken Essen Mitte, Essen, Germany. [Gonzalez Martin, A.] GEICO, Madrid, Spain. [Gonzalez Martin, A.] MD Anderson Canc Ctr Madrid, Madrid, Spain. [Follana, P.] GINECO, Nice, France. [Follana, P.] Ctr Antoine Lacassagne, Nice, France. [Berek, J. S.] Stanford Womens Canc Ctr, Stanford, CA USA. [Gilbert, L.] McGill Univ MUHC, Montreal, PQ, Canada. [Benigno, B.] Univ Gynecol Oncol, Atlanta, GA USA. [Rosenberg, P.] NSGO, Linkoping, Sweden. [Rosenberg, P.] Univ Sjukhuset, Linkoping, Sweden. [Rimel, B. J.] Cedars Sinai Med Ctr, West Hollywood, CA USA. [Buscema, J.] Arizona Oncol Associates PC, HOPE, Tucson, AZ USA. [Balser, J.] Veristat LLC, Southborough, MA USA. [Agarwal, S.] TESARO Inc, Waltham, MA USA. [Mirza, M. R.] NSGO, Copenhagen, Denmark. [Mirza, M. R.] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1048-891X EI 1525-1438 J9 INT J GYNECOL CANCER JI Int. J. Gynecol. Cancer PD OCT PY 2016 VL 26 SU 3 MA IGCS-0912 BP 19 EP 20 PG 2 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA EB1KD UT WOS:000387109100010 ER PT J AU Chase, D Huang, H Ramondetta, L Monk, B Penson, R Gil, K Landrum, L Leitao, M Oaknin, A Huh, W Pulaski, H Katina, R Guntupalli, S Richardson, D Salani, R Ali, S Tewari, K AF Chase, D. Huang, H. Ramondetta, L. Monk, B. Penson, R. Gil, K. Landrum, L. Leitao, M. Oaknin, A. Huh, W. Pulaski, H. Katina, R. Guntupalli, S. Richardson, D. Salani, R. Ali, S. Tewari, K. TI Patient-reported Outcomes and toxicity at discontinuation of therapy in advanced or persistent cervical cancer: an analysis of GOG protocol 240 SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER LA English DT Meeting Abstract C1 [Chase, D.] Univ Arizona, St Josephs Hosp & Med Ctr, Ctr Canc, Gynecol Oncol, Phoenix, AZ USA. [Huang, H.] NRG Oncol, Stat & Data Management Ctr, Buffalo, NY USA. [Ramondetta, L.] MD Anderson, Gynecol Oncol, Houston, TX USA. [Monk, B.] Univ Arizona, Ctr Canc, Gynecol Oncol, Phoenix, AZ USA. [Penson, R.] Massachusetts Gen Hosp, Gynecol Oncol, Boston, MA 02114 USA. [Gil, K.] Summa Hlth Grant & Proposal Dev, Akron, OH USA. [Landrum, L.] Univ Oklahoma, Hlth Sci Ctr, Gynecol Oncol, Oklahoma City, OK USA. [Leitao, M.] Mem Sloan Kettering Canc Ctr, Gynecol Oncol, 1275 York Ave, New York, NY 10021 USA. [Oaknin, A.] GEICO, Gynecol Oncol, Barcelona, Spain. [Huh, W.] Univ Alabama Birmingham, Gynecol Oncol, Birmingham, AL USA. [Pulaski, H.] Univ Cinncinati, Gynecol Oncol, Cinncinati, OH USA. [Katina, R.] Womens & Infants Hosp, Gynecol Oncol, Providence, RI USA. [Guntupalli, S.] Univ Colorado, Gynecol Oncol, Denver, CO 80202 USA. [Richardson, D.] UT Southwestern Gynecol Oncol, Dallas, TX USA. [Salani, R.] Ohio State Univ, Med Ctr, Gynecol Oncol, Columbus, OH 43210 USA. [Ali, S.] NRG Oncol Stat & Data management, Buffalo, NY USA. [Tewari, K.] Univ Calif Irvine, Med Ctr, Gynecol Oncol, Orange, CA 92668 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1048-891X EI 1525-1438 J9 INT J GYNECOL CANCER JI Int. J. Gynecol. Cancer PD OCT PY 2016 VL 26 SU 3 MA IGCS-0264 BP 40 EP 41 PG 2 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA EB1KD UT WOS:000387109100024 ER PT J AU Casablanca, Y Wang, G Tian, C Bateman, NW Miecznikowski, J Miller, C Chappell, NP Havrilesky, L Wallace, AH Ramirez, N Miller, DS Oliver, J Mitchell, D Litzi, T Blanton, B Birrer, MJ Hamilton, CA Conrads, TP Darcy, KM Maxwell, GL AF Casablanca, Y. Wang, G. Tian, C. Bateman, N. W. Miecznikowski, J. Miller, C. Chappell, N. P. Havrilesky, L. Wallace, A. H. Ramirez, N. Miller, D. S. Oliver, J. Mitchell, D. Litzi, T. Blanton, B. Birrer, M. J. Hamilton, C. A. Conrads, T. P. Darcy, K. M. Maxwell, G. L. TI A 7-TRANSCRIPT CLASSIFIER IDENTIFIES METASTATIC DISEASE AND WORSE PROGRESSION-FREE SURVIVAL IN ENDOMETRIOID ENDOMETRIAL CANCER PATIENTS SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER LA English DT Meeting Abstract C1 [Casablanca, Y.; Chappell, N. P.; Hamilton, C. A.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA. [Casablanca, Y.; Chappell, N. P.; Hamilton, C. A.] Uniformed Serv Univ Hlth Sci, Gynecol Canc Ctr Excellence, Bethesda, MD 20814 USA. [Wang, G.; Tian, C.; Bateman, N. W.; Oliver, J.; Mitchell, D.; Litzi, T.; Blanton, B.; Conrads, T. P.; Darcy, K. M.] Womens Hlth Integrated Res Ctr, Gynecol Canc Ctr Excellence, Annandale, VA USA. [Miecznikowski, J.] SUNY Buffalo, Biostat, Buffalo, NY USA. [Miller, C.] San Antonio Mil Med Ctr, Div Gynecol Oncol, Ft Sam Houston, TX USA. [Havrilesky, L.; Wallace, A. H.] Duke Univ, Div Gynecol Oncol, Durham, NC 27706 USA. [Ramirez, N.] Nationawide Childrens Hosp, GOG & NRG Oncol Tissue Bank, Columbus, OH USA. [Miller, D. S.] UT Southwestern Med Ctr, Div Gynecol Oncol, Dallas, TX USA. [Birrer, M. J.] Havard Med Sch, Massachusetts Gen Hosp, Gynecol Oncol Res Program, Boston, MA USA. [Maxwell, G. L.] Inova Fairfax Hosp, Dept Obstet & Gynecol, Falls Church, VA USA. [Maxwell, G. L.] Inova Fairfax Hosp, Gynecol Canc Ctr Excellence, Falls Church, VA USA. RI Miller, David/H-4604-2011 OI Miller, David/0000-0002-8215-5887 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1048-891X EI 1525-1438 J9 INT J GYNECOL CANCER JI Int. J. Gynecol. Cancer PD OCT PY 2016 VL 26 SU 3 MA IGCS-1282 BP 154 EP 155 PG 2 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA EB1KD UT WOS:000387109100114 ER PT J AU Diver, E Norris, A Borger, D Horick, N Finkelstein, D Growdon, W AF Diver, E. Norris, A. Borger, D. Horick, N. Finkelstein, D. Growdon, W. TI ONCOGENIC GAIN OF FUNCTION MUTATIONS ASSOCIATE WITH CHEMOTHERAPY RESPONSIVENESS IN ENDOMETRIAL CANCER SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER LA English DT Meeting Abstract C1 [Diver, E.; Norris, A.; Borger, D.; Horick, N.; Finkelstein, D.; Growdon, W.] Massachusetts Gen Hosp, Gynecol Oncol, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1048-891X EI 1525-1438 J9 INT J GYNECOL CANCER JI Int. J. Gynecol. Cancer PD OCT PY 2016 VL 26 SU 3 MA IGCS-0546 BP 182 EP 182 PG 1 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA EB1KD UT WOS:000387109100140 ER PT J AU Elias, K Emori, M Westerling, T Long, H Budina-Kolomets, A Brown, M Drapkin, R AF Elias, K. Emori, M. Westerling, T. Long, H. Budina-Kolomets, A. Brown, M. Drapkin, R. TI EPIGENETIC REMODELING OF THE PAX8 CISTROME DISTINGUISHES HIGH GRADE SEROUS CARCINOMAS FROM TUBAL PRECURSORS SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER LA English DT Meeting Abstract C1 [Elias, K.] Brigham & Womens Hosp, Gyneocol Oncol, 75 Francis St, Boston, MA 02115 USA. [Emori, M.] Harvard Univ, Grad Sch Arts & Sci, Cambridge, MA 02138 USA. [Westerling, T.; Long, H.; Brown, M.] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA. [Budina-Kolomets, A.; Drapkin, R.] Univ Penn, Perelman Sch Med, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1048-891X EI 1525-1438 J9 INT J GYNECOL CANCER JI Int. J. Gynecol. Cancer PD OCT PY 2016 VL 26 SU 3 MA IGCS-0558 BP 222 EP 222 PG 1 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA EB1KD UT WOS:000387109100176 ER PT J AU Diver, E Hinchcliff, E Gockley, A Melamed, A Contrino, L Feldman, S Growdon, W AF Diver, E. Hinchcliff, E. Gockley, A. Melamed, A. Contrino, L. Feldman, S. Growdon, W. TI ELDERLY WOMEN WITH CERVICAL CANCER ARE LESS LIKELY TO UNDERGO SURGERY AND HAVE LOWER OVERALL SURVIVAL COMPARED TO WOMEN UNDER 65 YEARS OLD SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER LA English DT Meeting Abstract C1 [Diver, E.; Hinchcliff, E.; Gockley, A.; Melamed, A.; Growdon, W.] Massachusetts Gen Hosp, Gynecol Oncol, Boston, MA 02114 USA. [Contrino, L.; Feldman, S.] Brigham & Womens Hosp, Gynecol Oncol, 75 Francis St, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1048-891X EI 1525-1438 J9 INT J GYNECOL CANCER JI Int. J. Gynecol. Cancer PD OCT PY 2016 VL 26 SU 3 MA IGCS-0186 BP 331 EP 331 PG 1 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA EB1KD UT WOS:000387109100275 ER PT J AU Ledermann, J Fujiwara, K Vergote, I Oza, A Birrer, M Disilvestro, P Beck, JT Randall, L Matulonis, U Shnaidman, M Potier, H Mather, CB Morozov, A Monk, B AF Ledermann, J. Fujiwara, K. Vergote, I. Oza, A. Birrer, M. Disilvestro, P. Beck, J. T. Randall, L. Matulonis, U. Shnaidman, M. Potier, H. Mather, C. B. Morozov, A. Monk, B. TI PHASE 3 TRIAL OF AVELUMAB (ANTI-PD-L1) IN COMBINATION WITH AND/OR FOLLOWING PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH UNTREATED OVARIAN CANCER SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER LA English DT Meeting Abstract C1 [Ledermann, J.] UCL Canc Inst, CR UK & UCL Canc Trials Ctr, London, England. [Fujiwara, K.] Saitama Med Univ, Int Med Ctr, Dept Gynecol Oncol, Yamane Hidaka City, Saitama, Japan. [Vergote, I.] Katholieke Univ Leuven, Dept Gynecol Oncol, Leuven, Belgium. [Oza, A.] Princess Margaret Canc Ctr, Canc Clin Res Unit CCRU, Toronto, ON, Canada. [Birrer, M.] Massachusetts Gen Hosp, Ctr Syst Biol, Richard B Simches Res Ctr, Boston, MA 02114 USA. [Disilvestro, P.] Women & Infants Hosp Rhode Isl, Dept Gynecol Oncol, Providence, RI USA. [Beck, J. T.] Highlands Oncol Grp, Dept Med Oncol, Fayetteville, AR USA. [Randall, L.] UC Irvine Hlth, Ovarian Canc Ctr, Deprartment Gynecol Canc, Orange, CA USA. [Matulonis, U.] Dana Farber Canc Inst, Dept Gynecol Oncol, Boston, MA 02115 USA. [Shnaidman, M.] Pfizer Inc, Biostat, New York, NY USA. [Potier, H.; Morozov, A.] Pfizer Inc, Immunooncol, New York, NY USA. [Mather, C. B.] Pfizer Inc, Immunooncol, Groton, CT 06340 USA. [Monk, B.] St Josephs Hosp, Dign Hlth, Ctr Womens Hlth, Phoenix, AZ USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1048-891X EI 1525-1438 J9 INT J GYNECOL CANCER JI Int. J. Gynecol. Cancer PD OCT PY 2016 VL 26 SU 3 MA IGCS-0214 BP 753 EP 753 PG 1 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA EB1KD UT WOS:000387109100624 ER PT J AU Cho, L Manuel, M Damato, A Schmidt, E Wang, W Buzurovic, I Tempany, C Viswanathan, A AF Cho, L. Manuel, M. Damato, A. Schmidt, E. Wang, W. Buzurovic, I. Tempany, C. Viswanathan, A. TI TOXICITIES ON A PROSPECTIVE TRIAL OF 3T MR-GUIDED BRACHYTHERAPY SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER LA English DT Meeting Abstract C1 [Cho, L.; Manuel, M.; Damato, A.; Buzurovic, I.; Viswanathan, A.] Brigham & Womens Hosp, Dana Farber Canc Inst, Radiat Oncol, 75 Francis St, Boston, MA 02115 USA. [Damato, A.; Buzurovic, I.; Viswanathan, A.] Harvard Med Sch, Radiat Oncol, Boston, MA USA. [Schmidt, E.; Wang, W.] Brigham & Womens Hosp, Radiol, 75 Francis St, Boston, MA 02115 USA. [Tempany, C.] Brigham & Womens Hosp, Dana Farber Canc Inst, Radiol, 75 Francis St, Boston, MA 02115 USA. [Tempany, C.] Harvard Med Sch, Radiol, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1048-891X EI 1525-1438 J9 INT J GYNECOL CANCER JI Int. J. Gynecol. Cancer PD OCT PY 2016 VL 26 SU 3 MA IGCS-1202 BP 866 EP 867 PG 2 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA EB1KD UT WOS:000387109100729 ER PT J AU Elias, K Fusco, A Kang, S Horowitz, N Berkowitz, R Wojciech, F Chowdhury, D Frendl, G AF Elias, K. Fusco, A. Kang, S. Horowitz, N. Berkowitz, R. Wojciech, F. Chowdhury, D. Frendl, G. TI EFFECTS OF REGIONAL ANALGESIA ON SERUM MIRNAS AFTER ONCOLOGIC SURGERY (THE ERASMOS STUDY) SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER LA English DT Meeting Abstract C1 [Elias, K.; Horowitz, N.; Berkowitz, R.] Brigham & Womens Hosp, Gyneocol Oncol, 75 Francis St, Boston, MA 02115 USA. [Fusco, A.] Abcam, Firefly Bioworks, Cambridge, MA USA. [Kang, S.; Frendl, G.] Brigham & Womens Hosp, Surg ICU Translat Res Ctr, 75 Francis St, Boston, MA 02115 USA. [Wojciech, F.] Med Univ Lodz, Dept Biostat & Translat Med, Lodz, Poland. [Chowdhury, D.] Dana Farber Canc Inst, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1048-891X EI 1525-1438 J9 INT J GYNECOL CANCER JI Int. J. Gynecol. Cancer PD OCT PY 2016 VL 26 SU 3 MA IGCS-0562 BP 898 EP 898 PG 1 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA EB1KD UT WOS:000387109100755 ER PT J AU Goodman, A Pervin, S AF Goodman, A. Pervin, S. TI PRIMARY MALIGNANT MELANOMA OF THE VAGINA IN BANGLADESH SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER LA English DT Meeting Abstract C1 [Goodman, A.] Massachusetts Gen Hosp, Obstet & Gynecol, Boston, MA 02114 USA. [Pervin, S.] Nat Inst Canc Res & Hosp, Gynecol Oncol, Dhaka, Bangladesh. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1048-891X EI 1525-1438 J9 INT J GYNECOL CANCER JI Int. J. Gynecol. Cancer PD OCT PY 2016 VL 26 SU 3 MA IGCS-0008 BP 1129 EP 1129 PG 1 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA EB1KD UT WOS:000387109100957 ER PT J AU Kerlikowske, K Vachon, CM AF Kerlikowske, Karla Vachon, Celine M. TI Breast Density: More Than Meets the Eye SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Editorial Material ID MAMMOGRAPHIC DENSITY; CANCER RISK; WOMEN; MODEL C1 [Kerlikowske, Karla] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Kerlikowske, Karla] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Kerlikowske, Karla] Univ Calif San Francisco, Dept Vet Affairs, Gen Internal Med Sect, San Francisco, CA 94143 USA. [Vachon, Celine M.] Mayo Clin, Div Epidemiol, Dept Hlth Sci Res, Rochester, MN USA. RP Kerlikowske, K (reprint author), San Francisco VA Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA. EM karla.kerlikowske@ucsf.edu NR 18 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-J. Natl. Cancer Inst. PD OCT PY 2016 VL 108 IS 10 AR djw128 DI 10.1093/jnci/djw128 PG 2 WC Oncology SC Oncology GA EA9FN UT WOS:000386947400012 ER PT J AU McCarthy, AM Keller, BM Pantalone, LM Hsieh, MK Synnestvedt, M Conant, EF Armstrong, K Kontos, D AF McCarthy, Anne Marie Keller, Brad M. Pantalone, Lauren M. Hsieh, Meng-Kang Synnestvedt, Marie Conant, Emily F. Armstrong, Katrina Kontos, Despina TI Racial Differences in Quantitative Measures of Area and Volumetric Breast Density SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID FIELD DIGITAL MAMMOGRAMS; CANCER RISK-FACTORS; TUMOR CHARACTERISTICS; TISSUE COMPOSITION; FILM MAMMOGRAPHY; UNITED-STATES; DATA SYSTEM; AGE; ASSOCIATION; COHORT AB Background: Increased breast density is a strong risk factor for breast cancer and also decreases the sensitivity of mammographic screening. The purpose of our study was to compare breast density for black and white women using quantitative measures. Methods: Breast density was assessed among 5282 black and 4216 white women screened using digital mammography. Breast Imaging-Reporting and Data System (BI-RADS) density was obtained from radiologists' reports. Quantitative measures for dense area, area percent density (PD), dense volume, and volume percent density were estimated using validated, automated software. Breast density was categorized as dense or nondense based on BI-RADS categories or based on values above and below the median for quantitative measures. Logistic regression was used to estimate the odds of having dense breasts by race, adjusted for age, bodymass index (BMI), age at menarche, menopause status, family history of breast or ovarian cancer, parity and age at first birth, and current hormone replacement therapy (HRT) use. All statistical tests were two-sided. Results: There was a statistically significant interaction of race and BMI on breast density. After accounting for age, BMI, and breast cancer risk factors, black women had statistically significantly greater odds of high breast density across all quantitative measures (eg, PD nonobese odds ratio [OR] = 1.18, 95% confidence interval [CI] = 1.02 to 1.37, P = .03, PD obese OR = 1.26, 95% CI = 1.04 to 1.53, P = .02). There was no statistically significant difference in BI-RADS density by race. Conclusions: After accounting for age, BMI, and other risk factors, black women had higher breast density than white women across all quantitative measures previously associated with breast cancer risk. These results may have implications for risk assessment and screening. C1 [McCarthy, Anne Marie; Armstrong, Katrina] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Keller, Brad M.; Pantalone, Lauren M.; Hsieh, Meng-Kang; Synnestvedt, Marie; Conant, Emily F.; Kontos, Despina] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA. RP McCarthy, AM (reprint author), Massachusetts Gen Hosp, Dept Gen Internal Med, 50 Staniford St,940F, Boston, MA 02114 USA. EM amccarthy8@partners.org FU National Cancer Institute at the National Institutes of Health, Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) program [U54 CA163313, 5R01CA161749-04] FX This work was supported by the National Cancer Institute at the National Institutes of Health, Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) program (U54 CA163313) and 5R01CA161749-04. NR 75 TC 2 Z9 2 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-J. Natl. Cancer Inst. PD OCT PY 2016 VL 108 IS 10 AR djw104 DI 10.1093/jnci/djw104 PG 8 WC Oncology SC Oncology GA EA9FN UT WOS:000386947400003 ER PT J AU Shahian, DM Mort, EA Pronovost, PJ AF Shahian, David M. Mort, Elizabeth A. Pronovost, Peter J. TI The Quality Measurement Crisis: An Urgent Need for Methodological Standards and Transparency SO JOINT COMMISSION JOURNAL ON QUALITY AND PATIENT SAFETY LA English DT Editorial Material ID PATIENT SAFETY INDICATORS; BYPASS-GRAFTING SURGERY; 30-DAY MORTALITY-RATES; MEASUREMENT TASK-FORCE; ADULT CARDIAC-SURGERY; HOSPITAL RATINGS; COMPOSITE SCORE; SOCIETY; VALIDITY C1 [Shahian, David M.] Harvard Med Sch, Surg, Boston, MA 02115 USA. [Shahian, David M.; Mort, Elizabeth A.] Massachusetts Gen Hosp, Ctr Qual & Safety, Boston, MA 02114 USA. [Pronovost, Peter J.] Johns Hopkins Med, Patient Safety & Qual, Baltimore, MD USA. [Pronovost, Peter J.] Johns Hopkins Med, Armstrong Inst Patient Safety & Qual, Baltimore, MD USA. [Pronovost, Peter J.] Johns Hopkins Univ, Anesthesiol & Crit Care Med Surg & Hlth Policy &, Baltimore, MD 21218 USA. RP Shahian, DM (reprint author), Harvard Med Sch, Surg, Boston, MA 02115 USA.; Shahian, DM (reprint author), Massachusetts Gen Hosp, Ctr Qual & Safety, Boston, MA 02114 USA. EM dshahian@partners.org NR 33 TC 0 Z9 0 U1 1 U2 1 PU JOINT COMMISSION RESOURCES INC PI OAK BROOK PA 1515 W 22 ST, STE 1300W, OAK BROOK, IL 60523 USA SN 1553-7250 EI 1938-131X J9 JT COMM J QUAL PATIE JI Jt. Comm. J. Qual. Patient Saf. PD OCT PY 2016 VL 42 IS 10 BP 435 EP 438 PG 4 WC Health Care Sciences & Services SC Health Care Sciences & Services GA EB7GI UT WOS:000387554200001 PM 27712601 ER EF